null
Skip to content Patent Blog Jobs Ethics Journal America's leading patent law source Search for: Although Functionally Claimed, Court Imports Structural Limitations from Specification October 27, 2016PatentDennis Crouch by Dennis Crouch â€“ Note,Â the prevailing party here (Merck & Co.) is represented in this case by MBHB Partner Dan Boehnen. MBHB is a major sponsor of Patently-O. ProFoot v. Merck & Co. (Fed. Cir. 2016) This case offers a straightforward narrowing claim construction analysis involvingÂ the ProFootâ€™sÂ patented method of fittingÂ shoe inserts. Â U.S. Patent No. 6,845,568. Â The decision alsoÂ lays traps for prosecutors hoping for implicitly broad claims.Â  After a narrowingÂ claim construction, the plaintiffÂ stipulated that Merckâ€™s Dr. Schollâ€™s process did not infringe and the case was dismissed. Â On appeal, the Federal Circuit has affirmed in a nonprecedential opinion. The claim construction processÂ looks to provide additional meaning and context to the expressly stated claims. Â TheÂ approach is to look for howÂ a personal of ordinary skill inÂ the art at the time of the application filing date would have interpreted the claim language. Â In this process, Phillips v. AWH indicates that the primary sources for interpretation are the intrinsic documents: the patent document (the single best guide) and the prosecution history (a helpful additional resource). Â When appealed,Â the Federal Circuit reviews claim construction determinations de novo while giving deference toÂ underlying factual findings. Here, the claimed insert-fitting method include use of a â€œneutralizerâ€ that is used to place a customerâ€™sÂ ankle in a â€œneutral position.â€ Â Following theÂ MarkmanÂ process,Â the district court construed the â€œneutralizerâ€ according to how it was described in the specification â€” requiring a housing, protractor, and angular-adjustable foot plate. Â On appeal, ProFoot argued that the district court improperly imported elements of the specification to limit the claims and that the claimed neutralizer does not require those specific components. Â Rather,Â according to ProFoot, a neutralizer should be defined based upon its functional ability rather than anyÂ particular physical elements. On appeal, the Federal Circuit rejected ProFootâ€™s broad-construction argument â€” holding that â€œwhen read in the context of the [asserted] patent, this term requires a device that includes these components.â€ Â To reach this conclusion the court started with claim language that require a user toÂ step on the neutralizer (claim 1 requires â€œplace right foot on a neutralizerâ€) and to use the neutralizer to measure an angle. Â Looking to the specification, the courtÂ found that the patentee had described â€œonlyÂ two embodiments of the neutralizerâ€ â€“ and both embodiments required all of the components found in the claim construction in ways that are consistent with the requirements of the claims. Although the appellate panel found that evidence from the specificationÂ was sufficient to support the district court ruling, it also noted thatÂ the prosecution history of the parent application offeredÂ additional support. The prosecution history story goes as follows:Â the claimed neutralizerÂ was not found in the originally filed claim set but was added during prosecutionÂ with an express claim requirement that the neutralizer include the physicalÂ elements (housing, protractor, etc.). Although the physical components are not included in the child application, the court noted that the patentee neverÂ Â indicated that it intended the child-patent neutralizer to be any different from the parent-patent neutralizer. Â ProFoot made the claim-differentiation argument here â€“ the child application does not include the express limitations that are included in the parent and therefore should be seen as broader.Â Â The court rejected that argument as not providing any furtherÂ information as to what the inventor understood â€œneutralizerâ€ to include. Â I the inventor had thought the word should be interpreted differently in the two cases â€œhe could have said so explicitlyÂ or revised the [asserted] patent to include other, broader embodiments of theÂ neutralizer.â€ One question that I have here involves the courtâ€™s use of prosecution history as providing â€œevidence of the inventorâ€™s understanding of neutralizer.â€ Â The court has previously held thatÂ inventorâ€™s understanding of claim meaning is not directly relevant to claim construction. Â Rather, the focus isÂ on the objective meaning understood by someone of ordinary skill in the art. = = = = ProFootâ€™s Claim 1. A method of fitting an individual with right and left foot inserts which place the ankles of the individual in a neutral position comprising the steps of: for creating a right foot insert, having the individual place the right foot on a neutralizer while elevating the left foot off of the neutralizer; using the neutralizer to determine the angle necessary to place the right ankle in a neutral position; providing an insert having an angle which represents the neutral state for the right ankle; for creating a left foot insert, having the individual place the left foot on a neutralizer while elevating the right foot off of the neutralizer; using the neutralizer to determine the angle necessary to place the left ankle in a neutral position; and providing an insert having an angle which represents the neutral state for the left ankle. About Dennis Crouch Law Professor at the University of Missouri School of Law. Co-director of the Center for Intellectual Property and Entrepreneurship. View all posts by Dennis Crouch â†’ Post navigation â† November Patent Quality Forum Series Remarks by Director Michelle K. Lee at the 2016 AIPLA Luncheon â†’ Hide comments 124 thoughts on â€œAlthough Functionally Claimed, Court Imports Structural Limitations from Specificationâ€ 11 David Boundy says: October 28, 2016 at 2:49 pm Dennis â€” The headline does not accurately characterize the case. â€œFunctionalâ€ is never mentioned as a relevant factor. The case turns on the fact that â€œneutralizerâ€ is a neologism coined for the purpose, with no definition in the art, no definition in the claim, and no express definition in the spec. On these facts, itâ€™s always been fair game to import every mention of the neologism from the whole specification into the neologism claim term. Watts v. XL Systems, Inc., 232 F.3d 877, 882â€“83, 56 USPQ2d 1836, 1840 (Fed. Cir. 2000); McGill, Inc. v. John Zink Co., 736 F.2d 666, 673, 221 USPQ 944, 949 (Fed. Cir. 1984). After all, if you canâ€™t look it up in a dictionary, where else would you look? And how would you choose one part of the specification that describes the neologism to import, and choose others to leave out? Reply link does not work in your browser because JavaScript is disabled. Reply 11.1 anon says: October 28, 2016 at 3:12 pm Thank you Mr. Boundy. Reply link does not work in your browser because JavaScript is disabled. Reply 11.2 MM says: October 28, 2016 at 5:26 pm DB: The headline does not accurately characterize the case. â€œFunctionalâ€ is never mentioned as a relevant factor. The case turns on the fact that â€œneutralizerâ€ is a neologism â€œNeologismâ€ isnâ€™t mentioned as â€œa relevant factorâ€, either. Itâ€™s never mentioned at all. On these facts, itâ€™s always been fair game to import every mention of the neologism from the whole specification into the neologism claim term. Or you could find the claim indefinite, which it surely is when the patentee says that the term refers to â€œsome kind of measuring deviceâ€ that performs the stated function of â€¦ measuring. Oops, I said â€œfunctionâ€. Pretty difficult to avoid doing that. Note also that without this â€œneutralizerâ€, this claim is unpatentable because people have been making measurements to prepare shoe parts, including â€œinsertsâ€, for a long, long time. Note that the CAFC doesnâ€™t cite any of the cases you mentioned. Note what the CAFC says instead: inclusion of these components is consistent with the specificationâ€™s description of how the neutralizer is used. In other words, the CAFC imported into the claim the components that were necessary to perform the function of the â€œneutralizer.â€ It certainly did not import all the elements that appear in the two pictured embodiments, which would have been perfectly â€œfairâ€ and would have rendered the claim even more worthless (as if thatâ€™s possible). Instead, the CAFC panel here â€œpicked and choseâ€ which elements to import. itâ€™s always been fair game to import Are you sure you donâ€™t mean â€œinformâ€? LOL Reply link does not work in your browser because JavaScript is disabled. Reply 11.3 Ned Heller says: October 28, 2016 at 5:59 pm And, David, and if the neologism was never used in the specification but was coined in the prosecution history to mean something specific, that is what it means in the claim. Reply link does not work in your browser because JavaScript is disabled. Reply 11.3.1 David Boundy says: October 28, 2016 at 9:17 pm I think I agree with that, partly â€” a term created mid-prosecution and defined in the prosecution history (but not in the spec) has that definition in a Markman/Phillips construction. If you mean â€œcoined to meanâ€ with the meaning existing only in the head of the attorney, but with no square statement of that meaning, I wouldnâ€™t bet on the attorneyâ€™s meaning sticking. As a practical matter, donâ€™t count on that construction in a â€œbroadest reasonable interpretationâ€ context without the intervention of the Federal Circuit. Reply link does not work in your browser because JavaScript is disabled. Reply 10 anon says: October 28, 2016 at 7:03 am In an aside to the tendency for sensatonalizing headlines, should we be clear about the difference between â€œinformâ€ and â€œimportâ€â€¦? Reply link does not work in your browser because JavaScript is disabled. Reply 10.1 MM says: October 28, 2016 at 10:10 am Dennisâ€™ headline seems accurate enough. The CAFC could have â€” and probably should have â€” found these junk claims indefinite so that nobody would ever have to worry about them again. Instead they imported limitations from the specification to breath life into this nebulous â€œneutralizerâ€. The patentee, youâ€™ll recall, wanted to construe the term to mean any measuring device which performs the measurement that is used to â€œprovideâ€ the super awesome shoe insert. How would you have re-written the headline? Reply link does not work in your browser because JavaScript is disabled. Reply 10.1.1 anon says: October 28, 2016 at 10:28 am What the patented wanted to do is a separate issue, Malcolm. What the court did was less â€œimportâ€ than it was â€œinform.â€ It is a subtle distinction that in your rush to criticize you have missed. Reply link does not work in your browser because JavaScript is disabled. Reply 10.1.1.1 MM says: October 28, 2016 at 10:37 am What the court did was less â€œimportâ€ than it was â€œinform.â€ It is a subtle distinction LOLOLOLOLOLOLOLOL Sure it is. Reply link does not work in your browser because JavaScript is disabled. Reply 10.1.1.1.1 anon says: October 28, 2016 at 11:05 am What was the point of your reply, Malcolm? Reply link does not work in your browser because JavaScript is disabled. Reply 10.1.1.1.1.1 MM says: October 28, 2016 at 11:09 am Oh, itâ€™s a â€œsubtleâ€ point that you must have missed. Tell everyone how you would rewrite Dennisâ€™ headline, â€œanon.â€ Câ€™mon, man. It should be easy for you, given your mastery of the English language and all its awesome nuances. What are you waiting for? Reply link does not work in your browser because JavaScript is disabled. Reply 10.1.1.1.1.1.1 anon says: October 28, 2016 at 11:25 am My comment was pretty clear already. What part of it has stumped you? Reply link does not work in your browser because JavaScript is disabled. Reply â€¦ MM says: October 28, 2016 at 11:31 am My comment was pretty clear already. What was â€œclearâ€ is that you had some very poorly articulated issue with Dennisâ€™ headline. Whatâ€™s even more â€œclearâ€ is that you have no clue what youâ€™re talking about, and youâ€™re incapable of expressing your allegedly â€œsubtleâ€ points in plain English. But we knew all this about you already. Keep the laughs coming, â€œanonâ€. Youâ€™re a very very serious person. Reply link does not work in your browser because JavaScript is disabled. Reply â€¦ anon says: October 28, 2016 at 11:59 am The articulation is clear. It is even in short declarative sentences that you are always on about. You are the one that seems to not be able to understand that there is a difference between â€œimportâ€ and â€œinform,â€ and your number one meme of ad hominem with accusing others of that which Malcolm does shows immediately (followed by your poker tell of â€œvery, very seriousâ€). â€¦ MM says: October 28, 2016 at 12:07 pm there is a difference between â€œimportâ€ and â€œinform,â€ LOLOLOLOLOLOLOLOL Thereâ€™s a difference between â€œblackâ€ and â€œwhiteâ€, too. Tell everyone how youâ€™d rewrite Dennisâ€™ headline, â€œanon.â€ You popped up here to whine about it but for some bizarre reason instead of showing everyone how youâ€™d rewrite the headline youâ€™ve chosen instead to drivel all over your shirt with some innuendo aobut â€œsubtlety.â€ Again. Friday laughs. Keep â€™em coming, â€œanonâ€! We all love you so much. â€¦ anon says: October 28, 2016 at 1:16 pm Again, Malcolm, your post says nothing. Maybe try saying something (anything) without ad hominem and see if you can make a little sense. Give it a try. â€¦ anon says: October 28, 2016 at 3:14 pm I wonder if Malcolm considers Dave Boundy to be a â€œcohortâ€ of mine or notâ€¦ ğŸ˜‰ â€¦ MM says: October 28, 2016 at 5:07 pm Youâ€™re always free to phone a friend, â€œanon.â€ Ideally once youâ€™ve done so, you can stop your unintelligible yapping and let your mouthpiece take over. But we all know that your yapping isnâ€™t something you can control. â€¦ anon says: October 28, 2016 at 5:57 pm Yet more of you accusing others of that which you doâ€¦.. 9 MaxDrei says: October 28, 2016 at 2:41 am Yet again (at 6.2.2) we are told that the EPO is too â€œpedanticâ€ in its requirement for a written description at the filing date. Yet again we are told that at the EPO drawings cannot provide that written description. Wrong. They can. A strict written description requirement is an artefact of any First to File system, as the USA is going to find out, in the coming years. Any patent system has to balance fair protection for the inventor with reasonable legal certainty for those having to design around. Reply link does not work in your browser because JavaScript is disabled. Reply 9.1 anon says: October 28, 2016 at 5:28 am â€œAny patent system has to balance fair protection for the inventor with reasonable legal certainty for those having to design around.â€ Agreed. Even the pre-AIA US system did that. As does the AIA (but not quite the same as ROW) First Inventor to File system does that. Not seeing what point you are trying to make MaxDrei. Reply link does not work in your browser because JavaScript is disabled. Reply 9.1.1 maxdrei says: October 28, 2016 at 6:23 am My point? That such a balance depends on consistently strict enforcement of a rigorous WD requirement. Without that, one cannot predict whether one is at risk from a published but not yet granted utility pat appln pending in the USPTO. Reply link does not work in your browser because JavaScript is disabled. Reply 9.1.1.1 anon says: October 28, 2016 at 7:06 am The point in reality though, MaxDrei, and the point of the jab at the EPO, was that a TOO strict view is not necessary. That seems to still go over your head. Reply link does not work in your browser because JavaScript is disabled. Reply 9.1.1.1.1 MaxDrei says: October 28, 2016 at 9:31 am Too strict? Granted, there are very many individual Examiners at the EPO who, when examining cases in English, find it difficult reliably to make the correct WD judgement. But that is invariably because their first language is not English (you will recall that EPO Examiners have to operate in all three EPO languages, regardless what is their language at home). In such cases, appeal is often needed, to get to a fair outcome. When you assert that â€œthe EPOâ€ is too strict, show me where this over-strictness manifests itself in the EPOâ€™s â€œestablished caselawâ€ or in its MPEP. Otherwise, your opinion (or that of AAA JJJ) that â€œthe EPOâ€ is over-strict on WD, impresses me not at all. Reply link does not work in your browser because JavaScript is disabled. Reply 9.1.1.1.1.1 anon says: October 28, 2016 at 9:47 am Whether you are impressed or not is one of the least concerns that I would ever have. Mayhaps the problem with your inability to grasp the jabs has to do with your own notion of â€œbeing impressed.â€ That would explain a lotâ€¦ Reply link does not work in your browser because JavaScript is disabled. Reply 9.1.1.1.1.2 AAA JJ says: October 28, 2016 at 12:11 pm â€œOtherwise, your opinion (or that of AAA JJJ) that â€˜the EPOâ€™ is over-strict on WD, impresses me not at all.â€ If slavish pedanticism gets your rocks off, flail away. Whatever. Reply link does not work in your browser because JavaScript is disabled. Reply 9.1.1.1.1.2.1 MM says: October 28, 2016 at 12:19 pm If slavish pedanticism gets your rocks off, flail away Says Mr. â€œAppeal! Appeal! Appeal!â€ We can all be totally sure thereâ€™s no â€œpedanticismâ€ in those appeal briefs. LOL Reply link does not work in your browser because JavaScript is disabled. Reply â€¦ AAA JJ says: October 28, 2016 at 12:54 pm I donâ€™t prosecute applications for gene bits and sequence fragments, and I donâ€™t even have any idea what those are, nor do I care what they are, but Iâ€™m pretty sure if I was handling a case you were examining I would smoke you at the Board. Cuz youâ€™re whole schpiel is nothing more than, â€œCome on your honors, you canâ€™t be serious. Everybody knows this stuff is so old and well known that nobody ever bothered to write it down.â€ Iâ€™ve gotten dozens of reversals of examiners like you. Reply link does not work in your browser because JavaScript is disabled. Reply 9.1.1.1.1.2.2 MaxDrei says: October 29, 2016 at 2:16 pm First, the courts in England construe Art 123(2) and (3) of the EPC at least as strictly as the Boards of Appeal of the EPO. But you know that already, donâ€™t you. Second, that very strictness is just the ticket, when you are being threatened by a patent owner with a claim, amended in prosecution, leaving it directed to an invention that was perceived later than the filing date of the patent application that founded the asserted patent. But you knew that already, didnâ€™t you, with all that experience you have accumulated, over your long career, of patent disputes in First to File country; oppositions, revocation actions and nullity suits under the EPC. Third, you seem to be fond of asserting that others here are too old to see the big picture, all the way from one side to the other . That gives me a clue to your own perceptions, junior. Reply link does not work in your browser because JavaScript is disabled. Reply 9.1.1.1.2 MM says: October 28, 2016 at 10:46 am the jab at the EPO, was that a TOO strict view is not necessary Itâ€™s not â€œtoo strictâ€ for most grown ups. Its just the way it is, for good reasons. But it easy to understand why less competent patent attorneys, accustomed to being coddled by the USPTO, would find international practice difficult. Of course, most of us competent prosecutors didnâ€™t cut our teeth claiming methods of â€œautomaticallyâ€ sending lists of DVD recommendations by email or other cessp00l â€œtechnologies.â€ Reply link does not work in your browser because JavaScript is disabled. Reply 9.1.1.1.2.1 anon says: October 28, 2016 at 11:05 am Your feelings are noted. Reply link does not work in your browser because JavaScript is disabled. Reply 9.1.1.1.2.2 AAA JJ says: October 28, 2016 at 12:05 pm â€œOf course, most of us competent prosecutors didnâ€™t cut our teethâ€¦â€ We know. You were cloning zygotes in your momâ€™s basement and writing cutting edge BASIC programs on your Commodore 64 when we were still in diapers. Thanks for the laughs, Grandpa. Reply link does not work in your browser because JavaScript is disabled. Reply 9.1.1.1.2.2.1 MM says: October 28, 2016 at 12:17 pm Dear AAA JJ and â€œanonâ€, There really are patent prosecutors out there whose life doesnâ€™t revolve around shoveling pure junk at the PTO and appealing it ad nauseum whenever you arenâ€™t crying on a patent blog about the mean old examiners and â€œstar chambersâ€ that are oh-so-unfair to you. Just because they never wanted to work alongside you doesnâ€™t mean those patent prosecutors donâ€™t exist. Keep struggling, though! You make a great team and eventually the tiny green shoot of your combined intellectually prowess will poke up through the sand and weâ€™ll all know how awesome you both are. P.S. Be sure to keep telling your clients that they donâ€™t need to define critical elements in their claims because â€œdrawingsâ€! Youâ€™ll have cashed their checks long before they discover that you were just beinâ€™ lazy. Reply link does not work in your browser because JavaScript is disabled. Reply â€¦ AAA JJ says: October 28, 2016 at 12:48 pm Iâ€™ll explain it to you again, Grandpa: Iâ€™m in-house at a Fortune 10 company. My docket is about 40% mechanical (think TC 3700), about 40% materials (think TC 1700), and about 20% semiconductors (think TC 2800). But keep cutting and pasting from your script that anybody who disagrees with you is a â€œsoftie woftieâ€ or a â€œdo it on a compooterâ€ â€œb0tt0m f##d!ng patent fl$ff#r.â€ Itâ€™s so original. Maybe you can get the people who are paying you to post here to write you some new material. Reply link does not work in your browser because JavaScript is disabled. Reply â€¦ anon says: October 28, 2016 at 1:22 pm Itâ€™s been a Decade, AAA JJ â€“ why would Malcolm change now? â€¦ AAA JJ says: October 28, 2016 at 1:25 pm I would say itâ€™s possible that the people who â€œwriteâ€ the â€œjokesâ€ on the new Matt LeBlanc sitcom are probably the same as the people who â€œwriteâ€ Mooneyâ€™s â€œjokesâ€ but that would be an insult to Mattâ€™s writers. â€¦ MM says: October 28, 2016 at 1:40 pm the new Matt LeBlanc sitcom Wow. Maybe the pendulum is swinging back. â€¦ anon says: October 28, 2016 at 1:58 pm Malcolm, again with â€œthe pendulumâ€ when neither AA JJ nor I have ever made reference to thatâ€¦? Because anyone not agreeing with you must all â€œthink the sameâ€ or somethingâ€¦.? â€¦ AAA JJ says: October 28, 2016 at 1:12 pm For filterâ€™s sake: Iâ€™ll explain it to you again, Grandpa: Iâ€™m in-house at a Fortune 10 company. My docket is about 40% mechanical (think TC 3700), about 40% materials (think TC 1700), and about 20% semiconductors (think TC 2800). But keep cutting and pasting from your script that anybody who disagrees with you is a â€œs0ftie w0ftie.â€ Itâ€™s so original. Maybe you can get the people who are paying you to post here to write you some new material. Reply link does not work in your browser because JavaScript is disabled. Reply â€¦ MM says: October 28, 2016 at 1:32 pm Iâ€™m in-house at a Fortune 10 company. Ah, well, we all know that the most detail-oriented and diligent patent prosecutors end up in-house at Fortune 10 companies. Thereâ€™s no corner cutting or â€œjust file itâ€ mentality there! Everybody knows that. Let â€œGrampsâ€ give you a little lesson: thereâ€™s a big difference between a well-drafted specification, on one hand, and â€œwhat you can get away with when nobodyâ€™s looking closelyâ€ on the other. Everybody in the business knows the difference. If youâ€™re an expert at the latter, well, congrats to you. Collect your paycheck and be happy. But defending lazy drafting practices just makes you look, well, lazy. And immature. Also, experience means nothing if you donâ€™t learn from it. The only reason Iâ€™ve ever brought up my background here is to address the mewlings of puffed-up script-reciting bl0whards who insist that anyone who doesnâ€™t love s0ftware patents as much as they do has never seen a computer or a patent before. But you knew that already. â€¦ AAA JJ says: October 28, 2016 at 1:41 pm â€œLet â€œGrampsâ€ give you a little lessonâ€¦â€ No thanks. Save it for somebody who cares. â€œThereâ€™s no corner cutting or â€˜just file itâ€™ mentality there! Everybody knows that.â€ Your cluelessness is showing. Prolly those examiner tendencies creeping in. â€œThe only reason Iâ€™ve ever brought up my background here is to address the mewlings of puffed-up script-reciting bl0whardsâ€¦â€ Thatâ€™s you. Go back and read the last 10,000 or so posts youâ€™ve made. â€¦ anon says: October 28, 2016 at 2:03 pm LOL â€“ AAA JJ, youâ€™ve noticed Malcolmâ€™s number one meme of Accusing Others Of That Which Malcolm Does. This has been noted so often that the mere acronym has found its way to the â€œpolitically incorrectâ€ cen cen list and is blocked. Pity that that same cen cen list cannot block the blight itself. Oh well, maybe Prof. Crouch did not want to buy pizzas for the local college boys down at the coffee shop this past weekend (or any other weekend over the last past ten years ğŸ˜‰ ) 8 Atari Man says: October 27, 2016 at 4:03 pm Dennis, please include the names of the judges on the panel in your write-ups. We all know that, as a practical matter, the outcome in many CAFC panel decision is dependent on the composition of that panel, so that information is helpful in putting a given decision in the proper context. (Here it was Prost, Taranto and Hughes.) Reply link does not work in your browser because JavaScript is disabled. Reply 8.1 Patent Investor says: October 27, 2016 at 5:57 pm Is there a decent reference point out there for the attitude of the CAFC judges toward patents? Iâ€™m sure several here could make a list if they so desired. Reply link does not work in your browser because JavaScript is disabled. Reply 8.1.1 Yes says: October 28, 2016 at 7:45 am Here are there Section 101 scorecards. link to bilskiblog.com Reply link does not work in your browser because JavaScript is disabled. Reply 8.1.2 MM says: October 28, 2016 at 10:40 am Patent Investor Hereâ€™s a suggestion: donâ€™t invest in patents whose validity hinges on the panel of CAFC judges who might hear the appeal. Reply link does not work in your browser because JavaScript is disabled. Reply 8.1.2.1 anon says: October 28, 2016 at 12:01 pm The one-way editing is itself pretty funny here Prof. Crouch. Reply link does not work in your browser because JavaScript is disabled. Reply 7 RandomGuy says: October 27, 2016 at 3:28 pm Bad law. Novelty claimed by function rather than structure so they write in the structure to save the claim. Should have reversed construction and let entire claim fail under 112a or 101. Here we see the very threat of overbreadth that Morse, Wabash, Halliburton, etc fear â€“ Applicant posits two ways of achieving a functional result, defendant clearly invented a third, unposited manner, and rather than the law rewarding him with his own patent he is put on trial as an infringer. There is zero record evidence that the infringerâ€™s manner of achieving the result was posited by the patentee, or else the construction would not be dispositive of the case. The office needs to properly train the examiners to recognize the functionally claimed invalidity to protect the later-inventor. Or what some short sighted people on here call â€œbeing anti patentâ€.â€ Reply link does not work in your browser because JavaScript is disabled. Reply 7.1 RandomGuy says: October 27, 2016 at 3:35 pm Btw, between this and the previous wrongly decided â€œno strong presumption of â€˜means forâ€™ invoking/not invoking 112fâ€ case, the federal circuit is setting itself up to decide a claim as â€œentirely invalidâ€ or â€œvalid but limited to embodiments in specâ€ at will. Reply link does not work in your browser because JavaScript is disabled. Reply 7.1.1 MM says: October 27, 2016 at 4:10 pm the federal circuit is setting itself up to decide a claim as â€œentirely invalidâ€ or â€œvalid but limited to embodiments in specâ€ at will. That game has been going on for years. I canâ€™t remember whose on which team anymore but thereâ€™s at least one CAFC judge still inclined to read limitations into claims to preserve their validity where the spec describes just one species (e.g., â€œa contoured Xâ€) but somehow (so mysterious!) the claim, on its face, recites just the generic â€œXâ€. Reply link does not work in your browser because JavaScript is disabled. Reply 7.1.2 anon says: October 28, 2016 at 8:18 am â€œprevious wrongly decided â€œno strong presumption of â€˜means forâ€™ invoking/not invoking 112fâ€â€ Which case and exactly why â€œwrongly decidedâ€â€¦? I mean if course, more than just your feelings or desired view of the lawâ€¦ Reply link does not work in your browser because JavaScript is disabled. Reply 7.2 MM says: October 27, 2016 at 4:01 pm Whatâ€™s hilariously desperate about the patenteeâ€™s theory of the case is how the claims read if we use the patenteeâ€™s definition of â€œneutralizerâ€, i.e., â€œjust some kind of measuring device.â€ Letâ€™s ignore the silliness of repeating the steps for each foot (surely that wasnâ€™t necessary for patentability). A method of fitting an individual with a shoe insert which places the ankle of the individual in a neutral position comprising the steps of: having the individual place one foot on some kind of measuring device while elevating the other foot off of said measuring device; using the measuring device to determine the angle necessary to place the foot in a neutral position; providing an insert having an angle which represents the neutral state for the foot Wow. Just â€¦ wow. Reply link does not work in your browser because JavaScript is disabled. Reply 7.3 MM says: October 27, 2016 at 4:15 pm The odds of a nearly identical claim out there â€œwherein said neutralizer comprises a computer configured to calculate the angleâ€ must be close to 100%. Totally different issues, of course. Totally. Reply link does not work in your browser because JavaScript is disabled. Reply 7.4 Ned Heller says: October 28, 2016 at 6:26 am Random, I think the problem is the claim is (at least potentially) indefinite. If a person of ordinary skill in the art cannot tell with reasonable certainty what the scope of the claim is, then the claim is invalid. Here, if what a neutralizer is was clearly defined in the specification, then I believe there is no problem with definiteness. However if that is not the case from reading the specification, and the prosecution history provides no reliable definition, then it is also indefinite. In this case I believe that the court might be right that the claim term at issue, neutralizer, was clearly defined in the parentâ€™s prosecution history. That is what saved this patent from being invalid. We get into scope issues if resort to the specification/prosecution history provides no definite structure â€“ here for example if the specification only said that a neutralizer was anything that performed a neutralizing function. Reply link does not work in your browser because JavaScript is disabled. Reply 7.4.1 anon says: October 28, 2016 at 7:20 am Ned, Under your â€œreasoning,â€ ALL claims are â€œpotentially indefiniteâ€ because we have to use this thing called language (in the view of â€œThis is not a pipeâ€). Breadth is simply not the same as indefinitenes. No matter how many times it appears that certain people may want to conflate the two. Reply link does not work in your browser because JavaScript is disabled. Reply 7.4.1.1 MM says: October 28, 2016 at 10:50 am Breadth is simply not the same as indefinitenes. Sometimes it is, sometimes it isnâ€™t. Different aspects of the patent statutes are informed by many of the same considerations. It should surprise nobody that a junk claim fails under multiple tests. And in many instances it doesnâ€™t particularly matter which one you choose. Invariably the folks who hyperventilate about the hardest about the differences are the same folks who never saw a junky patent claim they couldnâ€™t embrace and slober over. And we all know who Iâ€™m talking about. Reply link does not work in your browser because JavaScript is disabled. Reply 7.4.1.1.1 anon says: October 28, 2016 at 11:08 am It is not. Ever. You may have separation items occurring at the same time though. But that does not mean that you should attempt to conflate these two very different things. That path is merely obfuscation. Reply link does not work in your browser because JavaScript is disabled. Reply 7.4.1.1.1.1 anon says: October 28, 2016 at 11:27 am Separation ==> separate Reply link does not work in your browser because JavaScript is disabled. Reply 6 MM says: October 27, 2016 at 10:57 am Bookend provided by todayâ€™s CAFC decision in GE Lighting: As GEâ€™s expert admitted, an ordinarily skilled artisan cannot, without additional information, differentiate an â€œelongatedâ€ core from a â€œnon-elongatedâ€ core. â€œElongatedâ€ appears nowhere in the specification, nor, as GE admits, are the coreâ€™s dimensions otherwise described in text or drawings. And in the prosecution history, GE distinguished two prior art references disclosing heat sinks â€¦ as not containing an â€œelongatedâ€ element. This patent should never have left the PTO and if the PTO wants to pretend to be concerned about â€œpatent qualityâ€ it should apologize to the public for its rank incompetence here (and elsewhere) and teach applicants that they will never be allowed to overcome the prior art be relying on unsupported, much less undefined, claim terms that have been pulled from the ether. Reply link does not work in your browser because JavaScript is disabled. Reply 6.1 Les says: October 27, 2016 at 11:03 am But everyone knows what elongated means. Is a not very complicated portion of the English language. GEâ€™s expert was probably nervous. Of course he knows what elongated means. It means the item is long compared to its widthâ€¦. at least about 4 or 5 times longer than wide. Reply link does not work in your browser because JavaScript is disabled. Reply 6.1.1 MM says: October 27, 2016 at 11:08 am I canâ€™t tell if youâ€™re being sarcastic or not. It means the item is â€¦ at least about 4 or 5 times longer than wide In what dictionary did you find this definition? Not that it matters. You arenâ€™t allowed to â€œinventâ€ around the prior art by reaching into the void and grabbing limitations that you failed to include in your specification. Yes, we all know that the s0ftie w0ftie crowd was brought up to believe differently but, hey, everybody has to grow up sometime. Reply link does not work in your browser because JavaScript is disabled. Reply 6.1.1.1 anon says: October 27, 2016 at 11:29 am S0ftie w0ftieâ€¦? You just canâ€™t help yourself, can you Malcolm? Seek help for that 0bsess10n. Reply link does not work in your browser because JavaScript is disabled. Reply 6.1.1.1.1 MM says: October 27, 2016 at 11:31 am Says the guy who snarked about computers a half hour before my comment. But youâ€™re totally not a hypocrite! Nope. Not you. Reply link does not work in your browser because JavaScript is disabled. Reply 6.1.1.1.1.1 anon says: October 27, 2016 at 11:47 am Lol â€“ my â€œsnarkâ€ presages your actual â€œgoing there.â€ The fact that you saw that and still went there only shows just how 0bsessed YOU are. But thanks for pointing that out, O master clutcher of the shovel! Reply link does not work in your browser because JavaScript is disabled. Reply 6.1.1.2 Les says: October 27, 2016 at 11:43 am Having notably more length than width; being long and slender. usage: â€œan elongate tail tapering to a pointâ€; â€œthe old manâ€™s gaunt and elongated frameâ€ link to powerthesaurus.org Reply link does not work in your browser because JavaScript is disabled. Reply 6.1.1.3 tourbillon says: October 27, 2016 at 11:47 pm In what dictionary have you found the definition of â€œabstractâ€ hot shot? You have no problem when it comes to knowing what that undefined term means but at â€œelongatedâ€ you suddenly become befuddled. Reply link does not work in your browser because JavaScript is disabled. Reply 6.1.1.3.1 anon says: October 28, 2016 at 5:30 am A bit like when he became befuddled when the word â€œeffectivelyâ€ was in play awhile back. His selectivity is just sooo awesome. Reply link does not work in your browser because JavaScript is disabled. Reply 6.1.1.3.2 Les says: October 28, 2016 at 9:44 am Well said, sir. Reply link does not work in your browser because JavaScript is disabled. Reply 6.1.1.3.3 MM says: October 28, 2016 at 10:25 am In what dictionary have you found the definition of â€œabstractâ€ hot shot? You have no problem when it comes to knowing what that undefined term means but at â€œelongatedâ€ you suddenly become befuddled. And this is why nobody should ever take the s0ftie w0ftieâ€™s seriously. Welcome to elementary school, tourb! Itâ€™s a big step up from kindergarten. Youâ€™re going to miss the graham crackers. Nobodyâ€™s â€œbefuddledâ€ by the definition of â€œelongated.â€ There are two problems here. First, the term doesnâ€™t appear anywhere in the applicantâ€™s specification and until the applicant was presented with prior art there was no suggestion anywhere that an â€œelongatedâ€ anything was worthy of protecting. Second, the definition of â€œelongatedâ€ is a relative term and even if the prior art failed to show an â€œelongatedâ€ thing, there is no way that the mere recitation of â€œelongatedâ€ is going to make your claim non-obvious. This is basic stuff but, hey, Iâ€™m used to explaining basic stuff to ign0rant patent attorneys for whom every day is a profound intellectual struggle. Just learn how to write a patent application, guys. Grow up, stop whining, and learn how to do it right. Also, stop lying to your clients about all the awesome tricks you know for avoiding doing any work, learning about the prior art, or disclosing anything in meaningful detail. Itâ€™s gr0ss and it makes the whole profession look sleazy. Thanks, guys. LOL â€” who am I kidding? Youâ€™re born b0ttom-feeders and thatâ€™s never going to change. Reply link does not work in your browser because JavaScript is disabled. Reply 6.1.1.3.3.1 anon says: October 28, 2016 at 11:28 am And there goes Malcolm making his usual ad hominem accusationsâ€¦ Happy Decade of Decadence. Reply link does not work in your browser because JavaScript is disabled. Reply 6.1.1.3.3.2 anon says: October 28, 2016 at 12:04 pm A patent doctrine that you might find helpful to understand here Malcolm is the doctrine of inherency. It matters not at all whether something â€œseemedâ€ unimportant until any particular art was brought into the examination. I do not know why you would feel such. Reply link does not work in your browser because JavaScript is disabled. Reply 6.1.1.3.3.2.1 MM says: October 28, 2016 at 12:21 pm A patent doctrine that you might find helpful to understand here Malcolm is the doctrine of inherency. Maybe someday weâ€™ll all have a laugh about the irony of you pretending that I donâ€™t understand â€œthe doctrine of inherency.â€ In the meantime â€¦. LOL Reply link does not work in your browser because JavaScript is disabled. Reply â€¦ anon says: October 28, 2016 at 2:09 pm Rather than any faux pretending, perhaps you can simply adjust your usual scripts to reflect this (unseen) knowledge that you now seem to want to claim to have. Hint: your â€œfeelingsâ€ do not show any awareness of that doctrine. Reply link does not work in your browser because JavaScript is disabled. Reply 6.1.1.4 mike says: October 28, 2016 at 8:38 am Doesnâ€™t elongated merely mean a structure that is longer than it is wide? Reply link does not work in your browser because JavaScript is disabled. Reply 6.1.1.4.1 MM says: October 28, 2016 at 10:36 am Mike: Doesnâ€™t elongated merely mean a structure that is longer than it is wide? According to the opinion, that wouldnâ€™t have sufficed to get around the prior art in this case. Got any other definitions? Thereâ€™s one out there about â€œunusually lengthenedâ€. You think thatâ€™s â€œdefiniteâ€? Hereâ€™s the deal: applicants need to learn how to write an application. That means you understand whatâ€™s in the prior art and you include the terms and definitions of terms that you need to rely on to distinguish your claim from the art. It really isnâ€™t that difficult. But that assumes that somebody actually innovated something that you can patent. Reply link does not work in your browser because JavaScript is disabled. Reply 6.1.2 MaxDrei says: October 27, 2016 at 11:16 am Something that is much longer than it is wide is elongate. Elongated is what an elastic band is, when you are stretching it. So I for one am not sure, Les, that everyone agrees, on what â€œelongatedâ€ means. Reply link does not work in your browser because JavaScript is disabled. Reply 6.1.2.1 MM says: October 27, 2016 at 11:29 am Thereâ€™s no requirement for â€œmuch longerâ€ in the definition of â€œelongated.â€ Itâ€™s a relative term. If something is normally round and I stretch it a tiny bit along one axis, it is now â€œelongatedâ€ relative to the â€œnormalâ€ version. The relative nature of the adjective is the source of the ambiguity. Granted, there might be situations where the degree of elongation isnâ€™t critical to â€œthe inventionâ€. But thatâ€™s certainly not this case here, nor would it be wise to ever include such a term without a definition and a back up disclosure of more specific parameters. All this assumes that there is an actual â€œinnovationâ€ involved as opposed to scrivening for monetizationâ€™s sake. Reply link does not work in your browser because JavaScript is disabled. Reply 6.1.2.2 Les says: October 27, 2016 at 11:48 am I said everyone knows. Not that they agree. You will find infringers that disagree with the patent owner about the meaning of every word. Patents cannot define every word included in the patent. Where would one fine the definition of the words in the definitions? I suppose its possible to draft a self contained application wherein only words defined in the application are used in the application. But the destinations would have to be circular on the wholeâ€¦. Anyway, its clear that the Examiner new what elongated meant and the Examiner must have felt elongated was supported by the specification else there would have been an new matter rejection. Reply link does not work in your browser because JavaScript is disabled. Reply 6.1.2.2.1 MM says: October 27, 2016 at 12:29 pm the Examiner must have felt elongated was supported by the specification else there would have been an new matter rejection. Or the Examiner was on drugs. Reply link does not work in your browser because JavaScript is disabled. Reply 6.1.2.2.1.1 AAA JJ says: October 27, 2016 at 2:10 pm Or maybe the examiner is an EXPERT whoâ€™s examined and allowed 500+ patents. Maybe. Reply link does not work in your browser because JavaScript is disabled. Reply 6.1.2.2.1.1.1 PatentBob says: October 27, 2016 at 2:47 pm Has anyone ever seen MM say anything nice about anyone at any time? I canâ€™t remember a case. Heâ€™s here to put people down. He wants people to leave so that this is his forum (more that it already is â€” pretty much every post seems to become MMâ€™s playground). If you disagree with him, prepare to meet his wrath. Reply link does not work in your browser because JavaScript is disabled. Reply â€¦ anon says: October 27, 2016 at 3:13 pm PatentBob, It has only been going on like thatâ€¦. â€¦for a DECADE. Reply link does not work in your browser because JavaScript is disabled. Reply â€¦ MM says: October 27, 2016 at 4:03 pm I canâ€™t remember a case. Iâ€™m trying to remember why anyone should care what you remember about anything. Maybe you can refresh our collective memories? Reply link does not work in your browser because JavaScript is disabled. Reply â€¦ anon says: October 27, 2016 at 4:37 pm LOL â€“ maybe something about â€œecosystemâ€â€¦. Nahâ€¦ ğŸ˜‰ 6.1.2.2.1.2 Les says: October 27, 2016 at 3:17 pm I canâ€™t tell if you being sarcastic or not. Reply link does not work in your browser because JavaScript is disabled. Reply 6.2 MaxDrei says: October 27, 2016 at 11:23 am Itâ€™s particularly egregious when Applicant, having plucked â€œelongatedâ€ out of thin air, then has the bare-faced cheek to assert, in support of patentability, that none of the references discloses teaches or suggests â€œelongatedâ€. A PTO Examiner of ordinary skill in the patent examining arts might at that point hoist that Applicant with his own petard, by quietly enquiring of Applicant: â€œOK. That may be so but, by the same token, where in the application as filed do you announce that â€œelongatedâ€ is the invention here? Reply link does not work in your browser because JavaScript is disabled. Reply 6.2.1 6 says: October 27, 2016 at 1:32 pm I have to do this at least 4x a year. Reply link does not work in your browser because JavaScript is disabled. Reply 6.2.2 AAA JJ says: October 27, 2016 at 2:06 pm â€œItâ€™s particularly egregious when Applicant, having plucked â€˜elongatedâ€™ out of thin air, then has the bare-faced cheek to assert, in support of patentability, that none of the references discloses teaches or suggests â€˜elongatedâ€™.â€ It wasnâ€™t â€œplucked out of thin air.â€ It was clearly shown in the drawings. Drawings can provide written description support. Maybe not in the over infantilized, hyperpedantic EPO, but weâ€™re not talking about the EPO. â€œA PTO Examiner of ordinary skill in the patent examining arts might at that point hoist that Applicant with his own petard, by quietly enquiring of Applicant: â€˜OK. That may be so but, by the same token, where in the application as filed do you announce that â€˜elongatedâ€™ is the invention here?'â€ Again, itâ€™s in the drawings. You might want to see Vas-Cath: â€œThese cases support our holding that, under proper circumstances, drawings alone may provide a â€˜written descriptionâ€™ of an invention as required by Â§ 112.â€ So examiners are experts, huh? Interesting. I do hear that a lot. I hear it, of course, from the examiners themselves. I hear it from appeals court judges too. When it suits the conclusion based decision they are rendering. Of course, in this case, the examiner, oh excuse me!, I mean THE EXPERT, saw the amendment to add â€œelongatedâ€ and considered it to have written description support, and to define over the prior art. So now the so-called EXPERT is apparently a complete dolt. Interesting. Reply link does not work in your browser because JavaScript is disabled. Reply 6.2.2.1 MM says: October 27, 2016 at 2:32 pm Drawings can provide written description support. If the drawing being relied on to bring a new term into the claim is a drawing of an embodiment of the invention as opposed to an embodiment of a component of the invention, then the claim in which that term appears needs to be limited to whatâ€™s depicted in the drawing. If you donâ€™t like that result, learn how to draft an application properly. Itâ€™s really not that hard. Of course, you might have to actually understand the prior art instead of burying your head in the sand, pretending you were born yesterday and loading your application with a bunch of nonsense that youâ€™ll massage later. Oh, right, and I also forgot: Appeal, appeal, appeal! Because thatâ€™s another way to waste your s@cker clientâ€™s money. By the way, are you also advising your clients that the â€œpendulum is swinging backâ€ as other malpractice artists seem to be doing? Better grab that cash fast and run to the bank â€¦. Reply link does not work in your browser because JavaScript is disabled. Reply 6.2.2.1.1 AAA JJ says: October 27, 2016 at 2:46 pm â€œâ€¦and I also forgot: Appeal, appeal, appeal! Because thatâ€™s another way to waste your s@cker clientâ€™s money.â€ Itâ€™s simply amazing that youâ€™re the only person on this site that 1) knows how to draft an application, 2) has never committed inequitable conduct, and 3) has all the â€œsophisticatedâ€ clients. My clients are pretty happy with my appeals. Because I win. And they get what they are entitled to. You should try it sometime. But if your super sophisticated clients are content for you to get them picture claims, whatever. None of my business. Reply link does not work in your browser because JavaScript is disabled. Reply 6.2.2.1.1.1 MM says: October 27, 2016 at 3:23 pm youâ€™re the only person on this site that 1) knows how to draft an application, 2) has never committed inequitable conduct, and 3) has all the â€œsophisticatedâ€ clients. Hey, if you say so. Whatâ€™s amazing is the number of so-called â€œpatent attorneysâ€ who pop up in the wake of decisions like this one to defend the worst drafting practices out there. Go ahead and keep appeal!appeal!appealing! your poorly drafted cases. Yes, the patent attorneys do win when they can convince their clients that such appeals are just part of the cost of doing business. After all, â€œthe pendulum is swinging backâ€ and before we know it every junky functional claim littered with undefined abstract terms pulled out of the ether is going to be worth a zillion dollars. Itâ€™d be a shame to miss out! Some patent attorney on a blog told us so. So keep throwing money at your favorite patent attorney. They donâ€™t have enough money yet. Reply link does not work in your browser because JavaScript is disabled. Reply 6.2.2.1.2 anon says: October 28, 2016 at 5:37 am â€œIf the drawing being relied on to bring a new term into the claim is a drawing of an embodiment of the invention as opposed to an embodiment of a component of the invention, then the claim in which that term appears needs to be limited to whatâ€™s depicted in the drawing.â€ Doctor, heal thyself. Try those short declarative sentences you are always on about. â€œ learn how to draft an application properlyâ€ LOL â€“ and then in reply you kind of abandon this statement. It appears that what you mean by â€œproperlyâ€ Malcolm, is where your pedantic nature abounds. (and love how you attempt to lump AAA JJ into the â€œeveryone else must all believe the same stuffâ€ crowdâ€ with the pendulum comment. Has AAA JJ ever given any indication whatsoever that he believes such? Hint: no. But why let that get in the way of your scripted reply, eh?) Reply link does not work in your browser because JavaScript is disabled. Reply 6.2.2.2 Les says: October 27, 2016 at 3:20 pm Is it? I looked at the figs. And as best as I can tell the thing looks coin shaped. Reply link does not work in your browser because JavaScript is disabled. Reply 6.3 slaffles says: October 27, 2016 at 11:50 am link to patentimages.storage.googleapis.com Figures 1 and 2 of the subject patent. Core is 62, goes from 60 to 64 (the fin like things). It looks longer than it is wide â€“ so I would say inherently disclosed. Yes, the spec doesnâ€™t use the term â€œelongatedâ€ but the Figure shows it. Now, that does actually answer the question that the litigation asked â€“ what the f does â€œelongatedâ€ mean under 112(b) [really, 112, 2nd Paragraph, because it is pre-AIA]. Reply link does not work in your browser because JavaScript is disabled. Reply 6.4 AAA JJ says: October 27, 2016 at 12:21 pm â€œâ€¦teach applicants that they will never be allowed to overcome the prior art be relying on unsupported, much less undefined, claim terms that have been pulled from the ether.â€ Unlike DNA bits and protein fragments, many electrical and mechanical inventions include drawings as part of the disclosure. Relying on the drawingsâ€™ disclosure, and what one of ordinary skill in the art would understand from the drawings, without going into painstaking written detail as to any, and every, possible feature that the drawings disclose is part of the grown up arts that are electrical and mechanical. Reply link does not work in your browser because JavaScript is disabled. Reply 6.4.1 MM says: October 27, 2016 at 12:36 pm Did I say that drawings donâ€™t constitute support? No, I didnâ€™t. And it goes without saying that if youâ€™re only support for a newly introduced claim term is found in a drawing, then be prepared to have the claim in which that term appears limited to what appears in that drawing. Also, I know this hard for a person with a limited technological background (i.e., you) to understand, but biotech applications typically include drawings. Competent grown up practitioners still try to define their terms, particular the key terms. The failure to do so is almost always indicative of incompetence or chicanery. But competent practitioners know this already. [shrugs] Reply link does not work in your browser because JavaScript is disabled. Reply 6.4.1.1 AAA JJ says: October 27, 2016 at 1:26 pm The only person on this site impressed with your understanding of nucleic acids and the awesome FORTRAN programs you wrote as a post doc is yourself. Reply link does not work in your browser because JavaScript is disabled. Reply 6.4.1.1.1 anon says: October 28, 2016 at 5:37 am He is a legend (and guardian of those special fields of rye) in his own mind. Reply link does not work in your browser because JavaScript is disabled. Reply 6.5 AAA JJ says: October 27, 2016 at 12:24 pm â€œAs GEâ€™s expert admitted, an ordinarily skilled artisan cannot, without additional information, differentiate an â€˜elongatedâ€™ core from a â€˜non-elongatedâ€™ core.â€ Thatâ€™s some pretty turrible witness prep. I would expect better. Reply link does not work in your browser because JavaScript is disabled. Reply 6.5.1 MM says: October 27, 2016 at 12:31 pm Thatâ€™s some pretty turrible witness prep. I would expect better. Not everybody is as comfortable with perjuring themselves as you are, AAA JJ. Reply link does not work in your browser because JavaScript is disabled. Reply 6.5.1.1 AAA JJ says: October 27, 2016 at 1:29 pm Way to miss the point. Not preparing the witness to testify on the â€œordinary and customaryâ€ meaning of the claim terms is terrible practice. No need for perjury. But as we all know you consider yourself the only person on this site to never have committed inequitable conduct, itâ€™s not surprising. Good for you. Reply link does not work in your browser because JavaScript is disabled. Reply 6.5.1.1.1 MM says: October 27, 2016 at 2:22 pm Those of us who have litigated (at least) know that some cases are born l0sers. In those cases, itâ€™s often not too difficult to get the l0sing sideâ€™s expert to admit the truth, regardless of the amount of time spent â€œprepping.â€ This wasnâ€™t about looking up the dictionary definition of the term â€œelongated.â€ Itâ€™s about what exactly does the term â€œelongatedâ€ mean in the context of this technology. And the truthful answer is that you canâ€™t answer the question with any degree of specificity without â€œadditional information.â€ Note that with respect to the prior art which was allegedly distinguished as being â€œnon-elongatedâ€, the CAFC opinion observes that â€œthe disk â€¦ and the plate â€¦ [in each of the cited references] both extend in lengthâ€. But, according to the applicant, somehow those articles werenâ€™t â€œelongatedâ€. Why should the public be forced to play this game with patentees, at the cost of hundreds of thoudands of dollars? Applicants need to learn how write specifications, and the PTO needs to learn how to say â€œnoâ€ to its â€œstakeholdersâ€ when they venture far beyond the borders of the playground. Reply link does not work in your browser because JavaScript is disabled. Reply 6.5.1.1.1.1 AAA JJ says: October 27, 2016 at 2:42 pm â€œWhy should the public be forced to play this game with patentees, at the cost of hundreds of thoudands of dollars?â€ Wasnâ€™t aware that â€œthe publicâ€ was being sued in this case. Reply link does not work in your browser because JavaScript is disabled. Reply 6.5.1.1.1.1.1 anon says: October 27, 2016 at 3:17 pm In Malcolmâ€™s mind, the field of rye he protects is for ALL OTHERS except those E V I L patent holdersâ€¦. Reply link does not work in your browser because JavaScript is disabled. Reply 6.5.1.1.1.1.2 MM says: October 27, 2016 at 3:25 pm Wasnâ€™t aware that â€œthe publicâ€ was being sued in this case. Ah yes: patents donâ€™t really exist and have no impact on the public until the lawsuit is filed. Is this the latest script du jour? Reply link does not work in your browser because JavaScript is disabled. Reply 6.5.1.1.1.2 anon says: October 28, 2016 at 5:40 am â€œThose of us who have litigated (at least) know that some cases are born l0sers. In those cases, itâ€™s often not too difficult to get the l0sing sideâ€™s expert to admit the truth, regardless of the amount of time spent â€œprepping.â€â€ What delightful spin. Of course, this is exactly NOT what AAA JJ was saying. But hey, you managed to imply your own â€œgreatnessâ€ again, while moving those goalposts. How charming. Maybe now you want to go back and talk about what AAA JJ was actually talking aboutâ€¦. Reply link does not work in your browser because JavaScript is disabled. Reply 5 MM says: October 27, 2016 at 10:39 am according to ProFoot, a neutralizer should be defined based upon its functional ability rather than any particular physical elements. Hilarious. The â€œneutralizerâ€ is the key component to the method. The steps that donâ€™t recite the use of the â€œneutralizerâ€ simply recite â€œproviding the insertâ€ which has an angle â€œrepresentingâ€ the â€œneutral stateâ€ determined through use of â€¦ (wait for it) â€¦ the â€œneutralizer.â€ What a piece of junk. One question that I have here involves the courtâ€™s use of prosecution history as providing â€œevidence of the inventorâ€™s understanding of neutralizer.â€ The court has previously held that inventorâ€™s understanding of claim meaning is not directly relevant to claim construction. Rather, the focus is on the objective meaning understood by someone of ordinary skill in the art. Dennis, I think the prohibition on consideration of â€œthe inventorâ€™s understandingâ€ is narrower than you make it appear in your discussion here. Certainly the inventorâ€™s testimony about what he/she â€œunderstoodâ€ a claim term to mean canâ€™t trump the meaning of the term identified through the lens of Phillips. But thereâ€™s no avoiding the fact that when the Phillips methodology is followed, the court (standing in the shoes of one of ordinary skill) will at times be trying to figure out what â€œthe inventorâ€ (or the inventorâ€™s attorney) must have â€œmeantâ€ when he/she used or relied on certain words. The problem for claim interpreters arises in situations, as in this case, where â€œthe inventorâ€ uses a term to mean whatever is convenient at the moment. In such situations, the claim should be deemed indefinite or at least interpreted against the applicant/patentee. Reply link does not work in your browser because JavaScript is disabled. Reply 5.1 Paul F. Morgan says: October 27, 2016 at 1:49 pm I think Dennis asked a good question, and that you will find case law indicating that what the inventor now says he personally subjectively meant by a word in a claim is not relevant to what that word objectively means for a 103 [POSITA] test, and does not overcome intrinsic evidence. Of course the inventorâ€™s testimony could presumably be used to present evidence of what others in his field thought such a word meant at the filing date, if he had such evidence? Reply link does not work in your browser because JavaScript is disabled. Reply 5.1.1 anon says: October 27, 2016 at 8:00 pm Paul, see post 3, below. Reply link does not work in your browser because JavaScript is disabled. Reply 5.1.1.1 Paul F. Morgan says: October 28, 2016 at 8:46 am â€œBeing your own lexicographerâ€ refers to defining claim terms in the spec itself, and is clear intrinsic evidence. An attempt to better define a claim term in application prosecution history arguments, even if effective, could be considered an admission against interest and/or prosecution history estoppel. Neither is what Dennis was apparently referring to â€“ subsequent inventor patent litigation testimony. Reply link does not work in your browser because JavaScript is disabled. Reply 5.1.1.1.1 anon says: October 28, 2016 at 9:05 am Thanks Paul. I am not sure though that the timing (in the litigation phase) of the item being used for meaning was something actually stated during litigation as opposed to something stated during prosecution. In other words I do not take Prof. Crouchâ€™s comment to be what you are taking that same comment to be. The court was using prosecution history â€“ not litigation history. I do not see where you think that Prof. Crouch may have said anything about any statements strictly from litigation, as opposed to statements in litigation about what was said during prosecution. Reply link does not work in your browser because JavaScript is disabled. Reply 5.1.1.1.1.1 Paul F. Morgan says: October 28, 2016 at 9:29 am You may be right about the latter, but claim definition arguments in the application prosecution are usually mere attorney argumentation, not inventor declarations, unless supported with good evidence. Inventor declarations in the file history would still not be of proper evidentiary value [other than possible admissions against interest?] if not providing evidence of what the claim term meant to POSITAs [not just the inventor] as of the filing date. Reply link does not work in your browser because JavaScript is disabled. Reply 5.1.1.1.1.1.1 anon says: October 28, 2016 at 10:10 am Maybe Prof. Crouch will weigh in (although I think that we are close in view of the point here). Reply link does not work in your browser because JavaScript is disabled. Reply 4 Les says: October 27, 2016 at 10:35 am Has anyone reviewed the prosecution history? Was the Hokey-Pokey cited in a 103 rejection against claim 1? Reply link does not work in your browser because JavaScript is disabled. Reply 3 anon says: October 27, 2016 at 10:33 am Is not the use of prosecution history understood to be an exception to PHOSITA, as an express repudiation of anything except what is stated by applicant, forsaking the PHOSITA standard (and not incoincidently creating a type of â€œpatent profanityâ€ â€“ the very â€œtrap for the unwaryâ€ during prosecution)â€¦? Or in other words, PHOSITA remains the standard, except when the applicant affirmly says otherwise (akin to being his own lexicographer). Reply link does not work in your browser because JavaScript is disabled. Reply 2 anon says: October 27, 2016 at 10:25 am What? Functional claiming and no computers or software in sightâ€¦? ğŸ˜‰ Reply link does not work in your browser because JavaScript is disabled. Reply 2.1 Alex in Chicago says: October 27, 2016 at 2:40 pm Seems the court reviewed this as an implicit invocation of 112(f), which is not unheard of. Reply link does not work in your browser because JavaScript is disabled. Reply 2.1.1 anon says: October 27, 2016 at 3:10 pm Not so sure about that Alex. Courts doing that have not been shy about expressly saying that they are doing that. Reply link does not work in your browser because JavaScript is disabled. Reply 2.1.1.1 mike says: October 28, 2016 at 8:40 am during oral arguments the judges spent most of the time discussing how the term should have invoked a 112 6th issue Reply link does not work in your browser because JavaScript is disabled. Reply 2.1.1.1.1 anon says: October 28, 2016 at 9:13 am Thanks Mike â€“ that is helpful to know. Reply link does not work in your browser because JavaScript is disabled. Reply 2.1.2 K. David Crockett says: October 28, 2016 at 3:54 pm Seems like the court implicitly applied means-plus-function analysis to a nonce term, without understanding or mentioning that they were doing that. Reply link does not work in your browser because JavaScript is disabled. Reply 1 MaxDrei says: October 27, 2016 at 10:05 am As to â€œthe processâ€ of claim construction, the Decision has it as: â€œThe words of a claim are generally given their ordinary and customary meaning, which is the meaning that the term would have to a person of ordinary skill in the art at the time of the invention.â€ Meanwhile, Dennis has it as: â€œTheÂ approach is to look for howÂ a personal of ordinary skill inÂ the art at the time of the application filing date would have interpreted the claim languageâ€ Whereas the Supreme Court in the UK has it as: What was the writer of the claim using the language of the claim to mean (to the PHOSITA reader). Dennis and SCOTUK refer to the language of the claim whereas Philips is focussed on the meaning of an individual word in the claim. Is Dennis (perhaps unwittingly) closer to SCOTUK than to Philips? Reply link does not work in your browser because JavaScript is disabled. Reply Leave a Reply Cancel reply Your email address will not be published. Required fields are marked * Comment Name * Email * Website Don't subscribe All Replies to my comments Notify me of followup comments via e-mail. You can also subscribe without commenting. Patently-O Authors Dennis Crouch Associate Professor, University of Missouri School of Law SSRN Articles Jason Rantanen Associate Professor, University of Iowa College of Law SSRN Articles Occasional guest posts by IP practitioners and academics Patently-O Tools Subscribe to the blog 19,000+ individuals now receive Patently-O via e-mail each morning. Find a patent job We regularly post top patent jobs from leading firms, corporations, and government and educational institutions. Submit a patent job Find a patent professional among our 15,000+ monthly readers. Recent Patent Posts Ski at Snowmass: January 4-8, 2017 (and Talk Law) Supreme Court Patent Cases: Post Sale Exhaustion What Would Eliminating Chevron Deference mean for Patent Law Federal Circuitâ€™s Internal Debate of Eligibility Continues Citing to Supreme Courtâ€™s Eligibility Cases President Trump and the Patent Office Results of the Clarity of the Record Pilot A BETR Journal: The Business, Entrepreneurship & Tax Law Review Partial-Institution Decisions Blessed by En Banc Federal Circuit Vote 2016 CategoriesCategories Select Category â€“ US â€“ Southwest Academic Studies Accelerated Examination All Elements Amicus Brief Anticipation Articles and Publications assignment Attorney Fees Bayh-Dole Best Mode Biotech Bits and Bytes Blogroll Book Review Books BPAI Business Developments CAFC CBM Certificate of Correction Chemical Claim Construction Claim Drafting Tips collateral Conference or CLE conflict of interest Contributory Infringement Copyright Current Affairs Damages Declaratory Judgment Design Patent Disclaimer Dissent District Court Doctrine of Equivalents Doctrine of Patent Misuse EFiling En Banc Enablement Ethics False Marking Fee Shifting Fees First Sale / Exhaustion Food and Drink Games Gaming Graham Factors Guest Post Indefinite Inducement Inequitable Conduct Infringement Injunctions Interference Invalidity Inventors Inventorship IPR ITC Job Post Journal Jurisdiction Laches Law Firm Practice Law School Lear Doctrine License Local Rules malpractice mandamus Means Plus Function Medical Device Method Claims Motivation to Combine Novelty Obviousness On Sale Ownership Patent Patent Applications Patent Cases 2004 Patent Cases 2005 Patent Cases 2006 Patent Cases 2007 Patent Cases 2008 Patent Cases 2009 Patent Cases 2010 Patent Cases 2011 Patent Cases 2012 Patent Cases 2014 Patent Legislation Patent Prosecution Patent Q&A Patent Term Extension Patentable Subject Matter Petitions PGR Pharma PHOSITA Post Grant Review Preissuance Submissions Printed Matter Doctrine Prior Art Priority Rights Procedure Provisional Patent Application PTAB Public Use Rantanen Reexamination Reissue Revival Science Settlement Software Standing State Immunity Stats statutory bar Statutory Construction Summary Judgment Supreme Court Survey Takings Teaching Away Television TipCast Tools Trade Secret Trademark Transnational USITC USPTO News Vitiation Web/Tech Weblogs Work â€“ Patent Agent Work â€“ Patent Litigation Work â€“ Patent Prosecution Search for: Archives Archives Select Month November 2016 October 2016 September 2016 August 2016 July 2016 June 2016 May 2016 April 2016 March 2016 February 2016 January 2016 December 2015 November 2015 October 2015 September 2015 August 2015 July 2015 June 2015 May 2015 April 2015 March 2015 February 2015 January 2015 December 2014 November 2014 October 2014 September 2014 August 2014 July 2014 June 2014 May 2014 April 2014 March 2014 February 2014 January 2014 December 2013 November 2013 October 2013 September 2013 August 2013 July 2013 June 2013 May 2013 April 2013 March 2013 February 2013 January 2013 December 2012 November 2012 October 2012 September 2012 August 2012 July 2012 June 2012 May 2012 April 2012 March 2012 February 2012 January 2012 December 2011 November 2011 October 2011 September 2011 August 2011 July 2011 June 2011 May 2011 April 2011 March 2011 February 2011 January 2011 December 2010 November 2010 October 2010 September 2010 August 2010 July 2010 June 2010 May 2010 April 2010 March 2010 February 2010 January 2010 December 2009 November 2009 October 2009 September 2009 August 2009 July 2009 June 2009 May 2009 April 2009 March 2009 February 2009 January 2009 December 2008 November 2008 October 2008 September 2008 August 2008 July 2008 June 2008 May 2008 April 2008 March 2008 February 2008 January 2008 December 2007 November 2007 October 2007 September 2007 August 2007 July 2007 June 2007 May 2007 April 2007 March 2007 February 2007 January 2007 December 2006 November 2006 October 2006 September 2006 August 2006 July 2006 June 2006 May 2006 April 2006 March 2006 February 2006 January 2006 December 2005 November 2005 October 2005 September 2005 August 2005 July 2005 June 2005 May 2005 April 2005 March 2005 February 2005 January 2005 December 2004 November 2004 October 2004 September 2004 August 2004 July 2004 June 2004 May 2004 April 2004 A few links Patent Docs IP Kat Prof Goldman SCOTUS Blog ELS Spicy IP The Patent Law Journal Bill Vobach IP Watchdog Levin Crouch Patent Mediation Services SpiritFelt City Garden School Missouri-K Contact Us E-mail Dennis Crouch Post a Job on Patently-O E-mail Patently-O Jobs
null
null
null
null
< WRAL.com WRAL Tech Wire Processing, Please wait. You are about to be taken to our payment provider site to update your account information, Continue? Yes No Life Sciences VC & Funding Startups Mobile & Broadband Employment Analysis Insider Benefits Posted Oct. 26, 2016 at 1:55 p.m. Life science earnings: LabCorp, Merck, Novartis Published: 2016-10-26 13:55:52 Updated: 2016-10-26 13:55:52 Post a comment Print this blog postE-mail blog post Earnings By Wire reports Tags: Biotech & Life Science, LabCorp, Novartis, Merck Research Triangle Park, N.C. â€” Burlington-based LabCorp, Merck and Novartis have released their latest earnings. Here's a recap. LabCorp earnings lower than expected â€‹Laboratory Corp. of America Holdings reported third-quarter net earnings Wednesday that missed Wall Street expectations. Net earnings in the quarter were $179.5 million, compared to $154.7 million in the third quarter of 2015. Diluted earnings per shares were $1.71 in the period, an increase of 14 percent. Adjusted earnings per shares stood at $2.25, up 9 percent over last year. Analysts expected earnings to amount to $2.29 per share. Its stock fell by more than 6 percent in Wednesday morning trading. It was trading at $129.70, down $8.71. The laboratory network reported net revenue of $2.37 billion, up 4.5 percent compared with the same period last year. The company attributed the rise to the acquisitions and organic growth. â€œWe remain confident in our outlook for the balance of the year and our positioning for long-term profitable growth, as we deliver proprietary solutions that address our customersâ€™ greatest needs, and improve the health and lives of patients around the globe,â€ said David King, chairman and chief executive officer, in a statement. Headquartered in Burlington, LabCorp more than 48,000 people. Merck profits jump 20 percent Higher sales of vaccines and prescription medicines, coupled with restrained spending, helped Merck & Co. post a 20 percent jump in third-quarter profit, trouncing Wall Street expectations. The maker of Januvia diabetes pills raised and narrowed its 2016 financial forecasts, but noted someÂ headwinds, including the start of U.S. generic competition to three drugs by year's end. Its shares edged higher in midday trading Tuesday. The second-biggest U.S. drugmaker is in transition, with revenue from older products such as immune disorder treatmentÂ Remicade and theÂ Dulera asthma inhaler leveling off or falling amid increased competition. But sales are building for drugs launched since 2014, particularlyÂ immuno-oncology drugÂ Keytruda and hepatitis C-curingÂ Zepatier. Meanwhile, Zinplava for preventing recurrence of life-threatening C.Â difficile infections was approved Friday in the U.S., and Merck plans to apply soon for approval of experimental diabetes drugÂ ertugliflozin and additional uses forÂ Keytruda, its newest blockbuster, with more than $1 billion in sales over the past four quarters. In addition, chief executive Ken Frazier told analysts during a conference call that deals to boost Merck's pipeline of experimental drugs, with a focus on small -to-midsized assets that fit well within its business, are a priority. He noted Merck is calling attention to the innovation of its medicines amid the U.S. political furor over soaring drug prices. Novartis net profit drops Swiss drug company Novartis saw net profit slip in the third quarter as the loss of a key drug to generic use in the United States outweighed strong sales of its psoriasis drug Cosentyx and MS treatmentÂ Gilenya. Core net income fell 2 percent to $2.94 billion from $2.99 billion in the previous-year quarter. The loss of Gleevec, used to treat chronic myeloid leukemia, to generic use hurt sales revenue. Gilenya, a medicine for relapsing multiple sclerosis, brought in $790 million, an increase of 15 percent. The company said that Cosentyx, with $301 million in sales, was "on track for blockbuster status" in its first full year after approval. WRAL TechWire any time: Twitter, FacebookCopyright 2016 WRAL TechWire. All rights reserved. Editor's Blog The latest blog posts from our WRAL TechWire and WRAL editors. Read more articlesâ€¦ Â  Â  Â  Â  Please Log In to add a comment. Latest for Insiders Â  Â Healthcare organizations embrace mobile strategy Â  Â Good news for fintech: Revenues to double by 2020 Â  Â Net neutrality at risk? Plus: AT&T-DirecTV data move Â  Â Facebook captures nearly 80 percent of online audults Latest Tech News Â 2ULaundry, pickup and delivery service startup, raises $400K Bunker Labs program receives $1.5M funding boost Earnings: Novan, Argos, TransEnterix, Heat Bio, MaxPoint, ChannelAdvisor Hot Off The Wire Tracking WTW through social media: Like, track, link to us Following WTW through social media: Like, track, link to us Tracking WTW through social media: Like, track, link to us Biotech & Life Science Samsung $8B auto tech play; Facebook glitch; Pfizer price cut; airline computer outage; China's Singles Day 45 headlines not to be missed: WTW week in review, part 2 45 headlines not to be missed: WTW's week in review, part 1 Venture & Innovation Â Fundings: Undercover Colors, TCI Software raising cash Hatteras Ventures to manage NC's Venture Capital Multiplier Fund Catching up with Lizzie Hazeltine, from Startup Factory to interim editor at ExitEvent CONNECT Â Follow Us on Twitter Â Like Us on Facebook Â Follow Us on LinkedIn Rick Smith WRAL TechWire Editor The Skinny Catching up with Lizzie Hazeltine, from Startup Factory to interim editor at ExitEvent CED reports $175M through 62 capital deals in Q3 Google to offer real-time election returns for North Carolina NetApp cuts 6% of work force, won't say how many layoffs to hit RTP Â Lenovo exec: Shifting data center, other leaders are moves to 'optimize talent' Â Why is RTP such an agtech hot spot? Accelerator CEO explains Â AgTech Accelerator closes on $8.5M in additional capital CED counters HB2 blowback with positive 'WhyNC' campaign Lenovo to launch 'Kung Fu' smartphone Nov. 8 Lenovo unveils first US smartphone; 3D version coming Nov. 1 Trending Apple AT&T Biotech Broadband Cisco E-commerce EconomicÂ development Employment Fiber Google IBM Internet Layoffs Lenovo LocalÂ Firms OpinionÂ Analysis PCÂ industry Startups TelecommunicationsÂ andÂ Wireless Venture STEM News Â Planet Fitness franchise operator bringing 3 STEM campuses to Triangle Â Citing need for tech workers, report says computer science ed must be 'urgent priority' Â InnovateEDU: A summit to inspire minority, female students to study STEM Copyright Â© 2016 Capitol Broadcasting Company, Inc. FAQ Story Archive Contact Us Advertise With Us RSS Feed AdChoices Privacy Policy Terms of Use Valid XHTML 1.0 Â  CSS Load Check

Home News Weather Entertainment Sports Money More > Lifestyle Health & Fitness Food & Drink Travel Autos Video election 2016 lifestyle You are using an older browser version. Please use a supported version for the best MSN experience. Drug maker thwarted plan to limit OxyContin prescriptions at dawn of opioid epidemic STAT 10/26/2016 David Armstrong Â© Lawrence K. Ho/Los Angeles Times/Getty Images WELCH, W. Va. â€” The warning signs of what would become a deadly opioid epidemic emerged in early 2001. Thatâ€™s when officials of the state employee health plan in West Virginia noticed a surge in deaths attributed to oxycodone, the active ingredient in the painkiller OxyContin. They quickly decided to do something about it: OxyContin prescriptions would require prior authorization. It was a way to ensure that only people who genuinely needed the painkiller could get it and that people abusing opioids could not. But an investigation by STAT has found that Purdue Pharma, the manufacturer of OxyContin, thwarted the stateâ€™s plan by paying a middleman, known as a pharmacy benefits manager, to prevent insurers from limiting prescriptions ofÂ  the drug. The financial quid pro quo between the painkiller maker and the pharmacy benefits manager, Merck Medco, came to light in West Virginia court records unsealed by a state judge at the request of STAT, and in interviews with people familiar with the arrangement. â€œWe were screaming at the wall,â€ said Tom Susman, who headed the stateâ€™s public employee insurance agency in the early 2000s and led the push to limit OxyContin prescribing in West Virginia. â€œWe saw it coming,â€ he said of the opioid epidemic, which today causes 28,000 overdose deaths a year in the United States. â€œNow to see the aftermath is the most frustrating thing I have ever seen.â€ Overprescribing of OxyContin and other opioid painkillers is blamed for helping to plant the seeds for the current opioid crisis. West Virginia has been hit harder than any other state: It suffers the highest per capita drug overdose death rate in the country â€“ more than double the national average. It also has one of the highest rates of painkiller prescribing. In McDowell County, where the court records from a state lawsuit against Purdue were unsealed, the local sheriff said prescription pill abuse is so rampant that the county plans to file a new lawsuit against painkiller makers. The strategy to pay Merck Medco extended to other big pharmacy benefit managers and to many other states, according to a former Purdue official responsible for ensuring favorable treatment for OxyContin. The payments were in the form of â€œrebatesâ€ paid by Purdue to the companies. In return, the pharmacy benefit managers agreed to make the drug available without prior authorization and with low copayments. â€œThat was a national contract,â€ Bernadette Katsur, the former Purdue official, who negotiated contracts with pharmacy benefit managers, said in an interview. â€œWe would negotiate a certain rebate percentage for keeping it on a certain tier related to copay or whether it has prior authorization. We like to keep prior authorization off of any drug.â€ Katsur said prior authorization programs do little to eliminate inappropriate prescribing by â€œbad doctorsâ€ and usually just create needless paperwork for doctors working in the best interest of patients. She said some doctors simply wonâ€™t deal with the hassle of a prior authorization program, resulting in some legitimate patients not getting the medication they need. â€œYou donâ€™t want to make it harder for a doctor to prescribe when they are doing the right thing,â€ she said. Read more:Secret trove reveals bold â€˜crusadeâ€™ to make OxyContin a blockbuster But the arrangement between the painkiller maker and companies hired by insurance plans to manage prescription drug benefits removed a key safeguard in the system that may have slowed the growth of OxyContin as it became a national bestseller that eventually peaked at annual sales of $3 billion. The former Merck Medco was purchased by Express Scripts in 2012. A spokesman for Express Scripts said no one currently at the company had knowledge of the West Virginia contract. A spokesman for Purdue Pharma said the company had no comment. Prior authorization programs typically require doctors to get approval from an insurer before they can prescribe the drug to a patient. As part of such programs, insurers will often limit the conditions for which a drug can be used and the length of time the drug can be prescribed. A study published this month by the Centers for Disease Control and Prevention detailed how a private insurerâ€™s prior authorization plan in Massachusetts reduced the prescribing of opioids by 15 percent. The West Virginia court records reveal an agonizing situation in which several West Virginia health and insurance officials were early to spot the growing threat of OxyContin addiction and moved to blunt its impact. The well-intentioned bureaucrats, however, were no match for Purdue Pharma or its paid allies. In early 2001, the pharmacy director for the state employee health plan said her office noticed coroners listing oxycodone as the cause of death for some plan members. This occurred as the number of OxyContin prescriptions written for plan members skyrocketed; spending on the drug went from $11,000 in 1996, the first full year it was on the market, to $2 million in 2002.Â Purdue, aided at the time by its marketing partner Abbott Laboratories, aggressively marketed OxyContin to doctors with the claim, later shown to be false, that the risk of addiction was low. STAT reported last month that the unsealed West Virginia court records showed that an Abbott sales rep won over an orthopedic surgeon with a box of doughnuts and snack cakes arranged to spell OxyContin. â€œWe felt a need to put some type of management on the prescription because we saw death claim certificates come in with the cause of death of oxycodone,â€ said plan Pharmacy Director Felice Joseph in a 2004 deposition that was among the unsealed court records. The employee health plan contracted with Merck Medco to manage its pharmacy benefits, andÂ when state officials asked Merck to put in place a plan to limit OxyContin prescribing, â€œbasically they were refused,â€ she testified. The Medical Director for the state plan, Dr. Sandra Joseph, told a similar story in her deposition. â€œThey felt strongly, and they were very, very reluctant or resistant, for whatever reason,â€ she said of Merck. â€œThey did not want to put any limits or prior authorization criteria on that.â€ Merck downplayed concern about OxyContin abuse, Joseph testified, saying the companyÂ â€œreferred to other areas where there were not that many prescriptions for OxyContin, it was not that much of a problem.â€ The pharmacy director testified that the state initially wanted to limit OxyContin to terminally ill cancer patients only. â€œIt was because we felt there was a high abuse potential for its inappropriate use for short-term use,â€ she testified. She said a Merck official calculated that the company would lose $128,000 in rebate payments if OxyContin prescribing was limited in West Virginia. It was not specified if that was an annual or one-time loss. The extent of Purdueâ€™s rebate arrangements with Merck and other benefit managers in other states is not detailed in the West Virginia court records. Read more:26 overdoses in just hours: Inside a community on the front lines of the opioid epidemic Katsur, who left Purdue in 2005, said the payment of rebates was part of a strategy to keep insurers from limiting OxyContin prescriptions. She said such arrangements were common in the industry and not unique to Purdue. In addition to keeping OxyContin from being subject to prior authorization, the rebates paid to pharmacy benefit managers were used to guarantee favorable status for OxyContin on their listings of approved drugs, she said. PBMs commonly place drugs in different tiers on these lists, called formularies. Some tiers are more restrictive and require higher copayments. Purdue wanted OxyContin placed in the least restrictive tier â€” and succeeded. The relationship with Merck Medco was so important that Purdue moved Katsur to New Jersey so she could be close to Merckâ€™s national headquarters, she said. The court documents make clear that blocking any limits on OxyContin prescribing was a top priority for Purdue. In a memo listing the 2001 goals of Purdueâ€™s West Virginia sales team, the first listed item under Medicaid is â€œStop any preauthorization efforts for OxyContin.â€ In a separate memo, Purdue officials reported meeting with a state official to â€œinterruptâ€ any efforts to require prior authorization of OxyContin. And in a presentation prepared for a 2001 West Virginia district sales meeting, a Purdue official wrote in regard to the state employee insurance plan that the company was â€œworking with Medco (PBM) to try to make parameters less stringent.â€ Read more:Dope Sick: A harrowing story of best friends, addiction â€” and a stealth killer The internal memos and the actions of Merck contradicted claims by Purdue at the time that it was working with the state to curb abuse of OxyContin, lawyers for the state argued in a motion that was unsealed by the West Virginia court. â€œContrary to the picture of helpfulness and cooperation Purdue attempts to paint, Purdueâ€™s employees were actively and secretly trying to prevent West Virginia from imposing any control on the sale of OxyContin,â€ the state claimed. The case with Purdue was settled in 2004 when the company paid $10 million to West Virginia. Portions of the case file, including documents about marketing of the drug and Purdueâ€™s attempts to ward off limits on prescribing, remained sealed until STAT filed a motion in May to open the records. Nearly two years after the state insurance plan asked Merck to put a prior authorization plan in place for OxyContin, it finally got what it wanted. But the agency succeeded only after it brought in a new company to manage its prescription plan. By then, OxyContin and other painkillers had gained a firm grip on West Virginia, especially in McDowell County, where the state brought its lawsuit against Purdue. In 2001, the county was a proverbial canary in a coal mine when it came to the emerging national opioid crisis. The rate of accidental prescription drug overdose deaths in West Virginia was relatively low at the time â€” about 6 deaths per 100,000 residents. In McDowell, however, the rate was 38 deaths per 100,000. Since 2001, the death rate in the state has more than tripled to 21 deaths per 100,000 in 2012. McDowell Sheriff Martin West said lawyers contracted by the county are preparing a new lawsuit against pain-pill makers. He said the county is considered a â€œthird-world countryâ€ by state officials doling out funds to fight opioid abuse. â€œListen to the scanner here every night,â€ he said. â€œItâ€™s first responders out every night going up and down hollers for an overdose. Itâ€™s pitiful what is going on.â€ Go to MSN Home More in Medical Researchers Studying Role of Gender in Autism Associated Press More Physical Activity Can Lower Type 2 Diabetes Risk By 26 Percent Medical Daily 30% of Cancer Deaths Are Due to Smoking Time Should you let your dog lick your face? TODAY Brain Changes Seen in Kids After One Season of Football HealthDay Saturday, Oct. 22 Is Drug Take Back Day HealthDay Up Next Scientists Think This Is The Gene That Causes Intellectual Disabilities In Down Syndrome Medical Daily AdChoices AdChoices More from STAT Gilead hepatitis C pill was biggest 2015 drug cost for Medicare, Medicaid STAT State Medicaid programs continue to restrict access to hepatitis C drugs STAT Prisons fight opioids with $1,000 injection: Does it work? STAT Trump in 30 seconds: Science and medicine in flux STAT STAT View the full site Home News Weather Entertainment Sports Money Lifestyle Health & Fitness Food & Drink Travel Autos Video election 2016 Â© 2016 Microsoft Privacy Legal About our Ads Feedback Help MSN Worldwide Newsletter Disclaimer About Health

Skip to main content The Motley Fool Fool.com Fool.co.uk Fool.com.au Fool.ca Fool.sg Fool.de Hi, Fool! Premium Advice Help Fool Answers Contact Us Login MENU Stock Picks Learn More News Investing News Fool Podcasts Guides How to Invest Retirement Personal Finance Motley Fool Answers Options Trading Find a Broker Compare IRA Accounts Community Discussion Boards CAPS More About Help My Fool My Fool My Profile My Watchlist My Scorecard My Boards My CAPS My Reports My Subscriptions My Settings Premium Advice My Services None Other Services None Help Fool Answers Contact Us Login Search Search: 3 Key Questions for Gilead Sciences, Inc. in Q3 Here's what investors need to know from the big biotech when it reports Q3 results. Keith Speights (TMFFishBiz) Oct 26, 2016 at 8:03AM Image source: Getty Images. Gilead Sciences (NASDAQ:GILD) disappointed investors in the first quarter of 2016. The biotech disappointed again in the second quarter. A pattern seems to be emerging here. When Gilead announces its third-quarter results on Nov. 1, will the disappointments continue or is a positive surprise in store? It depends heavily on the answers to these three questions. 1. How much did Harvoni sales slow down? After storming out of the gate following its commercial launch in late 2014, blockbuster hepatitis C drug Harvoni has lost a good bit of steam. In the second quarter, sales for Harvoni declined nearly 29% year over year. No one is expecting Harvoni sales to rebound in the third quarter, but the market is anxious to find out how steep the decline might be. There are three main reasons behind the waning sales for the hep C drug. Competition is probably the most important. AbbVie's (NYSE:ABBV) Viekira and Merck's (NYSE:MRK) Zepatier go head-to-head with Harvoni. Gilead seems to have fended off AbbVie pretty well, although Viekira is claiming its fair share of the market. Merck, however, changed the game by launching Zepatier at a significantly lower price. Merck's move helped bring about the second main reason Harvoni's sales are slowing down. Payers are demanding -- and getting -- rebates and steep price discounts. Gilead reported much-lower average selling prices in the second quarter due to these concessions. The other factor behind Harvoni's sales decline relates to the hepatitis C patient population. When Harvoni was first launched, physicians prescribed the drug for a huge wave of patients with the most serious cases of hep C. Because Harvoni is so effective, many of those patients are now cured of the disease. Newer patients taking the drug tend to have less severe cases of hep C and can get by with shorter treatment periods. That reduces the sales volume for Harvoni. None of these things changed in the third quarter. We'll find out soon if the worst of the impact is over.Â  2. Did new drugs outperform expectations? Gilead rolled out a crop of impressive new drugs over the past year. Genvoya was launched in November 2015. The TAF-based HIV drug saw sales of $360 million in the first half of 2016. A couple of other TAF-based HIV drugs are also coming on strong. Descovy was launched in April 2016. Odefsey was launched in the U.S. a month earlier but didn't win European approval until June.Â  Possibly the biggest potential winner of the group, though, is Epclusa. The hepatitis C drug, which is the first to treat all genotypes of hep C, gained FDA approval in late June. With only three days of sales in the second quarter, Epclusa generated revenue of $64 million.Â The addition of Epclusa to its lineup should help Gilead battle more effectively against AbbVie and Merck. Gilead should see great numbers in the third quarter from all four of these newer drugs. If those numbers are even better than great, combined with Harvoni's sales coming in higher than expected, Gilead could have a nice quarter. 3. Will any hints be given about potential deals? At the end of the second quarter, Gilead sat on a cash stockpile totaling $24.6 billion (including cash, cash equivalents, and marketable securities). Inquiring minds want to know what the biotech will do with that money. Some of it will go to share buybacks. However, Gilead CFO Robin Washington noted in her second-quarter earnings call comments that the company would probably slow down repurchases in the second half of the year. Some will also go to pay out dividends, but Gilead spent only $1.2 billion on dividends in the first six months of the year. The only acquisition Gilead has made so far in 2016 is the purchase of Nimbus Apollo, in May. Gilead spent $400 million up front in the buyout. That amounts to pocket change for the biotech. Gilead has a lot of cash that it could use to forge a deal to bolster its pipeline. Any news (actually, any hint) that it is looking to make a smart strategic acquisition should be good for the stock. Keith Speights owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has the following options: short October 2016 $85 calls on Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. Author Keith Speights (TMFFishBiz) Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights Article Info Oct 26, 2016 at 8:03AM Health Care Stocks Merck and Co. NYSE:MRK $63.53 down $0.42 (-0.66%) Gilead Sciences NASDAQ:GILD $76.75 up $0.33 (0.43%) AbbVie NYSE:ABBV $62.97 down $0.13 (-0.21%) Read More Is a Donald Trump Presidency a Black Swan Event for Pharma Stocks? Should Biopharma Companies Buy Innovation? Gilead Sciences: Is the Bar Set Low Enough for a Beat? Unfazed by FDA Warning, Gilead Sciences' Stock Could Be Turning a Corner Will Gilead Sciences Inc. Set Its Sights on Incyte? Prev 1 2 3 4 5 6 7 8 Next Compare Brokers Terms of Use Privacy Policy Copyright, Trademark and Patent Information Terms and Conditions Â© 1995 - 2016 The Motley Fool. All rights reserved. Current New stock picks released in... Â  Â  Â  Â  Get The Picks x
MM&M Facebook MM&M Twitter MM&M LinkedIn Advertise Subscribe Log in | Register Home News Agencies Data/Analytics Campaigns Commercial Corporate Legal/Regulatory Media Opinion Payers Pipeline Technology 3 health tech innovations experts say will revolutionalize healthcare As digital-health funding increases, here's how VR, nanotechnology, and 3D printing could potentially improve the value of healthcare. Health Influencer 50 MM&M and PRWeek editors convened to select 50 battle-tested pros who are changing the healthcare game. Find out if you made the list. 10 things for pharma marketers to know about Facebook and Instagram With about 70 million users in six million health-related groups, drugmakers have tremendous opportunity to reach key audiences on Facebook. Here's how. Series Top 100 Agencies Live at Cannes Pharma Report Watson Week MM&M's Guide to DTC Top 40 Transformers Events Big Data Hall of Femme Leadership Exchanges MM&M Awards Transforming Healthcare Conference Webcasts Virtual Events Resources eBooks inVision Videos Podcasts The Agency Gallery The PMD Whitepapers Careers The Glass Ceiling Upward Moves At Work With Magazine Latest Issue Issue Archive MM&M > Channel > Corporate > Merck Consumer Health CMO on who makes healthcare decisions Tweet Diana Bradley October 25, 2016 Merck Consumer Health CMO on who makes healthcare decisions Share this content: facebook twitter linkedin google Comments Print Atilla Cansun, chief marketing officer at Merck Consumer Health, based in Darmstadt,Â Germany, talks to PRWeek about the company's WE100 platform, which is "about the right of everybody to look forward to 100 great years and ask their governments for all the support they need." You worked with Procter & Gamble for 17 years before joiningÂ MerckÂ in 2013. Why the transition? I never worked in healthcare before I joined Merck. It is very important to be able to relate to the category and its purpose. The contribution [Merck] gives to real people in their day-to-day lives showed me a different perspective than working on something like hair color.Â  How has marketing and communications changed since you joined? The first year, I wanted to see what moves consumers, doctors, and pharmacists by intentionally and significantly emotionalizing our communications. We wanted to visually soften our comms but also use terminology and ideas that speak to the heart versus speaking to the left brain, which is masculine, binary, and black and white. Around 2014, we decided to use every opportunity to position our brands as sympathy holders â€” the ones who care, listen, understand, and hold hands with consumers. We called them "Love Brands." At Cannes this year, Merck launchedÂ the WE100 platform. What inspired it? Love Brands was WE100's precursor. We want to prepare society for a new era where people live 100 years. Life expectancy has picked up significantly since the 1960s, even in the least developed country. But the legislative environment, government, system that is overlooking people has barely changed. You go from school to a job, the rest is smooth sailing and counting our days to the grave once you retire. What shaped the strategy? We placed a big study to find out the pain point and needs of people in this context. That shapes the content we are chewing on and about to roll out in Europe and Africa. WE100 is about the right of everybody to look forward to 100 great years and ask their governments for all the support they need. At Cannes, I was trying to find partners in crime that without any financial expectations, out of the goodness of their hearts, will help us out â€” such as the media industry, pharmaceutical industry, and even royalty such as [Queen Elizabeth II] and the Pope. His endorsement could be a great help for families to take this seriously for their kids. What initiatives do you have coming up around that? Healthy Hour is about raising awareness and teaching kids how to prepare for a 100-year life versus just learning about the next 20 years and how you can be good in math, physics, biology, and maybe literature so you can nail the best college and job. We are kicking that off in Africa this fall with support and engagement from governments over there. We are relying on pharmacists and doctors who in smaller villages may be the teachers of the courses. Another big project is We4You, which asks Merck employees to take time off in an organized way to help the elderly and better integrate them into society. We are doing this in Europe, working with the elderly on topics such as digital crash courses, knowledge about your bones, avoiding accidents, and restarting your professional life. What areas are you focused on? Women's and babies' health. Femibion is a pregnancy multivitamin. To support it, we came out with a campaign called Working Mothers, which is about recognizing the dedication of new moms to their babies that is perceived as holding back your career, turning it around, and recognizing your experience as a mom is a great qualification for a job as well. What can moms bring to the table? Skills moms have include listening, operational discipline, prioritizing, and multitasking, which are needed in the real world [for jobs ranging from] receptionist to the top manager. We have many female leaders. Our CEO, Uta Kemmerich-Keil, is a mother of two. The company has enabled her to go through her maternity leave, recognized her, and rewarded her to move forward. We have a lot of great stories from within our company that we will provocatively share with broader audiences in 2017. This is based in Germany and Austria, but we feel it is going to be universal. What came out of the first Global Consumer Health Debate you threw earlier this year?Â  The biggest realization is that 70% or more of big decisions are made by women. We had better understand their hopes, wishes, needs and contributions to the health industry. In terms of consumer health, they are the gatekeeper for the entire family. What's your biggest challenge from a marketing perspective? If doctors, pharmacists are not falling in love with what you say, they don't care or remember about the info you provide them. If your nose is decongested in 15 seconds or 12, who cares? It is a beautiful, wonderful story that can be passed onto the next person. It is worth tweeting about, and sharing on YouTube with your friends. That is what matters for doctors, pharmacists, and nurses. The challenge for the healthcare industry is how we digitize our interaction with doctors, healthcare professionals, and consumers. What agencies do you work with?Â  We work with Saatchi & Saatchi, SelectNY, and Ogilvy. From a PR perspective, Weber Shandwick helps us. This Q&A was first published by PRWeek.Â  Share this content: facebook twitter linkedin google Comments Print Related Articles Merck outspends Bristol-Myers Squibb on journal ads for Keytruda Merck's Keytruda wins approval in first-line lung cancer Infographic: Merck's Keytruda versus Bristol-Myers Squibb's Opdivo From One CMO to Another: What Chief Medical Officers Can Learn from Chief Marketing Officers The Story Behind the Story, Live From Cannes, Presented by McCann Health Merck's creative archive tells an industry story Related Topics Consumer Marketing & Communications Pharma Media People Please enable JavaScript to view the comments powered by Disqus. Next Article in Corporate Astellas boosts pharma's rep with corporate branding push MM&M Articles Popular Emailed Recent Infographic: what information doctors need from pharma Will drugmakers get what they're looking for at this week's FDA off-label hearing? Five things for pharma marketers to know: Friday, November 11, 2016 Five things for pharma marketers to know: Wednesday, November 9, 2016 Five things for pharma marketers to know: Monday, November 7, 2016 Merck educates doctors about biosimilars, long before it will sell one in the U.S. 4 trends with the potential to change behavior in the patient journey What do physicians think about biosimilars? Novartis considers new sales model for experimental cancer therapy Boehringer Ingelheim launches gamified support program Pfizer expands humanitarian access to Prevnar 13 vaccine Five things for pharma marketers to know: Monday, November 14, 2016 Will he or won't he? Pharma speculates on President-elect Trump Pharma pushes to share off-label info with payers at FDA hearing What's Next for the FDA During the Trump Administration Tweets by @MMMnews Events Weekly MM&M Breaking News MM&M KOL White Paper MM&M News Brief MM&M Sponsored Promotion MM&M Weekly Digest The Splash from MM&M United States United Kingdom Canada Afghanistan Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo (DRC) Cook Islands Costa Rica CÃ´te D'Ivoire Croatia Cuba Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Islands Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guinea Guinea-Bissau Guyana Haiti Heard Island and Mcdonald Islands Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Israel Italy Jamaica Japan Jordan Kazakhstan Kenya Kiribati Korea Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macao Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island North Korea Northern Mariana Islands Norway Oman Pakistan Palau Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russia Rwanda Saint Helena Saint Kitts and Nevis Saint Lucia Saint Martin Saint Pierre and Miquelon Saint Vincent and The Grenadines San Marino Sao Tome & Principe Saudi Arabia Senegal Serbia-Montenegro Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates Uruguay Uzbekistan Vanuatu Vatican City Venezuela Vietnam Virgin Islands Virgin Islands, British Wallis and Futuna Western Samoa Yemen Yugoslavia Zambia Zimbabwe Check out what's trending Healthcare Legal/Regulatory FDA Pharma Health Influencer 50 People Pricing Election Commercial More in Corporate Pfizer expands humanitarian access to Prevnar 13 vaccine Pfizer expanded its humanitarian efforts by providing the Prevnar 13 vaccine at a low price and donating proceeds to aid groups. How Ascension's Nick Ragone is rebranding one of ... The health system is one of the largest in the country. Most of Ascension's hospitals, Ragone says, used to operate almost independently from each other and the company's headquarters. Timeline of a crisis: How Mylan responded to ... Mylan was slammed by people unable to afford its lifesaving EpiPen injection device following a price hike â€” its response was seen as too little, too late. Medical Marketing & Media Return To Top News Agencies Campaigns Commercial Corporate Legal/Regulatory Media Payers Pipeline Opinion Back Talk Beltway Insider Editor's Desk Partner Forum Private View Viewpoint User Center Subscribe About us Contact us Media Information Sitemap Ad Choices Connect With Us Newsletters Facebook Twitter LinkedIn Copyright Â© 2016 Haymarket Media, Inc. All Rights Reserved This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions.
Subscribe | Marketing Packages | Forums | Cookie Law | Our sites ThePigSite ThePoultrySite TheFishSite TheCattleSite TheDairySite TheBeefSite TheMeatSite TheCropSite TheSheepSite ThePetSite.co.uk ElSitioAvicola ElSitioPorcino ThePigSite.cn ThePoultrySite.cn TheFishSite.cn AgriTimes.ru 5M Farm Supplies 5M Books Follow @thepigsite News & Analysis Features Markets & Reports Knowledge Centre Business Directory Events Our Shop Forums News Kelly Coulson Joins Merck Animal Healthâ€™s Food Animal Marketing Team26 October 2016 US - Merck Animal Health is pleased to announce that Kelly Coulson has joined the company as Swine Marketing Manager, U.S. Food Animal Marketing. With nearly two decades of sales and retail experience and 15 years of diverse livestock production knowledge, Kelly brings an extensive background in solution selling, husbandry training and customer service. â€œGiven his industry knowledge and strong ability to build and sustain relationships, we are confident Kelly will be a strong asset to our team and be able to make immediate contributions to our business,â€ said Todd Firkins, Executive Director, U.S. Food Animal Marketing, Merck Animal Health. â€œIn this role, Kelly will help us shape and drive our swine marketing strategies, as well as help lead our efforts to make Merck Animal Health our customersâ€™ first call for business solutions â€“ creating value for them well beyond our science and products.â€ Kelly, who joins us from Zoetis, most recently served as a territory business manager for the companyâ€™s pork business. He also has considerable experience educating and training producers and caregivers about early disease recognition and intervention, treatment protocols and responsible use of antibiotics. â€œI am truly excited to be joining Merck Animal Health,â€ Coulson said. â€œThere are many changes occurring in the swine industry â€“ and with change comes opportunities. I am looking forward to working with a great team of professionals as we navigate these changes and find ways to differentiate Merck Animal Health, our people and our products." A graduate of Kansas State University, Kelly holds numerous industry certifications. ThePigSite News Desk More MSD Animal Health News Conferences & Events, Company/Products, African Swine Fever, Castration (general/surgical), GM/GMO, Swine Delta Coronavirus, Foot & Mouth Disease, Organic production, Pain management Share This News By Please Select Advertiser 5M 5M On-line training AB Vista Adisseo ADM AnimalWorld - PORKEXPO 2008 Axcentive Big Dutchman Biomin Boehringer Ingelheim BPEX Cablevey CEVA CHR Hansen CID LINES CTB inc. Delacon Diamond V Du Pont EfferSan EPI Air ESPHM 2013 Eurotier EuroTier 2014 - News FAI Farms Fancom Feedlogic Garth Partnership Genesus Geohellas Harrisvaccines Hermitage Genetics Hipra Hogslat Hotraco Agri Huvepharma Hydro Systems IPPE Jefo Merial MSD Animal Health Novus International Nutraferma Nutriad Old - DuPont Animal Health Solutions Once Innovations Osborne Industries PIC PVS Pig Journal Roxell Schaumann Termotecnica Pericoli Thermo Fisher Scientific TPI Polytechniek VAV Vetagro VIV Vostermans Waldo Genetics World Pork Expo Zoetis Please Select CountryAfghanistanAlbaniaAlgeriaArgentinaArmeniaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBoliviaBotswanaBrazilBrunei DarussalamBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCentral African RepublicChadChileChinaColombiaCongo, Democratic RepublicCosta RicaCote D'IvoireCroatiaCubaCyprusCzech RepublicDenmarkDjiboutiDominican RepublicEcuadorEgyptEl SalvadorEstoniaEthiopiaEuropean UnionFalkland Islands (Malvinas)FijiFinlandFranceFrench PolynesiaGambiaGeorgiaGermanyGhanaGibraltarGlobalGreeceGuamGuatemalaGuyanaHaitiHondurasHong KongHungaryIcelandIndiaIndonesiaIranIraqIrelandIsraelItalyJamaicaJapanKazakhstanKenyaKorea, NorthKorea, SouthKuwaitKyrgyzstanLaoLatviaLebanonLiberiaLithuaniaMadagascarMalawiMalaysiaMaliMaltaMauritiusMexicoMoldovaMongoliaMozambiqueMyanmarNamibiaNepalNetherlandsNetherlands AntillesNew ZealandNicaraguaNigeriaNorwayPakistanPanamaPapua New GuineaParaguayPeruPhilippinesPolandPortugalQatarRomaniaRussian FederationRwandaSaint Kitts and NevisSao Tome and PrincipeSaudi ArabiaSerbiaSeychellesSingaporeSlovakiaSloveniaSolomon IslandsSouth AfricaSpainSri LankaSudanSwazilandSwedenSwitzerlandSyriaTaiwanTanzaniaThailandTrinidad and TobagoTunisiaTurkeyUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayVanuatuVenezuelaViet NamYemenZambiaZimbabwe Please Select CategoryH1N1 FluWaterAntibioticFarmer/Worker Health & SafetySmallholder/Hobby farmingCropDiagnosticsCompany/ProductsMarkets and EconomicsGovernment & RegulatoryPig HealthPig WelfareBiosecurity & HygieneArtificial InseminationBreeding & ReproductionGeneticsFeed & NutritionDrinkers & WaterHousing SystemsHeating & VentilationProduction ManagementEnvironmental ManagementWaste ManagementBiodigestion & BiofuelsOdour ControlTransportationSlaughterSustainabilityPig Meat QualityFood SafetyProcessingLabelling & TraceabilityMarketing PorkTraining & DevelopmentConferences & Events Related News Merck Animal Health to Acquire Brazilian Animal Health Company VallÃ©e Â  21 October 2016 Vaccination Is Solution for Ileitis, Antibiotic Stewardship Â  06 October 2016 MSD Animal Health Supports Young Veterinarian in Tropical Animal Health Research Â  06 September 2016 Pig Producers Can Now Evaluate Herd Health While On the Go Â  16 August 2016 Merck Animal Health Receives FDA Approval of Safe-GuardÂ® AquaSol for Use in Swine Â  05 August 2016 More News Ceva SantÃ© Animale Given European Commission Go Ahead to Acquire Merial Assets from Boehringer Ingleheim Â Â  14 November 2016 US Barrows and Gilt Cash Prices Decline Steeply Â Â  14 November 2016 Hog Outlook: Mexican Demand Drove September Pork Exports Â Â  14 November 2016 South East Asia Hog Market Â Â  14 November 2016 US Pork Exports to Mexico Continue Strong Momentum Â Â  14 November 2016 Amino Acid Utilisation and Value of Phytase Highlighted as International Phytate Summit Comes to a Close Â Â  14 November 2016 MRSA Detected in Norwegian Pig Herd Â Â  14 November 2016 Chinese Pork Demand Drives Growth in Hong Kong's Imports Â Â  14 November 2016 AHDB Seeking Pig Producer for AHDB Pork Board Â Â  11 November 2016 Danish Crown to Set Up Processing Plant in China Â Â  11 November 2016 Our Sponsors Partners Seasonal Picks News Pig News Company News Headline News News by Category Analysis Latest Analysis Features Latest Features Reports CME Futures Market USDA Cash Grain Alan Brugler CME Archive Knowledge Walking the Pens Sow Group Housing Artificial-Insemination Managing Pig Health Pig Diseases Treatment Options Stockmanship Standards Disease Problem Solver Reproduction Problem Solver Swine Bibliography A Focus on Ileitis PCVAD and PMWS SwineCast Breeds of Swine Mycotoxins Videos Newsletter Links Marketing Marketing Packages Business Directory Submit Business Events Latest Events Submit Event About About 5m Publishing Our Editors Â© 2000 - 2014. 5m Publishing, Benchmark House, 8 Smithy Wood Drive, Sheffield, S35 1QN, England. 5m Enterprises Inc., Suite 4120, CBoT, 141 West Jackson Boulevard, Chicago, IL, 60604-2900, USA.- A Benchmark Holdings plc. Company No part of this site may be reproduced without permission. Co. Registration 3332321 VAT No. 100 1348 86 Terms and Conditions | Privacy | Disclaimer
Xconomy Xperience EXOME National Regions Channels Events Whatâ€™s Hot in Healthtech â†’ EXOME all the information, none of the junk | biotech â€¢ healthcare â€¢ life sciences Want EXOME sent to you daily? Meet the Contributors â†’ FDA: Keytruda Now OK For Some Patients With Untreated Lung Cancer Alex Lash October 25th, 2016 @alexlash @xconomy Like Us Xconomy National â€”Â  The FDA has approved the use of pembrolizumab (Keytruda) for some previously untreated patients with a certain type of lung cancer, the drugâ€™s owner Merck (NYSE: MRK) announced late Monday. Pembrolizumab can now be used for patients who have never received treatment for non-small cell lung cancer (NSCLC) that has spread to other parts of the body. To be eligible for the drug, patients must take a test that shows their tumors produce a high amount of the protein PD-L1, which pembrolizumab has been designed to recognize. Roughly a quarter of all advanced NSCLC patients have cancer with high PD-L1 levels, according to earlier studies from Merck. That restriction is important. The new wave of cancer immunotherapies called checkpoint inhibitors, which include pembrolizumab, work well for a minority of patients, but doctors and researchers are only beginning to understand the signs that might point to a benefit for some patients but not others. Those efforts will need to improve if the promise of precision cancer medicineâ€”giving the right medicine to the right patientsâ€”is to bear fruit. (Another kind of cancer immunotherapy uses live, modified T cells but has yet to be approved. Xconomy has compiled a resource of T cell clinical studies here; a second part of the resource, compiling trials of checkpoint inhibitors, is coming soon.) Pembrolizumab becomes the first checkpoint inhibitor to be approved for first-line non-small cell lung cancer (NSCLC). Last year, the FDA approved the drug and another checkpoint inhibitor, Bristol Myers Squibbâ€™s nivolumab (Opdivo), for second-line patients whose tumors have resisted treatment with either chemotherapy or a drug that targets specific genetic mutations. The first-line approval for pembrolizumab comes weeks after Merck and its academic collaborators touted positive data from a 305-patient study, KEYNOTE-024. Merck and Bristol-Myers Squibb (NYSE: BMY) have been studying their flagship drugs in several cancer types. But nivolumab produced negative first-line NSCLC results in August when it failed to show it could do a better job than chemotherapy in progression-free survivalâ€”that is, shrinking tumors or keeping them in check. That news set the stage for pembrolizumabâ€™s positive data. For patients taking the drug in KEYNOTE-024, they showed progression-free survival for a median of 10.3 months, compared to 6.0 months for patients on chemotherapy. Forty five percent of the pembrolizumab patients had either partial or total shrinkage of their tumors, compared to 28 percent of the chemotherapy patients. The FDA also updated the guidelines for the use of pembrolizumab in second-line NSCLC. According to Merck, patients who have failed to improve with chemotherapy are now eligible for pembrolizumab even if their tumors produce a low level of PD-L1. Image courtesy of the National Cancer Institute. Alex Lash is Xconomy's National Biotech Editor. He is based in San Francisco. Follow @alexlash Share on Facebook Share on Twitter LinkedIn Email Reprints More from EXOME Immunotherapy Clinical Tests Spur Hope, and Plenty of Headaches Biotech Roundup: Kadmon Debt, Hemo Data, Loose Lips & More Talking Cure? For Cancer Immunotherapy, Still Many Rivers to Cross Trending on Xconomy Xconomy Special Report: 12 San Diego Tech Startups to Watch in 2017 Cord Cutting: How to Get High-Speed Internet Service Without Cable Texas Innovators in Health, Space, Energy, A.I. & More: The Disruptors Photos X Xconomyâ€™s EXOME Presents: State of the Biotech Union National health initiatives, the intersection of Big Data and healthcare, the looming presence of genetic modification, and our national response to infectious disease December 6, 2016 Register today! Underwriters and Partners From Our Advertisers The key trends and challenges of clinical outsourcing Exclusive interview with Prof Kenneth Getz from Tufts CSDD KNect365 Life Sciences Is commercial clinical research worth it for sites? The urgent issues with clinical trial & study site partnerships KNect365 Life Sciences The Fractured State of Sales Enablement & Training OnDemand Webinar Allego How Wisconsin is cultivating startup success New report highlights entrepreneurial programs available statewide Wisconsin Economic Development Corporation The Feed Tweets from https://twitter.com/Xconomy/lists/lifesci Home Privacy/DMCA Security Disclosures About Contact Us Archives Advertise Subscribe for Free Business, life sciences, and technology news â€” covering Boston, Seattle, San Diego, Detroit/Ann Arbor, San Francisco, New York, Raleigh-Durham, Boulder/Denver, Texas, Wisconsin, Indiana, and beyond. Â© 2007-2016, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved. Website development support from Andrew Koyfman with design support from Rob Hunter.

Latest News Dow 18,869 +21.03 +0.11% Nasdaq 5,218 -18.72 -0.36% S&P 500 2,164 -0.25 -0.01% 6:42 P.M. ET Bannonâ€™s Critics: Alt-Right is Wrong for White House 6:41 P.M. ET President Obama Details Transition in Press Conference 6:39 P.M. ET FriendFinder breach may have exposed 412 million usersâ€™ data 6:20 P.M. ET Google to block its ads from fake-news sites 6:18 P.M. ET 'Mars': National Geographic Network's Moonshot 6:04 P.M. ET Obama Addresses Concerns About Bannon's Appointment 6:06 P.M. ET Updated David Einhornâ€™s Greenlight Capital reduces stakes in Apple, GM, buys U.S. Steel 6:04 P.M. ET Updated SEC chief Mary Jo White announces plans to leave 6:02 P.M. ET Obama Addresses Concerns About Bannon's Appointment 5:47 P.M. ET Updated Deutsche Bank raises S&P 500 year-end target after postelection rally 5:35 P.M. ET George Soros buys stakes in Alphabet, Netflix, dumps Disney, General Motors 5:31 P.M. ET Updated Donald Trump and Vladimir Putin speak by phone 5:19 P.M. ET Financial services industry is at risk to get even whiter 5:15 P.M. ET David Tepper's hedge fund buys new stakes in Apple, Bank of America and Facebook 5:11 P.M. ET Estee Lauder to buy Too Faced for $1.45B, looks to 'win with millennials' 5:10 P.M. ET Einhorn adds Aercap, Calpine, United States Steel, trims Apple stake 5:02 P.M. ET My father-in-law married his girlfriend before he died â€” she wonâ€™t return our calls 5:02 P.M. ET Tepper's Appaloosa sells entire 4.4 mln-share stake in 21st Century Fox during Q3--SEC filing 5:02 P.M. ET SEC says Mary Jo White to leave at the end of the Obama administration 5:00 P.M. ET Nasdaq names Adena Friedman president and CEO Log In Home News Viewer Video SectorWatch Podcasts First Take Games Portfolio My MarketWatch News Viewer Markets U.S. Europe/Middle East Emerging Markets Asia Canada SectorWatch Columns Market Snapshot Movers & Shakers The Tell Currencies Futures Movers Pre-Market News Tools Earnings Wall Markets Overview IPO Calendar Earnings Calendar Currency Tools Futures Contracts Market Screener Hulbert Interactive Investing Stocks Mutual Funds ETFs Options Bonds Commodities Currencies Futures Hedge Funds/Insider Trades Getting Started MarketWatch Adviser Columns Options Trader Revolution Investing Tools Stock Screener Funds Finder ETF Screener Options Screener IPO Calendar Earnings Calendar More... Trading Deck . Personal Finance 10 Things Big Spender Real Estate Spending & Saving Taxes Columns The Moneyologist Brett Arends Bill Bischoff Amy Hoak Chuck Jaffe Jennifer Openshaw Jennifer Waters Tools Funds Finder Today's Rates Retirement RetireMentors Encore Taxes Retire Here, Not There How-to Guides Social Security Estate Planning Events Columns Robert Powell's Retirement Portfolio Andrea Coombes's Working Retirement Tools Retirement Planner How long will my money last? Economy Federal Reserve Capitol Report Economic Report Columns Darrell Delamaide Irwin Kellner Rex Nutting Tools Economic Calendar Real Estate Location Scouts realtor.com My MarketWatch Watchlist Alerts Games Log In Until Tokyo Markets Open US Market Snapshot Currencies Commodities Home Press Release Fitch Rates Merck's Euro Notes Offering 'A' By Published: Oct 27, 2016 1:50 p.m. ET Share CHICAGO, Oct 27, 2016 (BUSINESS WIRE) -- Fitch Ratings has assigned an 'A' rating to Merck & Co., Inc.'s (MRK/Merck) euro notes offering. A complete list of ratings follows at the end of this press release. KEY RATING DRIVERS The company's 'A' rating reflects the following: --Recently introduced therapies, an advancing pipeline and manageable patent expiries should support intermediate- to long-term growth. --Fitch believes that Merck will pursue targeted acquisitions as opposed to large transformative ones. An improving pipeline and narrowing strategic focus reduces the need to do big deals. --Fitch expects Merck will continue favor share repurchases to deleveraging, with the possibility of further debt-funded stock buybacks. --Fitch forecasts that Merck will generate solid FCF during the forecast period supported by improving margins and moderate revenue growth. New Products/ Growth Opportunities: Products approved during the last three years should help to drive intermediate- to long-term, top-line growth for Merck. Most importantly, Keytruda (skin and lung cancer) is gaining traction in the market, supported by an ongoing stream of clinical data, but facing competition from a Bristol-Myers product and potentially similar drugs that may receive approval during the next few years. Merck is also evaluating Keytruda's safety and efficacy in other cancers and in combination with other oncolytics. Bridion (post-surgical recovery), Belsomra (insomnia), Grastek (allergies) and Rawitek (allergies) are unique-acting therapies, which should provide these two drugs competitive positions. Zontivitiy (cardiovascular) and Zepatier (hepatitis C) have entered increasingly crowded segments but should be able to gain some share from both newer and older treatments. Expanding Late-Stage Pipeline: Fitch expects Merck to continue to build its late-stage pipeline with new molecular entities (NMEs) to treat cancers, bacterial and viral infections, diabetes, cardiovascular disorders, central nervous afflictions, osteoporosis, and other diseases. While the majority of these projects are internally developed, Merck has partnered with other innovator firms to take advantage of technological advancements that were discovered externally. The landscape for drug development is expanding, particularly as developers learn more about how genetics influence the development, prevention and treatment of disease. As such, Fitch believes that it is responsible and strategically advantageous for firms to look externally as well as internally regarding new drug development. Patent Exposure Manageable: The company has and will continue to face some significant patent expiries during the next year, but Fitch views the risk as manageable with roughly 18% of total firm sales are at risk. In addition, Remicade, which accounts for about 4.2% of total firm sales, is a biologic that has experienced less rapid sales losses to generic competition compared to traditional small-molecule pharmaceuticals. Vytorin and Zetia, however, are small molecules and account for roughly 10% of total revenues. Fitch expects these two products will lose significant sales shortly after their patents expire, as is typically the case for small-molecule drugs. Solid Free Cash Flow Expected: Fitch forecasts that Merck will generate $5.7 billion - $5.9 billion in free cash flow (FCF) during 2016. Improving margins driven by an improving sales mix and strong cost control should more than offset expected soft near-term, top-line growth. Fitch expects FCF to incrementally increase during the multi-year forecast period. Targeted Acquisition Most Likely: Fitch looks for Merck to pursue mainly targeted acquisitions in the intermediate term. The company has improved its operational and financial prospects through successfully gaining regulatory approvals on late-stage pipeline projects and has continued to back fill its pipeline with new and advancing projects. An improved growth and profitability profile decreases the need for the company to execute large strategic business combinations. Share Repurchases to Continue: Fitch assumes continued shareholder friendly actions during the near term, some of which the company may fund with debt. Merck has occasionally funded its share repurchases with debt. During 2015, the company purchased a net $3.7 billion of its common stock, compared to $6.1 billion during the prior LTM period. The repurchases were executed under a $15 billion program authorized in May 2013 as well as an additional $10 billion authorized in March 2015. As of June 30, 2016, the 2013 allotment was fully utilized, with $6.9 billion remaining on the $10 billion extension. KEY ASSUMPTIONS Fitch's key assumptions within the rating case for Merck's 'A' rating include the following: --Incrementally increasing revenue during the forecast period, driven by newer products, largely offset in the near term by foreign exchange headwinds and select product patent expirations. --EBITDA operating margin improvement driven by a focus on costs and an improving sales mix. --Annual FCF (cash flow from operations minus capital expenditures minus dividends) of roughly $5.9 billion during 2016. --Targeted acquisitions prioritized over strategic, transformative transactions. --Continued significant share repurchases. --Leverage to range between 1.7x - 1.9x during the next two years. RATING SENSITIVITIES Positive: Future developments that may, individually or collectively, lead to positive rating action include the following: --Improving operations including new product development that support long-term positive revenue growth and margin stability/increases; --An operational profile that would consistently generate significantly positive FCF; --Cash deployment strategy that maintains gross debt leverage below 1.7x, including managing through operational stress such as patent expiries. Negative: Future developments that may, individually or collectively, lead to negative rating action include the following: --Material and lasting deterioration in operations and FCF, possibly driven by patent expiries not being offset by new product development; --Leveraging acquisitions without the prospect of timely debt/leverage reduction; --Persistent leverage above 2.2x. LIQUIDITY Adequate Liquidity: Fitch looks for Merck to maintain adequate liquidity through strong FCF generation and ample access to the credit markets. FCF for the LTM ending June 30, 2016 was $4.7 billion. At the end of the period, Merck had approximately $11.8 billion in cash/short-term investments (u.s.:10% - 20% of total balances/OUS) and full availability on its $6 billion revolver, maturing in August 2019. Manageable Debt Maturities: As of June 30, 2016, the company had $24.1 billion in debt outstanding, with $234 million maturing in 2016, $317 million in 2017, $3 billion in 2018 and $1.3 billion in 2019. Fitch expects near- to mid-term maturities will be satisfied primarily through refinancing in the public debt markets. FULL LIST OF RATINGS Fitch has affirmed the following ratings: Merck & Co., Inc. --Long-Term Issuer Default Rating (IDR) at 'A'; --Senior unsecured credit facility at 'A'; --Senior unsecured debt at 'A'; --Short-term IDR at 'F1'; --Commercial paper at 'F1'. The Rating Outlook is Stable. Summary of Financial Statement Adjustments - Financial statement adjustments that depart materially from those contained in the published financial statements of the relevant rated entity or obligor are disclosed below: --Historical and projected EBITDA is adjusted to add back non-cash stock based compensation. During the LTM period ended March 31, 2016, Fitch added back $304 million in non-cash stock based compensation to its EBITDA calculation and $214 million in restructuring costs to gross profit. Date of Relevant Committee: July 7, 2016 Additional information is available on www.fitchratings.com. Applicable Criteria Corporate Rating Methodology - Including Short-Term Ratings and Parent and Subsidiary Linkage - Effective from 17 August 2015 to 27 September 2016 (pub. 17 Aug 2015) https://www.fitchratings.com/site/re/869362 Additional Disclosures Solicitation Status https://www.fitchratings.com/gws/en/disclosure/solicitation?pr_id=1013861 Endorsement Policy https://www.fitchratings.com/regulatory ALL FITCH CREDIT RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND DISCLAIMERS. PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING THIS LINK: HTTPS://WWW.FITCHRATINGS.COM/UNDERSTANDINGCREDITRATINGS. IN ADDITION, RATING DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE AVAILABLE ON THE AGENCY'S PUBLIC WEB SITE AT WWW.FITCHRATINGS.COM. PUBLISHED RATINGS, CRITERIA, AND METHODOLOGIES ARE AVAILABLE FROM THIS SITE AT ALL TIMES. FITCH'S CODE OF CONDUCT, CONFIDENTIALITY, CONFLICTS OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE, AND OTHER RELEVANT POLICIES AND PROCEDURES ARE ALSO AVAILABLE FROM THE CODE OF CONDUCT SECTION OF THIS SITE. FITCH MAY HAVE PROVIDED ANOTHER PERMISSIBLE SERVICE TO THE RATED ENTITY OR ITS RELATED THIRD PARTIES. DETAILS OF THIS SERVICE FOR RATINGS FOR WHICH THE LEAD ANALYST IS BASED IN AN EU-REGISTERED ENTITY CAN BE FOUND ON THE ENTITY SUMMARY PAGE FOR THIS ISSUER ON THE FITCH WEBSITE. CopyrightÂ© 2016 by Fitch Ratings, Inc., Fitch Ratings Ltd. and its subsidiaries. 33 Whitehall Street, NY, NY 10004. Telephone: 1-800-753-4824, (212) 908-0500. Fax: (212) 480-4435. Reproduction or retransmission in whole or in part is prohibited except by permission. All rights reserved. In issuing and maintaining its ratings and in making other reports (including forecast information), Fitch relies on factual information it receives from issuers and underwriters and from other sources Fitch believes to be credible. Fitch conducts a reasonable investigation of the factual information relied upon by it in accordance with its ratings methodology, and obtains reasonable verification of that information from independent sources, to the extent such sources are available for a given security or in a given jurisdiction. The manner of Fitch's factual investigation and the scope of the third-party verification it obtains will vary depending on the nature of the rated security and its issuer, the requirements and practices in the jurisdiction in which the rated security is offered and sold and/or the issuer is located, the availability and nature of relevant public information, access to the management of the issuer and its advisers, the availability of pre-existing third-party verifications such as audit reports, agreed-upon procedures letters, appraisals, actuarial reports, engineering reports, legal opinions and other reports provided by third parties, the availability of independent and competent third- party verification sources with respect to the particular security or in the particular jurisdiction of the issuer, and a variety of other factors. Users of Fitch's ratings and reports should understand that neither an enhanced factual investigation nor any third-party verification can ensure that all of the information Fitch relies on in connection with a rating or a report will be accurate and complete. Ultimately, the issuer and its advisers are responsible for the accuracy of the information they provide to Fitch and to the market in offering documents and other reports. In issuing its ratings and its reports, Fitch must rely on the work of experts, including independent auditors with respect to financial statements and attorneys with respect to legal and tax matters. Further, ratings and forecasts of financial and other information are inherently forward-looking and embody assumptions and predictions about future events that by their nature cannot be verified as facts. As a result, despite any verification of current facts, ratings and forecasts can be affected by future events or conditions that were not anticipated at the time a rating or forecast was issued or affirmed. The information in this report is provided "as is" without any representation or warranty of any kind, and Fitch does not represent or warrant that the report or any of its contents will meet any of the requirements of a recipient of the report. A Fitch rating is an opinion as to the creditworthiness of a security. This opinion and reports made by Fitch are based on established criteria and methodologies that Fitch is continuously evaluating and updating. Therefore, ratings and reports are the collective work product of Fitch and no individual, or group of individuals, is solely responsible for a rating or a report. The rating does not address the risk of loss due to risks other than credit risk, unless such risk is specifically mentioned. Fitch is not engaged in the offer or sale of any security. All Fitch reports have shared authorship. Individuals identified in a Fitch report were involved in, but are not solely responsible for, the opinions stated therein. The individuals are named for contact purposes only. A report providing a Fitch rating is neither a prospectus nor a substitute for the information assembled, verified and presented to investors by the issuer and its agents in connection with the sale of the securities. Ratings may be changed or withdrawn at any time for any reason in the sole discretion of Fitch. Fitch does not provide investment advice of any sort. Ratings are not a recommendation to buy, sell, or hold any security. Ratings do not comment on the adequacy of market price, the suitability of any security for a particular investor, or the tax-exempt nature or taxability of payments made in respect to any security. Fitch receives fees from issuers, insurers, guarantors, other obligors, and underwriters for rating securities. Such fees generally vary from US$1,000 to US$750,000 (or the applicable currency equivalent) per issue. In certain cases, Fitch will rate all or a number of issues issued by a particular issuer, or insured or guaranteed by a particular insurer or guarantor, for a single annual fee. Such fees are expected to vary from US$10,000 to US$1,500,000 (or the applicable currency equivalent). The assignment, publication, or dissemination of a rating by Fitch shall not constitute a consent by Fitch to use its name as an expert in connection with any registration statement filed under the United States securities laws, the Financial Services and Markets Act of 2000 of the United Kingdom, or the securities laws of any particular jurisdiction. Due to the relative efficiency of electronic publishing and distribution, Fitch research may be available to electronic subscribers up to three days earlier than to print subscribers. For Australia, New Zealand, Taiwan and South Korea only: Fitch Australia Pty Ltd holds an Australian financial services license (AFS license no. 337123) which authorizes it to provide credit ratings to wholesale clients only. Credit ratings information published by Fitch is not intended to be used by persons who are retail clients within the meaning of the Corporations Act 2001 View source version on businesswire.com: http://www.businesswire.com/news/home/20161027006514/en/ SOURCE: Fitch Ratings Fitch Ratings Primary Analyst Bob Kirby, CFA Director +1-312-368-3147 Fitch Ratings, Inc. 70 W. Madison Street Chicago, IL 60602 or Secondary Analyst Gregory Dickerson Director +1-212-908-0220 or Committee Chairperson Megan Neuburger Managing Director +1-212-908-0501 or Media Relations Alyssa Castelli, +1 212-908-0540 alyssa.castelli@fitchratings.com Copyright Business Wire 2016 MarketWatch Partner Center Celebrity Real Estate News Celebrities renege on their pledges to move out of U.S on the back of Trump win View More Investing If you're shocked that Trump won, you broke 3 basic principles of investing View More Barron's Next Dear President-Elect Trump, a millennial wishlist View More Investing Opinion: A 12-step plan to strengthen your portfolio after Trump's victory View More MarketWatch Site Index Topics Help Feedback Newsroom Roster Media Archive Premium Products Mobile Company Company Info Code of Conduct Corrections Advertising Media Kit Advertise Locally Reprints & Licensing Broker Center Your Ad Choices Dow Jones Network WSJ.com Barron's Online BigCharts Virtual Stock Exchange Financial News Online WSJ.com Small Business realtor.com Mansion Global Back to Top Copyright Â©2016 MarketWatch, Inc. All rights reserved. By using this site you agree to the Terms of Service, Privacy Policy, and Cookie Policy. Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. Intraday data delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Dow Jones & Company, Inc. All quotes are in local exchange time. Real time last sale data provided by NASDAQ. More information on NASDAQ traded symbols and their current financial status. Intraday data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. S&P/Dow Jones Indices (SM) from Dow Jones & Company, Inc. SEHK intraday data is provided by SIX Financial Information and is at least 60-minutes delayed. All quotes are in local exchange time. Advanced Search Stocks Columns Authors Topics No results found LatestNews
Contact Us Journalists Blog Log In Sign Up Send a Release News Solutions Resources Search News in Focus Browse News Releases All News Releases News Releases Overview English-only All Public Company Multimedia Gallery All Multimedia Multimedia Gallery Overview All Photos All Videos Trending Topics All Trending Topics Business & Money Auto & Transportation All Auto & Transportation Auto & Transportation Overview Aerospace, Defense Air Freight Airlines & Aviation Automotive Maritime & Shipbuilding Railroads and Intermodal Transportation Transportation, Trucking & Railroad Travel Trucking and Road Transportation Business Technology All Business Technology Business Technology Overview Broadcast Tech Computer Hardware Computer Software Computer & Electronics Electronic Commerce Electronic Components Electronic Design Automation Electronics Performance Measurement High Tech Security Internet Technology Nanotechnology Networks Peripherals RFID (Radio Frequency ID) Semantic Web Semiconductors EntertainÂ­ment & Media All EntertainÂ­ment & Media EntertainÂ­ment & Media Overview Advertising Art Books Entertainment Film and Motion Picture Magazines Music Publishing & Information Services Radio Television Financial Services & Investing All Financial Services & Investing Financial Services & Investing Overview Accounting News & Issues Acquisitions, Mergers and Takeovers Banking & Financial Services Bankruptcy Bond & Stock Ratings Conference Call Announcements Contracts Dividends Earnings Forecasts & Projections Earnings Financing Agreements Insurance Investments Opinions Joint Ventures Mutual Funds OTC, SmallCap Real Estate Restructuring & Recapitalization Sales Reports Shareholders' Rights Plan Stock Offering Stock Split Venture Capital General Business All General Business General Business Overview Agency Roster Awards Commercial Real Estate Corporate Expansion Earnings Human Resource & Workforce Management Licensing New Products & Services Obituaries Outsourcing Businesses Overseas Real Estate (non-US) Personnel Announcements Real Estate Transactions Residential Real Estate Small Business Services Socially Responsible Investing Surveys, Polls and Research Trade Show News Science & Tech Consumer Technology All Consumer Technology Consumer Technology Overview Computer Electronics Computer Hardware Computer Software Consumer Electronics Electronic Commerce Electronic Gaming Mobile Entertainment Multimedia & Internet Peripherals Social Media Web Site Wireless Communications Energy All Energy Energy Overview Alternative Energies Chemical Electrical Utilities Gas Mining Mining & Metals Oil & Energy Oil and Gas Discoveries Utilities Water Utilities EnvironÂ­ment All EnvironÂ­ment EnvironÂ­ment Overview Conservation & Recycling Environmental Issues Environmental Policy Environmental Products & Services Green Technology Heavy Industry & Manufacturing All Heavy Industry & Manufacturing Heavy Industry & Manufacturing Overview Aerospace & Defense Agriculture Chemical Construction & Building HVAC (Heating, Ventilation and Air-Conditioning) Machine Tools, Metalworking and Metallurgy Machinery Mining Mining & Metals Paper, Forest Products & Containers Precious Metals Textiles Tobacco TelecommÂ­unications All TelecommÂ­unications TelecommÂ­unications Overview Carriers and Services Mobile Entertainment Networks Peripherals TelecommunicÂ­ations Equipment TelecommunicaÂ­tions Industry VoIP (Voice over Internet Protocol) Wireless Communications Lifestyle & Health Consumer Products & Retail All Consumer Products & Retail Consumer Products & Retail Overview Animals & Pets Beers, Wines and Spirits Beverages Bridal Services Cosmetics and Personal Care Fashion Food & Beverages Furniture and Furnishings Home Improvement Household Products Household, Consumer & Cosmetics Jewelry Non-Alcoholic Beverages Office Products Organic Food Product Recalls Restaurants Retail Supermarkets Toys EntertainÂ­ment & Media All EntertainÂ­ment & Media EntertainÂ­ment & Media Overview Advertising Art Books Entertainment Film and Motion Picture Magazines Music Publishing & Information Services Radio Television Health All Health Health Overview Biometrics Biotechnology Dentistry Clinical Trials & Medical Discoveries FDA Approval Health Care & Hospitals Health Insurance Infection Control Medical Equipment Medical Pharmaceuticals Mental Health Pharmaceuticals Supplementary Medicine Sports All Sports Sports Overview General Sports Sporting Events Sports Equipment & Accessories Travel All Travel Travel Overview Amusement Parks and Tourist Attractions Gambling & Casinos Hotels and Resorts Leisure & Tourism Passenger Aviation Travel Industry Policy & Public Interest Policy & Public Interest All Policy & Public Interest Policy & Public Interest Overview Advocacy Group Opinion Animal Welfare Corporate Social Responsibility Domestic Policy Economic News, Trends, Analysis Education Environmental European Government FDA Approval Federal and State Legislation Federal Executive Branch & Agency Foreign Policy & International Affairs Homeland Security Labor & Union Legal Issues Not For Profit Patent Law Public Safety Trade Policy U.S. State Policy People & Culture People & Culture All People & Culture People & Culture Overview Aboriginal, First Nations & Native American African American Asian American Children Disabilities, Disabled People Hispanic Lesbian, Gay & Bisexual Religion Senior Citizens Veterans Women Other Language News dansk Deutsch espaÃ±ol FranÃ§ais italiano Nederlands norsk portuguÃªs suomeksi svenska Kallyope Inc. Appoints Ann E. Weber And William J. Rieflin To Key Roles - Ann E. Weber, Ph.D. named Senior Vice President, Drug Discovery - William J. Rieflin appointed to Board of Directors News provided by Kallyope Inc. Oct 27, 2016, 09:00 ET Share this article NEW YORK, Oct. 27, 2016 /PRNewswire-USNewswire/ --Â Kallyope Inc. ("Kallyope"), a biotechnology company focused on harnessing the potential of the gut-brain axis, today announced that it has appointed Ann E. Weber, Ph.D. to the position of Senior Vice President, Drug Discovery, and William J. Rieflin as an independent member of its Board of Directors. "The expansion of Kallyope's leadership team reflects the rapid advancement of our platform and confidence in our ability to generate valuable assets," said Nancy Thornberry, CEO of Kallyope. "The addition of such high-caliber individuals as Ann and Bill demonstrates our commitment to getting the right team together to realize the full potential of the gut-brain axis." Ann E. Weber, Ph.D. Dr. Weber will be responsible for taking opportunities arising from the company's state-of-the-art technology platform and translating them into drug discovery and development programs.Â  During her 28-year tenure at Merck & Co., where she was most recently Vice President, Lead Optimization Chemistry, her work led to over 40 development candidates, including the approved diabetes therapies JANUVIAÂ® (sitagliptin), JANUMETÂ® (sitagliptin and metformin), and MARIZEVÂ® (omarigliptin).Â Â  "I am excited to lead the translation of Kallyope's integrated platform for the interrogation of gut-brain circuits into new therapeutic opportunities," Dr. Weber said. "I also look forward to working closely again with Nancy."Â  Dr. Weber and Nancy Thornberry previously led the program at Merck that resulted in the discovery of JANUVIAÂ® (sitagliptin), for Type 2 Diabetes. Dr. Weber is the recipient of numerous awards, including the Robert M. Scarborough Award for Excellence in Medicinal Chemistry and the Heroes of Chemistry Award, both given by American Chemistry Society (ACS). She has also received PhRMA's Discoverer's Award, recognizing scientists whose work has been of special benefit to humankind, and Merck's Director's Award, the highest honor that the company confers on its employees. She is a 2013 Liberty Science Center Women in STEM Honoree, and in 2016 was named to the ACS's Medicinal Chemistry Hall of Fame. Dr. Weber obtained a B.S. in chemistry summa cum laude from the University of Notre Dame and a Ph.D. in synthetic organic chemistry from Harvard University.Â  Since leaving Merck in November 2015, Dr. Weber has been an independent consultant to biotech and pharmaceutical companies, including Kallyope. William J. Rieflin Mr. Rieflin is Chief Executive Officer of NGM Bio and has over 20 years of experience in the biotechnology industry. Prior to NGM, he was President of XenoPort, Inc. Prior to that, he was Executive Vice President, Administration, Chief Financial Officer, General Counsel and Secretary for Tularik Inc., which was acquired by Amgen Inc. in 2004. Previously, he was Vice President, Human Resources, General Counsel and Secretary for AMSCO International, Inc. and an associate at Sidley & Austin LLP in the corporate and securities department. "Kallyope is pioneering ways to improve human health and nutrition via the gut-brain axis with a sophisticated and unique technology platform," Mr. Rieflin said. "I look forward to working with the team and Board to realize the full potential of this platform." In addition to Kallyope and NGM, Mr. Rieflin serves on the Board of Directors of FLX Bio, Inc.. Mr. Rieflin earned a B.S. from Cornell University, his M.B.A. from the University of Chicago Booth School of Business, and his J.D. from Stanford Law School. About Kallyope Inc. Kallyope is a platform biotechnology company dedicated to unlocking the therapeutic potential of the gut-brain axis. The company integrates cutting-edge technologies in sequencing, bioinformatics, neural imaging, cellular and molecular biology, and human genetics to provide an understanding of gut-brain biology that can be translated into transformational therapeutics and products that improve human health and nutrition. The company's founders are Charles Zuker, Ph.D., Lasker Award winner Tom Maniatis, Ph.D., and Nobel laureate Richard Axel, M.D. Headquartered at the Alexandria CenterÂ® for Life Science in New York City, the company's founding investors include Lux Capital, Polaris Partners, and The Column Group. For more information visit www.kallyope.com. Logo - http://photos.prnewswire.com/prnh/20151209/294743LOGO Â  To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/kallyope-inc-appoints-ann-e-weber-and-william-j-rieflin-to-key-roles-300352078.html SOURCE Kallyope Inc. Related Links http://www.kallyope.com Dec 10, 2015, 08:00 ET Preview: Kallyope Inc. Launches With $44M Series A Financing To Harness The Potential Of The Gut-Brain Axis My News Release contains wide tables. View fullscreen. You just read: Kallyope Inc. Appoints Ann E. Weber And William J. Rieflin To Key Roles News provided by Kallyope Inc. Oct 27, 2016, 09:00 ET Share this article Looking to send a news release with PR Newswire? Take advantage of the world's leading distribution platform. Sign up to get started Request more information Have an account? Log In Phone 8AM - 10PM ET +1-888-776-0942 Send a Release Sign Up Blog For Journalists Contact Us Search Searching for your content... Advanced Search Contact 888-776-0942 from 8 AM - 10 PM ET Chat Online with an Expert Contact Us Solutions Cision Communication Cloudâ„¢ For Marketers For Public Relations For IR & Compliance For Agency For Small Business All Products About About PR Newswire About Cision Become a Publishing Partner Become a Channel Partner Careers Â  Global Sites Asia Brazil Canada Europe Finland France India Israel Mexico Middle East Netherlands Sweden United Kingdom My Services All News Releases Online Member Center ProfNetâ„  My Services All News Releases Online Member Center ProfNetâ„  888-776-0942 from 8 AM - 10 PM ET Terms of Use Privacy Policy Information Security Policy Statement Site Map RSS Feeds Copyright Â© 2016 PR Newswire Association LLC. All Rights Reserved. A Cision company. News Solutions Resources News in Focus Browse News Releases All News Releases News Releases Overview English-only All Public Company Multimedia Gallery All Multimedia Multimedia Gallery Overview All Photos All Videos Trending Topics All Trending Topics Business & Money Auto & Transportation All Auto & Transportation Auto & Transportation Overview Aerospace, Defense Air Freight Airlines & Aviation Automotive Maritime & Shipbuilding Railroads and Intermodal Transportation Transportation, Trucking & Railroad Travel Trucking and Road Transportation Business Technology All Business Technology Business Technology Overview Broadcast Tech Computer Hardware Computer Software Computer & Electronics Electronic Commerce Electronic Components Electronic Design Automation Electronics Performance Measurement High Tech Security Internet Technology Nanotechnology Networks Peripherals RFID (Radio Frequency ID) Semantic Web Semiconductors EntertainÂ­ment & Media All EntertainÂ­ment & Media EntertainÂ­ment & Media Overview Advertising Art Books Entertainment Film and Motion Picture Magazines Music Publishing & Information Services Radio Television Financial Services & Investing All Financial Services & Investing Financial Services & Investing Overview Accounting News & Issues Acquisitions, Mergers and Takeovers Banking & Financial Services Bankruptcy Bond & Stock Ratings Conference Call Announcements Contracts Dividends Earnings Forecasts & Projections Earnings Financing Agreements Insurance Investments Opinions Joint Ventures Mutual Funds OTC, SmallCap Real Estate Restructuring & Recapitalization Sales Reports Shareholders' Rights Plan Stock Offering Stock Split Venture Capital General Business All General Business General Business Overview Agency Roster Awards Commercial Real Estate Corporate Expansion Earnings Human Resource & Workforce Management Licensing New Products & Services Obituaries Outsourcing Businesses Overseas Real Estate (non-US) Personnel Announcements Real Estate Transactions Residential Real Estate Small Business Services Socially Responsible Investing Surveys, Polls and Research Trade Show News Science & Tech Consumer Technology All Consumer Technology Consumer Technology Overview Computer Electronics Computer Hardware Computer Software Consumer Electronics Electronic Commerce Electronic Gaming Mobile Entertainment Multimedia & Internet Peripherals Social Media Web Site Wireless Communications Energy All Energy Energy Overview Alternative Energies Chemical Electrical Utilities Gas Mining Mining & Metals Oil & Energy Oil and Gas Discoveries Utilities Water Utilities EnvironÂ­ment All EnvironÂ­ment EnvironÂ­ment Overview Conservation & Recycling Environmental Issues Environmental Policy Environmental Products & Services Green Technology Heavy Industry & Manufacturing All Heavy Industry & Manufacturing Heavy Industry & Manufacturing Overview Aerospace & Defense Agriculture Chemical Construction & Building HVAC (Heating, Ventilation and Air-Conditioning) Machine Tools, Metalworking and Metallurgy Machinery Mining Mining & Metals Paper, Forest Products & Containers Precious Metals Textiles Tobacco TelecommÂ­unications All TelecommÂ­unications TelecommÂ­unications Overview Carriers and Services Mobile Entertainment Networks Peripherals TelecommunicÂ­ations Equipment TelecommunicaÂ­tions Industry VoIP (Voice over Internet Protocol) Wireless Communications Lifestyle & Health Consumer Products & Retail All Consumer Products & Retail Consumer Products & Retail Overview Animals & Pets Beers, Wines and Spirits Beverages Bridal Services Cosmetics and Personal Care Fashion Food & Beverages Furniture and Furnishings Home Improvement Household Products Household, Consumer & Cosmetics Jewelry Non-Alcoholic Beverages Office Products Organic Food Product Recalls Restaurants Retail Supermarkets Toys EntertainÂ­ment & Media All EntertainÂ­ment & Media EntertainÂ­ment & Media Overview Advertising Art Books Entertainment Film and Motion Picture Magazines Music Publishing & Information Services Radio Television Health All Health Health Overview Biometrics Biotechnology Dentistry Clinical Trials & Medical Discoveries FDA Approval Health Care & Hospitals Health Insurance Infection Control Medical Equipment Medical Pharmaceuticals Mental Health Pharmaceuticals Supplementary Medicine Sports All Sports Sports Overview General Sports Sporting Events Sports Equipment & Accessories Travel All Travel Travel Overview Amusement Parks and Tourist Attractions Gambling & Casinos Hotels and Resorts Leisure & Tourism Passenger Aviation Travel Industry Policy & Public Interest Policy & Public Interest All Policy & Public Interest Policy & Public Interest Overview Advocacy Group Opinion Animal Welfare Corporate Social Responsibility Domestic Policy Economic News, Trends, Analysis Education Environmental European Government FDA Approval Federal and State Legislation Federal Executive Branch & Agency Foreign Policy & International Affairs Homeland Security Labor & Union Legal Issues Not For Profit Patent Law Public Safety Trade Policy U.S. State Policy People & Culture People & Culture All People & Culture People & Culture Overview Aboriginal, First Nations & Native American African American Asian American Children Disabilities, Disabled People Hispanic Lesbian, Gay & Bisexual Religion Senior Citizens Veterans Women Other Language News dansk Deutsch espaÃ±ol FranÃ§ais italiano Nederlands norsk portuguÃªs suomeksi svenska Phone +1-888-776-0942 8AM - 10PM ET Chat Chat Online with an Expert All contact info Send a ReleaseLog In
Dienstag, 15.11.2016 BÃ¶rsentÃ¤glich Ã¼ber 12.000 News von 551 internationalen Medien Indizes Kurs % News 24Â hÂ /Â 7Â T Aufrufe 7 Tage Aktien Kurs % News 24Â hÂ /Â 7Â T Aufrufe 7 Tage Xetra-Orderbuch Devisen Kurs % Rohstoffe Kurs % Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige) Erweiterte Suche Ad hoc-Mitteilungen Startseite Nachrichten Aktienkurse Fonds Anleihen Derivate Rohstoffe Devisen Watchlist Aufklappen Schliessen AktienÂ»NachrichtenÂ»ADAPTIMMUNE THERAPEUTICS AKTIEÂ»Adaptimmune Therapeutics plc: Adaptimmune Announces Collaboration with MSD to Evaluate KEYTRUDAÂ® (pembrolizumab) in Combination with NY-ESO SPEARÂ® T-Cell Therapy in Multiple Myeloma ADAPTIMMUNE THERAPEUTICS PLC ADR 4,687 Â Euro +0,273 +6,18 % WKN: A14SUX Â ISIN: US00653A1079Â Ticker-Symbol: 473AÂ  StuttgartÂ |Â 14.11.16Â |Â 21:52Â Uhr Nachrichten Analysen Kurse Chart Aktie: BrancheBiotechnologie AktienmarktSonstige 1-Jahres-Chart 1-Woche-Intraday-Chart 27.10.2016 | 16:28 (8 Leser) Schrift Ã¤ndern: (0 Bewertungen) GlobeNewswireÂ·Mehr Nachrichten von GlobeNewswire Adaptimmune Therapeutics plc: Adaptimmune Announces Collaboration with MSD to Evaluate KEYTRUDAÂ® (pembrolizumab) in Combination with NY-ESO SPEARÂ® T-Cell Therapy in Multiple Myeloma PHILADELPHIA and OXFORD, United Kingdom, 2016-10-27 16:20 CEST (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has entered into a clinical trial collaboration agreement with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the US and Canada), for the assessment of Adaptimmune's NY-ESO SPEARÂ® (Specific Peptide Enhanced Affinity Receptor) T-cell therapy in combination with MSD's anti-programmed death-1 (PD-1) inhibitor, KEYTRUDAÂ® (pembrolizumab), in patients with multiple myeloma. The study will evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination, and is planned for initiation in 1H 2017. Adaptimmune's SPEAR T-cell candidates are novel cancer immunotherapies that have been engineered to target and destroy cancer cells. Its NY-ESO SPEAR T-cell therapy has previously been evaluated in multiple myeloma in a single agent Phase I/II trial in which 20 out of 22 patients (91 percent) experienced a response at day 100 post autologous stem cell transplant. KEYTRUDA is a humanized monoclonal antibody that works by increasing the ability of the body's immune system to help detect and fight tumor cells. KEYTRUDA blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells. Blocking this interaction is reported to enable T-cell activation and potentiates antitumor activity. "In initial single-agent studies of our NY-ESO SPEAR T-cell therapy in patients with advanced myeloma in the context of stem cell transplantation, we have seen encouraging evidence of antitumor effect, safe administration and prolonged persistence of transduced cells," said Rafael Amado, Adaptimmune's chief medical officer. "KEYTRUDA has shown preliminary evidence of activity in multiple myeloma, and there is preclinical evidence to support the view that the combination of NY-ESO SPEAR T-cell therapy and anti-PD1 therapy may lead to meaningful anti-tumor activity. We look forward to evaluating our therapy alone and in combination with KEYTRUDA in a randomized trial of patients with multiple myeloma who are refractory or have relapsed with standard therapy. " The agreement is between Adaptimmune and Merck & Co., Inc., Kenilworth, NJ, USA, through a subsidiary. Under the agreement, the trial will be sponsored by Adaptimmune. The agreement also includes provision for potential expansion to include Phase III registration studies in the same indication. Additional details were not disclosed. About Multiple Myeloma Multiple myeloma is a cancer formed by malignant plasma cells. Normal plasma cells are found in the bone marrow and are an important part of the immune system, which is made up of several types of cells that work together to fight infections and other diseases. Multiple myeloma is characterized by several features, including low blood counts, bone and calcium problems, infections, kidney problems, monoclonal gammopathy, and others; and by the proliferation of these plasma cells within bone marrow. The American Cancer Society estimates that approximately 30,300 new cases will be diagnosed in the United States in 2016. Average five-year survival rates are estimated to be approximately 45 percent with survival rates depending on factors such as age, stage of diagnosis and suitability for auto-SCT, which is used as part of the treatment for eligible patients with multiple myeloma. Despite recent therapeutic advances, multiple myeloma remains an incurable but treatable cancer. Patients are typically treated with repeat rounds of combination therapy with the time intervals to relapse becoming shorter with each successive line of therapy. The majority of patients eventually have a relapse which cannot be further treated. About Adaptimmune's TCR Technology Adaptimmune's proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell receptor (TCR) technology enables the company to genetically optimize TCRs, equipping them to recognize cancer antigens that are presented in small quantities on the surface of a cancer cell, whether of intracellular or extracellular origin, thus initiating cell death. The company's differentiated, proprietary technology allows it to reliably generate parental TCRs to naturally presented targets, affinity optimize its TCRs to bind cancer proteins from solid and hematologic cancers that are generally unavailable to naturally occurring TCRs, and to significantly reduce the risk of side effects resulting from off-target binding of healthy tissues. About Adaptimmune Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its SPEARÂ® (Specific Peptide Enhanced Affinity Receptor) T-cell platform. Established in 2008, the company aims to utilize the body's own machinery - the T-cell - to target and destroy cancer cells by using engineered, increased affinity TCRs as a means of strengthening natural patient T-cell responses. Adaptimmune's lead program is a SPEAR T-cell therapy targeting the NY-ESO cancer antigen. Its NY-ESO SPEAR T-cell therapy has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types, including synovial sarcoma and multiple myeloma. Adaptimmune has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO TCR program. In addition, Adaptimmune has a number of proprietary programs. These include SPEAR T-cell therapies targeting the MAGE-A10 and AFP cancer antigens, which both have open INDs, and a further SPEAR T-cell therapy targeting the MAGE-A4 cancer antigen that is in pre-clinical phase with IND acceptance targeted for 2017. The company has identified over 30 intracellular target peptides preferentially expressed in cancer cells and is currently progressing 12 through unpartnered research programs. Adaptimmune has over 250 employees and is located in Oxfordshire, U.K. and Philadelphia, USA. For more information: http://www.adaptimmune.com Forward-Looking Statements This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 8, 2016, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances. KEYTRUDAÂ® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Adaptimmune Contacts Will Roberts Vice President, Investor Relations T: (215) 825-9306 E: will.roberts@adaptimmune.com Juli P. Miller, Ph.D. Associate Director, Investor Relations T: (215) 825-9310 E: juli.miller@adaptimmune.com Margaret Henry Head of PR T: +44 (0)1235 430036 Mob: +44 (0)7710 304249 E: margaret.henry@adaptimmune.com Â©Â 2016Â GlobeNewswire Nachrichten zu ADAPTIMMUNE THERAPEUTICS PLC ADR Zeit Aktuelle Nachrichten Mo Adaptimmune Therapeutics PLC Rating Reiterated by Cowen and Company â–º Artikel lesen Fr BRIEF-Adaptimmune announces update on clinical data from NY-ESO Spear T-cell synovial sarcoma study â–º Artikel lesen Fr Adaptimmune Therapeutics (ADAP) Updates on NY-ESO SPEAR T-Cell Study; Median Survival Seen Up ~39% â–º Artikel lesen Fr BRIEF-Adaptimmune presents preclinical data from SPEAR T-cell â–º Artikel lesen Fr Adaptimmune Therapeutics (ADAP) to Present at SITC Annual Meeting; Includes MAGE-A4 SPEAR T-Cell Data â–º Artikel lesen Firmen im Artikel 1-Woche-Intraday-Chart ADAPTIMMUNE THERAPEUTICS PLC ADR Unternehmen / Aktien Kurs % ADAPTIMMUNE THERAPEUTICS PLC ADR 4,687 +6,18Â % Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von Â und Â mit der Push-Technologie vonÂ Â  Wie bewerten Sie die aktuell angezeigte Seite?sehr gut123456schlechtProblem melden Google+ Seite NachrichtenÂ â€¢Â AktienkurseÂ â€¢Â DAXÂ â€¢Â Xetra-OrderbuchÂ â€¢Â Watchlist Ad hoc-MitteilungenÂ â€¢Â Nachrichten BÃ¶rsenÂ â€¢Â Aktien-Empfehlungen BranchenÂ â€¢Â MedienÂ â€¢Â Nachrichten-Archiv Impressum | AGB | DisclaimerÂ â€¢Â PresseÂ â€¢Â Mediadaten RSS-News von FinanzNachrichten.de kostenlos fÃ¼r Ihren Browser und Ihre Homepage
Skip to main content The Motley Fool Fool.com Fool.co.uk Fool.com.au Fool.ca Fool.sg Fool.de Hi, Fool! Premium Advice Help Fool Answers Contact Us Login MENU Stock Picks Learn More News Investing News Fool Podcasts Guides How to Invest Retirement Personal Finance Motley Fool Answers Options Trading Find a Broker Compare IRA Accounts Community Discussion Boards CAPS More About Help My Fool My Fool My Profile My Watchlist My Scorecard My Boards My CAPS My Reports My Subscriptions My Settings Premium Advice My Services None Other Services None Help Fool Answers Contact Us Login Search Search: Merck & Co.'s Patent Cliff In 2017 The expiration of patents on some of the company's top-selling drugs poses big headwinds for investors. Todd Campbell (TMFEBCapital) Oct 27, 2016 at 9:01AM Image source: Getty Images. Merck & Co.Â (NYSE:MRK)Â is a global pharmaceuticals giant with tens of billions in annualized sales, however, the company's top line is about to take a hit in the coming year because of patent expiration on Remicade, Cubicin, and Zetia -- three of its best selling medicines. Mounting patent headwinds Through the first nine months of 2016, sales of Merck's top selling autoimmune disease drug, Remicade, have plummeted from $1.4 billion last year to less than $1 billion. The drop is due primarily to the launch of Remicade biosimilars in Europe, where Merck is licensed to sell the drug.Â Biosimilars are effective inexact copies of brand name medicines, and since they're usually priced at a 30% to 40% discount to the brand-name drug, doctors and patients tend to favor them. Pfizer's Hospira launched the first Remicade biosimilar, Inflectra, in Europe last year, and BiogenÂ and Samsung BioLogics launched another Remicade biosimilar, Flexabi, earlier this year. Because there are multiple Remicade biosimilars on the market now, Merck's Remicade revenue is likely to continue falling in 2017.Â  Merck is also about to feel the pinch of patent expiration on Cubicin, a treatment for flesh-eating bacteria.Â After failing to block generic competitors from launching until 2020, U.S. patents on Cubicin expired this summer. Since that expiration puts roughly $1 billion of Merck's revenue in play, Merck's management is warning investors to expect "a significant decline inÂ U.S.Â Cubicin sales going forward." Patents protecting Merck's cholesterol-lowering therapy, Zetia, are also on the chopping block. Zetia patents expire in December and Merck anticipates a "significant decline inÂ U.S.Â Zetia sales thereafter."Â Zetia's U.S. sales were $411 million last quarter. Across all three drugs, competition due to patent losses will put nearly $4 billion of Merck's $42 billion in annualized third quarter sales at risk in 2017. Image source: Getty Images. Managing the risk To offset patent headwinds, Merck is going to need its fast-growing drugs, including Gardasil 9, Keytruda, and Zepatier, to over-deliver. Gardisal 9 is a vaccine that protects against human papillomavirus (HPV), and in Q3 combined Gardasil and Gardisal 9 sales totaled $860 million, up 38% year over year. Recently,Â a two-dose vaccination regimen for Gardasil 9 in certain girls and boys between ages 9 and 14 won FDAÂ approval, and theÂ U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization PracticesÂ voted to recommend that two-dose approach. Previously, Gardasil 9 was given via three-doses. Because the FDA estimatesÂ Gardasil 9 "has the potential to prevent approximately 90 percent of cervical, vulvar, vaginal and anal cancers," and the dosing burden on patients is falling, Gardisal 9 isÂ likely to remain a top-seller in 2017. Keytruda, a PD-L1 inhibitor that stops cancer from over-expressing PD-L1 to avoid detection by the immune system, also offers support to sales in the coming year. Initially, Keytruda was approved for use in melanoma patients in 2014, but Keytruda's label has expanded since then to include head and neck cancer patients and lung cancer patients, too. Because of those label expansions, Keytruda's sales climbed from $159 million in the third quarter of 2015 to $356 million in the third quarter of 2016. Keytruda's sales could head even higher next year because it recently secured approval as an alternative to chemotherapy in newly diagnosed metastatic non-small cell lung cancer patients with high PD-L1 levels. This approval has led to industry watchers increasing their outlook for Keytruda's sales in 2017. For example, Bernstein's analysts bumped up their Keytruda sales outlook for next year by roughly $1 billion following the FDA approval.Â  Zepatier, a hepatitis C drug, also offers the company top-line tailwinds heading into next year.Â Zepatier won FDA approval in January and aggressive pricing by management undercut competitors and resulted in first, second, and third quarter sales of $50 million, $112 million, and $164 million, respectively. Eyes on 2017 Historically, patent expiration causes the vast majority of brand-name drug sales to shift to competitors, however, it's anyone's guess exactly how quickly that will happen at Merck. Merck'sÂ fast-growing drugs provide it with some insulation, and if the company secures FDA approval of MK-1293, a biosimilar to the $6 billion plus per year insulin Lantus, then it may be in even better shape to handle the hit to sales caused by expiring patents. Nevertheless, since expiring patents could weigh down sales and profit next year and cause shares to trade lower, the company's patent risk can't be ignored by investors. Â  Todd Campbell has no position in any stocks mentioned.Â Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned.Â Like this article? Follow him onÂ Twitter where he goes by the handleÂ @ebcapitalÂ to see more articles like this. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. Author Todd Campbell (TMFEBCapital) Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn. Follow @ebcapital Article Info Oct 27, 2016 at 9:01AM Health Care Stocks Merck and Co. NYSE:MRK $63.53 down $0.42 (-0.66%) Read More Legal Dispute Puts Ionis Pharmaceuticals' Payday on Hold After Opdivo's Failure, Is Merck a Better Buy Than Bristol-Myers? Merck's Mixed Q1 Results Are Marred By 1 Disappointing Drug Debut Get Paid While You Wait: 3 Top Big Pharma Dividend Stocks A Big Breakthrough for Ovarian Cancer Patients Prev 1 2 3 4 5 6 7 8 Next Compare Brokers Terms of Use Privacy Policy Copyright, Trademark and Patent Information Terms and Conditions Â© 1995 - 2016 The Motley Fool. All rights reserved. Current New stock picks released in... Â  Â  Â  Â  Get The Picks x
Skip to main content The Motley Fool Fool.com Fool.co.uk Fool.com.au Fool.ca Fool.sg Fool.de Hi, Fool! Premium Advice Help Fool Answers Contact Us Login MENU Stock Picks Learn More News Investing News Fool Podcasts Guides How to Invest Retirement Personal Finance Motley Fool Answers Options Trading Find a Broker Compare IRA Accounts Community Discussion Boards CAPS More About Help My Fool My Fool My Profile My Watchlist My Scorecard My Boards My CAPS My Reports My Subscriptions My Settings Premium Advice My Services None Other Services None Help Fool Answers Contact Us Login Search Search: Merck & Co.'s Patent Cliff In 2017 The expiration of patents on some of the company's top-selling drugs poses big headwinds for investors. Todd Campbell (TMFEBCapital) Oct 27, 2016 at 9:01AM Image source: Getty Images. Merck & Co.Â (NYSE:MRK)Â is a global pharmaceuticals giant with tens of billions in annualized sales, however, the company's top line is about to take a hit in the coming year because of patent expiration on Remicade, Cubicin, and Zetia -- three of its best selling medicines. Mounting patent headwinds Through the first nine months of 2016, sales of Merck's top selling autoimmune disease drug, Remicade, have plummeted from $1.4 billion last year to less than $1 billion. The drop is due primarily to the launch of Remicade biosimilars in Europe, where Merck is licensed to sell the drug.Â Biosimilars are effective inexact copies of brand name medicines, and since they're usually priced at a 30% to 40% discount to the brand-name drug, doctors and patients tend to favor them. Pfizer's Hospira launched the first Remicade biosimilar, Inflectra, in Europe last year, and BiogenÂ and Samsung BioLogics launched another Remicade biosimilar, Flexabi, earlier this year. Because there are multiple Remicade biosimilars on the market now, Merck's Remicade revenue is likely to continue falling in 2017.Â  Merck is also about to feel the pinch of patent expiration on Cubicin, a treatment for flesh-eating bacteria.Â After failing to block generic competitors from launching until 2020, U.S. patents on Cubicin expired this summer. Since that expiration puts roughly $1 billion of Merck's revenue in play, Merck's management is warning investors to expect "a significant decline inÂ U.S.Â Cubicin sales going forward." Patents protecting Merck's cholesterol-lowering therapy, Zetia, are also on the chopping block. Zetia patents expire in December and Merck anticipates a "significant decline inÂ U.S.Â Zetia sales thereafter."Â Zetia's U.S. sales were $411 million last quarter. Across all three drugs, competition due to patent losses will put nearly $4 billion of Merck's $42 billion in annualized third quarter sales at risk in 2017. Image source: Getty Images. Managing the risk To offset patent headwinds, Merck is going to need its fast-growing drugs, including Gardasil 9, Keytruda, and Zepatier, to over-deliver. Gardisal 9 is a vaccine that protects against human papillomavirus (HPV), and in Q3 combined Gardasil and Gardisal 9 sales totaled $860 million, up 38% year over year. Recently,Â a two-dose vaccination regimen for Gardasil 9 in certain girls and boys between ages 9 and 14 won FDAÂ approval, and theÂ U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization PracticesÂ voted to recommend that two-dose approach. Previously, Gardasil 9 was given via three-doses. Because the FDA estimatesÂ Gardasil 9 "has the potential to prevent approximately 90 percent of cervical, vulvar, vaginal and anal cancers," and the dosing burden on patients is falling, Gardisal 9 isÂ likely to remain a top-seller in 2017. Keytruda, a PD-L1 inhibitor that stops cancer from over-expressing PD-L1 to avoid detection by the immune system, also offers support to sales in the coming year. Initially, Keytruda was approved for use in melanoma patients in 2014, but Keytruda's label has expanded since then to include head and neck cancer patients and lung cancer patients, too. Because of those label expansions, Keytruda's sales climbed from $159 million in the third quarter of 2015 to $356 million in the third quarter of 2016. Keytruda's sales could head even higher next year because it recently secured approval as an alternative to chemotherapy in newly diagnosed metastatic non-small cell lung cancer patients with high PD-L1 levels. This approval has led to industry watchers increasing their outlook for Keytruda's sales in 2017. For example, Bernstein's analysts bumped up their Keytruda sales outlook for next year by roughly $1 billion following the FDA approval.Â  Zepatier, a hepatitis C drug, also offers the company top-line tailwinds heading into next year.Â Zepatier won FDA approval in January and aggressive pricing by management undercut competitors and resulted in first, second, and third quarter sales of $50 million, $112 million, and $164 million, respectively. Eyes on 2017 Historically, patent expiration causes the vast majority of brand-name drug sales to shift to competitors, however, it's anyone's guess exactly how quickly that will happen at Merck. Merck'sÂ fast-growing drugs provide it with some insulation, and if the company secures FDA approval of MK-1293, a biosimilar to the $6 billion plus per year insulin Lantus, then it may be in even better shape to handle the hit to sales caused by expiring patents. Nevertheless, since expiring patents could weigh down sales and profit next year and cause shares to trade lower, the company's patent risk can't be ignored by investors. Â  Todd Campbell has no position in any stocks mentioned.Â Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned.Â Like this article? Follow him onÂ Twitter where he goes by the handleÂ @ebcapitalÂ to see more articles like this. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. Author Todd Campbell (TMFEBCapital) Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn. Follow @ebcapital Article Info Oct 27, 2016 at 9:01AM Health Care Stocks Merck and Co. NYSE:MRK $63.53 down $0.42 (-0.66%) Read More Legal Dispute Puts Ionis Pharmaceuticals' Payday on Hold After Opdivo's Failure, Is Merck a Better Buy Than Bristol-Myers? Merck's Mixed Q1 Results Are Marred By 1 Disappointing Drug Debut Get Paid While You Wait: 3 Top Big Pharma Dividend Stocks A Big Breakthrough for Ovarian Cancer Patients Prev 1 2 3 4 5 6 7 8 Next Compare Brokers Terms of Use Privacy Policy Copyright, Trademark and Patent Information Terms and Conditions Â© 1995 - 2016 The Motley Fool. All rights reserved. Current New stock picks released in... Â  Â  Â  Â  Get The Picks x
Skip to main content South China Morning Post Edition: International Hong Kong International Jobs Events Education Courses Newsletters Policies & Politics Register / Login Search " SIGN UP FOR eNEWSLETTER Main menu Home China HK Asia World Comment Business Tech Life Culture Sport Week in asia Post Mag Style .TV All South China Morning Post Main menu China HK Asia World Comment Business Tech Life Culture Sport Week in asia Post Mag Style .TV Search " Share PrintEmail Now Reading Delays in approving HPV vaccines in mainland China force women to seek shots in Hong KongÂ  Hong Kong Politics Economy Health & Environment Law & Crime Education & Community China Policies & Politics Diplomacy & Defence Money & Wealth Economy Society Tech This Week in Asia News Asia World Business Companies Markets Property Investor Relations Global Economy China Economy Money & Wealth Special Reports Country Reports Tech China Tech Enterprises Social & Gadgets Start-ups Apps & Gaming Innovation Leaders & Founders Science & Research Lifestyle Fashion & Luxury Travel & Leisure Motoring Families Food & Drink Health & Beauty Watches Style Sport Hong Kong China Golf Racing Rugby Soccer Tennis Boxing Motorsport Comment Insight & Opinion Harry's View Blogs Polls Letters Multimedia Infographics Photos Video Magazines Post Magazine Style Good Eating Destination Macau Popular Topics This Week in Asia US election: Trump v Clinton G20: Hangzhou South China Sea: Hague case Hong Kong bookseller disappearances South China Sea Jake's View A-shares Brexit Sino-Japanese relations Sino-US relations #SoHongKong Xi Jinping's anti-graft campaign China Briefing China: Around The Nation Hongcouver Occupy Central Advertising Solutions SCMP Mobile Edition SCMP Tablet Edition SCMP ePaper Edition SCMP.com search Historical Archive HK Magazine Archive Directories Luxehomes At your service Business Services Directory MICE Biz Restaurant Directory CPJobs.com Education Post Events Young Post Follow us on Facebook Follow us on Twitter Newsâ€ºChinaâ€ºPolicies & Politics PUBLIC HEALTH Delays in approving HPV vaccines in mainland China force women to seek shots in Hong Kong PUBLISHED : Thursday, 27 October, 2016, 9:34am UPDATED : Thursday, 27 October, 2016, 10:01pm Comments: Â  Zhuang Pinghui Share PrintEmail Delays in approvals on the Chinese mainland for HPV vaccines are prompting thousands women and girls to head across the border to Hong Kong for shots. Ming Gefan, who manages the Shenzhen branch of MJ HK Health Screening Centre in Guangdong province and helps mainland customers book appointments to take the shots in Hong Kong, said she Â­noticed an uptick in demand for protection against human papillomavirus after the mainland gave regulatory approval earlier this year for Cervarix, a vaccine that guards against the virus. But while Cervarix was the only HPV vaccine approved for sale on the mainland, it would be taken off shelves in the United States by its manufacturer, GlaxoSmithKline, due to weak demand, news outlet Fierce Pharma reported last week. Thousands set to benefit from Hong Kongâ€™s free HPV vaccination programme Cervarix, which protects against two HPV strains that account for 70 per cent of cervical cancer cases, was approved by the China Food and Drug Administration in July and not expected to go on sale there until next year. An unidentified spokesman for GlaxoSmithKline was quoted as saying the company decided to stop supplying Cervarix in the US due to weak demand. HPV is sexually transmissible and infection is the leading cause of cervical cancer, the fourth most common cancer in women worldwide according to the World Health Organisation. There are many strains of HPV, with some strains producing warts on various parts of the body. Many mainlanders learned of the vaccine on the internet Ming Gefan, manager, MJ HK Health Screening Centre, Shenzhen Gardasil and Gardasil 9, produced by Merck and which protect against four strains and nine strains of HPV respectively that account for 90 per cent of cervical cancer cases â€“ is also available in the US but not on the mainland. Shanghai-based Thepaper.cn quoted Merck as saying the company was still seeking regulatory approval from the Chinese authorities. Questions sent to GSK and the drug administration were not immediately answered. About 50 countries have added HPV vaccines to their national immunisation programme, but the mainland has been relatively late in doing so. Ming said many mainlanders learned of the vaccine on the internet. â€œThose with a progressive mindset are going to take the vaccine shot, especially after China approved Â­Cervarix,â€ she said. WHO launches new guide for cervical cancer prevention and control â€œThey go to Hong Kong to choose the vaccine that offers wider protection, against four strains of HPV or even nine strains.â€ Ming said the Hong Kong clinic regularly gave 5,000 HPV shots a month and up to 300 injections on busy days. The youngest client was nine years old and the oldest a woman in her 70s. Not all came from Guangdong province, with some making the journey from as far away as Inner Mongolia, she said. A previous GSK statement said cervical cancer was the second most common cancer among Chinese women aged 15 to 44, with an estimated 130,000 new cases seen every year. Research shows that early treatment can prevent up to 80 per cent of cases. This article appeared in the South China Morning Post print edition as: HPV shot delays prompt women to head to Hong Kong Â  Most Popular Viewed 1 WikiLeaks' Assange vows to release â€˜significantâ€™ documents before US election 2 Decision on Hong Kong localist duo should be made by Legco, not court, lawyers argue in high-stakes hearing over oath saga 3 Beijing â€˜strongly dissatisfiedâ€™ after South Korean coastguard fires machine guns at Chinese trawlers 4 Chinaâ€™s most powerful rocket lifts off from island launch centre 5 In extraordinary move, Obama condemns FBI for Clinton email disclosure: â€˜We donâ€™t operate on innuendoâ€™ Shared 1 Beijing â€˜strongly dissatisfiedâ€™ after South Korean coastguard fires machine guns at Chinese trawlers 2 Decision on Hong Kong localist duo should be made by Legco, not court, lawyers argue in high-stakes hearing over oath saga 3 Hong Kong government slammed for taking too long to test hairy crab samples for dioxins 4 Hong Kong quality of life nears lows of 2003 with sentiments on housing affordability, freedom of speech down 5 Chinaâ€™s most powerful rocket lifts off from island launch centre Commented 1 Hong Kong oath-taking saga shows ugly side of cityâ€™s colonial legacy 2 Pan-democratsâ€™ shameless exploitation of oath saga has brought the NPC down on us 3 Sorry to disappoint, doomsayers, but Hong Kong is far from finished 4 Hong Kong will pay a heavy price for yet another Basic Law interpretation 5 The next black swan could be fast approaching from a region that few are talking about Promotions Order your FREE copy of the MICE BIZ 2016 2H Â  Â  Â  You may also like China How new Xinjiang party boss became front runner in race to be one of Chinaâ€™s most powerful men 30 Oct 2016 - 11:24pm 2 Out on the town: experiencing Macau is far from a gamble In partnership with Macao Government Tourism Office Why bankers and cocaine are best of friends 30 Oct 2016 - 8:46pm 9 Linden Educational Servicesâ€™ Summer and Boarding School Expo helps parents choose an international boarding school Brought to you by: Ace Academy Limited Hong Kong Illegal fees, little rest and no documents: domestic helpers in Hong Kong continue to fight for their rights 30 Oct 2016 - 8:07am 21 Hong Kong Should history lessons in schools include details about Hong Kongâ€™s 1967 riots? 30 Oct 2016 - 10:29pm 9 China A billion billion calculations per second: where no computer has gone before 29 Oct 2016 - 8:00am 4 Hong Kong Meet Viveca Chow, Broadway musical star from Hong Kong Oct 28th 2016, 11:57pm World Plane bursts into flame at Chicago airport Oct 29th 2016, 3:45pm China China has worldâ€™s most skewed sex ratio at birth â€“ again 27 Oct 2016 - 10:04pm 2 Post Magazine The Asian men who buy sex with Cambodian virgins 28 Oct 2016 - 10:54am 3 Post Magazine With the paedophile-hunters on the streets of Phnom Penh 28 Oct 2016 - 10:55am 1 South China Morning Post Stay connected Facebook Twitter Hong Kong Politics Economy Health & Environment Law & Crime Education & Community News China Hong Kong Asia World China Policies & Politics Diplomacy & Defence Money & Wealth Society Economy Tech Business Companies Markets Property Investor Relations Mutual Funds Economy China Economy Money & Wealth Country Reports Tech China Tech Enterprises Social & Gadgets Start-ups Apps & Gaming Innovation Leaders & Founders Science & Research E-Commerce Lifestyle Arts & Entertainment Health & Beauty Film & TV Food & Drink Families Music Fashion & Luxury Books Travel & Leisure Watches Sport Hong Kong China Golf Racing Rugby Soccer Tennis Boxing Comment Insight & Opinion Harry's View Blogs Polls Letters Multimedia Video Photos Infographics SCMP Chronicles Magazine Post Magazine Style Good Eating Destination Macau HK Magazine Archive Other Weather Most Popular 7 Days Index Country Reports Crossword Promotions Directories Luxehomes At your service Business Services Directory MICE Biz Restaurant Directory Information Buy SCMP Photos Copyright Licensing RSS Feeds SCMP.com search Historical Archive Print Subscription Advertising Opportunities Contact our Advertising Sales HK Rate card Overseas Rate Card China Rate Card The Marketer SCMP Marketing Solutions SCMP Outdoor Advertising Recruitment Advertising Events SCMP Events Operation Santa Claus Other Sites CPJobs.com Education Post Young Post Cosmopolitan CosmoGIRL! Elle Harpers Bazaar Racing Post SCMP Mobile Edition IOS Android Window SCMP TABLET Edition iOS HTML5 Android HTML5 SCMP ePaper Edition SCMP ePaper Edition SIGN UP for SCMP eNewsletter SCMP Publishers Privacy Policy FAQs Terms & Conditions Work For Us Contact Us Copyright Â© 2016 South China Morning Post Publishers Ltd. All rights reserved.


17 Â°C Cavan Home News Farming Sponsored Editorial Events Weather Sport Entertainment Videos Puzzles Business & Tourism Awards 2016 ePaper Supplements Gallery Archive Pictures Shop Local Jobs More Contact Us News Adverse HPV reports 'taken seriously' - manufacturer Wednesday, 26th October, 2016 1:27pm Story by Seamus Enright Jump to comments The company behind the Gardasil HPV vaccine have assured, while they take reports of any adverse reaction â€œextremely seriouslyâ€, such outcomes do not necessarily prove a causal relationship with the vaccine and encourage further investigation, if required. The statement from Sanofi Pasteur MSD, the Irish subsidiary of Merek Sharp Dolhme, made the comments, after The Anglo-Celt was made aware of several incidents in the local region where families believe their daughters made have become seriously ill as a result of side-effects of the vaccine. Among the concerns highlighted are limb paralysis, early onset of MS, ovarian failure, even menopause. At the time of going to print, the HSE had still not responded with figures detailing the uptake rates of the vaccination in counties Cavan and Monaghan over since it was first introduced for young teenage girls back in 2010. But in a statement to The Anglo-Celt, Sanofi Pasteur MSD say that patient safety is the companyâ€™s â€œhighest priorityâ€. â€œWe encourage people to self-report or report on behalf of others, any changes to their health which may or may not be medically confirmed. These reports are taken extremely seriously and are used to monitor long-term safety, however, they do not necessarily prove a causal relationship with the vaccine, but provide health authorities with a line of enquiry for further investigation, if required.â€ The Gardasil HPV vaccine is the result of over 10 years of research and development. The safety of the vaccine has continued to be evaluated in several large post-licence surveillance studies in more than one million people (Vichnin et al, 2015). HPV vaccine protects against two high risk types of HPV (16 & 18) that cause 73% of all cervical cancers. To date, more than 213 million doses of Gardasil have been distributed globally, and, by January 2016, in Ireland over 580,000 doses of the vaccine has been administered and over 200,000 girls have been fully vaccinated. Sanofi Pasteur MSD added: â€œThrough constant worldwide surveillance, the safety of medicinal products, including vaccines, is routinely reviewed as part of an ongoing safety monitoring process. While no vaccine or medicine is completely without risk, leading international health organisations throughout the world continue to recommend routine HPV vaccination.â€ However, before the DÃ¡il earlier this month, by way of Parliamentary Questions, Deputies Tony McLoughlin (FG), Marc MacSharry (FF), and Martin Kenny (SF) each submitted individual questions to the Minister for Health Simon Harris for response. The were joined by Independents Michael Fitzmaurice and Clare Daly. Each highlighted concerns, including if incidence of adverse reactions are under-reported as most doctors will not acknowledge any connection between a vaccine and a subsequent serious medical condition that manifests in the weeks or months afterwards. Read 5187 Email Print Latest Video Latest Gallery Junior Infants School Pics - 22.09.2016 Issue Part 2 Keep up-to-date with the latest news from around the county with an Anglo Celt Epaper subscription from â‚¬2.20*Â  Post a Comment Previous Story New SuperValu to open in Kingscourt 25 Oct 2016Oâ€™Gormanâ€™s SuperValu in Kingscourt will employ up to 45 workers Next Story Country Club serves up double helping of music 28 Oct 2016Robert Mizzell and Derek Ryan take to the stage for Bank Holiday weekend at the Country Club ePaper Subscription Desktop, Tablet & Smartphone friendly Group Publications Simonstown star departs for Melbourne this week Death of former Meath county manager Tullamore boxer Grainne backs Fight for the Girls campaign New hotel plan for centre of Tullamore Tonight's supermoon is a global phenomenon Westmeath girl crowned Queen of the Land Ireland calls to Chicago for unforgettable Soldier's song 'Fit 2 Learn' competition winner announced ESB to tackle Ashbourne power outage problem Councillor calls for action on social housing land Mayo local authority chiefs under fire over transfer of outdoor staff New restaurant opens on Castlebar's Main Street Explore Our Range Of ServicesShop LocalAnglo Celt JobsMemorialsClassifiedsBook an AdDigital EditionPhotostore Cookies on Anglo Celt website We use cookies to ensure that we give you the best experience on our website. We also use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on the Anglo Celt website. However, if you would like to, you can change your cookie settings at any time by amending your browser settings. How does Anglo Celt use cookies? Cookies enable us to identify your device, or you when you have logged in. We use cookies that are strictly necessary to enable you to move around the site or to provide certain basic features. We use cookies to enhance the functionality of the website by storing your preferences, for example. We also use cookies to help us to improve the performance of our website to provide you with a better user experience. We don't sell the information collected by cookies, nor do we disclose the information to third parties, except where required by law (for example to government bodies and law enforcement agencies). Hide Message Menu Home News Sport Entertainment Shop Local Jobs ePaper Photostore About Us Terms of Use Privacy Accessibility PCI Info Contact Us Sitemap Other Titles Meath Chronicle Offaly Independent Westmeath Examiner Westmeath Independent Your Forum Connaught Telegraph Group Websites Celtic Media Group Celtic Media Print
Latest News Dow 18,869 +21.03 +0.11% Nasdaq 5,218 -18.72 -0.36% S&P 500 2,164 -0.25 -0.01% 6:42 P.M. ET Bannonâ€™s Critics: Alt-Right is Wrong for White House 6:41 P.M. ET President Obama Details Transition in Press Conference 6:39 P.M. ET FriendFinder breach may have exposed 412 million usersâ€™ data 6:20 P.M. ET Google to block its ads from fake-news sites 6:18 P.M. ET 'Mars': National Geographic Network's Moonshot 6:04 P.M. ET Obama Addresses Concerns About Bannon's Appointment 6:06 P.M. ET Updated David Einhornâ€™s Greenlight Capital reduces stakes in Apple, GM, buys U.S. Steel 6:04 P.M. ET Updated SEC chief Mary Jo White announces plans to leave 6:02 P.M. ET Obama Addresses Concerns About Bannon's Appointment 5:47 P.M. ET Updated Deutsche Bank raises S&P 500 year-end target after postelection rally 5:35 P.M. ET George Soros buys stakes in Alphabet, Netflix, dumps Disney, General Motors 5:31 P.M. ET Updated Donald Trump and Vladimir Putin speak by phone 5:19 P.M. ET Financial services industry is at risk to get even whiter 5:15 P.M. ET David Tepper's hedge fund buys new stakes in Apple, Bank of America and Facebook 5:11 P.M. ET Estee Lauder to buy Too Faced for $1.45B, looks to 'win with millennials' 5:10 P.M. ET Einhorn adds Aercap, Calpine, United States Steel, trims Apple stake 5:02 P.M. ET My father-in-law married his girlfriend before he died â€” she wonâ€™t return our calls 5:02 P.M. ET Tepper's Appaloosa sells entire 4.4 mln-share stake in 21st Century Fox during Q3--SEC filing 5:02 P.M. ET SEC says Mary Jo White to leave at the end of the Obama administration 5:00 P.M. ET Nasdaq names Adena Friedman president and CEO Log In Home News Viewer Video SectorWatch Podcasts First Take Games Portfolio My MarketWatch News Viewer Markets U.S. Europe/Middle East Emerging Markets Asia Canada SectorWatch Columns Market Snapshot Movers & Shakers The Tell Currencies Futures Movers Pre-Market News Tools Earnings Wall Markets Overview IPO Calendar Earnings Calendar Currency Tools Futures Contracts Market Screener Hulbert Interactive Investing Stocks Mutual Funds ETFs Options Bonds Commodities Currencies Futures Hedge Funds/Insider Trades Getting Started MarketWatch Adviser Columns Options Trader Revolution Investing Tools Stock Screener Funds Finder ETF Screener Options Screener IPO Calendar Earnings Calendar More... Trading Deck . Personal Finance 10 Things Big Spender Real Estate Spending & Saving Taxes Columns The Moneyologist Brett Arends Bill Bischoff Amy Hoak Chuck Jaffe Jennifer Openshaw Jennifer Waters Tools Funds Finder Today's Rates Retirement RetireMentors Encore Taxes Retire Here, Not There How-to Guides Social Security Estate Planning Events Columns Robert Powell's Retirement Portfolio Andrea Coombes's Working Retirement Tools Retirement Planner How long will my money last? Economy Federal Reserve Capitol Report Economic Report Columns Darrell Delamaide Irwin Kellner Rex Nutting Tools Economic Calendar Real Estate Location Scouts realtor.com My MarketWatch Watchlist Alerts Games Log In Home Press Release Superbugs Attendee List Released Featuring Leading Health Experts from US Government Bodies, Industry and Science By Published: Oct 27, 2016 7:06 p.m. ET Share SMi Group have released an attendee list 3 weeks ahead of its Superbugs & Superdrugs USA conference on antibiotic drug resistance. ISELIN, N.J., Oct. 27, 2016 /PRNewswire/ --Â Aimed at capturing the latest developments and breakthroughs against antimicrobial resistance (AMR), SMi Group's timely Superbugs & Superdrugs USA summit will gather scientists, US Government bodies and industry experts when it takes place on NOV 14TH & 15TH in Iselin, New Jersey. In the run-up to the event, SMi Group have released an attendee list featuring a global audience that emphasises a widespread international concern on the serious global threat of antibiotic resistance. Nations present will include Belgium, France, India, Russia, Spain, Sweden, Switzerland, United Kingdom and USA. A snapshot of organisations confirmed to join Superbugs & Superdrugs USA include: ABAC Therapeutics, Achaogen, Allecra Therapeutics, AstraZeneca, BARDA, Blueberry Therapeutics Ltd, Bugworks Research India, CUBRC, Destiny Pharma Ltd, Entasis Therapeutics, Janssen Research & Development, LLC, JSC R-PHARM, Merck, Mail Stop K-15-F 370, Micromyx LLC, Modern Medical PC, Morton Findlay Associates Ltd, Motif BioSciences, National Institute Of Allergy & Infectious Diseases, NeoSome Life Sciences LLC, Noigel LLC, Pan American Health Organization (PAHO), Pfizer Antibacterials RU, PHARMA OMNIUM, Phico Therapeutics Ltd, Polyphor Ltd, Purdue Pharma, Sanderling Consulting LLC, Seventure Partners, Spero Therapeutics, The Medicines Company, University of North Texas Health Science Center, Venaticus AB, Zoetis + more. When asked what was being done to strengthen the antibiotic pipeline, Dr. Christopher Houchens, Branch Chief of BARDA's Antibacterials Program and one of this year's keynote speakers said: "BARDA and NIAID have worked together to support the establishment of a Biopharmaceutical Accelerator. The CARB-X, represents one of the world's largest public-private partnerships focused on the preclinical discovery and development of new antimicrobial products. This partnership between BARDA, NIAID, the Wellcome Trust of London, the AMR Centre of Alderley Park, and Boston University School of Law, promotes innovation and funding to accelerate the number of antibacterial candidates in the preclinical drug-development pipeline. The end goal of CARB-X is to move promising antibiotic candidates through preclinical development to the point where they would merit additional private and/or public investment for clinical development and regulatory approval." A preliminary list of attendees and a series of interviews with some of those speaking such as Pfizer, Janssen and BARDA, is available to read in the event download centre. Further information including a detailed program and full speaker line-up is available at www.superbugs-usa.com. Superbugs & Superdrugs USA 2016 Conference: Nov 14 â€“ 15 Interactive workshops: Nov 16 Renaissance Woodbridge Hotel, Iselin, New Jersey Contact Information: For all media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk To register for the conference, visit http://www.superbugs-usa.com/prlog For delegate enquires contact Matthew Apps on Tel: +44 (0)20 7827 6093 / Email: mapps@smi-online.co.uk For sponsorship or exhibitor enquiries, contact Alia Malick on Tel: +44 (0)20 7827 6168 / Email: amalick@smi-online.co.uk About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk Photos:http://www.prlog.org/12597478 Press release distributed by PRLog Â  To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/superbugs-attendee-list-released-featuring-leading-health-experts-from-us-government-bodies-industry-and-science-300353165.html SOURCE SMi Group Copyright (C) 2016 PR Newswire. All rights reserved Celebrity Real Estate News Celebrities renege on their pledges to move out of U.S on the back of Trump win View More Investing If you're shocked that Trump won, you broke 3 basic principles of investing View More Barron's Next Dear President-Elect Trump, a millennial wishlist View More Investing Opinion: A 12-step plan to strengthen your portfolio after Trump's victory View More MarketWatch Site Index Topics Help Feedback Newsroom Roster Media Archive Premium Products Mobile Company Company Info Code of Conduct Corrections Advertising Media Kit Advertise Locally Reprints & Licensing Broker Center Your Ad Choices Dow Jones Network WSJ.com Barron's Online BigCharts Virtual Stock Exchange Financial News Online WSJ.com Small Business realtor.com Mansion Global Back to Top Copyright Â©2016 MarketWatch, Inc. All rights reserved. By using this site you agree to the Terms of Service, Privacy Policy, and Cookie Policy. Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. Intraday data delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Dow Jones & Company, Inc. All quotes are in local exchange time. Real time last sale data provided by NASDAQ. More information on NASDAQ traded symbols and their current financial status. Intraday data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. S&P/Dow Jones Indices (SM) from Dow Jones & Company, Inc. SEHK intraday data is provided by SIX Financial Information and is at least 60-minutes delayed. All quotes are in local exchange time. Advanced Search Stocks Columns Authors Topics No results found LatestNews
Contact Us Journalists Blog Log In Sign Up Send a Release News Solutions Resources Search Superbugs Attendee List Released Featuring Leading Health Experts from US Government Bodies, Industry and Science SMi Group have released an attendee list 3 weeks ahead of its Superbugs & Superdrugs USA conference on antibiotic drug resistance. News provided by SMi Group Oct 27, 2016, 19:06 ET Share this article ISELIN, N.J., Oct. 27, 2016 /PRNewswire/ --Â Aimed at capturing the latest developments and breakthroughs against antimicrobial resistance (AMR), SMi Group's timely Superbugs & Superdrugs USA summit will gather scientists, US Government bodies and industry experts when it takes place on NOV 14TH & 15TH in Iselin, New Jersey. In the run-up to the event, SMi Group have released an attendee list featuring a global audience that emphasises a widespread international concern on the serious global threat of antibiotic resistance. Nations present will include Belgium, France, India, Russia, Spain, Sweden, Switzerland, United Kingdom and USA. A snapshot of organisations confirmed to join Superbugs & Superdrugs USA include: ABAC Therapeutics, Achaogen, Allecra Therapeutics, AstraZeneca, BARDA, Blueberry Therapeutics Ltd, Bugworks Research India, CUBRC, Destiny Pharma Ltd, Entasis Therapeutics, Janssen Research & Development, LLC, JSC R-PHARM, Merck, Mail Stop K-15-F 370, Micromyx LLC, Modern Medical PC, Morton Findlay Associates Ltd, Motif BioSciences, National Institute Of Allergy & Infectious Diseases, NeoSome Life Sciences LLC, Noigel LLC, Pan American Health Organization (PAHO), Pfizer Antibacterials RU, PHARMA OMNIUM, Phico Therapeutics Ltd, Polyphor Ltd, Purdue Pharma, Sanderling Consulting LLC, Seventure Partners, Spero Therapeutics, The Medicines Company, University of North Texas Health Science Center, Venaticus AB, Zoetis + more. When asked what was being done to strengthen the antibiotic pipeline, Dr. Christopher Houchens, Branch Chief of BARDA's Antibacterials Program and one of this year's keynote speakers said: "BARDA and NIAID have worked together to support the establishment of a Biopharmaceutical Accelerator. The CARB-X, represents one of the world's largest public-private partnerships focused on the preclinical discovery and development of new antimicrobial products. This partnership between BARDA, NIAID, the Wellcome Trust of London, the AMR Centre of Alderley Park, and Boston University School of Law, promotes innovation and funding to accelerate the number of antibacterial candidates in the preclinical drug-development pipeline. The end goal of CARB-X is to move promising antibiotic candidates through preclinical development to the point where they would merit additional private and/or public investment for clinical development and regulatory approval." A preliminary list of attendees and a series of interviews with some of those speaking such as Pfizer, Janssen and BARDA, is available to read in the event download centre. Further information including a detailed program and full speaker line-up is available at www.superbugs-usa.com. Superbugs & Superdrugs USA 2016 Conference: Nov 14 â€“ 15 Interactive workshops: Nov 16 Renaissance Woodbridge Hotel, Iselin, New Jersey Contact Information: For all media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk To register for the conference, visit http://www.superbugs-usa.com/prlog For delegate enquires contact Matthew Apps on Tel: +44 (0)20 7827 6093 / Email: mapps@smi-online.co.uk For sponsorship or exhibitor enquiries, contact Alia Malick on Tel: +44 (0)20 7827 6168 / Email: amalick@smi-online.co.uk About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk Photos:http://www.prlog.org/12597478 Press release distributed by PRLog Â  To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/superbugs-attendee-list-released-featuring-leading-health-experts-from-us-government-bodies-industry-and-science-300353165.html SOURCE SMi Group Related Links http://www.smi-online.co.uk Jan 29, 2016, 10:11 ET Preview: SMi reports: Exclusive Interview with Colonel John M. Ferrell, US Army Released My News Release contains wide tables. View fullscreen. You just read: Superbugs Attendee List Released Featuring Leading Health Experts from US Government Bodies, Industry and Science News provided by SMi Group Oct 27, 2016, 19:06 ET Share this article Phone 8AM - 10PM ET +1-888-776-0942 Send a Release Sign Up Blog For Journalists Contact Us Search Searching for your content... Advanced Search Contact 888-776-0942 from 8 AM - 10 PM ET Chat Online with an Expert Contact Us Solutions Cision Communication Cloudâ„¢ For Marketers For Public Relations For IR & Compliance For Agency For Small Business All Products About About PR Newswire About Cision Become a Publishing Partner Become a Channel Partner Careers Â  Global Sites Asia Brazil Canada Europe Finland France India Israel Mexico Middle East Netherlands Sweden United Kingdom My Services All News Releases Online Member Center ProfNetâ„  My Services All News Releases Online Member Center ProfNetâ„  888-776-0942 from 8 AM - 10 PM ET Terms of Use Privacy Policy Information Security Policy Statement Site Map RSS Feeds Copyright Â© 2016 PR Newswire Association LLC. All Rights Reserved. A Cision company. News Solutions Resources Phone +1-888-776-0942 8AM - 10PM ET Chat Chat Online with an Expert All contact info Send a ReleaseLog In

MM&M Facebook MM&M Twitter MM&M LinkedIn Advertise Subscribe Log in | Register Home News Agencies Data/Analytics Campaigns Commercial Corporate Legal/Regulatory Media Opinion Payers Pipeline Technology 3 health tech innovations experts say will revolutionalize healthcare As digital-health funding increases, here's how VR, nanotechnology, and 3D printing could potentially improve the value of healthcare. Health Influencer 50 MM&M and PRWeek editors convened to select 50 battle-tested pros who are changing the healthcare game. Find out if you made the list. 10 things for pharma marketers to know about Facebook and Instagram With about 70 million users in six million health-related groups, drugmakers have tremendous opportunity to reach key audiences on Facebook. Here's how. Series Top 100 Agencies Live at Cannes Pharma Report Watson Week MM&M's Guide to DTC Top 40 Transformers Events Big Data Hall of Femme Leadership Exchanges MM&M Awards Transforming Healthcare Conference Webcasts Virtual Events Resources eBooks inVision Videos Podcasts The Agency Gallery The PMD Whitepapers Careers The Glass Ceiling Upward Moves At Work With Magazine Latest Issue Issue Archive MM&M > Features > Health Influencer 50: 50-41 Tweet MM&M and PRWeek staff October 26, 2016 2016 Health Influencer 50 Health Influencer 50: 50-41 Share this content: facebook twitter linkedin google Comments Print MM&M's and PRWeek's Health Influencer 50: 50-41 On the first day of our top 50 reveal, agency and in-house comms leaders, the top marketer at the American Heart Association/American Stroke Association, and a leading health correspondent for CNN make the list. Click here to return toÂ MM&M's and PRWeek's Health Influencer 50 list and features. 50. Diana Littman Paige, executive director, consumer lifestyle and healthcare practices, Marina Maher Communications Diana Littman Paige has effectively blended her expertise in healthcare and marketing to women in her role as executive director of consumer lifestyle and healthcare practices at Marina Maher Communications. The agency works with clients ranging from Tide to Merck. "Engagement and sharing are increasingly our success metrics because it's no longer what a brand says about itself that matters; it's what people say about the brand," Littman Paige said while moderating a panel at the 2015 Marketing to Women Conference. She joined Marina Maher in 2007 and moved quickly up the ladder, with three promotions in three years. Alongside her executive role, she is also head of Rx Mosaic, a division of Marina Maher focused on pharma and scientific comms. Littman Paige grew the agency's health and well-being practice partnering with a range of pharma and consumer health brands. â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“ 49. Meighan Girgus, chief marketing and programs officer, American Heart Association/American Stroke Association Meighan Girgus steered the AHA and ASA through the early internet revolution, evolving an aging brand with a minimalist website into a thriving digital presence. Its properties now attract 170 million visitors a year and cover the gamut of heart disease and stroke-related health needs. Throughout her two decades with the AHA and ASA, Girgus has been involved in national panels and writing groups to support the organization's battle against cardiovascular disease. Prior to being named chief mission officer in 2009, she served as EVP of healthcare. She's an academic at heart. The papers and programs she co-authored helped standardize stroke care and practices. During the past 13 years, more than three million patients received help through a program Girgus and her team created to improve patient care. The AHA and ASA have partnered with the Ad Council, launching a multiyear campaign that helped people recognize warning signs and encouraged them to call 911. Next up: Girgus is head of an AHA taskforce designed to help speed up the process through which newly published scientific guidelines can be implemented. â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“ 48. Lynn O'Connor Vos, CEO, ghg In addition to helming one of the industry's biggest and hottest agencies â€” by the time 2016's results are tallied, ghg will likely have blown past $120 million in U.S. revenue and grown staff size to about 650 â€” Lynn O'Connor Vos remains an in-demand speaker. And ghg was IBM Watson Health's first agency partner. Yet over the course of a conversation, she's as likely to devote considerable time to discussing nontraditional ventures as she is the addition of pharma brands, including Pfizer's Chantix and J&J's esketamine nasal spray, to the ghg roster. See also:Â 3 questions for 5 of the agency world's leading executives As an example, take ghg's work with GoNoodle, creators of an e-platform designed to prompt recess-deprived schoolchildren to engage in more physical activity. "We're curious about medicine and technology. We love problem-solving," Vos told MM&M earlier this year. "It's great to have startups mixed in with more traditional clients, though who knows what qualifies as â€˜traditional' anymore? Every company we work with is somewhere on the continuum of change." â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“ 47. James Greenwood, president and CEO, BIO Prior to joining BIO, James Greenwood represented PennÂ­sylvania in the House of Representatives for 12 years. He's still putting his political expertise to good use. He remains the biopharmaceutical industry's chief lobbyist in Washington and, since 2005, has been at times the industry's biggest cheerleader, as well as its watchdog. Given the recent backlash to industry pricing practices, Greenwood's role has never been more important. He kicked off the BIO International Convention in 2016 with a rousing defense of the sector, declaring "we're not going to let our industry be tarnished by insurance practices that burden patients with unaffordable cost. See also:Â Lobbyists create off-label principles following FDA lawsuits And we don't let ourselves be defined by companies like Turing â€” outlier hedge funds masquerading as biotech firms. That's not who we are." On the heels of that, BIO spearheaded two campaigns, Time Is Precious and Innovation Saves, to better tell the industry's story and promote its value. Both are shot in a sentimental style and show patients whose lives have been saved by new drugs. Greenwood said in a Bloomberg interview the campaigns were meant to "make the point that these drugs, expensive or not, do save lives." â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“ 46. Dr. Sanjay Gupta, chief medical correspondent, CNN At a time when many teleÂ­pundits are coming under fire, Dr. Sanjay Gupta remains one of the cable world's most reserved voices. In a media environment that prioritizes bluster and volume over restraint and accuracy, that's the highest of high praise. Gupta's formal training and his health-policy experience inform his reporting on medical issues: He's a practicing neurosurgeon and served as a White House fellow under Hillary Clinton during her time as first lady. He's one of the few medical correspondents who reports from war zones and regions battered by natural disaster. No journalist ever wants to become a part of the story, but Gupta often crosses this line for the worthiest of reasons: While embedded with the U.S. Navy's Devil Docs medical unit, he jumped into action five times, performing emergency brain surgery on soldiers and civilians. Gupta is equally comfortable embracing policy-level ideas. He played an integral role in shaping CNN's anti-obesity initiative Fit Nation, chronicling the progress of six CNN viewers as they trained for a triathlon. Did Gupta participate in the event alongside them? Of course he did. â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“ 45. Helene Ellison, chair, global healthcare practice, Burson-Marsteller By Aaron Graff, CEO Ferring Holding Insight. Creativity. Enthusiasm. Results. Helene Ellison makes it all look easy. Helene is savvy, and she gets the job done. For more than 30 years she has launched numerous drugs and managed diverse crises for a wide range of global clients. Through it all, her passion shines through as she quickly becomes an expert on any issue of relevance to her clients. But what makes Helene truly effective is her energy. I am consistently amazed by her ability to engage a team and infuse passion in the work. No matter the challenge, Helene approaches every project as if it's her first day on the job and it is the most important project of her life. This infectious enthusiasm is reflected in the teams she leads and in the results she delivers to her clients. â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“ 44. Andy Slavitt, acting administrator, Centers for Medicare and Medicaid Services Less than six months into Andy Slavitt's job atop the nation's largest public payer, he faced a key leadership test: UnitedHealthcare Group, the country's largest health insurer, announced it would pull out of the federal health insurance marketplace. The loss of UnitedHealthcare from the exchange, a key facet of the Affordable Care Act, set off a wave of other defections. Open enrollment began on November 1, so all eyes are on Slavitt to maintain order. Managing through volatility appears to be one of his strengths. He served for nearly two years as CMS chief deputy, and the Harvard graduate worked for two decades in the healthcare and technology private sector. See also:Â Health exchanges, Obama administration challenged by recent insurer exits Slavitt's take: Premium increases will be short-lived. The longer-term goal is to attract more young people to enroll and more states to expand Medicaid. Meanwhile, uncertainty reigns â€” owing to election rhetoric about changes or repeal of the ACA â€” and insurers face heavy losses. President Obama even made an appeal to the remaining insurers. Stabilizing the young marketplace could be Slavitt's signature achievement, or, if CMS fails to shore up the exchange, his defining downfall. â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“ 43. Rob Clark, VP, global communications and corporate marketing, Medtronic Steering global comms and corporate marketing at a company the size of medical device behemoth Medtronic is job enough. Add to that a heavy slate of acquisitions, including the January 2015 purchase of Dublin-based surgical supplier Covidien for $49.9 billion, and it's safe to say Rob Clark has a lot of irons in the fire. As VP, global comms and corporate marketing at Medtronic, which reported revenue of $28.7 billion in its last fiscal year, Clark played a pivotal role in communicating the strategy behind the Covidien deal to all stakeholder groups, especially Medtronic's post-acquisition employee count of 85,000. See also:Â Watson Health partners with drug and devicemakers to tap into real-world data Clark, who has held a number of roles at Medtronic, leads the brand's corporate marketing, global PR, employee comms, digital and social media, and philanthropy communication teams worldwide. Minnesota-based Medtronic last year signed a 10-year deal with the Vikings to create the 3-acre Medtronic Plaza between downtown Minneapolis and U.S. Bank Stadium, to sponsor the Medtronic Club inside the stadium to showcase medical technology innovations invented in Minnesota, and to develop a joint community service program. â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“ 42. Paul van Arkel, head of corporate strategy and healthcare systems, Novartis Paul van Arkel is, in many ways, Novartis' champion of value-based outcomes. After all, the Swiss drugmaker was one of the first pharma companies to embrace value-based pricing, for its chronic heart failure treatment Entresto. Outcomes-driven healthcare and value-based pricing have been the subject of discussions around the industry for years, but Novartis â€” under van Arkel's tutelage â€” is one of the few companies bringing those discussions to reality. The company unveiled a risk-sharing pricing model for Entresto upon its approval in July 2015, announcing the drug's results would be linked to insurer payments. Subsequently, Novartis inked deals with insurers Aetna and Cigna that were based on the drug delivering real-world results similar to those seen in clinical trials. See also:Â NovartisÂ considers new sales model for experimental cancer therapy In an interview with the European Federation of Pharmaceutical Industries and Associations, he espoused the advantages of these kinds of deals. "Outcomes-based approaches are a better way to organize health across the whole system," he said. "We as an industry should be part of the solution," he continued. "We should help by developing the right products â€” whether it's drugs or beyond-the-pill services." â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“ 41. Patrick Blair, chief marketing and consumer officer, Anthem One year after he was named CMO, Patrick Blair oversaw one of Anthem's (then Wellpoint's) biggest changes: a name change. The move at the time was billed as a way to foster transparency and direct relationships. The company markets its plans under the Anthem name, which people know best. Blair took that push toward direct relationships even further by targeting millennials in 2013. He revisited the company's campaign for Tonik â€” an insurance plan geared toward young adults in California, Colorado, Nevada, and Georgia. The ad used shadow outlines of young 20-somethings â€” reminiscent of the iconic iPod commercials. The product would not survive the enactment of the Affordable Care Act, but it was an innovative approach that fostered curiosity among young people about their health coverage. Under his direction, Anthem also embraced more marketing strategies driven by digital and social media. The company enlisted Publicis-owned digital shop Rokkan to shake up the company's media mix ahead of open enrollment on new, state-run online exchanges under the ACA. â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“â€“ MM&M's and PRWeek's Health Influencer 50 50-41 â€¢ 40-31 â€¢ 30-21 â€¢ 20-11 â€¢ 10 â€¢ 9 â€¢ 8 â€¢ 7 â€¢ 6 â€¢ 5 â€¢ 4 â€¢ 3 â€¢ 2 â€¢ 1 From the November 2016 Issue of MMM Â» Share this content: facebook twitter linkedin google Comments Print Previous Post Read the complete January 2016 Digital Edition Next Post Health Influencer 50 4031 Similar Articles Health Influencer 50 How We Picked the Health Influencer 50 Health Influencer 50: No. 9 Health Influencer 50: No. 3 Health Influencer 50: No. 8 Please enable JavaScript to view the comments powered by Disqus. Next Article in Features Health Influencer 50: 40-31 MM&M Articles Popular Emailed Recent Infographic: what information doctors need from pharma Will drugmakers get what they're looking for at this week's FDA off-label hearing? Five things for pharma marketers to know: Friday, November 11, 2016 Five things for pharma marketers to know: Wednesday, November 9, 2016 Five things for pharma marketers to know: Monday, November 7, 2016 Merck educates doctors about biosimilars, long before it will sell one in the U.S. 4 trends with the potential to change behavior in the patient journey What do physicians think about biosimilars? Novartis considers new sales model for experimental cancer therapy Boehringer Ingelheim launches gamified support program Pfizer expands humanitarian access to Prevnar 13 vaccine Five things for pharma marketers to know: Monday, November 14, 2016 Will he or won't he? Pharma speculates on President-elect Trump Pharma pushes to share off-label info with payers at FDA hearing What's Next for the FDA During the Trump Administration Tweets by @MMMnews The most recent MM&M Skill Sets Live event, "Personalizing the Healthcare Experience," surveyed a range of issues relating to some of the industry's hottest topics. This e-book conveys a wealth of information and opinion designed to help marketers demystify the challenges associated with the personalization of healthcare messaging. Click here to access. Check out what's trending Healthcare Legal/Regulatory FDA Pharma Health Influencer 50 People Pricing Election Commercial More in Features Health Influencer 50: No. 1 Health Influencer 50: No. 2 Health Influencer 50: No. 3 Medical Marketing & Media Return To Top News Agencies Campaigns Commercial Corporate Legal/Regulatory Media Payers Pipeline Opinion Back Talk Beltway Insider Editor's Desk Partner Forum Private View Viewpoint User Center Subscribe About us Contact us Media Information Sitemap Ad Choices Connect With Us Newsletters Facebook Twitter LinkedIn Copyright Â© 2016 Haymarket Media, Inc. All Rights Reserved This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions.
null
About Us Contact Us Help user name password Client login:Â Â Â  First time user sign up Forgot your login info? Website DirectoryÂ Â Â Â Â Submit Website Search All categoriesAdvertisingÂ Â GeneralAerospaceÂ Â GeneralAgricultureÂ Â GeneralAirlinesÂ Â GeneralAmerica - Post 9/11Â Â GeneralApparelÂ Â GeneralApple ProductsÂ Â GeneralArchitecturalÂ Â GeneralArchitectureÂ Â ArchitectureArt & EntertainmentsÂ Â BooksÂ Â CelebritiesÂ Â Country MusicÂ Â DanceÂ Â MagazinesÂ Â MoviesÂ Â MuseumsÂ Â MusicÂ Â Music DownloadsÂ Â News & Talk ShowsÂ Â Performing ArtsÂ Â PhotographyÂ Â TelevisionÂ Â Web SitesArts/CultureÂ Â GeneralAuctionÂ Â GeneralAutomotiveÂ Â AftermarketÂ Â Classic AutosÂ Â Consumer PublicationsÂ Â GeneralÂ Â Motorcycle & BikeÂ Â RacingÂ Â Recreational VehicleÂ Â Repair & ServiceÂ Â Trade PublicationsBlogging & Social MediaÂ Â Blogging & Social MediaBusinessÂ Â Advertising / MarketingÂ Â BooksÂ Â Consumer ResearchÂ Â Direct MarketingÂ Â e-CommerceÂ Â EntrepreneursÂ Â FinanceÂ Â FranchiseÂ Â Human ResourcesÂ Â InsuranceÂ Â InvestmentÂ Â ManagementÂ Â MarketsÂ Â Network MarketingÂ Â Online Marketing / SEOÂ Â Payday LoansÂ Â Public RelationsÂ Â PublicationsÂ Â Real EstateÂ Â RetailÂ Â StocksÂ Â SupermarketsÂ Â Women in BusinessCareers/HRÂ Â GeneralChemicalÂ Â GeneralCoaching / MentoringÂ Â Coaching / MentoringComputersÂ Â Apple ProductsÂ Â DatabasesÂ Â Games & EntertainmentÂ Â GeneralÂ Â HostingÂ Â InstructionÂ Â Linux / GNU "Open Source"Â Â MacintoshÂ Â Microsoft Windows PCÂ Â Operating SystemsÂ Â ProgrammingÂ Â SecurityÂ Â SoftwareÂ Â Tablet PCsÂ Â UtilitiesConstructionÂ Â GeneralConsumerÂ Â Gifts and CollectiblesÂ Â HobbiesÂ Â Web sites / InternetDesignÂ Â Graphic DesignÂ Â IndustrialÂ Â WebE-CigaretteÂ Â GeneraleCommerceÂ Â GeneralEconomyÂ Â GeneralEducationÂ Â College / UniversityÂ Â GeneralÂ Â Home SchoolingÂ Â K-12Â Â Post GraduateÂ Â TechnicalElectronicsÂ Â GeneralEmail MarketingÂ Â GeneralEmailWire Press ReleasesÂ Â Press Release TipsEmployment/CareersÂ Â GeneralEngineeringÂ Â GeneralEntertainmentÂ Â GeneralEnvironmentÂ Â GeneralEvents / Trade ShowsÂ Â GeneralFinanceÂ Â GeneralFoodÂ Â GeneralFranchiseÂ Â GeneralFraud / Identity TheftÂ Â GeneralGamingÂ Â GeneralGovernmentÂ Â GeneralÂ Â JudicialÂ Â Law EnforcementÂ Â LegislativeÂ Â LocalÂ Â NationalÂ Â Public ServicesÂ Â SecurityÂ Â StateÂ Â TransportationHealthcareÂ Â GeneralHome and FamilyÂ Â Banking / Personal FinanceÂ Â Bereavement / LossÂ Â Home Furnishings / InteriorsÂ Â Landscaping & GardeningÂ Â Marriage / RelationshipsÂ Â MoneyÂ Â ParentingÂ Â Payday LoansÂ Â PetsÂ Â TaxesÂ Â Wedding / BridalHome SchoolingÂ Â GeneralHotels/ResortsÂ Â GeneralHouseholdÂ Â GeneralIndustryÂ Â Aerospace / DefenseÂ Â AgricultureÂ Â Apparel / TextilesÂ Â BroadcastÂ Â Construction / BuildingÂ Â ElectricalÂ Â FoodÂ Â FuneralÂ Â HealthcareÂ Â Leisure / HospitalityÂ Â Logistics / ShippingÂ Â Manufacturing / ProductionÂ Â Mining / MetalsÂ Â Oil / EnergyÂ Â Paper / Forest ProductsÂ Â Plumbing, Heating & ACÂ Â Print MediaÂ Â PrintingÂ Â PublishingÂ Â RadioÂ Â RestaurantsÂ Â TobaccoÂ Â ToyInsuranceÂ Â GeneralInternet/OnlineÂ Â GeneralLegalÂ Â GeneralLeisureÂ Â GeneralLifestyleÂ Â BeautyÂ Â Dating / SinglesÂ Â Diet / Weight LossÂ Â FashionÂ Â Food / BeverageÂ Â Health & FitnessÂ Â Hotel / ResortsÂ Â PastimesÂ Â RestaurantsÂ Â RetirementÂ Â Travel & TourismMachineryÂ Â GeneralMaritimeÂ Â GeneralMedicalÂ Â AddictionÂ Â AllergiesÂ Â Alternative MedicineÂ Â AsthmaÂ Â CancerÂ Â CardiologyÂ Â ChiropracticÂ Â DentalÂ Â DermatologyÂ Â DiabetesÂ Â EmergencyÂ Â Family MedicineÂ Â GeneralÂ Â GeneralÂ Â GeriatricsÂ Â HospitalsÂ Â Infectious DiseasesÂ Â Internal MedicineÂ Â Managed Care / HMOÂ Â Medical ProductsÂ Â Mental HealthÂ Â NeurologyÂ Â NursingÂ Â NutritionÂ Â OB / GYNÂ Â PediatricsÂ Â PharmaceuticalsÂ Â Physical TherapyÂ Â Plastic SurgeryÂ Â PsychologyÂ Â Radiology / ImagingÂ Â ResearchÂ Â Sports MedicineÂ Â SurgeryÂ Â VisionMilitaryÂ Â GeneralMining/MetalsÂ Â GeneralMiscellaneousÂ Â GeneralNanotechnologyÂ Â NanotechnologyNon-profitÂ Â GeneralOccupational SafetyÂ Â Occupational SafetyOil/EnergyÂ Â GeneralOpinion / EditorialÂ Â Opinion / EditorialPaper ProductsÂ Â GeneralPaper/ForestÂ Â GeneralPharmaceuticalsÂ Â GeneralPodcastingÂ Â AnnounceÂ Â Tools and ServicesPoliticsÂ Â PoliticsPrint MediaÂ Â GeneralPublic UtilitiesÂ Â Public UtilitiesPublishingÂ Â GeneralRadioÂ Â GeneralReal EstateÂ Â GeneralReligionÂ Â ChristianÂ Â GeneralÂ Â IslamÂ Â JewishÂ Â OtherRestaurantsÂ Â GeneralRetailÂ Â GeneralRSS & Content SyndicationÂ Â RSS & Content SyndicationScience and ResearchÂ Â Science and ResearchSelf-Help / Personal GrowthÂ Â Self-Help / Personal GrowthShipbuildingÂ Â GeneralSocietyÂ Â African American InterestsÂ Â Asian InterestsÂ Â Childrens IssuesÂ Â Disabled Issues / DisabilitiesÂ Â Gay / LesbianÂ Â HispanicÂ Â Mens InterestsÂ Â Native AmericanÂ Â Senior CitizensÂ Â Social ServicesÂ Â Teen Issues/InterestsÂ Â Womens InterestSoftwareÂ Â GeneralSportsÂ Â BaseballÂ Â BasketballÂ Â BicyclingÂ Â Boating / MaritimeÂ Â BowlingÂ Â BoxingÂ Â FishingÂ Â FootballÂ Â GolfÂ Â HockeyÂ Â HuntingÂ Â Martial ArtsÂ Â OutdoorsÂ Â RugbyÂ Â SoccerÂ Â TennisÂ Â WaterÂ Â Winter/SnowSports/FitnessÂ Â GeneralStocksÂ Â GeneralSupermarketsÂ Â GeneralTechnologyÂ Â BiotechnologyÂ Â ComputerÂ Â ElectronicsÂ Â Enterprise SoftwareÂ Â GamesÂ Â Graphics/Printing/CADÂ Â Hardware / PeripheralsÂ Â IndustrialÂ Â InformationÂ Â InternetÂ Â MultimediaÂ Â NetworkingÂ Â Public Sector/GovernmentÂ Â RoboticsÂ Â SemiconductorÂ Â SoftwareÂ Â TelecommunicationsÂ Â WebmastersTelecomÂ Â GeneralÂ Â WirelessTelevisionÂ Â GeneralTobaccoÂ Â GeneralTradeÂ Â GeneralTransportationÂ Â GeneralTravelÂ Â GeneralUtilitiesÂ Â GeneralVolunteerÂ Â VolunteerWeatherÂ Â Weather Home > News By Company > ReportsWeb.com Tweet Â  Autoimmune Disease Therapeutics - Global Market Outlook (2015-2022) The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Â  (EMAILWIRE.COM, October 27, 2016 ) According to Publisher, the Global Autoimmune Disease Therapeutics Market is accounted for $51.2 billion in 2015 and is expected to reach $82.13 billion by 2022 growing at a CAGR of 6.9% during the forecast period. Rising healthcare expenditure in the region is one of the key factors fueling the market growth. On the other hand, insufficient funding in emerging countries and high cost involved in the treatment of the disease are hindering the market. Biologics drug acts as initial line of treatment due to therapeutic capabilities in controlling and treatment of different autoimmune complications. Report URL: http://www.reportsweb.com/autoimmune-disease-therapeutics-global-market-outlook-2015-2022 North America is the largest market for autoimmune disease therapeutics due to increasing incidence of different forms of autoimmune disorders, and government initiatives in the region. Europe is expected to be the second largest market due to rising healthcare infrastructure and penetration of new technologies. Some of the key players in the market include Johnson & Johnson Inc, Bayer Schering Pharma AG, Elan Corporation Plc, Abbott Laboratories, Genentech Inc, GlaxoSmithKline Plc, Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Merck & Co. Inc, Amgen Inc, Eli Lilly and Company, F. Hoffmann-La Roche AG, Biogen Idec Inc, Teva Pharmaceuticals, Industries Limited, UCB S.A., Sanofi-Aventis SA, Novartis AG and Shire Plc. Distribution Channel: - Drug Stores - Hospitals - Independent Pharmacies - Clinics Drug Class Covered: - Anti-Inflammatory Drugs - Biologics - Immunosuppressant's - Nonsteroidal anti-inflammatory drugs - Corticosteroids Request for Sample @ http://www.reportsweb.com/inquiry&RW0001216363/sample Regions Covered: - North America - US - Canada - Mexico - Europe - Germany - France - Italy - UK - Spain - Rest of Europe - Asia Pacific - Japan - China - India - Australia - New Zealand - Rest of Asia Pacific - Rest of the World - Middle East - Brazil - Argentina - South Africa - Egypt Inquire for Discount @ http://www.reportsweb.com/inquiry&RW0001216363/discount What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements About Us ReportsWeb is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. Contact Us: Call: +1-646- 491-9876 Email: sales@reportsweb.com Contact Information: ReportsWeb.com Priya Sisodia Tel: +1-646- 491-9876 Email us This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php. 
 Â  Search All categoriesAdvertisingÂ Â GeneralAerospaceÂ Â GeneralAgricultureÂ Â GeneralAirlinesÂ Â GeneralAmerica - Post 9/11Â Â GeneralApparelÂ Â GeneralApple ProductsÂ Â GeneralArchitecturalÂ Â GeneralArchitectureÂ Â ArchitectureArt & EntertainmentsÂ Â BooksÂ Â CelebritiesÂ Â Country MusicÂ Â DanceÂ Â MagazinesÂ Â MoviesÂ Â MuseumsÂ Â MusicÂ Â Music DownloadsÂ Â News & Talk ShowsÂ Â Performing ArtsÂ Â PhotographyÂ Â TelevisionÂ Â Web SitesArts/CultureÂ Â GeneralAuctionÂ Â GeneralAutomotiveÂ Â AftermarketÂ Â Classic AutosÂ Â Consumer PublicationsÂ Â GeneralÂ Â Motorcycle & BikeÂ Â RacingÂ Â Recreational VehicleÂ Â Repair & ServiceÂ Â Trade PublicationsBlogging & Social MediaÂ Â Blogging & Social MediaBusinessÂ Â Advertising / MarketingÂ Â BooksÂ Â Consumer ResearchÂ Â Direct MarketingÂ Â e-CommerceÂ Â EntrepreneursÂ Â FinanceÂ Â FranchiseÂ Â Human ResourcesÂ Â InsuranceÂ Â InvestmentÂ Â ManagementÂ Â MarketsÂ Â Network MarketingÂ Â Online Marketing / SEOÂ Â Payday LoansÂ Â Public RelationsÂ Â PublicationsÂ Â Real EstateÂ Â RetailÂ Â StocksÂ Â SupermarketsÂ Â Women in BusinessCareers/HRÂ Â GeneralChemicalÂ Â GeneralCoaching / MentoringÂ Â Coaching / MentoringComputersÂ Â Apple ProductsÂ Â DatabasesÂ Â Games & EntertainmentÂ Â GeneralÂ Â HostingÂ Â InstructionÂ Â Linux / GNU "Open Source"Â Â MacintoshÂ Â Microsoft Windows PCÂ Â Operating SystemsÂ Â ProgrammingÂ Â SecurityÂ Â SoftwareÂ Â Tablet PCsÂ Â UtilitiesConstructionÂ Â GeneralConsumerÂ Â Gifts and CollectiblesÂ Â HobbiesÂ Â Web sites / InternetDesignÂ Â Graphic DesignÂ Â IndustrialÂ Â WebE-CigaretteÂ Â GeneraleCommerceÂ Â GeneralEconomyÂ Â GeneralEducationÂ Â College / UniversityÂ Â GeneralÂ Â Home SchoolingÂ Â K-12Â Â Post GraduateÂ Â TechnicalElectronicsÂ Â GeneralEmail MarketingÂ Â GeneralEmailWire Press ReleasesÂ Â Press Release TipsEmployment/CareersÂ Â GeneralEngineeringÂ Â GeneralEntertainmentÂ Â GeneralEnvironmentÂ Â GeneralEvents / Trade ShowsÂ Â GeneralFinanceÂ Â GeneralFoodÂ Â GeneralFranchiseÂ Â GeneralFraud / Identity TheftÂ Â GeneralGamingÂ Â GeneralGovernmentÂ Â GeneralÂ Â JudicialÂ Â Law EnforcementÂ Â LegislativeÂ Â LocalÂ Â NationalÂ Â Public ServicesÂ Â SecurityÂ Â StateÂ Â TransportationHealthcareÂ Â GeneralHome and FamilyÂ Â Banking / Personal FinanceÂ Â Bereavement / LossÂ Â Home Furnishings / InteriorsÂ Â Landscaping & GardeningÂ Â Marriage / RelationshipsÂ Â MoneyÂ Â ParentingÂ Â Payday LoansÂ Â PetsÂ Â TaxesÂ Â Wedding / BridalHome SchoolingÂ Â GeneralHotels/ResortsÂ Â GeneralHouseholdÂ Â GeneralIndustryÂ Â Aerospace / DefenseÂ Â AgricultureÂ Â Apparel / TextilesÂ Â BroadcastÂ Â Construction / BuildingÂ Â ElectricalÂ Â FoodÂ Â FuneralÂ Â HealthcareÂ Â Leisure / HospitalityÂ Â Logistics / ShippingÂ Â Manufacturing / ProductionÂ Â Mining / MetalsÂ Â Oil / EnergyÂ Â Paper / Forest ProductsÂ Â Plumbing, Heating & ACÂ Â Print MediaÂ Â PrintingÂ Â PublishingÂ Â RadioÂ Â RestaurantsÂ Â TobaccoÂ Â ToyInsuranceÂ Â GeneralInternet/OnlineÂ Â GeneralLegalÂ Â GeneralLeisureÂ Â GeneralLifestyleÂ Â BeautyÂ Â Dating / SinglesÂ Â Diet / Weight LossÂ Â FashionÂ Â Food / BeverageÂ Â Health & FitnessÂ Â Hotel / ResortsÂ Â PastimesÂ Â RestaurantsÂ Â RetirementÂ Â Travel & TourismMachineryÂ Â GeneralMaritimeÂ Â GeneralMedicalÂ Â AddictionÂ Â AllergiesÂ Â Alternative MedicineÂ Â AsthmaÂ Â CancerÂ Â CardiologyÂ Â ChiropracticÂ Â DentalÂ Â DermatologyÂ Â DiabetesÂ Â EmergencyÂ Â Family MedicineÂ Â GeneralÂ Â GeneralÂ Â GeriatricsÂ Â HospitalsÂ Â Infectious DiseasesÂ Â Internal MedicineÂ Â Managed Care / HMOÂ Â Medical ProductsÂ Â Mental HealthÂ Â NeurologyÂ Â NursingÂ Â NutritionÂ Â OB / GYNÂ Â PediatricsÂ Â PharmaceuticalsÂ Â Physical TherapyÂ Â Plastic SurgeryÂ Â PsychologyÂ Â Radiology / ImagingÂ Â ResearchÂ Â Sports MedicineÂ Â SurgeryÂ Â VisionMilitaryÂ Â GeneralMining/MetalsÂ Â GeneralMiscellaneousÂ Â GeneralNanotechnologyÂ Â NanotechnologyNon-profitÂ Â GeneralOccupational SafetyÂ Â Occupational SafetyOil/EnergyÂ Â GeneralOpinion / EditorialÂ Â Opinion / EditorialPaper ProductsÂ Â GeneralPaper/ForestÂ Â GeneralPharmaceuticalsÂ Â GeneralPodcastingÂ Â AnnounceÂ Â Tools and ServicesPoliticsÂ Â PoliticsPrint MediaÂ Â GeneralPublic UtilitiesÂ Â Public UtilitiesPublishingÂ Â GeneralRadioÂ Â GeneralReal EstateÂ Â GeneralReligionÂ Â ChristianÂ Â GeneralÂ Â IslamÂ Â JewishÂ Â OtherRestaurantsÂ Â GeneralRetailÂ Â GeneralRSS & Content SyndicationÂ Â RSS & Content SyndicationScience and ResearchÂ Â Science and ResearchSelf-Help / Personal GrowthÂ Â Self-Help / Personal GrowthShipbuildingÂ Â GeneralSocietyÂ Â African American InterestsÂ Â Asian InterestsÂ Â Childrens IssuesÂ Â Disabled Issues / DisabilitiesÂ Â Gay / LesbianÂ Â HispanicÂ Â Mens InterestsÂ Â Native AmericanÂ Â Senior CitizensÂ Â Social ServicesÂ Â Teen Issues/InterestsÂ Â Womens InterestSoftwareÂ Â GeneralSportsÂ Â BaseballÂ Â BasketballÂ Â BicyclingÂ Â Boating / MaritimeÂ Â BowlingÂ Â BoxingÂ Â FishingÂ Â FootballÂ Â GolfÂ Â HockeyÂ Â HuntingÂ Â Martial ArtsÂ Â OutdoorsÂ Â RugbyÂ Â SoccerÂ Â TennisÂ Â WaterÂ Â Winter/SnowSports/FitnessÂ Â GeneralStocksÂ Â GeneralSupermarketsÂ Â GeneralTechnologyÂ Â BiotechnologyÂ Â ComputerÂ Â ElectronicsÂ Â Enterprise SoftwareÂ Â GamesÂ Â Graphics/Printing/CADÂ Â Hardware / PeripheralsÂ Â IndustrialÂ Â InformationÂ Â InternetÂ Â MultimediaÂ Â NetworkingÂ Â Public Sector/GovernmentÂ Â RoboticsÂ Â SemiconductorÂ Â SoftwareÂ Â TelecommunicationsÂ Â WebmastersTelecomÂ Â GeneralÂ Â WirelessTelevisionÂ Â GeneralTobaccoÂ Â GeneralTradeÂ Â GeneralTransportationÂ Â GeneralTravelÂ Â GeneralUtilitiesÂ Â GeneralVolunteerÂ Â VolunteerWeatherÂ Â Weather Advertising | How to contact us | Privacy Statement | EmailWire Press Releases | Partnership Opportunities EmailWire is a press release distribution service of GroupWeb Media LLC. Â© Copyright GroupWeb Media LLC 2016

null
About Us Contact Us Help user name password Client login:Â Â Â  First time user sign up Forgot your login info? Website DirectoryÂ Â Â Â Â Submit Website Search All categoriesAdvertisingÂ Â GeneralAerospaceÂ Â GeneralAgricultureÂ Â GeneralAirlinesÂ Â GeneralAmerica - Post 9/11Â Â GeneralApparelÂ Â GeneralApple ProductsÂ Â GeneralArchitecturalÂ Â GeneralArchitectureÂ Â ArchitectureArt & EntertainmentsÂ Â BooksÂ Â CelebritiesÂ Â Country MusicÂ Â DanceÂ Â MagazinesÂ Â MoviesÂ Â MuseumsÂ Â MusicÂ Â Music DownloadsÂ Â News & Talk ShowsÂ Â Performing ArtsÂ Â PhotographyÂ Â TelevisionÂ Â Web SitesArts/CultureÂ Â GeneralAuctionÂ Â GeneralAutomotiveÂ Â AftermarketÂ Â Classic AutosÂ Â Consumer PublicationsÂ Â GeneralÂ Â Motorcycle & BikeÂ Â RacingÂ Â Recreational VehicleÂ Â Repair & ServiceÂ Â Trade PublicationsBlogging & Social MediaÂ Â Blogging & Social MediaBusinessÂ Â Advertising / MarketingÂ Â BooksÂ Â Consumer ResearchÂ Â Direct MarketingÂ Â e-CommerceÂ Â EntrepreneursÂ Â FinanceÂ Â FranchiseÂ Â Human ResourcesÂ Â InsuranceÂ Â InvestmentÂ Â ManagementÂ Â MarketsÂ Â Network MarketingÂ Â Online Marketing / SEOÂ Â Payday LoansÂ Â Public RelationsÂ Â PublicationsÂ Â Real EstateÂ Â RetailÂ Â StocksÂ Â SupermarketsÂ Â Women in BusinessCareers/HRÂ Â GeneralChemicalÂ Â GeneralCoaching / MentoringÂ Â Coaching / MentoringComputersÂ Â Apple ProductsÂ Â DatabasesÂ Â Games & EntertainmentÂ Â GeneralÂ Â HostingÂ Â InstructionÂ Â Linux / GNU "Open Source"Â Â MacintoshÂ Â Microsoft Windows PCÂ Â Operating SystemsÂ Â ProgrammingÂ Â SecurityÂ Â SoftwareÂ Â Tablet PCsÂ Â UtilitiesConstructionÂ Â GeneralConsumerÂ Â Gifts and CollectiblesÂ Â HobbiesÂ Â Web sites / InternetDesignÂ Â Graphic DesignÂ Â IndustrialÂ Â WebE-CigaretteÂ Â GeneraleCommerceÂ Â GeneralEconomyÂ Â GeneralEducationÂ Â College / UniversityÂ Â GeneralÂ Â Home SchoolingÂ Â K-12Â Â Post GraduateÂ Â TechnicalElectronicsÂ Â GeneralEmail MarketingÂ Â GeneralEmailWire Press ReleasesÂ Â Press Release TipsEmployment/CareersÂ Â GeneralEngineeringÂ Â GeneralEntertainmentÂ Â GeneralEnvironmentÂ Â GeneralEvents / Trade ShowsÂ Â GeneralFinanceÂ Â GeneralFoodÂ Â GeneralFranchiseÂ Â GeneralFraud / Identity TheftÂ Â GeneralGamingÂ Â GeneralGovernmentÂ Â GeneralÂ Â JudicialÂ Â Law EnforcementÂ Â LegislativeÂ Â LocalÂ Â NationalÂ Â Public ServicesÂ Â SecurityÂ Â StateÂ Â TransportationHealthcareÂ Â GeneralHome and FamilyÂ Â Banking / Personal FinanceÂ Â Bereavement / LossÂ Â Home Furnishings / InteriorsÂ Â Landscaping & GardeningÂ Â Marriage / RelationshipsÂ Â MoneyÂ Â ParentingÂ Â Payday LoansÂ Â PetsÂ Â TaxesÂ Â Wedding / BridalHome SchoolingÂ Â GeneralHotels/ResortsÂ Â GeneralHouseholdÂ Â GeneralIndustryÂ Â Aerospace / DefenseÂ Â AgricultureÂ Â Apparel / TextilesÂ Â BroadcastÂ Â Construction / BuildingÂ Â ElectricalÂ Â FoodÂ Â FuneralÂ Â HealthcareÂ Â Leisure / HospitalityÂ Â Logistics / ShippingÂ Â Manufacturing / ProductionÂ Â Mining / MetalsÂ Â Oil / EnergyÂ Â Paper / Forest ProductsÂ Â Plumbing, Heating & ACÂ Â Print MediaÂ Â PrintingÂ Â PublishingÂ Â RadioÂ Â RestaurantsÂ Â TobaccoÂ Â ToyInsuranceÂ Â GeneralInternet/OnlineÂ Â GeneralLegalÂ Â GeneralLeisureÂ Â GeneralLifestyleÂ Â BeautyÂ Â Dating / SinglesÂ Â Diet / Weight LossÂ Â FashionÂ Â Food / BeverageÂ Â Health & FitnessÂ Â Hotel / ResortsÂ Â PastimesÂ Â RestaurantsÂ Â RetirementÂ Â Travel & TourismMachineryÂ Â GeneralMaritimeÂ Â GeneralMedicalÂ Â AddictionÂ Â AllergiesÂ Â Alternative MedicineÂ Â AsthmaÂ Â CancerÂ Â CardiologyÂ Â ChiropracticÂ Â DentalÂ Â DermatologyÂ Â DiabetesÂ Â EmergencyÂ Â Family MedicineÂ Â GeneralÂ Â GeneralÂ Â GeriatricsÂ Â HospitalsÂ Â Infectious DiseasesÂ Â Internal MedicineÂ Â Managed Care / HMOÂ Â Medical ProductsÂ Â Mental HealthÂ Â NeurologyÂ Â NursingÂ Â NutritionÂ Â OB / GYNÂ Â PediatricsÂ Â PharmaceuticalsÂ Â Physical TherapyÂ Â Plastic SurgeryÂ Â PsychologyÂ Â Radiology / ImagingÂ Â ResearchÂ Â Sports MedicineÂ Â SurgeryÂ Â VisionMilitaryÂ Â GeneralMining/MetalsÂ Â GeneralMiscellaneousÂ Â GeneralNanotechnologyÂ Â NanotechnologyNon-profitÂ Â GeneralOccupational SafetyÂ Â Occupational SafetyOil/EnergyÂ Â GeneralOpinion / EditorialÂ Â Opinion / EditorialPaper ProductsÂ Â GeneralPaper/ForestÂ Â GeneralPharmaceuticalsÂ Â GeneralPodcastingÂ Â AnnounceÂ Â Tools and ServicesPoliticsÂ Â PoliticsPrint MediaÂ Â GeneralPublic UtilitiesÂ Â Public UtilitiesPublishingÂ Â GeneralRadioÂ Â GeneralReal EstateÂ Â GeneralReligionÂ Â ChristianÂ Â GeneralÂ Â IslamÂ Â JewishÂ Â OtherRestaurantsÂ Â GeneralRetailÂ Â GeneralRSS & Content SyndicationÂ Â RSS & Content SyndicationScience and ResearchÂ Â Science and ResearchSelf-Help / Personal GrowthÂ Â Self-Help / Personal GrowthShipbuildingÂ Â GeneralSocietyÂ Â African American InterestsÂ Â Asian InterestsÂ Â Childrens IssuesÂ Â Disabled Issues / DisabilitiesÂ Â Gay / LesbianÂ Â HispanicÂ Â Mens InterestsÂ Â Native AmericanÂ Â Senior CitizensÂ Â Social ServicesÂ Â Teen Issues/InterestsÂ Â Womens InterestSoftwareÂ Â GeneralSportsÂ Â BaseballÂ Â BasketballÂ Â BicyclingÂ Â Boating / MaritimeÂ Â BowlingÂ Â BoxingÂ Â FishingÂ Â FootballÂ Â GolfÂ Â HockeyÂ Â HuntingÂ Â Martial ArtsÂ Â OutdoorsÂ Â RugbyÂ Â SoccerÂ Â TennisÂ Â WaterÂ Â Winter/SnowSports/FitnessÂ Â GeneralStocksÂ Â GeneralSupermarketsÂ Â GeneralTechnologyÂ Â BiotechnologyÂ Â ComputerÂ Â ElectronicsÂ Â Enterprise SoftwareÂ Â GamesÂ Â Graphics/Printing/CADÂ Â Hardware / PeripheralsÂ Â IndustrialÂ Â InformationÂ Â InternetÂ Â MultimediaÂ Â NetworkingÂ Â Public Sector/GovernmentÂ Â RoboticsÂ Â SemiconductorÂ Â SoftwareÂ Â TelecommunicationsÂ Â WebmastersTelecomÂ Â GeneralÂ Â WirelessTelevisionÂ Â GeneralTobaccoÂ Â GeneralTradeÂ Â GeneralTransportationÂ Â GeneralTravelÂ Â GeneralUtilitiesÂ Â GeneralVolunteerÂ Â VolunteerWeatherÂ Â Weather Home > News By Company > ReportsWeb.com Tweet Â  Pharmaceuticals and Glass Market Trends and 2021 Forecast ReportsWeb.com has announced the addition of the Â“Global Pharmaceuticals and Glass2021 Market Research ReportÂ” The report focuses on global major leading players with information such as company profiles, product picture and specification. Â  (EMAILWIRE.COM, October 27, 2016 ) This report studies Pharmaceuticals and Glass in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with Production, price, revenue and market share for each manufacturer, covering AbbVie/Abbott Actavis Asahi Glass Astellas AstraZeneca AvanStrate Inc Bayer Bristol-Myers Central Glass China Glass Corning Daiichi Sankyo Dr. Reddy Eli Lilly FUYAO GSK GUARDIAN Hebei Window Johnson & Johnson LG Chem Merck Mylan Nippon Electric For more information about this report at http://www.reportsweb.com/global-pharmaceuticals-and-glass-market-research-report-2016 Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of Pharmaceuticals and Glass in these regions, from 2011 to 2021 (forecast), like North America Europe China Japan Southeast Asia India Split by product type, with production, revenue, price, market share and growth rate of each type, can be divided into Type I Type II Type III Split by application, this report focuses on consumption, market share and growth rate of Pharmaceuticals and Glass in each application, can be divided into Application 1 Application 2 Application 3 Request a sample copy at http://www.reportsweb.com/inquiry&RW0001437491/sample Table of Content 1 Pharmaceuticals and Glass Overview 2 Global Pharmaceuticals and Glass Market Competition by Manufacturers 3 Global Pharmaceuticals and Glass Production, Revenue (Value) by Region (2011-2016) 4 Global Pharmaceuticals and Glass Supply (Production), Consumption, Export, Import by Regions (2011-2016) 4.1 Global Pharmaceuticals and Glass Consumption by Regions (2011-2016) 4.2 North America Pharmaceuticals and Glass Production, Consumption, Export, Import by Regions (2011-2016) 4.3 Europe Pharmaceuticals and Glass Production, Consumption, Export, Import by Regions (2011-2016) 4.4 China Pharmaceuticals and Glass Production, Consumption, Export, Import by Regions (2011-2016) 4.5 Japan Pharmaceuticals and Glass Production, Consumption, Export, Import by Regions (2011-2016) 4.6 Southeast Asia Pharmaceuticals and Glass Production, Consumption, Export, Import by Regions (2011-2016) 4.7 India Pharmaceuticals and Glass Production, Consumption, Export, Import by Regions (2011-2016) 5 Global Pharmaceuticals and Glass Production, Revenue (Value), Price Trend by Type 5.1 Global Pharmaceuticals and Glass Production and Market Share by Type (2011-2016) 5.2 Global Pharmaceuticals and Glass Revenue and Market Share by Type (2011-2016) 5.3 Global Pharmaceuticals and Glass Price by Type (2011-2016) 5.4 Global Pharmaceuticals and Glass Production Growth by Type (2011-2016) Ask for Discount at http://www.reportsweb.com/inquiry&RW0001437491/discount 6 Global Pharmaceuticals and Glass Market Analysis by Application 6.1 Global Pharmaceuticals and Glass Consumption and Market Share by Application (2011-2016) 6.2 Global Pharmaceuticals and Glass Consumption Growth Rate by Application (2011-2016) 6.3 Market Drivers and Opportunities 6.3.1 Potential Applications 6.3.2 Emerging Markets/Countries 7 Global Pharmaceuticals and Glass Manufacturers Profiles/Analysis 7.1 AbbVie/Abbott 7.1.1 Company Basic Information, Manufacturing Base and Its Competitors 7.1.2 Pharmaceuticals and Glass Product Type, Application and Specification 7.1.2.1 Type I 7.1.2.2 Type II 7.1.3 AbbVie/Abbott Pharmaceuticals and Glass Production, Revenue, Price and Gross Margin (2015 and 2016) 7.1.4 Main Business/Business Overview 7.2 Actavis 7.2.1 Company Basic Information, Manufacturing Base and Its Competitors 7.2.2 Pharmaceuticals and Glass Product Type, Application and Specification 7.2.2.1 Type I 7.2.2.2 Type II 7.2.3 Actavis Pharmaceuticals and Glass Production, Revenue, Price and Gross Margin (2015 and 2016) 7.2.4 Main Business/Business Overview 8 Research Findings and Conclusion 9 Industrial Chain, Sourcing Strategy and Downstream Buyers 10 Marketing Strategy Analysis, Distributors/Traders 11 Market Effect Factors Analysis 12 Global Pharmaceuticals and Glass Market Forecast (2016-2021) 13 Research Findings and Conclusion 14 Appendix Purchase Complete Report at http://www.reportsweb.com/buy&RW0001437491/buy/2900 Contact Information: ReportsWeb.com Priya Sisodia Tel: +1-646-491-9876 Email us This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php. 
 Â  Search All categoriesAdvertisingÂ Â GeneralAerospaceÂ Â GeneralAgricultureÂ Â GeneralAirlinesÂ Â GeneralAmerica - Post 9/11Â Â GeneralApparelÂ Â GeneralApple ProductsÂ Â GeneralArchitecturalÂ Â GeneralArchitectureÂ Â ArchitectureArt & EntertainmentsÂ Â BooksÂ Â CelebritiesÂ Â Country MusicÂ Â DanceÂ Â MagazinesÂ Â MoviesÂ Â MuseumsÂ Â MusicÂ Â Music DownloadsÂ Â News & Talk ShowsÂ Â Performing ArtsÂ Â PhotographyÂ Â TelevisionÂ Â Web SitesArts/CultureÂ Â GeneralAuctionÂ Â GeneralAutomotiveÂ Â AftermarketÂ Â Classic AutosÂ Â Consumer PublicationsÂ Â GeneralÂ Â Motorcycle & BikeÂ Â RacingÂ Â Recreational VehicleÂ Â Repair & ServiceÂ Â Trade PublicationsBlogging & Social MediaÂ Â Blogging & Social MediaBusinessÂ Â Advertising / MarketingÂ Â BooksÂ Â Consumer ResearchÂ Â Direct MarketingÂ Â e-CommerceÂ Â EntrepreneursÂ Â FinanceÂ Â FranchiseÂ Â Human ResourcesÂ Â InsuranceÂ Â InvestmentÂ Â ManagementÂ Â MarketsÂ Â Network MarketingÂ Â Online Marketing / SEOÂ Â Payday LoansÂ Â Public RelationsÂ Â PublicationsÂ Â Real EstateÂ Â RetailÂ Â StocksÂ Â SupermarketsÂ Â Women in BusinessCareers/HRÂ Â GeneralChemicalÂ Â GeneralCoaching / MentoringÂ Â Coaching / MentoringComputersÂ Â Apple ProductsÂ Â DatabasesÂ Â Games & EntertainmentÂ Â GeneralÂ Â HostingÂ Â InstructionÂ Â Linux / GNU "Open Source"Â Â MacintoshÂ Â Microsoft Windows PCÂ Â Operating SystemsÂ Â ProgrammingÂ Â SecurityÂ Â SoftwareÂ Â Tablet PCsÂ Â UtilitiesConstructionÂ Â GeneralConsumerÂ Â Gifts and CollectiblesÂ Â HobbiesÂ Â Web sites / InternetDesignÂ Â Graphic DesignÂ Â IndustrialÂ Â WebE-CigaretteÂ Â GeneraleCommerceÂ Â GeneralEconomyÂ Â GeneralEducationÂ Â College / UniversityÂ Â GeneralÂ Â Home SchoolingÂ Â K-12Â Â Post GraduateÂ Â TechnicalElectronicsÂ Â GeneralEmail MarketingÂ Â GeneralEmailWire Press ReleasesÂ Â Press Release TipsEmployment/CareersÂ Â GeneralEngineeringÂ Â GeneralEntertainmentÂ Â GeneralEnvironmentÂ Â GeneralEvents / Trade ShowsÂ Â GeneralFinanceÂ Â GeneralFoodÂ Â GeneralFranchiseÂ Â GeneralFraud / Identity TheftÂ Â GeneralGamingÂ Â GeneralGovernmentÂ Â GeneralÂ Â JudicialÂ Â Law EnforcementÂ Â LegislativeÂ Â LocalÂ Â NationalÂ Â Public ServicesÂ Â SecurityÂ Â StateÂ Â TransportationHealthcareÂ Â GeneralHome and FamilyÂ Â Banking / Personal FinanceÂ Â Bereavement / LossÂ Â Home Furnishings / InteriorsÂ Â Landscaping & GardeningÂ Â Marriage / RelationshipsÂ Â MoneyÂ Â ParentingÂ Â Payday LoansÂ Â PetsÂ Â TaxesÂ Â Wedding / BridalHome SchoolingÂ Â GeneralHotels/ResortsÂ Â GeneralHouseholdÂ Â GeneralIndustryÂ Â Aerospace / DefenseÂ Â AgricultureÂ Â Apparel / TextilesÂ Â BroadcastÂ Â Construction / BuildingÂ Â ElectricalÂ Â FoodÂ Â FuneralÂ Â HealthcareÂ Â Leisure / HospitalityÂ Â Logistics / ShippingÂ Â Manufacturing / ProductionÂ Â Mining / MetalsÂ Â Oil / EnergyÂ Â Paper / Forest ProductsÂ Â Plumbing, Heating & ACÂ Â Print MediaÂ Â PrintingÂ Â PublishingÂ Â RadioÂ Â RestaurantsÂ Â TobaccoÂ Â ToyInsuranceÂ Â GeneralInternet/OnlineÂ Â GeneralLegalÂ Â GeneralLeisureÂ Â GeneralLifestyleÂ Â BeautyÂ Â Dating / SinglesÂ Â Diet / Weight LossÂ Â FashionÂ Â Food / BeverageÂ Â Health & FitnessÂ Â Hotel / ResortsÂ Â PastimesÂ Â RestaurantsÂ Â RetirementÂ Â Travel & TourismMachineryÂ Â GeneralMaritimeÂ Â GeneralMedicalÂ Â AddictionÂ Â AllergiesÂ Â Alternative MedicineÂ Â AsthmaÂ Â CancerÂ Â CardiologyÂ Â ChiropracticÂ Â DentalÂ Â DermatologyÂ Â DiabetesÂ Â EmergencyÂ Â Family MedicineÂ Â GeneralÂ Â GeneralÂ Â GeriatricsÂ Â HospitalsÂ Â Infectious DiseasesÂ Â Internal MedicineÂ Â Managed Care / HMOÂ Â Medical ProductsÂ Â Mental HealthÂ Â NeurologyÂ Â NursingÂ Â NutritionÂ Â OB / GYNÂ Â PediatricsÂ Â PharmaceuticalsÂ Â Physical TherapyÂ Â Plastic SurgeryÂ Â PsychologyÂ Â Radiology / ImagingÂ Â ResearchÂ Â Sports MedicineÂ Â SurgeryÂ Â VisionMilitaryÂ Â GeneralMining/MetalsÂ Â GeneralMiscellaneousÂ Â GeneralNanotechnologyÂ Â NanotechnologyNon-profitÂ Â GeneralOccupational SafetyÂ Â Occupational SafetyOil/EnergyÂ Â GeneralOpinion / EditorialÂ Â Opinion / EditorialPaper ProductsÂ Â GeneralPaper/ForestÂ Â GeneralPharmaceuticalsÂ Â GeneralPodcastingÂ Â AnnounceÂ Â Tools and ServicesPoliticsÂ Â PoliticsPrint MediaÂ Â GeneralPublic UtilitiesÂ Â Public UtilitiesPublishingÂ Â GeneralRadioÂ Â GeneralReal EstateÂ Â GeneralReligionÂ Â ChristianÂ Â GeneralÂ Â IslamÂ Â JewishÂ Â OtherRestaurantsÂ Â GeneralRetailÂ Â GeneralRSS & Content SyndicationÂ Â RSS & Content SyndicationScience and ResearchÂ Â Science and ResearchSelf-Help / Personal GrowthÂ Â Self-Help / Personal GrowthShipbuildingÂ Â GeneralSocietyÂ Â African American InterestsÂ Â Asian InterestsÂ Â Childrens IssuesÂ Â Disabled Issues / DisabilitiesÂ Â Gay / LesbianÂ Â HispanicÂ Â Mens InterestsÂ Â Native AmericanÂ Â Senior CitizensÂ Â Social ServicesÂ Â Teen Issues/InterestsÂ Â Womens InterestSoftwareÂ Â GeneralSportsÂ Â BaseballÂ Â BasketballÂ Â BicyclingÂ Â Boating / MaritimeÂ Â BowlingÂ Â BoxingÂ Â FishingÂ Â FootballÂ Â GolfÂ Â HockeyÂ Â HuntingÂ Â Martial ArtsÂ Â OutdoorsÂ Â RugbyÂ Â SoccerÂ Â TennisÂ Â WaterÂ Â Winter/SnowSports/FitnessÂ Â GeneralStocksÂ Â GeneralSupermarketsÂ Â GeneralTechnologyÂ Â BiotechnologyÂ Â ComputerÂ Â ElectronicsÂ Â Enterprise SoftwareÂ Â GamesÂ Â Graphics/Printing/CADÂ Â Hardware / PeripheralsÂ Â IndustrialÂ Â InformationÂ Â InternetÂ Â MultimediaÂ Â NetworkingÂ Â Public Sector/GovernmentÂ Â RoboticsÂ Â SemiconductorÂ Â SoftwareÂ Â TelecommunicationsÂ Â WebmastersTelecomÂ Â GeneralÂ Â WirelessTelevisionÂ Â GeneralTobaccoÂ Â GeneralTradeÂ Â GeneralTransportationÂ Â GeneralTravelÂ Â GeneralUtilitiesÂ Â GeneralVolunteerÂ Â VolunteerWeatherÂ Â Weather Advertising | How to contact us | Privacy Statement | EmailWire Press Releases | Partnership Opportunities EmailWire is a press release distribution service of GroupWeb Media LLC. Â© Copyright GroupWeb Media LLC 2016

Latest News Dow 18,869 +21.03 +0.11% Nasdaq 5,218 -18.72 -0.36% S&P 500 2,164 -0.25 -0.01% 6:42 P.M. ET Bannonâ€™s Critics: Alt-Right is Wrong for White House 6:41 P.M. ET President Obama Details Transition in Press Conference 6:39 P.M. ET FriendFinder breach may have exposed 412 million usersâ€™ data 6:20 P.M. ET Google to block its ads from fake-news sites 6:18 P.M. ET 'Mars': National Geographic Network's Moonshot 6:04 P.M. ET Obama Addresses Concerns About Bannon's Appointment 6:06 P.M. ET Updated David Einhornâ€™s Greenlight Capital reduces stakes in Apple, GM, buys U.S. Steel 6:04 P.M. ET Updated SEC chief Mary Jo White announces plans to leave 6:02 P.M. ET Obama Addresses Concerns About Bannon's Appointment 5:47 P.M. ET Updated Deutsche Bank raises S&P 500 year-end target after postelection rally 5:35 P.M. ET George Soros buys stakes in Alphabet, Netflix, dumps Disney, General Motors 5:31 P.M. ET Updated Donald Trump and Vladimir Putin speak by phone 5:19 P.M. ET Financial services industry is at risk to get even whiter 5:15 P.M. ET David Tepper's hedge fund buys new stakes in Apple, Bank of America and Facebook 5:11 P.M. ET Estee Lauder to buy Too Faced for $1.45B, looks to 'win with millennials' 5:10 P.M. ET Einhorn adds Aercap, Calpine, United States Steel, trims Apple stake 5:02 P.M. ET My father-in-law married his girlfriend before he died â€” she wonâ€™t return our calls 5:02 P.M. ET Tepper's Appaloosa sells entire 4.4 mln-share stake in 21st Century Fox during Q3--SEC filing 5:02 P.M. ET SEC says Mary Jo White to leave at the end of the Obama administration 5:00 P.M. ET Nasdaq names Adena Friedman president and CEO Log In Home News Viewer Video SectorWatch Podcasts First Take Games Portfolio My MarketWatch News Viewer Markets U.S. Europe/Middle East Emerging Markets Asia Canada SectorWatch Columns Market Snapshot Movers & Shakers The Tell Currencies Futures Movers Pre-Market News Tools Earnings Wall Markets Overview IPO Calendar Earnings Calendar Currency Tools Futures Contracts Market Screener Hulbert Interactive Investing Stocks Mutual Funds ETFs Options Bonds Commodities Currencies Futures Hedge Funds/Insider Trades Getting Started MarketWatch Adviser Columns Options Trader Revolution Investing Tools Stock Screener Funds Finder ETF Screener Options Screener IPO Calendar Earnings Calendar More... Trading Deck . Personal Finance 10 Things Big Spender Real Estate Spending & Saving Taxes Columns The Moneyologist Brett Arends Bill Bischoff Amy Hoak Chuck Jaffe Jennifer Openshaw Jennifer Waters Tools Funds Finder Today's Rates Retirement RetireMentors Encore Taxes Retire Here, Not There How-to Guides Social Security Estate Planning Events Columns Robert Powell's Retirement Portfolio Andrea Coombes's Working Retirement Tools Retirement Planner How long will my money last? Economy Federal Reserve Capitol Report Economic Report Columns Darrell Delamaide Irwin Kellner Rex Nutting Tools Economic Calendar Real Estate Location Scouts realtor.com My MarketWatch Watchlist Alerts Games Log In Until Tokyo Markets Open US Market Snapshot Currencies Commodities Home Press Release ERYTECH Strengthens Executive Leadership Team with Appointments of Chief Scientific Officer and Chief Business Officer By Published: Oct 27, 2016 1:46 a.m. ET Share Dr. Alexander Scheer Joins Company as CSO and Jean-SÃ©bastien Cleiftie as CBO LYON, France, Oct 27, 2016 (BUSINESS WIRE) -- Regulatory News: ERYTECH Pharma (ERYP) (adr:EYRYY) (euronext paris:ERYP), the French biopharmaceutical company developing â€˜tumor starvationâ€™ treatments for acute leukemia and other oncology indications with unmet medical needs, today announced the appointments of Dr. Alexander Scheer, Ph.D. as the companyâ€™s Chief Scientific Officer and Jean-SÃ©bastien Cleiftie, as Chief Business Officer. â€œWe are delighted to welcome Alexander and Jean-SÃ©bastien to the Erytech leadership team as they both bring invaluable experience from cross-functional areas of the life science industry,â€ commented Gil Beyen, Chief Executive Officer and Chairman of the Board of ERYTECH Pharma. â€œAlexander brings a wealth of knowledge in leading global R&D and drug discovery across multiple disciplines and several therapeutic areas, while Jean-SÃ©bastienâ€™s deep expertise in biopharmaceutical business development and financial valuation will be instrumental to Erytech as we continue to diversify our programs and address unmet medical needs of patients.â€ Dr. Scheer said, â€œErytechâ€™s ERYCAPS technology represents a novel approach to anti-cancer tumor starvation treatment. The company has demonstrated exceptional progress in preclinical and clinical development of multiple pipeline programs and I look forward to leading the development of these promising therapies.â€ Mr. Cleiftie added, â€œI believe Erytech is very well positioned to be a successful biopharmaceutical company. I am eager to direct the strategic initiatives necessary for continued growth of the company and its operations as it enters the next phase of development.â€ Dr. Scheer has over 15 years of experience in R&D and the life science industry. Prior to joining ERYTECH, he served as the Head of Research at Pierre Fabre in France, focused primarily on oncology and central nervous system research, and also served as a Deputy Head of Research at Pierre Fabre. Prior to joining Pierre Fabre, Dr. Scheer served as a Director, Global Research Informatics & Knowledge Management R&D and Project Leader, Neglected Diseases at Merck Serono in Switzerland where, among other responsibilities, he led Merckâ€™s program to develop drugs for neglected diseases in collaboration with the World Health Organization (WHO). He also served as Head of Molecular Screening and Cellular Pharmacology Department, Group Leader of Biochemical Pharmacology and Research Scientist at Serono. Dr. Scheer holds a B.Sc in Natural Sciences and M.Sc. in Chemistry, both from the University of Gottingen, and a Ph.D. in Chemistry and Biochemistry from the German Cancer Research Center. Mr. Cleiftie brings 15 years of experience in drug development, life science venture capital, and business development and licensing within the U.S. and European biopharmaceutical ecosystem. Prior to joining ERYTECH, he served as Associate Vice-President, Global Business Development & Licensing at Sanofi in Paris, France, where he led licensing transactions across multiple therapeutic areas, financial valuation activities, and other strategic projects. Prior to joining Sanofi, Mr. Cleiftie was a Principal at Innoven Partners, a venture capital firm active as lead investor in healthcare and IT in Europe and the U.S. He was responsible for healthcare investment opportunity assessment, transaction execution, and active portfolio management, and led equity investments in a number of biotech and medtech companies which achieved successful exits. He started his career in drug development in the U.S. as a research scientist with Aventis (now Sanofi) in the fields of immunotherapy and gene therapy for cancer. Mr. Cleiftie earned a M.S. in Biological & Medical Sciences and a M.S. in Immunology from the University of Paris V, and received his M.B.A from Cornell University. About ERYTECH and eryaspase (eryasp/GRASPAÂ®): www.erytech.com Founded inÂ Lyon, FranceÂ in 2004, ERYTECH is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs. ERYTECHâ€™s initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), by depriving tumors of nutrients necessary for their survival. ERYTECH has recently filed for European Marketing Authorization for its lead product candidate, eryaspase, also known as ERY-ASP or under the trade name GRASPAÂ®, following positive efficacy and safety results from its completed Phase 2/3 pivotal clinical trial inÂ EuropeÂ in children and adults with relapsed or refractory ALL. ERYTECH also has an ongoing Phase 1 clinical trial of eryaspase inÂ the United StatesÂ in adults with newly diagnosed ALL, and a Phase 2b clinical trial inÂ EuropeÂ in elderly patients with newly diagnosed AML, each in combination with chemotherapy. ERYTECH believes that eryaspase also has the potential as a treatment approach in solid tumors and is conducting a Phase 2 clinical trial inÂ EuropeÂ in patients with metastatic pancreatic cancer. Eryaspase consists of an enzyme, L-asparaginase, encapsulated inside donor-derived red blood cells. L-asparaginase depletes asparagine, a naturally occurring amino acid essential for the survival and proliferation of cancer cells, from circulating blood plasma. ERYTECH produces eryaspase at its own GMP-approved and operational manufacturing site inÂ LyonÂ (France), and at a site for clinical production inÂ PhiladelphiaÂ (USA). ERYTECH has entered into licensing and distribution partnership agreements for eryaspase for ALL and AML inÂ EuropeÂ with Orphan Europe (Recordati Group), and for ALL inÂ IsraelÂ with TEVA, which will market the product under the GRASPAÂ® brand name. The EMA and the U.S. Food and Drug Administration (FDA) have granted orphan drug designations for eryaspase for the treatment of ALL, AML and pancreatic cancer. In addition to eryaspase, ERYTECH is developing two other product candidates that focus on using encapsulated enzymes to induce tumor starvation. The company is also exploring the use of its ERYCAPS platform for developing cancer immunotherapies and enzyme replacement therapies. ERYTECH is listed on Euronext regulated market in Paris (isin code:FR0011471135)(ticker:ERYP) and is part of the CACÂ Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. ERYTECH is also listed in the U.S. under an ADR level 1 program (OTC, ticker EYRYY). Forward-looking information This document may contain forward-looking statements and estimates with respect to the financial position, results of operations, business strategy, plans, objectives and anticipated future performance of ERYTECH and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, â€œbelievesâ€, â€œanticipatesâ€, â€œexpectsâ€, â€œintendsâ€, â€œplansâ€, â€œseeksâ€, â€œestimatesâ€, â€œmayâ€, â€œwillâ€ and â€œcontinueâ€ and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond ERYTECH's control. There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Documents filed by ERYTECH Pharma with the French AutoritÃ© des MarchÃ©s Financiers (www.amf-france.org), also available on ERYTECHâ€™s website (www.erytech.com) describe such risks and uncertainties. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this document. Readers are cautioned not to place undue reliance on any of these forward-looking statements. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in ERYTECHâ€™s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law. View source version on businesswire.com: http://www.businesswire.com/news/home/20161026006283/en/ SOURCE: ERYTECH Pharma ERYTECH Gil Beyen Chairman and CEO or Eric Soyer CFO and COO +33 4 78 74 44 38 investors@erytech.com or The Ruth Group Investor relations Lee Roth, +1 646 536 7012 lroth@theruthgroup.com or Media relations Kirsten Thomas, +1 508 280 6592 kthomas@theruthgroup.com or NewCap Julien Perez Investor relations or Nicolas Merigeau Media relations +33 1 44 71 98 52 erytech@newcap.eu Copyright Business Wire 2016 MarketWatch Partner Center Celebrity Real Estate News Celebrities renege on their pledges to move out of U.S on the back of Trump win View More Investing If you're shocked that Trump won, you broke 3 basic principles of investing View More Barron's Next Dear President-Elect Trump, a millennial wishlist View More Investing Opinion: A 12-step plan to strengthen your portfolio after Trump's victory View More MarketWatch Site Index Topics Help Feedback Newsroom Roster Media Archive Premium Products Mobile Company Company Info Code of Conduct Corrections Advertising Media Kit Advertise Locally Reprints & Licensing Broker Center Your Ad Choices Dow Jones Network WSJ.com Barron's Online BigCharts Virtual Stock Exchange Financial News Online WSJ.com Small Business realtor.com Mansion Global Back to Top Copyright Â©2016 MarketWatch, Inc. All rights reserved. By using this site you agree to the Terms of Service, Privacy Policy, and Cookie Policy. Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. Intraday data delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Dow Jones & Company, Inc. All quotes are in local exchange time. Real time last sale data provided by NASDAQ. More information on NASDAQ traded symbols and their current financial status. Intraday data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. S&P/Dow Jones Indices (SM) from Dow Jones & Company, Inc. SEHK intraday data is provided by SIX Financial Information and is at least 60-minutes delayed. All quotes are in local exchange time. Advanced Search Stocks Columns Authors Topics No results found LatestNews

Contact Newsagent Login Business Search Scoop Â  Â  WIRES: SCOOPS PARLIAMENT POLITICS REGIONAL BUSINESS SCI-TECH WORLD CULTURE EDUCATION HEALTH SECTIONS: HOME COMMENT MULTIMEDIA NZ POLITICS BIZ & SCI/TECH WORLD LIFESTYLE ARCHIVES MOST READ VIDEO Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search Â  Â Related Â Email Â Print Scoop >> Business Tweet While you were sleeping: Apple slides on outlook Thursday, 27 October 2016, 7:51 am Article: BusinessDesk While you were sleeping: Apple slides on outlook Oct. 27 (BusinessDesk) - Equities slid amid a disappointing outlook from Apple, while energy stocks fell with the price of oil. In 2.14pm trading in New York, the Dow Jones Industrial Average eked out a 0.03 percent advance. The Nasdaq Composite Index dropped 0.7 percent. In 2pm trading, the Standard & Poorâ€™s 500 Index fell 0.3 percent. In the Dow gains in shares of Boeing and those of Nike, recently trading 4.2 percent and 1.9 percent higher respectively, offset slides in shares of Apple and those of Merck, down 3 percent and 2.2 percent respectively. While Appleâ€™s latest quarterly earnings per share exceeded analysts expectations, analysts were disappointed with its outlook for iPhone salesâ€”especially given the rival Samsungâ€™s woes. "In essence, in China and elsewhere, while Appleâ€™s products are still seen favourably, the distance between Apple and its competitors is nowhere near as great as it once was," Neil Saunders, head of retail research firm Conlumino, wrote in a note, according to Reuters. The latest US economic data were better than anticipated. The US trade deficit shrank 5.2 percent to US$56.1 billion in September, bolstering hope that third-quarter GDP growth might beat expectations. â€œWe now believe the boost from trade could be closer to a full percentage point, almost twice what we had expected," Michelle Girard, chief economist at RBS in Stamford, Connecticut, told Reuters. Girard said she now predicts real GDP growth in the third quarter of 3.3 percent. Separately, a Commerce Department report showed new home sales rose 3.1 percent to a seasonally adjusted annual rate of 593,000 units in September, an unexpected gain. Mondelez International shares climbed, up 3.6 percent as of 1.35pm in New York, after the maker of Cadbury chocolate upgraded its full-year profit forecast. The company has increased its full-year adjusted earnings per share outlook and now expects growth of about 25 percent on a constant-currency basis, Mondelez said in a statement. "Our third quarter results underscore our continued commitment to improve operational efficiency, expand margins and profitably grow volume while also investing in strategic growth initiatives for the longer term," CEO Irene Rosenfeld said in the statement. â€œIn the face of challenging market conditions, we're building a stronger, more streamlined company that is well positioned to deliver sustainable, profitable growth and attractive cash generation,â€ Rosenfeld noted. In Europe, the Stoxx 600 Index finished the day with a 0.4 percent slide from the previous close. Franceâ€™s CAC 40 Index slipped 0.1 percent, Germanyâ€™s DAX Index declined 0.4 percent lower, while the UKâ€™s FTSE 100 Index shed 0.9 percent. Germanyâ€™s Bayer, which agreed to buy Monsanto in a US$66 billion deal, reported better-than-expected quarterly profit bolstered by its pharmaceutical unit. Even so, Bayer shares closed 1.4 percent lower in Frankfurt as investors were concerned about weakness in its Crop Science division. Pharmaceuticals posted â€œencouragingâ€ sales growth of 7.6 percent in the quarter, Consumer Health sales grew 3.6 percent, while sales of Crop Science were level year on year, Bayer said. â€œEarnings are not strong enough to fuel markets,â€ Ralf Zimmermann, an equity strategist at Bankhaus Lampe in Dusseldorf, Germany, told Bloomberg. â€œSome investors who had expected accelerating earnings may be disappointed.â€ (BusinessDesk) Â© Scoop Media BusinessDesk Independent, Trustworthy New Zealand Business News The Wellington-based BusinessDesk team led by former Bloomberg Asian top editor Jonathan Underhill and Qantas Award-winning journalist and commentator Pattrick Smellie provides a daily news feed for a serious business audience. CONTACT BUSINESSDESK Email - editor@businessdesk.co.nz Â  Tweet Â  Â  Â  Â  Business Headlines | Sci-Tech Headlines BUSINESS, SCIENCE & TECH > > Â  Easing Ending? RBNZ's Wheeler Cuts OCR Reserve Bank governor Graeme Wheeler cut the official cash rate to a new record low to try to stoke inflation in an economy growing ahead of expectations and signalled the end of the easing cycle. The kiwi dollar gained after the statement. More>> ALSO: BusinessDesk - RBNZ's Wheeler has 'open mind' on currency intervention Reserve Bank - Official Cash Rate reduced to 1.75 percent Media: Commerce Commission Initial Decision To Decline NZME/Fairfax Merger The Commission has assessed the impact of the merger on competition in both advertising and reader markets for a number of media platforms as well as the overall impact on quality and plurality (diversity of voices). More>> ALSO: BusinessDesk - NZME shares slump to new low - Concentration of NZME, Fairfax tie-up a concern - NZME, Fairfax NZ merger in trouble in ComCom draft decision Labour - ComCom merger decline a win for media diversity E tu - Union welcomes draft decision to reject NZME-Fairfax merger Simpson Grierson - Stance on NZME/Fairfax merger bound to be highly contentious Out-Link - Tim Murphy: The StuffMe merger is stuffed | The Spinoff Inflation: Those With Lowest Living Standards Face Highest Price Rises CTU: In the year to September, while a typical household experienced price increases of 0.1 percent, the lowest spending households saw prices rise by 0.6 percent, beneficiaries by 0.8 percent and superannuitants by 0.4 percent. At the end of the scale, the highest spending households saw prices fall by 0.3 percent. More>> ALSO: Statistics NZ - Superannuitants experience highest inflation Greens - New data shows Nationalâ€™s two-track economy Royal Society: Increased Number Of Projects Funded In 2016 A total of 117 research projects have been allocated $65.2 million (excl. GST) of funding in this yearâ€™s Marsden Fund grants, which support New Zealandâ€™s best investigator-initiated research in the areas of science, engineering, maths, social sciences and the humanities. More>> ALSO: NZ Govt - $65.2m in Marsden funding for NZ researchers University of Otago - Major Marsden funding for Otago researchers University of Auckland - University of Auckland celebrates Marsden fund success University of Canterbury - University of Canterbury snares 10% of Marsden Funding Massey University - Marsden funding awarded for Pacific customary land use study NZ Taxpayers' Union - Royal Society's Marsden grants an embarrassment Auckland University - Auckland medical science benefits from major grants Universities NZ - Te Pokai Tara - Universities awarded 92.5% of Marsden research funding Gordon Campbell: On Britainâ€™s Landmark Court Ruling Against Uber The shockwaves from Uberâ€™s defeat last week in a British court have reportedly already begun to wash up here in New Zealand with some local drivers thinking of taking a similar class action. More>> ALSO: NZ Uber Driver Association - Government's lack of apparent action against Uber BusinessDesk - Uber seeks government affairs manager to lobby on regulation Gordon Campbell - Gordon Campbell on special needs education funding changes Trade: NZ Trade Deficit Widens To A Record In September Oct. 27 (BusinessDesk) - New Zealand's monthly trade deficit widened to a record in September as meat exports dropped to their lowest level in more than three years. More>> ALSO: HiFX - HiFX Data Update - NZ Trade Balance (Sep) Statistics NZ - Meat exports fall 15 percent in September quarter Get More From Scoop Submit News/Press Releases To Scoop Scoop Online Community Scoop Media on Facebook Follow Scoop on Twitter Scoop YouTube Channel Â  LATEST HEADLINES BUSINESS SCI-TECH Theresa Gattung Venture Capital fund 12:11 PM | Angel Association Tower estimates quake could trim profit by up to $7.2 mln 12:09 PM | BusinessDesk MYOB awarded Service Provider of the Year 12:07 PM | MYOB Antipodes Gold Reverse Takeover Update 12:06 PM | Chatham Rock Phosphate Hamiltonâ€™s outlying villages see boost in house hunters 12:04 PM | Lodge Real Estate NZ dollar little changed below 71 US cents as greenback 11:59 AM | BusinessDesk Unique chance to develop consented lifestyle land in Twizel 11:37 AM | Colliers Internationa... More Â  RSS Nitrogen Recording Protects Water And Drives Efficiency 12:28 PM | Fonterra Project Echo part of international bat symposium in Hamilton 10:33 AM | Hamilton City Counci... Magnitude 7.5, 14 November, NZ Earthquake - Expert reaction 14/11/16 | Science Media Centre Severe weather to hit during quake clean-up 14/11/16 | MetService NZGL Supports Wide Reaching Research 14/11/16 | NZ Genomics NIWA's Hotspot Watch 11/11/16 | NIWA NZDF Survey Shows Lake Rotorua â€˜Hydrothermally Activeâ€™ 11/11/16 | New Zealand Defence Force More Â  RSS Â  Featured InfoPages Â  Bill Bennett on Tech Microsoft Surface Book one year on 1:41 AM | Bill Bennett More copper criticism as Vodafone joins fixed 4G w... 12 Nov | Bill Bennett Power poles may carry fibre to bush 10:36 PM | Bill Bennett Microsoft double-dipping with Outlook.com ads 5:08 PM | Bill Bennett Spark, Vodafone, Chorus and the battle for fibre 05 Nov | Bill Bennett Smartwatches not ticking 1:56 AM | Bill Bennett Wireless â€” a drop in the data ocean 29 Oct | Bill Bennett More Â  RSS Â  BUSINESS.scoop Valuecruncher NZ dollar little changed below 71 US cents as gree... 9:59 AM | admin Unique chance to develop consented lifestyle land ... 9:37 AM | admin Candidates for Fonterra Board of Directorsâ€™ Electi... 9:19 AM | admin Go Green Expo a breeding ground for pseudoscience 9:12 AM | admin Update to Wellington roads 8:55 AM | admin Wellington highways closed due to surface flooding 8:39 AM | admin When strangers call bearing investment gifts: hang... 8:26 AM | admin More Â  RSS News Alerts Valuecruncher data feeds 4:18 AM | The Crunch Updated Valuecruncher Dataset 02 Feb | The Crunch Guest Post â€“ Andrew Smith on Apple (AAPL) 25 Nov | The Crunch Woodward Research provides free equity research re... 25 Nov | The Crunch Some quick thoughts on the LinkedIn ($LNKD) IPO 20 May | The Crunch Company of the Day Tweets â€“ 30 December 2010 30 Dec | The Crunch NZX (New Zealand) Company of the Day Tweets â€“ 30 D... 30 Dec | The Crunch More Â  RSS News Alerts Â  Â  Powershop Loudhailer 1. Powershop and Pulse big winners of electricity customer switch 2. Stuff.co.nz: Stable power prices expected 3. Stuff.co.nz: Force against Powershop over Darth Vader image 4. Stuff.co.nz: Powershop 6th Fastest Growing Company in Asia Pacific 5. Forbes.com: Powershop - The eBay of Electricity by Tony Seba 6. NZ Herald: Powershop Tops Rankings For Consumer Satisfaction (Again) Â  Â  Business SciTech Section Blogroll Business Business.scoop - Jonathan Underhill and Pattrick Smellie The Main Report - Trends In NZ Business NZ Transport Intelligence Briefing Profitable Agri-Business Farming News 2011 Election Results Graphic - NZ Election Results - 2011 NZ Election Results - 2011 NZ General Election Results Finance NZ Dollar/US Graph NZ & AUS Shares JP Yen/US Dollar Graph Global Share Markets Global Currencies Oil Futures Spot Gold Science Weather Underground Te Papa's Blog Technology GPS fleet management ReadWriteWeb - Web Apps, Web Technology Trends, Social Networking & Social Media Other Links New Fisher & Paykel kitchen appliances Business Management Training Courses Scoop Newsagent Media Monitoring Email Alerts Media Tracking Â  Â  Contact Newsagent Login Business Search Scoop Â  Â  Â  Scoop.co.nz About Us Contact Submit News Services Advertise Newsagent Subscribe Login Scoop on Facebook Scoop on Twitter Scoop - Mobile Site Headline Wires Scoops Parliament Politics Regional Business Sci-Tech World Culture Education Health Sections Comment Multimedia NZ Politics Biz & Sci/Tech World Lifestyle Video Specialist Sites InfoPages TechLab Werewolf Gordon Campbell Business Scoop Pacific Scoop Gaza Scoop Auckland Scoop Wellington Scoop Community Scoop Parliament Today Advertising Scoop Search Scoop Scoop Media Cartel Scoop Public Address The Standard Theatreview LiveNews Pundit SpareRoom The Big Idea Â© Scoop MediaÂ |Â  Terms of UseÂ |Â  Privacy PolicyÂ |Â Feedback Â 
Home About us Languages Bulgarian Chinese Czech French German Hebrew Indonesian Italian Japanese Korean Persian Portuguese Romanian Russian Slovak Spanish Swedish Turkish Ukrainian Vietnamese Epoch Taste New York NY News Orange County NY NY Politics NYC Dining This is New York NYC City Life China China-US News Chinese Regime Business & Economy Chinese Culture China Human Rights China Society Nine Commentaries Organ Harvesting in China Hong Kong US US News US Features Politics Crime and Incidents World Africa Americas Asia & Pacific Canada Europe India International Middle East Opinion Thinking About China Viewpoints The Readerâ€™s Turn Business Companies Economies Markets Real Estate Tech Tech News Tech Products & Reviews Tips & Tricks Social Media Gaming Science News Beyond Science Space Environment Archaeology Health News Fitness & Nutrition Traditional Chinese Medicine Alternative Health Treatments & Techniques Health Videos Food Food News Recipes Drinks Arts Shen Yun Special Coverage Featured Topic: The Classics Performing Arts Fine Arts Literature Entertainment Film Reviews Film & TV Entertainment News Korean Trends Life Slice of Life Good to Know Inspired Home Autos Personal Finance Careers Family Education Green Living Travel Style Sports NFL Baseball NBA College Sports Tennis Soccer Hockey Motorsports Cycling Galleries Video Entertainment Health Science & Tech China Life Moments Animal Sports Fashion & Beuaty Food Travel Autos Programs China Uncensored Off the Great Wall Learn Chinese Now Asian Beauty Secrets Food Paradise Epoch Forum More Subscribe Advertise About Us Contact Us Print Editions RSS Feeds Terms of Service Privacy Policy Copyright Policy Sections Search Our Brands Ã—Close Subscribe PRINTÂ EDITION NEWSLETTERS Epoch Times on Twitter Epoch Times on Facebook Environment, Health News, US News Big Pharma Pressured to Clean Up Pollution That Creates Superbugs Environment, Health News, US News Big Pharma Pressured to Clean Up Pollution That Creates Superbugs By Tara MacIsaac, Epoch Times | October 26, 2016 AT 4:28 PM Last Updated: November 1, 2016 11:55 am A file photo of a pipe discharging effluent from a factory that manufactures pharmaceuticals, owned by the company Aurobindo, in Bollaram, India. (Courtesy of Changing Markets) The discharge from factories that produce antibiotics is a hotbed for growth of so-called â€œsuperbugs,â€ according to a report released Oct. 19 by environmental advocacy organization Changing Markets. Superbugs are bacteria that have developed a resistance to antibiotics. This antimicrobial resistance (AMR) is a major global health concern, rising to the level of HIV and Ebola. On Sept. 21, it became the fourth health issue ever taken up at the U.N. General Assembly.Â  A UN statement released after the meeting summarized the gravity of the problem: â€œCommon and life-threatening infections like pneumonia, gonorrhea, and post-operative infections, as well as HIV, tuberculosis, and malaria are increasingly becoming untreatable because of AMR.â€ While the two leading causes of AMR are (1) excessive human consumption of antibiotics and (2) the use of antibiotics in rearing livestock, industry leaders are increasingly treating pollution from pharmaceutical manufacturing with urgency as a third major cause.Â  Ahead of the General Assembly meeting, 13 major pharmaceutical companiesâ€”including American companies Pfizer, Merck & Co., and Johnson & Johnsonâ€”announced commitments to battle AMR. At the top of their list was to â€œreview our own manufacturing and supply chains to assess good practice in controlling releases of antibiotics into the environment.â€ They plan to establish a common framework for managing antibiotic discharge and put it into practice by 2018. Pfizer was identified by Changing Markets as one of the American companies that sources from factories in India and China, which are the main offenders. The report also identified American pharmaceutical companies McKesson and CVS Health as sourcing from factories that cause AMR, and it urged them and allÂ American and European companies to clean up their supply chains. About 80 percent of active pharmaceutical ingredients in U.S. drugs are sourced from overseas, mostly from India and China. McKesson spokesperson Jennifer Nelson told Epoch Times via email: â€œMcKesson understands that protecting the integrity of the supply chain is critically important to global health as well as to our business. â€¦ We are aware of claims against some of our suppliers and are actively reviewing the matter. We will take action if necessary.â€ CVS Health did not respond to inquiries. Both companies source from Aurobindo Pharma, based in Hyderabad, India, which Changing Markets identified as one of the worst offenders. The company has grown about 800 percent in the past decade, with its biggest market (55 percent) in the United States, according to the report. A file photo of an Aurobindo pharmaceutical factory in Pydibhimavaram, India. (Courtesy of Changing Markets) About 80 percent of active pharmaceutical ingredients in U.S. drugs are sourced from overseas, mostly from India and China, according to the Institute of Medicine.Â  Superbugs know no boundaries, easily spreading from factory effluent in India to the rest of the world. The superbugs can spread through the countryâ€™s waterways, to farmland and drinking water for livestock and people, and can easily hitch a ride on people or goods traveling abroad. The report touched on another emerging concern in the spread of these superbugs: Chinese pharmaceutical manufacturers are disposing of their solid waste, including antibiotic residues, by making it into fertilizer. Thus antibiotics are being spread over soil far and wide. â€œWhile experts see this as highly problematic from an environmental and human health perspective, the lack of specific laws or regulations covering fertilizer provides companies with a legal loophole which they are only too keen to exploit,â€ the report stated. Out of 34 sites tested, 16 were found to contain bacteria resistant to antibiotics. Dr. Mark Holmes from the University of Cambridge worked with Changing Markets to study the concentration of antibiotics and superbugs in some Indian waterways. Out of 34 sites tested, 16 were found to contain bacteria resistant to antibiotics. Holmes concluded, as haveÂ several other studies in recent years, that the pharmaceutical waste isÂ greatly contributing to the development ofÂ superbugs in Indiaâ€™s waterways. An example of another study with similar results was one conducted by researchers at Swedenâ€™s University of Gothenburg in 2014. They found that Kazipally Lake in India, affected by the dumping of pharmaceutical waste, harbored 81 types of resistance genes against â€œessentially every major class of antibiotics.â€ Thatâ€™s 7,000 times more AMR than a lake in Sweden testedÂ for comparison.Â  (Greentea Latte/Shutterstock) (Funnyangel/Shutterstock) The Changing Markets report not only highlighted the problem of pollution from pharmaceutical factories in Asia, it also traced the supply chains in the greatest detail yet from Asia to America and Europe. It called for greater transparency, as it was difficult, and in many cases impossible, to find the links in the chains using data that is publicly available. FDA Beyond US Borders The U.S. Food and Drug Administration (FDA) sends inspectors to Indian and Chinese pharmaceutical factories, and has made great strides toward cleaning up the problems, though many remain. In 2015 alone, the FDA issued notices of manufacturing violations at 80 Chinese production sites. Such a notice usually results in an import ban.Â  In an email to Epoch Times, the FDA stated: â€œDrug products approved for marketing in the U.S. are held to the same quality standards regardless of their manufacturing location. Our application review and facility inspections are conducted with the same rigor independent of geographic location of the manufacturer.â€ The inspectors take into consideration how the companies handle their waste, the FDA said, according to general manufacturing process regulations, such as â€œTrash and organic waste matter shall be held and disposed of in a timely and sanitary mannerâ€ (21 CFR 211.56). Â  As AMR death tolls rise, Former Rep. Henry Waxman and Department of Health and Human ServicesÂ Deputy Secretary Bill Corr are working on a campaign to encourage American companies to clean up their supply chains. They also encourage the FDA to pressure authorities in India and China to strengthen local regulations. Every year in the United States at least 2 million people become ill from superbugs, and at least 23,000 die, according to the Centers for Disease Control. Globally, about 700,000 die annually, according to a report commissioned by the British government this spring, and that number is expected to grow to 10 million annually by 2050. Editorâ€™s Picks â€˜Human Rights is Part of the DNA of Americaâ€™: An Interview with Gary Locke on Hillary Clinton, China, and the 2016 Election Trump Elected President: Hereâ€™s How He Plans to Change America Honoring Veterans Today, Preparing Our Young to Do So Tomorrow Receive Our Epoch 10 Newsletter Important stories from around the world, in your inbox daily. More in EnvironmentIs America Solving, or Just Exporting, Its Environmental Problems?Scientists Discover â€˜Staggeringly Large Amountâ€™ of Water Under a Volcano (Video)By 2100 Lisbon, Portugal Could Be a Desert (Video)New Device Could Detect GMOs That Have Escaped Into Environment Latest in Science Science & Tech videos Solar Flare Caused a â€˜Crackâ€™ in Protective Field Around Earth (Video) Science & Tech videos A Strange â€˜Funnelâ€™ on Mars Could Provide Suitable Conditions for Life (Video) archaeology â€˜Saddestâ€™ Dinosaur Fossil Found Shows Struggle Before Death (Video) Space Mondayâ€™s Supermoon to Be Extra Super; Closest in Nearly 70 Years Environment Is America Solving, or Just Exporting, Its Environmental Problems? Environment Scientists Discover â€˜Staggeringly Large Amountâ€™ of Water Under a Volcano (Video) Science & Tech videos Images Show Rare Eye-Shaped â€˜Tsunami of Stars and Gasâ€™ (Video) Space â€˜I Voted From Spaceâ€™: Lone American Off Planet Casts Ballot Science & Tech videos Scientists Find a â€˜Jacuzzi of Despairâ€™ in Gulf of Mexico (Video) Ã— close Subscribe Advertise About Us Contact Us Print Editions RSS Feeds Terms of Service Privacy Policy Copyright Policy Copyright Â© 2000- Top
Skip to main content The Meeting Place of Intelligent Business Business Banking & Finance Property Ad/Media Politics Tech Law & Courts Motoring Arts & Film Rich List Markets Appointments Poll Results AMA Print Edition Radio Masters of Business Search form Search Home Meet Our Journos Advertise Help Contact Special Reports Subscribe Search Log in Log in Business Banking & Finance Property Ad/Media Politics Tech Law & Courts Motoring Arts & Film Rich List Markets Appointments Poll Results AMA Print Edition Radio Masters of Business . While you were sleeping: UPDATED US stocks mixed, Apple slides on outlook Margreet Dietz Thursday October 27, 2016 Share Play NBR radio on Stocks on Wall Street were mixed amid a disappointing outlook from Apple. Energy stocks fell with the price of oil but Boeing boosted the blue chips. At the close, the Dow Jones Industrial Average was up 30.06 points, or 0.2%, to 18,199.33. The Nasdaq Composite Index dropped 0.6% to 5250.27 andÂ the Standard & Poor's 500 Index easedÂ 0.2% to 2139.43. In the Dow gains in Boeing and Nike shares, trading 4.7% and 1.9% higher respectively, offset slides in Apple and Merck shares, down 2.2% and 2.0% respectively. While Apple's latest quarterly earnings per share exceeded analystsâ€™ expectations, they were disappointed with its outlook for iPhone sales, especially given rival Samsung's woes. "In essence, in China and elsewhere, while Apple's products are still seen favourably, the distance between Apple and its competitors is nowhere near as great as it once was," retail research firm Conlumino head Neil Saunders wrote in a note, according to Reuters. The latest US economic data were better than anticipated. The US trade deficit shrank 5.2% to $US56.1 billion in September, bolstering hope the third-quarter GDP growth might beat expectations. "We now believe the boost from trade could be closer to a full percentage point, almost twice what we had expected," Connecticut-based RBS chief economist Michelle Girard told Reuters. Ms Girard now predicts real GDP growth in the third quarter at 3.3%. Separately, a Commerce Department report showed new home sales rose 3.1% to a seasonally adjusted annual rate of 593,000 units in September, an unexpected gain. Mondelez improves Mondelez International shares climbedÂ 3.6% after the maker of Cadbury chocolate upgraded its full-year profit forecast. The company has increased its full-year adjusted earnings per share outlook and now expects growth of about 25% on a constant-currency basis, Mondelez says. "Our third quarter results underscore our continued commitment to improving operational efficiency, expanding margins and profitably growing volume while also investing in strategic growth initiatives for the longer term," chief executive Irene Rosenfeld says. "In the face of challenging market conditions, we're building a stronger, more streamlined company that is well positioned to deliver sustainable, profitable growth and attractive cash generation." In Europe, the Stoxx 600 Index finished the day with a 0.4% slide from the previous close. France's CAC 40 Index slipped 0.1%, Germany's DAX Index dropped 0.4% lower, while the UK's FTSE 100 Index shed 0.9%. Bayer profit up Germany's Bayer, which agreed to buy Monsanto in a $US66 billion deal, reported better than expected quarterly profit bolstered by its pharmaceutical unit. Even so, Bayer shares closed 1.4% lower in Frankfurt as investors are concerned about weakness in its Crop Science division. Pharmaceuticals posted "encouraging" sales growth of 7.6% in the quarter, Consumer Health sales grew 3.6%, while sales of Crop Science were level year-on-year, Bayer says. "Earnings are not strong enough to fuel markets," Dusseldorf-based Bankhaus Lampe equity strategist Ralf Zimmermann told Bloomberg. "Some investors who had expected accelerating earnings may be disappointed." (BusinessDesk) Â  Got a question about this story? Leave it in Comments & Questions below. This article is tagged with the following keywords. Find out more about MyNBR Tags Comments & Questions Commenter icon key: Subscriber Verified Post New comment or question Your name Comment * More information about text formats Plain text No HTML tags allowed. Web page addresses and e-mail addresses turn into links automatically. Lines and paragraphs break automatically. Home page NZ Market Snapshot Forex Sym Price Change USD 0.7135 0.0026 0.37% AUD 0.9419 0.0016 0.17% EUR 0.6639 0.0074 1.13% GBP 0.5700 0.0048 0.85% HKD 5.5330 0.0186 0.34% JPY 77.2090 1.2300 1.62% Commods Commodity Price Change Time Gold Index 1221.7 -2.600 2016-11-14T00: Oil Brent 44.4 -0.320 2016-11-14T00: Oil Nymex 43.3 -0.090 2016-11-14T00: Silver Index 16.9 -0.490 2016-11-14T00: Indices Symbol Open High Last % NZX 50 6737.8 6743.1 6737.8 0.08% NASDAQ 5246.3 5247.2 5237.1 -0.36% DAX 10750.6 10802.4 10668.0 0.24% DJI 18876.8 18934.0 18847.7 0.11% FTSE 6730.4 6814.2 6730.4 0.34% HKSE 22344.2 22359.0 22531.1 -1.37% NI225 17467.5 17697.3 17374.8 1.71% ASX 5345.7 5345.7 5345.7 -0.76% Most Popular Read Statistics NZ Wellington building off-limits after floor pancaked in quake Quake day two: Wellington CBD reopens, rescue mission on way to Kaikoura Aucklanders detest new city slogan; want Ateed's wings clipped Liquidators stir bad blood at Mad Butcher Publishing giant accuses NZâ€™s largest high school of copyright infringement Commented Auckland bureaucrats 'out-of-control' with $500K new slogan Simon puts Telecom back together Aucklanders detest new city slogan; want Ateed's wings clipped New Zealand, Israel close to signing bilateral innovation agreement, summit told NZ POLITICS DAILY: 10 reasons why anti-Establishment politics could hit New Zealand Most listened to What's the story behind the story? Our special feature audio offers a mix of comment from journalists, experts and panel discussions. Auckland Chamber of Commerce head Michael Barnett gives a rundown on what's wrong with the city's new detested logo Tim Hunter on the latest turmoil at Mad Butcher National president of the Restaurant Association Mike Egan on how the earthquake has impacted small businesses in the capital â€œItâ€™s an ultra-cautious market,â€ says ANZ senior economist Philip Borkin on Currency Talk Nevil Gibson reveals Lion's plan to expand its New Zealand wine interests after selling its Australian premium brands Only available on Features NBR Rich List Full results and analysis of the 2016 NBR Rich List People Scene Catching people out and about Appointments People in business NBR Special Report Our reporters examine whatâ€™s happening in industry sectors The Meeting Place of Intelligent Business Home Meet Our Journos Advertise Help Contact Special Reports Subscribe Search Log in Log in Share Copyright Notice Privacy Policy Terms & Conditions RSS feeds Share width="1" height="1" alt="" /> While you were sleeping: UPDATED US stocks mixed, Apple slides on outlook
Contact Newsagent Login Scoop Search MARKETS Sharemarket Finance Company Results Real Estate SOEs ECONOMY Economy Reserve Bank Confidence Commerce Industrial Relations Employers Employment Statistics Taxation Trade Agreements Treasury INDUSTRY Agriculture Horticulture Fisheries Forestry Manufacturing Telecommunications Computing & Internet Media Retail Liquor Transport Tourism ENERGY Oil Coal Alternative Energy Electricity Gas Energy Policy Scoop Homepage | BizSciTech Homepage | Business Headlines | Business Most Read | Sci-Tech Headlines | Sci-Tech Most Read Powered by scoop.co.nz Tweet While you were sleeping: Apple slides on outlook 7:51 October 27, 2016ArticleComments Off on While you were sleeping: Apple slides on outlook Article â€“ BusinessDesk Oct. 27 (BusinessDesk) â€“ Equities slid amid a disappointing outlook from Apple, while energy stocks fell with the price of oil.While you were sleeping: Apple slides on outlook Oct. 27 (BusinessDesk) â€“ Equities slid amid a disappointing outlook from Apple, while energy stocks fell with the price of oil. In 2.14pm trading in New York, the Dow Jones Industrial Average eked out a 0.03 percent advance. The Nasdaq Composite Index dropped 0.7 percent. In 2pm trading, the Standard & Poorâ€™s 500 Index fell 0.3 percent. In the Dow gains in shares of Boeing and those of Nike, recently trading 4.2 percent and 1.9 percent higher respectively, offset slides in shares of Apple and those of Merck, down 3 percent and 2.2 percent respectively. While Appleâ€™s latest quarterly earnings per share exceeded analysts expectations, analysts were disappointed with its outlook for iPhone salesâ€”especially given the rival Samsungâ€™s woes. â€œIn essence, in China and elsewhere, while Appleâ€™s products are still seen favourably, the distance between Apple and its competitors is nowhere near as great as it once was,â€ Neil Saunders, head of retail research firm Conlumino, wrote in a note, according to Reuters. The latest US economic data were better than anticipated. The US trade deficit shrank 5.2 percent to US$56.1 billion in September, bolstering hope that third-quarter GDP growth might beat expectations. â€œWe now believe the boost from trade could be closer to a full percentage point, almost twice what we had expected,â€ Michelle Girard, chief economist at RBS in Stamford, Connecticut, told Reuters. Girard said she now predicts real GDP growth in the third quarter of 3.3 percent. Separately, a Commerce Department report showed new home sales rose 3.1 percent to a seasonally adjusted annual rate of 593,000 units in September, an unexpected gain. Mondelez International shares climbed, up 3.6 percent as of 1.35pm in New York, after the maker of Cadbury chocolate upgraded its full-year profit forecast. The company has increased its full-year adjusted earnings per share outlook and now expects growth of about 25 percent on a constant-currency basis, Mondelez said in a statement. â€œOur third quarter results underscore our continued commitment to improve operational efficiency, expand margins and profitably grow volume while also investing in strategic growth initiatives for the longer term,â€ CEO Irene Rosenfeld said in the statement. â€œIn the face of challenging market conditions, weâ€™re building a stronger, more streamlined company that is well positioned to deliver sustainable, profitable growth and attractive cash generation,â€ Rosenfeld noted. In Europe, the Stoxx 600 Index finished the day with a 0.4 percent slide from the previous close. Franceâ€™s CAC 40 Index slipped 0.1 percent, Germanyâ€™s DAX Index declined 0.4 percent lower, while the UKâ€™s FTSE 100 Index shed 0.9 percent. Germanyâ€™s Bayer, which agreed to buy Monsanto in a US$66 billion deal, reported better-than-expected quarterly profit bolstered by its pharmaceutical unit. Even so, Bayer shares closed 1.4 percent lower in Frankfurt as investors were concerned about weakness in its Crop Science division. Pharmaceuticals posted â€œencouragingâ€ sales growth of 7.6 percent in the quarter, Consumer Health sales grew 3.6 percent, while sales of Crop Science were level year on year, Bayer said. â€œEarnings are not strong enough to fuel markets,â€ Ralf Zimmermann, an equity strategist at Bankhaus Lampe in Dusseldorf, Germany, told Bloomberg. â€œSome investors who had expected accelerating earnings may be disappointed.â€ (BusinessDesk) Content Sourced from scoop.co.nz Original url Â Print This Post Tweet Â  Â  Blogroll China Economic Scan Compare house prices Deposit Rates Direct Broking â€“ NZX & ASX Trading & Prices Findata â€“ Market Data Good Returns Herald Business Interest.co.nz â€“ Interest Rates News & Views National Business Review Property Talk Sharechat Stuff Business Value Cruncher â€“ NZX Latest Business news Tower estimates quake could trim profit by up to $7.2 mln NZ dollar little changed below 71 US cents as greenback Unique chance to develop consented lifestyle land in Twizel Candidates for Fonterra Board of Directorsâ€™ Election Go Green Expo a breeding ground for pseudoscience Update to Wellington roads Wellington highways closed due to surface flooding When strangers call bearing investment gifts: hang up Fonterra chooses Epson projectors for dynamic edge blending Balex Marine makes the finals of international design awards Auckland more productive than other urban centres in NZ Advisory group a boost for NZ smart agriculture Bluebridge Cook Strait Ferry Update Wellington motorists asked to avoid unnecessary travel Update on insurance response to North Canterbury earthquake Text Links Recent Comments Lan: Unbelievable that a WEST AUSTR... jackp: Murray, when Key is involved t... Murray Guy: There are no boundaries when i... Lan: Canada & EU do it..Bryce ... Lan: I read somewhere that they do ... Simon Johnson: The former Department of Labou... Andrew P Nichols: Long overdue. Nowhere else in ... Rafi: I look forward to Mr Lees-Gall... Kevin McMahon: Yes, good on Lord Monckton. ... Bee: How do you think Kim Jon Key m... Categories Article Column Opinion PressRelease Uncategorized Monthly Archives November 2016 October 2016 September 2016 August 2016 July 2016 June 2016 May 2016 April 2016 March 2016 February 2016 January 2016 December 2015 November 2015 October 2015 September 2015 August 2015 July 2015 June 2015 May 2015 April 2015 March 2015 February 2015 January 2015 December 2014 November 2014 October 2014 September 2014 August 2014 July 2014 June 2014 May 2014 April 2014 March 2014 February 2014 January 2014 December 2013 November 2013 October 2013 September 2013 August 2013 July 2013 June 2013 May 2013 April 2013 March 2013 February 2013 January 2013 December 2012 November 2012 October 2012 September 2012 August 2012 July 2012 June 2012 May 2012 April 2012 March 2012 February 2012 January 2012 December 2011 November 2011 October 2011 September 2011 August 2011 July 2011 June 2011 May 2011 April 2011 March 2011 February 2011 January 2011 December 2010 November 2010 October 2010 September 2010 August 2010 July 2010 June 2010 May 2010 April 2010 March 2010 February 2010 January 2010 December 2009 November 2009 October 2009 September 2009 August 2009 July 2009 June 2009 May 2009 April 2009 March 2009 February 2009 January 2009 December 2008 November 2008 October 2008 September 2008 August 2008 November 1999 Feeds RSS Posts RSS Comments Scoop Business Â© 2016 | Powered by Scoop Media | Terms of Use
Ã— Weather Alert Information Alert data provided by http://alerts.weather.gov/ Close Contact Us Register Login DayExtra Classifieds Deals Jobs Homes Magazines Wheels Advertise Membership E-Paper High/Low: Humidity: Wind: Sunrise: Sunset: Visibility: View Full Forecast starting , ending . Powered by Forecast.io Business Toggle SECTIONS NEWS SPORTS OPINION COLUMNS & BLOGS ARTS & ENTERTAINMENT PHOTOS & VIDEO OBITUARIES News Sports Opinion Columns & Blogs Arts & Entertainment Photos & Video Obituaries DayExtra Classifieds Deals Jobs Homes Magazines WHEELS Advertise Membership E-Paper Police/Fire/Courts Business Local State/Northeast Nation/World 2016 Elections Special Reports Maps & Data Military UCONN High School Local Colleges Professional GameDay Editorials Letters Columns Op-Ed Guest Opinions Sports Features News Opinion Horoscopes Dear Abby Games & Puzzles Lifestyle Events & Exhibits Food & Drink Arts & Music Movies & TV Live Lunch Photo Galleries Videos GameDay Place an Ad Today's Listings Pets Garage & Yard Sales Map Jobs Day Saver Coupons Deal of the Day Rewards Business Directory Job Fair Local Jobs Homes of Distinction Find Local Listings Homes of Distinction Your Good Health Sound & Country Products Milestones Legal Obituary Classified Contact Us My Account Passport Rewards Subscribe Electronic Edition The Day's App Newspapers in Education Archives WARNING: This site requires JavaScript enabled to provide the best user experience possible. Please enable JavaScript within your browser for this site! LATEST NEWS Proposal to move Norwich parking commission to transportation center in the works 11-14 4:18 pm Still reeling, Democrats begin battling for future 11-14 3:43 pm PBS journalist Gwen Ifill dies of cancer 11-14 3:41 pm Overturned car snarls traffic on I-95 in Waterford 11-14 3:09 pm Tractor-trailer, car collide, close lane of I-95 in Waterford 11-14 12:45 pm Crews cleaning up hazmat spill at I-95 weigh station 11-14 12:21 pm Priebus says he and Bannon make effective Trump team 11-14 10:23 am Poquonnock Road closed in Groton after truck strikes bridge 11-14 9:08 am Report: carbon emissions flat in last 3 years 11-14 8:42 am School district pays 11-year-old $6,500 for keynote speech 11-14 8:38 am Hikers likely to be billed for their New Hampshire rescue 11-14 8:36 am Police: New Jersey resident arrested in NYC subway injury 11-14 8:34 am Local News Local Sports Local Entertainment all day, every day Thank you for visiting theday.com. You've read 3 free articles. To continue reading up to 10 premium articles, you must register, or sign up and take advantage of this exclusive offer: Full Digital Access 12 weeks of savings $1 for 12 weeks Enjoy the benefits of membership for less. ACT NOW Already registered on theday.com? Login. Not registered? Register. No, thank you. Ã—Close Bayer profit shows drugs eclipse crops before Monsanto deal Published October 26. 2016 10:06AMÂ  Johannes Koch, Bloomberg Bayer's third-quarter profit unexpectedly grew, powered by its prescription drugs unit -- the very business that risks being sidelined after its $66 billion takeover of Monsanto Co. Earnings before interest, taxes, depreciation and amortization, and excluding some costs, rose 6 percent to 2.68 billion euros ($2.92 billion) last quarter, the Leverkusen, Germany-based company said in a statement Wednesday. That compared with the 2.53 billion-euro average of analysts' estimates compiled by Bloomberg. Bayer's pharmaceuticals once again sustained earnings, led by demand for medicines such as the blood thinner Xarelto. The German company last month raised the annual sales forecast for its latest blockbuster drugs -- including Xarelto and the eye treatment Eylea -- to more than 10 billion euros from 7.5 billion euros. Crop sciences, which will probably replace prescription medicines as Bayer's biggest business after the Monsanto takeover is completed, showed little growth. Bayer shares fell 2.2 percent to 89.51 euros at 11:22 a.m. in Frankfurt trading after the company said brands like Claritin and Coppertone, gained with the purchase of Merck & Co.'s over-the-counter medicines in 2014, were a drag on the consumer health business. Earnings at the division dropped 3,5 percent last quarter. The unit's performance "underlines how disappointing the Merck over-the-counter integration has been," wrote Alistair Campbell, an analyst at Berenberg Bank, in a note to clients. Funded with a combination of debt and equity, the Monsanto purchase will leave the German company little scope for acquisitions to boost its pharmaceutical business. Bayer on Wednesday said it had finalized the syndication of a $57 billion bridge loan at the start of the month. It expects to apply for regulatory approval of the transaction this year in the U.S. and probably in the first quarter in the European Union and doesn't expect any major holdups. "This is a very manageable risk," Chief Executive Officer Werner Baumann said in an interview with Bloomberg TV's Guy Johnson and Caroline Hyde, pointing to Monsanto's relatively small presence outside the Americas. "We are very confident that we can resolve any issue that may come up there in product overlaps." Bayer isn't just working on buying Monsanto, it's also weighing the sale of its dermatology business, which includes the brand Desonate for eczema, according to people familiar with the plans. The German company may also offload its radiology business, which could be worth up to $3 billion, the people said. Bayer has agreed to a termination fee of $2 billion with Monsanto and may divest businesses from the combined entity with sales totaling $1.6 billion, if needed, to gain antitrust approval. Baumann declined to comment on whether the company plans to sell the radiology and dermatology units in a call with reporters. Bayer's sales rose 2 percent last quarter to 11.2 billion euros, buoyed by increased volumes of Xarelto in Europe and Japan. Older over-the-counter brands like Aleve and Alka-Seltzer also grew, but couldn't offset a broader cost-related decline at the consumer health unit. The "weak business environment, particularly in Latin America," held back crop science products in the quarter, the company said. Higher selling prices and a currency boost were offset by lower volumes and higher research spending in that business. Buying Monsanto will allow Bayer to tap growing demand as farmers seek to boost productivity to feed an estimated 10 billion people globally by 2050. Falling crop prices and a quest for greater efficiency have triggered a cascade of deals over the past year. DuPont Co. and Dow Chemical Co. have agreed to merge and then carve out a new crop-science unit and China National Chemical Corp. is buying Switzerland's Syngenta AG. Bayer's stock has declined almost 12 percent since March 21, when the possibility of a transaction with Monsanto first emerged. "In the short term we expect Bayer to remain trading below its intrinsic value as we await regulatory updates regarding the multiple agri-chemical transactions currently on the table," Peter Verdult, an analyst at Citigroup Inc., wrote in a note to clients. Bayer on Wednesday made a slight adjustment to its full-year outlook. Core earnings per share will probably rise by a high single-digit percentage this year, the company said. The previous forecast was for a gain of a mid- to high-single-digit percentage. It stuck to earlier estimates for two other measures of performance. In July, the company said sales this year would likely climb to between 46 billion euros and 47 billion euros including revenue from the plastics division Covestro AG. Ebitda before special items is likely to rise by a high-single-digit percentage. Bayer still holds a 64 percent stake in Covestro, which reported a 22 percent increase in profits on Tuesday. Â  Â  Â  Next Article Loading comment count... Commenting is closed. Comment threads are monitored for 48 hours after publication and then closed. READER COMMENTS Loading comments... Hide Comments MOST READ 1 Two arrested, one injured in fight over Donald Trump in Old Saybrook 2 Tractor-trailer, car collide, close lane of I-95 in Waterford 3 Montauk House raising the bar in New London 4 School district pays 11-year-old $6,500 for keynote speech 5 Overturned car snarls traffic on I-95 in Waterford 6 Poquonnock Road closed in Groton after truck strikes bridge 7 Hikers likely to be billed for their New Hampshire rescue 8 New London police chief ready to retire, her attorney says 9 Army Corps proposes lifting 341 structures along coast 10 Place presidential popular vote in context MOST VIEWED MEDIA 1 Time laspe: full moon over New London 2 Thames River seniors hope to leave winning legacy 3 Felling a tree with a two-man hand saw 4 Quick Hits: Prince Tech 50, Thames River 8 5 National graduation rate reaches record high MOST DISCUSSED STORIES 1 Eastern Connecticut is Trump country 86 2 Hillary Clinton blames Comey letters for defeat 42 3 About 100 million people couldn't be bothered to vote this year 37 4 Organizers encourage cooperation in face of 'anti-immigrant spirit' 34 5 Two arrested, one injured in fight over Donald Trump in Old Saybrook 23 Back to Top About The Day The Day Publishing Company 47 Eugene O'Neill Drive P.O. Box 1231 New London, CT 06320-1231 USA Staff Profiles FAQs Jobs at The Day Contact Us Connect with us Quick Links DayExtra E-Paper Contests Lottery Numbers Horoscopes Puzzles TV Weather Calendar Milestones Today's Headlines Advertising About Our Ads Advertise Place a Classified Ad Contacts Find New London Area Jobs Services Full-page Reprints Photo Reprints The Day Collection Privacy Policy/Terms RSS Text/SMS Alerts
For more local news from India, visit Bloombergquint.com Bloomberg the Company & Its ProductsBloomberg Anywhere Remote LoginBloomberg Anywhere LoginBloomberg Terminal Demo Request Bloomberg Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. Customer Support Americas +1 212 318 2000 Europe, Middle East, & Africa +44 20 7330 7500 Asia Pacific +65 6212 1000 Company Careers Diversity & Inclusion Sustainability Technology Facts & Spaces Philanthropy & Engagement Bloomberg London Communications Press Announcements Press Contacts Follow Us Facebook Twitter LinkedIn Instagram Vimeo Financial Products Bloomberg Terminal Bloomberg Tradebook Bloomberg Briefs Bloomberg Indices Bloomberg SEF Bloomberg Institute Bloomberg Customers Bloomberg Anywhere Remote Login Download Software Service Center Enterprise Products Enterprise Solutions Trading Solutions Bloomberg Vault Bloomberg PolarLake Industry Products Bloomberg Government Bloomberg Law/BNA Bloomberg Big Law Bloomberg New Energy Finance Media Bloomberg.com Bloomberg Politics Bloomberg View Bloomberg Gadfly Bloomberg Television Bloomberg Radio Bloomberg Mobile Apps News Bureaus Media Services Bloomberg Live Conferences Bloomberg Media Distribution Advertising Bloomberg Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. Customer Support Americas +1 212 318 2000 Europe, Middle East, & Africa +44 20 7330 7500 Asia Pacific +65 6212 1000 Communications Press Announcements Press Contacts Follow Us Facebook Twitter LinkedIn Instagram Vimeo Company Careers Diversity & Inclusion Philanthropy & Engagement Sustainability Technology Facts & Spaces Bloomberg London Media Bloomberg.com Bloomberg Politics Bloomberg View Bloomberg Gadfly Bloomberg Television Bloomberg Radio Bloomberg Mobile Apps News Bureaus Media Services Advertising Bloomberg Media Distribution Bloomberg Live Conferences Financial Products Bloomberg Terminal Bloomberg Tradebook Bloomberg Briefs Bloomberg Indices Bloomberg SEF Bloomberg Institute Enterprise Products Enterprise Solutions Trading Solutions Bloomberg Vault Bloomberg PolarLake Industry Products Bloomberg Government Bloomberg Law/BNA Bloomberg Big Law Bloomberg New Energy Finance Bloomberg Customers Bloomberg Anywhere Remote Login Download Software Service Center MENU Homepage Markets Stocks Currencies Commodities Rates + Bonds Economics Magazine Benchmark Watchlist Economic Calendar Tech U.S. Global Startups Cybersecurity Digital Media Bloomberg Technology TV Hello World Studio 1.0 Pursuits Cars & Bikes Style & Grooming Spend Watches & Gadgets Food & Drinks Travel Real Estate Art & Design Politics With All Due Respect Poll Decoder Culture Caucus Podcast Masters In Politics Podcast Ad Tracker Battlegrounds 2016 Opinion View Gadfly Businessweek Subscribe Cover Stories Opening Remarks Etc Features 85th Anniversary Issue Behind The Cover More Science + Energy Graphics Game Plan Small Business Personal Finance Inspire GO The David Rubenstein Show Sponsored Content Bloomberg About The Company Sign In Sign In Subscribe Italyâ€™s Bond Yields Touch Four-Month High as Debt Supply Weighs Anooja Debnath anoojad Marianna Duarte De Aragao aragaomarianna October 26, 2016 â€” 4:32 AM EDT Updated on October 26, 2016 â€” 11:07 AM EDT Share on FacebookShare on Twitter Share on LinkedInShare on RedditShare on Google+E-mailShare on TwitterShare on WhatsApp Germany and Portugal auction five-year sovereign securities Supply comes a day after Austria sold 70-year bonds via banks Share on FacebookShare on Twitter Share on LinkedInShare on RedditShare on Google+E-mailShare on TwitterShare on WhatsApp Italian bonds led a decline among euro-area securities as a glut of supply from governments and companies weighed on fixed-income markets. Italyâ€™s 10-year yield climbed to the highest since June after the country sold inflation-linked debt due in 2024 and 2026. The selloff deepened, with similar-maturity U.K. bond yields approaching the most since the Brexit vote, after the Bank of England said Tuesday there were limits to officialsâ€™ willingness to look beyond an overshoot of their inflation target. Gilts also declined after Britain sold 4 billion pounds ($4.9 billion) of securities due in July 2065 via banks on Tuesday. Portugal auctioned bonds for the first time since DBRS Ltd. maintained the nationâ€™s credit rating as investment grade, securing eligibility of its debt for the European Central Bankâ€™s asset-purchase program. Germany added to the weight of supply, selling 3 billion euros ($3.3 billion) of five-year notes, while companies including Merck & Co. and Verizon Communications Inc. sold bonds. The Treasury in Rome plans to auction as much as 8.5 billion euros of debt on Oct. 28. â€œGilts are leading us down, theyâ€™re underperforming, taking Europe as a whole after that,â€ said Craig Collins, managing director of rates trading at Bank of Montreal in London. U.K. bonds are vulnerable after Tuesdayâ€™s debt sale as well as â€œconcerns about BOE policy,â€ he said, while the supply from euro-zone nations is â€œadding to the mix.â€ Italyâ€™s 10-year bond yields climbed nine basis points, or 0.09 percentage point, to 1.48 percent as of 4:04 p.m. London time, the highest since June 28. The 1.6 percent bond due in June 2026 fell 0.84, or 8.40 euros per 1,000-euro face amount, to 101.15. Benchmark German 10-year bund yields rose seven basis points to 0.1 percent. Gilts Slide Yields on U.K. 10-year gilts increased eight basis points to 1.17 percent. The yield touched 1.22 percent on Oct. 17, the highest since the June 23 Brexit referendum. Portugalâ€™s 10-year bond yield added three basis points to 3.22 percent. The auctions Wednesday came a day after Austria joined the club of countries to have issued ultra-long-maturity bonds when it sold 2 billion euros of 70-year securities via banks. The nation also placed 3 billion euros of notes maturing in July 2023. The Austrian central bank retained 500 million euros of both securities. â€œYou have the perfect environment for a selloff,â€ said Martin van Vliet, an interest-rate strategist at ING Groep NV in Amsterdam. â€œFirst, you had this strong spillover from the gilts market. We also had some supply pressure with quite a lot of auctions.â€ Before it's here, it's on the Bloomberg Terminal. LEARN MORE Italy Debt Bonds Euro Terms of Service Trademarks Privacy Policy Â©2016 Bloomberg L.P. All Rights Reserved Careers Made in NYC Advertise Ad Choices Website Feedback Help
` Home NEWS Real Estate & Retail Health Care & Life Sciences Sports Business Small Business Banking & Finance Women in Biz More Industries Communications Education & Workforce Energy & Environment Government & Economic Development Law Manufacturing & Technology Philanthropy Transportation, Distribution & Logistics Workplace Issues Company News Eli Lilly and Co. Simon Property Group Anthem More Public Companies Private Companies REGIONAL Boone Co. Hamilton Co. Hancock Co. Hendricks Co. Johnson Co. Madison Co. Morgan Co. Shelby Co. Other counties THIS WEEK'S PAPER Top Stories Opinion A&E etc. IBJ Digital Newspaper Past Print Issues Magazines & Supplements BLOGS Property Lines Lou Harryâ€™s A&E The Score North of 96th The Dose Ballot Box OPINION IBJ Editorial Letters to the Editor Forefront Editorial Cartoons A&E A&E Home Lou's Views Column Lou Harry's A&E Blog Dining Reviews Mike Lopresti Column LISTS Book of Lists Individual Lists PEOPLE People Online Submit People News Submit Award Nominations Award Recipients CTO of the Year 2016 Honorees Women of Influence 2016 Honorees Past Recipients CFO of the Year 2015 Honorees Past Recipients Forty Under 40 Class of 2016 Past Recipients Health Care Heroes 2016 Honorees Nominations Past Recipients Michael A. Carroll Award Healthiest Employer 2013 Honorees Nominations EVENTS IBJ Events CTO of the Year 2016 Honorees Past Recipients Women of Influence 2016 Honorees Past Recipients CFO of the Year Register for event 2015 Honorees Nominations Past Recipients IBJ Extras Books Book Store IBJ Book Publishing Contact Us Custom Media Heart Health Awareness Cardiac Care Cancer Care Business Cares Breast Cancer Awareness Healthy Aging Women's Health eNewsletter Preview Multimedia Events Inside Dish Leading Questions More Videos Photo Galleries IBJ Mobile App RSS Feeds Classifieds Classifieds Place an Ad Subscriptions New Subscriptions Renewal Subscriptions eNewsletter Subscriptions eNewsletter Preview Change User Profile Subscription Services FAQ's Newsstand Locations Login [x] Email Password Remember Me Forgot your password? Subscribe Register Logged in as Logout Edit Profile View Cart Â  Quick Links: Forefront Election news Indiana 100 Highest-paid executives Anthem-Cigna full coverage Forty Under 40 Home NEWS Real Estate & Retail Health Care & Life Sciences Sports Business Small Business Banking & Finance Women in Biz More Industries Communications Education & Workforce Energy & Environment Government & Economic Development Law Manufacturing & Technology Philanthropy Transportation, Distribution & Logistics Workplace Issues Company News Eli Lilly and Co. Simon Property Group Anthem More Public Companies Private Companies REGIONAL Boone Co. Hamilton Co. Hancock Co. Hendricks Co. Johnson Co. Madison Co. Morgan Co. Shelby Co. Other counties THIS WEEK'S PAPER Top Stories Opinion A&E etc. IBJ Digital Newspaper Past Print Issues Magazines & Supplements BLOGS Property Lines Lou Harryâ€™s A&E The Score North of 96th The Dose Ballot Box OPINION IBJ Editorial Letters to the Editor Forefront Editorial Cartoons A&E A&E Home Lou's Views Column Lou Harry's A&E Blog Dining Reviews Mike Lopresti Column LISTS Book of Lists Individual Lists PEOPLE People Online Submit People News Submit Award Nominations Award Recipients CTO of the Year 2016 Honorees Women of Influence 2016 Honorees Past Recipients CFO of the Year 2015 Honorees Past Recipients Forty Under 40 Class of 2016 Past Recipients Health Care Heroes 2016 Honorees Nominations Past Recipients Michael A. Carroll Award Healthiest Employer 2013 Honorees Nominations EVENTS IBJ Events CTO of the Year 2016 Honorees Past Recipients Women of Influence 2016 Honorees Past Recipients CFO of the Year Register for event 2015 Honorees Nominations Past Recipients IBJ Extras Books Book Store IBJ Book Publishing Contact Us Custom Media Heart Health Awareness Cardiac Care Cancer Care Business Cares Breast Cancer Awareness Healthy Aging Women's Health eNewsletter Preview Multimedia Events Inside Dish Leading Questions More Videos Photo Galleries IBJ Mobile App RSS Feeds Classifieds Classifieds Place an Ad Subscriptions New Subscriptions Renewal Subscriptions eNewsletter Subscriptions eNewsletter Preview Change User Profile Subscription Services FAQ's Newsstand Locations Home Â» Drug firms fighting â€˜tooth and nailâ€™ against California ballot measure Drug firms fighting â€˜tooth and nailâ€™ against California ballot measure October 26, 2016 Bloomberg News KEYWORDS Health Care / Eli Lilly and Co. / Health Care Businesses / Health Care & Life Sciences / Health Care & Insurance / Pharmaceutical Comments Print Reprints / Text Size+ Larger Smaller [X] Related News and Opinion Pharmaceutical firms losing business to darknet drug deals Eli Lilly, Turkish firm in talks to sell drugs in 26 nations Lilly competitor claims early success with Alzheimer's drug WellPoint spending millions in California ballot battle Drugmakers, Interpol ramp up fight against fakes Related Products Largest Indianapolis-Area Law Firms - PDF Largest Indianapolis-Area Law Firms - Excel Largest Indianapolis-Area Accounting Firms - Excel Drugmakers are becoming increasingly vocal in fighting a California ballot proposition on drug prices, concerned that the more $100 million in funding raised by lobbies opposing the initiative wonâ€™t be enough to stop it. â€œWeâ€™re fighting that tooth and nail,â€ said John Lechleiter, CEO of Indianapolis-based of Eli Lilly and Co., on Tuesday during the companyâ€™s quarterly financial call. Merck & Co. CEO Ken Frazier also spoke of his â€œserious concerns,â€ warning on his companyâ€™s earnings call that the law would â€œnegatively impact millions of patients.â€ Known as Proposition 61, the initiative intends to bring down the cost of prescription drugs by prohibiting California state agencies, such as Medi-Cal and state prisons, from paying more than the price paid by the U.S. Department of Veteran Affairs. While Medi-Cal, the state health program for the poor, already can negotiate with drug companies, the national VA typically gets the best deal. VA rates may be about 20 percent lower than Medicaidâ€™s, according to Piper Jaffray analyst Joshua Schimmer. Political pressure The pharmaceutical industry has been under fire for how it prices its medications, with Mylan NVâ€™s $600 EpiPen pack and Turing Pharmaceuticals AGâ€™s 50-fold increase of an anti-parasiticâ€™s price in the national spotlight. High-profile politicians also have weighed in: Hillary Clinton, the Democratic presidential candidate, has pledged to crack down on what she has called outrageous drug costs. Vermont Senator Bernie Sanders, who has lambasted specific drugmakers for their pricing practices, supports Proposition 61. Opponents argue that the initiative wonâ€™t work as intended because drugmakers wouldnâ€™t be required to offer the drugs at the VA price, meaning they could decline to offer California agencies some treatments, or raise the VAâ€™s current drug prices. The law would apply only to about 25 percent of Medi-Cal enrollees who are part of its â€œfee-for-serviceâ€ program, not to the remaining 75 percent who are in the Medi-Cal managed-care system. Californiaâ€™s Legislative Analystâ€™s Office says the potential for savings is unclear, given the uncertainty over how drug manufacturers will respond. Pricey proposition Proposition 61 has become the most expensive ballot measure battle in 2016, according to the nonpartisan politics website Ballotpedia. Led by industry lobbying group Pharmaceutical Research and Manufacturers of America, known as PhRMA, the opposition has raised more than $100 million for its campaign, compared to $14 million by supporters. Despite the heavy spending, the drug industry remains concerned about the proposition since two polls have found California voters leaning toward passing it. In an early September survey conducted by USC Dornsife and the Los Angeles Times, about two-thirds of participants said they would vote yes, 23 percent said no and 12 percent had no answer. A late September poll by Field Research Corp. found half inclined to vote yes, 16 percent leaning toward no and 34 percent undecided. â€œNearly 200 groups including veterans, doctors, patients, taxpayers, seniors and aids/HIV groups are opposed, along with every daily newspaper in the state,â€ Kathy Fairbanks, spokeswoman for the No on Prop 61 Coalition, said in an e-mail. Representatives for the Aids Healthcare Foundation, which is the biggest backer of Proposition 61, didnâ€™t immediately respond to requests for comment. If the initiative passes on Nov. 8, itâ€™s not likely to have any â€œfundamental impactâ€ on drug companies, according to Michael Yee, an analyst at RBC Capital Markets. The industryâ€™s main concern is â€œemboldening 49 other states to look at these types of legislation to try to change prices,â€ Yee wrote Tuesday in a note to clients. Piper Jaffray analyst Schimmer also questions the ultimate effect of Proposition 61 if it were to pass: â€œWill the pharma industry really compromise profits, or simply find another way around this Act?â€ he wrote in an October note to clients. â€œThe industry is wilyâ€”cost shifting, cost cutting or raising prices to the VA will be the likely end result.â€ Email Tweet ADVERTISEMENT Recent Articles by Bloomberg News Pence to lead Trump transition team, replacing Christie as chairman Drugmakers' stocks jump on promise of Trump presidency Global markets rocked as traders see pathway for Trump victory Please enable JavaScript to view the comments powered by Disqus. Comments powered by Disqus Restricted Content You must have JavaScript enabled to enjoy a limited number of articles over the next 30 days. Please clik here to continue without javascript.. GO Advanced Search This Week's Paper Democrats regroup after getting pasted in election Carmel's Midtown project finds its momentum $7M project restores luster of storied office tower Most Read Comments Most Emailed UPDATE: Layoffs begin at Angie's List as firm seeks suitors Oil executive Lucas on Trump's short list for interior secretary Former controller of Estridge Homes accused of $364K fraud scheme Marian University facing suit over professor's alleged sexual misconduct Pence to lead Trump transition team, replacing Christie as chairman Multimedia Images Videos IBJ Events Shane Johnson's editorial cartoons More Photos 2017 Economic Forecast: Changing of the guard More Videos Videos 2012 CFOs of the Year: Bill Brunner More Videos Events Join IBJ and IEDC as we convene Indianaâ€™s CEOs, C-suite executives, & corporate social responsibility leaders as we discuss the benefits of an effective community engagement and advocacy strategy on the bottom line. For more information, visit www.ibj.com/events. IBJâ€™s CFO of the Year honorees are impressive financial professionals who steer the fortunes of their companies and organizations. Join IBJ to celebrate them on Dec. 1. Nominations Do you know an individual or organization that goes above and beyond to improve health care in the Indianapolis area? Let them know their contributions matter. Nominate them for IBJâ€™s 2017 Health Care Heroes Awards program. For more information or to submit a nomination, visit www.ibj.com/nominations More Events Back to Top SUBSCRIPTIONS Online & Print Subscriptions FREE eNews SUBMIT TO EDIT Submit People Submit Records IBJ Awards FTP to IBJ IBJ.COM ACCOUNT My Account FREE IBJ.com Registrations EVENTS Upcoming IBJ Events Event Sponsorship Award Nominations SUPPORT & INFORMATION Customer Service Contact Us Privacy Policy Career Opportunities Newsstand Locations Reprints ONLINE PRODUCTS Bookstore ADVERTISING IBJ Advertising Contacts Classifieds Submit Advertising MULTIMEDIA Photo Galleries Videos IBJ on Facebook IBJ on Twitter Get IBJ Widgets IBJ.com Book of Lists Editorial Calendar Archives IBJ Digital Newspaper Past Print Issues Magazines/Supplements Polls Sitemap OTHER IBJ MEDIA WEBSITES The Indiana Lawyer Court & Commercial Record IBJ Custom Publishing IBJ Book Publishing Copyright Â© 2016 All Rights Reserved. Privacy Policy | Terms of Use. Our Terms of Service and Privacy Policy Have Changed By using this site, you agree to the Privacy Policy and Terms of Service. ACCEPT IBJ MEDIA CORP 317-634-6200 Design, CMS, Hosting & Web Development :: ePublishing.
Enter your search terms Submit search form Â  Â  Â  Home | About Us | Sample Press Release Â  Press Release Articles | Press Releases and SEO | Press Release Book Â  Â  Global Nanopharmaceuticals Market Analysis 2016 Forecasts to 2021 Â  View as PDF Â Print View Â Â  Nanopharmaceuticals -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021 PUNE, INDIA - October 26, 2016 /MarketersMedia/ -- Nanopharmaceuticals Industry Description Wiseguyreports.Com Adds "Nanopharmaceuticals -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021" To Its Research Database This report studies Nanopharmaceuticals in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, with production, revenue, consumption, import and export in these regions, from 2011 to 2015, and forecast to 2021. Request for Sample Report @ https://www.wiseguyreports.com/sample-request/566046-global-nanopharmaceuticals-market-professional-survey-report-2016 This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering Merck Pfizer Novartis Abbott GlaxoSmithKline Roche Sanofi Eli Lilly Astrazeneca Johnson & Johnson Celgene Novavax Stryker Gilead Sciences OSI Pharmaceuticals Kadmon Pharmaceuticals Samyang Biopharm Mitsubishi Pharma Kaken Pharmaceutical Selecta Biosciences Par Pharmaceutical Cerulean Pharma Navidea Biopharmaceuticals Lummy Leave a Query @ https://www.wiseguyreports.com/enquiry/566046-global-nanopharmaceuticals-market-professional-survey-report-2016 By types, the market can be split into Type I Type II Type III By Application, the market can be split into Application 1 Application 2 Application 3 By Regions, this report covers (we can add the regions/countries as you want) North America China Europe Southeast Asia Japan India Table of Contents Global Nanopharmaceuticals Market Professional Survey Report 2016 1 Industry Overview of Nanopharmaceuticals 1.1 Definition and Specifications of Nanopharmaceuticals 1.1.1 Definition of Nanopharmaceuticals 1.1.2 Specifications of Nanopharmaceuticals 1.2 Classification of Nanopharmaceuticals 1.2.1 Type I 1.2.2 Type II 1.2.3 Type III 1.3 Applications of Nanopharmaceuticals 1.3.1 Application 1 1.3.2 Application 2 1.3.3 Application 3 1.4 Market Segment by Regions 1.4.1 North America 1.4.2 China 1.4.3 Europe 1.4.4 Southeast Asia 1.4.5 Japan 1.4.6 India ... 8 Major Manufacturers Analysis of Nanopharmaceuticals 8.1 Merck 8.1.1 Company Profile 8.1.2 Product Picture and Specifications 8.1.2.1 Type I 8.1.2.2 Type II 8.1.2.3 Type III 8.1.3 Merck 2015 Nanopharmaceuticals Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.1.4 Merck 2015 Nanopharmaceuticals Business Region Distribution Analysis 8.2 Pfizer 8.2.1 Company Profile 8.2.2 Product Picture and Specifications 8.2.2.1 Type I 8.2.2.2 Type II 8.2.2.3 Type III 8.2.3 Pfizer 2015 Nanopharmaceuticals Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.2.4 Pfizer 2015 Nanopharmaceuticals Business Region Distribution Analysis 8.3 Novartis 8.3.1 Company Profile 8.3.2 Product Picture and Specifications 8.3.2.1 Type I 8.3.2.2 Type II 8.3.2.3 Type III 8.3.3 Novartis 2015 Nanopharmaceuticals Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.3.4 Novartis 2015 Nanopharmaceuticals Business Region Distribution Analysis 8.4 Abbott 8.4.1 Company Profile 8.4.2 Product Picture and Specifications 8.4.2.1 Type I 8.4.2.2 Type II 8.4.2.3 Type III 8.4.3 Abbott 2015 Nanopharmaceuticals Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.4.4 Abbott 2015 Nanopharmaceuticals Business Region Distribution Analysis 8.5 GlaxoSmithKline 8.5.1 Company Profile 8.5.2 Product Picture and Specifications 8.5.2.1 Type I 8.5.2.2 Type II 8.5.2.3 Type III 8.5.3 GlaxoSmithKline 2015 Nanopharmaceuticals Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.5.4 GlaxoSmithKline 2015 Nanopharmaceuticals Business Region Distribution Analysis 8.6 Roche 8.6.1 Company Profile 8.6.2 Product Picture and Specifications 8.6.2.1 Type I 8.6.2.2 Type II 8.6.2.3 Type III 8.6.3 Roche 2015 Nanopharmaceuticals Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.6.4 Roche 2015 Nanopharmaceuticals Business Region Distribution Analysis 8.7 Sanofi 8.7.1 Company Profile 8.7.2 Product Picture and Specifications 8.7.2.1 Type I 8.7.2.2 Type II 8.7.2.3 Type III 8.7.3 Sanofi 2015 Nanopharmaceuticals Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.7.4 Sanofi 2015 Nanopharmaceuticals Business Region Distribution Analysis 8.8 Eli Lilly 8.8.1 Company Profile 8.8.2 Product Picture and Specifications 8.8.2.1 Type I 8.8.2.2 Type II 8.8.2.3 Type III 8.8.3 Eli Lilly 2015 Nanopharmaceuticals Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.8.4 Eli Lilly 2015 Nanopharmaceuticals Business Region Distribution Analysis 8.9 Astrazeneca 8.9.1 Company Profile 8.9.2 Product Picture and Specifications 8.9.2.1 Type I 8.9.2.2 Type II 8.9.2.3 Type III 8.9.3 Astrazeneca 2015 Nanopharmaceuticals Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.9.4 Astrazeneca 2015 Nanopharmaceuticals Business Region Distribution Analysis 8.10 Johnson & Johnson 8.10.1 Company Profile 8.10.2 Product Picture and Specifications 8.10.2.1 Type I 8.10.2.2 Type II 8.10.2.3 Type III 8.10.3 Johnson & Johnson 2015 Nanopharmaceuticals Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.10.4 Johnson & Johnson 2015 Nanopharmaceuticals Business Region Distribution Analysis 8.11 Celgene 8.11.1 Company Profile 8.11.2 Product Picture and Specifications 8.11.2.1 Type I 8.11.2.2 Type II 8.11.2.3 Type III 8.11.3 Celgene 2015 Nanopharmaceuticals Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.11.4 Celgene 2015 Nanopharmaceuticals Business Region Distribution Analysis 8.12 Novavax 8.12.1 Company Profile 8.12.2 Product Picture and Specifications 8.12.2.1 Type I 8.12.2.2 Type II 8.12.2.3 Type III 8.12.3 Novavax 2015 Nanopharmaceuticals Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.12.4 Novavax 2015 Nanopharmaceuticals Business Region Distribution Analysis 8.13 Stryker 8.13.1 Company Profile 8.13.2 Product Picture and Specifications 8.13.2.1 Type I 8.13.2.2 Type II 8.13.2.3 Type III 8.13.3 Stryker 2015 Nanopharmaceuticals Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.13.4 Stryker 2015 Nanopharmaceuticals Business Region Distribution Analysis 8.14 Gilead Sciences 8.14.1 Company Profile 8.14.2 Product Picture and Specifications 8.14.2.1 Type I 8.14.2.2 Type II 8.14.2.3 Type III 8.14.3 Gilead Sciences 2015 Nanopharmaceuticals Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.14.4 Gilead Sciences 2015 Nanopharmaceuticals Business Region Distribution Analysis 8.15 OSI Pharmaceuticals 8.15.1 Company Profile 8.15.2 Product Picture and Specifications 8.15.2.1 Type I 8.15.2.2 Type II 8.15.2.3 Type III 8.15.3 OSI Pharmaceuticals 2015 Nanopharmaceuticals Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.15.4 OSI Pharmaceuticals 2015 Nanopharmaceuticals Business Region Distribution Analysis 8.16 Kadmon Pharmaceuticals 8.16.1 Company Profile 8.16.2 Product Picture and Specifications 8.16.2.1 Type I 8.16.2.2 Type II 8.16.2.3 Type III 8.16.3 Kadmon Pharmaceuticals 2015 Nanopharmaceuticals Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.16.4 Kadmon Pharmaceuticals 2015 Nanopharmaceuticals Business Region Distribution Analysis 8.17 Samyang Biopharm 8.17.1 Company Profile 8.17.2 Product Picture and Specifications 8.17.2.1 Type I 8.17.2.2 Type II 8.17.2.3 Type III 8.17.3 Samyang Biopharm 2015 Nanopharmaceuticals Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.17.4 Samyang Biopharm 2015 Nanopharmaceuticals Business Region Distribution Analysis 8.18 Mitsubishi Pharma 8.18.1 Company Profile 8.18.2 Product Picture and Specifications 8.18.2.1 Type I 8.18.2.2 Type II 8.18.2.3 Type III 8.18.3 Mitsubishi Pharma 2015 Nanopharmaceuticals Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.18.4 Mitsubishi Pharma 2015 Nanopharmaceuticals Business Region Distribution Analysis 8.19 Kaken Pharmaceutical 8.19.1 Company Profile 8.19.2 Product Picture and Specifications 8.19.2.1 Type I 8.19.2.2 Type II 8.19.2.3 Type III 8.19.3 Kaken Pharmaceutical 2015 Nanopharmaceuticals Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.19.4 Kaken Pharmaceutical 2015 Nanopharmaceuticals Business Region Distribution Analysis 8.20 Selecta Biosciences 8.20.1 Company Profile 8.20.2 Product Picture and Specifications 8.20.2.1 Type I 8.20.2.2 Type II 8.20.2.3 Type III 8.20.3 Selecta Biosciences 2015 Nanopharmaceuticals Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.20.4 Selecta Biosciences 2015 Nanopharmaceuticals Business Region Distribution Analysis 8.21 Par Pharmaceutical 8.22 Cerulean Pharma 8.23 Navidea Biopharmaceuticals 8.24 Lummy Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=566046 Continued... Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK) For more information, please visit https://www.wiseguyreports.com/sample-request/566046-global-nanopharmaceuticals-market-professional-survey-report-2016 Contact Info: Name: Norah Trent Email: info@wiseguyreports.com Organization: WISE GUY RESEARCH CONSULTANTS PVT LTD Address: Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar Pune - 411028 Maharashtra, India Phone: +91 841 198 5042 Source: http://marketersmedia.com/global-nanopharmaceuticals-market-analysis-2016-forecasts-to-2021/141154 Release ID: 141154 Recent Press Releases By The Same User Kamloops Marriage Counselling Couples Therapy Psychologist Services Announced (Mon 14th Nov 16) Sell West Palm Beach Distressed Property & Tax Lien Home Fast Services Announced (Mon 14th Nov 16) TheGateadviser.com publishes a new guide on introducing new born babies to pets (Mon 14th Nov 16) AdLock Media now provides industry leading content locking offers (Mon 14th Nov 16) Links Between Cancer, Nutrition, and Exercise Revealed at AICR Conference (Mon 14th Nov 16) Long Island Certified Personal Trainer Individual Fitness Programs Launched (Mon 14th Nov 16) Sign in here Username: Password: Register here. Forgotten password? Press releases by industry Advertising Aerospace and Defense Architecture Arts and Entertainment Audio and Video Automotive Baseball Basketball Beauty Beverages Business Chemicals Christianity Communication Computers Consumer Crops eCommerce Economy Education Employment Energy Environment Events and Trade Shows Fashion Finance Food Football Forestry Golf Government Hardware Healthcare Holidays Human Resources Immigration Services Information Technology Insurance Internet Investment Services Legal Leisure Lifestyle Linux and Open Source Maritime Media Non-Profit Photography Plumbing and Heating Politics Public Relations Railroads Real Estate Religion and Faith Restaurants Retail Science Society Software Sports Technology Television Toys Trade Transportation Travel and Tourism Trucking Volunteer Waste Management Water [ Vist our sister sites: Linux news | Bible Study Tool ] Site design and layout copyright 2005-2015 Free Press Release Center
Enter your search terms Submit search form Â  Â  Â  Home | About Us | Sample Press Release Â  Press Release Articles | Press Releases and SEO | Press Release Book Â  Â  Global Allergy Immunotherapies Market Research Report 2016 Â  View as PDF Â Print View Â Â  Allergy Immunotherapies -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021 PUNE, INDIA - October 26, 2016 /MarketersMedia/ -- Allergy Immunotherapies Industry Description Wiseguyreports.Com Adds "Allergy Immunotherapies -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021" To Its Research Database This report studies Allergy Immunotherapies in Global market, especially in North America, Europe, China, Japan, India and Southeast Asia, focuses on top manufacturers in global market, with sales, price, revenue and market share for each manufacturer, covering ALK-Abello Stallergenes Merck Group Allergy Therapeutics Adamis Pharmaceuticals Aimmune Therapeutics Anergis ASIT biotech Biomay Circassia DBV Technologies Genentech HAL Allergy Laboratorios LETI Mitsubishi Tanabe Pharma Nycomed Sementis Shionogi Torii Tunitas Therapeutics VentiRx Pharmaceuticals Verona Pharma Request for Sample Report @ https://www.wiseguyreports.com/sample-request/556817-global-allergy-immunotherapies-market-research-report-2021 Market Segment by Region, this report splits Global into several key Regions, with sales, revenue, market share and growth rate of Allergy Immunotherapies in these regions, from 2011 to 2021 (forecast), like North America China Europe Japan India Southeast Asia Split by product type, with sales, revenue, price, market share and growth rate of each type, can be divided into Type 1 Type 2 Type 3 Split by application, this report focuses on sales, market share and growth rate of Allergy Immunotherapies in each application, can be divided into Application 1 Application 2 Application 3 Leave a Query @ https://www.wiseguyreports.com/enquiry/556817-global-allergy-immunotherapies-market-research-report-2021 Table of Contents Global Allergy Immunotherapies Market Research Report 2021 1 Allergy Immunotherapies Overview 1.1 Product Overview and Scope of Allergy Immunotherapies 1.2 Allergy Immunotherapies Segment by Types 1.2.1 Global Sales Market Share of Allergy Immunotherapies by Type in 2015 1.2.2 Type 1 1.2.3 Type 2 1.2.4 Type 3 1.3 Allergy Immunotherapies Segment by Applications 1.3.1 Application 1 1.3.2 Application 2 1.3.3 Application 3 1.4 Allergy Immunotherapies Market by Regions 1.4.1 North America Status and Prospect (2011-2021) 1.4.2 China Status and Prospect (2011-2021) 1.4.3 Europe Status and Prospect (2011-2021) 1.4.4 Japan Status and Prospect (2011-2021) 1.4.5 India Status and Prospect (2011-2021) 1.4.6 Southeast Asia Status and Prospect (2011-2021) 1.5 Global Market Size (Value and Volume) of Allergy Immunotherapies (2011-2021) 1.5.1 Global Allergy Immunotherapies Sales and Revenue (2011-2021) 1.5.2 Global Allergy Immunotherapies Sales and Growth Rate (2011-2021) 1.5.3 Global Allergy Immunotherapies Revenue and Growth Rate (2011-2021) .... 6 Global Allergy Immunotherapies Manufacturers Analysis 6.1 ALK-Abello 6.1.1 Company Basic Information, Manufacturing Base and Competitors 6.1.2 Allergy Immunotherapies Product Overview 6.1.2.1 Type 1 6.1.2.2 Type 2 6.1.2.3 Type 3 6.1.3 Allergy Immunotherapies Sales, Revenue, Price of ALK-Abello (2015 and 2016) 6.2 Stallergenes 6.2.1 Company Basic Information, Manufacturing Base and Competitors 6.2.2 Allergy Immunotherapies Product Overview 6.2.2.1 Type 1 6.2.2.2 Type 2 6.2.2.3 Type 3 6.2.3 Allergy Immunotherapies Sales, Revenue, Price of Stallergenes (2015 and 2016) 6.3 Merck Group 6.3.1 Company Basic Information, Manufacturing Base and Competitors 6.3.2 Allergy Immunotherapies Product Overview 6.3.2.1 Type 1 6.3.2.2 Type 2 6.3.2.3 Type 3 6.3.3 Allergy Immunotherapies Sales, Revenue, Price of Merck Group (2015 and 2016) 6.4 Allergy Therapeutics 6.4.1 Company Basic Information, Manufacturing Base and Competitors 6.4.2 Allergy Immunotherapies Product Overview 6.4.2.1 Type 1 6.4.2.2 Type 2 6.4.3 Allergy Immunotherapies Sales, Revenue, Price of Allergy Therapeutics (2015 and 2016) 6.5 Adamis Pharmaceuticals 6.5.1 Company Basic Information, Manufacturing Base and Competitors 6.5.2 Allergy Immunotherapies Product Overview 6.5.2.1 Type 1 6.5.2.2 Type 2 6.5.3 Allergy Immunotherapies Sales, Revenue, Price of Adamis Pharmaceuticals (2015 and 2016) 6.6 Aimmune Therapeutics 6.6.1 Company Basic Information, Manufacturing Base and Competitors 6.6.2 Allergy Immunotherapies Product Overview 6.6.2.1 Type 1 6.6.2.2 Type 2 6.6.3 Allergy Immunotherapies Sales, Revenue, Price of Aimmune Therapeutics (2015 and 2016) 6.7 Anergis 6.7.1 Company Basic Information, Manufacturing Base and Competitors 6.7.2 Allergy Immunotherapies Product Overview 6.7.2.1 Type 1 6.7.2.2 Type 2 6.7.3 Allergy Immunotherapies Sales, Revenue, Price of Anergis (2015 and 2016) 6.8 ASIT biotech 6.8.1 Company Basic Information, Manufacturing Base and Competitors 6.8.2 Allergy Immunotherapies Product Overview 6.8.2.1 Type 1 6.8.2.2 Type 2 6.8.3 Allergy Immunotherapies Sales, Revenue, Price of ASIT biotech (2015 and 2016) 6.9 Biomay 6.9.1 Company Basic Information, Manufacturing Base and Competitors 6.9.2 Allergy Immunotherapies Product Overview 6.9.2.1 Type 1 6.9.2.2 Type 2 6.9.3 Allergy Immunotherapies Sales, Revenue, Price of Biomay (2015 and 2016) 6.10 Circassia 6.10.1 Company Basic Information, Manufacturing Base and Competitors 6.10.2 Allergy Immunotherapies Product Overview 6.10.2.1 Type 1 6.10.2.2 Type 2 6.10.3 Allergy Immunotherapies Sales, Revenue, Price of Circassia (2015 and 2016) 6.11 DBV Technologies 6.12 Genentech 6.13 HAL Allergy 6.14 Laboratorios LETI 6.15 Mitsubishi Tanabe Pharma 6.16 Nycomed 6.17 Sementis 6.18 Shionogi 6.19 Torii 6.20 Tunitas Therapeutics 6.21 VentiRx Pharmaceuticals 6.22 Verona Pharma Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=556817 Continued... Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK) For more information, please visit https://www.wiseguyreports.com/sample-request/556817-global-allergy-immunotherapies-market-research-report-2021 Contact Info: Name: Norah Trent Email: info@wiseguyreports.com Organization: WISE GUY RESEARCH CONSULTANTS PVT LTD Address: Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar Pune - 411028 Maharashtra, India Phone: +91 841 198 5042 Source: http://marketersmedia.com/global-allergy-immunotherapies-market-research-report-2016/141193 Release ID: 141193 Recent Press Releases By The Same User Kamloops Marriage Counselling Couples Therapy Psychologist Services Announced (Mon 14th Nov 16) Sell West Palm Beach Distressed Property & Tax Lien Home Fast Services Announced (Mon 14th Nov 16) TheGateadviser.com publishes a new guide on introducing new born babies to pets (Mon 14th Nov 16) AdLock Media now provides industry leading content locking offers (Mon 14th Nov 16) Links Between Cancer, Nutrition, and Exercise Revealed at AICR Conference (Mon 14th Nov 16) Long Island Certified Personal Trainer Individual Fitness Programs Launched (Mon 14th Nov 16) Sign in here Username: Password: Register here. Forgotten password? Press releases by industry Advertising Aerospace and Defense Architecture Arts and Entertainment Audio and Video Automotive Baseball Basketball Beauty Beverages Business Chemicals Christianity Communication Computers Consumer Crops eCommerce Economy Education Employment Energy Environment Events and Trade Shows Fashion Finance Food Football Forestry Golf Government Hardware Healthcare Holidays Human Resources Immigration Services Information Technology Insurance Internet Investment Services Legal Leisure Lifestyle Linux and Open Source Maritime Media Non-Profit Photography Plumbing and Heating Politics Public Relations Railroads Real Estate Religion and Faith Restaurants Retail Science Society Software Sports Technology Television Toys Trade Transportation Travel and Tourism Trucking Volunteer Waste Management Water [ Vist our sister sites: Linux news | Bible Study Tool ] Site design and layout copyright 2005-2015 Free Press Release Center
Skip to content Satellite Press Releases Satellite Press Releases and News Research Reports on Drug Makers Equities â€” Pfizer, Merck, AbbVie, and Johnson & Johnson http://stock-callers.com/registration Pfizer Â  New York headquartered Pfizer Inc.â€™s shares rose 0.47% and finished Tuesdayâ€™s trading session at $32.28. A total volume of 19.32 million shares was traded, which was above their three months average volume of 18.96 million shares. Since the start of this year, the stock has advanced 2.76%. The Companyâ€™s shares are trading below their 200-day moving average by 1.43%. Moreover, shares of Pfizer, which discovers, develops, manufactures, and sells healthcare products worldwide, have a Relative Strength Index (RSI) of 32.20. On October 13th, 2016, research firm Jefferies downgraded the Companyâ€™s stock rating from â€˜Buyâ€™ to â€˜Holdâ€™. On October 21st, 2016, Astellas Pharma Inc. and Pfizer announced the U.S. Food and Drug Administration approved a supplemental New Drug Application to update the U.S. product labeling for XTANDIÂ® (enzalutamide) capsules to include new clinical data versus bicalutamide from the TERRAIN study. The data demonstrate improvement in radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer who were treated with enzalutamide compared to patients who were treated with bicalutamide. Free research report on PFE is available at: http://stock-callers.com/registration/?symbol=PFE Merck Â  On Tuesday, shares in Kenilworth, New Jersey headquartered Merck & Co. Inc. recorded a trading volume of 15.12 million shares, which was above their three months average volume of 10.25 million shares. The stock ended the session 1.98% higher at $61.95. The Companyâ€™s shares have gained 6.49% in the previous three months and 20.15% on an YTD basis. The stock is trading 10.39% above its 200-day moving average. Furthermore, shares of Merck, which provides health care solutions worldwide, have an RSI of 48.91. On October 13th, 2016, research firm Bank of America/ Merrill upgraded the Companyâ€™s stock rating from â€˜Neutralâ€™ to â€˜Buyâ€™. On October 25th, 2016, Merck reported that worldwide sales were $10.5 billion for Q3 2016, an increase of 5% compared with Q3 2015, including a 1% negative impact from foreign exchange. For Q3 2016, GAAP EPS assuming dilution were $0.78 compared to EPS of $0.64 in Q3 2015. Q3 2016 pharmaceutical sales increased 6% to $9.4 billion. The complimentary research report on MRK can be downloaded at: http://stock-callers.com/registration/?symbol=MRK AbbVie Â  Shares in Illinois-based AbbVie Inc. closed the day at $61.55, up 0.70%. The stock recorded a trading volume of 6.41 million shares, which was higher than its three months average volume of 6.16 million shares. The Companyâ€™s shares have gained 7.92% on an YTD basis, and are trading 3.07% above their 200-day moving average. Additionally, shares of AbbVie, which discovers, develops, manufactures, and sells pharmaceutical products worldwide, have an RSI of 45.56. On October 18th, 2016, research firm Leerink Partners initiated a â€˜Market Performâ€™ rating on the Companyâ€™s stock, issuing a target price of $70 per share. On October 19th, 2016, AbbVie in cooperation with Neurocrine Biosciences, Inc. announced detailed results from two replicate pivotal Phase 3 clinical trials evaluating the efficacy and safety of Elagolix in premenopausal women who suffer from endometriosis. The data demonstrate that, compared to placebo at month three and month six, patients treated with Elagolix reported statistically significant reductions in scores for menstrual pain and non-menstrual pelvic pain associated with endometriosis as measured by the Daily Assessment of Endometriosis Pain scale. Visit us today and access our complete research report on ABBV at: http://stock-callers.com/registration/?symbol=ABBV Johnson & Johnson Â  At the closing bell yesterday, shares in New Brunswick, New Jersey-based Johnson & Johnson ended 0.31% higher at $113.96 and with a total trading volume of 5.59 million shares. The stock has advanced 13.29% since the start of this year. The Companyâ€™s shares are trading above their 200-day moving average by 1.18%. Furthermore, shares of Johnson & Johnson, which together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide, have an RSI of 34.94. On October 19th, 2016, research firm UBS reiterated a â€˜Buyâ€™ rating on the Companyâ€™s stock with an increase of the target price from $137 a share to $144 a share. On October 20th, 2016, Johnson & Johnsonâ€™ Board of Directors declared a cash dividend for Q4 2016 of $0.80 per share. The dividend is payable on December 6th, 2016 to shareholders of record at the close of business on November 22nd, 2016. Get free access to your research report on JNJ at: http://stock-callers.com/registration/?symbol=JNJ â€” Stock Callers:Â  Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.Â  SC has not been compensated; directly or indirectly; for producing or publishing this document.Â  PRESS RELEASE PROCEDURES: The non-sponsored content contained herein has been prepared by a writer (the â€œAuthorâ€) and is fact checked and reviewed by a third party research service company (the â€œReviewerâ€) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFAÂ® charterholder (the â€œSponsorâ€), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. NO WARRANTYÂ  SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.Â  NOT AN OFFERINGÂ  This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://stock-callers.com/legal-disclaimer/ CONTACT For any questions, inquiries, or comments reach out to us directly. If youâ€˜re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: info@stock-callers.com Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP CFAÂ® and Chartered Financial AnalystÂ® are registered trademarks owned by CFA Institute. SOURCE Chelmsford Park SA Author MarcinPosted on October 26, 2016October 26, 2016Categories Uncategorized Post navigation Previous Previous post: Proline Market 2016-2021 Report for Global and China Industry Next Next post: Hollysys Automation Technologies to Announce Financial Results for Its Fiscal Year 2017 First Quarter Ended on September 30, 2016 and Host Earnings Conference Call Search for: Search Recent Posts TEAM HEALTH MERGER INVESTIGATION ALERT â€“ Andrews & Springer LLC Is Seeking More Cash for Shareholders of Team Health Holdings, Inc. Corporate Capital Trust announces third quarter 2016 results INTELIQUENT MERGER INVESTIGATION ALERT â€“ Andrews & Springer LLC Is Seeking More Cash for Shareholders of Inteliquent, Inc. ADDING MULTIMEDIA Costco, GameStop and Best Buy Join Activision Blizzard to Support Veteran Hiring with Special Call of DutyÂ®: Infinite Warfare Holiday Seasonal Items Dividend Capital Diversified Property Fund Provides Third Quarter 2016 Portfolio Update Recent Comments Archives November 2016 October 2016 September 2016 August 2016 July 2016 June 2016 May 2016 April 2016 March 2016 February 2016 January 2016 December 2015 November 2015 October 2015 September 2015 August 2015 July 2015 June 2015 May 2015 April 2015 March 2015 February 2015 January 2015 December 2014 November 2014 October 2014 September 2014 August 2014 July 2014 June 2014 May 2014 April 2014 March 2014 February 2014 January 2014 November 2013 September 2013 June 2013 March 2013 December 2012 November 2012 October 2012 September 2012 July 2012 March 2012 February 2012 January 2012 December 2011 November 2011 October 2011 September 2011 August 2011 July 2011 April 2010 March 2010 August 2009 January 1970 Categories Satellite Space Flights Uncategorized VSAT Meta Log in Entries RSS Comments RSS WordPress.org Partners TS2 Space Space Flights .news Satellite Press Releases Proudly powered by WordPress
Epaper search FOLLOW US: Home Archives Latest Arkansas Arkansas Politics 2016 Elections National National Politics World Legislature Weather Live Traffic Map Opinion/Voices Religion Today's Newspaper Right2Know Crime Weird News Interactives News Obituaries Arkansas Arkansas Stocks Markets Business Wire Technology Videos Today's Newspaper Jobs Business Weekend Movies Music Find a Restaurant Dining Today's Newspaper Events TV Listings Puzzles & Games Quizzes Entertainment Arkansas Razorbacks-WholeHogSports High School-Preps UA UALR ASU UCA Horse Racing Wally Hall- Like It Is Blog-Recruiting Guy College Football College Basketball Olympics NFL NFL Draft NBA MLB PGA NHL NASCAR TENNIS SOCCER Little Rock Marathon Today's Newspaper Sports Photo Galleries Staff Galleries & Multimedia AP Photos Top 10 Photos All Top Trending Videos News Recruiting Sports Features ActiveStyle HomeStyle Food Business More Videos Video Galleries Videos Travel High Profile Food Religion Special Sections Arkansas Bridal Community Wedding/Engagement Announcements Anniversary Announcements Family Style Dear Abby Blogs Columnists Polls Previous Features Tweets Big Bend Features Events Classifieds Jobs Homes Autos Crime Right2Know Traffic Broadway Bridge Archives News Tip Whole Hog Sports Arkansas Life Place an Ad Arkansas Daily Deal Monday, November 14, 2016, 5:46 p.m. Home / Business / Earnings report By Source: The Associated Press This article was published October 26, 2016 at 2:04 a.m. Comments aAFont Size Companies reporting quarterly earnings Tuesday included: This story is only available from the Arkansas Online archives. Stories can be purchased individually for $2.95. Click here to search for this story in the archives. Print Headline: Earnings report Tweet ADVERTISEMENT More Business Sales of high-profit models propel GM to best... Apple dips on iPhone prices, lower margins Consumer stocks prove a drag Business news in brief Earnings report News in brief China firm defiant over cyberattack role Judge approves Volkswagen emissions settlemen... Suit: Grain buyer cost Turner $14M More Business stories > Comments on: Earnings report To report abuse or misuse of this area please hit the "Suggest Removal" link in the comment to alert our online managers. Read our Terms of Use policy. You must login to make comments. ADVERTISEMENT MOST POPULAR Viewed Commented Hobbled Fournette remains sight to behold (5 comments) Retirement's in the weeds for ex-Arkansas Realtor (5 comments) 2 more armed robberies in Hillcrest, Heights neighborhoods reported, police say (19 comments) Company set to move 1st arch of new Broadway Bridge to final position (1 comment) Hogs look to simplify heading into home stretch (2 comments) Bald Knob schools cancel class after superintendent dies unexpectedly (1 comment) open this tab by default SHOPPING loading... Central Arkansas Auto Sales Central Arkansas Banking Central Arkansas Beauty Care Central Arkansas Dentists Central Arkansas Florists Central Arkansas Insurance Central Arkansas Lawyers Central Arkansas Movers Central Arkansas Physicians Central Arkansas Restaurants Central Arkansas Real Estate Home News Obituaries Business Entertainment Photos Videos Features Events Classifieds Jobs Real Estate Autos Daily Deal NEWS Today's Newspaper Arkansas Obituaries Opinion / Letters National Politics Elections World Religion Offbeat Sister Papers Weather Print Edition BUSINESS Business Business wire Tech wire Arkansas stocks Markets SPORTS Arkansas Sports Whole Hog - Razorbacks Preps Recruiting Guy Blog LR Marathon College sports galleries Preps sports galleries AP Sports College Football NFL NBA MLB PGA NASCAR Tennis FEATURES Events Calendar Event Photos FEATURES cont. Style Music Family Food Dining Out Find a Restaurant Television Travel High Profile Weddings/Engagements WEB EXTRAS E-mailÂ Updates Right2Know Databases Documents WEB EXTRAS cont. Archives Videos Photo Galleries FixIt Pothole Map War Casualties Democrat-Gazette History Arkansas Links Support Groups Blogs Facebook Twitter CONTACT FAQ/Contact Us Forgotten Password? SubscriberÂ Help Newspaper Delivery Corporate CONTACT cont. Advertising Newspaper Staff Website Staff Internships Terms of Use SUBMIT News Tip Event or Meeting Letter to the Editor Honor/Achievement Wedding/Anniversary PROMOTIONS Democrat-Gazette Store Bridal Show Capture Arkansas Spelling Bee PUBLICATIONS TriÂ Lakes ThreeÂ Rivers RiverÂ ValleyÂ &Â Ozark Arkansas Life Special Sections Where We Live CLASSIFIEDS Classifieds Jobs Real Estate Auto Jobs with Us ADVERTISING Advertise with us Copyright Â© 2016, Arkansas Democrat-Gazette, Inc. All rights reserved. This document may not be reprinted without the express written permission of Arkansas Democrat-Gazette, Inc. Material from the Associated Press is Copyright Â© 2016, Associated Press and may not be published, broadcast, rewritten, or redistributed. Associated Press text, photo, graphic, audio and/or video material shall not be published, broadcast, rewritten for broadcast or publication or redistributed directly or indirectly in any medium. Neither these AP materials nor any portion thereof may be stored in a computer except for personal and noncommercial use. The AP will not be held liable for any delays, inaccuracies, errors or omissions therefrom or in the transmission or delivery of all or any part thereof or for any damages arising from any of the foregoing. All rights reserved. We hope you've enjoyed your preview of ArkansasOnline.com. You've now read the maximum number of stories available without a subscription. Subscribe now for complete and uninterrupted access to the best local, state and national news. Already have an account? Â  Already a print subscriber? Â 
null
Breaking News Health+ Diet + FitnessLiving WellParenting + Family U.S.WorldPoliticsMoneyOpinionHealthEntertainmentStyleTravelSportsVideoLive TV Search Â» U.S. Edition+ U.S. International Arabic EspaÃ±ol Set edition preference:U.S.InternationalConfirm U.S. Edition+ U.S. International Arabic EspaÃ±ol Set edition preference:U.S.InternationalConfirm Home U.S. Crime + Justice Energy + Environment Extreme Weather Space + Science World Africa Americas Asia Europe Middle East 2016 Election Washington Nation World Markets Tech Media Personal Finance Luxury Opinion Political Op-Eds Social Commentary Health Diet + Fitness Living Well Parenting + Family Entertainment Celebrity Watch TV + Web Movies + Music Tech Gadgets Cyber Security Innovation Nation Fashion Design Architecture Autos Luxury Travel Best of Travel Sleeps + Eats Business Travel Aviation + Beyond Pro Football College Football Basketball Baseball Soccer Living Food Relationships Religion Video Live TV â€¢ Digital Studios CNN Films TV Schedule TV Shows A-Z Moreâ€¦ Photos Longform Investigations iReport CNN profiles CNN Leadership CNN Newsletters U.S. International EspaÃ±ol Arabic Set edition preference:U.S.InternationalConfirm FacebookTwitterInstagram <div class="banner" id="cnn_300x250_sync_freewheel-rail_0_banner"><span id="cnn_300x250_sync_freewheel-rail_0" class="_fwph"><form id="_fw_form_cnn_300x250_sync_freewheel-rail_0" style="display:none"><input type="hidden" name="_fw_input_cnn_300x250_sync_freewheel-rail_0" id="_fw_input_cnn_300x250_sync_freewheel-rail_0" value="ptgt=s&envp=g_js&w=300&h=250&slau=300x250_sync&adUnit=300x250_sync"></form><span id="_fw_container_cnn_300x250_sync_freewheel-rail_0" class="cn-shingle__ad"></span></span></div> Startups get closer to helping us live longer, stay healthier By Michaela N. Vincent, CNN Updated 7:20 AM ET, Fri October 28, 2016 Chat with us in Facebook Messenger. Find out what's happening in the world as it unfolds. JUST WATCHED A rape survivor's custody battle for her child Replay More Videos ... MUST WATCH (15 Videos) A rape survivor's custody battle for her child Inside the startup 'college' for Silicon Valley hackers Aspiring billionaires call this room home ... for now This officer has fired his weapon once in 16 years Inside a legal brothel Legal brothel owner: I don't have to recruit The racial divide of heroin The brutal world of female MMA fighters Female MMA fighter takes on Lisa Ling Female fighter must drop 25 pounds in a month Inside the largest jail system in the country Officer: I feel threatened 'on a daily basis' Inside a pickup artist camp Dealing with America's dead Who knew teen models had to do this? Story highlights Kendall Square in Cambridge is said to be "the most innovative square mile" in the US WHOOP's activity tracker helps elite athletes perform at ultimate levels Moderna's technology would allow your cells to make proteins needed to heal your body Indigo tests microbiomes in plants to feed the Earth's population, conserve water (CNN)It may not be Silicon Valley but it's where many tech companies of the East want to be. Kendall Square in Cambridge, Massachusetts, is home to 800 companies, from startups to MIT. Even Google and Microsoft have satellite offices there. Once a salt marsh and the former home of a NASA research center, Kendall Square today is known as "the most innovative square mile" in America, based on the concentration of innovative businesses in the area. Collectively, they have raised $14 billion. As Kendall Square continues to be the place where entrepreneurs and inventors are making their mark in the world, here are three game changers of the "Miracle Mile" that are using technology to help us live longer, stay healthier and work out better. WHOOP Read More Chances are you are one of the 50-plus million people who own a popular activity tracker such as a Fitbit or Jawbone. The devices have created a workout frenzy encouraging regular people to participate in physical activity, and it can become competitive. But, what about a device for those who compete for a living? Athletes. Until now, there was nothing on the market to track an athlete's training. Then WHOOP, the first scientifically-grounded device specifically designed to help elite athletes perform at an ultimate level, debuted in the fall of 2015. Worn on the wrist, WHOOP monitors an athlete's heart rate, ambient temperature, accelerometry and other vitals 100 times a second. Those factors determine an athlete's strain, sleep and recovery. Founder and CEO Will Ahmed believes that athletes may overlook those factors because there's a thin line between over training and training optimally. He says WHOOP's goal is to empower athletes and help them understand their bodies. Photos: Game changers of the 'Miracle Mile' Photos: Game changers of the 'Miracle Mile' Olympian Michael Phelps and several other professional and Olympic athletes have trained using WHOOP, the first scientifically-grounded device specifically designed to help elite athletes perform at ultimate levels. (Photo by Clive Rose/Getty Images) Hide Caption 1 of 9 Photos: Game changers of the 'Miracle Mile' Worn on the wrist, WHOOP monitors an athlete's heart rate, ambient temperature, accelerometry and other vitals 100 times a second. Hide Caption 2 of 9 Photos: Game changers of the 'Miracle Mile' The WHOOP app allows coaches, trainers and athletes to monitor an athlete's training level. A color-coded score helps determine if an athlete should continue training or let the body rest. Hide Caption 3 of 9 Photos: Game changers of the 'Miracle Mile' Carly Schnabel of the Northwestern swim team says the WHOOP technology allows her to adjust her training to accommodate how bad her body feels. Hide Caption 4 of 9 Photos: Game changers of the 'Miracle Mile' By altering the property of mRNA molecules in our cells, Moderna is seeking to create more personalized treatments to fight specific diseases. Hide Caption 5 of 9 Photos: Game changers of the 'Miracle Mile' Moderna is "very focused on infectious disease'' in addition to studying therapies for cancer, cystic fibrosis and vascular disease. Hide Caption 6 of 9 Photos: Game changers of the 'Miracle Mile' Scientists at Indigo have been studying microbiomes found in plants in an effort to increase food yields and water efficiency.. Hide Caption 7 of 9 Photos: Game changers of the 'Miracle Mile' Microbes naturally found in plants have a positive effect on a plant's water stress tolerance as well as its resistance to certain insects and fungi. Hide Caption 8 of 9 Photos: Game changers of the 'Miracle Mile' Indigo has tested more than a dozen plants in various climate conditions during all seasons. After natural microbes were added to seeds, the results showed a significant yield increase. Hide Caption 9 of 9 A digital dashboard allows coaches, trainers and athletes to monitor an athlete's training level. When training is complete, a color-coded recovery score is given, which determines if an athlete should continue or let their body rest. "When we started WHOOP we uncovered that there are a lot of biomarkers that predict how you're going to perform," says Ahmed. "Feelings in general aren't a very good predictor of your body's performance." NBA champion LeBron James, Olympic gold medalist Michael Phelps and about 20 other professional and Olympic athletes have trained using WHOOP. College athletic programs train with the device as well. "We started using WHOOP in the middle of September and this is the healthiest we've been as a team," says Roy Coates, Northeastern swim team head coach. "It plays a huge factor in our success as a team." A recent study of 120 college athletes showed that when athletes used WHOOP, they gained an average of 41 more minutes of sleep and reduced their alcohol consumption by 76%. "You have to budget your time wisely because coaches can see everything you're doing," says Carly Schnabel, Northeastern women's swim team member. If you're not a professional or collegiate athlete and you want to get your hands on a WHOOP, there's good news. WHOOP announced last July that their WHOOP Strap 2.0 would be available to the general public at the end of this year. Moderna JUST WATCHED Is this the cure to cancer? Replay More Videos ... MUST WATCH Is this the cure to cancer? 03:28 Will there ever be a cure for cancer or HIV? That's the question most of the world has been asking. One biotech company, Moderna, believes they are one step closer to finding a remedy. In fact, Moderna says the cure may be right in front of our eyes. "Your body is going to be the factory for your medicine," says Moderna's CEO Stephane Bancel. When someone becomes ill, Bancel says, it is usually due to the lack of a protein, which is then treated with a synthetic protein-based drug. However, those drugs are not always effective in curing the disease. Founded in 2011, Moderna says its technology will not only replace the missing protein but will swap it with a more natural protein. "Now we can have therapeutic proteins functioning inside cells," Tal Zaks, chief medical officer says. "And that's a huge difference." So, how will an emerging biotech startup be able to do what doctors have been unable to do for centuries? How will they change the makeup of proteins? By using Messenger RNA or mRNA. Messenger RNA is the molecules found in cells that carries the code for a particular protein and acts as a template for the formation of that protein. Moderna's technology will change the property of the mRNA molecules, then the mRNA will be injected into the body, theoretically allowing your cells to make any protein it needs to heal itself from a specific disease. "We are very focused on infectious disease," Bancel added. "Then we are trying to see if we could make personalized cancer vaccines." How Cuba is battling lung cancer with a vaccine Last June, Moderna announced a partnership with Merck to develop an mRNA-based personalized cancer vaccine with clinical studies anticipated to begin next year. Last July the company signed a deal with Vertex to create therapies for cystic fibrosis. With over $1.5 billion raised for research and development, including $20 million from the Gates Foundation to fight HIV, Moderna is establishing itself as a leader in clinical studies. An unprecedented two clinical studies are currently underway including a study with AstraZeneca on the experimental drug AZD8601, which treats vascular disease. With their ambitious work underway and the research continuing, the end results could potentially mean the end of devastating illnesses. "The next couple of years for us will be really transformational," Zaks says. Indigo JUST WATCHED Scientists grow natural supercrops to feed the planet Replay More Videos ... MUST WATCH Scientists grow natural supercrops to feed the planet 03:31 Ten billion. That's Earth's estimated population in 2050. That means 10 billion people will be consuming the Earth's food and water supply at the same time. In order to provide enough food and water for the population, agriculture productivity and water conservation needs to increase by 70%. Are we prepared? Tech startup Indigo says no, we are not. They however may have discovered an innovative way to meet the world's food and water needs. After studying human microbiomes found in or on the body that promote digestion and reproduction, scientists at Indigo studied microbiomes found in plants. The results showed that when added to a seed coding, microbes naturally found in plants have a positive effect on a plant's water stress tolerance as well as its resistance to certain insects and fungi. "It's almost like we've discovered a whole new organ inside of plants," says co-founder Geoffrey Ian von Maltzahn. "Now we have the tools to figure out what it's doing." After their discovery, more than a dozen plants were tested in various climate conditions during all seasons. When natural microbes were added, the results showed a 10% yield increase. How significant is that? With 75% of the Earth's food coming from just a dozen plants and five animals, that number is a game changer. "A 10% increase is a whole decade leap forward in terms of productivity," says CEO David Perry. The agricultural industry has taken notice of Indigo's groundbreaking advancements. Last July, the company announced that it received a record-breaking $100 million Series C investment. The investment will not only support Indigo's current and future research, but supports the newly launched Indigo Cotton, the company's first commercial product, which aims to increase water efficiency. Growing beyond its Kendall Square roots, Indigo is now housed in a 65,000-square-foot facility just a few miles north of its original hub. The company says it is preparing for growth -- expecting to double the size of its team as it strives to feed the world. Content by LendingTree Rates hit 2.75% APR (15 yr). See if you're eligible Reverse mortgage: Worth the risk? Fastest way to pay off $10,000 in credit card debt Vets could receive up to $42k with these VA benefits These 4 balance transfer credit cards could help you save big Paid partner content 10 mind-blowing credit cards charging 0% interest until 2018 NextAdvisor $69* + U.S. fare sale into march, one way Travelzoo 4 home technology essentials Wallpaper A jaw-dropping 21-month 0% intro APR credit card NextAdvisor $2199: Caribbean 7-nt cruise w/$400 credit & air Travelzoo Home U.S. Crime + Justice Energy + Environment Extreme Weather Space + Science World Africa Americas Asia Europe Middle East 2016 Election Washington Nation World Markets Tech Media Personal Finance Luxury Opinion Political Op-Eds Social Commentary Health Diet + Fitness Living Well Parenting + Family Entertainment Celebrity Watch TV + Web Movies + Music Tech Gadgets Cyber Security Innovation Nation Fashion Design Architecture Autos Luxury Travel Best of Travel Sleeps + Eats Business Travel Aviation + Beyond Pro Football College Football Basketball Baseball Soccer Living Food Relationships Religion Video Live TV Digital Studios CNN Films TV Schedule TV Shows A-Z Moreâ€¦ Photos Longform Investigations iReport CNN profiles CNN Leadership CNN Newsletters U.S. Edition Set edition preference: U.S. International Confirm U.S. International Arabic EspaÃ±ol Â©Â 2016Â CableÂ NewsÂ Network. TurnerÂ BroadcastingÂ System,Â Inc. AllÂ RightsÂ Reserved. CNNÂ SansÂ â„¢Â &Â Â©Â 2016Â CableÂ NewsÂ Network. Terms of Use Privacy Policy AdChoices Advertise with us About us Visit CNN Newsletters Work for us Help Transcripts License Footage CNN Newsource
Back Join Now Log In Fitness Workouts Workout Videos Workout Tips Training Cardio Workout Music Workout Trends Workout Clothes Workout Gear Healthy Eating Healthy Recipes Meal Ideas Healthy Drinks Diet Tips & Nutrition Healthy Cooking Cooking Videos Weight Loss Tips & Plans Weight Management Weight Loss Foods Success Stories Weight Loss Videos Lifestyle Beauty Sex & Love Mind & Body Fit Getaways Fashion Bride Celebrities Interviews Celebrity Photos Celebrity News Celebrity Workouts Star Trainers Celebrity Videos Videos Shop Sweepstakes #LoveMyShape Shape Activewear Shape Magazine just $5.99!Join Now Search form Search Shape Magazine You are here Lifestyle / Mind and Body This Woman Got So Stressed Out She Forgot Who She Was The weird side effects of stress are all too real By Refinery29 | Oct 27, 2016 Tyler Spangler We've long known stress can wreak havoc on your mind and body. It has the potential to hurtÂ your heart,Â your immune system, and evenÂ your memory. In an extreme case of stress-induced memory loss, a woman in England forgot her name, her husband's identity, and nearly everything else about her life after a nervous breakdown,Â The Daily MailÂ reports. Marie Coe, 55, was working upwards of 70 hours a week in a demanding job running an events company in the U.K., traveling constantly, all while also juggling a family and taking care of her household. One day, after she'd gone missing for 24 hours and couldn't remember anything, she asked a stranger at a gas station for help. An ambulance came, and she couldn't answer any of the paramedics' questions. After a CT scan revealed no head injuries, the doctors diagnosed her with "stress-induced amnesia,"according toÂ The Daily Mail. This is, apparently, a real thing: Memory loss caused by extreme stress or trauma is actually "dissociative amnesia," according toÂ Merck Manuals. It seems to run in families, according toÂ The Cleveland Clinic. It can cause someone to forget everything, as with Coe, or it can concern specific areas of the sufferer's life. Sometimes, a person with the condition will forget who they are and go on to assume an entirely new identity without realizing it (this is known as "dissociative fugue."). When Coe's husband Mark picked her up from the hospital, she had no idea who he was. She didn't even know she was married. "It was terrifying sitting in the car with a strange man who claimed he was my husband," she toldÂ The Daily Mail.Â  [For the full story, head to Refinery29] More from Refinery29: 7 Very Weird Side Effects Of Stress Here's How Stress Can Make You Sick Sex Makes You More Intelligent, Apparently Search Shape Shop activity trackers running shoes dresses shoes rings wetsuits sandals ski training shoes headphones boots skin care health plus size clothing sneakers fragrances workout clothes Shop More Your Account Help Newsletter Customer Service Log In Join Now! Update Your Account Logout Shape.com Fitness Healthy Eating Weight Loss Lifestyle Celebrities Videos Sweepstakes Shape Magazine Subscribe Digital Editions Gift Subscriptions Renew Subscriptions Customer Service Advertise with Us Affiliate Program Meredith Beauty Fitness Magazine Shape Martha Stewart Weddings Mywedding Divine Caroline More Siempre Mujer Â© Copyright 2016, Meredith Corporation. All Rights Reserved Â |Â Privacy Policy Â |Â Data Policy Â |Â Terms of ServiceÂ |Â  AdChoices
Â  Home U.K. News Sports U.S. Showbiz Australia Femail Health Science Money Video Travel Columnists Wires Home My Profile Logout Login Feedback DailyMail NEW ARTICLESHomeTop Share show ad AstraZeneca pauses two cancer drug trials' enrolment due to bleeding By Reuters Published: 13:23 EST, 27 October 2016 | Updated: 13:23 EST, 27 October 2016 e-mail By Ben Hirschler LONDON, Oct 27 (Reuters) - AstraZeneca's high hopes for cancer immunotherapy were dented on Thursday as the recruitment of new patients with head and neck cancer into two clinical studies was put on hold, following instances of bleeding. The drugmaker said the U.S. Food and Drug Administration (FDA) had placed a partial hold on enrolment into the final-stage Phase III trials involving two of its immune system-boosting drugs, although the studies are still continuing with existing patients. Trials of durvalumab and tremelimumab in different cancer types are also progressing as planned. Durvalumab is being tested on its own and with tremelimumab in various cancers. Expectations for the combination treatment have been building in particular in lung cancer, where the two-drug cocktail is being tested in a broad range of patients as an alternative to initial chemotherapy. News of the problems in head and neck cancer first surfaced on the website clinicaltrials.gov, run by the U.S. National Institutes of Health, which said one of the trials, known as KESTREL, had been "suspended". "The trial is not suspended," an AstraZeneca spokeswoman said. "We have a pause or a partial clinical hold on enrolment of new patients." Shares in AstraZeneca fell more than 4 percent in U.S. trading on concerns that the setback might signal wider problems for durvalumab. AstraZeneca sought to play down concerns, however, stressing that pivotal data in lung cancer were still expected in the first half of 2017. It also said that bleeding was a known complication in treating head and neck cancer, given the proximity of tumours to major blood vessels and use of prior cancer therapies, which may involve surgery and radiation. Merck's rival immunotherapy drug Keytruda is already approved for head and neck squamous cell carcinoma, the same condition that AstraZeneca is testing for. Bernstein analyst Tim Anderson said there was some reference in the medical literature to a decrease in blood platelets, which are needed for clotting, when patients were given so-called CTLA4 drugs like tremelimumab, although cases were rare. Both Anderson and Deutsche Bank's Richard Parkes said it was unclear if bleeding constituted a real drug side effect or not. AstraZeneca said it had submitted its analysis of bleeding events to the FDA for review and would work to provide the required information to resume new patient enrolment as soon as possible. (Editing by Martinne Geller) Share or comment on this article e-mail Sorry we are not currently accepting comments on this article. Bing Site Web Enter search term: Search Like DailyMail Follow MailOnline Follow DailyMail +1 DailyMail Â  Â  DON'T MISS 'She's modified her face beyond all recognition!' Carol Vorderman, 55, stuns viewers after exhibiting 'frozen' complexion on I'm A Celeb It's getting hot in here! Ola Jordan shows off her dancer's body in tiny red bikini as she hits the jungle shower with Sam Quek and Scarlett Moffatt on I'm a Celeb Carol Vorderman, 55, strips down to a VERY racy swimsuit on I'm A Celeb...as 'happily single' star tells campmates 'I do alright' when it comes to men She looks to be doing just fine! Kim Kardashian's friend shares rare photo of reality star recluse as she dresses up in belly dancer costume for fun Ashley James puts on a eye-popping display in an itsy-bitsy bikini as she soaks up the sun on the beach in Ibiza Making the most of the sun 'It's me or the wardrobe!' Frankie Gaff gives Jamie Laing an ultimatum. He found living with her and her 'floordrobe' too much to bear on Made In Chelsea, by Jim ShelleyÂ  Cor (rie) blimey! Helen Flanagan showcases her incredible figure in a racy cut-out bikini as she holidays in Dubai with boyfriend Scott Sinclair Chloe Ferry reportedly FIRED from Geordie Shore after 'kicking new housemate Zahida Allen in the head'Â  The 21-year-old was shown the door Now that's a lesson in style! Myleene Klass exposes her cleavage in plunging jumpsuit as she leads the red carpet glamour at School of Rock press night She's proud of that booty! Khloe Kardashian flaunts her derriere as she does squats at the gym Taking after her bigger sister (in both senses) Real men wear pink! Brooklyn Beckham follows in his mother Victoria's fashionable footsteps as he makes a statement with pink beanie hat Frankie Bridge is the picture of elegance in plunging patterned gown at Virgin awards... after her husband Wayne makes I'm A Celebrity debut PICTURE EXCLUSIVE: Tom Hiddleston steps out with a pretty blonde Taylor Swift lookalike... two months after split with pop star Flashed a beaming grin She needs a nap! Pregnant Marion Cotillard looks weary during LA dinner after tirelessly promoting Brad Pitt WWII film Allied Struggling Holly Willoughby is close to tears on This Morning as a distraught mother breaks down over her son's planned suicide during bullying phone-in The Eighties called! Sheridan Smith is unrecognisable as a busty brunette on set of the movie adaptation of comic Jo Brand's book As schizophrenic mum Newly-engaged Pixie Lott can barely contain her glee as she heads to jewellers hours after fiancÃ© Oliver Cheshire popped the question What a gem!Â  Emma Watson stars as Belle in the first trailer for Disney's long-awaited live action remake of Beauty And The Beast Looks stunning Choosing her prince wasn't ALWAYS such an easy choice! Meghan Markle giggles as she is asked to pick either William or Harry months before romance She's a good sport! Gigi Hadid tries her hand at table tennis as she makes a sweeping entrance at VIP dinner in stylish satin jumpsuit In high spirits 'Worst thing I've ever done': I'm A Celeb's Scarlett, Jordan, Ola and Sam do Bushtucker Trial featuring 120,000 critters... as Moffatt is voted in first From refurbished iPads to a good-as-new Sony PS4: Ways to save money on your children's gifts this Christmas (without any fewer smiles!) SPONSORED Make-up free Coleen Rooney flaunts her trim figure in semi-sheer mesh workout gear as she hits the gym Making the most of her free time Demure Dita! Burlesque extraordinaire Von Teese steps out in modest black polo neck and ornate silver skirt for evening in London Jessica Simpson's father Joe, 58, confirms he has prostate cancer and has already undergone surgery 'He's feeling great now and is optimistic' 'It's like we get a little bit of dad back': Bindi Irwin says she remembers her dad the best every time she puts on her Australia Zoo uniform Not very ladylike! Lady Victoria Hervey, 40, displays more than expected as she flashes perky assets when risquÃ© swimsuit unfastens Dapper Brad Pitt takes selfies with adoring fans at Allied screening in China... as he returns to the public eye after split with Angelina Jolie In better spirits again 'She works really hard': X Factor's Sam Lavery defends Honey G after elimination... as rapper faces backlash for surviving ANOTHER week 'He's such a good man': Marion Cotillard gushes about Allied co-star Brad Pitt... after shooting down rumours of an on set romance Caught up in split Naomi Campbell speaks for the first time about what it means to be black and British and joins other famous stars who were told to limit their ambitions due to their skin colour Take that! Bella Hadid throws a punch as she works out in boxing class after split from The Weeknd Was snug in her black, oversize fuzzy jacketÂ  Girl time! Bella Thorne and Demi Lovato don skinny jeans as they catch up over lunch at the trendy Urth Caffe They both have new romances 'I had a bit of a nervous breakdown' Ryan Reynolds admits secret battle with anxiety as he's named GQ's Man of the Year He's filming Deadpool Coy Khloe Kardashian attempts to go incognito in huge hoodie as she steps out in wake of Tristan Thompson split rumoursÂ  Looked glum 'I gave up my career for a really long time': Ayda Field admits she TURNED DOWN a major US TV show to be with husband Robbie Williams 'It was very romantic': Goldie Hawn gets VERY candid about her and Kurt Russell's sex life and discusses split with ex husband Bill Hudson In Aspen, Colorado,Â  'Fame is the best drug': Lady Gaga opens up about her addiction to stardom as she covers Harper's Bazaar She penned an open essay to the magazine Twice the star power! Madonna puckers up as she and Zac Efron take selfies together at UFC's Connor McGregor star-studded fight Lucky Star 20 years and counting! Ant and Dec sign new three-year deal with ITV marking a landmark anniversary with the channel and promising more I'm A Celeb and BGT until at least 2019 'It's really awkward': Girl On The Train star Haley Bennett on being constantly mistaken for Jennifer Lawrence There is an uncanny likeness 'I lost Jack': Natalie Portman is a heartbroken First Lady after JFK's assassination in emotionally charged trailer for Jackie Natalie Portman flatters her pregnant figure in a striped T-shirt as she runs errands A regular errand-running day, despite the relsease of a mega-bucks trailer Waiting on mom! Jennifer Garner grabs breakfast while Ben Affleck and son Samuel goof around in their car The amicable exes appeared to be relaxedÂ  'I could write a book on back problems!': Duncan James confirms he is fit and well after sudden visit to A&E... five months after emergency surgery on his spine Post election blues: Alec Baldwin looks depressed as he strolls with family before accusing NBC of not allowing SNL to endorse Hillary Clinton Back to her Mean Girls roots! Lindsay Lohan shows off new red locks reminiscent of her infamous movie character in cosy Instagram selfie Showdown! Exes Justin Bieber and Selena Gomez will compete for Artist Of The Year at the American Music Awards On November 20 It's only three weeks old! Amber Rose can't hide her horror as her brand new $371k Rolls-Royce gets rear-ended 'It's awesome!' Hailee Steinfeld opens up about being part of Taylor Swift's squad as she flashes her bra for magazine cover Gave glimpse of her bra 'I felt isolated': Robbie Williams describes the roller coaster ride with drugs, drink and depression that almost killed him... as he gets tearful over his daughter Hat's the way to do it! TOWIE's George Harrison flaunts her enviably svelte figure in a sizzling cut-out monokini as she enjoys a beach break in Spain 'Let's keep fighting to make it a better world for our children': Katie Holmes shares rare photo of daughter Suri with powerful message A productive playdate 'Sort your jaw out!' Vicky Pattison is slammed for 'gurning' on I'm A Celeb Extra Camp... as she mistakes show for Xtra Factor in awkward blunder 'I'm heartbroken, but proud of myself': Daisy Lowe flashes her toned abs in a crop top as she puts on a brave face after Strictly eliminationÂ  Put on a brave face 'She's built like a woman': Tommy Hilfiger praises 'smart, funny and humble' Gigi Hadid as he shows off his luxury New York apartmentÂ  'The 80s are back!' Luke Hemsworth channels He-Man for retro birthday bash with brother Liam and Miley Cyrus Time is rolling back 'They eat and stargaze': Sean Penn gripes about celebs who attend his foundation's annual gala... but don't donate a cent Looking rugged Ariel Winter posts a VERY cheeky Instagram snap from her Mexican holiday withÂ Levi Meaden and pals Certainly making a splash 'We had good gossip': Courtney Love reveals unlikely friendship with Hillary Clinton... after meeting as they got their hair cut at same salon They met in 1988 'Being right sucks': The Simpsons poke fun at themselves in opening credits of first episode since Trump's election after predicting his presidency 16 years ago Young And The Restless star Corey Sligh, 28, arrested for molesting a girl under the age of 10 in Georgia The arrest took place on October 14 in Georgia Pretty as a petal! Jaime King looks ultra feminine in romantic lace gown at intimate fashion dinner She was certainly the belle of the ball EXCLUSIVE: How Andy Cohen refused an invitation into Cher's bedroom and fuelleda feud between Mariah Carey and Jennifer Lopez Catherine Tyldesley flaunts her toned legs in skintight jeans as she presents radio show... after teasing Corrie's 'heartbreaking' Christmas storyline 'Why are you in, miss? You're a millionaire!' GBBO champ Candice Brown reveals pupils were shocked to see her return to her job as a PE teacher after win Off-duty beauty: Lottie Moss goes make-up free and rocks a casual outfit as she jets out of Barcelona after a girls' weekendÂ  Bare faced chic She's a peach! Adriana Lima flaunts her lean bronzed limbs in pretty floral mini dress as she shops in MiamiÂ  Turned sidewalk into her catwalk Nick Knowles moves into estranged wife Jessica's home following 'traumatic' split 11 months ago... after admitting they 'are working through things' 'I've NEVER eaten a takeaway': Mary Berry shares her biggest foodie secrets (and reveals what husband Paul will be getting her for Christmas this year) Secrets of an A-list body: We reveal how YOU can get Mark Wahlberg's pecs The 45-year-old actor is renowned for his toned pecs LeAnn Rimes holds hands with husband EddieÂ Cibrian as they reunite with his ex-wife Brandi Glanville at son's soccer match Families united Ola Jordan keeps her lace dress ON as she sets up camp in I'm A Celeb... as jealous husband James warns about hitting on his 'firecracker' 'He has never taken responsibility for her': I'm A Celebrity's Larry Lamb 'has a secret daughter who he had at 21... and hasn't seen for 46 years'Â  'She just didn't even try': Former I'm A Celeb winner Charlie Brooks calls out Helen Flanagan for being 'the worst' campmate at bushtucker trials 'I don't know if it was dancing or a seizure': Cheeky Robbie Williams gives mother-in-law Gwen harsh critique as she dances to Pray on Loose Women Jesy Nelson is seen without her engagement ring AGAIN during Sydney trip... as speculation heightens over 'split' from fiancÃ© Jake Roche PICTURE EXCLUSIVE: Hilary Duff shows off her fit figure in a skimpy bikini while on holiday with boyfriend Jason Walsh inÂ Puerto VallartaÂ  Feeling the heat 'There's so much I wish I could thank him for, just one last time': Leonard Cohen's son writes emotional tribute to his father following his death aged 82 Did Kendall Jenner quit Instagram? Model's account no longer available after ballerina outrage Following Kim's lead and taking a break? Jailed Apollo Nida set to return to Real Housewives Of Atlanta with his new FIANCEE (but what willÂ Phaedra Parks say?) Serving eight years Millie Mackintosh shows off her abs in a berry bikini as she models for boyfriend Hugo Taylor's sunglasses line in Mauritius Wish you were here? Final plans for Leonardo DiCaprio's ultra-luxury private eco resort on 104-acre island off Belize are releasedÂ  Bought in 2005 'It's been challenging, but like Alan Partridge, I'm bouncing back': Tony Blackburn opens up about returning to BBC radio months after being sackedÂ  'She should be ashamed of herself!' Sharon Osbourne is slammed on Twitter as X Factor fans accuse her of changing her mind at the last minute In need of a drink? Simon Cowell clutches a bottle of beer as he leaves The X Factor with Lauren Silverman after Honey G survives ANOTHER week Getting the after-party started! Dita Von Teese, Dominic Cooper and Ophelia Lovibond let loose at the Evening Standard Theatre Awards Madonna's age gap... between her face and hand: Wrinkled mitts give away the singer's age as she attends UFC bout in New YorkÂ  Unable to disguise age Chic Julia Roberts is every inch the stylish soccer mom in low-key skinny jeans and a hat as she cheers on her kids Low-key superstar 'You could bleed to death': Kris Jenner warns Kim Kardashian about seeking third natural pregnancy on KUWTK Hard to take in Chrissy Teigen oozes retro glamour in a super-plunging Seventies-style jumpsuit as Fergie goes for a sheer mini at intimate fashion dinner Lindsay Lohan at the centre of a battery case as 'two Russians assault a man accused of spreading rumours about her' More drama The People v OJ Simpson leads the way with six Critics' Choice Awards nominations... as Game Of Thrones gets five Booty-ful day at the beach! Larsa Pippen shows off her fit figure in plunging white swimsuit while sunbathing in Miami Kim K's BFF A head for heights! Carol Vorderman leads the way as she conquers terrifying 300ft walk above city in I'm A Celebrity's first Bushtucker Trial Â  Ultimate flashing champion! Newly-single Bella Hadid shows off her bra in sheer top as she goes hell for leather on way to Conor McGregor fight EXCLUSIVE: 'I didn't want to leave the house': Frankie Essex says fitness helped her combat depression... as she reveals remarkable weight loss in a bikini 'Who is voting for her?' Honey G faces fresh backlash as talented act Sam Lavery leaves and farcical X Factor rapper isn't even in bottom two Could she win? Wild thing! Busty Ashley James sets pulses racing in a barely-there leopard print bikini as she jets off to Malta Series of sizzling snaps Daisy Lowe misses out on Blackpool as she is voted off Strictly after aÂ  dance off against Greg Rutherford... but Ed Balls sails through again inÂ  Gangnam Style Khloe Kardashian posts cryptic Instagram message amid speculation she's split with new beau Tristan Thompson Over already? 'We never asked to be role models': Perrie Edwards says she feels 'pressure' to act responsibly as she joins Little Mix co-stars for sizzling photo shoot I'm a Celebrity... it's getting hot in here! Joel Dommett, Wayne Bridge and Adam Thomas flash their ripped chests in the first jungle shower of the season 'Larry Lamb for Bond!': Twitter left in hysterics as EastEnders star dives into swamp to save Scarlett Moffatt from canoe disaster on I'm A Celebrity PICTURE EXCLUSIVE: HilaryÂ buff! Ms Duff puts her sculpted physique on display in a studded bikini during Mexican holiday Let the sunshine! Biggest surprise ever': Pixie Lott reveals she's engaged to long-term love Oliver Cheshire as she shows off dazzling diamond ring on InstagramÂ  Cruel... No not nature's predators - Sir David Attenborough. He usedÂ  'rape' of Snow Leopards to make viewers suffer in Planet Earth II, writes JIM SHELLEYÂ  'If your ex has been an a***hole, it's nice to belittle them': Little Mix stars get candid about faking orgasms and shaming former boyfriends in song 'I thought my life would be normal': Hollywood megastar Goldie Hawn says she only ever wanted to get married, have children and run a dance schoolÂ  Lily Donaldson shows off her cleavage and legs in a daring dress with thigh-high slit at star-studded Evening Standard Theatre Awards Elizabeth Hurley wows in a plunging black dress as she's joined by her very dapper son Damian, 14, for a night at the Evening Standard Theatre AwardsÂ  Still part of the family! Billie Piper wows in glam gown as she jokes with ex Laurence Fox's cousin Freddie at theÂ Evening Standard Theatre Awards Margo Stilley flashes her lace bra and hot pants in raunchy sheer dress as she makes rare red carpet appearance atÂ Evening Standard Awards Now James Corden turns his talents to Christmas ads! Sainsbury's enters the fray with an animated commercial featuring singing from the star In a Potter bother! Fantastic Beasts star Eddie Redmayne reveals he got grilled over wand after trying to smuggle it through customs Pucker up! Jesse Metcalfe and fiancee Cara Santana pack on the PDA at their engagement party They got engaged in August after eight years 'Thank you all so much': The X Factor's Sam Lavery shows little emotion as she is latest contestant to be voted off... after tense singing battle with Ryan Lawrie SPOILER ALERT: 'She's not mine!': Rick Grimes makes explosive revelation about 'daughter' on The Walking Dead More trouble ahead Shameless actor Jody Latham is accused of 'terrorising' a former Apprentice star in feud over his ex-fianceeÂ  Appeared at Manchester Magistrates' Court PICTURE EXCLUSIVE: Kourtney Kardashian flaunts fabulous figure in skimpy bikini on romantic getaway in Mexico with on/off beau Scott Disick Alexander McQueen's London penthouse hits the market for Â£8.5 million (complete with bespoke chandeliers, a dining terrace and walk-in dressing rooms)Â  Lea Michele shimmers in strapless dress as Kristen Bell goes sheer daring in lacy top for Christmas event in LA Black was back at glitzy event 'Wolf with rabies': Teresa Giudice continues taunting Jacqueline Laurita as fiery RHONJ reunion concludes On/off friendshipÂ  Happiest place! Singer Ashlee Simpson and hubby Evan Ross enjoy family bonding day with kids at Disneyland Happy every afterÂ  Lily James is spring chic in yellow dress and denim jacket as she is seen for first time on set of Baby Driver Filming the crime comedy in Atlanta A man cave for her Tyga? Kylie Jenner stocks a special room with Playboy magazine for 'the boys' at her Hidden Hills mansion Mags and an ashtray Unhappy birthday to you! Glum Anne Hathaway is a lady in red as she heads out for fancy celebratory dinner She had been stumping for Hillary Clinton What a whirl-wand trip! Eddie Redmayne looks exhausted as he lands in London in time for the premiere of Fantastic Beasts after debuting movie in New York Pregnant Katherine Heigl dresses her baby bump with loose fitting tank top at flea market with husband Josh Kelley Looking for baby gifts? Chic but sombre, the Duchess of Cambridge joins Camilla and Sophie Wessex at the Cenotaph on Remembrance Sunday A von Furstenberg coatÂ  EXCLUSIVE: 'He pursued her heavily': I'm A Celeb's Lisa Snowdon 'devastated' to learn footballer ex Jay Bothroyd was married during eight-month affair 'FIRST look': Ruby Rose posts teaser of The Veronicas' new single On Your Side... which details her love story with singer Jess OrigliassoÂ  Kate Beckinsale shows off her slim figure in tight top as she attends AFI FEST in Los Angeles Always looks sensationalÂ  'He's the Trump of Strictly': Ed Balls divides viewers after Gangnam Style saves him as it's revealed he'll perform a Great Balls of Fire jive in Blackpool You must be jo-KING? EastEnders hardman Danny Dyer makes heir-larious discovery as it's revealed he is a descendant of royalty Cockney royalty Animal attraction! Make-up free Heidi Klum, 43, gets wild with leopard print at a celeb-studded fundraiser in Los Angeles Wild thing She's got some front! Rebecca Hall looks radiant in low-cut patterned dress at AFI Fest in Los Angeles The Christine star paired her unique dressÂ  Sharp-suited Tom Hiddleston arrives at Evening Standard Theatre Awards in good spirits... amid claims Taylor Swift will sing about their breakup Corrie's Beverley Callard 'hasn't met her 11-month-old grandchild' despite living just down the roadÂ  Laura Cross made the claims against the star 'People can call me a mug but we are happy': Megan McKenna stands by reunion with Pete Wicks after sexting scandal... and no longer checks his social media 'It's very sad': Iconic soap star Eileen Derbyshire, 85, may not return to Coronation Street after 55-year run Has been absent now for 12 months 'You had me at bonjour': Make-up free Rebecca Gayheart, 45, shows off her clear complexion as she dons cheeky T-shirt at charity event Nikki Reed stuns in white off-the-shoulder patterned top as she attends ACLU dinner in LA The 28-year-old looked gorgeous as ever She's a real page turner! Actress Emma Roberts goes make-up free as she peruses a newsstand in Los Angeles Looked simply chic SPOILER ALERT: Ecstatic Gemma Winter meets lifelong crush Peter Andre as the pop star makes a cameo on Coronation Street Getting star treatment 'I feel so sorry for her': Catherine Tyldesley steps out in a wintry ensemble as she heads to a radio appearance to tease 'heartbreaking' Xmas storyline Hollywood power couple Jennifer Aniston and Justin Theroux go unnoticed in Germany... after saying he makes her feel 'completely adored' Stunning at 70! Goldie Hawn cuts a fabulous figure in silk dress as she makes an appearance ahead of her comedy show in Melbourne Back to her pre-baby best! Kim Kardashian recycles 2009 Princess Jasmine costume for fun with North She worked hard to getÂ  back in pre-baby shape JK's fantastic new hero is just the magic we need: BRIAN VINER on the latest instalment of the Potter franchiseÂ  Plenty to say about restablishment stooges Nicole Kidman reunites with her To Die For director Gus Van Sant and co-star Casey Affleck for Variety taping Cult black comedy Coleen Rooney looks glam in an off-the-shoulder top as she enjoys a girls' night out at new Liverpool restaurant Flashed the flesh From Hollywood to Hollyoaks! Dallas star Linda Gray, 76, brings the glam to Chester in first look at her cameo in the Channel 4 soapÂ  An unlikely arrival She's ripped! Kelly Bensimon wears torn blue jeans while out with daughter Thadeus in New York City Stepped out in New York over the weekend Michelle Keegan 'house-hunting in South Africa' as she prepares to spend eight more months away from Mark Wright for Our Girl filming Billy Bob Thornton smokes a cigarette as he touches down in LA after saying ex-wife Angelina Jolie 'seems OK' following Brad Pitt split Hailey Baldwin flaunts her bikini body in a swimsuit before planting a kiss on her female friend Model and daughter of Stephen Baldwin From Ab Flab to Ab Fab! Helen Lederer sheds eight pounds and drops a dress size in just three days after surviving on 400 calories A DAY 'It's about finding the right balance': Marion Cotillard admits she struggles to balance her professional and personal life... after denying Brad romance The good life! Ariel Winter proudly flaunts backside as she twerks in bikini during Mexican holiday withÂ Levi Meaden and pals Continuing her holidayÂ  Feeding the flock! Jennifer Garner and Ben Affleck provide snacks for family church as they bring their children to Sunday service At Pacific Palisades No comment! Kanye West refuses to confirm if he still plans to run for President in 2020Â  The 39-year-old Life of Pablo artist ignored questions Kanye West launches a new 'unpretentious' range of clothes - but a jumper will still set you back Â£1,745 and a T-shirt Â£159 A real man of the people 'You always inspire': Sylvester Stallone presents Jackie Chan with honourary Oscar... as Arnold Schwarzenegger also pays tribute 'I had a good time with dalliances': Robbie Williams jokes about making the most of his fame, how many of the Spice Girls he's REALLY slept with Swift beatz? Pop princess Taylor calls on rumoured rapper flame Drake 'to help give her music a hip-hop vibe' She reportedly wants to sound edgier Puppy love! Sofia Richie shows taut tummy as pal Cameron Dallas carries cute canine at West Hollywood store Enjoyed some dog time Miranda Kerr is the belle of the ball in an exquisite gold gown as she cosies up to sharp-suited fiancÃ© Evan Spiegel at glittering Baby2Baby Gala Geordie Shore's Sophie Kasaei parades her sun-kissed curves on the beach after defending healthy Size 10 figure Showed off her bikiniÂ  'I'm no spring chicken': Ex-Strictly professional Ola Jordan, 34, says she's 'not body-confident' despite sneaking SIX sexy bikinis into I'm A Celeb 'I'm not having another baby, so screw you': EastEnders actress Jacqueline Jossa lashes out at cruel trolls who told her she looked pregnant 'He waited outside for her': Pregnant Amy Childs flees event after man 'threatened to punch her' Outside The Ideal Homes Show 'I only do the things I love': Mary Berry confirms filming for her own cooking show... as Bake-Off makers 'head to court over block on Channel 4 rival' 'That smile ain't nothing but a Dream!': Kris Jenner posts adorable snap of Rob Kardashian cradling his new baby girl Latest addition Jessica Alba goes casual chic as she takes her daughters to the Beverly Hills Farmers' Market She is known for her healthy lifestyle Mia Tyler announces she's expecting her first child by sharing picture of her bump First child for the artist, who is the daughter of Aerosmtih's Steven Scarlett Johansson shows off stunning curves in lilac cutaway dress at Ghost In The Shell trailer launch in Japan Glam evening Pamela Anderson cuts a chic figure as she brings MORE snacksÂ to WikiLeaks founder Julian Assange... after he joked that her vegan treats were 'torture' Jamie Foxx has fun on set with Robert Downey Jr and Jeremy Piven as they film All-Star Weekend Revolves around two tow-truck drivers Kurves ahead! Khloe Kardashian shows off her incredible physique in a burnt orange dress as she heads to stylist Monica Rose's baby shower PICTURE EXCLUSIVE: Megan Fox and Brian Austin Green take baby Journey and his older brothers on family outing Family unitedÂ  'I was a bit of a b***ard': Phil Collins admits to cheating on his ex-wife, but says he was just 'following his heart' Regrets the affair 'I had nothing left to give him': Daisy Lowe falls foul of Strictly curse... as she and beau Bradley 'Frankie' Wade couldn't 'cope with the pressure' If you wannabe my mother: Ex-Spice Girl Victoria Beckham 'wants to manage her son Cruz's pop career' Thinks her experiences make her the perfect candidate Rod Stewart's rarely-seen daughter Ruby follows in her father's footsteps as she opens his tour in Liverpool The apple never falls far from the tree From Top Gear to top rear! Little Mix's Leigh-Anne Pinnock teaches Jeremy Clarkson how to twerk on the Jonathan Ross Show Awkward! GIRL ABOUT TOWN: Finally, Jeremy Clarkson is silenced - by the raging wife of Sir Shifty, Lady Green Someone who can stop the motormouthÂ  GIRL ABOUT TOWN: Phasing out the Fogles! Prince William distances himself from Ben Fogle and his wifeÂ  Said to be fed up of Ben talking about him in public GIRL ABOUT TOWN: Doctor Who to marry Lady Rose? Besotted Matt Smith to pop the question to girlfriend Lily James by ChristmasÂ  Planning trip to New York Still the Princess of Darkness: X Factor judge Sharon Osbourne, 64, flips the bird as she leaves X Factor post-party looking a little worse for wear Outlandish behaviour Parkinson's sufferer Michael J. Fox appears to go Back To The Future with impassioned guitar solo as he leads special gig to support his charity Nicola Peltz flashes her taut abs in a crop top as she opts for an all-black look in Los Angeles Flashed a hint of her abs as she headed out Eye of the tiger, face of an angel: Ageless Madonna, 58, stuns with extremely taut appearance as she leads star-studded UFC fight crowd Kendall Jenner's hangout bar, Emma Stone's beloved salon and Jennifer Aniston's hiking spot: How to ditch the tourist traps and explore LA like a local A-Lister From Baywatch to bag watch: Giddy Kelly Rohrbach shops 'til she drops as she strains under a heavy load Made shopping look like hard work on Saturday PICTURE EXCLUSIVE: Kate Upton and fiancÃ© Justin Verlander put on a tactile display on romantic Italian vacation The 24-year-old model kept close in Florence Sheer delight! Nicole Kidman flashes her cleavage in plunging see-through gown at The Governors Awards... before slipping into classic white high-neck dress for later event 'I don't want to say!' Kris Jenner cries as her mother MJ asks her biggest fear in Keeping Up With The Kardashians Welled up on TV Getting some retail therapy! Julianne Moore and friend Laura Dern browse designer dresses at LA boutiqueÂ  The 55-year-old looked to be in good spiritsÂ  'Loved it!' Kelly Clarkson takes baby Remington and daughter River to Disney World River, 2, and Remington, 7 months,Â  will have been delighted Danniella Westbrook sports new brunette hairdo, but STILL wears a plaster under her nose... amid reports she's suing Celebrity Botched Up Bodies Hard man Mickey Rourke, 64, proves he's a big softy at heart as muscular actor cradles beloved fluffy pooch The age-defying actor, 64, showed off his bulging biceps People wanted to kill me, says Prince Harry's girl: Meghan Markle opens up to PIERS MORGAN about dating, death threats and most embarrassing momentÂ  Bataclan TURNS AWAY Eagles of Death Metal - who were playing when ISIS massacred 90 music fans - as the concert hall reopens a year after the attack with Sting performance Cringing Cowell! Simon is left red-faced after Dermot shares throwback picture of him with a VERY dodgy hairdo on X Factor Giving a gun show too! What happens in Vegas stays still in Vegas! Britney Spears does the Mannequin Challenge to celebrate Sin City successÂ  Flesh-flashing Charlotte Dawson flirts up a storm with new rugby player boyfriend Matt Sarsfield as they're spotted together for the first time Trinny Woodall's 'nightmare' Â£300,000 divorce battle from beyond the grave: Fashion guru's bizarre High Court battle over her dead ex's debtsÂ  Get Me Out Of Here already! Scarlett Moffatt can't contain her disgust as she's forced to canoe through swampy waters in I'm A Celebrity's first grizzly challenge 'Strictly viewers are delighted to spot Mary Berry in the audience... but are reduced to tears as Judge Rinder's granddad wells up on-screenÂ  She's got good jeans! Khloe Kardashian shows off her toned bottom...as she hits out at haters online Addressing all the criticism Frill-seeker! Slimmed-down Tina Malone shows off her TINY size six figure in black flamenco-style dress as she steps out at RTS Awards Disco fever! Leona Lewis oozes 70s glamour in corkscrew curls and plunging sequin gown as she steals the show at animal charity gala in LA Cara Delevingne flashes her abs with a sexy pin-up on her jacket... as she turns her mind to modelling following St Vincent split She had taken a step back from her modellingÂ  Donatella Versace claims that gay male fashion designers create clothes for the 'women they want to be' rather than their customers Â  Female style icon Rachel Weisz is cosy beneath a bizarre woolly hatÂ  She is famed for starring in cult classic The Mummy, butÂ Rachel Weisz looked like she was almost embalmedÂ  Ready to take the plunge! Ola Jordan glams up before the jungle in a low cut peachy dress as she meets her I'm A Celebrity team mates Slinky Scherzinger! Nicole shows off stunning figure in racy cut out dress on X Factor before changing into JUST a pink jacket for dinnerÂ  Chrissy Teigen and daughter Luna host baby shower for celebrity stylist Monica Rose... and Khloe Kardashian and Kris Jenner are on hand too Braided beauty! Cara Delevingne cuts a fashionable flyer in a chic bomber jacket as she touches down at LAX Eyes front, Philip! A playboy prince eyeing up the ladies? Don't worry, Ma'am - it's only a VERY impertinent scene from hit TV show The CrownÂ  What will Ma'am think? Hugh Jackman spotted cosying up with Madonna at UFC title fight in New YorkÂ  Watched Conor McGregor and Eddie Alvarez battle it out Vin Diesel and Nina Dobrev fuel the hype for xXx: Return of Xander Cage at Los Angeles fan event Diesel, 49, looked every part the action heroÂ  Will Smith is in high spirits as he has a laugh on set for upcoming fantasy film Bright Will Smith spent his Saturday hard at work on his forthcoming fantasy thriller Bright Liquid gold! Lily Collins oozes class in backless satin gown at the Academy's Governors Awards in Hollywood Perhaps Lily Collins had her sights set on a gold statue Blue bombshell! Bryce Dallas Howard stuns at star-studded Weinstein Company party featuring Matthew McConaughey A real showstopper All-natural beauty! Jenna Dewan is pretty in pink with husband Channing Tatum at Baby2Baby Gala in Los AngelesÂ  Had her black locks parted in the middle Kate Hudson shines in gold number as she poses with Matthew McConaughey and wife Camila at Baby2Baby Gala Sheerly amazing! Jessica Alba stuns in partially transparent black gown for star-studded Baby2Baby Gala in Los Angeles Charity that supports babies in need In the navy! Jennifer Garner is beautiful in blue as she stuns on red carpet of Baby2Baby Gala in LA The 44-year-old actress looked beautiful in blue Bella Thorne is epitome of casual chic in Daisy Dukes and snakeskin boots before slipping into crop top and ripped jeans Two different outfits 'Bonding with mommy!' Blac Chyna breastfeeds daughter Dream in newborn baby's first tweet Created an Instagram account in baby's name Blac Chyna's mother Tokyo Toni shows charitable side as she promotes food drive after second grandchild is born Tokyo Toni is feeling charitableÂ  Pretty in pattern! Emma Stone and Michelle Williams wow in sparkling gowns for the eighth annual Governors Awards in Hollywood The actresses arrived dressed to the nines Demi Lovato holds hands with rumoured MMA fighter beau Luke Rockhold as they arrive to UFC 205 in New York It's been the worst kept celebrity couple secret for a while now Head Start to Home Cooked Get Recipes more SHARE PICTURE Copy link to paste in your message Find out more... Find out more... Back to top Home U.K. News Sports U.S. Showbiz Australia Femail Health Science Money Video Travel Columnists Sitemap Archive Video Archive Topics Index Mobile Apps Screensaver RSS Text-based site Reader Prints Our Papers Top of page Daily Mail Mail on Sunday This is Network This is Money Metro Jobsite Mail Travel Zoopla.co.uk Prime Location Published by Associated Newspapers Ltd Part of the Daily Mail, The Mail on Sunday & Metro Media Group Â© Associated Newspapers Ltd Contact us How to complain Advertise with us Syndication Work with Us Terms Privacy policy & cookies Â  Â  Â 
Dienstag, 15.11.2016 BÃ¶rsentÃ¤glich Ã¼ber 12.000 News von 551 internationalen Medien Indizes Kurs % News 24Â hÂ /Â 7Â T Aufrufe 7 Tage Aktien Kurs % News 24Â hÂ /Â 7Â T Aufrufe 7 Tage Xetra-Orderbuch Devisen Kurs % Rohstoffe Kurs % Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige) Erweiterte Suche Ad hoc-Mitteilungen Startseite Nachrichten Aktienkurse Fonds Anleihen Derivate Rohstoffe Devisen Watchlist Aufklappen Schliessen NachrichtenÂ»Biotech Stocks Facing FDA Decision In November 27.10.2016 | 18:13 (5 Leser) Schrift Ã¤ndern: (0 Bewertungen) AFX NewsÂ·Mehr Nachrichten von AFX News Biotech Stocks Facing FDA Decision In November THOUSAND OAKS (dpa-AFX) - It looks like 2016 is going to be a relatively lackluster year in terms of new drug approvals. Only 19 new molecular entity drugs have been approved year-to-date compared to 32 approved during the same time frame last year. For the uninitiated, a new molecular entity, or NME in short, is an active ingredient that has never before been marketed in the United States in any form. Stock market showing of biotech stocks in October isn't inspiring. The NYSE Arca Biotechnology Index has slid 10.81 percent thus far this year compared to a more modest 1.16 percent drop by the broader S&P 500 Index and a 0.5 percent slippage by the Nasdaq Composite Index. In October, only 2 new molecular entity drugs were greenlighted by the FDA. The two lucky novel drugs are Eli Lilly & Co.'s (LLY) Lartruvo and Merck's (MRK) Zinplava. Lartruvo is approved for use with chemotherapy drug doxorubicin in adults with certain types of soft tissue sarcoma while Zinplava is approved to reduce recurrence of Clostridium difficile infection. However, Nicox and Egalet Corp. (EGLT), which faced the FDA in October, were not so lucky. The regulator turned down Nicox's application seeking approval of AC-170 for the treatment of ocular itching associated with allergic conjunctivitis while it sought more time to review Egalet's abuse-deterrent opioid medicine Arymo ER, extending the deadline of October 14, 2016. As we head into November, it's time to take a look at the upcoming FDA decisions of the month. Copyright RTT News/dpa-AFX Â©Â 2016Â AFX News Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von Â und Â mit der Push-Technologie vonÂ Â  Wie bewerten Sie die aktuell angezeigte Seite?sehr gut123456schlechtProblem melden Google+ Seite NachrichtenÂ â€¢Â AktienkurseÂ â€¢Â DAXÂ â€¢Â Xetra-OrderbuchÂ â€¢Â Watchlist Ad hoc-MitteilungenÂ â€¢Â Nachrichten BÃ¶rsenÂ â€¢Â Aktien-Empfehlungen BranchenÂ â€¢Â MedienÂ â€¢Â Nachrichten-Archiv Impressum | AGB | DisclaimerÂ â€¢Â PresseÂ â€¢Â Mediadaten RSS-News von FinanzNachrichten.de kostenlos fÃ¼r Ihren Browser und Ihre Homepage
â–® Home â–® Business Latest Headlines Top Stories Breaking News Earnings Biotech Investors IPOs M&A Canadian UK Key Wallstreet Events â–® Industry News Technology Software Banking Automotive Energy More â–® Stock Alerts Active Traders Before the Bell $5 and under Intraday Updates After the Bell â–® Corp. Calendars Dividends Stock Splits Buybacks Conference Calls â–® Earnings Calendars Earnings Calendar Pos Pre-announcements Profit Warnings Positive Surprise Negative Surprise Latest Earnings â–® FDA Calendars Drug Approvals Device Approvals Clinical Trial Calendar â–® Ratings Changes Upgrades Downgrades Cov Initiations Cov. Reiterated â–® Economy US Europe Asia Global Economic Calendar Economic Scorecard Fed Members â–® Markets Morning Mkt Analysis US Commentary European Commentary Asian Commentary Canadian Commentary Indian Commentary Commodities Bonds Currencies â–® Politics US World White House Elections Congress General News â–® Forex FX Top Stories Currency Analysis Currency Alerts Economic Calendar Economic Scorecard â–® Health Hot Topics Diet & Fitness Kids Health Men's Health Women's Health Cancer News Drug Development Mental Health â–® Tech Hot Topics Gadgets & Games Mobile Green Tech â–® Entertainment Top Stories TV News Movie News Slide Shows Game of Thrones â–® Music news Pop Rock Classic Rock Rap/Hip-Hop Country Alternative Oldies All Genre â–® Content Licensing Newswires & Feeds Content Syndication Digital Signage Services Radio News Services â–® Premium Emerging Biostocks Under The Radar Short-Term Investor NewsStream Login â–® More Free Content RSS Feeds Search â–® Blog Political Science / Nature Fundamental Analysis â–® Columns Science & Tech Arts & Leisure Politics & Policy Money Home Business Latest Headlines Top Stories Breaking News Earnings Biotech Investors IPOs M&A Canadian UK Key Wallstreet Events Industry News Technology Software Banking Automotive Energy More Stock Alerts Active Traders Before the Bell $5 and under Intraday Updates After the Bell Corp. Calendars Dividends Stock Splits Buybacks Conference Calls Earnings Calendars Earnings Calendar Pos Pre-announcements Profit Warnings Positive Surprise Negative Surprise Latest Earnings FDA Calendars Drug Approvals Device Approvals Clinical Trial Calendar Ratings Changes Upgrades Downgrades Cov Initiations Cov. Reiterated Economy US Europe Asia Global Economic Calendar Economic Scorecard Fed Members Markets Morning Mkt Analysis US Commentary European Commentary Asian Commentary Canadian Commentary Indian Commentary Commodities Bonds Currencies Politics US World White House Elections Congress General News Forex FX Top Stories Currency Analysis Currency Alerts Economic Calendar Economic Scorecard Health Hot Topics Diet & Fitness Kids Health Men's Health Women's Health Cancer News Drug Development Mental Health Tech Hot Topics Gadgets & Games Mobile Green Tech Entertainment Top Stories TV News Movie News Slide Shows Game of Thrones Music news Pop Rock Classic Rock Rap/Hip-Hop Country Alternative Oldies All Genre Content Licensing Newswires & Feeds Content Syndication Digital Signage Services Radio News Services Premium Emerging Biostocks Under The Radar Short-Term Investor NewsStream Login More Free Content RSS Feeds Search Blog Political Science / Nature Fundamental Analysis Columns Science & Tech Arts & Leisure Politics & Policy Money Corporate News Â  E-MAIL Â SHARE FONT-SIZEÂ Â Â  Tweet Share Biotech Stocks Facing FDA Decision In November 10/27/2016 11:56 AM ET It looks like 2016 is going to be a relatively lackluster year in terms of new drug approvals. Only 19 new molecular entity drugs have been approved year-to-date compared to 32 approved during the same time frame last year. For the uninitiated, a new molecular entity, or NME in short, is an active ingredient that has never before been marketed in the United States in any form. Stock market showing of biotech stocks in October isn't inspiring. The NYSE Arca Biotechnology Index has slid 10.81 percent thus far this year compared to a more modest 1.16 percent drop by the broader S&P 500 Index and a 0.5 percent slippage by the Nasdaq Composite Index. The underperformance may have something to do with the widely expected U.S. Presidential results. Hillary Clinton at the White House may mean a clampdown on biotech companies, which unscrupulously price their products for life threatening drugs. Two power-packed tweets regarding pricing of drugs sent out by the Democratic Party's Presidential candidate served to wreak havoc for two pertinent companies, namely Mylan (MYL) and Turing Pharmaceuticals LLC. Even as macroeconomic headwinds remain, this time and capital-intensive industry is gambling big time over novel products and technologies, giving them the status of risky bets. In October, only 2 new molecular entity drugs were greenlighted by the FDA. The two lucky novel drugs are Eli Lilly & Co.'s (LLY) Lartruvo and Merck's (MRK) Zinplava. Lartruvo is approved for use with chemotherapy drug doxorubicin in adults with certain types of soft tissue sarcoma while Zinplava is approved to reduce recurrence of Clostridium difficile infection. However, Nicox and Egalet Corp. (EGLT), which faced the FDA in October, were not so lucky. The regulator turned down Nicox's application seeking approval of AC-170 for the treatment of ocular itching associated with allergic conjunctivitis while it sought more time to review Egalet's abuse-deterrent opioid medicine Arymo ER, extending the deadline of October 14, 2016. As we head into November, it's time to take a look at the upcoming FDA decisions of the month. by RTT Staff Writer For comments and feedback: editorial@rttnews.com Business News The Most Influential Books In Business Fed Chatterbox: Economic Preview Week of November 14 Forget Canada: The Best Places To Flee Trump's America Corporate News Naughty Dating Site Adult Friendfinder Users Exposed By Hack Upgrade: Steel Stocks In For Trump Renaissance Amaya Gets Huge Buyout Bid From Former CEO Zuckerberg: Facebook Hoax News Did Not Get Trump Elected Kenneth Cole Closing Brick-and-Mortars EARNINGS SUMMARY: Details of InterOil Corp Q3 Earnings Report EARNINGS SUMMARY: Details of NII HOLDINGS INC Q3 Earnings Report Samsung To Buy Harman Intl' In About $8 Bln All-cash Deal Siemens To Buy Mentor Graphics For $4.5 Bln Enterprise Value Schnuck Markets Recalls Ready-to-eat Grilled Chicken Products AMGN Crosses BRIDGE, Anxiety Over PTCT's Translarna Eases, EGRX Opens Wallet Airlines Struggle With Computer Glitch Singles Day: Alibaba Sales Skyrocket Nasty Gal Files For Bankruptcy Allianz Stock Climbs On Q3 Profit Growth, Confirms FY16 Profit View <<Previous Â Â Â Â Â Â Â 70 Articles Please enable JavaScript to view the comments powered by Disqus. comments powered by Disqus RELATED NEWS AMGN Gets FDA Nod, Uncertainty Ends For CEMP, Clock Is Ticking For ANTH FDA Advisory Committee Narrowly Backs Cempra' Solithromycin For CAPD CEMP Loses Big As D-Day Nears, AVXS Catches Investors' Eyes, No Respite For OPXA CEMP Plunges, ALDR Promises Data In 1H 2017, AERI Withdraws NDA, AZN, CYH Abuzz Trade CEMP now withÂ  Follow RTT Editor's Pick Most Read Most Emailed Amaya Gets Huge Buyout Bid From Former CEO Zuckerberg: Facebook Hoax News Did Not Get Trump Elected Kenneth Cole Closing Brick-and-Mortars Samsung To Buy Harman Intl' In About $8 Bln All-cash Deal Siemens To Buy Mentor Graphics For $4.5 Bln Enterprise Value Nasty Gal Files For Bankruptcy Allianz Stock Climbs On Q3 Profit Growth, Confirms FY16 Profit View Walt Disney Q4 Profit Down - Update Forget Canada: The Best Places To Escape Trump's America Continental Stock Dips On Weak Q3 Profit; Sees Strong Earnings In Q4 AstraZeneca Q3 Pre-tax Profit Down On Crestor Generic; Backs FY View Alphabet Cancels Drone Deal With Starbucks As Project Leaders Pushed Out ADAP Surges As FDA Lifts Clinical Hold, OCUL Catches Eyes, RegeneRx On The Rise ARWR's Hepatitis B Drug On Clinical Hold, GMED Disappoints, A First For MYL AdvancePierre Foods Appoints Christopher Sliva As President ANTH Plunges As Lupus Trial Fails, BMY's Opdivo Is At It Again, FDA Nod For GILD Engie 9-month EBITDA Declines - Quick Facts AMGN Crosses BRIDGE, Anxiety Over PTCT's Translarna Eases, EGRX Opens Wallet Pfizer : IBRANCE Approved In Europe To Treat HR+/HER2- Metastatic Breast Cancer Forget Canada: The Best Places To Escape Trump's America Alphabet Cancels Drone Deal With Starbucks As Project Leaders Pushed Out Google Rejects EU Antitrust Charges Allianz Stock Climbs On Q3 Profit Growth, Confirms FY16 Profit View Walt Disney Q4 Profit Down - Update Facebook Taking Aim At LinkedIn Samsung To Buy Harman Intl' In About $8 Bln All-cash Deal Rio Tinto Suspends Unit CEO Alan Davies Amid Guinea Payments Investigation Alstom Turns To Profit In H1; Sales, Orders Up; Backs 2020 View - Quick Facts Kuka Group Q3 Profit Surges; Lowers FY16 Sales Outlook - Quick Facts HeidelbergCement Q3 Profit Down;says Confident To Exceed â‚¬400 Mln Synergy Target Osram Licht Q4 Profit Declines; Sees Growth In 2017 - Quick Facts Heidelberg Reports Positive Net Result In Q2; Affirms Fiscal Year Targets Carlsberg Q3 Revenues Decline; But Lifts FY16 Profit Outlook - Quick Facts E.ON 9-month Loss Narrows; Confirms 2016 Profit Outlook Munich Re Lifts FY View, Q3 Profit Rises - Quick Facts Swiss Life 9-month Fee Income Rises; Premiums Down; On Track For FY16 Targets Copyright Â© 2016 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service. About Us Â  | Â  Privacy Â  | Â  Feedback Â  | Â  Sitemap
Contact Us Journalists Blog Log In Sign Up Send a Release News Solutions Resources Search News in Focus Browse News Releases All News Releases News Releases Overview English-only All Public Company Multimedia Gallery All Multimedia Multimedia Gallery Overview All Photos All Videos Trending Topics All Trending Topics Business & Money Auto & Transportation All Auto & Transportation Auto & Transportation Overview Aerospace, Defense Air Freight Airlines & Aviation Automotive Maritime & Shipbuilding Railroads and Intermodal Transportation Transportation, Trucking & Railroad Travel Trucking and Road Transportation Business Technology All Business Technology Business Technology Overview Broadcast Tech Computer Hardware Computer Software Computer & Electronics Electronic Commerce Electronic Components Electronic Design Automation Electronics Performance Measurement High Tech Security Internet Technology Nanotechnology Networks Peripherals RFID (Radio Frequency ID) Semantic Web Semiconductors EntertainÂ­ment & Media All EntertainÂ­ment & Media EntertainÂ­ment & Media Overview Advertising Art Books Entertainment Film and Motion Picture Magazines Music Publishing & Information Services Radio Television Financial Services & Investing All Financial Services & Investing Financial Services & Investing Overview Accounting News & Issues Acquisitions, Mergers and Takeovers Banking & Financial Services Bankruptcy Bond & Stock Ratings Conference Call Announcements Contracts Dividends Earnings Forecasts & Projections Earnings Financing Agreements Insurance Investments Opinions Joint Ventures Mutual Funds OTC, SmallCap Real Estate Restructuring & Recapitalization Sales Reports Shareholders' Rights Plan Stock Offering Stock Split Venture Capital General Business All General Business General Business Overview Agency Roster Awards Commercial Real Estate Corporate Expansion Earnings Human Resource & Workforce Management Licensing New Products & Services Obituaries Outsourcing Businesses Overseas Real Estate (non-US) Personnel Announcements Real Estate Transactions Residential Real Estate Small Business Services Socially Responsible Investing Surveys, Polls and Research Trade Show News Science & Tech Consumer Technology All Consumer Technology Consumer Technology Overview Computer Electronics Computer Hardware Computer Software Consumer Electronics Electronic Commerce Electronic Gaming Mobile Entertainment Multimedia & Internet Peripherals Social Media Web Site Wireless Communications Energy All Energy Energy Overview Alternative Energies Chemical Electrical Utilities Gas Mining Mining & Metals Oil & Energy Oil and Gas Discoveries Utilities Water Utilities EnvironÂ­ment All EnvironÂ­ment EnvironÂ­ment Overview Conservation & Recycling Environmental Issues Environmental Policy Environmental Products & Services Green Technology Heavy Industry & Manufacturing All Heavy Industry & Manufacturing Heavy Industry & Manufacturing Overview Aerospace & Defense Agriculture Chemical Construction & Building HVAC (Heating, Ventilation and Air-Conditioning) Machine Tools, Metalworking and Metallurgy Machinery Mining Mining & Metals Paper, Forest Products & Containers Precious Metals Textiles Tobacco TelecommÂ­unications All TelecommÂ­unications TelecommÂ­unications Overview Carriers and Services Mobile Entertainment Networks Peripherals TelecommunicÂ­ations Equipment TelecommunicaÂ­tions Industry VoIP (Voice over Internet Protocol) Wireless Communications Lifestyle & Health Consumer Products & Retail All Consumer Products & Retail Consumer Products & Retail Overview Animals & Pets Beers, Wines and Spirits Beverages Bridal Services Cosmetics and Personal Care Fashion Food & Beverages Furniture and Furnishings Home Improvement Household Products Household, Consumer & Cosmetics Jewelry Non-Alcoholic Beverages Office Products Organic Food Product Recalls Restaurants Retail Supermarkets Toys EntertainÂ­ment & Media All EntertainÂ­ment & Media EntertainÂ­ment & Media Overview Advertising Art Books Entertainment Film and Motion Picture Magazines Music Publishing & Information Services Radio Television Health All Health Health Overview Biometrics Biotechnology Dentistry Clinical Trials & Medical Discoveries FDA Approval Health Care & Hospitals Health Insurance Infection Control Medical Equipment Medical Pharmaceuticals Mental Health Pharmaceuticals Supplementary Medicine Sports All Sports Sports Overview General Sports Sporting Events Sports Equipment & Accessories Travel All Travel Travel Overview Amusement Parks and Tourist Attractions Gambling & Casinos Hotels and Resorts Leisure & Tourism Passenger Aviation Travel Industry Policy & Public Interest Policy & Public Interest All Policy & Public Interest Policy & Public Interest Overview Advocacy Group Opinion Animal Welfare Corporate Social Responsibility Domestic Policy Economic News, Trends, Analysis Education Environmental European Government FDA Approval Federal and State Legislation Federal Executive Branch & Agency Foreign Policy & International Affairs Homeland Security Labor & Union Legal Issues Not For Profit Patent Law Public Safety Trade Policy U.S. State Policy People & Culture People & Culture All People & Culture People & Culture Overview Aboriginal, First Nations & Native American African American Asian American Children Disabilities, Disabled People Hispanic Lesbian, Gay & Bisexual Religion Senior Citizens Veterans Women Other Language News dansk Deutsch espaÃ±ol FranÃ§ais italiano Nederlands norsk portuguÃªs suomeksi svenska Asthma & COPD Market Report 2016-2026 News provided by Visiongain Ltd Oct 27, 2016, 09:00 ET Share this article LONDON, October 27, 2016 /PRNewswire/ -- Forecasts for Bronchodilator Monotherapy (Including Anticholinergics, SABAs and LABAs), Anti-Inflammatory Drugs (Including Corticosteroids, Anti-Leukotrienes and Monoclonal Antibodies) and Combination Drugs Visiongain's comprehensive new 313 page report reveals that the global asthma & COPD market will achieve revenues of $33.2bn in 2016. Are you involved in the asthma & COPD market or intend to be? If so, then you must read this report. It's vital that you keep your knowledge up to date. You need this report. Market scope: Asthma & COPD are among the most common and debilitating respiratory conditions. Drugs for the treatment of these conditions fall into 3 main categories: Bronchodilator monotherapy, anti-inflammatory drugs and combination drugs. Visiongain assesses how these three submarkets and the 12 largest national markets will evolve over the forecast period.The competitive landscape is further illustrated with examination of the 7 market leading manufacturers. The asthma & COPD Market 2016-2026 report responds to your need for definitive market data:Â  â€¢ Where are the asthma & COPD market opportunities? - 248 tables, charts, and graphs reveal market data allowing you to target your strategy more effectively â€¢ When will the asthma & COPD market grow? - Global, regional and asthma & COPD submarket forecasts and analysis from 2016-2026 illustrate the market progression â€¢ Which asthma & COPD submarkets will flourish from 2016-2026? - Individual application forecasts and analysis demonstrate the prospects â€¢ Combination drugs forecast 2016-2026 â€¢ Anti-inflammatory drugs forecast 2016-2026 - Corticosteroids forecast 2016-2026 - Anti-Leukotrienes forecast 2016-2026 - Monoclonal antibodies forecast 2016-2026 - Other anti-inflammatories forecast 2016-2026 â€¢ Bronchodilator monotherapy forecast 2016-2026 - Short-acting beta2-agonist (SABAs) forecast 2016-2026 - Long-acting beta2-agonist (LABAs) forecast 2016-2026 - Anticholinergics forecast 2016-2026 To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com â€¢ Where are the regional asthma & COPD market opportunities from 2016-2026? - Focused regional forecasts and analysis explore the future opportunities - US forecast 2016-2026, - China forecast 2016-2026 - Japan forecast 2016-2026 - India forecast 2016-2026 - Germany forecast 2016-2026 - UK forecast 2016-2026 - France forecast 2016-2026 - Mexico forecast 2016-2026 - Brazil forecast 2016-2026 - Russia forecast 2016-2026 â€¢ What are the factors influencing asthma & COPD market dynamics? - SWOT / Porter's Five Forces analysis explores the factors. - Research and development (R&D) strategy - Technological issues and constraints. - Supply and demand dynamics - Competition from new product types - Increasing specialisation by leading players - Advances in product quality â€¢ Who are the leading asthma & COPD companies? - Examine competitive positioning, product portfolios, R&D activity, M&A activity, and future outlook. - GSK - Boehringer Ingelheim - AstraZeneca - Merck & Co. Inc (Merck) - Novartis - Roche - Teva â€¢ Who should read this report? - Anyone within the asthma & COPD value chain, including - CEO's - COO's - CIO's - Business development managers - Marketing managers - Suppliers - Technologists - Investors - Banks - Government agencies - Contractors Get our report todayÂ Asthma & COPD Market Report 2016-2026: Forecasts for Bronchodilator Monotherapy (Including Anticholinergics, SABAs and LABAs), Anti-Inflammatory Drugs (Including Corticosteroids, Anti-Leukotrienes and Monoclonal Antibodies) and Combination Drugs. Avoid missing out - order our report now. To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com To request a report overview of this report please emails Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44 (0) 20 7336 6100 Or click on https://www.visiongain.com/Report/1746/Asthma-COPD-Market-Report-2016-2026 Companies Mentioned in the ReportÂ  3M Drug Delivery Systems AB Science Actavis Alcon Alembic Allen and Hanburys Allergan Almirall Apotex Ario Pharma Array BioPharma Aspen Pharmacare Astellas Pharma AstraZeneca Aurobindo Pharma Bellephron Ben Vue Laboratories BioWa BioXpress Therapeutics Boehringer Ingelheim Breath Limited Bristol-Meyer Squibbs Catalent Pharma Solutions Cephalon Ception Therapeutics Chiesi Pharmaceuticals Ciba-Geigy Cipla Circassia Pharmaceuticals CVS Caremark Daewoong Pharmaceutical Dainippon Sumimoto Dr. Reddy's Laboratories Express Scripts Forest Pharmaceuticals Fountain Biopharma Genentech (Roche) Grifols GSK Hikma Pharmaceuticals Ikaria Invion Kamada Kyorin Pharmaceuticals Kyowa Hakko Kirin Lilly Mariposa MedicNova Medimmune Menarini Merck & Co. Mylan Novartis Nycomed Omega Pharma Orion Pharmaceuticals Pearl Therapeutics Perrigo Pfizer Prosonix Reckitt Becnkiser Regeneron Roche Roxane Laboratories Sandoz (Novaris) Sanofi Schering-Plough's SkyePharma Sofotec Stempeutics Sunovion Pharmaceuticals Synairgen Takeda Pharmaceuticals Tanox Teva Theravance Vectura Viatris Watson (Actavis) To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com SOURCE Visiongain Ltd Oct 28, 2016, 09:00 ET Preview: EOR Yearbook 2016: The Ultimate Guide To Enhanced Oil Recovery (EOR) Oct 24, 2016, 09:00 ET Preview: Hydrogenated Hydrocarbon Resin Market Report 2016-2026 My News Release contains wide tables. View fullscreen. Also from this source Nov 03, 2016, 11:02 ETGlobal Cystic Fibrosis Therapeutics Market 2016-2026 Nov 02, 2016, 10:47 ETNon-Destructive Testing (Ndt) Market 2016-2026 Explore More news releases in similar topics Health Care & Hospitals Medical Pharmaceuticals Pharmaceuticals Surveys, Polls and Research You just read: Asthma & COPD Market Report 2016-2026 News provided by Visiongain Ltd Oct 27, 2016, 09:00 ET Share this article Looking to send a news release with PR Newswire? Take advantage of the world's leading distribution platform. Sign up to get started Request more information Have an account? Log In Phone 8AM - 10PM ET +1-888-776-0942 Send a Release Sign Up Blog For Journalists Contact Us Search Searching for your content... Advanced Search Contact 888-776-0942 from 8 AM - 10 PM ET Chat Online with an Expert Contact Us Solutions Cision Communication Cloudâ„¢ For Marketers For Public Relations For IR & Compliance For Agency For Small Business All Products About About PR Newswire About Cision Become a Publishing Partner Become a Channel Partner Careers Â  Global Sites Asia Brazil Canada Europe Finland France India Israel Mexico Middle East Netherlands Sweden United Kingdom My Services All News Releases Online Member Center ProfNetâ„  My Services All News Releases Online Member Center ProfNetâ„  888-776-0942 from 8 AM - 10 PM ET Terms of Use Privacy Policy Information Security Policy Statement Site Map RSS Feeds Copyright Â© 2016 PR Newswire Association LLC. All Rights Reserved. A Cision company. News Solutions Resources News in Focus Browse News Releases All News Releases News Releases Overview English-only All Public Company Multimedia Gallery All Multimedia Multimedia Gallery Overview All Photos All Videos Trending Topics All Trending Topics Business & Money Auto & Transportation All Auto & Transportation Auto & Transportation Overview Aerospace, Defense Air Freight Airlines & Aviation Automotive Maritime & Shipbuilding Railroads and Intermodal Transportation Transportation, Trucking & Railroad Travel Trucking and Road Transportation Business Technology All Business Technology Business Technology Overview Broadcast Tech Computer Hardware Computer Software Computer & Electronics Electronic Commerce Electronic Components Electronic Design Automation Electronics Performance Measurement High Tech Security Internet Technology Nanotechnology Networks Peripherals RFID (Radio Frequency ID) Semantic Web Semiconductors EntertainÂ­ment & Media All EntertainÂ­ment & Media EntertainÂ­ment & Media Overview Advertising Art Books Entertainment Film and Motion Picture Magazines Music Publishing & Information Services Radio Television Financial Services & Investing All Financial Services & Investing Financial Services & Investing Overview Accounting News & Issues Acquisitions, Mergers and Takeovers Banking & Financial Services Bankruptcy Bond & Stock Ratings Conference Call Announcements Contracts Dividends Earnings Forecasts & Projections Earnings Financing Agreements Insurance Investments Opinions Joint Ventures Mutual Funds OTC, SmallCap Real Estate Restructuring & Recapitalization Sales Reports Shareholders' Rights Plan Stock Offering Stock Split Venture Capital General Business All General Business General Business Overview Agency Roster Awards Commercial Real Estate Corporate Expansion Earnings Human Resource & Workforce Management Licensing New Products & Services Obituaries Outsourcing Businesses Overseas Real Estate (non-US) Personnel Announcements Real Estate Transactions Residential Real Estate Small Business Services Socially Responsible Investing Surveys, Polls and Research Trade Show News Science & Tech Consumer Technology All Consumer Technology Consumer Technology Overview Computer Electronics Computer Hardware Computer Software Consumer Electronics Electronic Commerce Electronic Gaming Mobile Entertainment Multimedia & Internet Peripherals Social Media Web Site Wireless Communications Energy All Energy Energy Overview Alternative Energies Chemical Electrical Utilities Gas Mining Mining & Metals Oil & Energy Oil and Gas Discoveries Utilities Water Utilities EnvironÂ­ment All EnvironÂ­ment EnvironÂ­ment Overview Conservation & Recycling Environmental Issues Environmental Policy Environmental Products & Services Green Technology Heavy Industry & Manufacturing All Heavy Industry & Manufacturing Heavy Industry & Manufacturing Overview Aerospace & Defense Agriculture Chemical Construction & Building HVAC (Heating, Ventilation and Air-Conditioning) Machine Tools, Metalworking and Metallurgy Machinery Mining Mining & Metals Paper, Forest Products & Containers Precious Metals Textiles Tobacco TelecommÂ­unications All TelecommÂ­unications TelecommÂ­unications Overview Carriers and Services Mobile Entertainment Networks Peripherals TelecommunicÂ­ations Equipment TelecommunicaÂ­tions Industry VoIP (Voice over Internet Protocol) Wireless Communications Lifestyle & Health Consumer Products & Retail All Consumer Products & Retail Consumer Products & Retail Overview Animals & Pets Beers, Wines and Spirits Beverages Bridal Services Cosmetics and Personal Care Fashion Food & Beverages Furniture and Furnishings Home Improvement Household Products Household, Consumer & Cosmetics Jewelry Non-Alcoholic Beverages Office Products Organic Food Product Recalls Restaurants Retail Supermarkets Toys EntertainÂ­ment & Media All EntertainÂ­ment & Media EntertainÂ­ment & Media Overview Advertising Art Books Entertainment Film and Motion Picture Magazines Music Publishing & Information Services Radio Television Health All Health Health Overview Biometrics Biotechnology Dentistry Clinical Trials & Medical Discoveries FDA Approval Health Care & Hospitals Health Insurance Infection Control Medical Equipment Medical Pharmaceuticals Mental Health Pharmaceuticals Supplementary Medicine Sports All Sports Sports Overview General Sports Sporting Events Sports Equipment & Accessories Travel All Travel Travel Overview Amusement Parks and Tourist Attractions Gambling & Casinos Hotels and Resorts Leisure & Tourism Passenger Aviation Travel Industry Policy & Public Interest Policy & Public Interest All Policy & Public Interest Policy & Public Interest Overview Advocacy Group Opinion Animal Welfare Corporate Social Responsibility Domestic Policy Economic News, Trends, Analysis Education Environmental European Government FDA Approval Federal and State Legislation Federal Executive Branch & Agency Foreign Policy & International Affairs Homeland Security Labor & Union Legal Issues Not For Profit Patent Law Public Safety Trade Policy U.S. State Policy People & Culture People & Culture All People & Culture People & Culture Overview Aboriginal, First Nations & Native American African American Asian American Children Disabilities, Disabled People Hispanic Lesbian, Gay & Bisexual Religion Senior Citizens Veterans Women Other Language News dansk Deutsch espaÃ±ol FranÃ§ais italiano Nederlands norsk portuguÃªs suomeksi svenska Phone +1-888-776-0942 8AM - 10PM ET Chat Chat Online with an Expert All contact info Send a ReleaseLog In
X Edition: United States Business Business Home Legal Deals Aerospace & Defense Finance Autos Reuters Summits ADventures Data Dive Markets Markets Home U.S. Markets European Markets Asian Markets Global Market Data Indices Stocks Bonds Currencies Comm & Energy Futures Funds Earnings Dividends World World Home U.S. Special Reports Reuters Investigates Euro Zone Middle East China Japan Mexico Brazil Africa Russia India Politics Politics Home Election 2016 Polling Explorer Just In: Election 2016 What Voters Want Supreme Court Tech Technology Home Science Top 100 Global Innovators Environment Innovation Commentary Commentary Home Podcasts Breakingviews Breakingviews Home Breakingviews Video Money Money Home Retirement Lipper Awards Analyst Research Stock Screener Fund Screener Life Health Sports Arts Entertainment Oddly Enough Pictures Pictures Home The Wider Image Photographers Focus 360 Video Bristol hikes 2016 profit forecast as top drugs deliver, shares jump Africa AmÃ©rica Latina Ø¹Ø±Ø¨ÙŠ Argentina Brasil Canada ä¸­å›½ Deutschland EspaÃ±a France India Italia æ—¥æœ¬ MÃ©xico Ğ ĞĞ¡Ğ¡Ğ˜Ğ¯ United Kingdom United States Thu Oct 27, 2016 | 9:18am EDT Bristol hikes 2016 profit forecast as top drugs deliver, shares jump A trader passes by a screen displaying the tickers symbols for Bristol-Myers Squibb and Intelsat, Ltd. on the floor at the New York Stock Exchange, April 25, 2013. REUTERS/Brendan McDermid By Ransdell Pierson Bristol-Myers Squibb Co (BMY.N), whose high-profile Opdivo immunotherapy failed an important lung-cancer trial last summer, sharply raised its 2016 profit forecast after strong quarterly sales of other leading medicines. The U.S. drugmaker on Thursday predicted 2016 earnings of $2.80 to $2.90 a share, up from its previous forecast range of $2.55 to $2.65. Bristol-Myers, whose shares rose 5 percent in premarket trading, said it expects 2017 earnings of $2.85 to $3.05 per share. Sales of Opdivo, which treats melanoma and lung cancer, tripled to $920 million in the third quarter, but trailed forecasts by $27 million. Opdivo had been considered the leader among a new class of cancer drugs called PD-1 inhibitors until August, when researchers said it failed to slow progression of symptoms in previously untreated patients with advanced lung cancer. Making matters worse for Opdivo, researchers earlier this month said Merck's rival Keytruda prolonged the life of similar patients, and on Monday, it became the first of new immunotherapy drugs approved in the United States for initial lung cancer treatment. The company said it authorized a new $3 billion share repurchase program, in addition to the $1.1 billion remaining under an authorization in 2012. And it predicted flat operating expenses through 2020, which analysts said should help profit margins. "We believe today's updates should begin to address Wall Street concerns on Bristol's near-term earnings outlook" in the wake of Opdivo's setbacks, JP Morgan analyst Chris Schott said in a research note. Sales of Yervoy, an older melanoma treatment, jumped 19 percent to $285 million, $45 million above expectations, while sales of leukemia treatment Sprycel grew 15 percent to $472 million, $25 million above forecasts. Eliquis, used to prevent blood clots and partnered with Pfizer Inc (PFE.N), jumped 90 percent to $884 million, $71 million above expectations, helped by compelling clinical trial data. It was not immediately clear how much of an impact price increases had on sales of Bristol-Myers drugs. Bristol-Myers earned $1.2 billion, or 72 cents per share in the quarter, compared with $706 million, or 42 cents per share, a year ago. Revenue jumped 21 percent to $4.9 billion, about $200 million above forecasts. Excluding special items, it earned 77 cents per share, well above expectations of 65 cents per share, according to Thomson Reuters I/B/E/S. Despite Bristol-Myers' rally on Thursday, its shares have fallen 31 percent since the unfavorable Opdivo lung cancer data was reported on Aug. 5. (Reporting by Ransdell Pierson; Editing by Bernadette Baum) Up Next BM&FBovespa third-quarter net profit drops 85 percent SAO PAULO BM&FBovespa SA , Brazil's sole listed bourse operator, missed third-quarter profit estimates by a wide margin, with earnings falling 85 percent from a year earlier, the company reported on Friday in a securities filing. Disney promises earnings growth next two years, shares rise Walt Disney Co executives promised earnings growth for the next two years, easing investor concerns over a quarterly drop in ad sales and subscribers at its ESPN sports network, sending the media company's shares up in after-hours trading. Toshiba returns to second quarter operating profit on strong memory chip sales TOKYO Japanese conglomerate Toshiba Corp swung to an operating profit in the July-September quarter, driven by strong demand for NAND flash memory chips from Chinese smartphone makers. MORE FROM REUTERS Sponsored Content From Around the Web Promoted by Taboola Trending Stories FOCUS 360 Video: Growing up as a refugee Sponsored Topics X Follow Reuters: Follow Us On Twitter Follow Us On Facebook Follow Us On RSS Follow Us On Instagram Follow Us On YouTube Follow Us On LinkedIn Subscribe: Feeds | Newsletters | Podcasts | Apps Reuters News Agency | Brand Attribution Guidelines Reuters is the news and media division of Thomson Reuters. Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Learn more about Thomson Reuters products: Eikon Information, analytics and exclusive news on financial markets - delivered in an intuitive desktop and mobile interface Elektron Everything you need to empower your workflow and enhance your enterprise data management World-Check Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks Westlaw Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology ONESOURCE The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs CHECKPOINT The industry leader for online information for tax, accounting and finance professionals All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. Site Feedback Corrections Advertise With Us Advertising Guidelines AdChoices Terms of Use Privacy Policy

Home Download News App Live Video Channel 1 Channel 2 Traffic Map Incidents Weather 7 Day Forecast Alerts Forecast Hourly Radar School/Business Closings Web Cameras News Local Tennessee Kentucky National/World Sports Tennessee Friday Night Hits High School Community Community Calendar Day of Service WATE 6 On Your Side Heroes As Seen On WATE Good Morning Tennessee Good Day Tennessee WATE 6 On Your Side News at 4:00 p.m. WATE 6 On Your Side News at 5:00 p.m. WATE 6 On Your Side News at 5:30 p.m. WATE 6 On Your Side News at 6:00 p.m. CW20 News at 10:00 p.m. WATE 6 On Your Side News at 11:00 p.m. Report It! Send News Tips Contact Us Meet the Team 57Â° F Few Clouds Hi: 64Â° F Lo: 40Â° F Forecast Radar WebCams 2 Weather Alerts Menu Skip to content Â  Home News News Traffic Local Tennessee Kentucky Watercooler National/World Closings Food For Thought Caring for Our Kids Knox County Blount County Sevier County Anderson County Hamblen County Campbell County Roane County Cumberland County Loudon County More Featured: Your Vote 2016 Latest Headlines Sevierville couple loses hundreds in bizarre customer service scam Updated: 5 mins ago A Sevierville couple lost several hundreds of dollars to a new hoax that could have cost them more. They believed they were talking with a câ€¦ Pat Summitt Alzheimerâ€™s Clinic set to open in December Updated: 1 min ago The clinic is a partnership between the UT Medical Center and The Pat Summitt Foundation. Sevierville police see rise in use of credit card skimmers Updated: 39 mins ago Group works to ensure equality in education, discipline in Knox County Schools Updated: 14 mins ago Knoxville State Street Garage accepting submissions for permanent sculpture 4:24 pm Weather Weather Alerts Almanac Closings Current Conditions Current Temperatures Forecast Hour-by-Hour Radar Web Cameras Download the Knoxville Wx App More Current Conditions 57Â° F Few Clouds Feels Like: 57Â° F Wind: WSW 3 Humidity: 44% Dewpoint: 35Â° F Sunrise: 7:11 AM Sunset: 5:28 PM Knoxville Area Weather Forecast Radar WebCams 7-Day Sponsored by: Sports Tennessee Friday Night Hits High School More Community News Calendar Day of Service WATE 6 On Your Side Heroes Habitat For Humanity More As Seen On WATE Good Day Tennessee Good Morning Tennessee WATE 6 On Your Side News at 4:00 p.m. WATE 6 On Your Side News at 5:00 p.m. WATE 6 On Your Side News at 5:30 p.m. WATE 6 On Your Side News at 6:00 p.m. CW20 News at 10:00 p.m. WATE 6 On Your Side News at 11:00 p.m. Report It Report It Galleries Watch Watch Now As Seen On WATE Television Schedule Find our Channel Hollywood Today LIVE Tennessee This Week More About Us Contact Meet the Team Download our WATE 6 On Your Side apps Text Alerts Email Alerts Closings Jobs at WATE On Your Side Local Business Request a Tour Contests Advertising Search for: Search the site 57Â° F Few Clouds Hi: 64Â° F Lo: 40Â° F Bid to speed transplants with hepatitis C-infected kidneys The Associated Press Published: October 27, 2016, 4:56 am Click to share on Twitter (Opens in new window) Click to share on Google+ (Opens in new window) Share on Facebook (Opens in new window) Click to share on Pinterest (Opens in new window) Irma Hendricks, right, talks with her physician Peter P. Reese, MD at Hospital of the University of Pennsylvania in Philadelphia, on Oct. 6, 2016. Hendricks received a kidney transplant from a donor with hepatitis C, and took medications after surgery that cleared away the virus and left her feeling healthy again. Hendricks is part of a pilot study testing if new drugs that promise to cure most hepatitis C could allow use of organs that today go to waste, and speed transplants to people who might otherwise die waiting. (AP Photo/Jessica Kourkounis) WASHINGTON (AP) â€” Some patients facing a years-long wait for a kidney transplant are jumping ahead in line thanks to a startling experiment: Theyâ€™re agreeing to an organ almost sure to infect them with hepatitis C. Knowingly transmitting a dangerous virus may sound drastic but two leading transplant centers are betting the strategy will save lives â€” if new medications that promise to cure hepatitis C allow use of organs that today go to waste. Pilot studies are under way at the University of Pennsylvania and Johns Hopkins University to test transplanting kidneys from deceased donors with hepatitis C into recipients who donâ€™t already have that virus. If the research eventually pans out, hundreds more kidneys â€” and maybe some hearts and lungs, too â€” could be transplanted every year. â€œWe always dreaded hepatitis C,â€ said Dr. Peter Reese, a Penn kidney specialist who is helping lead the research. â€œBut now hepatitis C is just a different disease,â€ enough to consider what he calls the tradeoff of getting a new kidney years faster but one that comes with a hopefully treatable infection. Itâ€™s a tradeoff prompted by the nationâ€™s organ shortage. More than 99,000 people are on the national kidney waiting list but only about 17,000 people a year get a transplant and 4 percent a year die waiting, according to the United Network for Organ Sharing (UNOS). â€œIf we had enough organs, we wouldnâ€™t do this,â€ said Dr. Niraj Desai, who is leading the Hopkins study. But, â€œmost patients are pretty open to the idea once they hear what the alternatives are.â€ Doctors had told Irma Hendricks, 66, to expect at least a five-year wait for a kidney transplant. Dialysis three times a week was keeping the East Stroudsburg, Pennsylvania, woman alive but left her with no energy for even routine activities. â€œI call it the zombie syndrome,â€ she said. So she jumped at the chance to enroll in Pennâ€™s study, even though doctors made clear they hoped for but couldnâ€™t guarantee a hepatitis cure. â€œMy son said, â€˜Mom, this is a no-brainer. Just do it,'â€ Hendricks said, She swallowed an anti-hepatitis pill daily for three months, in addition to the usual post-transplant medications. Testing showed the drugs rapidly cleared hepatitis C out of her bloodstream. And with her new kidney functioning well, she now has enough energy to play with her toddler grandson. â€œThis is giving people in my situation new hope,â€ Hendricks said. Kidney transplant specialists are closely watching the research. â€œIt makes sense to me,â€ said Dr. Matthew Cooper, a transplant surgeon at MedStar Georgetown University Hospital, who is not involved in the research. He cautioned that the studies should use only kidneys that are young and otherwise high-quality, and that patients must understand the risks. â€œThey need to know you place their safety as the highest priority,â€ Cooper said. â€œBut at the same time, recognize that we have these obstacles. We donâ€™t want people to die on dialysis and there are not enough organs available for everybody.â€ Hepatitis C is a simmering infection that, if untreated, over two to three decades can quietly destroy someoneâ€™s liver. At least 2.7 million people in the U.S. have chronic hepatitis C. Until a few years ago, it was treatable only by medications with grueling side effects and poor cure rates. Now, breakthrough drugs promise to cure 95 percent of hepatitis C cases with fewer side effects â€” for people who can afford them. Treatment costs tens of thousands of dollars. Normally, hepatitis C-infected organs are transplanted only into patients who already have hepatitis C themselves, so as not to further spread the virus. Giving hepatitis C-positive organs to hepatitis C-negative recipients is allowed if the patient agrees, but itâ€™s rare, said Dr. David Klassen, UNOSâ€™ chief medical officer. UNOS statistics show a few dozen such transplants, mostly kidneys, last year, presumably when doctors feared their patients wouldnâ€™t survive the wait for a healthier organ. More often, hospitals discard hepatitis C-infected organs. Reese and fellow Penn transplant surgeon Dr. David Goldberg found only 37 percent of hepatitis C-positive kidney donations between 2005 and 2014 were transplanted. The discards could have helped more than 4,000 patients during that time period, they reported in the New England Journal of Medicine last year. And the opioid epidemic is prompting a jump in donations from people who died of drug overdoses â€” typically young organs that, absent an infection risk, would be sought after. The small Penn and Hopkins trials are a first step; much larger studies are needed to prove if more routine use of these organs in immune-suppressed transplant recipients really works. Cost also is a question. Merck & Co. is helping to fund the pilot trials, donating its medication Zepatier, which costs $54,000 for a round of treatment. Thatâ€™s still cheaper than a lifetime of a dialysis, which costs about $75,000 a year, UNOSâ€™ Klassen noted. While the studies began with kidneys because of their demand, â€œI donâ€™t think thereâ€™s any reason, if it proves safe and effective in kidneys, that we wouldnâ€™t want to try it in other organs,â€ noted Pennâ€™s Goldberg. Even if the hepatitis C-infected organs prove useful, the nation still is â€œdesperate for more donors,â€ cautioned Hopkinsâ€™ Desai. â€œItâ€™s a practical solution to help some of the people. It wonâ€™t solve the problem.â€ Share this: Click to share on Twitter (Opens in new window) Share on Facebook (Opens in new window) Click to share on Google+ (Opens in new window) Click to share on Reddit (Opens in new window) Click to print (Opens in new window) Click to email (Opens in new window) More Click to share on Pinterest (Opens in new window) Click to share on Tumblr (Opens in new window) Click to share on LinkedIn (Opens in new window) Click to share on Pocket (Opens in new window) Click to send this to your Kindle device (Opens in new window) Related Posts Vitamin D deficiency is widely overestimated, doctors warn Wife of real-life â€˜Fault in Our Starsâ€™ couple dies days after husband TNTâ€™s Craig Sager hangs tough in leukemia battle Toddler with cancer who completed bucket list passes away Advertisement Â« Previous Story â€” Next Story Â» Please enable JavaScript to view the comments powered by Disqus. Leave a Reply Cancel reply Enter your comment here... Fill in your details below or click an icon to log in: Email (required) (Address never made public) Name (required) Website You are commenting using your WordPress.com account. (Â LogÂ OutÂ /Â ChangeÂ ) You are commenting using your Twitter account. (Â LogÂ OutÂ /Â ChangeÂ ) You are commenting using your Facebook account. (Â LogÂ OutÂ /Â ChangeÂ ) You are commenting using your Google+ account. (Â LogÂ OutÂ /Â ChangeÂ ) Cancel Connecting to %s Notify me of new comments via email. Notify me of new posts via email. Advertisement Trending on WATE.com Advertisement Advertisement Advertisement WATE.com Â© Copyright 2000 - 2016 Young Broadcasting of Knoxville, Inc. A Media General Company. Powered by WordPress.com VIP Site News Knoxville, TN Weather Sports Community Report It Watch More County Anderson County Blount County Campbell County Claiborne County Cocke County Cumberland County Fentress County Grainger County Greene County Hamblen County Hancock County Hawkins County Jefferson County Knox County Loudon County McMinn County Monroe County Morgan County Roane County Sevier County Scott County Union County Station Contact Terms of Use Privacy Policy Advertising Terms and Conditions and Credit Policy FCC Public File For problems with the FCC File Jobs at WATE EEO Public Filings Childrenâ€™s Programming Closed Captioning Media General Contests Follow Subscribe via RSS Follow us on Twitter Join us on Facebook Follow us on YouTube Follow us on Google+ Follow us on Instagram Send to Email Address Your Name Your Email Address Cancel Post was not sent - check your email addresses! Email check failed, please try again Sorry, your blog cannot share posts by email.
Home News Traffic map Local News NC News National International Politics Check This Out Whatâ€™s Next Education #Brake4Buses Entertainment WNCN News App Safe Drive Pledge Consumer Protection Health with Dr. Campbell Watch Live CBS on WNCN Weather Hurricane Central Radar Current conditions Flight tracker Weather Alerts WNCN Weather App Webcams Satellite SatRad Severe Forecast 3-Degree Guarantee Closings N. Carolina TV listings Investigates Sports UNC College basketball Duke N.C. State On the Rise Hurricanes High school Pro sports WNCN Blitz Whatâ€™s On TV Listings CBS Shows CBS North Carolina Business Leaders Pet of the Day AntennaTV Technical Help Watch Live About Us News Team Technical Help #Brake4Buses At Your Service WNCN Mobile Apps CBS on WNCN 51Â° F Overcast Hi: 55Â° F Lo: 44Â° F Radar Forecast Current conditions Menu Skip to content Â  Home News News Traffic map Local News NC News National International Politics Check This Out Whatâ€™s Next Education #Brake4Buses Entertainment WNCN News App Safe Drive Pledge Consumer Protection Health with Dr. Campbell Watch Live CBS on WNCN Featured: Campaign 2016 HB2 Latest Headlines White supremacist site: New Balance official shoe for whites Updated: 9 mins ago BOSTON (AP) â€” A white supremacist website has declared the Boston-based footwear manufacturer New Balance the â€œOfficial Shoes of White Peoplâ€¦ ICC prosecutor: US forces may have tortured in Afghanistan Updated: 9 mins ago THE HAGUE, Netherlands (AP) â€” International Criminal Court prosecutors say that a preliminary probe indicates that members of the United Staâ€¦ 1,000+ evacuated as NC mountain wildfires grow to neary 39,000 acres Updated: 2 mins ago Nephew in â€˜Making a Murdererâ€™ ordered released Updated: 30 mins ago Fayettevilleâ€™s Special Forces Association looks to rebound from Matthewâ€™s damage Updated: 39 mins ago Weather Weather Hurricane Central Radar Current conditions Flight tracker Weather Alerts WNCN Weather App Webcams Satellite SatRad Severe Forecast 3-Degree Guarantee Closings Current Conditions 51Â° F Overcast Feels Like: 51Â° F Wind: NNE 5 Humidity: 92% Dewpoint: 49Â° F Sunrise: 6:50 AM Sunset: 5:07 PM Forecast Radar Currently Webcams Sponsored by: N. Carolina TV listings Investigates Sports UNC College basketball Duke N.C. State On the Rise Hurricanes High school Pro sports WNCN Blitz Whatâ€™s On TV Listings CBS Shows CBS North Carolina Business Leaders Pet of the Day AntennaTV Technical Help Watch Live About Us News Team Technical Help #Brake4Buses At Your Service WNCN Mobile Apps CBS on WNCN Search for: Search the site 51Â° F Overcast Hi: 55Â° F Lo: 44Â° F Bid to speed transplants with hepatitis C-infected kidneys LAURAN NEERGAARD, The Associated Press Published: October 27, 2016, 4:10 am Updated: October 27, 2016, 10:40 am Click to share on Twitter (Opens in new window) Click to share on Google+ (Opens in new window) Share on Facebook (Opens in new window) Click to share on Pinterest (Opens in new window) WASHINGTON (AP) â€” Some patients facing a years-long wait for a kidney transplant are jumping ahead in line thanks to a startling experiment: Theyâ€™re agreeing to an organ almost sure to infect them with hepatitis C. Knowingly transmitting a dangerous virus may sound drastic but two leading transplant centers are betting the strategy will save lives â€” if new medications that promise to cure hepatitis C allow use of organs that today go to waste. Pilot studies are under way at the University of Pennsylvania and Johns Hopkins University to test transplanting kidneys from deceased donors with hepatitis C into recipients who donâ€™t already have that virus. If the research eventually pans out, hundreds more kidneys â€” and maybe some hearts and lungs, too â€” could be transplanted every year. â€œWe always dreaded hepatitis C,â€ said Dr. Peter Reese, a Penn kidney specialist who is helping lead the research. â€œBut now hepatitis C is just a different disease,â€ enough to consider what he calls the tradeoff of getting a new kidney years faster but one that comes with a hopefully treatable infection. Itâ€™s a tradeoff prompted by the nationâ€™s organ shortage. More than 99,000 people are on the national kidney waiting list but only about 17,000 people a year get a transplant and 4 percent a year die waiting, according to the United Network for Organ Sharing (UNOS). â€œIf we had enough organs, we wouldnâ€™t do this,â€ said Dr. Niraj Desai, who is leading the Hopkins study. But, â€œmost patients are pretty open to the idea once they hear what the alternatives are.â€ Doctors had told Irma Hendricks, 66, to expect at least a five-year wait for a kidney transplant. Dialysis three times a week was keeping the East Stroudsburg, Pennsylvania, woman alive but left her with no energy for even routine activities. â€œI call it the zombie syndrome,â€ she said. So she jumped at the chance to enroll in Pennâ€™s study, even though doctors made clear they hoped for but couldnâ€™t guarantee a hepatitis cure. â€œMy son said, â€˜Mom, this is a no-brainer. Just do it,'â€ Hendricks said, She swallowed an anti-hepatitis pill daily for three months, in addition to the usual post-transplant medications. Testing showed the drugs rapidly cleared hepatitis C out of her bloodstream. And with her new kidney functioning well, she now has enough energy to play with her toddler grandson. â€œThis is giving people in my situation new hope,â€ Hendricks said. Kidney transplant specialists are closely watching the research. â€œIt makes sense to me,â€ said Dr. Matthew Cooper, a transplant surgeon at MedStar Georgetown University Hospital, who is not involved in the research. He cautioned that the studies should use only kidneys that are young and otherwise high-quality, and that patients must understand the risks. â€œThey need to know you place their safety as the highest priority,â€ Cooper said. â€œBut at the same time, recognize that we have these obstacles. We donâ€™t want people to die on dialysis and there are not enough organs available for everybody.â€ Hepatitis C is a simmering infection that, if untreated, over two to three decades can quietly destroy someoneâ€™s liver. At least 2.7 million people in the U.S. have chronic hepatitis C. Until a few years ago, it was treatable only by medications with grueling side effects and poor cure rates. Now, breakthrough drugs promise to cure 95 percent of hepatitis C cases with fewer side effects â€” for people who can afford them. Treatment costs tens of thousands of dollars. Normally, hepatitis C-infected organs are transplanted only into patients who already have hepatitis C themselves, so as not to further spread the virus. Giving hepatitis C-positive organs to hepatitis C-negative recipients is allowed if the patient agrees, but itâ€™s rare, said Dr. David Klassen, UNOSâ€™ chief medical officer. UNOS statistics show a few dozen such transplants, mostly kidneys, last year, presumably when doctors feared their patients wouldnâ€™t survive the wait for a healthier organ. More often, hospitals discard hepatitis C-infected organs. Reese and fellow Penn transplant surgeon Dr. David Goldberg found only 37 percent of hepatitis C-positive kidney donations between 2005 and 2014 were transplanted. The discards could have helped more than 4,000 patients during that time period, they reported in the New England Journal of Medicine last year. And the opioid epidemic is prompting a jump in donations from people who died of drug overdoses â€” typically young organs that, absent an infection risk, would be sought after. The small Penn and Hopkins trials are a first step; much larger studies are needed to prove if more routine use of these organs in immune-suppressed transplant recipients really works. Cost also is a question. Merck & Co. is helping to fund the pilot trials, donating its medication Zepatier, which costs $54,000 for a round of treatment. Thatâ€™s still cheaper than a lifetime of a dialysis, which costs about $75,000 a year, UNOSâ€™ Klassen noted. While the studies began with kidneys because of their demand, â€œI donâ€™t think thereâ€™s any reason, if it proves safe and effective in kidneys, that we wouldnâ€™t want to try it in other organs,â€ noted Pennâ€™s Goldberg. Even if the hepatitis C-infected organs prove useful, the nation still is â€œdesperate for more donors,â€ cautioned Hopkinsâ€™ Desai. â€œItâ€™s a practical solution to help some of the people. It wonâ€™t solve the problem.â€ ___ Associated Press Writer Michael Rubinkam contributed to this report. Share this: Click to share on Twitter (Opens in new window) Share on Facebook (Opens in new window) Click to share on Pinterest (Opens in new window) Click to share on Reddit (Opens in new window) Click to print (Opens in new window) Click to email (Opens in new window) More Click to share on Pocket (Opens in new window) Click to share on Google+ (Opens in new window) Click to share on LinkedIn (Opens in new window) Advertisement Â« Previous Story â€” Next Story Â» Please enable JavaScript to view the comments powered by Disqus. Leave a Reply Cancel reply Enter your comment here... Fill in your details below or click an icon to log in: Email (required) (Address never made public) Name (required) Website You are commenting using your WordPress.com account. (Â LogÂ OutÂ /Â ChangeÂ ) You are commenting using your Twitter account. (Â LogÂ OutÂ /Â ChangeÂ ) You are commenting using your Facebook account. (Â LogÂ OutÂ /Â ChangeÂ ) You are commenting using your Google+ account. (Â LogÂ OutÂ /Â ChangeÂ ) Cancel Connecting to %s Notify me of new comments via email. Notify me of new posts via email. Advertisement Sunny & warm through the start of the weekend 5:30 pm Get the latest weather forecast from the CBS North Carolina weather team. NORTH CAROLINA NEWS McCrory seeking $1B from Congress for Matthew relief, repair Updated: 6 mins ago RALEIGH, N.C. (AP) â€” Gov. Pat McCrory is asking North Carolinaâ€™s congressional delegation for help getting a little over $1 billion from theâ€¦ 1,000+ evacuated as NC mountain wildfires grow to neary 39,000 acres Updated: 5 mins ago The Party Rock Fire, which is threatening Lake Lure and nearby areas in Rutherford County, neared 3,500 acres. Durham novelist loses bid to get murder case dismissed Updated: 6 mins ago DURHAM, N.C. (AP) â€” The former Durham newspaper columnist and novelist accused in his wifeâ€™s death 15 years ago has lost a bid to have his câ€¦ The Latest: SBI investigates Durham county primary election Updated: 5 mins ago RALEIGH, N.C. (AP) â€” The Latest on disputed election results in Durham County, North Carolina, after the stateâ€™s still-undecided election foâ€¦ Advertisement Advertisement Advertisement WNCN.com All content Â© Copyright 2000 - 2016 Media General Communications Holdings, LLC. A Media General Company. Powered by WordPress.com VIP Sections News Weather Sports Station Contact us Work at CBS North Carolina Closings Closed Captioning Terms of Use Privacy Policy Business Advertising Terms and Conditions and Credit Policy FCC Public File For problems with the FCC Public File email jwilliams@wncn.com EEO Public Filings Childrenâ€™s Programming Follow Subscribe via RSS Follow us on Twitter Join us on Facebook Follow us on YouTube Follow us on Instagram Send to Email Address Your Name Your Email Address Cancel Post was not sent - check your email addresses! Email check failed, please try again Sorry, your blog cannot share posts by email.
Home Watch Live Video Headlines Whatâ€™s on NBC Hollywood Today Live News Western Mass. I-Team Crime Massachusetts Boston Statehouse Decision 2016 I-91 Reconstruction inFocus Sex Offenders World News Entertainment Hollywood Today Sports News Health News Weather Todayâ€™s Forecast 7 Day Forecast Closings & Delays Flight Tracker Interactive Radar Jr Weather Academy Satellite Sat Rad Severe Weather Snowfall Forecast Temperatures Weather Alerts Weather App Weather News Weather Photos Webcams The CW Shows Videos Text Alerts CW Photo Galleries Like us on Facebook Follow us on Twitter Shows on Social Media Report It Photo Galleries Report It! Community Stop the Swerve Working for a Better Tomorrow A Look at the Movies Live Traffic Map Pump Prices Lottery Obituaries Mass Appeal Watch Live Contact Us Taste Appeal Family Appeal Relationship Appeal Community Appeal Gardening Appeal Leisure Appeal Personal Appeal Parent Appeal DIY Appeal Home Appeal Pet Appeal Fashion Appeal Fitness Appeal Health Appeal More About Us Contact Us Advertise with us Jobs at WWLP Mobile Apps Text Alerts Email Alerts WWLP-22News Team News in Review TV Schedule 62Â° F Clear Hi: 62Â° F Lo: 30Â° F Todayâ€™s Forecast Radar/Satellite 22News Apps Menu Skip to content Â  Home Watch Live Video Headlines Whatâ€™s on NBC Hollywood Today Live News News Western Mass. I-Team Crime Massachusetts Boston Statehouse Decision 2016 I-91 Reconstruction inFocus Sex Offenders World News Entertainment Hollywood Today Sports News Health News Featured: Casino News Marijuana News Mass Pike Tolls Springfield off-duty police beating Syrian Refugees Toys for Tots at 22News Latest Headlines UMass Amherst fundraiser breaks record with $379-million in donations Updated: 6 mins ago UMass Rising Campaign began in 2010 and surpassed the $300 million original goal in June 2016 when it ended. Firefighters working to put out a fire in Ludlow Updated: 1 min ago BREAKING NEWS Firefighters are working to control a house fire in Ludlow, Monday night, on Alden Street and Poole Street. Malloy touts Connecticut homeless vets plan at White House Updated: 4 mins ago Trinity Health New England Bus Tour stops at Mercy Medical Center Updated: 13 mins ago ICC prosecutor: US forces may have tortured in Afghanistan Updated: 5 mins ago Weather Weather Todayâ€™s Forecast 7 Day Forecast Closings & Delays Flight Tracker Interactive Radar Jr Weather Academy Satellite Sat Rad Severe Weather Snowfall Forecast Temperatures Weather Alerts Weather App Weather News Weather Photos Webcams Current Conditions 62Â° F Clear Feels Like: 62Â° F Wind: SSW 7 Humidity: 19% Dewpoint: 19Â° F Sunrise: 6:40 AM Sunset: 4:29 PM 7 Day Forecast Live Radar Â  Â  Video Webcast Almanac Sponsored by: The CW The CW Shows Videos Text Alerts CW Photo Galleries Like us on Facebook Follow us on Twitter Shows on Social Media Featured: Season Finale Season Premiere Series Premiere Latest Headlines MassDOT discusses plans to expand rail service in the Pioneer Valley November 10, 2016 The state will spend a quarter million dollars just to gather the data, but the entire project will cost millions. Behind The Seams of The Flash November 8, 2016 Go behind the scenes with costume designer Maya Mani! The Flash is new Tuesdays at 8/7c on The CW Springfield. Supergirl â€“ Changing Trailer November 8, 2016 Jane The Virgin â€“ Chapter Forty-Nine Trailer November 8, 2016 Jane The Virgin â€“ Chapter Forty-Eight Scene November 7, 2016 Report It Photo Galleries Report It! Community Stop the Swerve Working for a Better Tomorrow A Look at the Movies Live Traffic Map Pump Prices Lottery Obituaries Mass Appeal Mass Appeal Watch Live Contact Us Taste Appeal Family Appeal Relationship Appeal Community Appeal Gardening Appeal Leisure Appeal Personal Appeal Parent Appeal DIY Appeal Home Appeal Pet Appeal Fashion Appeal Fitness Appeal Health Appeal Featured: Caregiver Series Herbs A-Z NBC Shows Pet of the Week Latest Headlines Monteâ€™s March â€“ Fighting Hunger in the Valley 1:11 pm 26 miles and a shopping cart. Five Tips for Junior Year Success 1:15 pm When it comes to college preparedness, itâ€™s important that you impress potential colleges with a great performance in your junior year. â€˜Festival of Treesâ€™ takes over Tower Square 1:26 pm Maintaining a healthy lifestyle this Holiday season! 1:29 pm Real Estate Minute: Are you ready to buy? 1:56 pm More About Us Contact Us Advertise with us Jobs at WWLP Mobile Apps Text Alerts Email Alerts WWLP-22News Team News in Review TV Schedule Search for: Search the site 62Â° F Clear Hi: 62Â° F Lo: 30Â° F Bid to speed transplants with hepatitis C-infected kidneys LAURAN NEERGAARD, The Associated Press Published: October 27, 2016, 4:00 am Updated: October 27, 2016, 10:20 am Click to share on Twitter (Opens in new window) Click to share on Google+ (Opens in new window) Share on Facebook (Opens in new window) Click to share on Pinterest (Opens in new window) WASHINGTON (AP) â€” Some patients facing a years-long wait for a kidney transplant are jumping ahead in line thanks to a startling experiment: Theyâ€™re agreeing to an organ almost sure to infect them with hepatitis C. Knowingly transmitting a dangerous virus may sound drastic but two leading transplant centers are betting the strategy will save lives â€” if new medications that promise to cure hepatitis C allow use of organs that today go to waste. Pilot studies are under way at the University of Pennsylvania and Johns Hopkins University to test transplanting kidneys from deceased donors with hepatitis C into recipients who donâ€™t already have that virus. If the research eventually pans out, hundreds more kidneys â€” and maybe some hearts and lungs, too â€” could be transplanted every year. â€œWe always dreaded hepatitis C,â€ said Dr. Peter Reese, a Penn kidney specialist who is helping lead the research. â€œBut now hepatitis C is just a different disease,â€ enough to consider what he calls the tradeoff of getting a new kidney years faster but one that comes with a hopefully treatable infection. Itâ€™s a tradeoff prompted by the nationâ€™s organ shortage. More than 99,000 people are on the national kidney waiting list but only about 17,000 people a year get a transplant and 4 percent a year die waiting, according to the United Network for Organ Sharing (UNOS). â€œIf we had enough organs, we wouldnâ€™t do this,â€ said Dr. Niraj Desai, who is leading the Hopkins study. But, â€œmost patients are pretty open to the idea once they hear what the alternatives are.â€ Doctors had told Irma Hendricks, 66, to expect at least a five-year wait for a kidney transplant. Dialysis three times a week was keeping the East Stroudsburg, Pennsylvania, woman alive but left her with no energy for even routine activities. â€œI call it the zombie syndrome,â€ she said. So she jumped at the chance to enroll in Pennâ€™s study, even though doctors made clear they hoped for but couldnâ€™t guarantee a hepatitis cure. â€œMy son said, â€˜Mom, this is a no-brainer. Just do it,'â€ Hendricks said, She swallowed an anti-hepatitis pill daily for three months, in addition to the usual post-transplant medications. Testing showed the drugs rapidly cleared hepatitis C out of her bloodstream. And with her new kidney functioning well, she now has enough energy to play with her toddler grandson. â€œThis is giving people in my situation new hope,â€ Hendricks said. Kidney transplant specialists are closely watching the research. â€œIt makes sense to me,â€ said Dr. Matthew Cooper, a transplant surgeon at MedStar Georgetown University Hospital, who is not involved in the research. He cautioned that the studies should use only kidneys that are young and otherwise high-quality, and that patients must understand the risks. â€œThey need to know you place their safety as the highest priority,â€ Cooper said. â€œBut at the same time, recognize that we have these obstacles. We donâ€™t want people to die on dialysis and there are not enough organs available for everybody.â€ Hepatitis C is a simmering infection that, if untreated, over two to three decades can quietly destroy someoneâ€™s liver. At least 2.7 million people in the U.S. have chronic hepatitis C. Until a few years ago, it was treatable only by medications with grueling side effects and poor cure rates. Now, breakthrough drugs promise to cure 95 percent of hepatitis C cases with fewer side effects â€” for people who can afford them. Treatment costs tens of thousands of dollars. Normally, hepatitis C-infected organs are transplanted only into patients who already have hepatitis C themselves, so as not to further spread the virus. Giving hepatitis C-positive organs to hepatitis C-negative recipients is allowed if the patient agrees, but itâ€™s rare, said Dr. David Klassen, UNOSâ€™ chief medical officer. UNOS statistics show a few dozen such transplants, mostly kidneys, last year, presumably when doctors feared their patients wouldnâ€™t survive the wait for a healthier organ. More often, hospitals discard hepatitis C-infected organs. Reese and fellow Penn transplant surgeon Dr. David Goldberg found only 37 percent of hepatitis C-positive kidney donations between 2005 and 2014 were transplanted. The discards could have helped more than 4,000 patients during that time period, they reported in the New England Journal of Medicine last year. And the opioid epidemic is prompting a jump in donations from people who died of drug overdoses â€” typically young organs that, absent an infection risk, would be sought after. The small Penn and Hopkins trials are a first step; much larger studies are needed to prove if more routine use of these organs in immune-suppressed transplant recipients really works. Cost also is a question. Merck & Co. is helping to fund the pilot trials, donating its medication Zepatier, which costs $54,000 for a round of treatment. Thatâ€™s still cheaper than a lifetime of a dialysis, which costs about $75,000 a year, UNOSâ€™ Klassen noted. While the studies began with kidneys because of their demand, â€œI donâ€™t think thereâ€™s any reason, if it proves safe and effective in kidneys, that we wouldnâ€™t want to try it in other organs,â€ noted Pennâ€™s Goldberg. Even if the hepatitis C-infected organs prove useful, the nation still is â€œdesperate for more donors,â€ cautioned Hopkinsâ€™ Desai. â€œItâ€™s a practical solution to help some of the people. It wonâ€™t solve the problem.â€ ___ Associated Press Writer Michael Rubinkam contributed to this report. Share this: Click to email (Opens in new window) Click to print (Opens in new window) Share on Facebook (Opens in new window) Click to share on Twitter (Opens in new window) Click to share on Google+ (Opens in new window) Click to share on LinkedIn (Opens in new window) More Click to share on Pinterest (Opens in new window) Click to send this to your Kindle device (Opens in new window) Click to share on Reddit (Opens in new window) Click to share on Pocket (Opens in new window) Click to share on Tumblr (Opens in new window) Like this: Like Loading... Advertisement Â« Previous Story â€” Next Story Â» Please enable JavaScript to view the comments powered by Disqus. Leave a Reply Cancel reply Enter your comment here... Fill in your details below or click an icon to log in: Email (required) (Address never made public) Name (required) Website You are commenting using your WordPress.com account. (Â LogÂ OutÂ /Â ChangeÂ ) You are commenting using your Twitter account. (Â LogÂ OutÂ /Â ChangeÂ ) You are commenting using your Facebook account. (Â LogÂ OutÂ /Â ChangeÂ ) You are commenting using your Google+ account. (Â LogÂ OutÂ /Â ChangeÂ ) Cancel Connecting to %s Notify me of new comments via email. Notify me of new posts via email. Advertisement Trending on WWLP.com Current Conditions change location Chicopee n/a F n/a Wind n/a Dewpoint n/a Humidity 0.00" Barometer 6:41 am Sunrise 4:29 pm Sunset change location Greenfield 40Â° F 0 N Wind 29Â° Dewpoint 65% Humidity 29.98" Barometer 6:40 am Sunrise 4:26 pm Sunset change location Holyoke 62Â° F 7 SW Wind 19Â° Dewpoint 19% Humidity 29.95" Barometer 6:40 am Sunrise 4:28 pm Sunset change location MGM Springfield Casino 62Â° F 7 SW Wind 19Â° Dewpoint 19% Humidity 29.95" Barometer 6:40 am Sunrise 4:28 pm Sunset change location Northampton 54Â° F 0 SSW Wind 23Â° Dewpoint 31% Humidity 29.98" Barometer 6:41 am Sunrise 4:28 pm Sunset change location Pittsfield 43Â° F 0 N Wind 21Â° Dewpoint 42% Humidity 29.97" Barometer 6:44 am Sunrise 4:31 pm Sunset change location Springfield 62Â° F 7 SW Wind 19Â° Dewpoint 19% Humidity 29.95" Barometer 6:40 am Sunrise 4:28 pm Sunset change location Westfield 46Â° F 0 N Wind 24Â° Dewpoint 42% Humidity 29.97" Barometer 6:41 am Sunrise 4:29 pm Sunset change location Westover AFB 62Â° F 7 SW Wind 19Â° Dewpoint 19% Humidity 29.95" Barometer 6:40 am Sunrise 4:28 pm Sunset Chicopee n/a Greenfield 40Â° Holyoke 62Â° MGM Springfield Casino 62Â° Northampton 54Â° Pittsfield 43Â° Springfield 62Â° Westfield 46Â° Westover AFB 62Â° Advertisement Advertisement Advertisement WWLP-22News Â© 2000-2016 LIN Television Corporation, a Media General company. All rights reserved Powered by WordPress.com VIP Sections Local News Weather I-Team Crime inFocus Mass Appeal Watch 22News Station About Us Contact Us News Team Job at WWLP Advertise with us Regional News Hampden Hampshire Franklin Berkshire Boston Statehouse Massachusetts Connecticut Business Privacy Policy Terms of Use FCC Public File EEO Report Childrenâ€™s TV Report Platforms Text Alerts Email Alerts Report It Mobile Facebook Twitter YouTube Our Partners Media General NBC CNN The Westfield News Hampshire Gazette Follow Subscribe via RSS Follow us on Twitter Join us on Facebook Follow us on YouTube Follow us on Google+ Follow us on Pinterest Follow us on Instagram NEWS ARCHIVE: View Stories by Date November 2016 M T W T F S S Â« Oct Â  Â  Â  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 Â  News Archive: Select Month News Archive: Select Month Select Month November 2016 October 2016 September 2016 August 2016 July 2016 June 2016 May 2016 April 2016 March 2016 February 2016 January 2016 December 2015 November 2015 October 2015 September 2015 August 2015 July 2015 June 2015 May 2015 April 2015 March 2015 February 2015 January 2015 December 2014 November 2014 October 2014 September 2014 August 2014 July 2014 June 2014 May 2014 April 2014 March 2014 February 2014 January 2014 May 2013 May 2012 Send to Email Address Your Name Your Email Address Cancel Post was not sent - check your email addresses! Email check failed, please try again Sorry, your blog cannot share posts by email. %d bloggers like this:
Home Markets World markets Stocks decline with oil as Apple tumbles on forecast; BondsÂ fall Stocks decline with oil as Apple tumbles on forecast; BondsÂ fall A barrage of uninspiring outlooks from bellwethers including Apple Inc. and Bayer AG sent global equities down. Oil slumped. By: Bloomberg | Published: October 27, 2016 5:43 AM The MSCI All Country World Index posted a back-to-back slide as oil retreated after data showed an unexpected decrease in US stockpiles was centered on the West Coast. (Bloomberg) A barrage of uninspiring outlooks from bellwethers including Apple Inc. and Bayer AG sent global equities down. Oil slumped.Â The MSCI All Country World Index posted a back-to-back slide as oil retreated after data showed an unexpected decrease in US stockpiles was centered on the West Coast. Yields on two-year Treasuries, the most sensitive to Federal Reserve expectations, rose to the highest since June as traders bet on tighter policy by December. Italian bonds led losses in the euro-area as a glut of supply from governments and companies weighed on the market. Equities have failed to gain momentum since the start of the earnings season as traders grapple with disappointing forecasts from behemoths including Apple, Intel Corp. and 3M Co. amid uneven economic data. Meanwhile, investors have assessed the likely trajectory of interest rates and the outcome of U.S. presidential elections, with the next Fed meeting and the vote both due in November. â€œApple earnings were probably in line with expectations, but nevertheless are going to subtract from the S&P,â€ said Bruce Bittles, chief investment strategist at Milwaukee-based Robert W. Baird. â€œThe markets typically trade defensively in October before an election anyway, I expect more of the same. The market is going to go lower before it goes higher. Itâ€™s going to require a springboard and that springboard requires slightly lower prices.â€ Stocks MSCIâ€™s global gauge of equities fell 0.2 percent at 4 p.m. in New York, extending this monthâ€™s slide to 1.3 percent. The S&P 500 Index retreated 0.2 percent to 2,139.43, after swinging between gains and losses. Apple sank 2.3 percent after predicting holiday sales that barely topped analyst estimates amid the first annual revenue drop since 2001. The KBW Bank Index rose to its best level this year, while Boeing Co. surged after reporting a jump in profit. Among shares moving on earnings news: Chipotle Mexican Grill Inc. sank to a three-year low as results missed estimates. Southwest Airlines Co. slid after saying a revenue measure may worsen this quarter. Biogen Inc. rallied after its quarterly profit topped estimates. Mondelez International Inc. rose after boosting its earnings forecast. Northrop Grumman Corp. climbed to a record after raising its earnings outlook. Akamai Technologies Inc. and Juniper Networks Inc. surged on better-than-predicted profits. Losses worsened in the Stoxx Europe 600 Index, which dropped the most in more than a week, as firms from Bayer to builder Vinci SA reported disappointing earnings. Antofagasta Plc led miners down after forecasting a slide in copper production next year. Industrial shares led declines on the MSCI Emerging Markets Index as South Koreaâ€™s industrial-goods makers fell amid speculation there will be more job losses. Bonds Treasuries fell as BlackRock Inc.â€™s Rick Rieder said he considers a December Fed hike a done deal. Traders are pricing in a 73 percent probability of tighter policy by year-end, according to futures data compiled by Bloomberg. Yields on two-year notes rose for a fifth day, while a gauge of the yield curve steepened as reports showed U.S. wholesale inventories rose more than expected while the service sector expanded more than forecast, boosting the outlook for economic growth. Benchmark U.S. 10-year yields rose four basis points to 1.79 percent. Italyâ€™s 10-year yield climbed to the highest since June after the country sold inflation-linked debt due in 2024 and 2026. The selloff deepened, with similar-maturity U.K. bond yields approaching the most since the Brexit vote, after the Bank of England said Tuesday there were limits to officialsâ€™ willingness to look beyond an overshoot of their inflation target. Gilts also declined after Britain sold securities due in July 2065 via banks on Tuesday. Portugal auctioned bonds for the first time since DBRS Ltd. maintained the nationâ€™s rating as investment grade. Germany added to the supply, selling five-year notes, while companies including Merck & Co. and Verizon Communications Inc. sold bonds. The Treasury in Rome plans to auction as much as 8.5 billion euros of debt on Oct. 28. Mozambiqueâ€™s Eurobonds slumped to a record for a second day after the government hired advisers to negotiate a restructuring that at least one adviser said could involve write downs for investors. Currencies The euro advanced from a seven-month low on signs the European economy may be improving enough to reduce pressure on the European Central Bank to further ease monetary policy. The shared currency rose 0.2 percent to $1.0907. â€œThe recent data has been positive,â€ said Jane Foley, a senior currency strategist at Rabobank International in London. â€œThat helps to bring some sense of stability into the euro.â€ Bloombergâ€™s Dollar Spot Index, which tracks the currency against 10 major peers, rose 0.2 percent. Mexicoâ€™s peso slid as a Bloomberg poll showed U.S. presidential candidate Donald Trump ahead of Hillary Clinton in Florida. South Africaâ€™s rand slipped as Finance Minister Pravin Gordhan delivered a mid-term budget speech that highlighted downgrades to growth estimates, wider budget deficits and shortfalls in tax collection. The real fell as a drop in commodities outweighed optimism with another victory in Congress for President Michel Temer. Commodities Oil futures for December delivery fell 1.6 percent to settle at $49.18 a barrel on the New York Mercantile Exchange. Brent for December settlement slipped 1.6 percent to $49.98 a barrel on the London-based ICE Futures Europe exchange. Nationwide crude stockpiles fell 553,000 barrels last week, according to the Energy Information Administration. Analysts surveyed by Bloomberg projected a gain and the American Petroleum Institute data showed an increase. Supplies along the West Coast decreased to the lowest since January 2015. But the region is sometimes ignored by traders because its distribution system is isolated from the rest of the country. â€œThis is a sloppy market,â€ said Adam Wise, who helps run a $7 billion oil and natural gas bond and private equity portfolio at John Hancock in Boston. â€œNews and changes of sentiment can easily send it moving into the opposite direction. We have mixed signals from todayâ€™s data.â€ Copper capped its longest stretch of gains this month as a run on stockpiles boosted speculation that demand for the metal is increasing. Please Wait while comments are loading... Trending Now Donald Trump will get wake-up call when he takes office: US President Barack Obama India's efforts to protect children fail due lack of budget: Nobel laureate Kailash Satyarthi Donald Trump considering woman, openly gay man for leadership posts Businessman surrenders Rs 6,000 crore following Narendra Modi government's demonetisation policy? Lok Sabha speaker Sumitra Mahajan meets delegates from all parties ahead of Parliament session Racist post about Michelle Obama causes backlash Dubbing artist Bhagyalakshmi on gangrape victim's petition: Sad there is no response from Chief Minister's office Terror-hit Dhaka bakery returned to property owner Cash on Delivery Business hit by demonetisation, says Snapdeal Apollo Hospitals in expansion mode; to invest Rs 1,400-crore Wife hit by cancer, man accidentally tears only Rs 2000 note he had! Â EDITORâ€™S PICKS MSDE to seek Cabinet nod to set up ITIs in 2,500 blocks Mastercard, Visa hail government's demonetisation move Infosys chief Narayana Murthy rues Americans failure to ink history through Hillary Clinton Thippagondanahalli tragedy: Missing actor Raghav Uday's body found Barack Obama campaigns for Hillary Clinton, for the last time as a President US Presidential Elections: Voters say they might leave America if 'lunatic, racist, anti-national' Donald Trump wins US presidential elections: Here's what will happen in Congress especially if Hillary Clinton wins Lady Gaga calls Melania Trumpâ€™s anti-bullying campaign â€˜hypocrisyâ€™ Videos Netflix launches new horror series in LA Free wifi: a wolf in sheeps clothing? Delhi woman, teenager blame each other of rape in a hotel room 2016 Range Rover Discovery Sport Startech Exterior Interior Walk around 2016 Geneva Motor Show Go to Top Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  The Express Group The Indian Express The Financial Express Loksatta Jansatta inUth Ramnath Goenka Awards Privacy Policy Advertise with Us Contact Us Feedback Â  Copyright Â© The Indian Express [P] Ltd. All Rights Reserved. SECTIONS Home Markets Companies Economy Tech Auto Mutual Funds Stocks Currency Opinions Todays Paper E-Paper Horoscope Photos Video Photo Story

Change Country United States Germany United Kingdom Featured Sections Video Fashion Beauty Living Health Entertainment Tech News Holiday Follow Us Video The Skinny Sh*tty Boyfriends Behind The Seams Style Out There The Walker Shatterbox Anthology All R29 Series Fashion Styling Tips Designers Street Style Trends Celebs & Influencers College Shopping Boutiques Beauty Hair Nails Makeup Skin Care Fragrance Celebs & Influencers Beauty Prep School Living Travel Home Food & Drinks Work & Money Weddings Health Trends Diet & Nutrition Fitness Sex Spirit Entertainment News TV Movies Books & Art Music Pop Culture Red Carpet Tech News Vote Your Values Election 2016 Culture People U.S. News World News Holiday Follow @refinery29 Refinery29 de uk Now Reading Stress-Induced Amnesia Is Apparently A Thing This Woman Got So Stressed Out She Forgot Who She Was Suzannah Weiss October 26, 2016, 5:15 PM Illustrated by Tyler Spangler. We've long known stress can wreak havoc on your mind and body. It has the potential to hurt your heart, your immune system, and even your memory. In an extreme case of stress-induced memory loss, a woman in England forgot her name, her husband's identity, and nearly everything else about her life after a nervous breakdown, The Daily Mail reports. Marie Coe, 55, was working upwards of 70 hours a week in a demanding job running an events company in the U.K., traveling constantly, all while also juggling a family and taking care of her household. One day, after she'd gone missing for 24 hours and couldn't remember anything, she asked a stranger at a gas station for help. An ambulance came, and she couldn't answer any of the paramedics' questions. After a CT scan revealed no head injuries, the doctors diagnosed her with "stress-induced amnesia,"according to The Daily Mail. This is, apparently, a real thing: Memory loss caused by extreme stress or trauma is actually "dissociative amnesia," according to Merck Manuals. It seems to run in families, according to The Cleveland Clinic. It can cause someone to forget everything, as with Coe, or it can concern specific areas of the sufferer's life. Sometimes, a person with the condition will forget who they are and go on to assume an entirely new identity without realizing it (this is known as "dissociative fugue."). When Coe's husband Mark picked her up from the hospital, she had no idea who he was. She didn't even know she was married. "It was terrifying sitting in the car with a strange man who claimed he was my husband," she told The Daily Mail. In a scenario reminiscent of 50 First Dates, he told her about their relationship and showed her photos of their grandchildren, and they got to know each other all over again â€” while living together. "Although it was frightening, it was exciting at the same time. Like a first date," she told the paper. "I looked at Mark's kind face and smiling eyes and knew I could see why the old me had fallen in love with him... We had romantic dinners together and talked and laughed until the small hours of the morning." She turned to hypnosis and meditation to regain her memory and manage her stress. These are common treatments for dissociative amnesia, along with individual and family therapy, art and music therapy, and sometimes medication, according to The Cleveland Clinic. The hypnotist explained to her that the amnesia was her brain's way of shutting down when she didn't allow it any other way to rest. Coe has since learned to practice better self-care. She closed her business and got a less demanding job in order to reduce her stress. "I've realized you can't give from an empty cup, so I look after myself rather than running myself ragged for everyone else's sake," she said. She still suffers from short-term memory problems, but her long-term memory is back. The silver lining of all this is that the incident has strengthened Coe's relationship with her husband. "When Mark said he'd look after me in sickness and in health, he really meant it," she said. "When I look back to that day in [the] hospital, I think I'd always hoped that man they were telling me was my hubby, as he was handsome and had a twinkle in his eye. I know he really is the man for me because I fell in love with him twice â€” and that must mean he's the one." Advertisement How To Deal With Stress â€¢ Mind â€¢ Wellness Illustrated by Tyler Spangler. More from Mind What Happens When Women Cry In Public Mind Elizabeth Kiefer Nov 11, 2016 30 Reddit Users Share The Dark Secrets They Keep From Everyone Mind Sara Coughlin Nov 11, 2016 How I Finally Got Over My Fear Of Driving Mind Anna Maltby Nov 11, 2016 Improve Your Productivity At Work With These Easy Steps Dedicated Feature Colleen Barrett Sep 7, 2016 The Uncomfortable Truth About My Rape â€” & Why I'm Coming Forward Now Mind Audi Martel Nov 10, 2016 The Emotional Aftermath Of Facing America's Racist Reality Mind Carla Bruce-Eddings Nov 9, 2016 Why Itâ€™s Okay â€” Necessary, Even â€” To Sit With Your Grief & Anger Right... Mind Sarah Jacoby Nov 9, 2016 Your Mood Is Going To Significantly Improve After Watching This Video Dedicated Feature R29 Brand Experience... Sep 12, 2016 How American Women Are Caring For Themselves Today Mind Sara Coughlin Nov 9, 2016 Need Help After The Election? These Mental Health Resources Are Completely Free Of... Mind Kimberly Truong Nov 9, 2016 Here's An Election-Night Meditation To Help You Chill In The Final Days Mind Sarah Jacoby Nov 4, 2016 27 Gifts For Your Friend Who Always Gets Too High Gift Guide Sarah Jacoby Nov 4, 2016 These Are The Best Songs To Fall Asleep To Music Tracker Kimberly Truong Nov 2, 2016 These 8 Zen Dogs Will Help You Chill Out Instantly Mind Kimberly Truong Nov 1, 2016 Â© 2016 Refinery29 Terms Privacy About Press Advertising Jobs Feedback R29 News Site Map RSS By using our service, you agree to our Terms (effective 5/13/2015) and Privacy (effective 8/23/2016). REFINERY29 name & logo and R29 logo are trademarks of Refinery 29 Inc.
About Us Contact Us Help user name password Client login:Â Â Â  First time user sign up Forgot your login info? Website DirectoryÂ Â Â Â Â Submit Website Search All categoriesAdvertisingÂ Â GeneralAerospaceÂ Â GeneralAgricultureÂ Â GeneralAirlinesÂ Â GeneralAmerica - Post 9/11Â Â GeneralApparelÂ Â GeneralApple ProductsÂ Â GeneralArchitecturalÂ Â GeneralArchitectureÂ Â ArchitectureArt & EntertainmentsÂ Â BooksÂ Â CelebritiesÂ Â Country MusicÂ Â DanceÂ Â MagazinesÂ Â MoviesÂ Â MuseumsÂ Â MusicÂ Â Music DownloadsÂ Â News & Talk ShowsÂ Â Performing ArtsÂ Â PhotographyÂ Â TelevisionÂ Â Web SitesArts/CultureÂ Â GeneralAuctionÂ Â GeneralAutomotiveÂ Â AftermarketÂ Â Classic AutosÂ Â Consumer PublicationsÂ Â GeneralÂ Â Motorcycle & BikeÂ Â RacingÂ Â Recreational VehicleÂ Â Repair & ServiceÂ Â Trade PublicationsBlogging & Social MediaÂ Â Blogging & Social MediaBusinessÂ Â Advertising / MarketingÂ Â BooksÂ Â Consumer ResearchÂ Â Direct MarketingÂ Â e-CommerceÂ Â EntrepreneursÂ Â FinanceÂ Â FranchiseÂ Â Human ResourcesÂ Â InsuranceÂ Â InvestmentÂ Â ManagementÂ Â MarketsÂ Â Network MarketingÂ Â Online Marketing / SEOÂ Â Payday LoansÂ Â Public RelationsÂ Â PublicationsÂ Â Real EstateÂ Â RetailÂ Â StocksÂ Â SupermarketsÂ Â Women in BusinessCareers/HRÂ Â GeneralChemicalÂ Â GeneralCoaching / MentoringÂ Â Coaching / MentoringComputersÂ Â Apple ProductsÂ Â DatabasesÂ Â Games & EntertainmentÂ Â GeneralÂ Â HostingÂ Â InstructionÂ Â Linux / GNU "Open Source"Â Â MacintoshÂ Â Microsoft Windows PCÂ Â Operating SystemsÂ Â ProgrammingÂ Â SecurityÂ Â SoftwareÂ Â Tablet PCsÂ Â UtilitiesConstructionÂ Â GeneralConsumerÂ Â Gifts and CollectiblesÂ Â HobbiesÂ Â Web sites / InternetDesignÂ Â Graphic DesignÂ Â IndustrialÂ Â WebE-CigaretteÂ Â GeneraleCommerceÂ Â GeneralEconomyÂ Â GeneralEducationÂ Â College / UniversityÂ Â GeneralÂ Â Home SchoolingÂ Â K-12Â Â Post GraduateÂ Â TechnicalElectronicsÂ Â GeneralEmail MarketingÂ Â GeneralEmailWire Press ReleasesÂ Â Press Release TipsEmployment/CareersÂ Â GeneralEngineeringÂ Â GeneralEntertainmentÂ Â GeneralEnvironmentÂ Â GeneralEvents / Trade ShowsÂ Â GeneralFinanceÂ Â GeneralFoodÂ Â GeneralFranchiseÂ Â GeneralFraud / Identity TheftÂ Â GeneralGamingÂ Â GeneralGovernmentÂ Â GeneralÂ Â JudicialÂ Â Law EnforcementÂ Â LegislativeÂ Â LocalÂ Â NationalÂ Â Public ServicesÂ Â SecurityÂ Â StateÂ Â TransportationHealthcareÂ Â GeneralHome and FamilyÂ Â Banking / Personal FinanceÂ Â Bereavement / LossÂ Â Home Furnishings / InteriorsÂ Â Landscaping & GardeningÂ Â Marriage / RelationshipsÂ Â MoneyÂ Â ParentingÂ Â Payday LoansÂ Â PetsÂ Â TaxesÂ Â Wedding / BridalHome SchoolingÂ Â GeneralHotels/ResortsÂ Â GeneralHouseholdÂ Â GeneralIndustryÂ Â Aerospace / DefenseÂ Â AgricultureÂ Â Apparel / TextilesÂ Â BroadcastÂ Â Construction / BuildingÂ Â ElectricalÂ Â FoodÂ Â FuneralÂ Â HealthcareÂ Â Leisure / HospitalityÂ Â Logistics / ShippingÂ Â Manufacturing / ProductionÂ Â Mining / MetalsÂ Â Oil / EnergyÂ Â Paper / Forest ProductsÂ Â Plumbing, Heating & ACÂ Â Print MediaÂ Â PrintingÂ Â PublishingÂ Â RadioÂ Â RestaurantsÂ Â TobaccoÂ Â ToyInsuranceÂ Â GeneralInternet/OnlineÂ Â GeneralLegalÂ Â GeneralLeisureÂ Â GeneralLifestyleÂ Â BeautyÂ Â Dating / SinglesÂ Â Diet / Weight LossÂ Â FashionÂ Â Food / BeverageÂ Â Health & FitnessÂ Â Hotel / ResortsÂ Â PastimesÂ Â RestaurantsÂ Â RetirementÂ Â Travel & TourismMachineryÂ Â GeneralMaritimeÂ Â GeneralMedicalÂ Â AddictionÂ Â AllergiesÂ Â Alternative MedicineÂ Â AsthmaÂ Â CancerÂ Â CardiologyÂ Â ChiropracticÂ Â DentalÂ Â DermatologyÂ Â DiabetesÂ Â EmergencyÂ Â Family MedicineÂ Â GeneralÂ Â GeneralÂ Â GeriatricsÂ Â HospitalsÂ Â Infectious DiseasesÂ Â Internal MedicineÂ Â Managed Care / HMOÂ Â Medical ProductsÂ Â Mental HealthÂ Â NeurologyÂ Â NursingÂ Â NutritionÂ Â OB / GYNÂ Â PediatricsÂ Â PharmaceuticalsÂ Â Physical TherapyÂ Â Plastic SurgeryÂ Â PsychologyÂ Â Radiology / ImagingÂ Â ResearchÂ Â Sports MedicineÂ Â SurgeryÂ Â VisionMilitaryÂ Â GeneralMining/MetalsÂ Â GeneralMiscellaneousÂ Â GeneralNanotechnologyÂ Â NanotechnologyNon-profitÂ Â GeneralOccupational SafetyÂ Â Occupational SafetyOil/EnergyÂ Â GeneralOpinion / EditorialÂ Â Opinion / EditorialPaper ProductsÂ Â GeneralPaper/ForestÂ Â GeneralPharmaceuticalsÂ Â GeneralPodcastingÂ Â AnnounceÂ Â Tools and ServicesPoliticsÂ Â PoliticsPrint MediaÂ Â GeneralPublic UtilitiesÂ Â Public UtilitiesPublishingÂ Â GeneralRadioÂ Â GeneralReal EstateÂ Â GeneralReligionÂ Â ChristianÂ Â GeneralÂ Â IslamÂ Â JewishÂ Â OtherRestaurantsÂ Â GeneralRetailÂ Â GeneralRSS & Content SyndicationÂ Â RSS & Content SyndicationScience and ResearchÂ Â Science and ResearchSelf-Help / Personal GrowthÂ Â Self-Help / Personal GrowthShipbuildingÂ Â GeneralSocietyÂ Â African American InterestsÂ Â Asian InterestsÂ Â Childrens IssuesÂ Â Disabled Issues / DisabilitiesÂ Â Gay / LesbianÂ Â HispanicÂ Â Mens InterestsÂ Â Native AmericanÂ Â Senior CitizensÂ Â Social ServicesÂ Â Teen Issues/InterestsÂ Â Womens InterestSoftwareÂ Â GeneralSportsÂ Â BaseballÂ Â BasketballÂ Â BicyclingÂ Â Boating / MaritimeÂ Â BowlingÂ Â BoxingÂ Â FishingÂ Â FootballÂ Â GolfÂ Â HockeyÂ Â HuntingÂ Â Martial ArtsÂ Â OutdoorsÂ Â RugbyÂ Â SoccerÂ Â TennisÂ Â WaterÂ Â Winter/SnowSports/FitnessÂ Â GeneralStocksÂ Â GeneralSupermarketsÂ Â GeneralTechnologyÂ Â BiotechnologyÂ Â ComputerÂ Â ElectronicsÂ Â Enterprise SoftwareÂ Â GamesÂ Â Graphics/Printing/CADÂ Â Hardware / PeripheralsÂ Â IndustrialÂ Â InformationÂ Â InternetÂ Â MultimediaÂ Â NetworkingÂ Â Public Sector/GovernmentÂ Â RoboticsÂ Â SemiconductorÂ Â SoftwareÂ Â TelecommunicationsÂ Â WebmastersTelecomÂ Â GeneralÂ Â WirelessTelevisionÂ Â GeneralTobaccoÂ Â GeneralTradeÂ Â GeneralTransportationÂ Â GeneralTravelÂ Â GeneralUtilitiesÂ Â GeneralVolunteerÂ Â VolunteerWeatherÂ Â Weather Home > News By Company > ReportsWeb.com Tweet Â  Chronic Obstructive Pulmonary Disease Drugs Market 2016 Trend, Analysis and Overview ReportsWeb.com published Â“Chronic Obstructive Pulmonary Disease Drugs MarketÂ” from its database. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in t (EMAILWIRE.COM, October 26, 2016 ) COPD is a chronic disease condition with a combination of symptoms of both chronic bronchitis and emphysema. Chronic bronchitis results in inflammation in the bronchioles, which results in increased mucus production. The condition is usually associated with a long-term cough with mucus. Emphysema results in the destruction of the walls of the alveoli, resulting in difficulty in breathing. Publisher's analysts forecast the global chronic obstructive pulmonary disease (COPD) drugs market to grow at a CAGR of 4.85% during the period 2016-2020. For more information about this report: http://www.reportsweb.com/global-chronic-obstructive-pulmonary-disease-drugs-market-2016-2020 Covered in this report The report covers the present scenario and the growth prospects of the global chronic obstructive pulmonary disease (COPD) drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used to treat COPD. The market is divided into the following segments based on geography: -Americas -APAC -EMEA Publisher's report, Global Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Key vendors -AstraZeneca -Boehringer Ingelheim -GSK -Merck -Novartis -Teva Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001332793/sample Other prominent vendors -Ache Laboratorios Farmaceuticos -Almirall -Aquinox Pharmaceuticals -Ario Pharma -Asmacure -Astellas Pharma -BioMarck Pharmaceuticals -Chiesi Farmaceutici -Cytokinetics -F. Hoffmann-La Roche -Gilead Sciences -Innoviva -Invion -MediciNova -Mereo BioPharma -Mylan -Orion Corporation -Palobiofarma -Pearl Therapeutics -Pharmaxis -Prosonix -Pulmagen Therapeutics -RespiVert -SolAeroMed -Sunovion Pharmaceuticals -Theravance Biopharma -Theron Pharmaceuticals -Verona Pharma -Xention -Yungjin Pharm -ZAI Lab Market driver -Uptake of LABA/LAMA combination therapies -For a full, detailed list, view our report Market challenge -Negligence toward use of controller medications -For a full, detailed list, view our report Market trend -Increased adoption of e-cigarettes and smoking cessation products -For a full, detailed list, view our report Inquire for Report at http://www.reportsweb.com/inquiry&RW0001332793/buying Contact Information: ReportsWeb.com Priya Sisodia Tel: +1-646-491-9876 Email us This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php. 
 Â  Search All categoriesAdvertisingÂ Â GeneralAerospaceÂ Â GeneralAgricultureÂ Â GeneralAirlinesÂ Â GeneralAmerica - Post 9/11Â Â GeneralApparelÂ Â GeneralApple ProductsÂ Â GeneralArchitecturalÂ Â GeneralArchitectureÂ Â ArchitectureArt & EntertainmentsÂ Â BooksÂ Â CelebritiesÂ Â Country MusicÂ Â DanceÂ Â MagazinesÂ Â MoviesÂ Â MuseumsÂ Â MusicÂ Â Music DownloadsÂ Â News & Talk ShowsÂ Â Performing ArtsÂ Â PhotographyÂ Â TelevisionÂ Â Web SitesArts/CultureÂ Â GeneralAuctionÂ Â GeneralAutomotiveÂ Â AftermarketÂ Â Classic AutosÂ Â Consumer PublicationsÂ Â GeneralÂ Â Motorcycle & BikeÂ Â RacingÂ Â Recreational VehicleÂ Â Repair & ServiceÂ Â Trade PublicationsBlogging & Social MediaÂ Â Blogging & Social MediaBusinessÂ Â Advertising / MarketingÂ Â BooksÂ Â Consumer ResearchÂ Â Direct MarketingÂ Â e-CommerceÂ Â EntrepreneursÂ Â FinanceÂ Â FranchiseÂ Â Human ResourcesÂ Â InsuranceÂ Â InvestmentÂ Â ManagementÂ Â MarketsÂ Â Network MarketingÂ Â Online Marketing / SEOÂ Â Payday LoansÂ Â Public RelationsÂ Â PublicationsÂ Â Real EstateÂ Â RetailÂ Â StocksÂ Â SupermarketsÂ Â Women in BusinessCareers/HRÂ Â GeneralChemicalÂ Â GeneralCoaching / MentoringÂ Â Coaching / MentoringComputersÂ Â Apple ProductsÂ Â DatabasesÂ Â Games & EntertainmentÂ Â GeneralÂ Â HostingÂ Â InstructionÂ Â Linux / GNU "Open Source"Â Â MacintoshÂ Â Microsoft Windows PCÂ Â Operating SystemsÂ Â ProgrammingÂ Â SecurityÂ Â SoftwareÂ Â Tablet PCsÂ Â UtilitiesConstructionÂ Â GeneralConsumerÂ Â Gifts and CollectiblesÂ Â HobbiesÂ Â Web sites / InternetDesignÂ Â Graphic DesignÂ Â IndustrialÂ Â WebE-CigaretteÂ Â GeneraleCommerceÂ Â GeneralEconomyÂ Â GeneralEducationÂ Â College / UniversityÂ Â GeneralÂ Â Home SchoolingÂ Â K-12Â Â Post GraduateÂ Â TechnicalElectronicsÂ Â GeneralEmail MarketingÂ Â GeneralEmailWire Press ReleasesÂ Â Press Release TipsEmployment/CareersÂ Â GeneralEngineeringÂ Â GeneralEntertainmentÂ Â GeneralEnvironmentÂ Â GeneralEvents / Trade ShowsÂ Â GeneralFinanceÂ Â GeneralFoodÂ Â GeneralFranchiseÂ Â GeneralFraud / Identity TheftÂ Â GeneralGamingÂ Â GeneralGovernmentÂ Â GeneralÂ Â JudicialÂ Â Law EnforcementÂ Â LegislativeÂ Â LocalÂ Â NationalÂ Â Public ServicesÂ Â SecurityÂ Â StateÂ Â TransportationHealthcareÂ Â GeneralHome and FamilyÂ Â Banking / Personal FinanceÂ Â Bereavement / LossÂ Â Home Furnishings / InteriorsÂ Â Landscaping & GardeningÂ Â Marriage / RelationshipsÂ Â MoneyÂ Â ParentingÂ Â Payday LoansÂ Â PetsÂ Â TaxesÂ Â Wedding / BridalHome SchoolingÂ Â GeneralHotels/ResortsÂ Â GeneralHouseholdÂ Â GeneralIndustryÂ Â Aerospace / DefenseÂ Â AgricultureÂ Â Apparel / TextilesÂ Â BroadcastÂ Â Construction / BuildingÂ Â ElectricalÂ Â FoodÂ Â FuneralÂ Â HealthcareÂ Â Leisure / HospitalityÂ Â Logistics / ShippingÂ Â Manufacturing / ProductionÂ Â Mining / MetalsÂ Â Oil / EnergyÂ Â Paper / Forest ProductsÂ Â Plumbing, Heating & ACÂ Â Print MediaÂ Â PrintingÂ Â PublishingÂ Â RadioÂ Â RestaurantsÂ Â TobaccoÂ Â ToyInsuranceÂ Â GeneralInternet/OnlineÂ Â GeneralLegalÂ Â GeneralLeisureÂ Â GeneralLifestyleÂ Â BeautyÂ Â Dating / SinglesÂ Â Diet / Weight LossÂ Â FashionÂ Â Food / BeverageÂ Â Health & FitnessÂ Â Hotel / ResortsÂ Â PastimesÂ Â RestaurantsÂ Â RetirementÂ Â Travel & TourismMachineryÂ Â GeneralMaritimeÂ Â GeneralMedicalÂ Â AddictionÂ Â AllergiesÂ Â Alternative MedicineÂ Â AsthmaÂ Â CancerÂ Â CardiologyÂ Â ChiropracticÂ Â DentalÂ Â DermatologyÂ Â DiabetesÂ Â EmergencyÂ Â Family MedicineÂ Â GeneralÂ Â GeneralÂ Â GeriatricsÂ Â HospitalsÂ Â Infectious DiseasesÂ Â Internal MedicineÂ Â Managed Care / HMOÂ Â Medical ProductsÂ Â Mental HealthÂ Â NeurologyÂ Â NursingÂ Â NutritionÂ Â OB / GYNÂ Â PediatricsÂ Â PharmaceuticalsÂ Â Physical TherapyÂ Â Plastic SurgeryÂ Â PsychologyÂ Â Radiology / ImagingÂ Â ResearchÂ Â Sports MedicineÂ Â SurgeryÂ Â VisionMilitaryÂ Â GeneralMining/MetalsÂ Â GeneralMiscellaneousÂ Â GeneralNanotechnologyÂ Â NanotechnologyNon-profitÂ Â GeneralOccupational SafetyÂ Â Occupational SafetyOil/EnergyÂ Â GeneralOpinion / EditorialÂ Â Opinion / EditorialPaper ProductsÂ Â GeneralPaper/ForestÂ Â GeneralPharmaceuticalsÂ Â GeneralPodcastingÂ Â AnnounceÂ Â Tools and ServicesPoliticsÂ Â PoliticsPrint MediaÂ Â GeneralPublic UtilitiesÂ Â Public UtilitiesPublishingÂ Â GeneralRadioÂ Â GeneralReal EstateÂ Â GeneralReligionÂ Â ChristianÂ Â GeneralÂ Â IslamÂ Â JewishÂ Â OtherRestaurantsÂ Â GeneralRetailÂ Â GeneralRSS & Content SyndicationÂ Â RSS & Content SyndicationScience and ResearchÂ Â Science and ResearchSelf-Help / Personal GrowthÂ Â Self-Help / Personal GrowthShipbuildingÂ Â GeneralSocietyÂ Â African American InterestsÂ Â Asian InterestsÂ Â Childrens IssuesÂ Â Disabled Issues / DisabilitiesÂ Â Gay / LesbianÂ Â HispanicÂ Â Mens InterestsÂ Â Native AmericanÂ Â Senior CitizensÂ Â Social ServicesÂ Â Teen Issues/InterestsÂ Â Womens InterestSoftwareÂ Â GeneralSportsÂ Â BaseballÂ Â BasketballÂ Â BicyclingÂ Â Boating / MaritimeÂ Â BowlingÂ Â BoxingÂ Â FishingÂ Â FootballÂ Â GolfÂ Â HockeyÂ Â HuntingÂ Â Martial ArtsÂ Â OutdoorsÂ Â RugbyÂ Â SoccerÂ Â TennisÂ Â WaterÂ Â Winter/SnowSports/FitnessÂ Â GeneralStocksÂ Â GeneralSupermarketsÂ Â GeneralTechnologyÂ Â BiotechnologyÂ Â ComputerÂ Â ElectronicsÂ Â Enterprise SoftwareÂ Â GamesÂ Â Graphics/Printing/CADÂ Â Hardware / PeripheralsÂ Â IndustrialÂ Â InformationÂ Â InternetÂ Â MultimediaÂ Â NetworkingÂ Â Public Sector/GovernmentÂ Â RoboticsÂ Â SemiconductorÂ Â SoftwareÂ Â TelecommunicationsÂ Â WebmastersTelecomÂ Â GeneralÂ Â WirelessTelevisionÂ Â GeneralTobaccoÂ Â GeneralTradeÂ Â GeneralTransportationÂ Â GeneralTravelÂ Â GeneralUtilitiesÂ Â GeneralVolunteerÂ Â VolunteerWeatherÂ Â Weather Advertising | How to contact us | Privacy Statement | EmailWire Press Releases | Partnership Opportunities EmailWire is a press release distribution service of GroupWeb Media LLC. Â© Copyright GroupWeb Media LLC 2016
About Us Contact Us Help user name password Client login:Â Â Â  First time user sign up Forgot your login info? Website DirectoryÂ Â Â Â Â Submit Website Search All categoriesAdvertisingÂ Â GeneralAerospaceÂ Â GeneralAgricultureÂ Â GeneralAirlinesÂ Â GeneralAmerica - Post 9/11Â Â GeneralApparelÂ Â GeneralApple ProductsÂ Â GeneralArchitecturalÂ Â GeneralArchitectureÂ Â ArchitectureArt & EntertainmentsÂ Â BooksÂ Â CelebritiesÂ Â Country MusicÂ Â DanceÂ Â MagazinesÂ Â MoviesÂ Â MuseumsÂ Â MusicÂ Â Music DownloadsÂ Â News & Talk ShowsÂ Â Performing ArtsÂ Â PhotographyÂ Â TelevisionÂ Â Web SitesArts/CultureÂ Â GeneralAuctionÂ Â GeneralAutomotiveÂ Â AftermarketÂ Â Classic AutosÂ Â Consumer PublicationsÂ Â GeneralÂ Â Motorcycle & BikeÂ Â RacingÂ Â Recreational VehicleÂ Â Repair & ServiceÂ Â Trade PublicationsBlogging & Social MediaÂ Â Blogging & Social MediaBusinessÂ Â Advertising / MarketingÂ Â BooksÂ Â Consumer ResearchÂ Â Direct MarketingÂ Â e-CommerceÂ Â EntrepreneursÂ Â FinanceÂ Â FranchiseÂ Â Human ResourcesÂ Â InsuranceÂ Â InvestmentÂ Â ManagementÂ Â MarketsÂ Â Network MarketingÂ Â Online Marketing / SEOÂ Â Payday LoansÂ Â Public RelationsÂ Â PublicationsÂ Â Real EstateÂ Â RetailÂ Â StocksÂ Â SupermarketsÂ Â Women in BusinessCareers/HRÂ Â GeneralChemicalÂ Â GeneralCoaching / MentoringÂ Â Coaching / MentoringComputersÂ Â Apple ProductsÂ Â DatabasesÂ Â Games & EntertainmentÂ Â GeneralÂ Â HostingÂ Â InstructionÂ Â Linux / GNU "Open Source"Â Â MacintoshÂ Â Microsoft Windows PCÂ Â Operating SystemsÂ Â ProgrammingÂ Â SecurityÂ Â SoftwareÂ Â Tablet PCsÂ Â UtilitiesConstructionÂ Â GeneralConsumerÂ Â Gifts and CollectiblesÂ Â HobbiesÂ Â Web sites / InternetDesignÂ Â Graphic DesignÂ Â IndustrialÂ Â WebE-CigaretteÂ Â GeneraleCommerceÂ Â GeneralEconomyÂ Â GeneralEducationÂ Â College / UniversityÂ Â GeneralÂ Â Home SchoolingÂ Â K-12Â Â Post GraduateÂ Â TechnicalElectronicsÂ Â GeneralEmail MarketingÂ Â GeneralEmailWire Press ReleasesÂ Â Press Release TipsEmployment/CareersÂ Â GeneralEngineeringÂ Â GeneralEntertainmentÂ Â GeneralEnvironmentÂ Â GeneralEvents / Trade ShowsÂ Â GeneralFinanceÂ Â GeneralFoodÂ Â GeneralFranchiseÂ Â GeneralFraud / Identity TheftÂ Â GeneralGamingÂ Â GeneralGovernmentÂ Â GeneralÂ Â JudicialÂ Â Law EnforcementÂ Â LegislativeÂ Â LocalÂ Â NationalÂ Â Public ServicesÂ Â SecurityÂ Â StateÂ Â TransportationHealthcareÂ Â GeneralHome and FamilyÂ Â Banking / Personal FinanceÂ Â Bereavement / LossÂ Â Home Furnishings / InteriorsÂ Â Landscaping & GardeningÂ Â Marriage / RelationshipsÂ Â MoneyÂ Â ParentingÂ Â Payday LoansÂ Â PetsÂ Â TaxesÂ Â Wedding / BridalHome SchoolingÂ Â GeneralHotels/ResortsÂ Â GeneralHouseholdÂ Â GeneralIndustryÂ Â Aerospace / DefenseÂ Â AgricultureÂ Â Apparel / TextilesÂ Â BroadcastÂ Â Construction / BuildingÂ Â ElectricalÂ Â FoodÂ Â FuneralÂ Â HealthcareÂ Â Leisure / HospitalityÂ Â Logistics / ShippingÂ Â Manufacturing / ProductionÂ Â Mining / MetalsÂ Â Oil / EnergyÂ Â Paper / Forest ProductsÂ Â Plumbing, Heating & ACÂ Â Print MediaÂ Â PrintingÂ Â PublishingÂ Â RadioÂ Â RestaurantsÂ Â TobaccoÂ Â ToyInsuranceÂ Â GeneralInternet/OnlineÂ Â GeneralLegalÂ Â GeneralLeisureÂ Â GeneralLifestyleÂ Â BeautyÂ Â Dating / SinglesÂ Â Diet / Weight LossÂ Â FashionÂ Â Food / BeverageÂ Â Health & FitnessÂ Â Hotel / ResortsÂ Â PastimesÂ Â RestaurantsÂ Â RetirementÂ Â Travel & TourismMachineryÂ Â GeneralMaritimeÂ Â GeneralMedicalÂ Â AddictionÂ Â AllergiesÂ Â Alternative MedicineÂ Â AsthmaÂ Â CancerÂ Â CardiologyÂ Â ChiropracticÂ Â DentalÂ Â DermatologyÂ Â DiabetesÂ Â EmergencyÂ Â Family MedicineÂ Â GeneralÂ Â GeneralÂ Â GeriatricsÂ Â HospitalsÂ Â Infectious DiseasesÂ Â Internal MedicineÂ Â Managed Care / HMOÂ Â Medical ProductsÂ Â Mental HealthÂ Â NeurologyÂ Â NursingÂ Â NutritionÂ Â OB / GYNÂ Â PediatricsÂ Â PharmaceuticalsÂ Â Physical TherapyÂ Â Plastic SurgeryÂ Â PsychologyÂ Â Radiology / ImagingÂ Â ResearchÂ Â Sports MedicineÂ Â SurgeryÂ Â VisionMilitaryÂ Â GeneralMining/MetalsÂ Â GeneralMiscellaneousÂ Â GeneralNanotechnologyÂ Â NanotechnologyNon-profitÂ Â GeneralOccupational SafetyÂ Â Occupational SafetyOil/EnergyÂ Â GeneralOpinion / EditorialÂ Â Opinion / EditorialPaper ProductsÂ Â GeneralPaper/ForestÂ Â GeneralPharmaceuticalsÂ Â GeneralPodcastingÂ Â AnnounceÂ Â Tools and ServicesPoliticsÂ Â PoliticsPrint MediaÂ Â GeneralPublic UtilitiesÂ Â Public UtilitiesPublishingÂ Â GeneralRadioÂ Â GeneralReal EstateÂ Â GeneralReligionÂ Â ChristianÂ Â GeneralÂ Â IslamÂ Â JewishÂ Â OtherRestaurantsÂ Â GeneralRetailÂ Â GeneralRSS & Content SyndicationÂ Â RSS & Content SyndicationScience and ResearchÂ Â Science and ResearchSelf-Help / Personal GrowthÂ Â Self-Help / Personal GrowthShipbuildingÂ Â GeneralSocietyÂ Â African American InterestsÂ Â Asian InterestsÂ Â Childrens IssuesÂ Â Disabled Issues / DisabilitiesÂ Â Gay / LesbianÂ Â HispanicÂ Â Mens InterestsÂ Â Native AmericanÂ Â Senior CitizensÂ Â Social ServicesÂ Â Teen Issues/InterestsÂ Â Womens InterestSoftwareÂ Â GeneralSportsÂ Â BaseballÂ Â BasketballÂ Â BicyclingÂ Â Boating / MaritimeÂ Â BowlingÂ Â BoxingÂ Â FishingÂ Â FootballÂ Â GolfÂ Â HockeyÂ Â HuntingÂ Â Martial ArtsÂ Â OutdoorsÂ Â RugbyÂ Â SoccerÂ Â TennisÂ Â WaterÂ Â Winter/SnowSports/FitnessÂ Â GeneralStocksÂ Â GeneralSupermarketsÂ Â GeneralTechnologyÂ Â BiotechnologyÂ Â ComputerÂ Â ElectronicsÂ Â Enterprise SoftwareÂ Â GamesÂ Â Graphics/Printing/CADÂ Â Hardware / PeripheralsÂ Â IndustrialÂ Â InformationÂ Â InternetÂ Â MultimediaÂ Â NetworkingÂ Â Public Sector/GovernmentÂ Â RoboticsÂ Â SemiconductorÂ Â SoftwareÂ Â TelecommunicationsÂ Â WebmastersTelecomÂ Â GeneralÂ Â WirelessTelevisionÂ Â GeneralTobaccoÂ Â GeneralTradeÂ Â GeneralTransportationÂ Â GeneralTravelÂ Â GeneralUtilitiesÂ Â GeneralVolunteerÂ Â VolunteerWeatherÂ Â Weather Home > News By Company > ReportsWeb.com Tweet Â  Monoclonal Antibodies Market 2016 Geographical segmentation, Size, Trends, Growth and Forecasts ReportsWeb.com published Â“Monoclonal Antibodies MarketÂ” from its database. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. (EMAILWIRE.COM, October 26, 2016 ) Antibodies are the proteins produced by B-cells (in the bone marrow) in the immune system. These proteins attach themselves to antigens, which act as markers, and are then destroyed by phagocytes. B-cells produce different antibodies, which attach themselves to different sites of an antigen. mAbs are monospecific, as they are the clones of a single parent cell. They are complex proteins with high molecular weight, and were first developed in 1975 by Kohler and Milstein. Publisher's analysts forecast the global monoclonal antibodies (mAbs) market to grow at a CAGR of 9.84% during the period 2016-2020. For more information about this report: http://www.reportsweb.com/global-monoclonal-antibodies-market-2016-2020 Covered in this report The report covers the present scenario and the growth prospects of the global monoclonal antibodies (mAbs) market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded mAbs and biosimilars used to treat cancer, autoimmune and inflammatory diseases, respiratory diseases, and ophthalmology. It also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market, along with the decline in revenues from the patent expiries of the marketed drugs, during the forecast period. The market is divided into the following segments based on geography: -Americas -APAC -EMEA Publisher's report, Global Monoclonal Antibodies (mAbs) Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Key vendors -AbbVie -Amgen -Bristol-Myers Squibb -F. Hoffmann-La Roche -Johnson & Johnson -Merck Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001332795/sample Other prominent vendors -AbGenomics -ADC Therapeutics -Agensys -Alexion Pharmaceuticals -ALMAC Group -Ambrx -Astellas Pharma -AstraZeneca -Bayer HealthCare -Biogen -Celgene -Celldex Therapeutics -Daiichi Sankyo -Eisai -Eli Lilly -Formation Biologics -Genmab -GlaxoSmithKline -Human Genome Sciences -Immunogen -MedImmune -Novartis -Pfizer -Seattle Genetics -Stemcentrx -Synthon Biopharmaceuticals -Takeda Pharmaceuticals -Teva -UCB Market driver -Special regulatory drug designations -For a full, detailed list, view our report Market challenge -High manufacturing costs coupled with stringent regulations -For a full, detailed list, view our report Market trend -Growing focus of vendors on untapped markets -For a full, detailed list, view our report Inquire for Report at http://www.reportsweb.com/inquiry&RW0001332795/buying Contact Information: ReportsWeb.com Priya Sisodia Tel: +1-646-491-9876 Email us This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php. 
 Â  Search All categoriesAdvertisingÂ Â GeneralAerospaceÂ Â GeneralAgricultureÂ Â GeneralAirlinesÂ Â GeneralAmerica - Post 9/11Â Â GeneralApparelÂ Â GeneralApple ProductsÂ Â GeneralArchitecturalÂ Â GeneralArchitectureÂ Â ArchitectureArt & EntertainmentsÂ Â BooksÂ Â CelebritiesÂ Â Country MusicÂ Â DanceÂ Â MagazinesÂ Â MoviesÂ Â MuseumsÂ Â MusicÂ Â Music DownloadsÂ Â News & Talk ShowsÂ Â Performing ArtsÂ Â PhotographyÂ Â TelevisionÂ Â Web SitesArts/CultureÂ Â GeneralAuctionÂ Â GeneralAutomotiveÂ Â AftermarketÂ Â Classic AutosÂ Â Consumer PublicationsÂ Â GeneralÂ Â Motorcycle & BikeÂ Â RacingÂ Â Recreational VehicleÂ Â Repair & ServiceÂ Â Trade PublicationsBlogging & Social MediaÂ Â Blogging & Social MediaBusinessÂ Â Advertising / MarketingÂ Â BooksÂ Â Consumer ResearchÂ Â Direct MarketingÂ Â e-CommerceÂ Â EntrepreneursÂ Â FinanceÂ Â FranchiseÂ Â Human ResourcesÂ Â InsuranceÂ Â InvestmentÂ Â ManagementÂ Â MarketsÂ Â Network MarketingÂ Â Online Marketing / SEOÂ Â Payday LoansÂ Â Public RelationsÂ Â PublicationsÂ Â Real EstateÂ Â RetailÂ Â StocksÂ Â SupermarketsÂ Â Women in BusinessCareers/HRÂ Â GeneralChemicalÂ Â GeneralCoaching / MentoringÂ Â Coaching / MentoringComputersÂ Â Apple ProductsÂ Â DatabasesÂ Â Games & EntertainmentÂ Â GeneralÂ Â HostingÂ Â InstructionÂ Â Linux / GNU "Open Source"Â Â MacintoshÂ Â Microsoft Windows PCÂ Â Operating SystemsÂ Â ProgrammingÂ Â SecurityÂ Â SoftwareÂ Â Tablet PCsÂ Â UtilitiesConstructionÂ Â GeneralConsumerÂ Â Gifts and CollectiblesÂ Â HobbiesÂ Â Web sites / InternetDesignÂ Â Graphic DesignÂ Â IndustrialÂ Â WebE-CigaretteÂ Â GeneraleCommerceÂ Â GeneralEconomyÂ Â GeneralEducationÂ Â College / UniversityÂ Â GeneralÂ Â Home SchoolingÂ Â K-12Â Â Post GraduateÂ Â TechnicalElectronicsÂ Â GeneralEmail MarketingÂ Â GeneralEmailWire Press ReleasesÂ Â Press Release TipsEmployment/CareersÂ Â GeneralEngineeringÂ Â GeneralEntertainmentÂ Â GeneralEnvironmentÂ Â GeneralEvents / Trade ShowsÂ Â GeneralFinanceÂ Â GeneralFoodÂ Â GeneralFranchiseÂ Â GeneralFraud / Identity TheftÂ Â GeneralGamingÂ Â GeneralGovernmentÂ Â GeneralÂ Â JudicialÂ Â Law EnforcementÂ Â LegislativeÂ Â LocalÂ Â NationalÂ Â Public ServicesÂ Â SecurityÂ Â StateÂ Â TransportationHealthcareÂ Â GeneralHome and FamilyÂ Â Banking / Personal FinanceÂ Â Bereavement / LossÂ Â Home Furnishings / InteriorsÂ Â Landscaping & GardeningÂ Â Marriage / RelationshipsÂ Â MoneyÂ Â ParentingÂ Â Payday LoansÂ Â PetsÂ Â TaxesÂ Â Wedding / BridalHome SchoolingÂ Â GeneralHotels/ResortsÂ Â GeneralHouseholdÂ Â GeneralIndustryÂ Â Aerospace / DefenseÂ Â AgricultureÂ Â Apparel / TextilesÂ Â BroadcastÂ Â Construction / BuildingÂ Â ElectricalÂ Â FoodÂ Â FuneralÂ Â HealthcareÂ Â Leisure / HospitalityÂ Â Logistics / ShippingÂ Â Manufacturing / ProductionÂ Â Mining / MetalsÂ Â Oil / EnergyÂ Â Paper / Forest ProductsÂ Â Plumbing, Heating & ACÂ Â Print MediaÂ Â PrintingÂ Â PublishingÂ Â RadioÂ Â RestaurantsÂ Â TobaccoÂ Â ToyInsuranceÂ Â GeneralInternet/OnlineÂ Â GeneralLegalÂ Â GeneralLeisureÂ Â GeneralLifestyleÂ Â BeautyÂ Â Dating / SinglesÂ Â Diet / Weight LossÂ Â FashionÂ Â Food / BeverageÂ Â Health & FitnessÂ Â Hotel / ResortsÂ Â PastimesÂ Â RestaurantsÂ Â RetirementÂ Â Travel & TourismMachineryÂ Â GeneralMaritimeÂ Â GeneralMedicalÂ Â AddictionÂ Â AllergiesÂ Â Alternative MedicineÂ Â AsthmaÂ Â CancerÂ Â CardiologyÂ Â ChiropracticÂ Â DentalÂ Â DermatologyÂ Â DiabetesÂ Â EmergencyÂ Â Family MedicineÂ Â GeneralÂ Â GeneralÂ Â GeriatricsÂ Â HospitalsÂ Â Infectious DiseasesÂ Â Internal MedicineÂ Â Managed Care / HMOÂ Â Medical ProductsÂ Â Mental HealthÂ Â NeurologyÂ Â NursingÂ Â NutritionÂ Â OB / GYNÂ Â PediatricsÂ Â PharmaceuticalsÂ Â Physical TherapyÂ Â Plastic SurgeryÂ Â PsychologyÂ Â Radiology / ImagingÂ Â ResearchÂ Â Sports MedicineÂ Â SurgeryÂ Â VisionMilitaryÂ Â GeneralMining/MetalsÂ Â GeneralMiscellaneousÂ Â GeneralNanotechnologyÂ Â NanotechnologyNon-profitÂ Â GeneralOccupational SafetyÂ Â Occupational SafetyOil/EnergyÂ Â GeneralOpinion / EditorialÂ Â Opinion / EditorialPaper ProductsÂ Â GeneralPaper/ForestÂ Â GeneralPharmaceuticalsÂ Â GeneralPodcastingÂ Â AnnounceÂ Â Tools and ServicesPoliticsÂ Â PoliticsPrint MediaÂ Â GeneralPublic UtilitiesÂ Â Public UtilitiesPublishingÂ Â GeneralRadioÂ Â GeneralReal EstateÂ Â GeneralReligionÂ Â ChristianÂ Â GeneralÂ Â IslamÂ Â JewishÂ Â OtherRestaurantsÂ Â GeneralRetailÂ Â GeneralRSS & Content SyndicationÂ Â RSS & Content SyndicationScience and ResearchÂ Â Science and ResearchSelf-Help / Personal GrowthÂ Â Self-Help / Personal GrowthShipbuildingÂ Â GeneralSocietyÂ Â African American InterestsÂ Â Asian InterestsÂ Â Childrens IssuesÂ Â Disabled Issues / DisabilitiesÂ Â Gay / LesbianÂ Â HispanicÂ Â Mens InterestsÂ Â Native AmericanÂ Â Senior CitizensÂ Â Social ServicesÂ Â Teen Issues/InterestsÂ Â Womens InterestSoftwareÂ Â GeneralSportsÂ Â BaseballÂ Â BasketballÂ Â BicyclingÂ Â Boating / MaritimeÂ Â BowlingÂ Â BoxingÂ Â FishingÂ Â FootballÂ Â GolfÂ Â HockeyÂ Â HuntingÂ Â Martial ArtsÂ Â OutdoorsÂ Â RugbyÂ Â SoccerÂ Â TennisÂ Â WaterÂ Â Winter/SnowSports/FitnessÂ Â GeneralStocksÂ Â GeneralSupermarketsÂ Â GeneralTechnologyÂ Â BiotechnologyÂ Â ComputerÂ Â ElectronicsÂ Â Enterprise SoftwareÂ Â GamesÂ Â Graphics/Printing/CADÂ Â Hardware / PeripheralsÂ Â IndustrialÂ Â InformationÂ Â InternetÂ Â MultimediaÂ Â NetworkingÂ Â Public Sector/GovernmentÂ Â RoboticsÂ Â SemiconductorÂ Â SoftwareÂ Â TelecommunicationsÂ Â WebmastersTelecomÂ Â GeneralÂ Â WirelessTelevisionÂ Â GeneralTobaccoÂ Â GeneralTradeÂ Â GeneralTransportationÂ Â GeneralTravelÂ Â GeneralUtilitiesÂ Â GeneralVolunteerÂ Â VolunteerWeatherÂ Â Weather Advertising | How to contact us | Privacy Statement | EmailWire Press Releases | Partnership Opportunities EmailWire is a press release distribution service of GroupWeb Media LLC. Â© Copyright GroupWeb Media LLC 2016
Menu Topics Biomedicine Business Computing Energy Mobile Robotics 10 Breakthrough Technologies 35 Innovators Under 35 50 Smartest Companies Views Views from the Marketplace Top Stories Magazine Events More Events Special Publications MIT News Magazine Help/Support Log in / Register Subscribe Log in / Register Search Click search or press enter Business Searching the Human Immune System for Clues to Cancer A new test is changing cancer treatment and has implications for other illnesses, too. by Arlene Weintraub October 26, 2016 After a young man with acute leukemia was treated successfully with traditional chemotherapy, he found himself facing a tough decision. He could stay on chemo and face the high risk of relapse associated with his particular disease, or he could undergo a blood or bone marrow transplant, which would offer the best chance of a cure but put him at risk for severe complications. To help guide the decision, Frederick Appelbaum, an expert in clinical research at the Fred Hutchinson Cancer Research Center in Seattle, and other doctors there used a new diagnostic test that analyzed the patientâ€™s own cancer DNA, as well as the genetic makeup of his immune cells, and then used that information to detect whether trace amounts of the disease remained after his treatment. Thatâ€™s something standard diagnostic tests canâ€™t do well. The new test revealed leukemia cells still lurking in the patientâ€™s body, so he opted for the transplant, despite the additional risk. Heâ€™s now in remission, says Appelbaum. A T cell from the immune system of a person in good health. The diagnostic test, called ClonoSEQ, is the first product introduced by Adaptive Biotechnologies, which was founded in 2009 by brothers Chad and Harlan Robins. (Appelbaum is an advisor to Adaptive.) Harlan originally came up with the concept for the test at Hutchinson, where he holds a faculty position. His idea was to use DNA sequencing to scrutinize the genes of T and B cells, which are the building blocks of the immune system. Unlike other cells in the body, T and B cells constantly reshuffle their DNA in response to pathogens in their environment. Adaptiveâ€™s technology is designed to detect those changesâ€”essentially tracking the immune responses of individual patients over time. The idea of sequencing the DNA of immune cells is still in its infancy and pursued mostly by academics and a handful of companies, so Adaptive must establish demand for a whole new category of test. In the past seven years, working with his brother Chad, a Wharton MBA and experienced executive, Robins has raised more than $400 million from a cadre of A-list investors including Matrix Capital Management, biotechnology giant Celgene, and Illumina, the leading maker of gene-sequencing technology. Understanding the immune system has become a priority in oncology research, particularly with the recent success of a class of drugs called checkpoint inhibitors, which block proteins in the body that would normally prevent the immune system from recognizing and fighting cancer. Two leading examples are Merckâ€™s Keytruda and Bristol-Myers Squibbâ€™s Opdivo, used to treat melanoma, lung cancer, and other tumor types. Many more checkpoint inhibitors are being developed, as are other immune approaches, such as removing T cells from patients and engineering them to attack their specific cancers (see 10 Breakthrough Technologies 2016: Immune Engineering). Such immune-based treatments have improved the prognosis for some cancer patients, but others donâ€™t respond to them at allâ€”and scientists have not yet figured out why. â€œOncologists had been trying to figure out how to coÃ¶pt the immune system to help kill cancer for 40 years, and finally theyâ€™re finding success,â€ Robins says. For treatments like checkpoint inhibitors to be effective, he explains, there must first be an existing immune response in the tumor. Adaptiveâ€™s technology measures that response. Illumina sees Adaptiveâ€™s approach as the next frontier in gene sequencing, says John Leite, vice president of marketing for Illuminaâ€™s oncology business, in addition to looking for genetic mutations in cancer cells that may help patients respond to particular therapies. Adaptive has shown that its test can be much more sensitive to disease than other tools, such as the cell-counting technology called flow cytometry. The insights gained from sequencing immune cells may include identifying which patients are most likely to respond to a particular immuno-oncology drug, pinpointing other drugs that might be effectively used in combination with that treatment, and suggesting what order the drugs should be taken in for best results, says Chad Robins. In January Adaptive formed a partnership with Pfizer aimed at identifying patients who are most likely to benefit from the immuno-oncology drugs the company is developing. And it is working with other large pharmaceutical companies as well. Beyond cancer, the technology could be useful in treating other diseases with a strong immune component, including autoimmune disorders such as rheumatoid arthritis, the Robinses say. It could be helpful in controlling infectious diseases, too. The brothers wonâ€™t reveal their pricing strategy for ClonoSEQ or future products, but they believe theyâ€™ll ultimately be able to prove that immuno-sequencing lowers costs by reducing the risk of disease recurrence and helping patients avoid expensive treatments that are unlikely to work for them. To prove the value of its test to oncologists, Adaptive has worked with scientists at the University of California, Los Angeles, to study its use in patients with melanoma, myeloma, leukemia, and lymphoma. Last year the company opened a research center in San Diego thatâ€™s using its system to generate ideas for new drugs. The ability to genetically profile immune cells is part of a larger push in oncology to scrutinize the cells and tissues that coexist with cancer and affect its ability to persist, says Jill Oâ€™Donnell-Tormey, chief executive officer and director of scientific affairs at the Cancer Research Institute in New York. Surviving cancer, she says, â€œis about what is happening not just in the tumor, but in the immune cells.â€ From Our Advertisers In partnership with Dynatrace Emerging Trend Analysis: What is Digital Performance Management? In partnership with Google Analytics Data Analytics and Machine Learning: Driving Speed to Insight Sponsored by Lenovo Trend Roundup: Data Storage and the Cloud Tagged cancer, immune cells, immuno-sequencing, Adaptive Biotechnologies Arlene Weintraub Guest Contributor Subscribe to Continue Reading Uh ohâ€“you've read all five of your free articles for this month. Become an Insider for unlimited access to online stories for less than $2 per month. Insider Online Only $19.95/yr US PRICE Subscribe See international, alumni and otherÂ pricingÂ options Already an Insider? Log in. Have a magazine subscription? Activate your Insider account. Business Technologies are revolutionizing how we work and how companies operate. Amazonâ€™s Next Big Move: Take Over the Mall Unable to resist any opportunity to sell you something, the e-commerce leader is opening up brick-and-mortar bookstores. But its online prowess doesnâ€™t yet translate into a very good retail experience. by Nicholas Carr Enabling the Digital Revolution: SDN and Beyond The promise of software-defined networking and solutions for its wider adoption were explored in depth at VMwareâ€™s inaugural future:net event. Silicon Valleyâ€™s Call to Secede Shows How Out of Touch It Is Clamoring for California to leave the U.S. is little better than Donald Trumpâ€™s plan to build a border wall with Mexico. by Jamie Condliffe More from Business The Download What's important in technology and innovation, delivered to you every day. Follow us Twitter Facebook RSS Â  The mission of MIT Technology Review is to equip its audiences with the intelligence to understand a world shaped by technology. Browse International Editions Company About Us Careers Advertise with Us Reprints and Permissions Your Account Log In / Create Account Newsletters Manage Account Manage Subscription Customer Support Help/FAQs Contact Us Feedback Sitemap More Events MIT Enterprise Forum MIT News Policies Ethics Statement Terms of Service Privacy Commenting Guidelines MIT Technology Review Â© 2016 v.|eiÏ€| You've read of free articles this month. Subscribe Become an Insider or Sign in for unlimited access Â to online articles .
Latest News Dow 18,869 +21.03 +0.11% Nasdaq 5,218 -18.72 -0.36% S&P 500 2,164 -0.25 -0.01% 6:42 P.M. ET Bannonâ€™s Critics: Alt-Right is Wrong for White House 6:41 P.M. ET President Obama Details Transition in Press Conference 6:39 P.M. ET FriendFinder breach may have exposed 412 million usersâ€™ data 6:20 P.M. ET Google to block its ads from fake-news sites 6:18 P.M. ET 'Mars': National Geographic Network's Moonshot 6:04 P.M. ET Obama Addresses Concerns About Bannon's Appointment 6:06 P.M. ET Updated David Einhornâ€™s Greenlight Capital reduces stakes in Apple, GM, buys U.S. Steel 6:04 P.M. ET Updated SEC chief Mary Jo White announces plans to leave 6:02 P.M. ET Obama Addresses Concerns About Bannon's Appointment 5:47 P.M. ET Updated Deutsche Bank raises S&P 500 year-end target after postelection rally 5:35 P.M. ET George Soros buys stakes in Alphabet, Netflix, dumps Disney, General Motors 5:31 P.M. ET Updated Donald Trump and Vladimir Putin speak by phone 5:19 P.M. ET Financial services industry is at risk to get even whiter 5:15 P.M. ET David Tepper's hedge fund buys new stakes in Apple, Bank of America and Facebook 5:11 P.M. ET Estee Lauder to buy Too Faced for $1.45B, looks to 'win with millennials' 5:10 P.M. ET Einhorn adds Aercap, Calpine, United States Steel, trims Apple stake 5:02 P.M. ET My father-in-law married his girlfriend before he died â€” she wonâ€™t return our calls 5:02 P.M. ET Tepper's Appaloosa sells entire 4.4 mln-share stake in 21st Century Fox during Q3--SEC filing 5:02 P.M. ET SEC says Mary Jo White to leave at the end of the Obama administration 5:00 P.M. ET Nasdaq names Adena Friedman president and CEO Log In Home News Viewer Video SectorWatch Podcasts First Take Games Portfolio My MarketWatch News Viewer Markets U.S. Europe/Middle East Emerging Markets Asia Canada SectorWatch Columns Market Snapshot Movers & Shakers The Tell Currencies Futures Movers Pre-Market News Tools Earnings Wall Markets Overview IPO Calendar Earnings Calendar Currency Tools Futures Contracts Market Screener Hulbert Interactive Investing Stocks Mutual Funds ETFs Options Bonds Commodities Currencies Futures Hedge Funds/Insider Trades Getting Started MarketWatch Adviser Columns Options Trader Revolution Investing Tools Stock Screener Funds Finder ETF Screener Options Screener IPO Calendar Earnings Calendar More... Trading Deck . Personal Finance 10 Things Big Spender Real Estate Spending & Saving Taxes Columns The Moneyologist Brett Arends Bill Bischoff Amy Hoak Chuck Jaffe Jennifer Openshaw Jennifer Waters Tools Funds Finder Today's Rates Retirement RetireMentors Encore Taxes Retire Here, Not There How-to Guides Social Security Estate Planning Events Columns Robert Powell's Retirement Portfolio Andrea Coombes's Working Retirement Tools Retirement Planner How long will my money last? Economy Federal Reserve Capitol Report Economic Report Columns Darrell Delamaide Irwin Kellner Rex Nutting Tools Economic Calendar Real Estate Location Scouts realtor.com My MarketWatch Watchlist Alerts Games Log In Until Tokyo Markets Open US Market Snapshot Currencies Commodities Home Industries Biotechnology Biogen profit beats estimates on sales of MS drug By Joshua Jamerson Published: Oct 26, 2016 7:55 a.m. ET Share By JoshuaJamerson Biogen Inc., which has been working to reinvigorate growth, said its profit rose and easily topped Wall Street's expectations in the latest quarter as sales of its largest multiple sclerosis drug drove higher sales. Shares, which have climbed 4.2% in the past 12 months, rose 2.1% to $292 in premarket trading. The vast majority of Biogen's revenue comes from multiple sclerosis drugs that some analysts see as growing relatively slowly. Cambridge, Mass.-based Biogen has focused its research-and-development efforts on new treatments for multiple sclerosis and other neurodegenerative conditions, such as Alzheimer's disease and Parkinson's disease. The firm is spinning off its hemophilia drug business, where sales have been rising at a faster clip but make up a smaller chunk of total revenue. Sales of its biggest drug, Tecfidera, grew 10% its latest quarter and drove growth. Tecfidera brought in $1.03 billion during the period, representing roughly 41% of product revenue. The company said the MS drug was helped by inventory build. Meanwhile, the company's two hemophilia drugs grew at a much faster pace, and brought in a combined $217 million. Chief Executive George Scangos announced in July he would be leaving the company, allowing a new chief to lead the company as it works to reignite growth. The biotechnology giant has also drawn takeover interest from drug companies such as Merck Co. and Allergan PLC, The Wall Street Journal reported in August. Overall for the third quarter, Biogen reported a profit of $1.03 billion, or $4.71 a share, up from $965.6 million, or $4.15 a share, a year earlier. Excluding the restructuring charges, among other items, per-share earnings rose to $5.19 from $4.48. Total revenue rose 6% to $2.96 billion. Analysts had projected adjusted earnings of $4.97 a share on sales of $2.91 billion, according to Thomson Reuters. Write to Joshua Jamerson at joshua.jamerson@wsj.com More from MarketWatch Donald Trump Upsets Hillary Clinton to Win Presidency Why investors could come to regret last weekâ€™s appetite for stocks Trump reportedly stumped by how West Wing works MarketWatch Partner Center We Want to Hear from You Join the conversation Comment Celebrity Real Estate News Celebrities renege on their pledges to move out of U.S on the back of Trump win View More Investing If you're shocked that Trump won, you broke 3 basic principles of investing View More Barron's Next Dear President-Elect Trump, a millennial wishlist View More Investing Opinion: A 12-step plan to strengthen your portfolio after Trump's victory View More MarketWatch Site Index Topics Help Feedback Newsroom Roster Media Archive Premium Products Mobile Company Company Info Code of Conduct Corrections Advertising Media Kit Advertise Locally Reprints & Licensing Broker Center Your Ad Choices Dow Jones Network WSJ.com Barron's Online BigCharts Virtual Stock Exchange Financial News Online WSJ.com Small Business realtor.com Mansion Global Back to Top Copyright Â©2016 MarketWatch, Inc. All rights reserved. By using this site you agree to the Terms of Service, Privacy Policy, and Cookie Policy. Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. Intraday data delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Dow Jones & Company, Inc. All quotes are in local exchange time. Real time last sale data provided by NASDAQ. More information on NASDAQ traded symbols and their current financial status. Intraday data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. S&P/Dow Jones Indices (SM) from Dow Jones & Company, Inc. SEHK intraday data is provided by SIX Financial Information and is at least 60-minutes delayed. All quotes are in local exchange time. Advanced Search Stocks Columns Authors Topics No results found LatestNews

null
Home Markets Companies Opinion Politics Technology Specials PF Portfolio My Page Gallery Today's Paper Latest News Economy Finance Current Affairs International Management The Strategist Weekend Data Stories Chat News Stocks Commodities IPOs Mutual Funds Mutual Fund Tools Derivatives BS Fund Manager News Results Auto Engineering Financials Infra IT Oil & Gas Telecom Services All Sectors Punditry Editorial Comment Columnists Have Your Say Financial X-Ray Business Law & Tax Breakingviews Lunch Poll North East West South Election News Mobiles & Tablets Apps People Computers Weekend Digital Consumer PE/VC Brand World SME Start-ups Defence B2B Connect Power & Energy Sponsored Content News Features Investments Loans & Credit Cards Tax Insurance Financial Tools Photo Gallery Video Gallery Home Today's Paper Latest News Economy Finance Current Affairs International Management The Strategist Weekend Data Stories Chat Markets News Stocks Commodities IPOs Mutual Funds Mutual Fund Tools Derivatives BS Fund Manager Companies News Results Auto Engineering Financials Infra IT Oil & Gas Telecom Services All Sectors Opinion Punditry Editorial Comment Columnists Have Your Say Financial X-Ray Business Law & Tax Breakingviews Lunch Poll Politics North East West South Election Technology News Mobiles & Tablets Apps People Computers Specials Weekend Digital Consumer PE/VC Brand World SME Start-ups Defence B2B Connect Power & Energy Sponsored Content PF News Features Investments Loans & Credit Cards Tax Insurance Financial Tools Portfolio My Page Gallery Photo Gallery Video Gallery Home Today's Paper Latest News Economy Finance Current Affairs International Management The Strategist Weekend Data Stories Chat Markets News Stocks Commodities IPOs Mutual Funds Mutual Fund Tools Derivatives BS Fund Manager Companies News Results Auto Engineering Financials Infra IT Oil & Gas Telecom Services All Sectors Opinion Punditry Editorial Comment Columnists Have Your Say Financial X-Ray Business Law & Tax Breakingviews Lunch Poll Politics North East West South Election Technology News Mobiles & Tablets Apps People Computers Specials Weekend Digital Consumer PE/VC Brand World SME Start-ups Defence B2B Connect Power & Energy Sponsored Content PF News Features Investments Loans & Credit Cards Tax Insurance Financial Tools Portfolio My Page Gallery Photo Gallery Video Gallery Home Today's Paper Latest News Economy Finance Current Affairs International Management The Strategist Weekend Data Stories Chat Markets News Stocks Commodities IPOs Mutual Funds Mutual Fund Tools Derivatives BS Fund Manager Companies News Results Auto Engineering Financials Infra IT Oil & Gas Telecom Services All Sectors Opinion Punditry Editorial Comment Columnists Have Your Say Financial X-Ray Business Law & Tax Breakingviews Lunch Poll Politics North East West South Election Technology News Mobiles & Tablets Apps People Computers Specials Weekend Digital Consumer PE/VC Brand World SME Start-ups Defence B2B Connect Power & Energy Sponsored Content PF News Features Investments Loans & Credit Cards Tax Insurance Financial Tools Portfolio My Page Gallery Photo Gallery Video Gallery BS APPS iPad iPhone Android Wap BS PRODUCTS Smart Investor BS Hindi BS Motoring BS Books Today's Paper Economy & Industry BS SPECIALS B2B Connect Power & Energy SME BS E-Paper Hi, Change Password Subscribe Sign out Change Password Manage My Account Sign out SIGN IN Subscribe Â  Â  Â  Â  Â  Â  TRENDING ON BS #RoadToWhiteHouse #BlackMoney News Stock Quote Authors Â News Â  Â Stock Quote Â  Â Authors You are here: Home Â» News-CM Â» International Â» Market Report Shemaroo Entertainment standalone net profit rises 45.14% in the September 2016 quarter Business Standard US stocks end in the red Capital MarketÂ  October 26, 2016 Last Updated at 11:30 IST email this article Message: Recipients' Email: Type address separated by commas Your Email: Enter the characters shown in the image. Send me a copy: Â  http://mybs.in/2TIW2JV Copy tiny URL to save and share articles. ALSO READ US stocks end in the red US stocks end in the red US stocks end in the red US stocks end in the red US stocks end in the red Lackluster spate of earnings and weak economic data affect momentum U.S. stocks finished lower on Tuesday, 25 October 2016 giving back some of the previous day's advance as worries about a lackluster spate of earnings and a slip in a reading of consumer confidence weighed on market sentiment. A drop in the price of oil below $50 a barrel, lingering uncertainty about the U.S. presidential election and growing expectations of a rate increase by the Federal Reserve, also contributed to the downbeat mood. The Dow Jones Industrial Average declined 53.76 points, or 0.3%, at 18,169.27, as shares of Home Depot weighed on blue-chips with a 3.2% decline. Earlier, the average had been down as many as 71 points. The Nasdaq Composite Index gave up 26.45 points, or 0.5%, to wrap at 5,283.40. The S&P 500 declined by 8.17 points, or 0.4%, to 2,143.16. Nine of the 11 main sectors ended in the red. The consumer-discretionary closed off 1.2%, while materials lost 1%. Shares of Dow component 3M fell 2.9% after reporting earnings that beat Wall Street expectations, but the company posted sales that were flat relative to the prior year and reduced the top end of its yearly earnings forecast. Market participants have been wrestling with third-quarter earnings that have outperformed lowered expectations, but a number of companies have cut their annual outlooks, which has raised questions about future earnings. Investors were eager to find out the results from two of the tech giants this week, with Apple reporting after the closing bell on Tuesday. Traders continued to eye economic data for hints on the prospects for a Federal Reserve interest-rate increase before the end of the year. Higher rates tend to send investors away from precious metals into investments that carry a yield. A reading on consumer confidence Tuesday showed a decline to 98.6 in October, a three-month low, from 103.5 in September. The FHFA Housing Price Index for August rose 0.7%, which followed an increase of 0.5% in July. Separately, the Case-Shiller 20-city Home Price Index for August rose 5.1%, which fell in-line with the consensus. This followed the previous month's unrevised reading of 5.0%. Shares in Whirlpool dropped 11% after the appliance maker reported third-quarter profit and sales that missed expectations, and issued a downbeat outlook. Merck & Co. rose 2% after the drugmaker's third-quarter earnings and sales came in above expectations. Chemicals maker DuPont& Co. shares fell 0.7% despite the company raising its yearly profit forecast and better-than-expected quarterly earnings. The company is working on its merger with Dow Chemical. Procter & Gamble gained 3.4% after the consumer goods company reported earnings ahead of forecasts. Lockheed Martin shares jumped 7.4% after the aerospace company posted higher-than-expected revenue and hiked its dividend. Baker Hughes shares rallied 4.3% after the oil-field services company reported a narrower-than-expected loss. General Motors shares ended down 4.2% even as auto giant's quarterly profit doubled. GM also posted higher revenue on strong U.S. truck sales. But it signaled continued weakness in Europe because of the fallout from the U.K.'s pending exit from the European Union, or Brexit. Crude futures fell on Tuesday, 25 October 2016 with prices in New York settling below $50 a barrel for the first time in just over a week, pressured by the possibility that the Organization of the Petroleum Exporting Countries' plan to curb output will fail after Iraq signaled unwillingness to take part in the proposed deal. December West Texas Intermediate crude fell by 56 cents, or 1.1%, to settle at $49.96 a barrel on the New York Mercantile Exchange. That was the lowest settlement and first finish below $50 since 17 October 2016. OPEC members in late September reached a preliminary agreement to limit the group's daily production to between 32.5 million to 33 million barrels a day. Bullion prices ended higher at Comex on Tuesday, 25 october 2016. Gold futures settled Tuesday at their highest level in about three weeks, rebounding from the previous day's decline as uncertainty ahead of the U.S. presidential election, some weakness in the U.S. dollar and a fall in domestic equities boosted the metal's appeal. December gold rose $9.90, or 0.8%, to settle at $1,273.60 an ounce. Prices settled at their highest level since 3 October 2016. Prices are still down about 3.1% so far this month. December silver gained 17.6 cents, or 1%, to $17.78 an ounce. Treasuries finished on a mixed note with the short end of the curve underperforming. The yield on the 2-yr note rose two basis points to 0.86% while the yield on the benchmark 10-yr note ended down one basis point at 1.76%. Today's trading volume was below the average of 853 million as 819 million shares changed hands at the NYSE floor. Tomorrow's economic data will include the weekly MBA Mortgage Index and International Trade in Goods for September, which will be released at 7:00 ET and 8:30 ET, respectively. The day's data will be capped off with the 10:00 ET release of New Home Sales for September (consensus 610k). Powered by Capital Market - Live News (This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.) Read More On Us Stocks End In The Red | News-cm | Market Report PREVIOUS STORY NEXT STORY RECOMMENDED FOR YOU Advertisements Buy New Age Health Insurance with Added Benefits New to the stock market? Take your FirstStep Fiat Linea - 125PS Power &TouchScreen Navigation System.T&C. Learn the Art of Investing through Sharekhan Open Free Demat A/c with low brokerage fee Yet to open a Sharekhan Account? 6 mistakes to avoid while trading online US stocks end in the red Lackluster spate of earnings and weak economic data affect momentum Lackluster spate of earnings and weak economic data affect momentum U.S. stocks finished lower on Tuesday, 25 October 2016 giving back some of the previous day's advance as worries about a lackluster spate of earnings and a slip in a reading of consumer confidence weighed on market sentiment. A drop in the price of oil below $50 a barrel, lingering uncertainty about the U.S. presidential election and growing expectations of a rate increase by the Federal Reserve, also contributed to the downbeat mood. The Dow Jones Industrial Average declined 53.76 points, or 0.3%, at 18,169.27, as shares of Home Depot weighed on blue-chips with a 3.2% decline. Earlier, the average had been down as many as 71 points. The Nasdaq Composite Index gave up 26.45 points, or 0.5%, to wrap at 5,283.40. The S&P 500 declined by 8.17 points, or 0.4%, to 2,143.16. Nine of the 11 main sectors ended in the red. The consumer-discretionary closed off 1.2%, while materials lost 1%. Shares of Dow component 3M fell 2.9% after reporting earnings that beat Wall Street expectations, but the company posted sales that were flat relative to the prior year and reduced the top end of its yearly earnings forecast. Market participants have been wrestling with third-quarter earnings that have outperformed lowered expectations, but a number of companies have cut their annual outlooks, which has raised questions about future earnings. Investors were eager to find out the results from two of the tech giants this week, with Apple reporting after the closing bell on Tuesday. Traders continued to eye economic data for hints on the prospects for a Federal Reserve interest-rate increase before the end of the year. Higher rates tend to send investors away from precious metals into investments that carry a yield. A reading on consumer confidence Tuesday showed a decline to 98.6 in October, a three-month low, from 103.5 in September. The FHFA Housing Price Index for August rose 0.7%, which followed an increase of 0.5% in July. Separately, the Case-Shiller 20-city Home Price Index for August rose 5.1%, which fell in-line with the consensus. This followed the previous month's unrevised reading of 5.0%. Shares in Whirlpool dropped 11% after the appliance maker reported third-quarter profit and sales that missed expectations, and issued a downbeat outlook. Merck & Co. rose 2% after the drugmaker's third-quarter earnings and sales came in above expectations. Chemicals maker DuPont& Co. shares fell 0.7% despite the company raising its yearly profit forecast and better-than-expected quarterly earnings. The company is working on its merger with Dow Chemical. Procter & Gamble gained 3.4% after the consumer goods company reported earnings ahead of forecasts. Lockheed Martin shares jumped 7.4% after the aerospace company posted higher-than-expected revenue and hiked its dividend. Baker Hughes shares rallied 4.3% after the oil-field services company reported a narrower-than-expected loss. General Motors shares ended down 4.2% even as auto giant's quarterly profit doubled. GM also posted higher revenue on strong U.S. truck sales. But it signaled continued weakness in Europe because of the fallout from the U.K.'s pending exit from the European Union, or Brexit. Crude futures fell on Tuesday, 25 October 2016 with prices in New York settling below $50 a barrel for the first time in just over a week, pressured by the possibility that the Organization of the Petroleum Exporting Countries' plan to curb output will fail after Iraq signaled unwillingness to take part in the proposed deal. December West Texas Intermediate crude fell by 56 cents, or 1.1%, to settle at $49.96 a barrel on the New York Mercantile Exchange. That was the lowest settlement and first finish below $50 since 17 October 2016. OPEC members in late September reached a preliminary agreement to limit the group's daily production to between 32.5 million to 33 million barrels a day. Bullion prices ended higher at Comex on Tuesday, 25 october 2016. Gold futures settled Tuesday at their highest level in about three weeks, rebounding from the previous day's decline as uncertainty ahead of the U.S. presidential election, some weakness in the U.S. dollar and a fall in domestic equities boosted the metal's appeal. December gold rose $9.90, or 0.8%, to settle at $1,273.60 an ounce. Prices settled at their highest level since 3 October 2016. Prices are still down about 3.1% so far this month. December silver gained 17.6 cents, or 1%, to $17.78 an ounce. Treasuries finished on a mixed note with the short end of the curve underperforming. The yield on the 2-yr note rose two basis points to 0.86% while the yield on the benchmark 10-yr note ended down one basis point at 1.76%. Today's trading volume was below the average of 853 million as 819 million shares changed hands at the NYSE floor. Tomorrow's economic data will include the weekly MBA Mortgage Index and International Trade in Goods for September, which will be released at 7:00 ET and 8:30 ET, respectively. The day's data will be capped off with the 10:00 ET release of New Home Sales for September (consensus 610k). Powered by Capital Market - Live News (This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.) Capital Market Business Standard http://bsmedia.business-standard.com/_media/bs/wap/images/bs_logo_amp.png 177 22 US stocks end in the red Lackluster spate of earnings and weak economic data affect momentum U.S. stocks finished lower on Tuesday, 25 October 2016 giving back some of the previous day's advance as worries about a lackluster spate of earnings and a slip in a reading of consumer confidence weighed on market sentiment. A drop in the price of oil below $50 a barrel, lingering uncertainty about the U.S. presidential election and growing expectations of a rate increase by the Federal Reserve, also contributed to the downbeat mood. The Dow Jones Industrial Average declined 53.76 points, or 0.3%, at 18,169.27, as shares of Home Depot weighed on blue-chips with a 3.2% decline. Earlier, the average had been down as many as 71 points. The Nasdaq Composite Index gave up 26.45 points, or 0.5%, to wrap at 5,283.40. The S&P 500 declined by 8.17 points, or 0.4%, to 2,143.16. Nine of the 11 main sectors ended in the red. The consumer-discretionary closed off 1.2%, while materials lost 1%. Shares of Dow component 3M fell 2.9% after reporting earnings that beat Wall Street expectations, but the company posted sales that were flat relative to the prior year and reduced the top end of its yearly earnings forecast. Market participants have been wrestling with third-quarter earnings that have outperformed lowered expectations, but a number of companies have cut their annual outlooks, which has raised questions about future earnings. Investors were eager to find out the results from two of the tech giants this week, with Apple reporting after the closing bell on Tuesday. Traders continued to eye economic data for hints on the prospects for a Federal Reserve interest-rate increase before the end of the year. Higher rates tend to send investors away from precious metals into investments that carry a yield. A reading on consumer confidence Tuesday showed a decline to 98.6 in October, a three-month low, from 103.5 in September. The FHFA Housing Price Index for August rose 0.7%, which followed an increase of 0.5% in July. Separately, the Case-Shiller 20-city Home Price Index for August rose 5.1%, which fell in-line with the consensus. This followed the previous month's unrevised reading of 5.0%. Shares in Whirlpool dropped 11% after the appliance maker reported third-quarter profit and sales that missed expectations, and issued a downbeat outlook. Merck & Co. rose 2% after the drugmaker's third-quarter earnings and sales came in above expectations. Chemicals maker DuPont& Co. shares fell 0.7% despite the company raising its yearly profit forecast and better-than-expected quarterly earnings. The company is working on its merger with Dow Chemical. Procter & Gamble gained 3.4% after the consumer goods company reported earnings ahead of forecasts. Lockheed Martin shares jumped 7.4% after the aerospace company posted higher-than-expected revenue and hiked its dividend. Baker Hughes shares rallied 4.3% after the oil-field services company reported a narrower-than-expected loss. General Motors shares ended down 4.2% even as auto giant's quarterly profit doubled. GM also posted higher revenue on strong U.S. truck sales. But it signaled continued weakness in Europe because of the fallout from the U.K.'s pending exit from the European Union, or Brexit. Crude futures fell on Tuesday, 25 October 2016 with prices in New York settling below $50 a barrel for the first time in just over a week, pressured by the possibility that the Organization of the Petroleum Exporting Countries' plan to curb output will fail after Iraq signaled unwillingness to take part in the proposed deal. December West Texas Intermediate crude fell by 56 cents, or 1.1%, to settle at $49.96 a barrel on the New York Mercantile Exchange. That was the lowest settlement and first finish below $50 since 17 October 2016. OPEC members in late September reached a preliminary agreement to limit the group's daily production to between 32.5 million to 33 million barrels a day. Bullion prices ended higher at Comex on Tuesday, 25 october 2016. Gold futures settled Tuesday at their highest level in about three weeks, rebounding from the previous day's decline as uncertainty ahead of the U.S. presidential election, some weakness in the U.S. dollar and a fall in domestic equities boosted the metal's appeal. December gold rose $9.90, or 0.8%, to settle at $1,273.60 an ounce. Prices settled at their highest level since 3 October 2016. Prices are still down about 3.1% so far this month. December silver gained 17.6 cents, or 1%, to $17.78 an ounce. Treasuries finished on a mixed note with the short end of the curve underperforming. The yield on the 2-yr note rose two basis points to 0.86% while the yield on the benchmark 10-yr note ended down one basis point at 1.76%. Today's trading volume was below the average of 853 million as 819 million shares changed hands at the NYSE floor. Tomorrow's economic data will include the weekly MBA Mortgage Index and International Trade in Goods for September, which will be released at 7:00 ET and 8:30 ET, respectively. The day's data will be capped off with the 10:00 ET release of New Home Sales for September (consensus 610k). Powered by Capital Market - Live News (This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.) Capital Market Business Standard http://bsmedia.business-standard.com/_media/bs/wap/images/bs_logo_amp.png 177 22 MORE ON MARKETS: Quick Links Stock Market Live Portfolio Commodity Market Upcoming IPO Personal Finance Stock Market News Derivatives Mutual Funds Gold Price Sensex Browse STOCK Companies A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 1 2 3 4 5 6 7 8 9 Browse Mutual Funds A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Index Stocks ACC Adani Ports Ambuja Cem. Asian Paints Aurobindo Pharma Axis Bank B H E L B P C L Bajaj Auto Bank of Baroda Bharti Airtel Bharti Infra. Bosch Cipla Coal India Dr Reddy's Labs Eicher Motors GAIL (India) Grasim Inds H D F C HCL Technologies HDFC Bank Hero Motocorp Hind. Unilever Hindalco Inds. ICICI Bank Idea Cellular IndusInd Bank Infosys ITC Kotak Mah. Bank Larsen & Toubro Lupin M & M Maruri Suzuki NTPC O N G C Power Grid Corpn Reliance Inds. St Bk of India Sun Pharma. Inds. Tata Motors Tata Motors-DVR Tata Power Co. Tata Steel TCS Tech Mahindra UltraTech Cement Ltd Wipro Yes Bank Zee Entertainment Copyrights Â© 2015 Business Standard Private Ltd. All rights reserved. From BS Website Home Companies Markets Opinion Politics Technology Specials Personal Finance Budget Latest News Today's Paper RBI Policy General News General Videos General Photo Gallery Events Authors About us About Us Code of Conduct Terms & Conditions Disclaimer Investor Communication Support & Contact Partner with Us Careers Advertise with Us Contact Us Feedback Browser Support Sitemap Subscribe E-Paper BS Magazines Portfolio Tracker BS Products Smart Investor BS Hindi BS Motoring BS Books B2B Connect iPhone iPad android wap BS Banking Round Table 2016 BS Fund Cafe 2016 Elections 2016 Assam Elections Kerala Elections Tamil Nadu Elections West Bengal Elections Connect with BS Facebook Google+ Linkedin Twitter Youtube RSS Upgrade To Premium Services Welcome User Business Standard is happy to inform you of the launch of "Business Standard Premium Services" As a premium subscriber you get an across device unfettered access to a range of services which include: Access Exclusive content - articles, features & opinion pieces Weekly Industry/Genre specific newsletters - Choose multiple industries/genres Access to 17 plus years of content archives Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box End of day news alerts on 5 companies (via email) NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required. Â  Premium Services In Partnership with Â  Dear Guest, Â  Welcome to the premium services of Business Standard brought to you courtesy FIS. Kindly visit the Manage my subscription page to discover the benefits of this programme. Enjoy Reading! Team Business Standard Â 
Contact Us Member LoginRegister New Account My 24-7 Press Release Account Media Desk for Journalists, Bloggers & Readers Products & Services Press Release Distribution Pricing & Distribution Plans Why Choose 24-7 Press Release? Where Does Your News Go? Take a Tour Editorial/Submission Guidelines Press Release Writing Writing Services Agency PReferred Program What is Agency PReferred Become an Agency PReferred Client News Releases Select News Type Today's News News by Industry News with Video Search News News by Date News Releases 2016 News Releases 2015 News Releases 2014 News Releases 2013 News by RSS RSS Feed Top News Industry Arts & Entertainment Business Computer Consumer Education Environment Fashion Home & Family Home & Garden Industry Internet Law & Legal Lifestyle Medical Sports Technology Media Desk Journalists, bloggers, and readers can now access our exclusive Media Desk for enhanced, personalized news searching and tracking. Partners Become a Syndication Partner Real-Time News Content Hosted Content Delivery Solutions News Widget RSS Host Content on Your Server FTP/XML Data Feed Apply Now Knowledge Base FAQ We have all answers to your questions about our products and services. VIDEOS Watch our videos to learn about what we have to offer. ARTICLES Our articles will guide you in writing attractive and successful press releases. DOCUMENTS View our help documents for tips and resources. Company About Us About 24-7 Press Release Executive Team Clients Newsletter Newsletter Sign-Up Affiliate Program Become an Affiliate What's New Newsroom Blog Testimonials What Our Customers Say Submit a Testimonial Toll Free Telephone 1-888-880-9539 Hours of Business M-F 8:30am - 5:00pm PST Follow Us Through Social Media All Press Releases for October 26, 2016 Â» Email This Story Printer Friendly PDF Version RSS Feed Sales Outsourcing Provider is One of the 50 Fastest Growing Companies in NJ CEO uses childhood experience to become a top NJ company "I am proud and honored to be included among the community of high-growth companies but I'm mostly proud of the growth we've contributed to our clients' businesses," says Caryn Kopp, Chief Door Opener Â Â Â Â BEDMINSTER, NJ, October 26, 2016 /24-7PressRelease/ -- Bedminster's Caryn Kopp, known as the Chief Door Opener started her career in sales in an unlikely way. At the age of 11, while babysitting for a Lawn Doctor franchise owner, she was asked to help out after the children went to bed by making phone calls to schedule lawn evaluation appointments. Armed with a phone book, Caryn quickly learned that using the right words and connecting with the right person was the difference between a successful call and a "no-go." She also learned not to give up. A graduate of J.P. Stevens High School in Edison, that early experience helped her launch a successful business development company. Kopp Consulting's Door Opener Service helps b2b clients access the sales opportunities they wouldn't otherwise access so they can close more sales. Today, Kopp Consulting, has evolved into a MULTI-MILLION DOLLAR A YEAR BUSINESS and has earned a spot on the prestigious NJ Biz Fast 50 list as one of the state's 50 most successful and fastest growing private companies, an honor most every NJ business strives to achieve. "I am proud and honored to be included among the community of high-growth companies but I'm mostly proud of the growth we've contributed to our clients' businesses," says Caryn Kopp, Founder and Chief Door Opener at Kopp Consulting. Recently, two New Jersey based Door Opener clients, TeamPar and Phoenix Marketing Solutions, each closed sales of over $1 million dollars as a direct result of their partnership with Kopp's Door Opener Service. Additionally, one of Kopp's clients, GD (General Devices) has also won the 2016 NJ Fast 50 Award. One of Kopp's technology clients targeting C level executives in large media and entertainment companies had meetings with ABC, NBC, Universal, HBO, Cable Vision and the list goes on, due to Door Opener strategies. "We grew this company because we are a team of high level, strategic business developers who create the right sales messaging and work to personally engage decision makers. We get our clients more of the initial conversations and meetings they can't get on their own. Our proprietary strategies work and clients keep coming back for more because we're helping them grow their businesses and give them access to sales opportunities they previously only dreamed about," adds Caryn. Many companies struggle with their own sales and sales teams, quarter after quarter, year after year. Kopp's proprietary Door Opener Service, Strategic Sales Insights and trademarked Moment of Yes Sales Message Development Process pave the way for clients to have a seat at the table with high profile, difficult to reach prospects. These introductions help Kopp clients accelerate profitable sales and eliminate the barriers to success they previously experienced. "When clients achieve success like adding over $5 million dollars in new revenue to their businesses, increasing close ratios from 20% to 48% or being included in RFPs AFTER the RFP process officially closed, we know we're doing business development right!" says Kopp. The NJBIZ recognition follows Kopp Consulting being featured on the 2016 Inc. 5000, being selected as Smart CEO Future 50 recipient and being named Sales Outsourcing Provider of the Year. We're very proud to be honored with the NJ Biz Fast 50 status, thankful for our wonderful clients and the magic our Door Openers create for our clients every day," said Kopp. About Kopp Consulting Inc. Kopp Consulting's Door Opener Service has helped thousands of business owners and sellers secure initial meetings with high-level decision makers in major companies including Pfizer, GE, Merck, Verizon, Disney, and the list goes on. In addition to providing clients with new sales opportunities, Kopp Consulting gets the doors opened for their clients and then provides guidance on how to get the sales closed www.koppconsultingusa.com. About the NJBiz Fast 50 Award The NJBIZ 50 Fastest Growing Companies awards program celebrates New Jersey's most dynamic companies who progressively contribute to the success of the state's economic growth and stability. The award honors the top companies in New Jersey based on revenue size and revenue growth achieved over the recent three-year time period. Award winners will be honored at a ceremony on November 10th at The Palace, 333 Davidson Avenue, Somerset, NJ. The complete list of all the honorees of the NJBIZ Fast 50 and awards program information can be seen at http://www.njbiz.com/section/50-Fast-Grow-Comp For Press/Inquiries, to learn more about the Door Opener Service or secure Caryn for a speaking engagement, please contact: Amy Chewey 908-482-0299 achewey@koppconsultingusa.com # # # Read more Press Releases from Amy Chewey: Women-Owned Company Makes Prestigious Inc. 5000 List Chief Door Opener Caryn Kopp hits Amazon.com's Best-Seller Status SmartCEO Names Kopp Consulting a Future 50 Award Winner Comment on this story... Share This Story Contact Information Amy Chewey Kopp Consulting Bedminster, NJ United States Voice: 908-482-0299 E-Mail: Email Us Here Website: Visit Our Website Blog: Visit Our Blog Follow Us: Like This Story? I like it! 0 Tweets Disclaimer If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact 24-7 Press Release Newswire. We are unable to assist you with any information regarding this release. 24-7 Press Release Newswire disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information. Pricing & Distribution Agency PReferred Program Syndicate Our News News Widget RSS Feeds Affiliate Program About Us Contact Us Today's News News by Industry FAQs Testimonials Business Directory Privacy Policy Terms of Service Site Map Connect with 24-7 Press Release: Accelerate Business Exposure with 24-7 Press Release Service. Â© 2004-2016 24-7Pressrelease.com. All Rights Reserved.
Post Profile for Your BusinessÂ Â Â Â Â Â Submit Press Release Join NowÂ Â Â Â Â Sign In Â  Businesses Articles Press Releases Â  Business Directory Products & Services Jobs Recent Press Releases Press Release Pricing Submit Press Release Businesses Products & Services Products Services Press Releases Jobs Press Release Pricing | News by Category | News by Country | News by US Region | Recent News | PR.com News on Your Site Â  Press Releases Â  iHealthcareAnalyst, Inc. Press Release Receive press releases from iHealthcareAnalyst, Inc.: By Email RSS Feeds: Chemotherapy-Induced Nausea and Vomiting Drugs Market USD 1.8 Billion by 2020, Research Study by iHealthcareAnalyst, Inc. Maryland Heights, MO, October 26, 2016 --(PR.com)-- According to a market research report, Chemotherapy-induced Nausea and Vomiting Drugs Market 2013-2020, published by iHealthcareAnalyst, Inc., the global chemotherapy-induced nausea and vomiting drugs market is estimated to reach USD 1.8 Billion in 2020, expanding at a CAGR of 8.4% from 2016 to 2020. Visit the Chemotherapy-induced Nausea and Vomiting Drugs Market 2013-2020 report at https://www.ihealthcareanalyst.com/report/chemotherapy-induced-nausea-and-vomiting-drugs-market/ The global chemotherapy-induced nausea and vomiting drugs market report provides market size (Revenue USD Million 2013 to 2020), market share, market trends and forecasts growth trends (CAGR%, 2016 to 2020). Nausea and vomiting are serious side effects of cancer chemotherapy that can cause significant negative impacts on patientsâ€™ quality of life and on their ability to tolerate and comply with therapy. Chemotherapy-induced Nausea and Vomiting (CINV) can be defined as acute CINV, delayed CINV or anticipatory CINV. Antiemetic agents are the most common intervention in the management of treatment-related nausea and vomiting (N&V) that completely block the peripheral neuroreceptors and the chemoreceptor trigger zone (CTZ) that are known to contain receptors for serotonin, histamine (H1 and H2), dopamine, acetylcholine, opioids, and numerous other endogenous neurotransmitters. The global chemotherapy-induced nausea and vomiting drugs market segmentation is based on major drugs (Marketed Drugs, and Pipeline Drugs). The global chemotherapy-induced nausea and vomiting drugs market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. 1. Drug Type 1.1 Marketed Drugs 1.1.1 Aloxi(palonosetron) 1.1.2 Zofran Generic (ondansetron) 1.1.3 Kytril generic (granisetron) 1.1.4 Emend (aprepitant) 1.1.5 Akynzeo (Netupitant-palonosetron FDC) 1.2 Pipeline Drugs 1.2.1 SUSTOL (Granisetron injection - extended release) 1.2.2 Rolapitant 2. Geography (Region, Country) 2.1 North America (U.S., Canada) 2.2 Latin America (Brazil, Mexico, Rest of LA) 2.3 Europe (U.K., Germany, France, Italy, Spain, Rest of EU) 2.4 Asia Pacific (Japan, China, India, Rest of APAC) 2.5 Rest of the World 3. Company Profiles 3.1 GlaxoSmithKline plc 3.2 Helsinn Holding S.A. 3.3 Heron Therapeutics, Inc. 3.4 Merck & Co., Inc. 3.5 Tesaro, Inc. About Us iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals. iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas. Contact Us iHealthcareAnalyst, Inc. 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043 United States Email: sales@ihealthcareranalyst.com Website: https://www.ihealthcareanalyst.com Contact Information iHealthcareAnalyst, Inc. Ana Aitawa (314) 736-9294 Contact http://www.ihealthcareanalyst.com/ Click here to view the list of recent Press Releases from iHealthcareAnalyst, Inc. Promote Your Business Affiliate Program Link To Us Email this page to a friend PR.com Contact Us About Us Terms of Use Help

Close Worth it? A faster transplant but a kidney with hepatitis C - Brownsville Herald: Life Subscribe Herald Alerts | Online Edition | Subscribe Welcome to the site! Login or Signup below. Login|Signup Login|My Dashboard|Register Logout|My Dashboard 70Â° Broken Clouds Brownsville Herald News Local Valley Texas US & World Business Education SpaceX LNG in the RGV Elections Weather Entertainment El Extra App for Android and iOS The Latest City planning department working to update zoning laws Brownsville has changed a lot over the last several decades, though in many cases its zoning regulations havenâ€™t kept up. Posted: November 14 rss Texas News Buffett's Berkshire Hathaway invests in major airlines 2 sentenced to prison for disrupting Southwest flight Lawmakers pre-file bevy of bills ahead of 2017 session A look at Trump's immigration plans by the numbers Some Texas Muslims note concerns after Donald Trump election Trump starting to sound like Obama on immigration Sports H.S. Football H.S. Baseball H.S. Basketball H.S. Soccer H.S. Track H.S. Volleyball H.S. Sports Local Sports National Sports RGVSports.com South Texas Outdoors UTRGV Athletic Survey The Latest Seager becomes latest Dodger honored as Rookie of the Year AP New! Los Angeles Dodgers shortstop Corey Seager has been voted National League Rookie of the Year, becoming the first player in two decades to win the award for the franchise that has historically dominated the honor. Posted: November 14 Sports, Professional Baseball, Baseball More From The Latest Walker, Hellickson accept $17.2M qualifying offers Texans look to improve before facing Raiders Bears' WR Jeffery suspended 4 games for PED violation Goodman's family sold 'Go Cubs Go' just before song took off Obituaries Life Tu Salud Autism Contests Puzzles Comics Kingdom Texas Lottery Community Community Calendar Business Directory Church Directory Health Directory NIE Opinion Letters to the Editor Editorials Customer Service Subscribe MyBrownsvilleHerald.com Activate Account Start/Stop Delivery Pay Your Bill Complaints Contact Us About Us Home Delivery Legal Notices Classifieds Jobs Autos Homes Service Directory RGV Alerts Careers Don't Miss: Hurricane Safety Guide Celebrating the Port of Brownsville Home Life Worth it? A faster transplant but a kidney with hepatitis C Story Comments Image (3) Print Create a hardcopy of this page Font Size: Default font size Larger font size Previous Next Jessica Kourkounis Worth it? A faster transplant but a kidney with hepatitis C Irma Hendricks has blood drawn at the Hospital of the University of Pennsylvania in Philadelphia, on Oct. 6, 2016. Hendricks received a kidney transplant from a donor with hepatitis C, and took medications after surgery that cleared away the virus and left her feeling healthy again. Hendricks is part of a pilot study testing if new drugs that promise to cure most hepatitis C could allow use of organs that today go to waste, and speed transplants to people who might otherwise die waiting. (AP Photo/Jessica Kourkounis) Michael Rubinkam Worth it? A faster transplant but a kidney with hepatitis C In this photo taken Oct. 13, 2016, Irma Hendricks poses for a portrait with her grandson, C.J., at her home in East Stroudsburg, Pa. Hendricks received a kidney transplant from a donor with hepatitis C, and took medications after surgery that cleared away the virus and left her feeling healthy again. Hendricks is part of a pilot study testing if new drugs that promise to cure most hepatitis C could allow use of organs that today go to waste, and speed transplants to people who might otherwise die waiting. (AP Photo/Michael Rubinkam) Jessica Kourkounis Worth it? A faster transplant but a kidney with hepatitis C Irma Hendricks, right, talks with her physician Peter P. Reese, MD at Hospital of the University of Pennsylvania in Philadelphia, on Oct. 6, 2016. Hendricks received a kidney transplant from a donor with hepatitis C, and took medications after surgery that cleared away the virus and left her feeling healthy again. Hendricks is part of a pilot study testing if new drugs that promise to cure most hepatitis C could allow use of organs that today go to waste, and speed transplants to people who might otherwise die waiting. (AP Photo/Jessica Kourkounis) Posted: Thursday, October 27, 2016 3:31 pm | Updated: 4:00 pm, Thu Oct 27, 2016. Worth it? A faster transplant but a kidney with hepatitis C Associated Press | WASHINGTON (AP) â€” A bold experiment is giving some patients a chance at cutting years off their wait for a kidney transplant if they agree to a drastic-sounding option â€” getting an organ almost sure to infect them with hepatitis C. Betting on new medications that promise to cure hepatitis C, two leading transplant centers aim to use organs that today go to waste, a bid to put a dent in the nation's long transplant waiting list. Pilot studies are underway at the University of Pennsylvania and Johns Hopkins University to test transplanting kidneys from deceased donors with hepatitis C into recipients who don't already have that virus. If the groundbreaking research eventually pans out, hundreds more kidneys â€” and maybe some hearts and lungs, too â€” could be transplanted every year. "We always dreaded hepatitis C," said Dr. Peter Reese, a Penn kidney specialist who is helping lead the research. "But now hepatitis C is just a different disease," enough to consider what he calls the trade-off of getting a new kidney years faster but one that comes with a hopefully treatable infection. It's a trade-off prompted by an organ shortage. More than 99,000 people are on the national kidney waiting list, but only about 17,000 people a year get a transplant and 4 percent a year die waiting, according to the United Network for Organ Sharing (UNOS). "If we had enough organs, we wouldn't do this," said Dr. Niraj Desai, who is leading the Hopkins study. But, Desai said, "most patients are pretty open to the idea once they hear what the alternatives are." Doctors had told 66-year-old Irma Hendricks of East Stroudsburg, Pennsylvania, to expect at least a five-year wait for a kidney transplant. Dialysis three times a week was keeping her alive, but leaving her with no energy for even routine activities. "I call it the zombie syndrome," she said. She jumped at the chance to enroll in Penn's study, even though doctors made clear they hoped for but couldn't guarantee a hepatitis cure. "My son said, 'Mom, this is a no-brainer. Just do it,'" Hendricks said. She swallowed an anti-hepatitis pill daily for three months, in addition to the usual post-transplant medications. Testing showed the drugs rapidly cleared hepatitis C out of her bloodstream. With her new kidney functioning well, she now has enough energy to play with her toddler grandson. "This is giving people in my situation new hope," Hendricks said. Kidney transplant specialists are closely watching the research. "It makes sense to me," said Dr. Matthew Cooper, a transplant surgeon at MedStar Georgetown University Hospital who is not involved in the research. He cautioned that the studies should use only kidneys that are young and otherwise high-quality, and that patients must understand the risks. "They need to know you place their safety as the highest priority," Cooper said. "But at the same time, recognize that we have these obstacles. We don't want people to die on dialysis, and there are not enough organs available for everybody." Hepatitis C is a simmering infection that, if untreated, over two to three decades can quietly destroy someone's liver. At least 2.7 million people in the United States have chronic hepatitis C. Until a few years ago, it was treatable only by medications with grueling side effects and poor cure rates. Now, breakthrough drugs promise to cure 95 percent of hepatitis C cases with fewer side effects â€” for people who can afford them. Treatment costs tens of thousands of dollars. Normally, hepatitis C-infected organs are transplanted only into patients who already have hepatitis C themselves, so as not to further spread the virus. Giving hepatitis C-positive organs to hepatitis C-negative recipients is allowed if the patient agrees, but it's rare, said Dr. David Klassen, UNOS' chief medical officer. UNOS statistics show a few dozen such transplants, mostly kidneys, last year, presumably when doctors feared their patients wouldn't survive the wait for a healthier organ. More often, hospitals discard hepatitis C-infected organs. Reese and fellow Penn physician Dr. David Goldberg found only 37 percent of hepatitis C-positive kidney donations between 2005 and 2014 were transplanted. The discards could have helped more than 4,000 patients during that time period, they reported in the New England Journal of Medicine last year. The opioid epidemic is prompting a jump in donations from people who died of drug overdoses â€” typically young organs that, absent an infection risk, would be sought after. The small Penn and Hopkins trials are a first step. Much larger studies are needed to prove whether more routine use of these organs in immune-suppressed transplant recipients really works. Cost also is a question. Merck & Co. is helping to fund the pilot trials, donating its medication Zepatier, which costs $54,000 for a round of treatment. That's still cheaper than a lifetime of a dialysis, which costs about $75,000 a year, UNOS' Klassen noted. While the studies began with kidneys because of their demand, "I don't think there's any reason, if it proves safe and effective in kidneys, that we wouldn't want to try it in other organs," Penn's Goldberg noted. Even if the hepatitis C-infected organs prove useful, the nation still is "desperate for more donors," cautioned Hopkins' Desai. "It's a practical solution to help some of the people. It won't solve the problem." ___ Associated Press writer Michael Rubinkam in northeastern Pennsylvania contributed to this report. Â© 2016 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed. More about Health ARTICLE: Readying for Trump, Congress faces lame duck to-do list ARTICLE: South African rhino that survived attack dies of infection Readying for Trump, Congress faces lame duck to-do list Prisons fight opioids with $1,000 injection: Does it work? Prisons fight opioids with $1,000 injection: Does it work? More about Government And Politics ARTICLE: 2 sentenced to prison for disrupting Southwest flight ARTICLE: Ginsburg acknowledges Trump will fill Supreme Court vacancy ARTICLE: Lawmakers pre-file bevy of bills ahead of 2017 session ARTICLE: Hillary Clinton wins New Hampshire after deadline to request a recount passes ARTICLE: A look at Trump's immigration plans by the numbers More about Organ Transplants Worth it? A faster transplant but a kidney with hepatitis C Worth it? A faster transplant but a kidney with hepatitis C Worth it? A faster transplant but a kidney with hepatitis C ARTICLE: Doctors hail China's pledge to stop harvesting inmate organs Discuss Print Posted in Life, Elections on Thursday, October 27, 2016 3:31 pm. Updated: 4:00 pm. | Tags: Health, Government And Politics, Organ Transplants, Medical Research, Diseases And Conditions, Medication, Gambling, Diagnosis And Treatment, Liver Disease, Infectious Diseases, Recreation And Leisure, Lifestyle Custom Search Site Web tab 0 tab 1 Marketplace Discount Finance & P... Brownsville, TX 78520, TX 956-621-1090 Reynaldo Pena & Asso... Brownsville, TX 956-574-0480 The Grasshopper Toba... Brownsville, TX 956-465-1532 Discount Title Loan Brownsville, TX 956-621-1238 Find Local Businesses Search Popular Searches | Browse By Category Popular Categories Attorneys & Lawyers Automobile Dealers Automobile Parts Automobile Service Beauty Salons Clothing Stores Computers Dentists Entertainment Food & Dining Movie Theaters Physicians & Surgeons Pizza Plumbing Contractors Real Estate tab 0 tab 1 tab 2 Cars 1996 BMW 3181C White w/black ragtop, leather, clean, new tires $2,500 Updated: November 08 2015 MUSTANG ECO BOOST AUTO TRANS MUST SEE. posted: November 14 1994 Safari, wide body, new upgrades, $9,500. Must see to $9,500 Updated: November 07 More Cars Calendar today's events browse submit Follow us on Facebook Follow us on Twitter Tweets from https://twitter.com/BrownsvilleNews/herald-newsroom Today's Edition Online Features Online Features Real Estate 3 reasons why winter is a smart time ... Brandpoint (BPT) 6 holiday-friendly home design features Brandpoint (BPT) An affordable way to qualify for a ho... Brandpoint (BPT) Autumn and early winter: The best tim... Brandpoint (BPT) Site-built, manufactured or modular: ... Brandpoint (BPT) 5 ways to reinvent your garage Brandpoint (BPT) Smart tips for buying a first-home th... Brandpoint (BPT) How New Buildings are Going Green The rise of the basement: Top tips fo... Brandpoint (BPT) 5 residential design trends in hardwood Brandpoint (BPT) Pet Central Having a pet is a lot of responsibility, and weâ€™ll help by giving you lots of tips and tricks! More >> Fitness Our fitness articles will help teach you how to work out with gym- and home-based exercises. More >> Crosswords Enjoy the crosswords challenge in our free daily puzzles, from the harder Sunday crossword to the quicker daily. More >> Sudoku Every Sudoku has a unique solution that can be reached logically. Enter numbers into the blank spaces so that each row, column and 3x3 box contains the numbers 1 to 9. More >> Ads by Google Site Web Custom Search Advertising Advertising Place an Ad Co-op Advertising Commercial Print National Advertising Archives Archives Story Archives Obituaries Archives Subscriber Services Subscriber Services Subscribe Services Online Services Online Services RSS Feeds WebSites WebSites ElNuevoHeraldo.com RGVSports.com Copyright Â© 2016 The contents of this website may not be reproduced without written permission from The Brownsville Herald. All rights reserved. 1135 E. Van Buren St, Brownsville, TX 78520 | (956) 542-4301 Careers | Autos | Homes | Jobs | Classifieds AIM Media TX LLC Â© Copyright 2016, Brownsville Herald, Brownsville, TX. Powered by BLOX Content Management System from TownNews.com. [Terms of Use | Privacy Policy] Screen Name or Email Password Forgot? Login Screen Name or Email Now I remember! Need an account? Create one now.
Want up-to-the- minute news? Sign up for HAMODIA'S Breaking News Emails* *You can select which emails you'd like to receive. Go Ã— Home | Archive | Advertise | Subscribe | About Us | Contact Us ×™"×’Â ×—×©×•×ŸÂ ×ª×©×¢"×– Â Â |Â Â  Monday, November 14, 2016 Hamodia - The daily newspaper of torah jewry Subscribe to the Hamodia print edition Sections Business Tech World Regional Israel Community National Politics Op-Ed Features Letters Classifieds Technology Betting on Hepatitis C-Infected Kidneys to Speed Transplants Betting on Hepatitis C-Infected Kidneys to Speed Transplants Thursday, October 27, 2016 at 5:18 pm | ×›"×”Â ×ª×©×¨×™Â ×ª×©×¢"×– (AP Photo/Jessica Kourkounis) WASHINGTON (AP) - A bold experiment is giving some patients a chance at cutting years off their wait for a kidney transplant if they agree to a drastic-sounding option â€” getting an organ almost sure to infect them with hepatitis C. Betting on new medications that promise to cure hepatitis C, two leading transplant centers aim to use organs that today go to waste, a bid to put a dent in the nationâ€™s long transplant waiting list. Pilot studies are underway at the University of Pennsylvania and Johns Hopkins University to test transplanting kidneys from deceased donors with hepatitis C into recipients who donâ€™t already have that virus. If the groundbreaking research eventually pans out, hundreds more kidneys â€” and maybe some hearts and lungs, too â€” could be transplanted every year. â€œWe always dreaded hepatitis C,â€ said Dr. Peter Reese, a Penn kidney specialist who is helping lead the research. â€œBut now hepatitis C is just a different disease,â€ enough to consider what he calls the trade-off of getting a new kidney years faster but one that comes with a hopefully treatable infection. Itâ€™s a trade-off prompted by an organ shortage. More than 99,000 people are on the national kidney waiting list, but only about 17,000 people a year get a transplant and 4 percent a year die waiting, according to the United Network for Organ Sharing (UNOS). â€œIf we had enough organs, we wouldnâ€™t do this,â€ said Dr. Niraj Desai, who is leading the Hopkins study. But, Desai said, â€œmost patients are pretty open to the idea once they hear what the alternatives are.â€ Doctors had told 66-year-old Irma Hendricks of East Stroudsburg, Pennsylvania, to expect at least a five-year wait for a kidney transplant. Dialysis three times a week was keeping her alive, but leaving her with no energy for even routine activities. â€œI call it the zombie syndrome,â€ she said. She jumped at the chance to enroll in Pennâ€™s study, even though doctors made clear they hoped for but couldnâ€™t guarantee a hepatitis cure. â€œMy son said, â€˜Mom, this is a no-brainer. Just do it,'â€ Hendricks said. She swallowed an anti-hepatitis pill daily for three months, in addition to the usual post-transplant medications. Testing showed the drugs rapidly cleared hepatitis C out of her bloodstream. With her new kidney functioning well, she now has enough energy to play with her toddler grandson. â€œThis is giving people in my situation new hope,â€ Hendricks said. Kidney transplant specialists are closely watching the research. â€œIt makes sense to me,â€ said Dr. Matthew Cooper, a transplant surgeon at MedStar Georgetown University Hospital who is not involved in the research. He cautioned that the studies should use only kidneys that are young and otherwise high-quality, and that patients must understand the risks. â€œThey need to know you place their safety as the highest priority,â€ Cooper said. â€œBut at the same time, recognize that we have these obstacles. We donâ€™t want people to die on dialysis, and there are not enough organs available for everybody.â€ Hepatitis C is a simmering infection that, if untreated, over two to three decades can quietly destroy someoneâ€™s liver. At least 2.7 million people in the United States have chronic hepatitis C. Until a few years ago, it was treatable only by medications with grueling side effects and poor cure rates. Now, breakthrough drugs promise to cure 95 percent of hepatitis C cases with fewer side effects â€” for people who can afford them. Treatment costs tens of thousands of dollars. Normally, hepatitis C-infected organs are transplanted only into patients who already have hepatitis C themselves, so as not to further spread the virus. Giving hepatitis C-positive organs to hepatitis C-negative recipients is allowed if the patient agrees, but itâ€™s rare, said Dr. David Klassen, UNOSâ€™ chief medical officer. UNOS statistics show a few dozen such transplants, mostly kidneys, last year, presumably when doctors feared their patients wouldnâ€™t survive the wait for a healthier organ. More often, hospitals discard hepatitis C-infected organs. Reese and fellow Penn physician Dr. David Goldberg found only 37 percent of hepatitis C-positive kidney donations between 2005 and 2014 were transplanted. The discards could have helped more than 4,000 patients during that time period, they reported in the New England Journal of Medicine last year. The opioid epidemic is prompting a jump in donations from people who died of drug overdoses â€” typically young organs that, absent an infection risk, would be sought-after. The small Penn and Hopkins trials are a first step. Much larger studies are needed to prove whether more routine use of these organs in immune-suppressed transplant recipients really works. Cost also is a question. Merck & Co. is helping to fund the pilot trials, donating its medication Zepatier, which costs $54,000 for a round of treatment. Thatâ€™s still cheaper than a lifetime of a dialysis, which costs about $75,000 a year, UNOSâ€™ Klassen noted. While the studies began with kidneys because of their demand, â€œI donâ€™t think thereâ€™s any reason, if it proves safe and effective in kidneys, that we wouldnâ€™t want to try it in other organs,â€ Pennâ€™s Goldberg noted. Even if the hepatitis C-infected organs prove useful, the nation still is â€œdesperate for more donors,â€ cautioned Hopkinsâ€™ Desai. â€œItâ€™s a practical solution to help some of the people. It wonâ€™t solve the problem.â€ Filed under: Health Print Email Gmail Related New Rules Bringing Kidneys to Hardest-to-Transplant Patients Kidneys, Cash and Caring Transplant Chains Let Strangers Give Kidney Patients New Life Police Shut Down Gang That Traded in Organs FDA Approves Breakthrough Hepatitis C Drug Subscribe to the Hamodia print edition More in Technology Life-Saving Technology for Autos Is Here, Just Not in Most Cars Intel Launches $6 Billion Production Line in Kiryat Gat Vroom: Govâ€™t to Require Hybrid, Electric Cars to Make Noise Samsungâ€™s $8B Ticket Into the Red-Hot Automotive Tech Race Itâ€™s Not All in the Genes: Clean Living Can Cut Heart Risks OP-ED A Seriously Trumped-Up Charge Time for Conservatives to Come Together To Support Our New President Trump Voters: We Did Hear You â€“ We Just Thought Better of You Without Calculations To Many, Trump Offered Fresh, Appealing Message Kristallnacht Lessons for the Present Sanctity of the Kosel Is Everyoneâ€™s Concern Spreading the Light of Shabbos Ripe Citrons and Ruby Slippers Reflections Of A Kohen A Time to Heal Thereâ€™s a Strong Case to Be Made for Electoral College Voting as a Rational Act These Ballot Initiatives Could Help Fix Our Broken Election System Features This Day In History 13 Cheshvan/November 14 Sudoku â€“ November 14, 2016 Helping Pre-Teenagers Nichum Aveilim 13 Cheshvan/November 14 Mrs. Rivka Herbst (Part IV) Editorial Cartoon â€“ November 14, 2016 Get the Point Please Do Me a Favor Independence Mishmeres HaSholom: Ask the Rav This Day In History 10 Cheshvan/November 11 Not So Sure ××¨×Ÿ ×”â€×—×–×•×Ÿ ××™×©â€ ×–×™â€×¢ Editorial Cartoon â€“ November 11, 2016 Weather Â» Brooklyn 59Â°F Clear See more locations Â» Stocks Â» NASDAQ 5,218.40 -18.72 (-0.36%) S&P 500 2,164.20 -0.25 (-0.01%) See more stocks Â» Currency Â» EUR 0.9302 GBP 0.8001 ILS 3.8462 CHF 0.9955 See more currencies Â» Got a news tip, picture or story to share? Contribute Sections Business Markets Technology World Regional Israel Community National Op-Ed Features Resources Weather Currency Stocks Zmanim Shiurim Simchas Readers Subscribe Letters Archives Classifieds Company Advertise Privacy Policy Terms of Use About Us Contact Us â§
You are the owner of this article. Edit Article Add New Article Sign Up Log In Dashboard Logout My Account Dashboard Profile Saved items Logout Home News Summary - Story List About Us Advertise Contact Us Local Weather Pay Your Bill Report a Delivery Problem Subscribe to The Times Daily Subscription Services Vacation Start / Stop News Local News Business Columnists Crime Education Local Elections State Nation World Weather Sports High School Sports Prep Athlete of the Year Alabama Sports Auburn Sports UNA Sports More College Headlines Pro Sports Sports Contests Outdoors Life Celebrations TNValleyBrides.com Entertainment Health Food Music Religion General Interest Arts and Theater Columnists Savings Blog Comics Games and Puzzles Horoscopes WC Handy Festival Opinion Editorials Reader's View Columnists You said it Obituaries Multimedia Photo Gallery Video Gallery Classifieds For Sale / Wanted Rentals Real Estate Legals TNValleyHomeFinder.com Autos TNValleyWheels.com Place a Classifieds Ad Yellow Pages Deals Jobs Cars Real Estate Weather Toggle navigation Menu Search Search Select A Location The Shoals Decatur Guntersville Athens HuntsvilleMadison Moulton Custom Location Within 5 mi. 10 mi. 25 mi. 50 mi. 100 mi. 200 mi. of zip code USA Canada Results per page 10 25 50 100 Sort by Distance Name Search Log In Using Your Account Log In Don't have an account? Sign Up Today My Account Dashboard Profile Saved items Logout News Local News Business Columnists Crime Education Local Elections 2016 Election Sample Ballots State State Capital Contact Local Lawmakers Nation World Weather Sports High School Sports Prep Athlete of the Year Belgreen Brooks Central Cherokee Colbert County Colbert Heights Collinwood Covenant Christian Deshler Florence Football Scores Hackleburg Haleyville Hamilton Hatton Lauderdale County Lawrence Co. Tenn Lexington Loretto Mars Hill Muscle Shoals Phil Campbell Phillips R.A. Hubbard Red Bay Rogers Russellville Sheffield Shoals Christian Tharptown Vina Waterloo Wayne County Wilson Prep Athlete of the Year Alabama Sports Auburn Sports UNA Sports More College Headlines Pro Sports Sports Contests Outdoors Life Celebrations TNValleyBrides.com Entertainment Health Food Music Religion General Interest Arts and Theater Columnists Savings Blog Comics Games and Puzzles Horoscopes WC Handy Festival Obituaries Classifieds For Sale / Wanted Autos Jobs Real Estate Rentals Legals TNValleyHomeFinder.com TNValleyWheels.com Place a Classifieds Ad Yellow Pages TNValleyDeals.com Close 1 of 3 Jessica Kourkounis Irma Hendricks has blood drawn at the Hospital of the University of Pennsylvania in Philadelphia, on Oct. 6, 2016. Hendricks received a kidney transplant from a donor with hepatitis C, and took medications after surgery that cleared away the virus and left her feeling healthy again. Hendricks is part of a pilot study testing if new drugs that promise to cure most hepatitis C could allow use of organs that today go to waste, and speed transplants to people who might otherwise die waiting. (AP Photo/Jessica Kourkounis) Michael Rubinkam In this photo taken Oct. 13, 2016, Irma Hendricks poses for a portrait with her grandson, C.J., at her home in East Stroudsburg, Pa. Hendricks received a kidney transplant from a donor with hepatitis C, and took medications after surgery that cleared away the virus and left her feeling healthy again. Hendricks is part of a pilot study testing if new drugs that promise to cure most hepatitis C could allow use of organs that today go to waste, and speed transplants to people who might otherwise die waiting. (AP Photo/Michael Rubinkam) Jessica Kourkounis Irma Hendricks, right, talks with her physician Peter P. Reese, MD at Hospital of the University of Pennsylvania in Philadelphia, on Oct. 6, 2016. Hendricks received a kidney transplant from a donor with hepatitis C, and took medications after surgery that cleared away the virus and left her feeling healthy again. Hendricks is part of a pilot study testing if new drugs that promise to cure most hepatitis C could allow use of organs that today go to waste, and speed transplants to people who might otherwise die waiting. (AP Photo/Jessica Kourkounis) AP Worth it? A faster transplant but a kidney with hepatitis C By LAURAN NEERGAARD AP Medical Writer Oct 27, 2016 0 Jessica Kourkounis Irma Hendricks has blood drawn at the Hospital of the University of Pennsylvania in Philadelphia, on Oct. 6, 2016. Hendricks received a kidney transplant from a donor with hepatitis C, and took medications after surgery that cleared away the virus and left her feeling healthy again. Hendricks is part of a pilot study testing if new drugs that promise to cure most hepatitis C could allow use of organs that today go to waste, and speed transplants to people who might otherwise die waiting. (AP Photo/Jessica Kourkounis) Michael Rubinkam In this photo taken Oct. 13, 2016, Irma Hendricks poses for a portrait with her grandson, C.J., at her home in East Stroudsburg, Pa. Hendricks received a kidney transplant from a donor with hepatitis C, and took medications after surgery that cleared away the virus and left her feeling healthy again. Hendricks is part of a pilot study testing if new drugs that promise to cure most hepatitis C could allow use of organs that today go to waste, and speed transplants to people who might otherwise die waiting. (AP Photo/Michael Rubinkam) Jessica Kourkounis Irma Hendricks, right, talks with her physician Peter P. Reese, MD at Hospital of the University of Pennsylvania in Philadelphia, on Oct. 6, 2016. Hendricks received a kidney transplant from a donor with hepatitis C, and took medications after surgery that cleared away the virus and left her feeling healthy again. Hendricks is part of a pilot study testing if new drugs that promise to cure most hepatitis C could allow use of organs that today go to waste, and speed transplants to people who might otherwise die waiting. (AP Photo/Jessica Kourkounis) WASHINGTON (AP) â€” A bold experiment is giving some patients a chance at cutting years off their wait for a kidney transplant if they agree to a drastic-sounding option â€” getting an organ almost sure to infect them with hepatitis C. Betting on new medications that promise to cure hepatitis C, two leading transplant centers aim to use organs that today go to waste, a bid to put a dent in the nation's long transplant waiting list. Pilot studies are underway at the University of Pennsylvania and Johns Hopkins University to test transplanting kidneys from deceased donors with hepatitis C into recipients who don't already have that virus. If the groundbreaking research eventually pans out, hundreds more kidneys â€” and maybe some hearts and lungs, too â€” could be transplanted every year. "We always dreaded hepatitis C," said Dr. Peter Reese, a Penn kidney specialist who is helping lead the research. "But now hepatitis C is just a different disease," enough to consider what he calls the trade-off of getting a new kidney years faster but one that comes with a hopefully treatable infection. It's a trade-off prompted by an organ shortage. More than 99,000 people are on the national kidney waiting list, but only about 17,000 people a year get a transplant and 4 percent a year die waiting, according to the United Network for Organ Sharing (UNOS). "If we had enough organs, we wouldn't do this," said Dr. Niraj Desai, who is leading the Hopkins study. But, Desai said, "most patients are pretty open to the idea once they hear what the alternatives are." Doctors had told 66-year-old Irma Hendricks of East Stroudsburg, Pennsylvania, to expect at least a five-year wait for a kidney transplant. Dialysis three times a week was keeping her alive, but leaving her with no energy for even routine activities. "I call it the zombie syndrome," she said. She jumped at the chance to enroll in Penn's study, even though doctors made clear they hoped for but couldn't guarantee a hepatitis cure. "My son said, 'Mom, this is a no-brainer. Just do it,'" Hendricks said. She swallowed an anti-hepatitis pill daily for three months, in addition to the usual post-transplant medications. Testing showed the drugs rapidly cleared hepatitis C out of her bloodstream. With her new kidney functioning well, she now has enough energy to play with her toddler grandson. "This is giving people in my situation new hope," Hendricks said. Kidney transplant specialists are closely watching the research. "It makes sense to me," said Dr. Matthew Cooper, a transplant surgeon at MedStar Georgetown University Hospital who is not involved in the research. He cautioned that the studies should use only kidneys that are young and otherwise high-quality, and that patients must understand the risks. "They need to know you place their safety as the highest priority," Cooper said. "But at the same time, recognize that we have these obstacles. We don't want people to die on dialysis, and there are not enough organs available for everybody." Hepatitis C is a simmering infection that, if untreated, over two to three decades can quietly destroy someone's liver. At least 2.7 million people in the United States have chronic hepatitis C. Until a few years ago, it was treatable only by medications with grueling side effects and poor cure rates. Now, breakthrough drugs promise to cure 95 percent of hepatitis C cases with fewer side effects â€” for people who can afford them. Treatment costs tens of thousands of dollars. Normally, hepatitis C-infected organs are transplanted only into patients who already have hepatitis C themselves, so as not to further spread the virus. Giving hepatitis C-positive organs to hepatitis C-negative recipients is allowed if the patient agrees, but it's rare, said Dr. David Klassen, UNOS' chief medical officer. UNOS statistics show a few dozen such transplants, mostly kidneys, last year, presumably when doctors feared their patients wouldn't survive the wait for a healthier organ. More often, hospitals discard hepatitis C-infected organs. Reese and fellow Penn physician Dr. David Goldberg found only 37 percent of hepatitis C-positive kidney donations between 2005 and 2014 were transplanted. The discards could have helped more than 4,000 patients during that time period, they reported in the New England Journal of Medicine last year. The opioid epidemic is prompting a jump in donations from people who died of drug overdoses â€” typically young organs that, absent an infection risk, would be sought after. The small Penn and Hopkins trials are a first step. Much larger studies are needed to prove whether more routine use of these organs in immune-suppressed transplant recipients really works. Cost also is a question. Merck & Co. is helping to fund the pilot trials, donating its medication Zepatier, which costs $54,000 for a round of treatment. That's still cheaper than a lifetime of a dialysis, which costs about $75,000 a year, UNOS' Klassen noted. While the studies began with kidneys because of their demand, "I don't think there's any reason, if it proves safe and effective in kidneys, that we wouldn't want to try it in other organs," Penn's Goldberg noted. Even if the hepatitis C-infected organs prove useful, the nation still is "desperate for more donors," cautioned Hopkins' Desai. "It's a practical solution to help some of the people. It won't solve the problem." ___ Associated Press writer Michael Rubinkam in northeastern Pennsylvania contributed to this report. Tags Health Government And Politics Organ Transplants Diagnosis And Treatment Liver Disease Diseases And Conditions Infectious Diseases Medical Research Medication Gambling Recreation And Leisure Lifestyle Ã— Post a comment Emoticons [smile] [beam] [wink] [sad] [cool] [innocent] [rolleyes] [whistling] [lol] [huh] [tongue] [love] [sleeping] [yawn] [unsure] [angry] [blink] [crying] [ohmy] [scared] [sleep] [sneaky] [tongue_smile] [thumbdown] [thumbup] [censored] [happybirthday] [ban] [spam] [offtopic] [batman] [ninja] [pirate] [alien] Comment Text Cancel Post comment Ã— Report Cancel Report Abuse Ã— Watch this discussion. Stop watching this discussion. Get an email notification whenever someone contributes to the discussion Notifications from this discussion will be disabled. Cancel Start watching Stop watching (0) comments Welcome to the discussion. Log In Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language. PLEASE TURN OFF YOUR CAPS LOCK. Don't Threaten. Threats of harming another person will not be tolerated. Be Truthful. Don't knowingly lie about anyone or anything. Be Nice. No racism, sexism or any sort of -ism that is degrading to another person. Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts. Share with Us. We'd love to hear eyewitness accounts, the history behind an article. Post a comment Watch this discussion. Stop watching this discussion. News updates Berms on council agenda to prevent spills from spreading 'We'll be home for Christmas' program set for Dec. 6 Holly and Ivy event scheduled for Dec. 5-9 Fundraiser shoot to be held Saturday Registration for Christmas children assistance program Tuesday Law and Order 11-14-16 Local briefs Sign up for our Newsletter Success! An email has been sent with a link to confirm list signup. Error! There was an error processing your request. News Updates Would you like to receive our daily news?Â Signup today!Â  Manage your lists Games, Puzzles and Horoscopes Comics Interactive Games and Puzzles Horoscopes Public Information Databases Area crime reports Area storm shelters Alabama unemployment rates by county Restaurant Health Ratings Shoals Birth Announcements Franklin Grand Jury Indictments Lauderdale Grand Jury Indictments Online Poll Do you smoke cigars? You voted: Yes: No: Vote View Results Back Sections News Sports Life Business Opinion Obituaries Gallery Video Gallery Weather About Us Contact Us Employment Opportunities Follow Us Affiliated Websites Times Daily Decatur Daily Courier Journal Moulton Advertiser The Redstone Rocket Madison Weekly News American Classifieds Terms of Use Refund Policy Contact Information timesdaily.com 219 W. Tennessee Street Florence, AL 35630 Â© Copyright 2016 timesdaily.com, 219 W. Tennessee Street Florence, ALÂ | Terms of Use Powered by BLOX Content Management System from TownNews.com.

null
View mobile site View mobile site Follow us on Â  Â  Â  Â  Tulsa's 24-Hour News, Weather and Traffic Hi, (not you?) | Member Center | Sign Out Sign In | Register recent on-air advertisers Now Playing Now PlayingNews-Talk 740 KRMG Tulsa's 24-Hour News, ... Listen Live Search Home News Top Stories Oklahoma News US News World News Breaking News Text Alerts Weather 5-Day Forecast KRMG NexRad HD Radar Severe Weather Preparedness TAKE ACTION: Avoid illness during the summer heat Winter Weather Tips Severe Weather Text Alerts School/Business/Church Closings LIVE StormCenter Chase Cameras Traffic Accidents in Tulsa Current ODOT Construction Projects Traffic Cameras Find the lowest gas prices Accident Report Form Red Alert Traffic Texts The KRMG Morning News Behind the Scenes Blog JAMIE DUPREE Jamie Dupree on Twitter Inside KRMG Air Staff Submit A News Tip KRMG Insider Newsletter Event Guide Community Page How To Advertise On KRMG Concerts Contact Us CoxHSHub.com Tulsa Live Events Union Football Shows KRMG Morning News Herman Cain Rush Limbaugh Sean Hannity KRMG Evening News Clark Howard Kilmeade & Friends The Dana Show Chad Benson Show Wheels Car Care Show KRMG.com Presents Voices of Oklahoma Radio KRMG Ask the Experts Weekend The KRMG Gardening Show Contests The KRMG App KRMG TEXT ALERTS Breaking News Alerts Weather Alerts Red Alert Traffic 3 Big Things Home Â Â >Â Â AP Â Â >Â Â Pennsylvania Updated: 3:31 p.m. Thursday, Oct. 27, 2016 | Posted: 3:31 p.m. Thursday, Oct. 27, 2016 Worth it? A faster transplant but a kidney with hepatitis C Related View LargerÂ  In this photo taken Oct. 13, 2016, Irma Hendricks poses for a portrait with her grandson, C.J., at her home in East Stroudsburg, Pa. Hendricks received a kidney transplant from a donor with hepatitis C, and took medications after surgery that cleared away the virus and left her feeling healthy again. Hendricks is part of a pilot study testing if new drugs that promise to cure most hepatitis C could allow use of organs that today go to waste, and speed transplants to people who might otherwise die waiting. (AP Photo/Michael Rubinkam) View LargerÂ  Irma Hendricks, right, talks with her physician Peter P. Reese, MD at Hospital of the University of Pennsylvania in Philadelphia, on Oct. 6, 2016. Hendricks received a kidney transplant from a donor with hepatitis C, and took medications after surgery that cleared away the virus and left her feeling healthy again. Hendricks is part of a pilot study testing if new drugs that promise to cure most hepatitis C could allow use of organs that today go to waste, and speed transplants to people who might otherwise die waiting. (AP Photo/Jessica Kourkounis) View LargerÂ  Irma Hendricks, right, has blood drawn at the Hospital of the University of Pennsylvania in Philadelphia, on Oct. 6, 2016. Hendricks received a kidney transplant from a donor with hepatitis C, and took medications after surgery that cleared away the virus and left her feeling healthy again. Hendricks is part of a pilot study testing if new drugs that promise to cure most hepatitis C could allow use of organs that today go to waste, and speed transplants to people who might otherwise die waiting. (AP Photo/Jessica Kourkounis) View LargerÂ  Irma Hendricks has blood drawn at the Hospital of the University of Pennsylvania in Philadelphia, on Oct. 6, 2016. Hendricks received a kidney transplant from a donor with hepatitis C, and took medications after surgery that cleared away the virus and left her feeling healthy again. Hendricks is part of a pilot study testing if new drugs that promise to cure most hepatitis C could allow use of organs that today go to waste, and speed transplants to people who might otherwise die waiting. (AP Photo/Jessica Kourkounis) By LAURAN NEERGAARD The Associated Press WASHINGTON â€” A bold experiment is giving some patients a chance at cutting years off their wait for a kidney transplant if they agree to a drastic-sounding option â€” getting an organ almost sure to infect them with hepatitis C. Betting on new medications that promise to cure hepatitis C, two leading transplant centers aim to use organs that today go to waste, a bid to put a dent in the nation's long transplant waiting list. Pilot studies are underway at the University of Pennsylvania and Johns Hopkins University to test transplanting kidneys from deceased donors with hepatitis C into recipients who don't already have that virus. If the groundbreaking research eventually pans out, hundreds more kidneys â€” and maybe some hearts and lungs, too â€” could be transplanted every year. "We always dreaded hepatitis C," said Dr. Peter Reese, a Penn kidney specialist who is helping lead the research. "But now hepatitis C is just a different disease," enough to consider what he calls the trade-off of getting a new kidney years faster but one that comes with a hopefully treatable infection. It's a trade-off prompted by an organ shortage. More than 99,000 people are on the national kidney waiting list, but only about 17,000 people a year get a transplant and 4 percent a year die waiting, according to the United Network for Organ Sharing (UNOS). "If we had enough organs, we wouldn't do this," said Dr. Niraj Desai, who is leading the Hopkins study. But, Desai said, "most patients are pretty open to the idea once they hear what the alternatives are." Doctors had told 66-year-old Irma Hendricks of East Stroudsburg, Pennsylvania, to expect at least a five-year wait for a kidney transplant. Dialysis three times a week was keeping her alive, but leaving her with no energy for even routine activities. "I call it the zombie syndrome," she said. She jumped at the chance to enroll in Penn's study, even though doctors made clear they hoped for but couldn't guarantee a hepatitis cure. "My son said, 'Mom, this is a no-brainer. Just do it,'" Hendricks said. She swallowed an anti-hepatitis pill daily for three months, in addition to the usual post-transplant medications. Testing showed the drugs rapidly cleared hepatitis C out of her bloodstream. With her new kidney functioning well, she now has enough energy to play with her toddler grandson. "This is giving people in my situation new hope," Hendricks said. Kidney transplant specialists are closely watching the research. "It makes sense to me," said Dr. Matthew Cooper, a transplant surgeon at MedStar Georgetown University Hospital who is not involved in the research. He cautioned that the studies should use only kidneys that are young and otherwise high-quality, and that patients must understand the risks. "They need to know you place their safety as the highest priority," Cooper said. "But at the same time, recognize that we have these obstacles. We don't want people to die on dialysis, and there are not enough organs available for everybody." Hepatitis C is a simmering infection that, if untreated, over two to three decades can quietly destroy someone's liver. At least 2.7 million people in the United States have chronic hepatitis C. Until a few years ago, it was treatable only by medications with grueling side effects and poor cure rates. Now, breakthrough drugs promise to cure 95 percent of hepatitis C cases with fewer side effects â€” for people who can afford them. Treatment costs tens of thousands of dollars. Normally, hepatitis C-infected organs are transplanted only into patients who already have hepatitis C themselves, so as not to further spread the virus. Giving hepatitis C-positive organs to hepatitis C-negative recipients is allowed if the patient agrees, but it's rare, said Dr. David Klassen, UNOS' chief medical officer. UNOS statistics show a few dozen such transplants, mostly kidneys, last year, presumably when doctors feared their patients wouldn't survive the wait for a healthier organ. More often, hospitals discard hepatitis C-infected organs. Reese and fellow Penn physician Dr. David Goldberg found only 37 percent of hepatitis C-positive kidney donations between 2005 and 2014 were transplanted. The discards could have helped more than 4,000 patients during that time period, they reported in the New England Journal of Medicine last year. The opioid epidemic is prompting a jump in donations from people who died of drug overdoses â€” typically young organs that, absent an infection risk, would be sought after. The small Penn and Hopkins trials are a first step. Much larger studies are needed to prove whether more routine use of these organs in immune-suppressed transplant recipients really works. Cost also is a question. Merck & Co. is helping to fund the pilot trials, donating its medication Zepatier, which costs $54,000 for a round of treatment. That's still cheaper than a lifetime of a dialysis, which costs about $75,000 a year, UNOS' Klassen noted. While the studies began with kidneys because of their demand, "I don't think there's any reason, if it proves safe and effective in kidneys, that we wouldn't want to try it in other organs," Penn's Goldberg noted. Even if the hepatitis C-infected organs prove useful, the nation still is "desperate for more donors," cautioned Hopkins' Desai. "It's a practical solution to help some of the people. It won't solve the problem." ___ Associated Press writer Michael Rubinkam in northeastern Pennsylvania contributed to this report. Copyright The Associated Press Â  Â  Newsletters RSS Feeds Mobile @KRMGTulsa Trending News Injured, rescued Florida bald eagle takes turn for worse, caregivers say Princess Kate looks just like Princess Diana in stunning photo Mannequin challenge: Beyonce, Britney Spears, other celebrities get in on the trend Justin Ross Harris found guilty of murder in son's hot car death Trump may deport up to 3 million illegal immigrants Â  News/Weather/Traffic News Weather Traffic Event Guide Events Follow and Share RSS Feeds Advertisers and Sponsors How to Advertise Recent on-air advertisers Cars at Autotrader Local Services at Kudzu Valpak Tulsa Coupons Rare - Conservative News About Us Contact Us Work With Us EEOC Statement Help Audio Help Video Help Search Help Â  Â© 2016 Cox Media Group. By using this website, you accept the terms of our Visitor Agreement and Privacy Policy, and understand your options regarding Ad Choices. Learn about careers at Cox Media Group Â  View mobile site View mobile site Enterprise Feedback Management Survey Software Sign In / Register Sign in with your existing account {* loginWidget *} Sign in with your email {* #userInformationForm *} {* traditionalSignIn_emailAddress *} {* traditionalSignIn_password *} {* traditionalSignIn_signInButton *} Forgot your password? {* /userInformationForm *} New User?Create a New Account Sign In / Register Welcome Back {* welcomeName *} {* loginWidget *} Use another account Sign In / Register Welcome back. Please sign in {* #userInformationForm *} {* traditionalSignIn_emailAddress *} {* traditionalSignIn_password *} {* traditionalSignIn_signInButton *} Forgot your password? Use another account {* /userInformationForm *} You're Almost Done! Select a display name and password {* #socialRegistrationForm *} {* socialRegistration_displayName *} {* socialRegistration_emailAddress *} {* traditionalRegistration_password *} {* traditionalRegistration_passwordConfirm *} Tell us about yourself {* registration_firstName *} {* registration_lastName *} {* registration_postalZip *} {* registration_birthday *} {* registration_gender *} *Indicates Required Field {* agreeToTerms *} {* backButton *} {* socialRegistration_signInButton *} {* /socialRegistrationForm *} Create a New Account Select a display name and password Already have an account? Sign In {* #registrationForm *} {* traditionalRegistration_displayName *} {* traditionalRegistration_emailAddress *} {* traditionalRegistration_password *} {* traditionalRegistration_passwordConfirm *} Tell us about yourself {* registration_firstName *} {* registration_lastName *} {* registration_postalZip *} {* registration_birthday *} {* registration_gender *} *Indicates Required Field {* agreeToTerms *} {* createAccountButton *} {* /registrationForm *} Create a New Account Already have an account? Sign In {* #registrationFormBlank *} {* registration_firstName *} {* registration_lastName *} {* traditionalRegistration_displayName *} {* traditionalRegistration_emailAddressBlank *} {* registration_birthday *} {* registration_gender *} {* registration_postalZip *} {* traditionalRegistration_passwordBlank *} {* traditionalRegistration_passwordConfirmBlank *} *Indicates Required Field {* agreeToTerms *} {* backButton *} {* createAccountButton *} {* /registrationForm *} Thank you for registering! We have sent you a confirmation email. Please check your email and click on the link to activate your account. Close Thank you for registering! We look forward to seeing you frequently. Visit us and sign in to update your profile, receive the latest news and keep up to date with mobile alerts. Close Create a new password Don't worry, it happens. We'll send you a link to create a new password. {* #forgotPasswordForm *} {* forgotPassword_emailAddress *} {* backButton *} {* forgotPassword_sendButton *} {* /forgotPasswordForm *} Email sent We have sent you an email with a link to change your password. Close Create a new password We've sent an email with instructions to create a new password. Your existing password has not been changed. Close {* mergeAccounts *} Sign in to complete account merge {* #tradAuthenticateMergeForm *} {* traditionalSignIn_emailAddress *} {* mergePassword *} {* backButton *} {* traditionalSignIn_signInButton *} {* /tradAuthenticateMergeForm *} Resend Email Verification To sign in you must verify your email address. Fill out the form below and we'll send you an email to verify. {* #resendVerificationForm *} {* resendVerification_emailAddress *} {* newPasswordFormButton *} {* /resendVerificationForm *} Your Verification Email Has Been Sent Check your email for a link to verify your email address. Sign in
Transplant experiment relies on hepatitis C-infected kidneys | CTV News Video Shows Canada World Politics Entertainment Sci-Tech Health Autos Business Sports CTV News Mobile CTV Search Search CTV News X Skip to Main Content Skip to Section Links Home Headlines Diet and Nutrition Fitness Body and Mind Lifestyle Advertisement Transplant experiment relies on hepatitis C-infected kidneys Irma Hendricks, who received a kidney transplant from a donor with hepatitis C, has blood drawn at the Hospital of the University of Pennsylvania in Philadelphia, on Oct. 6, 2016. (AP / Jessica Kourkounis) Lauren Neergaard, The Associated Press Published Thursday, October 27, 2016 4:00AM EDT Last Updated Thursday, October 27, 2016 11:04AM EDT WASHINGTON -- Some patients facing a years-long wait for a kidney transplant are jumping ahead in line thanks to a startling experiment: They're agreeing to an organ almost sure to infect them with hepatitis C. Knowingly transmitting a dangerous virus may sound drastic, but two leading transplant centres are betting the strategy will save lives, if new medications that promise to cure hepatitis C allow use of organs that today go to waste. Pilot studies are underway at the University of Pennsylvania and Johns Hopkins University to test transplanting kidneys from deceased donors with hepatitis C into recipients who don't already have that virus. If the research eventually pans out, hundreds more kidneys -- and maybe some hearts and lungs, too -- could be transplanted every year. "We always dreaded hepatitis C," said Dr. Peter Reese, a Penn kidney specialist who is helping lead the research. "But now hepatitis C is just a different disease," enough to consider what he calls the trade-off of getting a new kidney years faster but one that comes with a hopefully treatable infection. It's a trade-off prompted by the nation's organ shortage. More than 99,000 people are on the national kidney waiting list, but only about 17,000 people a year get a transplant and 4 per cent a year die waiting, according to the United Network for Organ Sharing (UNOS). "If we had enough organs, we wouldn't do this," said Dr. Niraj Desai, who is leading the Hopkins study. But, Desai said, "most patients are pretty open to the idea once they hear what the alternatives are." Doctors had told 66-year-old Irma Hendricks of East Stroudsburg, Pennsylvania, to expect at least a five-year wait for a kidney transplant. Dialysis three times a week was keeping her alive, but leaving her with no energy for even routine activities. "I call it the zombie syndrome," she said. She jumped at the chance to enrol in Penn's study, even though doctors made clear they hoped for but couldn't guarantee a hepatitis cure. "My son said, 'Mom, this is a no-brainer. Just do it,"' Hendricks said. She swallowed an anti-hepatitis pill daily for three months, in addition to the usual post-transplant medications. Testing showed the drugs rapidly cleared hepatitis C out of her bloodstream. With her new kidney functioning well, she now has enough energy to play with her toddler grandson. "This is giving people in my situation new hope," Hendricks said. Kidney transplant specialists are closely watching the research. "It makes sense to me," said Dr. Matthew Cooper, a transplant surgeon at MedStar Georgetown University Hospital who is not involved in the research. He cautioned that the studies should use only kidneys that are young and otherwise high-quality, and that patients must understand the risks. "They need to know you place their safety as the highest priority," Cooper said. "But at the same time, recognize that we have these obstacles. We don't want people to die on dialysis and there are not enough organs available for everybody." Hepatitis C is a simmering infection that, if untreated, over two to three decades can quietly destroy someone's liver. At least 2.7 million people in the United States have chronic hepatitis C. Until a few years ago, it was treatable only by medications with grueling side effects and poor cure rates. Now, breakthrough drugs promise to cure 95 per cent of hepatitis C cases with fewer side effects -- for people who can afford them. Treatment costs tens of thousands of dollars. Normally, hepatitis C-infected organs are transplanted only into patients who already have hepatitis C themselves, so as not to further spread the virus. Giving hepatitis C-positive organs to hepatitis C-negative recipients is allowed if the patient agrees, but it's rare, said Dr. David Klassen, UNOS' chief medical officer. UNOS statistics show a few dozen such transplants, mostly kidneys, last year, presumably when doctors feared their patients wouldn't survive the wait for a healthier organ. More often, hospitals discard hepatitis C-infected organs. Reese and fellow Penn transplant surgeon Dr. David Goldberg found only 37 per cent of hepatitis C-positive kidney donations between 2005 and 2014 were transplanted. The discards could have helped more than 4,000 patients during that time period, they reported in the New England Journal of Medicine last year. The opioid epidemic is prompting a jump in donations from people who died of drug overdoses -- typically young organs that, absent an infection risk, would be sought after. The small Penn and Hopkins trials are a first step. Much larger studies are needed to prove if more routine use of these organs in immune-suppressed transplant recipients really works. Cost also is a question. Merck & Co. is helping to fund the pilot trials, donating its medication Zepatier, which costs $54,000 for a round of treatment. That's still cheaper than a lifetime of a dialysis, which costs about $75,000 a year, UNOS' Klassen noted. While the studies began with kidneys because of their demand, "I don't think there's any reason, if it proves safe and effective in kidneys, that we wouldn't want to try it in other organs," noted Penn's Goldberg. Even if the hepatitis C-infected organs prove useful, the nation still is "desperate for more donors," cautioned Hopkins' Desai. "It's a practical solution to help some of the people. It won't solve the problem." ------ Associated Press writer Michael Rubinkam contributed to this report. Related Stories In Iran, unique system allows payments for kidney donors Organ transplants have come a long way but hurdles remain Doctors hail China's pledge to stop harvesting inmate organs Photos Irma Hendricks, right, has blood drawn at the Hospital of the University of Pennsylvania in Philadelphia, on Oct. 6, 2016. Hendricks received a kidney transplant from a donor with hepatitis C, and took medications after surgery that cleared away the virus and left her feeling healthy again. (AP Photo/Jessica Kourkounis) Report Error MOST WATCHED false Cows stranded after New Zealand quake Air Date: November 14, 2016 false CTV News Channel: Investigating mid-air collision Air Date: November 14, 2016 false CTV News Channel: Chappelle hosts SNL Air Date: November 13, 2016 CTV News CTV News CTV News CTV News CTV News CTV News CTV News CTV News CTV News More Stories from Health News Drug decriminalization would bring health benefits, internal federal study says Antidepressant and antipsychotic prescriptions up for Canadians under 18: study Depression rising among U.S. teens: study Big-dose prescriptions of opioid painkillers to 2,100 Nova Scotians 'disturbing': expert Sleep issues, skipping breakfast strong predictors of childhood obesity: study Emotional damage from trauma of childhood sexual abuse can last a lifetime Join the conversation... Advertisement CTV News Video Network false Obama trying to convey 'weighty' duties of White House CTV News CTV News CTV News CTV News Most Popular Stories 1 9 key takeaways from Trump's '60 Minutes' interview 2 Award-winning 'Corner Gas' star Janet Wright dead at 71 3 $50M lotto winner offers hope for small-town jackpot dreamers 1 4 'Huge' opportunity for Canada following Trump's win 1 5 Sister accused of killing twin in Hawaii jailed in New York 1 6 2 flight attendants injured after Toronto-bound plane's 'evasive maneuvers' 4 7 40 km over and 4 decades overdue: Man caught speeding with expired licence 8 Pastor faces trial on decades-old sex-crime allegations 1 9 '90210' cast pays tribute to ailing Shannen Doherty 10 Trump considering woman, openly gay man for leadership posts 10 Don't Miss false Ottawa benched? NHL looking at other cities for outdoor game false Cows stranded after New Zealand quake triggers landslide false 2016 is set to become the hottest year on record You will need to enable JavaScript in order to use the Widget. MyHealth Videos false Brain implant offers communication for ALS patients false New program to monitor concussions at schools catching on false Report calls for better monitoring of opioid prescriptions CTV News My Health CANADA Mohamed Fahmy on writing his memoir: 'it was very traumatic' Former aide testifies Michael Applebaum was 'open to corruption' B.C. man pleads not guilty to four terrorism-related charges WORLD Turkish warplanes attack IS stronghold in northern Syria South Africa moves Pistorius to another prison Israeli minister: Trump election is time to 'reset' policies ENTERTAINMENT Award-winning 'Corner Gas' star Janet Wright dead at 71 Nephew in 'Making a Murderer' ordered released '90210' cast pays tribute to ailing Shannen Doherty HEALTH Drug decriminalization would bring health benefits, internal federal study says Antidepressant and antipsychotic prescriptions up for Canadians under 18: study Depression rising among U.S. teens: study POLITICS Liberal government to repeal section of Criminal Code on anal intercourse Trudeau affirms commitment to NATO, Latvia mission following Trump victory Trudeau to talk trade, investment to open doors in Cuba, South America SCI-TECH Google Doodle celebrates Canada's Sir Frederick Banting South African rhino that survived attack dies of infection Israel to launch major expedition to find Dead Sea Scrolls BUSINESS Two gamblers spearhead class action against Casino Rama data breach Medical marijuana producer Canopy Growth Corp. expands as client base grows Gold, energy stocks lift TSX; Dow gains for a sixth straight day to new record SPORTS After van breakdown, Jamaican bobsledders have new wheels for journey to Whistler race Canadian women drop one spot to No. 3 in the World Rugby rankings Lindros' Hall of Fame career was without compare: 'He's one in a lifetime' AUTOS U.S. government to require hybrid, electric cars to make noise Canadians need to learn of marijuana-while-driving risks: CAA Faraday Future crossover: Tesla Model X rival in the pipeline Lifestyle How to haggle: Tips on how to negotiate price cuts, freebies when shopping Defiant activists crown Miss Transgender in Indonesia Iran resort hopes relaxed rules will attract tourists CTV News on the Go CTV News on the Go: Monday, Nov. 14 Cows stranded after New Zealand quake triggers landslide Ukrainian lawmakers throw punches during parliament meeting In Pictures Â  Supermoon around the world Lest we Forget: Remembrance Day marked in Canada Leonard Cohen, a life in pictures Advertise on CTVNews.ca Advertise with Bell Media About CTV Careers CTV News Stox Press Room Producer Guidelines Contact Us Local News CTV News Atlantic CTV News Calgary CTV News Edmonton CTV News Kitchener CTV News Montreal CTV News Northern Ontario CTV News Ottawa CTV News Regina CTV News Saskatoon CTV News Toronto CTV News Vancouver CTV News Winnipeg CTV Two Atlantic Alberta Barrie London Ottawa Windsor Vancouver Island CTV News Programs CTV National News Power Play W5 CTV Question Period Video Sign In Video Sign Out CTV News GO Video Help CTV News on Mobile Site login View Mobile Site Use of this Website assumes acceptance of Terms & Conditions and Privacy Policy Â© 2016 All rights reserved. Bell Media Television Back to top
Â  Home U.K. News Sports U.S. Showbiz Australia Femail Â  Â  Health Science Money Video Travel Columnists Latest Headlines Health Health Directory Health Boards Diets My Profile Logout Login Feedback DailyMail NEW ARTICLESHomeTop Share show ad Obama takes thinly-veiled swipe at Hillary for losing presidency to Trump as he tells how HE won by going to 'every fish fry' - in first post-election news conference Ross Harris found GUILTY of murdering his 22-month-old son by intentionally leaving him in a hot car for seven hours because the child 'didn't fit with his sex-obsessed lifestyle' Illegal immigrant 'crashed his car into young woman's vehicle before dragging her out and RAPING her in a ditch for two hours' Obama: Trump is committed to 'strong and robust' NATO. President says 'there is no weakening of resolve' on key allianceÂ  'We need men onboard': Gretchen Carlson urges men to join the fight to end sexual harassment and admits she has many sleepless nights since leaving Fox News 'Reality has a way of asserting itself!' Condescending Obama says Trump can't keep his promises as he warns his successor's 'temperament' will be his doom unless he 'corrects' it Respected PBS NewsHour anchor Gwen Ifill dies aged 61 after a short, private battle with cancer Why sense of SMELL is the biggest tell-tale factor for Alzheimer's - and could be spotted 10 YEARS before memory loss symptoms 'I came here to kill you': Ex-con who killed New York cop 'had been stalking estranged wife by sleeping on the roof of the building she was staying in for DAYS' Judge orders Making A Murderer 'accomplice' Brendan Dassey be set FREE after 10 years in prison Jilted groom, 31, launches lawsuit against ex-fiancÃ©e overÂ a $125,000 diamond engagement ring after their wedding was suddenly called off Beauty Crash Course: A leading dermatologist explains how YOU can tackle dry skin and holiday-related acne this fall for a flawless complexion Young And The Restless star Corey Sligh, 28, arrested for molesting a girl under the age of 10 in Georgia Bodies of former Polish president and his wife are to be exhumed along with 80 other victims of 2010 plane crash following claims they were murderedÂ  California doctor 'faked his own death and fled to Egypt where he worked as a scuba instructor' to avoid jail for alleged multi-million dollar health insurance fraud She smelled a rat! Manhattan woman is suing clothing giant Zara after 'finding DEAD RODENT sewn into the hem of her dress' REVEALED: Sumner Redstone's five grandchildren who are set to split his $5BILLION fortune - and the private dealings with Viacom that helped them secure their trust Four-year-old girl playing with a gun accidentally shoots herself and her sleeping mother in the head PIERS MORGAN: And the award for the worst election loser goes to . . . every deluded millionaire celebrity who can't deal with the fact that America couldn't care less what they think President-elect Trump and Russian President Vladimir Putin connect for first phone call since Trump's historic win - and word breaks just as Obama prepares to face the media before trip 'Women are scared a predator will soon be residing in the White House': Lena Dunham talks Donald Trump win at Glamour's Summit Ivanka's husband Jared Kushner will beÂ 'very involved in decision-making' when Trump becomes president says incoming chief of staff Silicon Valley issues plea to Donald Trump to support strong encryption and let them hire more foreign workers Trump could shatter a different glass ceiling by naming first openly gay man to cabinet-level post - and might pick a woman to run the GOP Previous Next Why people are lining up for organs infected with hepatitis C: Patients are betting on cure for the virus in desperate bid to move up the transplant list Patients who need a kidney transplant face years on a waiting list Two top transplant centers are offering instant organs - that have hep C Hundreds of organs infected with hepatitis C go to waste every year But these two centers think they may have found a cure for the virus They are offered patients to willingly infect themselves with hep C and hope that the new treatments result in a cureÂ  By Associated Press Published: 10:09 EST, 27 October 2016 | Updated: 22:30 EST, 27 October 2016 e-mail 36 shares 5 View comments Some patients facing a years-long wait for a kidney transplant are jumping ahead in line thanks to a startling experiment. They're agreeing to an organ almost sure to infect them with hepatitis C. Knowingly transmitting a dangerous virus may sound drastic but two leading transplant centers are betting the strategy will save lives - if new medications that promise to cure hepatitis C allow use of organs that today go to waste. Pilot studies are under way at the University of Pennsylvania and Johns Hopkins University to test transplanting kidneys from deceased donors with hepatitis C into recipients who don't already have that virus.Â  If the research eventually pans out, hundreds more kidneys - and maybe some hearts and lungs, too - could be transplanted every year. Scroll down for videoÂ  Success: Irma Hendricks received a kidney transplant from a donor with hepatitis C, and took medications after surgery that cleared away the virus and left her feeling healthy again. She is pictured with her grandson CJ at her home in East Stroudsburg, Pennsylvania Hepatitis is inflammation of the liver. Hepatitis A never progresses to a chronic infection like hepatitis B and C. But C is the only one for which there is no preventative vaccine. Spread through contaminated blood, hepatitis C tends to develop into a chronic infection after six months. The infection attacks the liver, leading to cirrhosis or liver cancer. 'We always dreaded hepatitis C,' said Dr Peter Reese, a Penn kidney specialist who is helping lead the research.Â  'But now hepatitis C is just a different disease,' enough to consider what he calls the tradeoff of getting a new kidney years faster but one that comes with a hopefully treatable infection. It's a tradeoff prompted by the nation's organ shortage.Â  More than 99,000 people are on the national kidney waiting list but only about 17,000 people a year get a transplant and four per cent a year die waiting, according to the United Network for Organ Sharing (UNOS). 'If we had enough organs, we wouldn't do this,' said Dr. Niraj Desai, who is leading the Hopkins study.Â  RELATED ARTICLES Previous 1 Next How killer superbugs like MRSA are being spread around... Cancers survivors are TWICE as likely to be on... Share this article Share But, 'most patients are pretty open to the idea once they hear what the alternatives are.' Doctors had told Irma Hendricks, 66, to expect at least a five-year wait for a kidney transplant.Â  Dialysis three times a week was keeping the East Stroudsburg, Pennsylvania, woman alive but left her with no energy for even routine activities. 'I call it the zombie syndrome,' she said. So she jumped at the chance to enroll in Penn's study, even though doctors made clear they hoped for but couldn't guarantee a hepatitis cure. 'My son said, 'Mom, this is a no-brainer. Just do it,'' Hendricks said, She swallowed an anti-hepatitis pill daily for three months, in addition to the usual post-transplant medications.Â  WHAT IS HEPATITIS C?Â  Hepatitis is inflammation of the liver.Â  Hepatitis A never progresses to a chronic infection like hepatitis B and C.Â  But hepatitis C is the only one for which there is no preventative vaccine. Spread through contaminated blood, hepatitis C tends to develop into a chronic infection after six months. The infection attacks the liver, leading to cirrhosis or liver cancer. Testing showed the drugs rapidly cleared hepatitis C out of her bloodstream. And with her new kidney functioning well, she now has enough energy to play with her toddler grandson. 'This is giving people in my situation new hope,' Hendricks said. Kidney transplant specialists are closely watching the research. 'It makes sense to me,' said Dr Matthew Cooper, a transplant surgeon at MedStar Georgetown University Hospital, who is not involved in the research.Â  He cautioned that the studies should use only kidneys that are young and otherwise high-quality, and that patients must understand the risks. 'They need to know you place their safety as the highest priority,' Cooper said.Â  'But at the same time, recognize that we have these obstacles. We don't want people to die on dialysis and there are not enough organs available for everybody.' Hepatitis C is a simmering infection that, if untreated, over two to three decades can quietly destroy someone's liver.Â  At least 2.7 million people in the U.S. have chronic hepatitis C. Until a few years ago, it was treatable only by medications with grueling side effects and poor cure rates.Â  Now, breakthrough drugs promise to cure 95 per cent of hepatitis C cases with fewer side effects - for people who can afford them. Treatment costs tens of thousands of dollars. Normally, hepatitis C-infected organs are transplanted only into patients who already have hepatitis C themselves, so as not to further spread the virus. Giving hepatitis C-positive organs to hepatitis C-negative recipients is allowed if the patient agrees, but it's rare, said Dr David Klassen, UNOS' chief medical officer.Â  UNOS statistics show a few dozen such transplants, mostly kidneys, last year, presumably when doctors feared their patients wouldn't survive the wait for a healthier organ. More often, hospitals discard hepatitis C-infected organs.Â  Reese and fellow Penn transplant surgeon Dr. David Goldberg found only 37 per cent of hepatitis C-positive kidney donations between 2005 and 2014 were transplanted.Â  The discards could have helped more than 4,000 patients during that time period, they reported in the New England Journal of Medicine last year. And the opioid epidemic is prompting a jump in donations from people who died of drug overdoses - typically young organs that, absent an infection risk, would be sought after. The small Penn and Hopkins trials are a first step; much larger studies are needed to prove if more routine use of these organs in immune-suppressed transplant recipients really works. Cost also is a question.Â  Merck & Co. is helping to fund the pilot trials, donating its medication Zepatier, which costs $54,000 for a round of treatment.Â  That's still cheaper than a lifetime of a dialysis, which costs about $75,000 a year, UNOS' Klassen noted. While the studies began with kidneys because of their demand, 'I don't think there's any reason, if it proves safe and effective in kidneys, that we wouldn't want to try it in other organs,' noted Penn's Goldberg. Even if the hepatitis C-infected organs prove useful, the nation still is 'desperate for more donors,' cautioned Hopkins' Desai. 'It's a practical solution to help some of the people. It won't solve the problem.' Â  Share or comment on this article e-mail 36 shares Most watched News videos SNL mocks confident Clinton supporters with Dave Chappelle Dashcam footage captures moment van swerves before crashing Chili's manager snatches veteran's free meal after complaint Mob storm police station and lynch suspected paedophile Moment of impact as earthquake rattles home in Wellington SNL mocks government shutdown with Gravity skit Got any oink-tment?: Excited piglets take a warm bath Adorable boxer dog jumps far better than the John Lewis dog Malcolm Turnbull accuses Lisa Wilkinson of 'interrogating' him Obama and Trump sit down to discuss the transfer of power James Corden sings for the 2016 Sainsbury's Christmas advert Clinton makes final appearance at campaign headquarters 'Don't be afraid': Trump looks to reassure divided America... PICTURED: The 71 protesters arrested during fourth night of... Obama's pointed rebuke to Clinton for election loss as he... African-American soldier with his service dog, Barack, has... Christian mom blogger reveals she is dating disgraced soccer... Residents forced to flee huge 'wall of water' after... PIERS MORGAN: And the award for the worst election loser... 'What the f**? Oprah?!' Outraged celebrities turn on Winfrey... Trump says he will 'immediately' deport two to three million... 'Oh my God, I think America is racist!' Dave Chappelle is... Will Donald Trump live in the White House? The... 'You gotta print a fake birth certificate, put it in an... MOST READ NEWS Previous Next â— â— â— More top stories Bing Site Web Enter search term: Search Like DailyMail Follow MailOnline Follow DailyMail +1 DailyMail Â  Â  DON'T MISS 'She's modified her face beyond all recognition!' Carol Vorderman, 55, stuns viewers after exhibiting 'frozen' complexion on I'm A Celeb It's getting hot in here! Ola Jordan shows off her dancer's body in tiny red bikini as she hits the jungle shower with Sam Quek and Scarlett Moffatt on I'm a Celeb Carol Vorderman, 55, strips down to a VERY racy swimsuit on I'm A Celeb...as 'happily single' star tells campmates 'I do alright' when it comes to men She looks to be doing just fine! Kim Kardashian's friend shares rare photo of reality star recluse as she dresses up in belly dancer costume for fun Ashley James puts on a eye-popping display in an itsy-bitsy bikini as she soaks up the sun on the beach in Ibiza Making the most of the sun 'It's me or the wardrobe!' Frankie Gaff gives Jamie Laing an ultimatum. He found living with her and her 'floordrobe' too much to bear on Made In Chelsea, by Jim ShelleyÂ  Cor (rie) blimey! Helen Flanagan showcases her incredible figure in a racy cut-out bikini as she holidays in Dubai with boyfriend Scott Sinclair Chloe Ferry reportedly FIRED from Geordie Shore after 'kicking new housemate Zahida Allen in the head'Â  The 21-year-old was shown the door Now that's a lesson in style! Myleene Klass exposes her cleavage in plunging jumpsuit as she leads the red carpet glamour at School of Rock press night She's proud of that booty! Khloe Kardashian flaunts her derriere as she does squats at the gym Taking after her bigger sister (in both senses) Real men wear pink! Brooklyn Beckham follows in his mother Victoria's fashionable footsteps as he makes a statement with pink beanie hat Frankie Bridge is the picture of elegance in plunging patterned gown at Virgin awards... after her husband Wayne makes I'm A Celebrity debut PICTURE EXCLUSIVE: Tom Hiddleston steps out with a pretty blonde Taylor Swift lookalike... two months after split with pop star Flashed a beaming grin She needs a nap! Pregnant Marion Cotillard looks weary during LA dinner after tirelessly promoting Brad Pitt WWII film Allied Struggling Holly Willoughby is close to tears on This Morning as a distraught mother breaks down over her son's planned suicide during bullying phone-in The Eighties called! Sheridan Smith is unrecognisable as a busty brunette on set of the movie adaptation of comic Jo Brand's book As schizophrenic mum Newly-engaged Pixie Lott can barely contain her glee as she heads to jewellers hours after fiancÃ© Oliver Cheshire popped the question What a gem!Â  Emma Watson stars as Belle in the first trailer for Disney's long-awaited live action remake of Beauty And The Beast Looks stunning Choosing her prince wasn't ALWAYS such an easy choice! Meghan Markle giggles as she is asked to pick either William or Harry months before romance She's a good sport! Gigi Hadid tries her hand at table tennis as she makes a sweeping entrance at VIP dinner in stylish satin jumpsuit In high spirits 'Worst thing I've ever done': I'm A Celeb's Scarlett, Jordan, Ola and Sam do Bushtucker Trial featuring 120,000 critters... as Moffatt is voted in first From refurbished iPads to a good-as-new Sony PS4: Ways to save money on your children's gifts this Christmas (without any fewer smiles!) SPONSORED Make-up free Coleen Rooney flaunts her trim figure in semi-sheer mesh workout gear as she hits the gym Making the most of her free time Demure Dita! Burlesque extraordinaire Von Teese steps out in modest black polo neck and ornate silver skirt for evening in London Jessica Simpson's father Joe, 58, confirms he has prostate cancer and has already undergone surgery 'He's feeling great now and is optimistic' 'It's like we get a little bit of dad back': Bindi Irwin says she remembers her dad the best every time she puts on her Australia Zoo uniform Not very ladylike! Lady Victoria Hervey, 40, displays more than expected as she flashes perky assets when risquÃ© swimsuit unfastens Dapper Brad Pitt takes selfies with adoring fans at Allied screening in China... as he returns to the public eye after split with Angelina Jolie In better spirits again 'She works really hard': X Factor's Sam Lavery defends Honey G after elimination... as rapper faces backlash for surviving ANOTHER week 'He's such a good man': Marion Cotillard gushes about Allied co-star Brad Pitt... after shooting down rumours of an on set romance Caught up in split Naomi Campbell speaks for the first time about what it means to be black and British and joins other famous stars who were told to limit their ambitions due to their skin colour Take that! Bella Hadid throws a punch as she works out in boxing class after split from The Weeknd Was snug in her black, oversize fuzzy jacketÂ  Girl time! Bella Thorne and Demi Lovato don skinny jeans as they catch up over lunch at the trendy Urth Caffe They both have new romances 'I had a bit of a nervous breakdown' Ryan Reynolds admits secret battle with anxiety as he's named GQ's Man of the Year He's filming Deadpool Coy Khloe Kardashian attempts to go incognito in huge hoodie as she steps out in wake of Tristan Thompson split rumoursÂ  Looked glum 'I gave up my career for a really long time': Ayda Field admits she TURNED DOWN a major US TV show to be with husband Robbie Williams 'It was very romantic': Goldie Hawn gets VERY candid about her and Kurt Russell's sex life and discusses split with ex husband Bill Hudson In Aspen, Colorado,Â  'Fame is the best drug': Lady Gaga opens up about her addiction to stardom as she covers Harper's Bazaar She penned an open essay to the magazine Twice the star power! Madonna puckers up as she and Zac Efron take selfies together at UFC's Connor McGregor star-studded fight Lucky Star 20 years and counting! Ant and Dec sign new three-year deal with ITV marking a landmark anniversary with the channel and promising more I'm A Celeb and BGT until at least 2019 'It's really awkward': Girl On The Train star Haley Bennett on being constantly mistaken for Jennifer Lawrence There is an uncanny likeness 'I lost Jack': Natalie Portman is a heartbroken First Lady after JFK's assassination in emotionally charged trailer for Jackie Natalie Portman flatters her pregnant figure in a striped T-shirt as she runs errands A regular errand-running day, despite the relsease of a mega-bucks trailer Waiting on mom! Jennifer Garner grabs breakfast while Ben Affleck and son Samuel goof around in their car The amicable exes appeared to be relaxedÂ  'I could write a book on back problems!': Duncan James confirms he is fit and well after sudden visit to A&E... five months after emergency surgery on his spine Post election blues: Alec Baldwin looks depressed as he strolls with family before accusing NBC of not allowing SNL to endorse Hillary Clinton Back to her Mean Girls roots! Lindsay Lohan shows off new red locks reminiscent of her infamous movie character in cosy Instagram selfie Showdown! Exes Justin Bieber and Selena Gomez will compete for Artist Of The Year at the American Music Awards On November 20 It's only three weeks old! Amber Rose can't hide her horror as her brand new $371k Rolls-Royce gets rear-ended 'It's awesome!' Hailee Steinfeld opens up about being part of Taylor Swift's squad as she flashes her bra for magazine cover Gave glimpse of her bra 'I felt isolated': Robbie Williams describes the roller coaster ride with drugs, drink and depression that almost killed him... as he gets tearful over his daughter Hat's the way to do it! TOWIE's George Harrison flaunts her enviably svelte figure in a sizzling cut-out monokini as she enjoys a beach break in Spain 'Let's keep fighting to make it a better world for our children': Katie Holmes shares rare photo of daughter Suri with powerful message A productive playdate 'Sort your jaw out!' Vicky Pattison is slammed for 'gurning' on I'm A Celeb Extra Camp... as she mistakes show for Xtra Factor in awkward blunder 'I'm heartbroken, but proud of myself': Daisy Lowe flashes her toned abs in a crop top as she puts on a brave face after Strictly eliminationÂ  Put on a brave face 'She's built like a woman': Tommy Hilfiger praises 'smart, funny and humble' Gigi Hadid as he shows off his luxury New York apartmentÂ  'The 80s are back!' Luke Hemsworth channels He-Man for retro birthday bash with brother Liam and Miley Cyrus Time is rolling back 'They eat and stargaze': Sean Penn gripes about celebs who attend his foundation's annual gala... but don't donate a cent Looking rugged Ariel Winter posts a VERY cheeky Instagram snap from her Mexican holiday withÂ Levi Meaden and pals Certainly making a splash 'We had good gossip': Courtney Love reveals unlikely friendship with Hillary Clinton... after meeting as they got their hair cut at same salon They met in 1988 'Being right sucks': The Simpsons poke fun at themselves in opening credits of first episode since Trump's election after predicting his presidency 16 years ago Young And The Restless star Corey Sligh, 28, arrested for molesting a girl under the age of 10 in Georgia The arrest took place on October 14 in Georgia Pretty as a petal! Jaime King looks ultra feminine in romantic lace gown at intimate fashion dinner She was certainly the belle of the ball EXCLUSIVE: How Andy Cohen refused an invitation into Cher's bedroom and fuelleda feud between Mariah Carey and Jennifer Lopez Catherine Tyldesley flaunts her toned legs in skintight jeans as she presents radio show... after teasing Corrie's 'heartbreaking' Christmas storyline 'Why are you in, miss? You're a millionaire!' GBBO champ Candice Brown reveals pupils were shocked to see her return to her job as a PE teacher after win Off-duty beauty: Lottie Moss goes make-up free and rocks a casual outfit as she jets out of Barcelona after a girls' weekendÂ  Bare faced chic She's a peach! Adriana Lima flaunts her lean bronzed limbs in pretty floral mini dress as she shops in MiamiÂ  Turned sidewalk into her catwalk Nick Knowles moves into estranged wife Jessica's home following 'traumatic' split 11 months ago... after admitting they 'are working through things' 'I've NEVER eaten a takeaway': Mary Berry shares her biggest foodie secrets (and reveals what husband Paul will be getting her for Christmas this year) Secrets of an A-list body: We reveal how YOU can get Mark Wahlberg's pecs The 45-year-old actor is renowned for his toned pecs LeAnn Rimes holds hands with husband EddieÂ Cibrian as they reunite with his ex-wife Brandi Glanville at son's soccer match Families united Ola Jordan keeps her lace dress ON as she sets up camp in I'm A Celeb... as jealous husband James warns about hitting on his 'firecracker' 'He has never taken responsibility for her': I'm A Celebrity's Larry Lamb 'has a secret daughter who he had at 21... and hasn't seen for 46 years'Â  'She just didn't even try': Former I'm A Celeb winner Charlie Brooks calls out Helen Flanagan for being 'the worst' campmate at bushtucker trials 'I don't know if it was dancing or a seizure': Cheeky Robbie Williams gives mother-in-law Gwen harsh critique as she dances to Pray on Loose Women Jesy Nelson is seen without her engagement ring AGAIN during Sydney trip... as speculation heightens over 'split' from fiancÃ© Jake Roche PICTURE EXCLUSIVE: Hilary Duff shows off her fit figure in a skimpy bikini while on holiday with boyfriend Jason Walsh inÂ Puerto VallartaÂ  Feeling the heat 'There's so much I wish I could thank him for, just one last time': Leonard Cohen's son writes emotional tribute to his father following his death aged 82 Did Kendall Jenner quit Instagram? Model's account no longer available after ballerina outrage Following Kim's lead and taking a break? Jailed Apollo Nida set to return to Real Housewives Of Atlanta with his new FIANCEE (but what willÂ Phaedra Parks say?) Serving eight years Millie Mackintosh shows off her abs in a berry bikini as she models for boyfriend Hugo Taylor's sunglasses line in Mauritius Wish you were here? Final plans for Leonardo DiCaprio's ultra-luxury private eco resort on 104-acre island off Belize are releasedÂ  Bought in 2005 'It's been challenging, but like Alan Partridge, I'm bouncing back': Tony Blackburn opens up about returning to BBC radio months after being sackedÂ  'She should be ashamed of herself!' Sharon Osbourne is slammed on Twitter as X Factor fans accuse her of changing her mind at the last minute In need of a drink? Simon Cowell clutches a bottle of beer as he leaves The X Factor with Lauren Silverman after Honey G survives ANOTHER week Getting the after-party started! Dita Von Teese, Dominic Cooper and Ophelia Lovibond let loose at the Evening Standard Theatre Awards Madonna's age gap... between her face and hand: Wrinkled mitts give away the singer's age as she attends UFC bout in New YorkÂ  Unable to disguise age Chic Julia Roberts is every inch the stylish soccer mom in low-key skinny jeans and a hat as she cheers on her kids Low-key superstar 'You could bleed to death': Kris Jenner warns Kim Kardashian about seeking third natural pregnancy on KUWTK Hard to take in Chrissy Teigen oozes retro glamour in a super-plunging Seventies-style jumpsuit as Fergie goes for a sheer mini at intimate fashion dinner Lindsay Lohan at the centre of a battery case as 'two Russians assault a man accused of spreading rumours about her' More drama The People v OJ Simpson leads the way with six Critics' Choice Awards nominations... as Game Of Thrones gets five Booty-ful day at the beach! Larsa Pippen shows off her fit figure in plunging white swimsuit while sunbathing in Miami Kim K's BFF A head for heights! Carol Vorderman leads the way as she conquers terrifying 300ft walk above city in I'm A Celebrity's first Bushtucker Trial Â  Ultimate flashing champion! Newly-single Bella Hadid shows off her bra in sheer top as she goes hell for leather on way to Conor McGregor fight EXCLUSIVE: 'I didn't want to leave the house': Frankie Essex says fitness helped her combat depression... as she reveals remarkable weight loss in a bikini 'Who is voting for her?' Honey G faces fresh backlash as talented act Sam Lavery leaves and farcical X Factor rapper isn't even in bottom two Could she win? Wild thing! Busty Ashley James sets pulses racing in a barely-there leopard print bikini as she jets off to Malta Series of sizzling snaps Daisy Lowe misses out on Blackpool as she is voted off Strictly after aÂ  dance off against Greg Rutherford... but Ed Balls sails through again inÂ  Gangnam Style Khloe Kardashian posts cryptic Instagram message amid speculation she's split with new beau Tristan Thompson Over already? 'We never asked to be role models': Perrie Edwards says she feels 'pressure' to act responsibly as she joins Little Mix co-stars for sizzling photo shoot I'm a Celebrity... it's getting hot in here! Joel Dommett, Wayne Bridge and Adam Thomas flash their ripped chests in the first jungle shower of the season 'Larry Lamb for Bond!': Twitter left in hysterics as EastEnders star dives into swamp to save Scarlett Moffatt from canoe disaster on I'm A Celebrity PICTURE EXCLUSIVE: HilaryÂ buff! Ms Duff puts her sculpted physique on display in a studded bikini during Mexican holiday Let the sunshine! Biggest surprise ever': Pixie Lott reveals she's engaged to long-term love Oliver Cheshire as she shows off dazzling diamond ring on InstagramÂ  Cruel... No not nature's predators - Sir David Attenborough. He usedÂ  'rape' of Snow Leopards to make viewers suffer in Planet Earth II, writes JIM SHELLEYÂ  'If your ex has been an a***hole, it's nice to belittle them': Little Mix stars get candid about faking orgasms and shaming former boyfriends in song 'I thought my life would be normal': Hollywood megastar Goldie Hawn says she only ever wanted to get married, have children and run a dance schoolÂ  Lily Donaldson shows off her cleavage and legs in a daring dress with thigh-high slit at star-studded Evening Standard Theatre Awards Elizabeth Hurley wows in a plunging black dress as she's joined by her very dapper son Damian, 14, for a night at the Evening Standard Theatre AwardsÂ  Still part of the family! Billie Piper wows in glam gown as she jokes with ex Laurence Fox's cousin Freddie at theÂ Evening Standard Theatre Awards Margo Stilley flashes her lace bra and hot pants in raunchy sheer dress as she makes rare red carpet appearance atÂ Evening Standard Awards Now James Corden turns his talents to Christmas ads! Sainsbury's enters the fray with an animated commercial featuring singing from the star In a Potter bother! Fantastic Beasts star Eddie Redmayne reveals he got grilled over wand after trying to smuggle it through customs Pucker up! Jesse Metcalfe and fiancee Cara Santana pack on the PDA at their engagement party They got engaged in August after eight years 'Thank you all so much': The X Factor's Sam Lavery shows little emotion as she is latest contestant to be voted off... after tense singing battle with Ryan Lawrie SPOILER ALERT: 'She's not mine!': Rick Grimes makes explosive revelation about 'daughter' on The Walking Dead More trouble ahead Shameless actor Jody Latham is accused of 'terrorising' a former Apprentice star in feud over his ex-fianceeÂ  Appeared at Manchester Magistrates' Court PICTURE EXCLUSIVE: Kourtney Kardashian flaunts fabulous figure in skimpy bikini on romantic getaway in Mexico with on/off beau Scott Disick Alexander McQueen's London penthouse hits the market for Â£8.5 million (complete with bespoke chandeliers, a dining terrace and walk-in dressing rooms)Â  Lea Michele shimmers in strapless dress as Kristen Bell goes sheer daring in lacy top for Christmas event in LA Black was back at glitzy event 'Wolf with rabies': Teresa Giudice continues taunting Jacqueline Laurita as fiery RHONJ reunion concludes On/off friendshipÂ  Happiest place! Singer Ashlee Simpson and hubby Evan Ross enjoy family bonding day with kids at Disneyland Happy every afterÂ  Lily James is spring chic in yellow dress and denim jacket as she is seen for first time on set of Baby Driver Filming the crime comedy in Atlanta A man cave for her Tyga? Kylie Jenner stocks a special room with Playboy magazine for 'the boys' at her Hidden Hills mansion Mags and an ashtray Unhappy birthday to you! Glum Anne Hathaway is a lady in red as she heads out for fancy celebratory dinner She had been stumping for Hillary Clinton What a whirl-wand trip! Eddie Redmayne looks exhausted as he lands in London in time for the premiere of Fantastic Beasts after debuting movie in New York Pregnant Katherine Heigl dresses her baby bump with loose fitting tank top at flea market with husband Josh Kelley Looking for baby gifts? Chic but sombre, the Duchess of Cambridge joins Camilla and Sophie Wessex at the Cenotaph on Remembrance Sunday A von Furstenberg coatÂ  EXCLUSIVE: 'He pursued her heavily': I'm A Celeb's Lisa Snowdon 'devastated' to learn footballer ex Jay Bothroyd was married during eight-month affair 'FIRST look': Ruby Rose posts teaser of The Veronicas' new single On Your Side... which details her love story with singer Jess OrigliassoÂ  Kate Beckinsale shows off her slim figure in tight top as she attends AFI FEST in Los Angeles Always looks sensationalÂ  'He's the Trump of Strictly': Ed Balls divides viewers after Gangnam Style saves him as it's revealed he'll perform a Great Balls of Fire jive in Blackpool You must be jo-KING? EastEnders hardman Danny Dyer makes heir-larious discovery as it's revealed he is a descendant of royalty Cockney royalty Animal attraction! Make-up free Heidi Klum, 43, gets wild with leopard print at a celeb-studded fundraiser in Los Angeles Wild thing She's got some front! Rebecca Hall looks radiant in low-cut patterned dress at AFI Fest in Los Angeles The Christine star paired her unique dressÂ  Sharp-suited Tom Hiddleston arrives at Evening Standard Theatre Awards in good spirits... amid claims Taylor Swift will sing about their breakup Corrie's Beverley Callard 'hasn't met her 11-month-old grandchild' despite living just down the roadÂ  Laura Cross made the claims against the star 'People can call me a mug but we are happy': Megan McKenna stands by reunion with Pete Wicks after sexting scandal... and no longer checks his social media 'It's very sad': Iconic soap star Eileen Derbyshire, 85, may not return to Coronation Street after 55-year run Has been absent now for 12 months 'You had me at bonjour': Make-up free Rebecca Gayheart, 45, shows off her clear complexion as she dons cheeky T-shirt at charity event Nikki Reed stuns in white off-the-shoulder patterned top as she attends ACLU dinner in LA The 28-year-old looked gorgeous as ever She's a real page turner! Actress Emma Roberts goes make-up free as she peruses a newsstand in Los Angeles Looked simply chic SPOILER ALERT: Ecstatic Gemma Winter meets lifelong crush Peter Andre as the pop star makes a cameo on Coronation Street Getting star treatment 'I feel so sorry for her': Catherine Tyldesley steps out in a wintry ensemble as she heads to a radio appearance to tease 'heartbreaking' Xmas storyline Hollywood power couple Jennifer Aniston and Justin Theroux go unnoticed in Germany... after saying he makes her feel 'completely adored' Stunning at 70! Goldie Hawn cuts a fabulous figure in silk dress as she makes an appearance ahead of her comedy show in Melbourne Back to her pre-baby best! Kim Kardashian recycles 2009 Princess Jasmine costume for fun with North She worked hard to getÂ  back in pre-baby shape JK's fantastic new hero is just the magic we need: BRIAN VINER on the latest instalment of the Potter franchiseÂ  Plenty to say about restablishment stooges Nicole Kidman reunites with her To Die For director Gus Van Sant and co-star Casey Affleck for Variety taping Cult black comedy Coleen Rooney looks glam in an off-the-shoulder top as she enjoys a girls' night out at new Liverpool restaurant Flashed the flesh From Hollywood to Hollyoaks! Dallas star Linda Gray, 76, brings the glam to Chester in first look at her cameo in the Channel 4 soapÂ  An unlikely arrival She's ripped! Kelly Bensimon wears torn blue jeans while out with daughter Thadeus in New York City Stepped out in New York over the weekend Michelle Keegan 'house-hunting in South Africa' as she prepares to spend eight more months away from Mark Wright for Our Girl filming Billy Bob Thornton smokes a cigarette as he touches down in LA after saying ex-wife Angelina Jolie 'seems OK' following Brad Pitt split Hailey Baldwin flaunts her bikini body in a swimsuit before planting a kiss on her female friend Model and daughter of Stephen Baldwin From Ab Flab to Ab Fab! Helen Lederer sheds eight pounds and drops a dress size in just three days after surviving on 400 calories A DAY 'It's about finding the right balance': Marion Cotillard admits she struggles to balance her professional and personal life... after denying Brad romance The good life! Ariel Winter proudly flaunts backside as she twerks in bikini during Mexican holiday withÂ Levi Meaden and pals Continuing her holidayÂ  Feeding the flock! Jennifer Garner and Ben Affleck provide snacks for family church as they bring their children to Sunday service At Pacific Palisades No comment! Kanye West refuses to confirm if he still plans to run for President in 2020Â  The 39-year-old Life of Pablo artist ignored questions Kanye West launches a new 'unpretentious' range of clothes - but a jumper will still set you back Â£1,745 and a T-shirt Â£159 A real man of the people 'You always inspire': Sylvester Stallone presents Jackie Chan with honourary Oscar... as Arnold Schwarzenegger also pays tribute 'I had a good time with dalliances': Robbie Williams jokes about making the most of his fame, how many of the Spice Girls he's REALLY slept with Swift beatz? Pop princess Taylor calls on rumoured rapper flame Drake 'to help give her music a hip-hop vibe' She reportedly wants to sound edgier Puppy love! Sofia Richie shows taut tummy as pal Cameron Dallas carries cute canine at West Hollywood store Enjoyed some dog time Miranda Kerr is the belle of the ball in an exquisite gold gown as she cosies up to sharp-suited fiancÃ© Evan Spiegel at glittering Baby2Baby Gala Geordie Shore's Sophie Kasaei parades her sun-kissed curves on the beach after defending healthy Size 10 figure Showed off her bikiniÂ  'I'm no spring chicken': Ex-Strictly professional Ola Jordan, 34, says she's 'not body-confident' despite sneaking SIX sexy bikinis into I'm A Celeb 'I'm not having another baby, so screw you': EastEnders actress Jacqueline Jossa lashes out at cruel trolls who told her she looked pregnant 'He waited outside for her': Pregnant Amy Childs flees event after man 'threatened to punch her' Outside The Ideal Homes Show 'I only do the things I love': Mary Berry confirms filming for her own cooking show... as Bake-Off makers 'head to court over block on Channel 4 rival' 'That smile ain't nothing but a Dream!': Kris Jenner posts adorable snap of Rob Kardashian cradling his new baby girl Latest addition Jessica Alba goes casual chic as she takes her daughters to the Beverly Hills Farmers' Market She is known for her healthy lifestyle Mia Tyler announces she's expecting her first child by sharing picture of her bump First child for the artist, who is the daughter of Aerosmtih's Steven Scarlett Johansson shows off stunning curves in lilac cutaway dress at Ghost In The Shell trailer launch in Japan Glam evening Pamela Anderson cuts a chic figure as she brings MORE snacksÂ to WikiLeaks founder Julian Assange... after he joked that her vegan treats were 'torture' Jamie Foxx has fun on set with Robert Downey Jr and Jeremy Piven as they film All-Star Weekend Revolves around two tow-truck drivers Kurves ahead! Khloe Kardashian shows off her incredible physique in a burnt orange dress as she heads to stylist Monica Rose's baby shower PICTURE EXCLUSIVE: Megan Fox and Brian Austin Green take baby Journey and his older brothers on family outing Family unitedÂ  'I was a bit of a b***ard': Phil Collins admits to cheating on his ex-wife, but says he was just 'following his heart' Regrets the affair 'I had nothing left to give him': Daisy Lowe falls foul of Strictly curse... as she and beau Bradley 'Frankie' Wade couldn't 'cope with the pressure' If you wannabe my mother: Ex-Spice Girl Victoria Beckham 'wants to manage her son Cruz's pop career' Thinks her experiences make her the perfect candidate Rod Stewart's rarely-seen daughter Ruby follows in her father's footsteps as she opens his tour in Liverpool The apple never falls far from the tree From Top Gear to top rear! Little Mix's Leigh-Anne Pinnock teaches Jeremy Clarkson how to twerk on the Jonathan Ross Show Awkward! GIRL ABOUT TOWN: Finally, Jeremy Clarkson is silenced - by the raging wife of Sir Shifty, Lady Green Someone who can stop the motormouthÂ  GIRL ABOUT TOWN: Phasing out the Fogles! Prince William distances himself from Ben Fogle and his wifeÂ  Said to be fed up of Ben talking about him in public GIRL ABOUT TOWN: Doctor Who to marry Lady Rose? Besotted Matt Smith to pop the question to girlfriend Lily James by ChristmasÂ  Planning trip to New York Still the Princess of Darkness: X Factor judge Sharon Osbourne, 64, flips the bird as she leaves X Factor post-party looking a little worse for wear Outlandish behaviour Parkinson's sufferer Michael J. Fox appears to go Back To The Future with impassioned guitar solo as he leads special gig to support his charity Nicola Peltz flashes her taut abs in a crop top as she opts for an all-black look in Los Angeles Flashed a hint of her abs as she headed out Eye of the tiger, face of an angel: Ageless Madonna, 58, stuns with extremely taut appearance as she leads star-studded UFC fight crowd Kendall Jenner's hangout bar, Emma Stone's beloved salon and Jennifer Aniston's hiking spot: How to ditch the tourist traps and explore LA like a local A-Lister From Baywatch to bag watch: Giddy Kelly Rohrbach shops 'til she drops as she strains under a heavy load Made shopping look like hard work on Saturday PICTURE EXCLUSIVE: Kate Upton and fiancÃ© Justin Verlander put on a tactile display on romantic Italian vacation The 24-year-old model kept close in Florence Sheer delight! Nicole Kidman flashes her cleavage in plunging see-through gown at The Governors Awards... before slipping into classic white high-neck dress for later event 'I don't want to say!' Kris Jenner cries as her mother MJ asks her biggest fear in Keeping Up With The Kardashians Welled up on TV Getting some retail therapy! Julianne Moore and friend Laura Dern browse designer dresses at LA boutiqueÂ  The 55-year-old looked to be in good spiritsÂ  'Loved it!' Kelly Clarkson takes baby Remington and daughter River to Disney World River, 2, and Remington, 7 months,Â  will have been delighted Danniella Westbrook sports new brunette hairdo, but STILL wears a plaster under her nose... amid reports she's suing Celebrity Botched Up Bodies Hard man Mickey Rourke, 64, proves he's a big softy at heart as muscular actor cradles beloved fluffy pooch The age-defying actor, 64, showed off his bulging biceps People wanted to kill me, says Prince Harry's girl: Meghan Markle opens up to PIERS MORGAN about dating, death threats and most embarrassing momentÂ  Bataclan TURNS AWAY Eagles of Death Metal - who were playing when ISIS massacred 90 music fans - as the concert hall reopens a year after the attack with Sting performance Cringing Cowell! Simon is left red-faced after Dermot shares throwback picture of him with a VERY dodgy hairdo on X Factor Giving a gun show too! What happens in Vegas stays still in Vegas! Britney Spears does the Mannequin Challenge to celebrate Sin City successÂ  Flesh-flashing Charlotte Dawson flirts up a storm with new rugby player boyfriend Matt Sarsfield as they're spotted together for the first time Trinny Woodall's 'nightmare' Â£300,000 divorce battle from beyond the grave: Fashion guru's bizarre High Court battle over her dead ex's debtsÂ  Get Me Out Of Here already! Scarlett Moffatt can't contain her disgust as she's forced to canoe through swampy waters in I'm A Celebrity's first grizzly challenge 'Strictly viewers are delighted to spot Mary Berry in the audience... but are reduced to tears as Judge Rinder's granddad wells up on-screenÂ  She's got good jeans! Khloe Kardashian shows off her toned bottom...as she hits out at haters online Addressing all the criticism Frill-seeker! Slimmed-down Tina Malone shows off her TINY size six figure in black flamenco-style dress as she steps out at RTS Awards Disco fever! Leona Lewis oozes 70s glamour in corkscrew curls and plunging sequin gown as she steals the show at animal charity gala in LA Cara Delevingne flashes her abs with a sexy pin-up on her jacket... as she turns her mind to modelling following St Vincent split She had taken a step back from her modellingÂ  Donatella Versace claims that gay male fashion designers create clothes for the 'women they want to be' rather than their customers Â  Female style icon Rachel Weisz is cosy beneath a bizarre woolly hatÂ  She is famed for starring in cult classic The Mummy, butÂ Rachel Weisz looked like she was almost embalmedÂ  Ready to take the plunge! Ola Jordan glams up before the jungle in a low cut peachy dress as she meets her I'm A Celebrity team mates Slinky Scherzinger! Nicole shows off stunning figure in racy cut out dress on X Factor before changing into JUST a pink jacket for dinnerÂ  Chrissy Teigen and daughter Luna host baby shower for celebrity stylist Monica Rose... and Khloe Kardashian and Kris Jenner are on hand too Braided beauty! Cara Delevingne cuts a fashionable flyer in a chic bomber jacket as she touches down at LAX Eyes front, Philip! A playboy prince eyeing up the ladies? Don't worry, Ma'am - it's only a VERY impertinent scene from hit TV show The CrownÂ  What will Ma'am think? Hugh Jackman spotted cosying up with Madonna at UFC title fight in New YorkÂ  Watched Conor McGregor and Eddie Alvarez battle it out Vin Diesel and Nina Dobrev fuel the hype for xXx: Return of Xander Cage at Los Angeles fan event Diesel, 49, looked every part the action heroÂ  Will Smith is in high spirits as he has a laugh on set for upcoming fantasy film Bright Will Smith spent his Saturday hard at work on his forthcoming fantasy thriller Bright Liquid gold! Lily Collins oozes class in backless satin gown at the Academy's Governors Awards in Hollywood Perhaps Lily Collins had her sights set on a gold statue Blue bombshell! Bryce Dallas Howard stuns at star-studded Weinstein Company party featuring Matthew McConaughey A real showstopper All-natural beauty! Jenna Dewan is pretty in pink with husband Channing Tatum at Baby2Baby Gala in Los AngelesÂ  Had her black locks parted in the middle Kate Hudson shines in gold number as she poses with Matthew McConaughey and wife Camila at Baby2Baby Gala Sheerly amazing! Jessica Alba stuns in partially transparent black gown for star-studded Baby2Baby Gala in Los Angeles Charity that supports babies in need In the navy! Jennifer Garner is beautiful in blue as she stuns on red carpet of Baby2Baby Gala in LA The 44-year-old actress looked beautiful in blue Bella Thorne is epitome of casual chic in Daisy Dukes and snakeskin boots before slipping into crop top and ripped jeans Two different outfits 'Bonding with mommy!' Blac Chyna breastfeeds daughter Dream in newborn baby's first tweet Created an Instagram account in baby's name Blac Chyna's mother Tokyo Toni shows charitable side as she promotes food drive after second grandchild is born Tokyo Toni is feeling charitableÂ  Pretty in pattern! Emma Stone and Michelle Williams wow in sparkling gowns for the eighth annual Governors Awards in Hollywood The actresses arrived dressed to the nines Demi Lovato holds hands with rumoured MMA fighter beau Luke Rockhold as they arrive to UFC 205 in New York It's been the worst kept celebrity couple secret for a while now Progresso 40 Delicious Flavors 100 calories or less. more Today's headlines Most Read The two-year-old girl who can only SQUEAK: Emily suffers from 20 seizures a day and is unable to walk, talk... Is YOUR hospital facing the axe? Secret plan to close maternity units and A&Es is revealed as NHS tackles... Dementia is now the leading cause of death and women are the most vulnerable, new statistics revealÂ  Fitbit failure: Do those must-have fitness trackers really work? We put five high-tech gadgets to the test -... Counting the days until Christmas? We reveal the 7 tastiest low calorie and allergy-friendly advent... Why sense of SMELL is the biggest tell-tale factor for Alzheimer's - and could be spotted 10 YEARS before... A pint a day keeps the doctor away! Regular drinking preserves 'good cholesterol' levels - drastically... Does YOUR snoring keep your partner up at night? A 3D-printed mask may make sleepless nights a thing of the... 'Do we REALLY have to pay Â£2,000 for a Lyme disease test?' A reader is worried his daughter may need an... Secrets of an A-list body: We reveal how YOU can get Mark Wahlberg's pecs 'Going to the loo seemed to take hours': The newly approved prostate op that can help men turn their taps... Why meat really IS deadly: Middle-aged women who follow the celebrity-endorsed Atkins diet are at 'higher... 'I have a nightmare of being the first journalist selected to go into space': News presenter Jon Snow takes... Why you really shouldn't binge drink: Heavy drinking as a teenager puts their future children's brain... Cannabis users age FASTER than those who avoid the drug, study claimsÂ  MORE HEADLINES Why sense of SMELL is the biggest tell-tale factor for Alzheimer's - and could be spotted 10 YEARS before memory loss symptoms Purple power! How drinking beetroot juice can make you run faster, help the elderly climb the stairs - and give competitors an advantage in sports The two-year-old girl who can only SQUEAK: Emily suffers from 20 seizures a day and is unable to walk, talk or eat for the rest of her short life Fitbit failure: Do those must-have fitness trackers really work? We put five high-tech gadgets to the test - with astonishing resultsÂ  Brain training games help to prevent dementia in people at high risk of the disease - and improve their mood Toxic water panic: More than 28,000 people in New York and more than 70,000 people in Philadelphia 'exposed to cancerous toxins in drinking water' Dementia is now the leading cause of death and women are the most vulnerable, new statistics revealÂ  Why meat really IS deadly: Middle-aged women who follow the celebrity-endorsed Atkins diet are at 'higher risk of heart failure' Keep calm...and carry on breathing: The simple exercises that can alleviate pain and help sufferers cope with anxiety, stress and depression Record number of 'sumo babies' because parents are weaning their babies too soon and turning to pureed junk food Secrets of an A-list body: We reveal how YOU can get Mark Wahlberg's pecs A pint a day keeps the doctor away! Regular drinking preserves 'good cholesterol' levels - drastically cutting your risk of a stroke, study reveals Cannabis users age FASTER than those who avoid the drug, study claimsÂ  New cases of diabetes have risen by a THIRD in just 10 years: Theresa May says 'more needs to be done' as a record 4.5 million now have the condition Why YOU should worry if you wake up during the night: Disturbed sleep increases the risk of having an irregular heartbeat MOST READ IN DETAIL Â  Â  MORE DON'T MISS Calling the shots! Katie Holmes puts on sexy display in silky off-the-shoulder jumpsuit at Napa Valley Film Festival At the festival to show All We Had Kris Jenner is all smiles as she joins in stylist's baby shower two days after becoming a grandma for fifth time The shower was for stylist Monica Rose A Dream come true! Rob Kardashian chose baby name based on life-long fatherhood aspirations He called his newborn girl Dream Prince Harry's new girlfriend Meghan Markle is already back in Canada after two days in London - despite claims he might introduce her to Queen Dear Harry, don't be such a hot-head over Meghan, says RACHEL JOHNSON in an impassioned open letter to the PrinceÂ  After his letter to press Coronation HEAT! Jane Danson and Tina O'Brien steal the spotlight in chic black dresses at the North West RTS Awards At North West awards Thrilling, funny and a little bit sexy: J. K. Rowling's new film Fantastic Beasts And Where To Find Them is just magicÂ  Worth the wait Growing up fast! Jamie Oliver cuddles up to wife Jools and adorable baby son River Rocket in a sweet Instagram Shared another sweet snap I'm A Celebrity's Sam Quek is fighting back against breast implants: Team GB hockey star says she will represent women 'with small boobs' on the showÂ  Robbie Williams brings the razzle dazzle in a green metallic tuxedo as he joins stunning French singer Jenifer at theÂ NRJ Music AwardsÂ  Brought some dazzleÂ  Millie Mackintosh flaunts her enviable washboard abs in TINY white bikini as she jets off on exotic Mauritius break with boyfriend Hugo Taylor Cristiano Ronaldo takes centre stage as Portugal star poses in just his white pants for the mannequin challenge Super toned What a catch! Hilary Duff shows off her bikini body after reeling in two fish on holiday with boyfriend Jason Walsh Showcased killer abs and fishing skillsÂ  EXCLUSIVE PICTURES: Kim Kardashian's former bodyguard Pascal Duvier spotted working for Fergie on Malibu beach shoot EXCLUSIVE PICTURES: Fergie makes a splash as she writhes around on the beach during sexy music video shoot The 41-year-old Don't Lie singer was in Malibu Baby on board! Rob Kardashian and Blac Chyna pictured taking newborn daughter Dream home from the hospital in Los Angeles Ready for parenthood Julian Lloyd Webber's war on a G-string: Composer fights to close brothels after his WIFE is mistaken for a sex worker just yards from their home 'Sunday funday': Naomi Watts cuddles up with two sons in the sand as they enjoy bonding time after shock split with Liev Schreiber A break from promoting Wahoo! Justin Timberlake catches a big fish during Caribbean holiday with golfer Justin Rose Shared his haul on social media Saturday night fever! Saara Aalto dazzles on X Factor disco week in 'dangerous' futuristic outfit, but Five After Midnight give her a run for her money 'Saturday coffee shuffle': Kate Hudson kicks off weekend by dancing in her underwear to new Alicia Keys album Shared on SnapchatÂ  Abs-olutely stunning! Kendall Jenner displays toned stomach in sports bra as she leaves gym before posting butt shot on Instagram Looked super fit Now that's a recipe for success! The Great British Bake Off winner Candice Brown cuts a chic figure in elegant skater dress as she leads cookery presentation Movie night! Taylor Swift smiles as she unwinds with mother Andrea at theater in LA The 26-year-old was in Hollywood with her mother on Friday night.Â  Tatt's new! Geordie Shore's Chantelle Connelly shows off latest inking which covers her entire thigh in raunchy underwear snap on Instagram Flower power The bare cheek of it! Amanda Holden can't resist taking a sneak peak at a workman's exposed bum as she saunters through Portsmouth Life is just peachy! Kendall Jenner flashes her derriere in racy black suspenders as she struts her stuff backstage at La Perla shoot Just roll with it! Curlers-clad Chloe Khan flaunts her ample cleavage in a tight plunging dress for saucy selfie Sent her fans wild. 'That will go down in Strictly history!': Judges are left speechless as Ed Balls performs his most daring routine to date with a salsa toÂ Gangnam Style Hot metal! Mischa Barton shines in silver jacket for night out at LA hotspot The former O.C. star was unmissable in the statement pieceÂ  Megan McKenna vamps it up in ribbed LBD and racy thigh-high boots for salon launch after reuniting with beau Pete Wicks following sexting scandal Christina Hendricks rocks trendy choker with curly updo at Bad Santa 2 press event Tried new look alongside Billy Bob Thornton and Kathy Bates Photograph in Taylor Swift's sexual assault lawsuit against radio DJ is leaked despite judge's order to seal the image The accused is former radio DJ David MuellerÂ  Nicola McLean dazzles in a stylish leopard print top as she cuddles up to herÂ chihuahua at The Secret Life of Pets premiere At London DVD launch Eating for two! Pregnant Natalie Portman stocks up on healthy groceries while out in LA She's sticking to a clean, organic diet Make-up free Louise Redknapp flashes a bright white smile as she parks her Â£90k Mercedes in a permit only bay on her way to Strictly rehearsals Bumping along nicely! Pregnant Katherine Heigl shows off growing belly in striped maxi skirt as she heads to a birthday party Announced back in June 'I didn't think I could love him any more': Vicky Pattison reignites romance rumours with best friend Alex Cannon as she shares sweet snapÂ  Justin Bieber's ex Chantel Jeffries takes the plunge in rose-gold mini-dress at Nocturnal Animals screening in LA Making a name for herself in her own right Michelle Williams cuts a chic figure in slinky black cocktail dress at Variety's Actors on Actors taping Dishing about their work for the TV series Is Pink secretly pregnant? Singer sparks baby rumours as she emerges after months out of the spotlight looking radiant in flowing dress Martine McCutcheon looks effortlessly chic in a black faux fur coat as she cuddles up to husband Jack McManus and their pet pooch Happily loved-up Kerry Katona shows off daughter Molly's hidden talents as she tweets Simon Cowell a clip of the talented teenager performingÂ  Musical parents Bruce Springsteen is rescued by veterans on Veterans Day after his motorcycle breaks down in New Jersey He broke down on the side of the roadside Baby, it's cold outside! Gigi Hadid wraps up warm in all-black outfit while on a stroll through New York The Â 21-year-old was spotted all bundled up Showing The Weeknd what he's missing? Newly single Bella Hadid accentuates model frame in skintight leggings... just days after split Actress Julie Gregg, who played Sandra Corleone in The Godfather, dies at 79 after cancer battle She also starred in Man of La Mancha in 1972 Golden balls, golden touch! David Beckham 'earned Â£11 MILLION in one year' through endorsemens Retirement deal Kate Beckinsale looks gorgeous in two-piece ensemble while promoting Underworld: Blood Wars Stunning appearance 'Surely she has to go now!': Angry X Factor fans demand Honey G gets the boot after revealing she was addicted to Class A drugs Imogen Thomas slips her gorgeous figure into casually chic roll neck and leather leggings as she poses up a storm at Secret Life of Pets premiere 'It will be used a number of times throughout the series': Producers 'build secret sex cave' in push for jungle romance on I'm A Celebrity... Get Me Out Of Here! Busty Chloe Goodman showcases her womanly curves in lace-up swimsuit as she embarks on a raunchy beach photoshoot in Mykonos She's back! Kim Kardashian smiles again in sexy princess costume with North and Saint in first pictures taken at home since Paris heist terror The Sixties called! Rita Ora rocks a bouffant beehive as she flaunts her enviably toned legs in quirky oversized shirt dress Oh beehive! Bryce Dallas Howard works off her Black Mirror weight gain at LA gym Exercising her curvaceous figure 'My little model!': Kim Zolciak gushes on social media over daughter Kaia's penchant for posing Kaia has already caught the modeling bug Robbie Williams blows kisses to devoted fans during radio interview in Milan... after scoring his TWELFTH number one Happy man 'They are very much an item': Kate Moss, 42, and former beau Count Nikolai Von Bismarck, 29, fuel reconciliation rumours with 'touchy feely' display at David Bowie musical Amy Adams is the picture of elegance in sleek black maxi dress with low-cut sides at Nocturnal Animals screening in LA Incredibly elegant Ashley Tisdale and Christopher French start their weekend with a hike in LA's Runyon Canyon The actress, 31, wed in 2014 Taking tips from Myleene? Carol Vorderman, 55, flaunts her youthful figure and ample cleavage in a sexy white swimsuit ahead of I'm A Celebrity Doctor Who's Pearl Mackie holds a concerned gaze while filming scenes for upcoming series in eerie woodland in Cardiff Angelina Jolie's father Jon Voight reveals he wants 'things to work out' between his daughter and her estranged husband Brad Pitt 'My body, my choice!'Â Emily Ratajkowski posts topless shot to protest Donald Trump's stance on women's issues Battle of the boobs! Isla Fisher and January Jones unleash the cleavage at Nocturnal Animals premiere in LAÂ  Like Nocturnal Animals - they came out at night Helen Mirren and Taylor Hackford look more loved-up than ever as they enjoy a date nigth at premiere of his new star-studded film The Comedian ABBA's Benny Andersson and Bjorn Ulvaeus join Simon Fuller for dinner in London after it's announced they're working on a 'groundbreaking venture' 'I did cocaine, pills and magic mushrooms': X Factor's Honey G admits she was addicted to Class A drugs after string of personal issues I'm Fur-Real! Make-up free Jennifer Lopez wraps up in a cosy winter coat as she prepares to shoot scenes for Shades Of Blue Victoria's Secret model Bridget Malcolm slams 'fat and skinny shamers'... after being trolled online for her slender frame Accused of having an eating disorder last year Wild thing! Thandie Newton catches the eye in colourful leopard print coat and printed pencil skirt as she steps out in NYC Sartorial flair Perrie Edwards stuns in EXTREMELY ripped jeans as she arrives at Sydney Airport with Little Mix to promote their new album Glory Days 'I trust her with all of my heart': Lewis Bloor puts his faith in Marnie Simpson as she prepares to film Geordie Shore... while she predicts the series will be 'eventful' 'Watching my girls sleep': Rob Kardashian shares sweet video of Blac Chyna and new daughter Dream... but can't help jibing at his snoring fiancee Daisy Lowe displays her leggy model figure in super-short dress and grungy biker jacket as she makes her way to Strictly filming Terri Seymour shows off slim figure in slinky black leather dress as she interviews the stars at Nocturnal Animals screening in LA No Bad Blood here! Taylor Swift 'is writing songs about exes Calvin Harris and Tom Hiddleston'... but will focus on their 'friendly' breakups Home And Away's Pia Miller flaunts her slim frame and flawless make-up free complexion in backless swimsuit for romantic trip withÂ Tyson Mullane Sofia Vergara looks sensational in a plunging metallic dress as she steps out with handsome husband JoeÂ Manganiello for a dinner date in LA Simply stylish! Emma Watson and Thandie Newton show their support at premiere of City of Joy documentary Understated style 'Already starting to fall in love with Sydney': Bachelor's Megan Marx and Tiffany Scanlon strip down to black bikinis to soak up the sun at the beach White hot! Cobie Smulders flashes her long stems in monochrome ensemble at the Moves Power Women gala in NYC 'He can't do manly or strong': Ed Balls' Strictly dance partner Katya Jones reveals the politician has embraced his 'inner camp' Shine bright! Nicole Kidman glistens as she floats down the red carpet in angelic white for the LA premiere of Lion Â  Sexy seÃ±orita! Ariel Winter steams up Snapchat with bikini selfie before posing in lacy crop top on Mexico trip She's not shy Chanelle Hayes parades her curves in a barely-there glitzy bikini as she puts on a VERY amorous display with boyfriend Ryan Oates in Ibiza Poised in purple! Jessica Chastain wows in plunging gown at Miss Sloane premiere in Los Angeles Natural beauty Lady Victoria Hervey, 40, leaves little to the imagination as she flaunts her incredible figure in sheer lingerie at fashion showÂ  All dressed up Amber Rose keeps it simple in black top and jeans as she visits Blac Chyna again... and even brings son Sebastian along to meet new baby Rolling in deep space! Adele gets private tour of NASA headquarters from astronaut who presented her Brit AwardÂ  Behind-the-scenes tour Hilaria Baldwin shows off yoga prowess for upside down kiss with husband Alec... as she writes lengthy post-election messageÂ  That's a wrap! Jorgie Porter channels winter chic in sweater dress, shearling coat and over-the-knee boots for dinner date with friendsÂ  'It's great his gene will live on!': Lewis Hamilton reveals his Bulldog Roscoe had its sperm frozen before having the snip Baring all! Imogen Anthony flaunts her pert derriere and under-bust as she poses for a provocative series of photos dressed in Â little more than a sheer g-string Just like daddy! Josh Duhamel's son Axl steals the show as he poses up a storm on star-studded red carpet for new Avatar-inspiredÂ Cirque du Soleil Looking CAPE-tivating! Rebecca Ferguson flaunts her toned legs in dazzling play-suit as she performs at concert in SheffieldÂ  Tracks from new album Her favourite spot! Sofia Richie wears a sports luxe look to grab a bite at her go-to eateryÂ  Catching up with a pal Hello petal! Jennifer Garner flashes her legs in floaty skirt as she lugs vase of pretty flowers into Venice cafe Blooming lovely Chic Pixie Geldof puts on a brave face at charity fundraiser as debut album flops, selling just 197 copies in first week of release She was in good spirits Flamin' hot! Charlotte Dawson sizzles in an electric blue gilet and knee-high boots as she unveils her newly dyed ginger locksÂ  At Â salon in LiverpoolÂ  'He showed me how women should be treated and respected': Shanina Shaik takes a dig at her ex Tyson Beckford while gushing about fiancÃ© DJ Ruckus SEBASTIAN SHAKESPEARE: Dame Joan's THREE parties in one night shows her passion for life remains undimmedÂ  At Sir David Tang's book launch SEBASTIAN SHAKESPEARE: What HAS happened to Kate Winslet's wonky eyebrows?Â  One is more arched than the other Peek-a-boo! Ashley James flashes her toned tummy in cropped sweater and baseball jacket as she heads out to her radio show Casual Meg Ryan goes incognito in a cap, sunglasses and long coat for a London shopping tripÂ  Blended into the crowd on Â Oxford Street. Working his magic! Eddie Redmayne looks dashing as he chats his new role in J.K. Rowling'sÂ Fantastic Beasts And Where To Find Them The final curtain for the 'Godfather of gloom': Footage surfaces of Leonard Cohen's last EVER performance in almost three years ago Took place in New Zealand Taking flight! Serena Williams takes comfort to new heights as she rocks green aviator onesie at LAX Making the most of the off-season Heading to cooler climates? Kanye West bundles up in layers as catches flight out of LAX West decided to bundle up in multiple layersÂ  'He gave me a little back massage': Eddie Redmayne reveals Fantastic Beasts co-star Colin Farrell had to comfort him before 'intense' San Diego Comic-Con appearance Ready to Seal the deal: British singer 'hunts for Sydney home with girlfriend James Packer's ex wife Erica Â ahead of The Voice Australia return 'Kisses, hugs and sex galore!': Kim Zolciak celebrates fifth anniversary with husband Kroy BiermannÂ  Romantic messageÂ  'Everything shuts down around you': Devastated Michael BublÃ© 'will not sing again' until his son Noah, 3, overcomes liver cancer treatmentÂ  'Look at him, the chubby little chap': Strictly judge Len Goodman pokes fun at Ed Balls's weight on TV but admits fan favourite COULD win dance show Going strong! Megan McKenna and beau Pete Wicks look loved-up as they leave spa together after reuniting on TOWIE following sexting scandal TV Penelope's Â£500k pit stop: The stunning home that actress Penelope Keith created from scratch - before reluctantly moving on Loves Beckside House Oh dear Ed, Strictly really IS taking it out of you! Former shadow chancellor looks pale and puffy-eyed as he walks to the shops with his MP wife Just one glance at the first picture of Brad Pitt since his split from Angelina and you can see the pain etched on his gaunt face, writes AMANDA PLATELL I'm A Celebrity... get me down from here! Ola Jordan and Carol Vorderman are suspended over 32-storey building for the show's first terrifying challenge Heidi Klum hits the runway in style as she dons patterned knit sweater and scarf after touching down at LAX The 43-year-old German was looking chicÂ  Not your average party animal! Bindi Irwin spends time tending to a rhino... as she snubs Maxim's Hot 100 Party in Sydney after making the top tenÂ  'Time to turn words into action!': Katy Perry donates $10k to Planned Parenthood in face of Donald Trump's looming defundÂ  Oscar-nominated Man From U.N.C.L.E. Â and Hustle star Robert Vaughn dies aged 83 surrounded by his family after brief battle with cancer She's a low-key VIP! Jet-set Renee Zellweger lugs her own bags through airportÂ  Proved she's one of the people as she forewent special treatment Val Kilmer gasps and struggles to speak while revealing he's cancelled upcoming tour after once again denying he has throat cancerÂ  Throwback surprise! The View brings back original co-hosts Meredith Vieira, Debbie Matenopoulos and Star Jones for 20th anniversary I do! Adrienne Bailon marries gospel singer Israel Houghton in romantic weddingÂ  Tied the knot with the gospel singer at a ceremony in Paris Olivia Wilde holds her baby girl close as she and fiancÃ© Jason Sudeikis enjoy a leisurely walk in NYC Daisy Josephine was born one month ago The Survivors scrub up well! Winner Kristie joins JL, Phoebe, Brooke and Flick in glamorous style at the Maxim Hottest 100 party Newly single Jemma Lucy flaunts her new jet-black hairpiece in a cleavage baring Instagram snap... a week after dumping boyfriend Stephen Bear Russell Crowe quietly lists lavish apartment he bought for $14.35 million... as he and estranged wife Danielle Spencer get closer to a divorce settlement That's a bit cheeky! X Factor star Joey Hadjia, formerly Joelle, shares VERY close-up snap of her pertÂ derriÃ¨re in lengthy 'body transformation' post 'Never give up': Lindsey Vonn reveals she badly fractured arm from crash during training... and even shares x-ray of gruesome injury Batter up! Mark-Paul Gosselaar and co-starÂ Kylie Bunbury pose completely NUDE in sexy new photos for baseball show Pitch Fictional photoshootÂ  Ham you believe it? RosieÂ Huntington-Whiteley oozes glamour in a plunging floral dress... before cuddling up to a pig in cute snap She's enjoying California Danniella Westbrook sues Celebrity Botched Up Bodies after 'contracting blood poisoning through the TV show's dental work' Winn-ing! Harlow flaunts her model credentials in sexy tiered lace dress and pointed stilettos for awards show in Mexico Such a hot commodity 'I missed ya': Negan surprises Rick Grimes by arriving in Alexandria with Daryl in sneak peek of new The Walking Dead episode He's got a baseball bat Beach babe! Bikini-clad Hilary Duff flashes her cleavage on a tropical getaway with her beau Jason Walsh Arrived at an undisclosed paradise 'They turned out wonderfully!' Proud father Sylvester Stallone says he gives wife Jennifer Flavin 'all the credit' in raising their three daughters Hello sunshine! Hailee Steinfeld stuns in yellow sheer number as she leads stars atÂ Nickelodeon Halo Awards Kylie kopycat strikes again! Ariel Winter follows Jenner's style by wearing Kanye tour sweatshirt as she jets out of LAXÂ  Had an early flight 'We were both naked and had just met!' Evan Rachel Wood spills on steamy Gucci Guilty shoot with Chris Evans She says it wasn't too uncomfortableÂ  Hold that pose! The 'mannequin challenge' hits X Factor as super-still Nicole Scherzinger works a flexible side split... but Louis Walsh breaks the sequence Patrick Dempsey and wife Jill officially call off divorce after working hard to save 15-year relationshipÂ  They have the papers to confirm reconciliationÂ  Who knew? Shia LaBeouf reveals his tattoos of rap legends and freestyles for nearly five minutes on radio show With host Sway Calloway 'I can't believe I'm crying!' Emotional Kris Jenner sobs as she reveals her 'biggest fear' is losing a loved one On latest KUWTK promoÂ  'We are enjoying our honeymoon!' Jinger Duggar and Jeremy Vuolo share first video after heading off on tour of Australia and New Zealand The lap of luxury! Heather Dubrow debuts new web series offering a tour of her lavish walk-in wardrobe It's not for the faint-hearted 'I'm keen to do everything he did': Robert Irwin aims to follow in late father Steve's footsteps as he's nominated for a kid's Emmy Award 'I feel like I did after 9/11': Robert De Niro shares his anger following Trump's victoryÂ  Previously said Trump is 'a punk,' and 'a pig.' 'I've had three!' Million Dollar Listing's Josh Flagg confesses to multiple nose jobs as David Parnes reveals why he went under the knife again Sizzling hot! Swimsuit model Elyse Knowles flaunts her taut torso and trim pins in a skimpy white bikini as she bids farewell to Dallas We get it, you're a model! Bachelor reject Sam Johnston can't stop posing as he flirts with Olivia Phyland after admitting he'd like to get into TV presenting 'I found it!' Real Housewives Of Sydney's Lisa Oldfield celebrates finding her missing $70,000 diamond bracelet thanks to her co-star 'I hope you enjoy the read!': Bryan Cranston surprises fan by leaving free signed copy of his book at the airport Released memoir, A Life in Parts, last month John Legend pays tribute to his 'beautiful wife and daughter' as baby Luna makes her starring debut in new music video for Love Me Now Big hair don't care! Pixie Lott channels retro glamour in pink floral mini dress and voluminous updo as she steps out in LA Left Disney HQ in LA What would Tiffany say? Busty Bachelor babe Megan Marx sidles up to mystery bearded man in BUDGIE SMUGGLERS at Maxim's Hot 100 party 'It's a myth that models don't eat': Heidi Klum, 43, sizzles in swimsuits as she reveals her body secrets She's the cover girl for SHAPE magazine 'Goodbye to all that': Robert Redford, 80, reveals intention to retire from acting...and refocus on directing Acting career began in 1960 on TV's Maverick.Â  Young and in love: Lovebirds Daryl Hannah and Neil Young co-ordinate in black as they jet out of LA They looked in sync in Los Angeles Looking like a Greek Goddessex! TOWIE's Frankie flaunts her slimmed-down figure in a skimpy pink bikini for idyllic Mykonos beach break 'Dynamite recordings' of Angelina Jolie 'could dent her bid to get primary custody of her six children during bitter divorce with Brad Pitt ' She's nearly freed the nipple! Braless Zilda Williams flaunts her famed bust in a VERY sheer top... before cosying up to Bachelorette contestant Sam Johnston Harry's love in London: Pictures that shows TV star girlfriend Meghan Markle is staying with prince at Kensington Palace Getting seriousÂ  Pregnant Rebekah Vardy shows off her burgeoning baby bump in a grey top as she takes daughter Sofia to watch husband Jamie's England match Crazy cardigan! Lea Michele dons interesting high-low cardigan while out and about in LA The petite Â beauty was spotted with a pal running errandsÂ  Katie Piper displays her enviable washboard abs in her first workout session after having surgery The TV personality, 33, showcased her enviably taut abs and lean legs Kate Beckinsale sizzles in saucy leather catsuit as she fiercely tears down her enemies as a vampire in new Underworld: Blood Wars trailer Is she an auntie or a stepmom? Tyga's girlfriend Kylie Jenner babysits King Cairo after Blac Chyna gave birth to daughter Dream Complicated family tree 'She's an exact copy, Pops sent us an angel': New dad Rob Kardashian gushes that daughter Dream is the spitting image of his late father in sweet snap Head Start to Home Cooked Get Recipes more SHARE PICTURE Copy link to paste in your message Find out more... Find out more... Back to top Home U.K. News Sports U.S. Showbiz Australia Femail Health Science Money Video Travel Columnists Sitemap Archive Video Archive Topics Index Mobile Apps Screensaver RSS Text-based site Reader Prints Our Papers Top of page Daily Mail Mail on Sunday This is Network This is Money Metro Jobsite Mail Travel Zoopla.co.uk Prime Location Published by Associated Newspapers Ltd Part of the Daily Mail, The Mail on Sunday & Metro Media Group Â© Associated Newspapers Ltd Contact us How to complain Advertise with us Syndication Work with Us Terms Privacy policy & cookies Â  Â  Â 
PBS NEWSHOUR WATCH politics Shields and Brooks Supreme Court Vote 2016 Politics Monday arts Art Beat Poetry Where Poetry Lives Photo Essays nation Supreme Court Race Matters Essays Brief But Spectacular world Social Entrepreneurship economy Making Sen$e Social Security Ask the Headhunter Paul Solman science Science Wednesday Innovation and Invention Miles Oâ€™Brien health Long-Term Care education Teachers Teachersâ€™ Lounge Student Reporting Labs teachers The Rundown TV SCHEDULE ABOUT US FEEDBACK PRESS SUBSCRIPTIONS PRIVACY JOB OPENINGS RECENT PROGRAMS POLITICS ARTS NATION WORLD ECONOMY SCIENCE HEALTH EDUCATION TEACHERS THE RUNDOWN SUBSCRIBE FOLLOW US A BLOG OF NEWS AND INSIGHT News Now: Health Supreme Court Vote 2016 Health Bid to speed transplants with hepatitis C-infected kidneys EMAIL BY Lauren Neergaard, Associated PressÂ  October 27, 2016 at 9:33 AM EST File photo by Getty Images WASHINGTON â€” Some patients facing a years-long wait for a kidney transplant are jumping ahead in line thanks to a startling experiment: Theyâ€™re agreeing to an organ almost sure to infect them with hepatitis C. Knowingly transmitting a dangerous virus may sound drastic but two leading transplant centers are betting the strategy will save lives â€” if new medications that promise to cure hepatitis C allow use of organs that today go to waste. Pilot studies are under way at the University of Pennsylvania and Johns Hopkins University to test transplanting kidneys from deceased donors with hepatitis C into recipients who donâ€™t already have that virus. If the research eventually pans out, hundreds more kidneys â€” and maybe some hearts and lungs, too â€” could be transplanted every year. â€œWe always dreaded hepatitis C,â€ said Dr. Peter Reese, a Penn kidney specialist who is helping lead the research. â€œBut now hepatitis C is just a different disease,â€ enough to consider what he calls the tradeoff of getting a new kidney years faster but one that comes with a hopefully treatable infection. Itâ€™s a tradeoff prompted by the nationâ€™s organ shortage. More than 99,000 people are on the national kidney waiting list but only about 17,000 people a year get a transplant and 4 percent a year die waiting, according to the United Network for Organ Sharing (UNOS). â€œIf we had enough organs, we wouldnâ€™t do this,â€ said Dr. Niraj Desai, who is leading the Hopkins study. But, â€œmost patients are pretty open to the idea once they hear what the alternatives are.â€ Doctors had told Irma Hendricks, 66, to expect at least a five-year wait for a kidney transplant. Dialysis three times a week was keeping the East Stroudsburg, Pennsylvania, woman alive but left her with no energy for even routine activities. â€œI call it the zombie syndrome,â€ she said. So she jumped at the chance to enroll in Pennâ€™s study, even though doctors made clear they hoped for but couldnâ€™t guarantee a hepatitis cure. â€œWe always dreaded hepatitis C. But now hepatitis C is just a different disease.â€ â€” Dr. Peter Reese â€œMy son said, â€˜Mom, this is a no-brainer. Just do it,'â€ Hendricks said, She swallowed an anti-hepatitis pill daily for three months, in addition to the usual post-transplant medications. Testing showed the drugs rapidly cleared hepatitis C out of her bloodstream. And with her new kidney functioning well, she now has enough energy to play with her toddler grandson. â€œThis is giving people in my situation new hope,â€ Hendricks said. Kidney transplant specialists are closely watching the research. â€œIt makes sense to me,â€ said Dr. Matthew Cooper, a transplant surgeon at MedStar Georgetown University Hospital, who is not involved in the research. He cautioned that the studies should use only kidneys that are young and otherwise high-quality, and that patients must understand the risks. â€œThey need to know you place their safety as the highest priority,â€ Cooper said. â€œBut at the same time, recognize that we have these obstacles. We donâ€™t want people to die on dialysis and there are not enough organs available for everybody.â€ Hepatitis C is a simmering infection that, if untreated, over two to three decades can quietly destroy someoneâ€™s liver. At least 2.7 million people in the U.S. have chronic hepatitis C. Until a few years ago, it was treatable only by medications with grueling side effects and poor cure rates. Now, breakthrough drugs promise to cure 95 percent of hepatitis C cases with fewer side effects â€” for people who can afford them. Treatment costs tens of thousands of dollars. Normally, hepatitis C-infected organs are transplanted only into patients who already have hepatitis C themselves, so as not to further spread the virus. Giving hepatitis C-positive organs to hepatitis C-negative recipients is allowed if the patient agrees, but itâ€™s rare, said Dr. David Klassen, UNOSâ€™ chief medical officer. UNOS statistics show a few dozen such transplants, mostly kidneys, last year, presumably when doctors feared their patients wouldnâ€™t survive the wait for a healthier organ. More often, hospitals discard hepatitis C-infected organs. Reese and fellow Penn transplant surgeon Dr. David Goldberg found only 37 percent of hepatitis C-positive kidney donations between 2005 and 2014 were transplanted. The discards could have helped more than 4,000 patients during that time period, they reported in the New England Journal of Medicine last year. And the opioid epidemic is prompting a jump in donations from people who died of drug overdoses â€” typically young organs that, absent an infection risk, would be sought after. The small Penn and Hopkins trials are a first step; much larger studies are needed to prove if more routine use of these organs in immune-suppressed transplant recipients really works. Cost also is a question. Merck & Co. is helping to fund the pilot trials, donating its medication Zepatier, which costs $54,000 for a round of treatment. Thatâ€™s still cheaper than a lifetime of a dialysis, which costs about $75,000 a year, UNOSâ€™ Klassen noted. While the studies began with kidneys because of their demand, â€œI donâ€™t think thereâ€™s any reason, if it proves safe and effective in kidneys, that we wouldnâ€™t want to try it in other organs,â€ noted Pennâ€™s Goldberg. Even if the hepatitis C-infected organs prove useful, the nation still is â€œdesperate for more donors,â€ cautioned Hopkinsâ€™ Desai. â€œItâ€™s a practical solution to help some of the people. It wonâ€™t solve the problem.â€ ___ Associated Press Writer Michael Rubinkam contributed to this report. SHARE ON FACEBOOK SHARE ON TWITTER SHARE VIA TEXT Hepatitis-C transplant PREVIOUS POST Clinton and Obama: First ladies form political odd couple NEXT POST Iron deficient? These edible insects pack more minerals than sirloin steak Are you aware of our comment policy? PBS NewsHour allows open commenting for all registered users, and encourages discussion amongst you, our audience. However, if a commenter violates our terms of use or abuses the commenting forum, their comment may go into moderation or be removed entirely. We reserve the right to remove posts that do not follow these basic guidelines: comments must be relevant to the topic of the post; may not include profanity, personal attacks or hate speech; may not promote a business or raise money; may not be spam. Anything you post should be your own work. The PBS NewsHour reserves the right to read on the air and/or publish on its website or in any medium now known or unknown the comments or emails that we receive. By submitting comments, you agree to the PBS Terms of Use and Privacy Policy, which include more details. Please enable JavaScript to view the comments powered by Disqus. READ THIS NEXT Hospitals are throwing out organs and denying transplants to meet federal standards SUBSCRIBE FOLLOW US SUPPORT FOR PBS NEWSHOUR PROVIDED BY The Rundown offers the NewsHour's unique perspective on the important events of the day with insights from the journalists you trust. SUBSCRIBE Receive The Rundown news blog in your inbox. SUBSCRIBE PODCAST: ITUNES | XML HEADLINE FEEDS: XML | ALL BROADCAST REPORTS PBS NewsHour Weekend full episode Nov. 13, 2016 What a Trump administration means for foreign relations Trump begins building team for transition Could the Electoral College system ever change? Hollande pays tribute one year after Paris attacks PBS NewsHour Weekend full episode Nov. 12, 2016 Trump promises to make infrastructure a major focus MOST READ MOST DISCUSSED 1 Remembering Gwen 2 Do you live in a bubble? A quiz 3 PBS NewsHour Co-anchor Gwen Ifill Dies at 61 4 Read President-elect Donald Trump's plan for his first 100 days 5 Watch the PBS NewsHour Live 1 Reince Priebus tapped as White House chief of staff 2 Anti-Trump march in NYC draws thousands as other cities protest 3 Americans don safety pins in solidarity with minorities after election 4 On last foreign tour, Obama must find a way to explain Trump 5 Clinton blames FBI director for presidential election loss Loading... WATCH FULL BROADCASTS LISTEN FULL AUDIO PODCASTS SUPPORT FOR PBS NEWSHOUR PROVIDED BY TOPICS RECENT PROGRAMS POLITICS ARTS NATION WORLD ECONOMY SCIENCE HEALTH EDUCATION TEACHERS TV LISTINGS ABOUT US PRESS FEEDBACK SUBSCRIPTIONS PRIVACY JOB OPENINGS Â© 1996 - 2016 NewsHour Productions LLC. All Rights Reserved. Support the kind of journalism done by the NewsHour... Become a member of your local PBS station.
Home Issues Experts Newsletters & Trading Services Login 60% of Americans to Pay Up as Prescriptions Get Pricier Posted on October 27, 2016 by Brad Hoppmann The Obama administration said Monday that health insurance premiums under the "Affordable Care Act" will go up an average of 22% in 39 states next year. Meanwhile there will be 28% fewer health insurance providers for 2017, as major insurers like Aetna (AET), UnitedHealthcare (UNH) and Humana (HUM) withdraw from the exchange. Rising premiums in a shrinking marketplace is only one health challenge that Americans face. Thatâ€™s true whether they are covered in the marketplace or through their employer, the VA or another source. Factor in the cost of co-pays, deductibles and life-saving medications, and your pocketbook is getting crushed from every direction. Thatâ€™s especially true if youâ€™re one of the 3-in-5 Americans who take prescription drugs. In fact, you may already be reeling from their skyrocketing costs. In the U.S., we now spend over $309 billion on prescription drugs every single year. Thatâ€™s a rise of over 38% in just the last two years! This staggering price increase isnâ€™t because people are using more meds, though. Itâ€™s because pharmaceutical companies can get away with charging more. And hospitals, doctors and patients who need the medicine have little choice except to pay up. Both generic and branded drug prices are increasing as well, eliminating once-more-affordable alternatives. And the most-expensive drugs arenâ€™t necessarily new and innovative miracle cures. In fact, many are commonly used and have been on the market for decades. For Americans, prescription drugs are becoming one of the biggest financial burdens we face. Especially for retirees who could never have predicted or planned for this. You really only have two options when a medicine you take increases in price: 1. Make monetary sacrifices elsewhere to afford the new rate, or 2. Stop taking the drugs altogether and face the consequences. For most people, option two isnâ€™t even an option. If youâ€™ve been reading my Afternoon Editions for any length of time, you know that I am a fan of free markets, free minds and the free choice of individuals to do what they want with their hard-earned money. That also means having a healthy dose of skepticism when it comes to government solutions that come in the forms of more laws and regulations. Especially when the biggest beneficiaries arenâ€™t the citizens themselves â€¦ Consider that Big Pharma has spent $3.4 billion in federal lobbying since 1998 â€” more than any other industry â€” to get lawmakers on the payroll and make sure no one gets in their way. One of the most-famous cases of pharmaceutical price-gouging came in late 2015. That was when Martin Shkreli, now-former CEO of Turing Pharmaceuticals, raised the price of the drug Daraprim by 5,000%. Although price hikes like this have happened before, Shkreli instantly became public enemy No. 1 for his complete lack of empathy toward consumers. Unapologetic to this day, the former CEO doubled down on his decision by saying, "I would have raised prices even higher." Related story: A Smirk of Defiance, or Just Dumb Hubris? Daraprim is used to treat a rare condition known as toxoplasmosis. It is only prescribed to around 2,000 patients in the U.S. For as notorious as Shkreli has become, not that many people use Daraprim and thus were mostly affected by the increase. Then there is pharmaceutical supplier Mylan (MYL), which took the price-hiking practice much further when it raised the prices of its popular allergen injection, the EpiPen. Mylan acquired the decades-old product in 2007 when pharmacies paid less than $100 for a two-pen set. Since then, the company has been steadily raising the price of this life-saving device. Related story: Price-gouging; the Senatorâ€™s Daughter; Cover from Washington In 2009, a pharmacy paid $103.50 for a set. By July 2013 the price was up to $264.50, and it rose 75% to $461 by last May. This May, the price spiked again to $608.61. Unlike the small group effected by the Daraprim increase, 3.6 million Americans were prescribed EpiPens last year. This type of price hike has a much greater impact and has affected the livelihood of millions of families in the U.S. Meanwhile, Mylan CEO Heather Breschâ€™s annual compensation has soared more than 700%, to $19 million. These examples, while extreme, are far from unusual â€¦ Take a look at some of the other recent price increases involving the most-prescribed drugs in America â€¦ Â Pfizerâ€™s pain medication Lyrica jumped 45% on a per-prescription basis between 2014 and 2013, according to Medicare data. Â Lantus, a popular form of insulin, jumped 41% on a per-prescription basis, reaching $403 in 2014 from $285 in the prior year. Â Merckâ€™s cholesterol medication, Zetia, had a 21% jump in per-prescription prices in 2014, rising to $290. Â Abilify, used to treat a number of psychiatric illnesses, rose 17% in the last year. Itâ€™s not like this is happening behind closed doors, either. But there is something we can do about it. And it starts at the ballot box. Now, I know many of you are frustrated with whatâ€™s happening at the national political level, and I donâ€™t blame you. However, there are state and local races where you can also make your voice heard. California is voting this upcoming November on Proposition 61, which would enact various forms of price regulation. A similar type of bill is being voted on in Ohio in 2017. If radical drug price increases are something you or a loved one have fallen victim to, please share your story with us. Happy and healthy investing, Brad Hoppmann Your thoughts on â€œ60% of Americans to Pay Up as Prescriptions Get Pricierâ€ Paul says: October 27, 2016 at 9:04 am I am not an American but I donâ€™t need to face this problem because I donâ€™t believe in drugs. At my age of 83, all i take are supplements that have made me healthy. Iâ€™ve been wondering why doctors, I suppose everywhere, never teach people to take supplements to keep healthy. There are various supplements to help prevent illness. But then, if everybody is healthy who will need the doctors and the big pharmaceuticals? Reply Gary says: October 27, 2016 at 9:55 am And one other thing. There is a legal alternative to standard health insurance that was included as an option in ObamaCare. That means that if you have this sort of sharing of medical expenses you are not penalized for not having conventional health insurance. You can read about it here: http://www.naturalhealth365.com/obamacare-healthcare-2014.html. The person who started this company three years ago is interviewed there. I donâ€™t know enough about it to say it is financially workable or that I think that the program is for me or anyone else. Only if I see the details will I be able to endorse it. Reply Michelle says: October 27, 2016 at 10:15 am A member of my family takes Enbrel for rheumatoid arthritis. It has increased in a few years from $18,000/year to $55,000/year. Enbrel is heavily advertised along with other similar drugs like Humira. There is an increase at least quarterly and I expect this to continue. All drugs will eventually have a huge increase until the country is pushed into a recession. Corporations that self insure will have to lay off employees to pay these pharmaceutical companies. Then people who defend with the â€œR&D is expensiveâ€ and this is â€œfree marketâ€ will be singing a different tune as they clean out their office and are escorted out of the building. Reply thomas says: October 29, 2016 at 11:16 am i had taken Enbrel from Amgen, but it was not discovered by them they bought out a one horse pony Co who in their labs discovered it. And thatâ€™s a fact, i lived in NJ where this was all happening, we where told to invest in this little Co because it was going to be bought out. There was soo much demand from Embrel for that only people who had been using it could get it, I was one of those people, insurance paid it all and it wasnâ€™t that expensive. Then Amgen built a new factory to produce it, by then my doctors told me to go to Humira because one only needs to inject every 2 weeks, but later it was once a week as it lost effectiveness or my condition worsened. that;s the story folks believe it or not. Reply Mark says: October 27, 2016 at 11:07 am Forget government price controls. We need the ultimate price control and that is competition. Terminate the patent protection on drugs and drug delivery systems whenever a company violates the public trust. That will get their attention. Reply Leave a Reply Cancel reply Your email address will not be published. Required fields are marked * Comment 
 Name * Email * Website â†Â Previous NextÂ â†’ Brad Hoppmann Brad Hoppmann originally grew up in Florida, but has lived in Baltimore, Charlotte and New York as well throughout his career. Always an athlete, he played varsity football and water polo at the University of Florida and received All-SEC/SCC honors. â†’ Recently by Brad Hoppmann 14 Nov How to Make $1 Trillion Disappear in a Week 12 Nov Sleep Less, Eat More? Plus, 5 More Trends Affecting Your Health 11 Nov A Financial Battle Plan to Honor Veterans 11 Nov Is There Really Power in Positive Thinking? Weiss Research Contact Us Uncommon Wisdom Daily 4400 Northcorp Parkway Palm Beach Gardens, FL 33410 Copyright Â© 2016 Uncommon Wisdom Daily | Contact | Privacy | Terms | Advertising
PMGroup PME CommuniquÃ© The Directory Quality in Care How to Advertise Privacy and cookies My Account Register Please login to the form below Not currently logged in Email: Password: I have forgotten my password PME CommuniquÃ© The Directory Opening up market access Advanced search Home News Intelligence Thought leadership Appointments Awards Blogs Clinical Top Pharma List PMHub Jobs News Research Sales Marketing Regulatory Healthcare Jobs and recruitment Trending AstraZeneca's durvalumab trial Novartis biosimilar sales Lilly's solanezumab results in Alzheimer's Remicade-biosimilar switch trial PMEA 2016 finalists GSK's Bexsero vaccine growing fast, despite "tight" supply Meningitis drugâ€™s sales double as third quarter results exceed expectations GlaxoSmithKline's meningitis vaccine Bexsero saw sales double in the third quarter, forcing the company to race to bring new manufacturing capacity online. The vaccine was one of the stars of GSK's third-quarter results, which benefited from the weakness of sterling but nevertheless outperformed expectations, defying critics who have called for a shift away from the company's high-volume, low-margin business focus. Revenues came in at Â£7.54bn ($9.21bn) in the quarter - around Â£300m more than consensus forecasts - driven by a "standout performance" from vaccines as well as gains for GSK's HIV drugs and a recovery in respiratory sales. For some time the back story at GSK has been the loss of patent protection for asthma and chronic obstructive pulmonary disease blockbuster Advair/Seretide (salmeterol and fluticasone). The product continued to slide, but newer drugs such as Anoro (vilanterol/umeclidinium bromide), Breo (vilanterol/fluticasone furoate) and new severe asthma therapy Nucala (mepolizumab) more than offset the decline, with total respiratory sales up 8%. Downward pricing pressure on Advair over the last few years, as well as GSK's broad portfolio of drugs, could allow it to make a compelling case to keep Advair on US formularies after the patent expires next year, according to GSK chief executive Sir Andrew Witty. GSK is also getting ready to file its much anticipated triple COPD therapy before the end of the year, which along with the rest of the portfolio "puts us in a very interesting position to have a competitive dynamic in the US," he said. Bexsero meanwhile brought in Â£133m in the quarter, with annual volume now running at around 10m doses this year, up from 2.5m a couple of years ago. That is making capacity "tight", said Witty, adding that the company is working hard to ramp that up so as not to put a brake on sales. Witty estimates that penetration of the vaccine is still only at around 10%, so "there is an awful lot of opportunity to go on a global basis". And with shingles vaccine Shingrix now filed for approval in the US and tipped for blockbuster sales, GSK's investment in the sector seems to be paying off, although it has suffered some setbacks as well. A few weeks ago the company ceded the US cervical cancer vaccine market to Merck & Co after withdrawing its Cervarix product, finding it was not competitive. There were some other disappointments in GSK's announcement, including decisions to terminate development of an HIV maturation inhibitor partnered with Bristol-Myers Squibb (BMS) and COPD candidate losmapimod, which had reached phase II testing. Witty said the company has back-up maturation inhibitors coming through and he does not expect a lengthy delay to the programme. Please enable JavaScript to view the comments. Article by Phil Taylor 27th October 2016 From: Sales Share Â Print Friendly Tags Related content Back to the future GSK's blockbuster hopeful Shingrix filed in US Opening up innovation Pharma 'could do better' on social media engagement Opening up innovation Related Hub content Infographic: The vaccine opportunity in Asia Case Study: Private market opportunity for a travel vaccine Exploring the Opportunity For Halal In Healthcare PME Digital Edition Featured jobs Pharma/ Life Sciences - Social / Digital Account Director Industry leading package and bens SAE & Account Manager - Victoria â€“ Healthcare Advertising Salary TBC Client Lead, Consumer Health & Wellness, South East UK Excellent Package Senior Account Manager / Jr AD - Consumer & Prescription â€“ H... Salary TBC Account Director, Healthcare PR, London Excellent Package Account Director â€“ Medical Communications Salary TBC Chief Operating Officer â€“ Medical Education â€“ London Salary TBC Senior Account Manager â€“ Medical Education â€“ Boutique Agency Salary TBC Account Director â€“ Med Ed â€“ Publications Salary TBC Scientific Director- Immuno Oncology Specialist - Med Comms (Lon... Neg PR Associate Director â€“ Healthcare PR â€“ London Salary TBC Director of Strategy/ Scientific Services â€“ Full Home working, E... Neg Deputy Managing Director, Medical Communications, South East UK Excellent Package SYDNEY BASED ROLE - Senior Account Director â€“ Associate CSD - Me... D.O.E Healthcare PR Innovator, London Excellent Package Creative Team â€“ Mid-weight & Senior Art Director & Senio... SUPERB PACKAGES AVAILABLE SINGAPORE - Senior or Principal Medical Writer Opportunity - Med... D.O.E New Business and Marketing Manager, circa Â£50K, Healthcare Commu... Excellent Package Managing Director, Healthcare PR, London Excellent Package Medical Writer, Healthcare Education Design & Development, L... Competitive Salary Editor, Medical Communications, London Competitive Salary Subscribe to our email news alerts Most read Most shared Latest content Pharma stocks rise after Donald Trump's election win Siemens' healthcare unit to become standalone business Pfizerâ€™s first-in-class breast cancer therapy wins EU licence NICE backs Novartis' Afinitor and Pfizer's Xalkori Pfizer to shut down two UK manufacturing sites NICE set to knock-back Amgen's myeloma treatment Kyprolis Gilead's hepatitis B virus treatment set for European approval CHMP recommends Merck & Co's Lantus biosimilar Amgen wins European approval for Parsabiv Lilly bags EU approval for cancer treatment Lartruvo A rock and a hard place greyhealth group appoints digital strategy director PMHubAdd my company Any category... Advertising Branding Clinical research Conferences meetings events Creative and design Digital communications Homecare Industry associations IT solutions Management consultancies Manufacturing packaging logistics Market access Market research Marketing consultancies Media planning and buying Medical communications Medical education Patient support and adherence Pharmacy Print services Policy and government affairs Public relations Publishers Recruitment and career development Regulatory affairs Research and development Sales Training Translation services Complete HealthVizion Complete HealthVizion is a team outstanding healthcare communications experts who provide innovative strategic evidence based solutions through scientific and commercial... Latest intelligence Are we harnessing the full emotional power of brand creativity? Creative Director Damien Parsonage breaks down the common misconception that pharma and healthcare marketing for healthcare professionals ought to be entirely scientific and rational. Brands are powerful; here's how to... Opinion piece: Personalisation â€“ the future of medical education Alex Goonesinghe, Research Manager, and Nigel Campbell, Multichannel Communications Director, share their thoughts on the growing trend towards personalised medical education.... Rethinking pharma communications Guide: How do you adjust your communications to the new multichannel and multi-stakeholder environment?... Quick links Country reports Digital Handbook The Gallery Healthcare glossary How to advertise HTA guidance tracker Orphan drugs and rare diseases PME supplements Social media hub Webinars Infographics Multimedia<> Webinar: Customer engagement design CommuniquÃ© Awards 2015: Winners in pictures CommuniquÃ© Awards 2015: Gallery PMEA 2015: Winners in pictures PMEA 2015: Pictures About us Contact us How to advertise Site map All content copyright Â© PMGroup Worldwide Ltd 2016
Post Register Monday November 14, 2016 46â€‰Â°F Subscribe Now | Services | Log In | Search Services | Log In News Top Headlines Local News West Nation & World Commentary Business Shoptalk People in Business Food & Home Outdoors Idaho Trails In the Woods Ticket Smart Living Sports High School Prep Stats PR Preps College Pro Obituaries Farm & Ranch Classifieds Announcements Automotive Employment Farm & Agriculture Garage Sales Merchandise Pets & Supplies Real Estate Recreational Vehicles Rentals Service Directory Jobs Real Estate Local First Events Restaurants Weather Local Deals More Legal Notices Photos eBooks Contact Us Newsroom Staff Letters to the Editor Advertising Staff Circulation Staff Printing Services Connect With Us General Transplants with hepatitis C-infected kidneys eyed Posted: October 27, 2016 4:24 a.m. Irma Hendricks has blood drawn at the Hospital of the University of Pennsylvania in Philadelphia, on Oct. 6, 2016. Hendricks received a kidney transplant from a donor with hepatitis C, and took medications after surgery that cleared away the virus and left her feeling healthy again. Hendricks is part of a pilot study testing if new drugs that promise to cure most hepatitis C could allow use of organs that today go to waste, and speed transplants to people who might otherwise die waiting. (AP Photo/Jessica Kourkounis) In this photo taken Oct. 13, 2016, Irma Hendricks poses for a portrait with her grandson, C.J., at her home in East Stroudsburg, Pa. Hendricks received a kidney transplant from a donor with hepatitis C, and took medications after surgery that cleared away the virus and left her feeling healthy again. Hendricks is part of a pilot study testing if new drugs that promise to cure most hepatitis C could allow use of organs that today go to waste, and speed transplants to people who might otherwise die waiting. (AP Photo/Michael Rubinkam) Irma Hendricks, right, talks with her physician Peter P. Reese, MD at Hospital of the University of Pennsylvania in Philadelphia, on Oct. 6, 2016. Hendricks received a kidney transplant from a donor with hepatitis C, and took medications after surgery that cleared away the virus and left her feeling healthy again. Hendricks is part of a pilot study testing if new drugs that promise to cure most hepatitis C could allow use of organs that today go to waste, and speed transplants to people who might otherwise die waiting. (AP Photo/Jessica Kourkounis) By LAURAN NEERGAARD AP Medical Writer WASHINGTON (AP) â€” Some patients facing a years-long wait for a kidney transplant are jumping ahead in line thanks to a startling experiment: Theyâ€™re agreeing to an organ almost sure to infect them with hepatitis C. Knowingly transmitting a dangerous virus may sound drastic but two leading transplant centers are betting the strategy will save lives â€” if new medications that promise to cure hepatitis C allow use of organs that today go to waste. Pilot studies are under way at the University of Pennsylvania and Johns Hopkins University to test transplanting kidneys from deceased donors with hepatitis C into recipients who donâ€™t already have that virus. If the research eventually pans out, hundreds more kidneys â€” and maybe some hearts and lungs, too â€” could be transplanted every year. â€œWe always dreaded hepatitis C,â€ said Dr. Peter Reese, a Penn kidney specialist who is helping lead the research. â€œBut now hepatitis C is just a different disease,â€ enough to consider what he calls the tradeoff of getting a new kidney years faster but one that comes with a hopefully treatable infection. Itâ€™s a tradeoff prompted by the nationâ€™s organ shortage. More than 99,000 people are on the national kidney waiting list but only about 17,000 people a year get a transplant and 4 percent a year die waiting, according to the United Network for Organ Sharing (UNOS). â€œIf we had enough organs, we wouldnâ€™t do this,â€ said Dr. Niraj Desai, who is leading the Hopkins study. But, â€œmost patients are pretty open to the idea once they hear what the alternatives are.â€ Doctors had told Irma Hendricks, 66, to expect at least a five-year wait for a kidney transplant. Dialysis three times a week was keeping the East Stroudsburg, Pennsylvania, woman alive but left her with no energy for even routine activities. â€œI call it the zombie syndrome,â€ she said. So she jumped at the chance to enroll in Pennâ€™s study, even though doctors made clear they hoped for but couldnâ€™t guarantee a hepatitis cure. â€œMy son said, â€˜Mom, this is a no-brainer. Just do it,â€™â€ Hendricks said, She swallowed an anti-hepatitis pill daily for three months, in addition to the usual post-transplant medications. Testing showed the drugs rapidly cleared hepatitis C out of her bloodstream. And with her new kidney functioning well, she now has enough energy to play with her toddler grandson. â€œThis is giving people in my situation new hope,â€ Hendricks said. Kidney transplant specialists are closely watching the research. â€œIt makes sense to me,â€ said Dr. Matthew Cooper, a transplant surgeon at MedStar Georgetown University Hospital, who is not involved in the research. He cautioned that the studies should use only kidneys that are young and otherwise high-quality, and that patients must understand the risks. â€œThey need to know you place their safety as the highest priority,â€ Cooper said. â€œBut at the same time, recognize that we have these obstacles. We donâ€™t want people to die on dialysis and there are not enough organs available for everybody.â€ Hepatitis C is a simmering infection that, if untreated, over two to three decades can quietly destroy someoneâ€™s liver. At least 2.7 million people in the U.S. have chronic hepatitis C. Until a few years ago, it was treatable only by medications with grueling side effects and poor cure rates. Now, breakthrough drugs promise to cure 95 percent of hepatitis C cases with fewer side effects â€” for people who can afford them. Treatment costs tens of thousands of dollars. Normally, hepatitis C-infected organs are transplanted only into patients who already have hepatitis C themselves, so as not to further spread the virus. Giving hepatitis C-positive organs to hepatitis C-negative recipients is allowed if the patient agrees, but itâ€™s rare, said Dr. David Klassen, UNOSâ€™ chief medical officer. UNOS statistics show a few dozen such transplants, mostly kidneys, last year, presumably when doctors feared their patients wouldnâ€™t survive the wait for a healthier organ. More often, hospitals discard hepatitis C-infected organs. Reese and fellow Penn transplant surgeon Dr. David Goldberg found only 37 percent of hepatitis C-positive kidney donations between 2005 and 2014 were transplanted. The discards could have helped more than 4,000 patients during that time period, they reported in the New England Journal of Medicine last year. And the opioid epidemic is prompting a jump in donations from people who died of drug overdoses â€” typically young organs that, absent an infection risk, would be sought after. The small Penn and Hopkins trials are a first step; much larger studies are needed to prove if more routine use of these organs in immune-suppressed transplant recipients really works. Cost also is a question. Merck & Co. is helping to fund the pilot trials, donating its medication Zepatier, which costs $54,000 for a round of treatment. Thatâ€™s still cheaper than a lifetime of a dialysis, which costs about $75,000 a year, UNOSâ€™ Klassen noted. While the studies began with kidneys because of their demand, â€œI donâ€™t think thereâ€™s any reason, if it proves safe and effective in kidneys, that we wouldnâ€™t want to try it in other organs,â€ noted Pennâ€™s Goldberg. Even if the hepatitis C-infected organs prove useful, the nation still is â€œdesperate for more donors,â€ cautioned Hopkinsâ€™ Desai. â€œItâ€™s a practical solution to help some of the people. It wonâ€™t solve the problem.â€ â€”â€”â€” Associated Press Writer Michael Rubinkam contributed to this report. About | Advertise | Newsroom Ethics | Newsroom Staff | NIE | Printing Services | Privacy Policy Post Register â€¢ 333 Northgate Mile â€¢ PO Box 1800 â€¢ Idaho Falls, ID. 83401 Office Hours: Monday - Friday, 8:30 am to 5:00 pm Phone: (208) 522.1800 Copyright Â© 2016 Post Register
Search Contact Us Sign In | Sign Up Home On-Air Rich Peterson Kim David Andy Brownell Tracy McCray Shows Listen Listen Live Podcasts Mobile App Events Rochester on Tap Rochester Home, Vacation and RV Show Calendar Submit Your Community Calendar Event Community Engagement Request Form KROC Club Sign Up Contests and Perks Contest Rules VIP Support Closings Closings Weather Links Mayo Clinic Radio Minnesota Lottery Minnesota Twins Minnesota Gophers Power of Learning with Jim Walters City of Rochester Rochester Public Schools Olmsted County State of Minnesota Minnesota Veterans & Emergency Services Museum History Center of Olmsted County Destination Medical Center Win Stuff Contact Us On-Air Hosts Contact Info Help & Contact Info EEO Report Careers Send Feedback Advertise Community Engagement Request Form Follow on Facebook Follow on Twitter Subscribe on YouTube subscribe via RSS Trending: Destination Medical Center Weather Win $10,000 Cash Rochester on Tap Beer Festival Seize the Deal Auction New Experiment Involving Kidney Transplants By Associated Press October 27, 2016 4:37 AM Share on Facebook Share on Twitter Getty Images WASHINGTON (AP) â€” Some patients facing a years-long wait for a kidney transplant are jumping ahead in line thanks to a startling experiment: Theyâ€™re agreeing to an organ almost sure to infect them with hepatitis C. Knowingly transmitting a dangerous virus may sound drastic but two leading transplant centers are betting the strategy will save lives â€“ if new medications that promise to cure hepatitis C allow use of organs that today go to waste. Pilot studies are under way at the University of Pennsylvania and Johns Hopkins University to test transplanting kidneys from deceased donors with hepatitis C into recipients who donâ€™t already have that virus. If the research eventually pans out, hundreds more kidneys â€“ and maybe some hearts and lungs, too â€“ could be transplanted every year. â€œWe always dreaded hepatitis C,â€ said Dr. Peter Reese, a Penn kidney specialist who is helping lead the research. â€œBut now hepatitis C is just a different disease,â€ enough to consider what he calls the tradeoff of getting a new kidney years faster but one that comes with a hopefully treatable infection. Itâ€™s a tradeoff prompted by the nationâ€™s organ shortage. More than 99,000 people are on the national kidney waiting list but only about 17,000 people a year get a transplant and 4 percent a year die waiting, according to the United Network for Organ Sharing (UNOS). â€œIf we had enough organs, we wouldnâ€™t do this,â€ said Dr. Niraj Desai, who is leading the Hopkins study. But, â€œmost patients are pretty open to the idea once they hear what the alternatives are.â€ Doctors had told Irma Hendricks, 66, to expect at least a five-year wait for a kidney transplant. Dialysis three times a week was keeping the East Stroudsburg, Pennsylvania, woman alive but left her with no energy for even routine activities. â€œI call it the zombie syndrome,â€ she said. So she jumped at the chance to enroll in Pennâ€™s study, even though doctors made clear they hoped for but couldnâ€™t guarantee a hepatitis cure. â€œMy son said, â€˜Mom, this is a no-brainer. Just do it,'â€ Hendricks said, She swallowed an anti-hepatitis pill daily for three months, in addition to the usual post-transplant medications. Testing showed the drugs rapidly cleared hepatitis C out of her bloodstream. And with her new kidney functioning well, she now has enough energy to play with her toddler grandson. â€œThis is giving people in my situation new hope,â€ Hendricks said. Kidney transplant specialists are closely watching the research. â€œIt makes sense to me,â€ said Dr. Matthew Cooper, a transplant surgeon at MedStar Georgetown University Hospital, who is not involved in the research. He cautioned that the studies should use only kidneys that are young and otherwise high-quality, and that patients must understand the risks. â€œThey need to know you place their safety as the highest priority,â€ Cooper said. â€œBut at the same time, recognize that we have these obstacles. We donâ€™t want people to die on dialysis and there are not enough organs available for everybody.â€ Hepatitis C is a simmering infection that, if untreated, over two to three decades can quietly destroy someoneâ€™s liver. At least 2.7 million people in the U.S. have chronic hepatitis C. Until a few years ago, it was treatable only by medications with grueling side effects and poor cure rates. Now, breakthrough drugs promise to cure 95 percent of hepatitis C cases with fewer side effects â€“ for people who can afford them. Treatment costs tens of thousands of dollars. Normally, hepatitis C-infected organs are transplanted only into patients who already have hepatitis C themselves, so as not to further spread the virus. Giving hepatitis C-positive organs to hepatitis C-negative recipients is allowed if the patient agrees, but itâ€™s rare, said Dr. David Klassen, UNOSâ€™ chief medical officer. UNOS statistics show a few dozen such transplants, mostly kidneys, last year, presumably when doctors feared their patients wouldnâ€™t survive the wait for a healthier organ. More often, hospitals discard hepatitis C-infected organs. Reese and fellow Penn transplant surgeon Dr. David Goldberg found only 37 percent of hepatitis C-positive kidney donations between 2005 and 2014 were transplanted. The discards could have helped more than 4,000 patients during that time period, they reported in the New England Journal of Medicine last year. And the opioid epidemic is prompting a jump in donations from people who died of drug overdoses â€“ typically young organs that, absent an infection risk, would be sought after. The small Penn and Hopkins trials are a first step; much larger studies are needed to prove if more routine use of these organs in immune-suppressed transplant recipients really works. Cost also is a question. Merck & Co. is helping to fund the pilot trials, donating its medication Zepatier, which costs $54,000 for a round of treatment. Thatâ€™s still cheaper than a lifetime of a dialysis, which costs about $75,000 a year, UNOSâ€™ Klassen noted. While the studies began with kidneys because of their demand, â€œI donâ€™t think thereâ€™s any reason, if it proves safe and effective in kidneys, that we wouldnâ€™t want to try it in other organs,â€ noted Pennâ€™s Goldberg. Even if the hepatitis C-infected organs prove useful, the nation still is â€œdesperate for more donors,â€ cautioned Hopkinsâ€™ Desai. â€œItâ€™s a practical solution to help some of the people. It wonâ€™t solve the problem.â€ Filed Under: hepatitis C | kidney disease | national news | New Experiment Involving Kidney Transplants Category: Articles Share on Facebook Share on Twitter More Send to a friend! Print this page Pin it! Reddit This! Share on Tumblr! Best of 1340 KROC-AM State Taskforce Studies Possible MNsure Fixes First Degree Murder Indictment in Winona Case Three ISIS Conspirators Sentenced by Minnesota Federal Judge Serious Charges Dropped in Rochester Murder Case Recommended for You ZergNet Best of the Web ZergNet Leave a Comment Listen Live Meet the Hosts Andy Brownell Kim David Rich Peterson Tom Ostrom Facebook Sign up for our newsletter Sign up for our newsletter! KROC Club Sign up to get exclusive access to VIP events, contests, coupons, giveaways, presales and much more! Sign Up Now Closings Weather-Related Announcements for Thursday March 24, 2016 March 23, 2016 5:18 PM Weather-Related Announcements for Wednesday March 23, 2016 March 23, 2016 9:21 AM Weather-Related Announcements For Monday, March 14th March 14, 2016 6:10 AM Recent Stories Vikings Still Havenâ€™t Won Since Bye Week Break November 13, 2016 3:48 PM Gophers Playing in BTNâ€™s First-Ever Virtual Reality-Produced Football Game Saturday November 11, 2016 3:35 PM Watch for The Super Supermoon November 11, 2016 10:49 AM 5 Rochester Restaurants Offering Veterans Free Meals on Veterans Day November 10, 2016 10:01 PM Get Ready to Save Big with Our â€˜Seize the Dealâ€™ Fall Auction! November 10, 2016 11:39 AM Advertise Terms VIP Terms FAQ Contest Rules Privacy Policy (Updated: 5/9/16) Contact Townsquare Welcome back to KROC Club It appears that you already have an account created within our VIP network of sites on . To keep your personal information safe, we need to verify that it's really you. To activate your account, please confirm your password. When you have confirmed your password, you will be able to log in through Facebook on both sites. Enter your password Forgot your password? YES, Activate My Account Now! *Please note that your prizes and activities will not be shared between programs within our VIP network. Welcome back to KROC Club It appears that you already have an account on this site associated with . To connect your existing account just click on the account activation button below. You will maintain your existing VIP profile. After you do this, you will be able to always log in to http://krocam.com using your original account information. YES, Activate My Account Now! *Please note that your prizes and activities will not be shared between programs within our VIP network. We're Almost There! Please fill out the information below to help us provide you a better experience. Zip Continue and Activate Log in to KROC Club (Forgot your password?) Log In Not a member? Sign up here KROC Club brought to you by: Sign up for KROC Club Register Now Sign up for KROC Club quickly by connecting your Facebook account. It's just as secure and no password to remember! KROC Club brought to you by: Sign up to have exclusive KROC Club contests, events, coupons, presales, and much more delivered to you for FREE. Like Us on Facebook KROC Club brought to you by: KROC-AM Song*Please enter a song name. Artist(Optional) Your Name*Please enter your name. Your Email*Please enter your email. Submit Thank you for your request.
The allÂ new CBS News App for AndroidÂ® for iPadÂ® for iPhoneÂ® Fully redesigned. Featuring CBSN, 24/7Â liveÂ news. Get the App â•³ CBS News CBS Evening News CBS This Morning 48 Hours 60 Minutes Sunday Morning Face The Nation CBSN GO Log In Log In Join CBSNews.com Sign in with Â  Â  Â  Â  CBSNews.com - Breaking News Video US World Politics Entertainment Health MoneyWatch SciTech Crime Sports Photos More Blogs Battleground The WH Web Shows 60 Overtime Face to Face Resources Mobile Radio Local In Depth CBS News Store AP October 27, 2016, 5:19 AM Some kidney transplants coming with big potential catch -- hepatitis C Comment Share Tweet Stumble Email WASHINGTON -- Some patients facing a years-long wait for a kidney transplant are jumping ahead in line thanks to a startling experiment: Theyâ€™re agreeing to an organ almost sure to infect them with hepatitis C. Knowingly transmitting a dangerous virus may sound drastic, but two leading transplant centers are betting the strategy will save lives -- if new medications that promise to cure hepatitis C enable use of organs that today go to waste. Pilot studies are under way at the University of Pennsylvania and Johns Hopkins University to test transplanting kidneys from deceased donors with hepatitis C into recipients who donâ€™t already have that virus. If the research eventually pans out, hundreds more kidneys -- and maybe some hearts and lungs, too -- could be transplanted every year. â€œWe always dreaded hepatitis C,â€ said Dr. Peter Reese, a Penn kidney specialist who is helping lead the research. â€œBut now hepatitis C is just a different disease,â€ enough to consider what he calls the tradeoff of getting a new kidney years faster but one that comes with a hopefully treatable infection. Itâ€™s a tradeoff prompted by the nationâ€™s organ shortage. More than 99,000 people are on the national kidney waiting list but only about 17,000 people a year get a transplant and 4 percent a year die waiting, according to the United Network for Organ Sharing (UNOS). â€œIf we had enough organs, we wouldnâ€™t do this,â€ said Dr. Niraj Desai, who is leading the Hopkins study. But, â€œMost patients are pretty open to the idea once they hear what the alternatives are.â€ Doctors had told Irma Hendricks, 66, to expect at least a five-year wait for a kidney transplant. Dialysis three times a week was keeping the East Stroudsburg, Pennsylvania, woman alive but left her with no energy for even routine activities. â€œI call it the zombie syndrome,â€ she said. So she jumped at the chance to enroll in Pennâ€™s study, even though doctors made clear they hoped for but couldnâ€™t guarantee a hepatitis cure. â€œMy son said, â€˜Mom, this is a no-brainer. Just do it,â€â€™ Hendricks said. She swallowed an anti-hepatitis pill daily for three months, in addition to the usual post-transplant medications. Testing showed the drugs rapidly cleared hepatitis C out of her bloodstream. And with her new kidney functioning well, she now has enough energy to play with her toddler grandson. â€œThis is giving people in my situation new hope,â€ Hendricks said. Kidney transplant specialists are closely watching the research. â€œIt makes sense to me,â€ said Dr. Matthew Cooper, a transplant surgeon at MedStar Georgetown University Hospital, who is not involved in the research. He cautioned that the studies should use only kidneys that are young and otherwise high-quality, and that patients must understand the risks. â€œThey need to know you place their safety as the highest priority,â€ Cooper said. â€œBut at the same time, recognize that we have these obstacles. We donâ€™t want people to die on dialysis and there are not enough organs available for everybody.â€ Hepatitis C is a simmering infection that, if untreated, over two to three decades can quietly destroy someoneâ€™s liver. At least 2.7 million people in the U.S. have chronic hepatitis C. Until a few years ago, it was treatable only by medications with grueling side effects and poor cure rates. Now, breakthrough drugs promise to cure 95 percent of hepatitis C cases with fewer side effects - for people who can afford them. Treatment costs tens of thousands of dollars. Normally, hepatitis C-infected organs are transplanted only into patients who already have hepatitis C themselves, so as not to further spread the virus. Giving hepatitis C-positive organs to hepatitis C-negative recipients is allowed if the patient agrees, but itâ€™s rare, said Dr. David Klassen, UNOSâ€™ chief medical officer. UNOS statistics show a few dozen such transplants, mostly kidneys, last year, presumably when doctors feared their patients wouldnâ€™t survive the wait for a healthier organ. More often, hospitals discard hepatitis C-infected organs. Reese and fellow Penn transplant surgeon Dr. David Goldberg found only 37 percent of hepatitis C-positive kidney donations between 2005 and 2014 were transplanted. The discards could have helped more than 4,000 patients during that time period, they reported in the New England Journal of Medicine last year. And the opioid epidemic is prompting a jump in donations from people who died of drug overdoses -- typically young organs that, absent an infection risk, would be sought after. The small Penn and Hopkins trials are a first step; much larger studies are needed to prove if more routine use of these organs in immune-suppressed transplant recipients really works. Cost also is a question. Merck & Co. is helping to fund the pilot trials, donating its medication Zepatier, which costs $54,000 for a round of treatment. Thatâ€™s still cheaper than a lifetime of a dialysis, which costs about $75,000 a year, UNOSâ€™ Klassen noted. While the studies began with kidneys because of their demand, â€œI donâ€™t think thereâ€™s any reason, if it proves safe and effective in kidneys, that we wouldnâ€™t want to try it in other organs,â€ noted Pennâ€™s Goldberg. Even if the hepatitis C-infected organs prove useful, the nation still is â€œdesperate for more donors,â€ cautioned Hopkinsâ€™ Desai. â€œItâ€™s a practical solution to help some of the people. It wonâ€™t solve the problem.â€ Â© 2016 The Associated Press. All Rights Reserved. This material may not be published, broadcast, rewritten, or redistributed. Comment Share Tweet Stumble Email Featured in Health Best bug sprays for fighting Zika Consumer Reports tested insect repellents and came up with the best brands for fending off mosquitoes that could spread Zika virus 7 bad habits that could be wrecking your diet If you're having a hard time shedding pounds, try adjusting these common eating habits Popular Most Popular 01 Who's Winning the 2016 US Presidential Election - Live Results 4536463 views 02 Commentary: The unbearable smugness of the press 1444486 views 03 Hiker crosses paths with Hillary Clinton on Chappaqua trail 1077057 views 04 Presidential election results 2016: What time, how to watch and live stream online 1049004 views 05 President-elect Trump on immigrants heâ€™ll deport 839185 views Play Video Trump speaks to "60 Minutes" Play Video Trump transition Play Video House Majority Leader McCarthy Play Video Trump's conflicts of interest Play Video Supermoon flooding in Fla. Previous Next 107 Photos Trump protests 48 Photos Warren Beatty 150 Photos Notable deaths in 2016 7 Photos Newspaper front pages tell story of shocking Trump win 33 Photos A crash course on Melania Trump Previous Next Most Discussed Who's Winning the 2016 US Presidential Election - Live Results President-elect Trump on immigrants heâ€™ll deport In a stunner, Donald Trump wins the presidency Commentary: The unbearable smugness of the press Thousands protest Trump victory across nation New Fire TV App CBSNews.com Site Map Help Contact Us CBS Bios Careers CBSi Careers Internships Development Programs CBS Interactive Privacy Policy Ad Choice Terms of Use Mobile User Agreement About CBS Advertise Closed Captioning CBS News Store Follow Us Facebook Twitter RSS Email Newsletters YouTube CBS Radio News CBS Local CBS News Copyright Â© 2016 CBS Interactive Inc. All rights reserved. Search
Home News Local News Crime Mug Shots Call 4 Action Photo Galleries National News International Politics Decision 2016 Religion Featured Stories New York Business Health Entertainment Hollywood Today Live Whatâ€™s Trending Traffic Orlando Shootings Break Out Wake Up! Weather Todayâ€™s Forecast 7-Day Forecast Radar Current Conditions Satellite Weather Blog Fall Foliage Free Weather App Alerts Closings Marine Forecast Canada News 4 Investigates Investigations Inside The Epidemic Your Food Dicey Dining Sports Buffalo Bills News 4 in London Buffalo Sabres UB Bulls Buffalo Bandits Buffalo Bisons High School Scholar Athletes Super Bowl 50 Report It Watch Live Watch News 4 Now The CW23 TV Listings More Free Mobile Apps Text Alerts Email Newsletters Healthy Living Company Listings Events Calendar Contests Community Fun 4 Families Staff Bios Careers Broadcast Scholarship Fall Festivals Company Listings 49Â° F Broken Clouds Hi: 56Â° F Lo: 39Â° F Todayâ€™s Forecast Radar 7-Day Menu Skip to content Â  Home News News Local News Crime Mug Shots Call 4 Action Photo Galleries National News International Politics Decision 2016 Religion Featured Stories New York Business Health Entertainment Hollywood Today Live Whatâ€™s Trending Traffic Orlando Shootings Break Out Wake Up! Latest Headlines The right look for the job: Hair stylists give free haircuts to Buffaloâ€™s unemployed Updated: 2 mins ago As the weather turns colder, thereâ€™s a new effort to get Buffaloâ€™s homeless and unemployed community off the streets and back to work. Judge delays Dylann Roof competency hearing for a day Updated: 15 mins ago CHARLESTON, S.C. (AP) â€” A federal judge has delayed a hearing to determine whether Dylann Roof is competent to stand trial in the deaths of â€¦ Judge sets $0 option price for historic presidential yacht Updated: 15 mins ago ICC prosecutor: US forces may have tortured in Afghanistan Updated: 15 mins ago Local reaction to President-elect Trumpâ€™s â€™60 Minutesâ€™ interview Updated: 19 mins ago Weather Weather Todayâ€™s Forecast 7-Day Forecast Radar Current Conditions Satellite Weather Blog Fall Foliage Free Weather App Alerts Closings Marine Forecast Canada Current Conditions 49Â° F Broken Clouds Feels Like: 49Â° F Wind: WSW 3 Humidity: 66% Dewpoint: 38Â° F Sunrise: 7:06 AM Sunset: 4:52 PM Buffalo Weather Forecast 7-Day Currently Buffalo Radar Sponsored by: News 4 Investigates News 4 Investigates Investigations Inside The Epidemic Your Food Dicey Dining Latest Headlines Agents in the air help protect the border Updated: 57 mins ago Look up the next you visit one of Western New Yorkâ€™s landmarks, and thereâ€™s a chance youâ€™ll see federal agents in the air. U.S. Customs and â€¦ Love Canal lawsuits continue 40 years later October 31, 2016 The fight over one of Americaâ€™s worst hazardous waste sites may be far from over. Nearly forty years after tons of toxic waste poisoned partâ€¦ WNY Family fighting for domestic violence registry October 5, 2016 EPA plans next phase of creek clean-up September 7, 2016 State audit critical of nursing home enforcement procedures August 10, 2016 Sports Sports Buffalo Bills News 4 in London Buffalo Sabres UB Bulls Buffalo Bandits Buffalo Bisons High School Scholar Athletes Super Bowl 50 Latest Headlines Bills refreshed after injury-plagued start Updated: 7 mins ago ORCHARD PARK, N.Y. (AP) â€” The Buffalo Bills are healthier and refreshed following a much-needed week off. And they may have some new faces iâ€¦ Notre Dame, Baylor, UConn lead way in womenâ€™s basketball Updated: 8 mins ago NEW YORK (AP) â€” Top-ranked Notre Dame cruised to an easy win in its opener. The rest of the Top 25 didnâ€™t face much of a challenge either. Tâ€¦ Duke stays solid No. 1 in menâ€™s basketball 1:32 pm AP POLL ALERT: Duke holds onto lead in AP Top 25 menâ€™s hoops poll; Kentucky next, then Villanova; Kansas falls to No. 7 1:02 pm Here is the Illinois Scorecard from The Associated Press 12:20 pm Report It Watch Live Watch News 4 Now The CW23 TV Listings More Free Mobile Apps Text Alerts Email Newsletters Healthy Living Company Listings Events Calendar Contests Community Fun 4 Families Staff Bios Careers Broadcast Scholarship Fall Festivals Company Listings Search for: Search the site 49Â° F Broken Clouds Hi: 56Â° F Lo: 39Â° F Bid to speed transplants with hepatitis C-infected kidneys LAURAN NEERGAARD, The Associated Press Published: October 27, 2016, 4:00 am Updated: October 27, 2016, 10:32 am Click to share on Twitter (Opens in new window) Click to share on Google+ (Opens in new window) Share on Facebook (Opens in new window) Click to share on Pinterest (Opens in new window) WASHINGTON (AP) â€” Some patients facing a years-long wait for a kidney transplant are jumping ahead in line thanks to a startling experiment: Theyâ€™re agreeing to an organ almost sure to infect them with hepatitis C. Knowingly transmitting a dangerous virus may sound drastic but two leading transplant centers are betting the strategy will save lives â€” if new medications that promise to cure hepatitis C allow use of organs that today go to waste. Pilot studies are under way at the University of Pennsylvania and Johns Hopkins University to test transplanting kidneys from deceased donors with hepatitis C into recipients who donâ€™t already have that virus. If the research eventually pans out, hundreds more kidneys â€” and maybe some hearts and lungs, too â€” could be transplanted every year. â€œWe always dreaded hepatitis C,â€ said Dr. Peter Reese, a Penn kidney specialist who is helping lead the research. â€œBut now hepatitis C is just a different disease,â€ enough to consider what he calls the tradeoff of getting a new kidney years faster but one that comes with a hopefully treatable infection. Itâ€™s a tradeoff prompted by the nationâ€™s organ shortage. More than 99,000 people are on the national kidney waiting list but only about 17,000 people a year get a transplant and 4 percent a year die waiting, according to the United Network for Organ Sharing (UNOS). â€œIf we had enough organs, we wouldnâ€™t do this,â€ said Dr. Niraj Desai, who is leading the Hopkins study. But, â€œmost patients are pretty open to the idea once they hear what the alternatives are.â€ Doctors had told Irma Hendricks, 66, to expect at least a five-year wait for a kidney transplant. Dialysis three times a week was keeping the East Stroudsburg, Pennsylvania, woman alive but left her with no energy for even routine activities. â€œI call it the zombie syndrome,â€ she said. So she jumped at the chance to enroll in Pennâ€™s study, even though doctors made clear they hoped for but couldnâ€™t guarantee a hepatitis cure. â€œMy son said, â€˜Mom, this is a no-brainer. Just do it,'â€ Hendricks said, She swallowed an anti-hepatitis pill daily for three months, in addition to the usual post-transplant medications. Testing showed the drugs rapidly cleared hepatitis C out of her bloodstream. And with her new kidney functioning well, she now has enough energy to play with her toddler grandson. â€œThis is giving people in my situation new hope,â€ Hendricks said. Kidney transplant specialists are closely watching the research. â€œIt makes sense to me,â€ said Dr. Matthew Cooper, a transplant surgeon at MedStar Georgetown University Hospital, who is not involved in the research. He cautioned that the studies should use only kidneys that are young and otherwise high-quality, and that patients must understand the risks. â€œThey need to know you place their safety as the highest priority,â€ Cooper said. â€œBut at the same time, recognize that we have these obstacles. We donâ€™t want people to die on dialysis and there are not enough organs available for everybody.â€ Hepatitis C is a simmering infection that, if untreated, over two to three decades can quietly destroy someoneâ€™s liver. At least 2.7 million people in the U.S. have chronic hepatitis C. Until a few years ago, it was treatable only by medications with grueling side effects and poor cure rates. Now, breakthrough drugs promise to cure 95 percent of hepatitis C cases with fewer side effects â€” for people who can afford them. Treatment costs tens of thousands of dollars. Normally, hepatitis C-infected organs are transplanted only into patients who already have hepatitis C themselves, so as not to further spread the virus. Giving hepatitis C-positive organs to hepatitis C-negative recipients is allowed if the patient agrees, but itâ€™s rare, said Dr. David Klassen, UNOSâ€™ chief medical officer. UNOS statistics show a few dozen such transplants, mostly kidneys, last year, presumably when doctors feared their patients wouldnâ€™t survive the wait for a healthier organ. More often, hospitals discard hepatitis C-infected organs. Reese and fellow Penn transplant surgeon Dr. David Goldberg found only 37 percent of hepatitis C-positive kidney donations between 2005 and 2014 were transplanted. The discards could have helped more than 4,000 patients during that time period, they reported in the New England Journal of Medicine last year. And the opioid epidemic is prompting a jump in donations from people who died of drug overdoses â€” typically young organs that, absent an infection risk, would be sought after. The small Penn and Hopkins trials are a first step; much larger studies are needed to prove if more routine use of these organs in immune-suppressed transplant recipients really works. Cost also is a question. Merck & Co. is helping to fund the pilot trials, donating its medication Zepatier, which costs $54,000 for a round of treatment. Thatâ€™s still cheaper than a lifetime of a dialysis, which costs about $75,000 a year, UNOSâ€™ Klassen noted. While the studies began with kidneys because of their demand, â€œI donâ€™t think thereâ€™s any reason, if it proves safe and effective in kidneys, that we wouldnâ€™t want to try it in other organs,â€ noted Pennâ€™s Goldberg. Even if the hepatitis C-infected organs prove useful, the nation still is â€œdesperate for more donors,â€ cautioned Hopkinsâ€™ Desai. â€œItâ€™s a practical solution to help some of the people. It wonâ€™t solve the problem.â€ ___ Associated Press Writer Michael Rubinkam contributed to this report. Share this: Click to share on Twitter (Opens in new window) Click to share on Google+ (Opens in new window) Share on Facebook (Opens in new window) Click to share on Pinterest (Opens in new window) Click to email (Opens in new window) Click to print (Opens in new window) Advertisement Â« Previous Story â€” Next Story Â» WIVB.com provides commenting to allow for constructive discussion on the stories we cover. In order to comment here, you acknowledge you have read and agreed to our Terms of Service. Commenters who violate these terms, including use of vulgar language or racial slurs, will be banned. Please be respectful of the opinions of others. If you see an inappropriate comment, please flag it for our moderators to review. Note: Comments containing links are not allowed. Please enable JavaScript to view the comments powered by Disqus. Leave a Reply Cancel reply Enter your comment here... Fill in your details below or click an icon to log in: Email (required) (Address never made public) Name (required) Website You are commenting using your WordPress.com account. (Â LogÂ OutÂ /Â ChangeÂ ) You are commenting using your Twitter account. (Â LogÂ OutÂ /Â ChangeÂ ) You are commenting using your Facebook account. (Â LogÂ OutÂ /Â ChangeÂ ) You are commenting using your Google+ account. (Â LogÂ OutÂ /Â ChangeÂ ) Cancel Connecting to %s Notify me of new comments via email. Notify me of new posts via email. Advertisement Special Report Number of drug dependent babies in parts of WNY on track to double this year November 11, 2016 Hundreds of babies are expected to go through withdrawal this year as the opioid epidemic continues in Erie County. Latest Stories Trending Stories Advertisement Advertisement Advertisement WIVB News 4 Buffalo, NY Â© 2000-2016 LIN Television Corporation, a Media General company. All rights reserved. Powered by WordPress.com VIP Sections Local News Weather Investigative Sports Report It Watch News 4 Live Station Contact Us Send a Birthday Photo Advertise Careers Internship Application Broadcast Scholarship Privacy Policy Terms of Use FCC Public File EEO Report Childrenâ€™s TV Programming Report More Free Mobile Apps Text Alerts Email Newsletters Calendar Contests Community Staff Bios Our Partners CW23 WNLO Media General CBS CNN Follow Subscribe via RSS Follow us on Twitter Join us on Facebook Follow us on YouTube Follow us on Google+ Follow us on Instagram Send to Email Address Your Name Your Email Address Cancel Post was not sent - check your email addresses! Email check failed, please try again Sorry, your blog cannot share posts by email.
null
Subscribe Login Slight chance of snow / Tonight's low: 26Â° The Gazette 2014 Pulitzer Prize Winner News Sports Business Politics Opinion Life A&E Obits Shopping About Us Popular Top Local News U.S. & World Crime & Justice Weather Graduations Closings & Delays Military Education Colorado Politics Special Interest Fire & Environment Marijuana Traffic The Cheyenne Edition The Woodmen Edition Submit a news tip Anxiety and fear rampant among undocumented immigrants after Trump's victory Glenn came closer than expected, but enigmatic candidacy hampered U.S. Senate bid Archives Subscriber Benefits Search Subscriber Services Account Center Archives Carrier Portal Buy Our Photos Advertising SpringsCoupons.com Place An Ad About Us Contact Us About The Gazette Employment Opportunities Copyright Information Reprint Information Google Survey FAQ Gazette Charities Become a Carrier Report an Issue Subscriber Services Account Center Archives Carrier Portal Buy Our Photos Online News e-Edition Newsletters Mobile Apps Popular Top Sports Stories Olympics David Ramsey Paul Klee Woody Paige Brent Briggeman Blog Joe Paisley Blog Paul Klee Blog Pro Teams Broncos Avalanche Rockies Sky Sox Switchbacks FC Nuggets College Teams Air Force Academy Colorado College UCCS Preps Coverage Preps Peak Performers Preps Game of the Week Paul Klee: Broncos shock Saints on Block in the Bayou Popular Top Business Stories Economic Indicators Movers & Shakers Get a Job Monday Ted Rayburn Resources Leading Lawyers Leading Medical Professionals Colorado Springs' largest defense contractor announces merger InterQuest area on Colorado Springs' north side poised to become development hub Popular Top Life Stories Out There Travel Home & Garden Food Health Faith & Values Parenting Around Town My Colorado Pets Advertising Special Sections OutThereColorado.com Nonprofit News Think Pink Celebrate Pulse Heart Health Month Stroke Awareness Month Business Spotlight New book by Colorado Springs author profiles influential figures in adoption Colorado winter festivals for 2016-2017 season Popular GO! Top Entertainment ColoradoSprings.com Best of the Springs Dining & Drink Restaurant Reviews Discover Guide Cinema Guide Pop Culture Beer Map Fun Comics/Puzzles Horoscopes Celebs TV Barenaked Ladies announce U.S. tour dates, including Colorado Springs Evolution of Castle Rock native Amy Adams on view in 'Arrival,' 'Nocturnal' Popular Top Editorials Guest Editorial Letters to the Editor Submit a Letter Contact Elected Officials Blogs Popular Top Politics Election 2016 Local/County State Colorado Politics Photos Top Images The Latest Best of Local Best of Sports Videos Top Videos Best of Local Best of Sports Best of Life Best of Military Features Government Videos A&E Videos Blogs Business Spotlight Eric Singer Chestnut Street Bridge Reopens in Colorado Springs Turkey Lady tries to shoo in frozen birds in Colorado Springs Obits Latest Obituaries Death Notices Place an obituary Place a death notice Deals Circulars Jobs Deal of the Day Real Estate Garage Sales Shop for Cars Legal Notices Classifieds Merchandise Dogs Rentals Service Directory Springs Coupons Various/Misc. Post an ad Toggle navigation Home Account Login Register Search Google Survey FAQ Contact Us Contact Contact Us Become a Carrier Carrier Portal Employment Opportunities Report an Issue Mobile Apps Archives Subscriber Benefits News Local News Local News Top Local headlines Crime & Justice Government Elections Military Education Fire & Environment Marijuana Traffic Closings & Delays Submit a News Tip U.S. & World U.S. & World Sports Sports Top Sports Headlines David Ramsey Paul Klee Broncos Peyton Manning Nuggets Avs Rockies Sky Sox Switchbacks FC Air Force Academy Colorado College Olympics Preps OutThere Colorado Business Business Top Business Headlines Local Stocks Wall Street Journal Economic Indicators Opinion Opinion Top Editorial Guest Editorial Submit a Letter Contact Elected Officials Life Life Top Life Headlines OutThere Colorado Travel Home & Garden Dining & Drink Beer Map Food Health Faith & Values Parenting My Colorado Around Town Pets A&E A&E Top A&E Headlines Entertainment Best of the Springs Discover Guide ColoradoSprings.com Cinema Guide Celebrity News T.V. Comics & Puzzles Horoscopes Colorado Politics Video & Photo Top Videos Videos News Videos Sports Videos Life Videos Military Videos Government Videos A&E Videos Business Spotlight Eric Singer Top Photos Photos View Photos Buy Photos Most Recent Videos Obits Latest Obituaries Death Notices Place an obituary Place a death notice Coupons and Deals Deal of the Day Circulars Springs Coupons Marketplace Jobs Homes Cars Classifieds Classifieds Garage Sales Legal Notices Merchandise Real Estate Rentals Service Directory Various/Misc. Post an ad Colorado Springs News, Sports & Business | Colorado Springs Gazette, News News: Local News Colorado Springs' largest defense contractor announces merger Mon, Nov 14, 2016 - 4:34 PM 0 Intelligent Software Solutions Inc., the largest defense contractor based in Colorado Springs, is merging with Maryland-based Proteus Technologies LLC and... Ted Rayburn: Economic uncertainty? Take a breath Colorado Springs road closed to massive sinkhole reopens after 15 months Mon, Nov 14, 2016 - 4:20 PM 0 A northwest Colorado Springs road has reopened, more than a year after it was closed due to a massive sinkhole. The Chestnut Street bridge on the road between... Sports: Broncos Yes, it was all legal what the Denver Broncos did vs. Saints Mon, Nov 14, 2016 - 2:39 PM 0 ENGLEWOOD â€” Just last month, Joe DeCamillis, the Denver Broncos special teams coach, vehemently defended the NFL rule that allows players to leap over the... Broncos-Chiefs game moved to 'Sunday Night Football' InterQuest area on Colorado Springs' north side poised to become development hub Mon, Nov 14, 2016 - 6:34 AM 0 Move over, Powers Boulevard; hello, InterQuest. For 15 years, a 7-mile stretch of Powers on... New book by Colorado Springs author profiles influential figures in adoption Mon, Nov 14, 2016 - 3:42 PM 0 Paul Batura set out to write a book that would be a gift to his three sons, that celebrated... Latest Local Man on the loose after jumping out window, chase with Colorado Springs police By: Tom Roeder - 3 min ago Denver man who spent 28 years in prison acquitted of rape By: SADIE GURMAN, Associated Press - 37 min ago Gun battle over truck kills pregnant Colorado woman By: The Denver Post - 52 min ago Mugshot Monday: Most wanted in Colorado Springs area By: the gazette email@gazette.com - 1 hr ago Bar set high environmentally for new Pikes Peak Summit House By: Billie Stanton Anleu - 1 hr ago Anti-Trump protests held Sunday in Colorado Springs By: Jessica Leicht, KKTV - 1 hr ago Colorado to test taxing drivers per mile By: The Associated Press - 1 hr ago Top Stories Trump considering woman, openly gay man for leadership posts 6 min ago '90210' cast pays tribute to ailing Shannen Doherty By: The Associated Press - 9 min ago Trump set to roll back Obama policies on energy, environment By: MATTHEW DALY and JULIE PACE, Associated Press - 12 min ago Smoked pot? No college? The police still might hire you By: DAVE COLLINS and LISA MARIE PANE, Associated Press - 27 min ago LETTERS: CC, CU-Boulder students need to grow up; kudos to Omaha hockey fans By: Gazette readers - 30 min ago Rapids goalkeeper Tim Howard to undergo season-ending surgery By: News services - 34 min ago Trump considering woman, openly gay man for leadership posts By: STEVE PEOPLES and JULIE PACE, Associated Press - 55 min ago <p>Your browser does not support IFrame Embeds, please update your browser to view this gallery</p> Photo Galleries Supermoon 2016 Broncos vs. Saints Lewis-Palmer win 4A state title in Volleyball AFA 49, CSU 46 TCA wins first 4A boys soccer championship Discovery Canyon 48 - Skyview 0 Air Force vs. Rochester Institute of Technology Hockey Air Force vs. McPherson College 2016 winter fun guide: Colorado ski areas TCA heading to state soccer finals High school signing day in the Colorado Springs area 15 Veterans Day freebies to snag around Colorado Springs A Look Back Election Day in the U.S. Election Night 2016 Peak Performers 2016-17 Funeral procession for Cimarron Hills firefighter Denver Broncos vs. Oakland Raiders 2016 Diwali Show Rehearsal TCA 2, Denver West 0 Veterans Day Parade in Colorado Springs Vista Ridge vs. Rampart Football Doherty 47 - Boulder 28 15 fascinating presidential facts you probably don't know 10 great political films for a stranger-than-fiction race Cubs win the World Series 50th Country Music Awards D'Evelyn 3, Cheyenne Mountain 2 Introducing ColoradoPolitics.com, driving the state's political conversation every day Latest Local 1 min ago Man on the loose after jumping out window, chase with Colorado Springs police 35 min ago Denver man who spent 28 years in prison acquitted of rape 50 min ago Gun battle over truck kills pregnant Colorado woman 1 hr ago Mugshot Monday: Most wanted in Colorado Springs area 1 hr ago Bar set high environmentally for new Pikes Peak Summit House 1 hr ago Anti-Trump protests held Sunday in Colorado Springs 1 hr ago Colorado to test taxing drivers per mile Most Read InterQuest area on Colorado Springs' north side poised to become development hub Trump names top aides, says heâ€™ll move quickly to deport up to 3 million people SNLâ€™s first-post election show had an entirely serious cold open Colorado Springs road closed to massive sinkhole reopens after 15 months Man at large after speeding away from Colorado Springs police, slamming tree Chiliâ€™s apologizes after manager takes back free meal on Veterans Day Ex-sheriff Maketa will attempt to have charges against him dropped Monday Colorado Springs' largest defense contractor announces merger Paul Klee: Broncos shock Saints on Block in the Bayou EDITORIAL: What Trump's tax cuts may do Sports 32 min ago Rapids goalkeeper Tim Howard to undergo season-ending surgery 7 hr ago Paul Klee: Broncos shock Saints on Block in the Bayou 7 hr ago Rask stops 21 shots, Bruins beat Avalanche 7 hr ago Colorado moves up four spots in Top 25 with Washington State showdown next 9 hr ago The Classical Academy romps to its first boys' soccer state title 18 hr ago Air Force hoops freshmen hope to capitalize on more early opportunities 18 hr ago Subplots we watched in the Air Force football game Business 1 min ago Buffett's Berkshire Hathaway invests in major airlines 23 min ago SEC Chair White leaving at end of Obama administration 31 min ago PetSmart fined for not reporting injury-causing fish bowls 31 min ago HP Enterprise ordered to keep working on Rhode Island system 1 hr ago US stocks finish level as tech losses cancel out bank gains 1 hr ago Dodge truck owners accuse Chrysler of VW-like cheating 1 hr ago Samsung to buy Harman for $8 billion in bold autos gambit Opinion 26 min ago LETTERS: CC, CU-Boulder students need to grow up; kudos to Omaha hockey fans 2 hr ago GUEST COLUMN: Millennials and mountains are our future Mon, Nov 14, 2016 LETTERS: Another utility rate increase; politics is the new religion Yesterday EDITORIAL: What Trump's tax cuts may do Sun, Nov 13, 2016 GUEST COLUMN: Freedom of speech includes freedom to preach Sat, Nov 12, 2016 Commentary: Democrats caught in snares they set for the GOP Fri, Nov 11, 2016 EDITORIAL: Let Colorado Springs take care of clean water Elections 5 hr ago Darryl Glenn came closer than expected, but enigmatic candidacy hampered U.S. Senate bid Yesterday Weighing the potential of a Trump presidency from a military point of view Sat, Nov 12, 2016 Donald Trump on '60 Minutes': Hillary Clinton 'couldn't have been nicer' Sat, Nov 12, 2016 Safety pin campaign signals post-election support for minorities Fri, Nov 11, 2016 Zuckerberg: 'Crazy' to say Facebook influenced election Fri, Nov 11, 2016 Denver students leave class to protest Trump Fri, Nov 11, 2016 Ann Coulter: "Without fat girls, there would be no protests" Around the Web 8 min ago '90210' cast pays tribute to ailing Shannen Doherty 1 hr ago Critics jab 'safety pin' campaign amid Trump presidency fear 4 hr ago Chiliâ€™s apologizes after manager takes back free meal on Veterans Day 9 hr ago Trump names top aides, says heâ€™ll move quickly to deport up to 3 million people Yesterday SNLâ€™s first-post election show had an entirely serious cold open Sat, Nov 12, 2016 Facebook accidentally 'killed' a bunch of people, including Mark Zuckerberg Sat, Nov 12, 2016 Former AFA player Gregg Popovich uncensored: Full transcript of thoughts on Donald Trump Sponsored Content 7 things to do if you're hurt in a game day car accident Latest Videos Chestnut Street Bridge Reopens in Colorado Springs Turkey Lady tries to shoo in frozen birds in Colorado Springs Pikes Peak region forecast Priebus Tapped as White House Chief of Staff Raw: Anniversary of Attacks Marked Across Paris Air Force defenseman Matt Koch on Saturday's home win over RIT The Classical Academy romps to its first boys' soccer state title Recovery Through Sport in Colorado Springs Saluting our Veterans on Veterans Day Get A Job Monday: Spoiler Dude wants You! Group Embraces Veterans with Handmade Tribute Raw: Second Night of NYC Anti-Trump Protests Sports Latest Sports Rapids goalkeeper Tim Howard to undergo season-ending surgery33 min ago Rask stops 21 shots, Bruins beat Avalanche7 hr ago Colorado moves up four spots in Top 25 with Washington State showdown next7 hr ago The Classical Academy romps to its first boys' soccer state title9 hr ago Broncos Paul Klee: Broncos shock Saints on Block in the Bayou7 hr ago Woody Paige: Denver Broncos' victory akin to Mississippi River flowing north22 hr ago Woody Paige: Broncos should have lured Drew Brees to DenverYesterday Paul Klee: Von Miller: Broncos in 'tough patch' at New OrleansSat, Nov 12, 2016 Photo Galleries Broncos vs. Saints Lewis-Palmer win 4A state title in Volleyball AFA 49, CSU 46 TCA wins first 4A boys soccer championship Discovery Canyon 48 - Skyview 0 Air Force vs. Rochester Institute of Technology Hockey Air Force vs. McPherson College TCA heading to state soccer finals High school signing day in the Colorado Springs area Peak Performers 2016-17 Denver Broncos vs. Oakland Raiders TCA 2, Denver West 0 Vista Ridge vs. Rampart Football Doherty 47 - Boulder 28 Cubs win the World Series Opinion Gazette Editorials EDITORIAL: What Trump's tax cuts may doYesterday Commentary: Democrats caught in snares they set for the GOPSat, Nov 12, 2016 EDITORIAL: Let Colorado Springs take care of clean waterFri, Nov 11, 2016 EDITORIAL: With variety of choices, voters opt to have balance in ColoradoThu, Nov 10, 2016 Letters to the Editor LETTERS: CC, CU-Boulder students need to grow up; kudos to Omaha hockey fans29 min ago LETTERS: Another utility rate increase; politics is the new religionMon, Nov 14, 2016 LETTERS: The people have spoken; 2016 has been an amazing yearFri, Nov 11, 2016 LETTERS: Background on "A Look Back" photo; we will move onThu, Nov 10, 2016 Columns GUEST COLUMN: Millennials and mountains are our future2 hr ago GUEST COLUMN: Freedom of speech includes freedom to preachSun, Nov 13, 2016 GUEST COLUMN: Old soldiers continue to fight their wars and rememberFri, Nov 11, 2016 GUEST COLUMN: Pioneering spirit fueled Air Guard 'firsts' and path to F-35Fri, Nov 11, 2016 Local News Local News Denver man who spent 28 years in prison acquitted of rape33 min ago Bar set high environmentally for new Pikes Peak Summit House1 hr ago Anti-Trump protests held Sunday in Colorado Springs1 hr ago Colorado to test taxing drivers per mile1 hr ago Local and State Politics Colorado to test taxing drivers per mile1 hr ago Turnover among El Paso County commissioners could end long-standing division8 hr ago This Week: Meetings and events around Colorado Springs9 hr ago Biggest election night winners and losers in Colorado: Business, unions and the Catholic ChurchFri, Nov 11, 2016 Local Business Colorado Springs' Norris-Penrose aims for year-round exhibitions with renovation of indoor arenaSat, Nov 12, 2016 Colorado Springs business a finalist in video contestFri, Nov 11, 2016 Economist: Cybersecurity industry trying to fill 450 jobs in Colorado SpringsFri, Nov 11, 2016 Beefed-up equipment has Colorado Springs Airport ready for winter weatherFri, Nov 11, 2016 More Top Reads Nation and World Trump considering woman, openly gay man for leadership posts2 min ago Police: Missouri father shoved fingers down infant's throat2 min ago 2 sentenced to prison for disrupting Southwest flight11 min ago The Latest: Enhanced video shown in man's shooting death12 min ago Military Bergdahl: Firefight recalled in search for missing soldier1 hr ago The Latest: Missing diver's body found near Manhattan Beach1 hr ago The Latest: Trump, Putin talk about better relations1 hr ago The Latest: Soldiers recall firefight in search for Bergdahl1 hr ago Blogs Another Arizona State hockey arena deal brewing4 hr ago Ramsey Rapid Reaction: 3 reasons why Broncos survived SaintsYesterday Air Force notebook: Falcons praise Colorado State receiverYesterday Pregame: Two AFA, RIT players suspended for Saturday's gameSat, Nov 12, 2016 Crime and Justice Local Crime Man on the loose after jumping out window, chase with Colorado Springs police0 min ago Gun battle over truck kills pregnant Colorado woman48 min ago Mugshot Monday: Most wanted in Colorado Springs area1 hr ago Colorado Springs police find shooting victim but no crime scene8 hr ago National Crime California deputy shot twice in the head, suspect arrested2 hr ago Alaska officer 'ambushed' and shot multiple times, police saySat, Nov 12, 2016 Successful real-estate firm built during hidden crime spreeSat, Nov 12, 2016 Principal of Denver metro high school arrested, suspendedFri, Nov 11, 2016 Life Life 125 Colorado Springs-area holiday events3 hr ago New luxury hotels coming to Vail, Telluride and Taos7 hr ago Colorado Springs area literary events starting Nov. 14, 2016Mon, Nov 14, 2016 Ceramic artists ride design's trend toward the handcraftedMon, Nov 14, 2016 Arts and Entertainment '90210' cast pays tribute to ailing Shannen Doherty5 min ago Barenaked Ladies announce U.S. tour dates, including Colorado Springs2 hr ago Evolution of Castle Rock native Amy Adams on view in 'Arrival,' 'Nocturnal'2 hr ago Rocker Leon Russell dies in Nashville20 hr ago Religion Parallel lives? Trump and BerlusconiSat, Nov 12, 2016 Muslim Americans reassure their children and prepare for a new dayFri, Nov 11, 2016 Pope Francis meets ex-priests in gesture of mercyFri, Nov 11, 2016 On Veterans Day, a chaplainâ€™s saluteFri, Nov 11, 2016 National National Politics Trump considering woman, openly gay man for leadership posts4 min ago Civil rights group wary of incoming Trump administration6 min ago Trump set to roll back Obama policies on energy, environment10 min ago SD-YouthMinimumWage-All,10019 min ago National Business Buffett's Berkshire Hathaway invests in major airlines0 min ago SEC Chair White leaving at end of Obama administration22 min ago PetSmart fined for not reporting injury-causing fish bowls30 min ago HP Enterprise ordered to keep working on Rhode Island system30 min ago Get the Newsletter The latest breaking news, delivered straight to your email! Subscribe Get a Subscription Access all of our premium content, get unlimited digital access and more! Subscribe Follow our Facebook Get real time news updates Follow Ã— Login Required You must be logged in to post a comment. If you already have an account, login here: Login New user? Register Now Advertising SpringsCoupons.com Place An Ad About Us Contact Us About The Gazette Work For Us Copyright Information Reprint Information Google Survey FAQ Gazette Charities Become a Carrier Subscriber Services Subscriber Services Archives Carrier Portal Buy Our Photos Online News e-Edition Newsletters Mobile Apps Gazette.com Coloradosprings.com Gazettepreps.com Best of the Springs My Colorado OutThereColorado.com Privacy Policy Terms of Service Â© 2016 Produced by Colorado Springs Gazette
Contact Us Journalists Blog Log In Sign Up Send a Release News Solutions Resources Search Global Animal Healthcare Market Size, Share, Development, Growth and Demand Forecast to 2022 - Industry Insights by Product, by Animal Type News provided by ReportBuyer Oct 26, 2016, 20:52 ET Share this article LONDON, Oct. 26, 2016 /PRNewswire/ -- The global animal healthcare market is driven by increasing trend of pet adoption, and growing global consumption of meat and milk. The adoption of western culture and changing lifestyle in the developing countries, such as India and China, has increased the adoption of pet animals, which supports the growth of the animal healthcare market. Pet ownership is considered as status symbol in the developing countries. Cats and dogs are adopted by people for psychological and therapeutic benefits. The evolution of new animal diseases offers untapped opportunities for the animal healthcare market. One such disease is porcine epidemic diarrhea virus (PEDV), which is caused by corona virus, and leads to infection within the cell lining in the small intestine of pigs. The trend of adopting pets is increasing globally, which is supporting the growth of the global animal healthcare market to some extent. The adoption of western culture and changing lifestyles in the developing countries, such as India and China, has increased the adoption of pet animals. One of the major status symbols observed in the developing countries is pet ownership. The American Psychological Association published a survey in the Journal of Personality and Social Psychology in 2011, which shows that dog and cat owners in the U.S. were observed to be healthier, happier, and well-organized, in comparison to the non-owners. The dog and cat owners were also mentally more conscientious, balanced, extraverted, and less fearful. Dogs are also kept for thief detection and security reasons. Due to the growing population of the U.S., pet ownership doubled from 65 million households in 1970 and reached approximately 160 million households in 2012. According to the American Pet Products Association (APPA), in 2012, 47% of the total households had at least one dog within their families in the U.S. There were also 83.3 million owned-dogs within the country in the same year. Additionally, there were 46% of the total households having at least one cat, and 96 million owned-cats in the country in 2012. Australia is one of the countries having the highest rate of pet ownership globally. According to the Australian Veterinary Association, in 2013, there were 4.2 million dogs and 3.3 million cats accounting for 39% and 29% market shares respectively in the country. Approximately 27% of the dogs and 20% of the cats in the country have been insured with health insurance by their owners. Some of the transmissible diseases, such as zoonosis, in vertebrate animals can be transferred indirectly or directly to humans. If consumers digest worm through undercooked or raw infected fish, they can get infected with anisakiasis. In animals, food borne zoonotic diseases are spread due to consuming food or water contaminated with pathogenic microorganism, such as campylobacter, brucellosis, listeria, parasites, anisakiasis, and salmonella. The increasing prevalence of zoonotic and food borne diseases has raised the concern of animal farm owners and pet owners for the health of their animals. In the U.S. and other countries, brucellosis (bacterial infection) is increasing, which causes still birth or abortion in animals. The bacterial infection generally affects goats and livestock animals, such as cows and sheep. According to the European Food Safety Authority (EFSA), about 320,000 cases of zoonotic and food borne diseases are registered every year in the European Union. The most common zoonosis observed in animals is campylobacteriosis, which affected around 220,000 people in 2012 in the European Union (EU) countries. Due to animal care initiatives taken by the animal owning population in the European Union countries, the salmonellosis cases in humans had decreased by 5.4% during 2010-2012. Some of the major companies operating in the global animal healthcare market include Zoetis, Merck, Merial, Bayer, Virbac, Ceva Sante Animal S.A., Boehringer Ingelheim GmbH, Elanco, and Vetoquinol. Download the full report: https://www.reportbuyer.com/product/3861598/ About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers http://www.reportbuyer.com For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com Tel: +44 208 816 85 48 Website: www.reportbuyer.com To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-animal-healthcare-market-size-share-development-growth-and-demand-forecast-to-2022---industry-insights-by-product-by-animal-type-300352229.html SOURCE ReportBuyer Related Links http://www.reportbuyer.com Oct 26, 2016, 20:52 ET Preview: Frontier Pharma: Schizophrenia and Associated Indications - Small but Diverse Range of First-in-Class Molecular Targets Hold Promise for Treatment of Negative and Cognitive Symptoms Oct 26, 2016, 20:52 ET Preview: Development and Market of General Aviation in Globe and China 2015-2020 My News Release contains wide tables. View fullscreen. Also from this source Nov 10, 2016, 21:48 ETModular Data Center Market by Functional Module Solution,... Nov 10, 2016, 21:21 ETPhilippines Dental Care Market Outlook to 2019 - Increasing... Explore More news releases in similar topics Publishing & Information Services Animals & Pets Surveys, Polls and Research Animal Welfare You just read: Global Animal Healthcare Market Size, Share, Development, Growth and Demand Forecast to 2022 - Industry Insights by Product, by Animal Type News provided by ReportBuyer Oct 26, 2016, 20:52 ET Share this article Phone 8AM - 10PM ET +1-888-776-0942 Send a Release Sign Up Blog For Journalists Contact Us Search Searching for your content... Advanced Search Contact 888-776-0942 from 8 AM - 10 PM ET Chat Online with an Expert Contact Us Solutions Cision Communication Cloudâ„¢ For Marketers For Public Relations For IR & Compliance For Agency For Small Business All Products About About PR Newswire About Cision Become a Publishing Partner Become a Channel Partner Careers Â  Global Sites Asia Brazil Canada Europe Finland France India Israel Mexico Middle East Netherlands Sweden United Kingdom My Services All News Releases Online Member Center ProfNetâ„  My Services All News Releases Online Member Center ProfNetâ„  888-776-0942 from 8 AM - 10 PM ET Terms of Use Privacy Policy Information Security Policy Statement Site Map RSS Feeds Copyright Â© 2016 PR Newswire Association LLC. All Rights Reserved. A Cision company. News Solutions Resources Phone +1-888-776-0942 8AM - 10PM ET Chat Chat Online with an Expert All contact info Send a ReleaseLog In
Toggle navigation Email Sign-Up Contact Us About Us Republish Our Content Follow Us: @KHNews Facebook LinkedIn RSS Feeds Toggle navigation Home The Health Law Medicare Medicaid Elections Cost & Quality Health Industry Insurance Aging Mental Health Uninsured KHN Morning Briefing Summaries of health policy coverage from major news organizations Oct 26 2016 full issue Twitter Facebook LinkedIn Email Print Republish Twitter Facebook LinkedIn Email Print Republish Investors With Ties To Religious Groups Jump Into Fray On High Drug Prices News outlets report on stories related to pharmaceutical drug pricing. The Wall Street Journal: Faith-Based Investor Group Calls For Drugmakers To Be Transparent On Pricing A group of 300 institutional investors, including many with ties to religious organizations, is waging a new campaign to press drugmakers to justify their price increases. The investors, members of the New York-based Interfaith Center on Corporate Responsibility, are asking 17 drug companiesâ€”including Johnson & Johnson, Pfizer Inc. and Merck & Co.â€”to be more transparent about when and why they raise prices. (Loftus, 10/24) Stat: Interfaith Investor Coalition Pushes Shareholder Resolutions On Drug Prices In the latest bid to put a lid on rising drug costs, a coalition of 300 institutional investors has filed shareholder resolutions with 11 big US drug makers to explain and justify all price increases and the risks these may pose to stockholders. At the same time, the Interfaith Center on Corporate Responsibility also wrote six large European companies to schedule talks about transparency around their pricing. The resolutions ask the companies to issue reports by November that list the rates of price increases for all of their top-selling brand-name medicines between 2010 and 2016, along with the rationale and criteria used to raise prices. (Silverman, 10/24) Roll Call: FDA Approval Changes Could Affect Drug Prices Upcoming changes to the Food and Drug Administrationâ€™s reviews for generic drugs could have an impact on drug prices if they help introduce more competition to the market. In separate public meetings on Thursday and Friday, FDA officials discussed their plans for renewing the programs that charge generic drugmakers a fee to go through the application process. The FDA has been scrutinized for aspects of its generic approval programs that critics contend prevent cheaper generic therapies from coming to market. (Siddons, 10/24) The Fiscal Times: Prescription Drug Prices Headed For Double-Digit Increases In 2017 Specialty drugs get a lot of attention when it comes to higher costs, although price increases are occurring across the board. Specialty drug prices are projected to increase 18.7 percent next year (after growing 18.9 percent in 2016). Although they comprise less than 1 percent of prescriptions, specialty drugs account for 35 percent of the prescription drug price trend, according to HR Consultancy Segal. Meanwhile, the overall cost of all drugs prescribed for employees under age 65 is expected to grow 11.6 percent next year, on top of an 11.3 percent hike this year. (Braverman, 10/24) Stat: FDA Official Warns Other Drug Makers Not To Copy Sarepta Any company that plans to mimic the approach taken by Sarepta Therapeutics to win regulatory approval of a drug should think twice. That was the blunt message delivered on Tuesday by a high-ranking US Food and Drug Administration official in the wake of simmering controversy over a recent decision to approve a Sarepta drug for Duchenne muscular dystrophy, a rare and fatal disease. (Silverman, 10/20) Stat: Elizabeth Warren Criticizes Feds For A 'Shamefully Weak' Deal With Mylan For the third time this month, a US senator is harshly criticizing a deal that Mylan Pharmaceuticals reached with the US Department of Justice for shortchanging Medicaid over rebates for its EpiPen device, which sparked national outrage after a series of price hikes. In an Oct. 21 letter, Elizabeth Warren (D-Mass.) complained to US Attorney General Loretta Lynch that the $465 million settlement â€œfails to hold Mylan accountableâ€ and is â€œshockingly soft on this corporate wrongdoer,â€ because Mylan did not admit any wrongdoing, none of its executives were penalized, and the company can deduct the payment from its corporate taxes. (Silverman, 10/24) Bloomberg: Senator Warren Says Mylan Settlement With DOJ â€˜Shamefully Weakâ€™ Massachusetts Senator Elizabeth Warren is the latest critic of the $465 million settlement that drugmaker Mylan NV said it reached with the federal government over Medicaid rebates for its EpiPen allergy shot. In a letter Friday to Attorney General Loretta Lynch, the Democratic senator wrote that her staff calculated Mylan underpaid Medicaid rebates by an estimated $530 million -- $65 million more than the settlement -- mostly because Mylan didnâ€™t pay the required inflation rebate. Warren wrote the settlement with theÂ Department of JusticeÂ is â€œshamefully weakâ€ because it lacks criminal penalties or any incentive to â€œprevent drug companies from engaging in abusive schemes to defraud Medicaid and rip off taxpayers.â€ (Hopkins, 10/21) Stat: Senator Richard Burr, A Pharma Favorite, Gets Help From His Friends If you leave the American Tobacco Trail and drive east, past Dameâ€™s Almost Famous Chicken & Waffles, Bullockâ€™s Bar-B-Que, and the Truly Blessed Hair Salon, you will eventually come to the worldâ€™s largest research park. This 16-square-mile stretch of Piedmont pine forest is home to about 200 companies that develop drugs and devices, run clinical trials, and otherwise push the boundaries of bioscience. GlaxoSmithKline, Merck & Co., and Biogen all have offices here, as do other industry leaders and startups. This is Burr country. (Kaplan, 10/25) Stat: EpiPen Prescriptions Continue To Climb, But Market Share Dropped EpiPen may be a budget buster for some households, but new data indicates prescriptions for the allergy emergency device are outpacing last yearâ€™s figures. At the same time, though, more prescriptions were written recently for lower-cost alternatives and, as a result, last month marked the first time in three years that EpiPenâ€™s share of prescriptions for such devices fell. The number of prescriptions written for the auto-injector in August rose 19 percent from the same month a year ago. Overall, the number of prescriptions are up 14 percent through September, compared with the same period in 2015. In fact, there were 40 percent more prescriptions written in the first nine months of this year compared with 2013, even as the price for EpiPen was rising, according to Athenahealth, which provides technology services to physicians. (Silverman, 10/25) Stat: Congressman Calls For Probe Into Valeant's Pricing Of Lead Poisoning Drug The huge increase in the price of a lifesaving lead poisoning treatment has prompted a Michigan lawmaker to call for a congressional investigation into Valeant Pharmaceuticals. Two years ago, the drug maker boosted the list price for Calcium EDTA by roughly 2,700 percent. After Valeant bought the drug in 2013 as part of a deal in which it took over another company, the list price for a package of vials started rising quickly. After being stable at $950, Valeant raised the price several times before closing out 2014 at more than $26,900. (Silverman, 10/21) The Fiscal Times: How Big Pharma Lobbyists Keep Medicare Drug Prices HighÂ  An analysis jointly published this week by the Center for Responsive Politics and FairWarning, a non-profit news organization, highlights the political clout exerted by the Pharmaceutical Research and Manufacturers of America (PhRMA), a major industry group, and some of the largest U.S. drug companies. Since early 2003, the drug manufacturing industry spent more than $1.9 billion on lobbying members of Congress on Medicare Part D and other issues important to the industry. In just 2015 and the first half of this year, the industryâ€™s lobbying bill was equivalent to spending $468,108 on every member of Congress, according to the Center for Responsive Politics. (Pianin, 10/20) Chicago Tribune: Drug Price Control? AbbVie, Takeda, Astellas Vote 'No' With Their Millions Three of the area's largest pharmaceutical companies are in the thick of an intense California-based battle over rising drug costs, a fight that could spread to Illinois and other states. AbbVie, Takeda and Astellas, along with other major drug companies, have contributed nearly $86 million toward an effort to defeat Proposition 61. That's an Election Day ballot referendum where voters decide yes or no about regulating prices of drugs purchased by some California agencies on behalf of 4.4 million people whose health care is covered by the state. (Reed, 10/21) The New York Times: Unicef Cuts Cost Of Vaccine That Protects Against 5 Diseases The United Nations Childrenâ€™s Fund has made a deal with six vaccine manufacturers that will cut in half the price of a shot that protects children against five diseases, the fund announced last week. The deal will mean three yearsâ€™ worth of vaccine at an average price of 84 cents a dose; buyers currently pay about $1.84, according to Unicef. (McNeil, 10/24) Columbus Dispatch: Middlemen Drive Up Prescription Drug Prices, Critics SayÂ  The industry created to keep drug prices in check is capitalizing on a lack of government oversight to rake in huge profits â€” often at the expense of patients, health plans and pharmacies, critics say. Drugmakers such as Mylan have been the target of much consumer wrath after the cost of its EpiPen, used to treat potentially deadly reactions to food allergies and bee stings, rose by more than 500 percent in just a few years. But a lesser-known group of companies called pharmacy benefit managers, or PBMs, also play a critical role in driving up drug prices, said former state Rep. Tim Brown, a Bowling Green Republican. And not enough people know about it. (Pyle, 10/23) This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription. Twitter Facebook LinkedIn Email Print Republish We want to hear from you: Contact KHN Previous Pharma Goes All In Against Californiaâ€™s Ballot Initiative To Curb Drug Prices Next Perspectives: Ariadâ€™s Actions Spotlight Pharmaâ€™s Warped Logic On Drug Pricing Recent Morning Briefings Today, November 14 Friday, November 11 Thursday, November 10 Wednesday, November 9 Tuesday, November 8 Monday, November 7 More RSS Top Stories Community Paramedics Work To Link Patients With Mental Health Care 5:00 AM EST Abortion By Mail Delivers Promise For Better Access But Political Questions Remain 5:00 AM EST Study: Many Caregivers Spend $7K Annually Out Of Pocket 5:00 AM EST RSS Email Sign-Up Stay informed by signing up for the KHN Morning Briefing and other emails. Sign Up Most Viewed Most Shared Most Popular Seniors Suffer Amid Widespread Fraud By Medicaid Caretakers Millions Could Lose Medicaid Coverage Under Trump Plan Obamacare â€˜Replacementâ€™ Might Look Familiar Repealing The Affordable Care Act Could Be More Complicated Than It Looks Trump, GOP In Congress Could Use â€˜Must-Passâ€™ Bills To Bring Health Changes Most Shared Millions Could Lose Medicaid Coverage Under Trump Plan Seniors Suffer Amid Widespread Fraud By Medicaid Caretakers Concerned About Losing Your Marketplace Plan? ACA Repeal May Take Awhile Obamacare â€˜Replacementâ€™ Might Look Familiar Repealing The Affordable Care Act Could Be More Complicated Than It Looks Home The Health Law Medicare Medicaid Elections Cost & Quality Health Industry Insurance Aging Mental Health Uninsured Republish Our Content Original KHN stories can be republished for free, and XML feeds are available. Learn More Ways to Follow Us @KHNews Facebook LinkedIn RSS Feeds Email Sign-Up The KHN Morning Briefing and other emails. Sign Up Â© 2016 Kaiser Family Foundation. All rights reserved. About Us Contact Us Editorial Policy Staff Powered by WordPress.com VIP Send to Email Address Your Name Your Email Address Cancel Post was not sent - check your email addresses! Email check failed, please try again Sorry, your blog cannot share posts by email.
PMGroup PME CommuniquÃ© The Directory Quality in Care How to Advertise Privacy and cookies My Account Register Please login to the form below Not currently logged in Email: Password: I have forgotten my password PME CommuniquÃ© The Directory Opening up market access Advanced search Home News Intelligence Thought leadership Appointments Awards Blogs Clinical Top Pharma List PMHub Jobs News Research Sales Marketing Regulatory Healthcare Jobs and recruitment Trending AstraZeneca's durvalumab trial Novartis biosimilar sales Lilly's solanezumab results in Alzheimer's Remicade-biosimilar switch trial PMEA 2016 finalists Lilly promises solanezumab news in Alzheimer's 'before year-end' If anti-amyloid drug proves effective, sales could reach $7.5bn according to analysts Eli Lilly has enrolled the last patient in its EXPEDITION3 trial of beta amyloid-targeting antibody solanezumab, and says it should be ready to unveil the top-line result from the study in December. If the results are positive it would represent a step forward in the treatment of Alzheimer's as well as a great parting gift for Lilly's chief executive John Lechleiter, who will retire at the end of the year after leading the company for eight years. There is no doubt that given the huge number of anti-amyloid drugs that have failed in trials solanezumab is a high-risk project, but Lilly's CEO-in-waiting David Ricks said that while it is possible that the drug will perform no better than placebo, he considers that the "least probable outcome". The company hasn't seen any preliminary data from the trial however. A win in the EXPEDITION3 trial could lead to rapid regulatory filings, said Ricks, and if approved could be a massive product for Lilly with analysts forecasting recently that sales could reach up to $7.5bn at peak. Many scientists continue to believe that amyloid is the main pathogenic factor responsible for the degenerative changes that occur in the brain during Alzheimer's, and if solanezumab does show any efficacy, it would be the first drug to support that hypothesis in a late-stage trial. Solanezumab failed to show a clear benefit in trials involving patients with more advanced Alzheimer's, but led to speculation that amyloid needs to be blocked early in the course of the disease in order to prevent the formation of plaques that seem to cause the neuronal damage that in turn leads to cognitive and memory decline. The company recently began another phase III trial of solanezumab in prodromal (very early) Alzheimer's that will have 2,500 subjects when fully enrolled. Results from that trial are due in 2021. Ricks said that if EXPEDITION3 is a bust the prodromal trial will probably be abandoned. The comments on solanezumab came during Lilly's third-quarter results call, in which it reported a sales increase of 5% to $5.2bn driven by new product launches. Among these, diabetes drugs Trulicity (dulaglutide) and Jardiance (empagliflozin) both saw solid sales gains that did not however meet analysts' expectations, while lung cancer therapy Cyramza (ramucirumab) fell 12% thanks to competition from immuno-oncology rivals, Merck & Co's Keytruda (pembrolizumab) and Bristol-Myers Squibb's Opdivo (nivolumab). Initial sales of Taltz (ixekizumab), which was approved by the FDA in March for the treatment of adults with moderate-to-severe plaque psoriasis, were $33m. The interleukin-17 (IL-17) inhibitor is chasing Novartis' Cosentyx (secukinumab), which has the same mechanism of action and made $301m in the third quarter. Please enable JavaScript to view the comments. Article by Phil Taylor 26th October 2016 From: Research, Sales Share Â Print Friendly Tags Related content Deal Watch October 2016 Pfizer dropping bococizumab casts shadow over PCSK9 class Manufacturing issues scupper Sanofi's sarilumab launch plans Stronger together Pharma 'could do better' on social media engagement Related Hub content Alzheimerâ€™s disease: reviewing the immediate treatment horizon Alzheimer's: the numbers we cannot forget Worldâ€™s Largest Pharmaceutical Summit Brings Latest Innovations To Light In New Award Ceremony PME Digital Edition Featured jobs Deputy Managing Director, Medical Communications, South East UK Excellent Package Senior Account Manager â€“ Medical Education â€“ Boutique Agency Salary TBC Creative Team â€“ Mid-weight & Senior Art Director & Senio... SUPERB PACKAGES AVAILABLE Pharma/ Life Sciences - Social / Digital Account Director Industry leading package and bens New Business and Marketing Manager, circa Â£50K, Healthcare Commu... Excellent Package Account Director, Healthcare PR, London Excellent Package Healthcare PR Innovator, London Excellent Package SAE & Account Manager - Victoria â€“ Healthcare Advertising Salary TBC Medical Writer, Healthcare Education Design & Development, L... Competitive Salary Director of Strategy/ Scientific Services â€“ Full Home working, E... Neg Account Director â€“ Medical Communications Salary TBC SYDNEY BASED ROLE - Senior Account Director â€“ Associate CSD - Me... D.O.E Senior Account Manager / Jr AD - Consumer & Prescription â€“ H... Salary TBC PR Associate Director â€“ Healthcare PR â€“ London Salary TBC Editor, Medical Communications, London Competitive Salary Scientific Director- Immuno Oncology Specialist - Med Comms (Lon... Neg Client Lead, Consumer Health & Wellness, South East UK Excellent Package Account Director â€“ Med Ed â€“ Publications Salary TBC Chief Operating Officer â€“ Medical Education â€“ London Salary TBC SINGAPORE - Senior or Principal Medical Writer Opportunity - Med... D.O.E Managing Director, Healthcare PR, London Excellent Package Subscribe to our email news alerts Most read Most shared Latest content Pharma stocks rise after Donald Trump's election win Siemens' healthcare unit to become standalone business Pfizerâ€™s first-in-class breast cancer therapy wins EU licence NICE backs Novartis' Afinitor and Pfizer's Xalkori Pfizer to shut down two UK manufacturing sites NICE set to knock-back Amgen's myeloma treatment Kyprolis Gilead's hepatitis B virus treatment set for European approval CHMP recommends Merck & Co's Lantus biosimilar Amgen wins European approval for Parsabiv Lilly bags EU approval for cancer treatment Lartruvo A rock and a hard place greyhealth group appoints digital strategy director PMHubAdd my company Any category... Advertising Branding Clinical research Conferences meetings events Creative and design Digital communications Homecare Industry associations IT solutions Management consultancies Manufacturing packaging logistics Market access Market research Marketing consultancies Media planning and buying Medical communications Medical education Patient support and adherence Pharmacy Print services Policy and government affairs Public relations Publishers Recruitment and career development Regulatory affairs Research and development Sales Training Translation services CMR Specialising in medical device market research, our approach is people-centric and we thrive on making connections with clients and research... Latest intelligence Are we harnessing the full emotional power of brand creativity? Creative Director Damien Parsonage breaks down the common misconception that pharma and healthcare marketing for healthcare professionals ought to be entirely scientific and rational. Brands are powerful; here's how to... Opinion piece: Personalisation â€“ the future of medical education Alex Goonesinghe, Research Manager, and Nigel Campbell, Multichannel Communications Director, share their thoughts on the growing trend towards personalised medical education.... Rethinking pharma communications Guide: How do you adjust your communications to the new multichannel and multi-stakeholder environment?... Quick links Country reports Digital Handbook The Gallery Healthcare glossary How to advertise HTA guidance tracker Orphan drugs and rare diseases PME supplements Social media hub Webinars Infographics Multimedia<> Webinar: Customer engagement design CommuniquÃ© Awards 2015: Winners in pictures CommuniquÃ© Awards 2015: Gallery PMEA 2015: Winners in pictures PMEA 2015: Pictures About us Contact us How to advertise Site map All content copyright Â© PMGroup Worldwide Ltd 2016
Contact Us Journalists Blog Log In Sign Up Send a Release News Solutions Resources Search News in Focus Browse News Releases All News Releases News Releases Overview English-only All Public Company Multimedia Gallery All Multimedia Multimedia Gallery Overview All Photos All Videos Trending Topics All Trending Topics Business & Money Auto & Transportation All Auto & Transportation Auto & Transportation Overview Aerospace, Defense Air Freight Airlines & Aviation Automotive Maritime & Shipbuilding Railroads and Intermodal Transportation Transportation, Trucking & Railroad Travel Trucking and Road Transportation Business Technology All Business Technology Business Technology Overview Broadcast Tech Computer Hardware Computer Software Computer & Electronics Electronic Commerce Electronic Components Electronic Design Automation Electronics Performance Measurement High Tech Security Internet Technology Nanotechnology Networks Peripherals RFID (Radio Frequency ID) Semantic Web Semiconductors EntertainÂ­ment & Media All EntertainÂ­ment & Media EntertainÂ­ment & Media Overview Advertising Art Books Entertainment Film and Motion Picture Magazines Music Publishing & Information Services Radio Television Financial Services & Investing All Financial Services & Investing Financial Services & Investing Overview Accounting News & Issues Acquisitions, Mergers and Takeovers Banking & Financial Services Bankruptcy Bond & Stock Ratings Conference Call Announcements Contracts Dividends Earnings Forecasts & Projections Earnings Financing Agreements Insurance Investments Opinions Joint Ventures Mutual Funds OTC, SmallCap Real Estate Restructuring & Recapitalization Sales Reports Shareholders' Rights Plan Stock Offering Stock Split Venture Capital General Business All General Business General Business Overview Agency Roster Awards Commercial Real Estate Corporate Expansion Earnings Human Resource & Workforce Management Licensing New Products & Services Obituaries Outsourcing Businesses Overseas Real Estate (non-US) Personnel Announcements Real Estate Transactions Residential Real Estate Small Business Services Socially Responsible Investing Surveys, Polls and Research Trade Show News Science & Tech Consumer Technology All Consumer Technology Consumer Technology Overview Computer Electronics Computer Hardware Computer Software Consumer Electronics Electronic Commerce Electronic Gaming Mobile Entertainment Multimedia & Internet Peripherals Social Media Web Site Wireless Communications Energy All Energy Energy Overview Alternative Energies Chemical Electrical Utilities Gas Mining Mining & Metals Oil & Energy Oil and Gas Discoveries Utilities Water Utilities EnvironÂ­ment All EnvironÂ­ment EnvironÂ­ment Overview Conservation & Recycling Environmental Issues Environmental Policy Environmental Products & Services Green Technology Heavy Industry & Manufacturing All Heavy Industry & Manufacturing Heavy Industry & Manufacturing Overview Aerospace & Defense Agriculture Chemical Construction & Building HVAC (Heating, Ventilation and Air-Conditioning) Machine Tools, Metalworking and Metallurgy Machinery Mining Mining & Metals Paper, Forest Products & Containers Precious Metals Textiles Tobacco TelecommÂ­unications All TelecommÂ­unications TelecommÂ­unications Overview Carriers and Services Mobile Entertainment Networks Peripherals TelecommunicÂ­ations Equipment TelecommunicaÂ­tions Industry VoIP (Voice over Internet Protocol) Wireless Communications Lifestyle & Health Consumer Products & Retail All Consumer Products & Retail Consumer Products & Retail Overview Animals & Pets Beers, Wines and Spirits Beverages Bridal Services Cosmetics and Personal Care Fashion Food & Beverages Furniture and Furnishings Home Improvement Household Products Household, Consumer & Cosmetics Jewelry Non-Alcoholic Beverages Office Products Organic Food Product Recalls Restaurants Retail Supermarkets Toys EntertainÂ­ment & Media All EntertainÂ­ment & Media EntertainÂ­ment & Media Overview Advertising Art Books Entertainment Film and Motion Picture Magazines Music Publishing & Information Services Radio Television Health All Health Health Overview Biometrics Biotechnology Dentistry Clinical Trials & Medical Discoveries FDA Approval Health Care & Hospitals Health Insurance Infection Control Medical Equipment Medical Pharmaceuticals Mental Health Pharmaceuticals Supplementary Medicine Sports All Sports Sports Overview General Sports Sporting Events Sports Equipment & Accessories Travel All Travel Travel Overview Amusement Parks and Tourist Attractions Gambling & Casinos Hotels and Resorts Leisure & Tourism Passenger Aviation Travel Industry Policy & Public Interest Policy & Public Interest All Policy & Public Interest Policy & Public Interest Overview Advocacy Group Opinion Animal Welfare Corporate Social Responsibility Domestic Policy Economic News, Trends, Analysis Education Environmental European Government FDA Approval Federal and State Legislation Federal Executive Branch & Agency Foreign Policy & International Affairs Homeland Security Labor & Union Legal Issues Not For Profit Patent Law Public Safety Trade Policy U.S. State Policy People & Culture People & Culture All People & Culture People & Culture Overview Aboriginal, First Nations & Native American African American Asian American Children Disabilities, Disabled People Hispanic Lesbian, Gay & Bisexual Religion Senior Citizens Veterans Women Other Language News dansk Deutsch espaÃ±ol FranÃ§ais italiano Nederlands norsk portuguÃªs suomeksi svenska Pharmaceutical and Biotechnology Construction Sector Report - UK 2016-2020 Analysis News provided by Reportlinker Oct 25, 2016, 22:36 ET Share this article NEW YORK, Oct. 25, 2016 /PRNewswire/ -- The 3rd edition of the report 'Pharmaceutical and Biotechnology Construction Sector Report â€“ UK 2016-2020 Analysis' addresses the scale of construction activity in the pharmaceutical and biotechnology industry alongside the key contractors operating in that sector. It also assesses the health of the pharmaceutical industry and whether prospective industry performance is likely to lead to greater levels of capital and construction investment. Key sections covered: - Market size and overview â€“ value, market drivers and key issues, R&D and manufacturing activity. - Construction activity - in the pharmaceutical and biotechnology industries. - Main manufacturing and R&D facilities â€“ the key centres of the South East, East of England, North West, North East and Scotland. - Construction capability - major companies involved in the pharmaceutical and biotechnology sectors including contractors, consultants and architects. - Funding and investment - analysis of Government resource and capital funding for science and research. Key areas of insight include: - Analysis of the impact of Brexit on the UK pharmaceutical sector â€“ there are significant issues for the industry including the regulation of medicines, EU clinical trials regulation, EU funding for research, access to R&D facilities, the single market, skills base. - Leading specialist supply companies to the pharmaceutical industry including: cleanroom design, construction and fit-out; clean and controlled air environments; clean air products; bio-containment and contamination control; validation and maintenance. - Construction costs and issues in the design of pharmaceutical R&D and manufacturing facilities including legislation, regulatory requirements, containment and environmental issues, cleanroom and laboratory design. - Detailed analysis of pharmaceutical clusters and centres of excellence in the UK. Many of the UK's biotech firms are located in an area known as 'The Golden Triangle', with the centres of London, Cambridge, Oxford and Stevenage housing the UK's largest biomedical cluster in the UK. - Review of the main challenges facing the pharmaceutical sector including slowing R&D pipelines, dwindling healthcare budgets, rising costs, impending 'patent cliffs', increased regulatory controls, the influence of the generic drugs market and increased pricing pressures. Key areas covered in the report include: MARKET OVERVIEW - Market definition, size and value, overview of the global pharmaceutical market, overview of the UK pharmaceutical market: biopharmaceuticals; medical technology; digital health; genomics sector. - Location of UK biopharmaceutical manufacturing and R&D sites. - Pharmaceutical/biotechnology clusters and centres of excellence: Oxfordshire biocluster; London, Cambridge and Stevenage bioclusters. - Regional concentration of pharmaceutical manufacturing and R&D: Northwest; East, Southeast and London; Northeast; Scotland. - Future of pharmaceutical manufacturing operations in the UK. - Value of pharmaceutical industry to the UK economy: UK trade in pharmaceuticals, sales of pharmaceutical drugs to the NHS. - Pharmaceutical R&D in the UK: government funding for science R&D (resource & capital funding); pharmaceutical company investment in R&D; R&D pipeline. - Market drivers and key issues in the pharmaceutical industry: drug patent expirations; generic drugs market; university collaboration with the pharmaceutical industry; tax implications and government legislation; long-term implications of 'brexit' on the UK pharmaceutical industry. CONSTRUCTION ACTIVITY - Construction output in the UK pharmaceutical and biotechnology sector, forecast through to 2020, prospects for development in construction within this end use sector. - Construction in the industrial sector, future prospects in construction output within the sector, key influencing factors, growth in factories and warehouses. - Capital expenditure in the UK pharmaceutical & biotechnology sectors: R&D capital and manufacturing capital. - Pharmaceutical construction/development pipeline â€“ confirmed projects to 2020. - Construction issues in the pharmaceutical industry â€“ construction costs; contamination control issues; clean rooms; containment laboratories; legislation/guidelines/standards for cleanroom construction. - UK science parks and university innovation campuses. - UK Enterprise Zones and Catapult Centres. CONSTRUCTION CAPABILITY - Leading specialist supply companies to the pharmaceutical industry including: cleanroom design, construction and fit-out; clean and controlled air environments; clean air products; bio-containment and contamination control; validation and maintenance. - Major engineering construction companies involved in the pharmaceutical and biotechnology sectors including contractors, consultants and architects - capability and project experience. LEADING PHARMACEUTICAL COMPANIES - Overview and Pharmaceutical Company League Tables (Global and UK). - Pharmaceutical company profiles: Abbvie; AstraZeneca; Boehringer Ingelheim; GSK; Johnson & Johnson; Merck; Novartis; Pfizer; Roche; Sanofi. - Other smaller pharmaceutical/biotechnology companies: biotechnology/therapeutics & diagnostics; biotechnology R&D; pharmaceutical. Read the full report: http://www.reportlinker.com/p04246044-summary/view-report.html About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. http://www.reportlinker.com __________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pharmaceutical-and-biotechnology-construction-sector-report---uk-2016-2020-analysis-300351312.html SOURCE Reportlinker Related Links http://www.reportlinker.com Oct 25, 2016, 22:39 ET Preview: Contrast Media/Contrast Agent Market by Type, Procedure & Application - Global Forecasts to 2021 Oct 25, 2016, 22:34 ET Preview: China Antiscalant Market Analysis By Type, By Application and Segment Forecasts to 2024 My News Release contains wide tables. View fullscreen. Also from this source 17:24 ETElectrically Conductive Adhesives 2016-2026 : Technologies,... 17:19 ETElectric Vehicle Traction Motors, Belt Driven & Integrated... Explore More news releases in similar topics Publishing & Information Services Health Care & Hospitals Pharmaceuticals Surveys, Polls and Research You just read: Pharmaceutical and Biotechnology Construction Sector Report - UK 2016-2020 Analysis News provided by Reportlinker Oct 25, 2016, 22:36 ET Share this article Looking to send a news release with PR Newswire? Take advantage of the world's leading distribution platform. Sign up to get started Request more information Have an account? Log In Phone 8AM - 10PM ET +1-888-776-0942 Send a Release Sign Up Blog For Journalists Contact Us Search Searching for your content... Advanced Search Contact 888-776-0942 from 8 AM - 10 PM ET Chat Online with an Expert Contact Us Solutions Cision Communication Cloudâ„¢ For Marketers For Public Relations For IR & Compliance For Agency For Small Business All Products About About PR Newswire About Cision Become a Publishing Partner Become a Channel Partner Careers Â  Global Sites Asia Brazil Canada Europe Finland France India Israel Mexico Middle East Netherlands Sweden United Kingdom My Services All News Releases Online Member Center ProfNetâ„  My Services All News Releases Online Member Center ProfNetâ„  888-776-0942 from 8 AM - 10 PM ET Terms of Use Privacy Policy Information Security Policy Statement Site Map RSS Feeds Copyright Â© 2016 PR Newswire Association LLC. All Rights Reserved. A Cision company. News Solutions Resources News in Focus Browse News Releases All News Releases News Releases Overview English-only All Public Company Multimedia Gallery All Multimedia Multimedia Gallery Overview All Photos All Videos Trending Topics All Trending Topics Business & Money Auto & Transportation All Auto & Transportation Auto & Transportation Overview Aerospace, Defense Air Freight Airlines & Aviation Automotive Maritime & Shipbuilding Railroads and Intermodal Transportation Transportation, Trucking & Railroad Travel Trucking and Road Transportation Business Technology All Business Technology Business Technology Overview Broadcast Tech Computer Hardware Computer Software Computer & Electronics Electronic Commerce Electronic Components Electronic Design Automation Electronics Performance Measurement High Tech Security Internet Technology Nanotechnology Networks Peripherals RFID (Radio Frequency ID) Semantic Web Semiconductors EntertainÂ­ment & Media All EntertainÂ­ment & Media EntertainÂ­ment & Media Overview Advertising Art Books Entertainment Film and Motion Picture Magazines Music Publishing & Information Services Radio Television Financial Services & Investing All Financial Services & Investing Financial Services & Investing Overview Accounting News & Issues Acquisitions, Mergers and Takeovers Banking & Financial Services Bankruptcy Bond & Stock Ratings Conference Call Announcements Contracts Dividends Earnings Forecasts & Projections Earnings Financing Agreements Insurance Investments Opinions Joint Ventures Mutual Funds OTC, SmallCap Real Estate Restructuring & Recapitalization Sales Reports Shareholders' Rights Plan Stock Offering Stock Split Venture Capital General Business All General Business General Business Overview Agency Roster Awards Commercial Real Estate Corporate Expansion Earnings Human Resource & Workforce Management Licensing New Products & Services Obituaries Outsourcing Businesses Overseas Real Estate (non-US) Personnel Announcements Real Estate Transactions Residential Real Estate Small Business Services Socially Responsible Investing Surveys, Polls and Research Trade Show News Science & Tech Consumer Technology All Consumer Technology Consumer Technology Overview Computer Electronics Computer Hardware Computer Software Consumer Electronics Electronic Commerce Electronic Gaming Mobile Entertainment Multimedia & Internet Peripherals Social Media Web Site Wireless Communications Energy All Energy Energy Overview Alternative Energies Chemical Electrical Utilities Gas Mining Mining & Metals Oil & Energy Oil and Gas Discoveries Utilities Water Utilities EnvironÂ­ment All EnvironÂ­ment EnvironÂ­ment Overview Conservation & Recycling Environmental Issues Environmental Policy Environmental Products & Services Green Technology Heavy Industry & Manufacturing All Heavy Industry & Manufacturing Heavy Industry & Manufacturing Overview Aerospace & Defense Agriculture Chemical Construction & Building HVAC (Heating, Ventilation and Air-Conditioning) Machine Tools, Metalworking and Metallurgy Machinery Mining Mining & Metals Paper, Forest Products & Containers Precious Metals Textiles Tobacco TelecommÂ­unications All TelecommÂ­unications TelecommÂ­unications Overview Carriers and Services Mobile Entertainment Networks Peripherals TelecommunicÂ­ations Equipment TelecommunicaÂ­tions Industry VoIP (Voice over Internet Protocol) Wireless Communications Lifestyle & Health Consumer Products & Retail All Consumer Products & Retail Consumer Products & Retail Overview Animals & Pets Beers, Wines and Spirits Beverages Bridal Services Cosmetics and Personal Care Fashion Food & Beverages Furniture and Furnishings Home Improvement Household Products Household, Consumer & Cosmetics Jewelry Non-Alcoholic Beverages Office Products Organic Food Product Recalls Restaurants Retail Supermarkets Toys EntertainÂ­ment & Media All EntertainÂ­ment & Media EntertainÂ­ment & Media Overview Advertising Art Books Entertainment Film and Motion Picture Magazines Music Publishing & Information Services Radio Television Health All Health Health Overview Biometrics Biotechnology Dentistry Clinical Trials & Medical Discoveries FDA Approval Health Care & Hospitals Health Insurance Infection Control Medical Equipment Medical Pharmaceuticals Mental Health Pharmaceuticals Supplementary Medicine Sports All Sports Sports Overview General Sports Sporting Events Sports Equipment & Accessories Travel All Travel Travel Overview Amusement Parks and Tourist Attractions Gambling & Casinos Hotels and Resorts Leisure & Tourism Passenger Aviation Travel Industry Policy & Public Interest Policy & Public Interest All Policy & Public Interest Policy & Public Interest Overview Advocacy Group Opinion Animal Welfare Corporate Social Responsibility Domestic Policy Economic News, Trends, Analysis Education Environmental European Government FDA Approval Federal and State Legislation Federal Executive Branch & Agency Foreign Policy & International Affairs Homeland Security Labor & Union Legal Issues Not For Profit Patent Law Public Safety Trade Policy U.S. State Policy People & Culture People & Culture All People & Culture People & Culture Overview Aboriginal, First Nations & Native American African American Asian American Children Disabilities, Disabled People Hispanic Lesbian, Gay & Bisexual Religion Senior Citizens Veterans Women Other Language News dansk Deutsch espaÃ±ol FranÃ§ais italiano Nederlands norsk portuguÃªs suomeksi svenska Phone +1-888-776-0942 8AM - 10PM ET Chat Chat Online with an Expert All contact info Send a ReleaseLog In
